[
    {
        "instruction":"已知信息：\n'它可能在许多患者中主要是功能性（或“功能障碍性”）障碍，但是有一些证据表明在FMS中CNS中的疼痛和感觉处理改变。 FMS的既定诊断标准（美国风湿病学院纤维肌痛诊断标准（ACRFDC）包括广泛疼痛指数（WPI） 和症状严重程度量表（SSS））并不只强调疼痛强度。'可被翻译为：It may be largely a functional (or “dysfunctional”) disorder in many patients but there is some evidence for alterations in pain and sensory processing in the CNS in FMS. The established diagnostic criteria for FMS (American College of Rheumatology Fibromyalgia Diagnostic Criteria (ACR FDC) including Widespread Pain Index (WPI) and Symptom Severity Scale (SSS)) do not emphasise pain intensity exclusively.\n'FMS的病理生理学没有得到充分表征。'可被翻译为：The pathophysiology of FMS is not well characterised.\n'6.5.纤维肌痛综合征'可被翻译为：6.5.Fibromyalgia Syndrome\n'描述了关于研究设计、持续时间、目标患者人群和结果测量的要求。预期用于治疗具有除伤害性或神经性疼痛之外的主要元素的其它疼痛综合征（包括具有单独指南的偏头痛）的药品的临床研究不是本指南的焦点，尽管给出了关于数据要求的一些一般性指导 以支持例如纤维肌痛适应症。'可被翻译为：Requirements with regard to study design, duration, target patient population and outcome measures are described. The clinical investigation of medicinal products for the treatment of other pain syndromes that have major elements other than nociceptive or neuropathic pain (including migraine for which there is a separate guideline) are not the focus of this guideline, although some general guidance is given on the data requirements to support e.g. claims for fibromyalgia.\n\n根据上述已知信息，请将'纤维肌痛综合征（FMS）可能归类为具有未知病因的软组织疼痛综合征。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The Fibromyalgia Syndrome (FMS) may be categorized with the soft tissue pain syndromes of unknown aetiology."
    },
    {
        "instruction":"已知信息：\n'症状量表  应该使用经过验证的覆盖患者完整年龄范围的量表对症状进行评估。'可被翻译为：Symptomatic scales Symptoms should be assessed with scales validated for the full age range of patients to be studied.\n'从疾病特异性生活质量的措施的信息也可以被认为是包含在标记。'可被翻译为：Information from disease-specific quality-of-life measures also can be considered for inclusion in labeling.\n'应尽可能使用适当的量表对变量（例如年龄、性别、症状的严重程度和功能障碍）的随机化进行分层。'可被翻译为：Efforts should be made to stratify randomisation for variables such as age, gender, severity of symptoms and functional impairment using appropriate scales.\n'这可能可以用整体 “令人厌烦”或严重程度水平评级标准或在入选时用经验证的量表通过频率和严 重程度41来定义和分级症状来实现。'可被翻译为：This may be done with either the criterion of rating “troublesomeness” or severity on a global level, or with defining and rating the symptoms with a validated scale by frequency and severity41 at the time of inclusion.\n\n根据上述已知信息，请将'如在症状评级量表中加入符号视觉标记和\/或与年龄相当的内容。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"such as incorporating symbolic visual anchors and\/or age-appropriate text in symptom rating scales."
    },
    {
        "instruction":"已知信息：\n'当申办方充当监查有效性或安全性比较的角色并因此 可以获取非盲的比较信息时，应特别注意保护试验的完整性， 并适当地管理和限制信息共享。申办方应当确保并记录内部 监查委员会遵守书面的标准操作规程，以及含有期中分析结果记录的决策会议纪要被维护。'可被翻译为：When a sponsor assumes the role of monitoring efficacy or safety comparisons and therefore has access to unblinded comparative information, particular care should be taken to protect the integrity of the trial and to manage and limit appropriately the sharing of information. The sponsor should assure and document that the internal monitoring committee has complied with written standard operating procedures and that minutes of decision making meetings including records of interim results are maintained.\n'当然，由于某些监管的要求，如 稳定性研究，或其他区域性要求，可能仍需要进行一些检验。'可被翻译为：Some product testing will be expected for certain regulatory processes such as stability studies or regional requirements.\n'当一种基因生物标志物在探索性研发中表现出充分的前景时，在正常情况下可以对预测性基因组生物标志物的临床有效性进行验证。'可被翻译为：Confirmation of the clinical validity of a predictive genomic biomarker would normally be undertaken when a genomic biomarker has shown sufficient promise during exploratory development.\n'采用不同技术和\/或化学方法的多种分析程序目前应用在基因组生物标志物分析中。'可被翻译为：A variety of procedures with different technical and\/or chemical approaches are currently used for genomic biomarker analytics.\n\n根据上述已知信息，请将'因此，适当的监督是必要的，这可能要求在不同成员国获得认证或遵循预测性生物标志物分析的国别公认程序进行验证，包括实验室能力比对验证。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Therefore, appropriate oversight is necessary and this may require accreditation in the different member states or be subjected to validation using nationally accepted procedures for predictive biomarker analytics, including intra-laboratory proficiency testing."
    },
    {
        "instruction":"已知信息：\n'应当在方案中提供详细的统计分析计划。'可被翻译为：The details of the planned statistical procedures should be given in the protocol.\n'应预先计划关于 MRD 和 PFS 的统计分析和评估方法，并在统计分析计划中清楚地描述。'可被翻译为：The statistical analysis and methods for assessment of MRD and PFS should be pre-planned and clearly described in the statistical analysis plan.\n'F. 缺失及无法解读的数据的评估及处理 研究者应开发一个用于评估和处理缺失及无法解读的数据的计划。'可被翻译为：F. Assessment and Handling of Missing and Uninterpretable Data Investigators should develop a plan to assess and handle missing and uninterpretable data.\n'为减少缺失数 据，可采取措施将受试者保留在试验中。'可被翻译为：To reduce missing data, measures can be implemented to retain subjects in the trial.\n\n根据上述已知信息，请将'- 描述统计方法，包括开发完善的统计分析计划和最小化及处理缺失数 据的计划。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Describing the statistical approach, including a well-developed statistical analysis plan and plans for minimizing and dealing with missing data."
    },
    {
        "instruction":"已知信息：\n'应该表征生物药物的免疫原性以及免疫应答对 全身暴露、药效学反应和药物毒性的影响。'可被翻译为：The immunogenicity of the biopharmaceutical and the effect of the immune response on systemic exposure, pharmacodynamic response, and toxicity of a drug should be characterized.\n'除了一般产品安全性和临床疗效方面外，还须关注免疫原性，特别是抑制物形成、过敏性反应和血栓形成效应。'可被翻译为：Besides aspects like the general product safety and clinical efficacy, there has to be a focus on immunogenicity, particularly on inhibitor development, anaphylactic reactions and thrombogenic effects.\n'相反,一个受试的将长期使用的血小板生成素受体激动剂药物则应该以另一个已经获得批准的血小板生成素受体激动剂药物作为活性对照，进行试验研究。'可被翻译为：On the contrary, an experimental TPO-R agonist drug intended for chronic use may be studied in trial against another approved TPO-R agonist.\n'血小板生成素受体(TPO-R)激 动剂活化血小板生成素受体(c-Mpl)是调节血小板生成的主要因素。'可被翻译为：Thrombopoietin receptor (TPO-R) agonists activate the thrombopoietin receptor (c-Mpl) which is the primary factor that regulates platelet production.\n\n根据上述已知信息，请将'对于生物药品，应该进行免疫原性风险评价,尤其是潜在的血小板生成素受 体激动剂与内源性血小板生成素之间的交叉反应。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In the case of biological medicinal products the risk for immunogenicity should be addressed, in particular the potential cross-reactivity seen in TPO-R agonists with endogenous thrombopoietin."
    },
    {
        "instruction":"已知信息：\n'为了帮助选择合适的研究患者群和评估终点，建议在进行有预定目标的关键性研究之前 进行至少一项探索性研究。'可被翻译为：To assist in selecting appropriate patient populations for study and endpoints for evaluation it is suggested that at least one exploratory study is conducted before proceeding to pivotal studies with pre-defined objectives.\n'因此强烈建议在具有良 好特征性的患者人群中开展探索性试验。'可被翻译为：Exploratory trials in well-characterized patient populations are therefore strongly encouraged.\n'因为骨髓衰竭和存活依赖于患者的基线特性，任何疗效或安全性的结论仅适用于有相同预后特征的患者。但是，也普遍认为许多因素（如细胞遗传学特征）可能会导致药理学活性差异。因此，需要相当广泛的探索性研究来为验证性研究确认合适的目标人群。'可被翻译为：Since evolution of bone marrow failure and survival depend on patients’ baseline characteristics, any efficacy or safety conclusion may apply only to patients sharing similar prognostic features. It is, however, also acknowledged that pharmacological activity may vary in relation to, e.g. cytogenetic characteristics. There is thus a need for rather extensive exploratory studies in order to identify the proper target population for confirmatory studies.\n'在第6节探索性研究中，强调了常规的目的：例如确定合适的剂量和计划，并强调 了确定最佳获益风险的目标人群的重要性。'可被翻译为：Alongside conventional aims such as defining the proper dose(s) and schedule(s), the importance of identifying a target population with optimised benefit risk is emphasised in Section 6: Exploratory Studies.\n\n根据上述已知信息，请将'因此，需要相当广泛的探索性研究来为验证性研究确认合适的目标人群。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"There is thus a need for rather extensive exploratory studies in order to identify the proper target population for confirmatory studies."
    },
    {
        "instruction":"已知信息：\n'Whirl- pak®袋的无菌控制：放入一个未开封的 Whirl- pak®袋作为密封控制。'可被翻译为：Whirl-pak® bag Sterility Control: Include one unopened Whirl- pak® bag as a closed control.\n'无菌技术控制：将一个无菌涤纶或棉签放入无菌水中，并放回其无菌输送培养基溶液中，将此阴性对照放入无菌 Whirl- pak®袋中。\n注：如果海绵和\/或棉签在收到之前就已蘸湿则不需要该控制。该控制没有表面接触。'可被翻译为：Aseptic Technique Control: Place one (1) sterile Dacron or cotton swab into sterile water and place back into its sterile transport media solution. Place this negative control into a sterile Whirl- pak® bag.\nNote: This control may not be needed if the sponges and\/or swabs are received premoistened. There is no surface contact for this control.\n'将棉签（或海绵）重新放回装载容器（如果有）并放置在另一个 Whirl-pak®无菌袋中。确认已将海绵手柄折断去除。'可被翻译为：Place the swab (or sponge) back into the carrier container (if it came with one) and place into the additional sterile Whirl-pak® bag. Be sure to break off the handle portion of the sponge applicator stick.\n'RODAC\/Hycheck 无菌控制：将未使用的 RODAC 碟和\/或 Hycheck 碟放入无菌Whirl- pak®袋中。'可被翻译为：RODAC\/Hycheck Sterility Control: Place an unused RODAC plate and\/or Hycheck plate within a sterile Whirl-pak® bag.\n\n根据上述已知信息，请将'棉签\/海绵无菌控制：将完整的未使用的棉签（或海绵）单元放入无菌 Whirl-pak®袋中。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Swab\/Sponge Sterility Control: Place an intact unus ed swab (or sponge) unit into a sterile Whirl-pak® bag."
    },
    {
        "instruction":"已知信息：\n'6．特殊情况 # 批准日期 问题 解答 6.1 ICH E14 指导原则陈 述，在某些情况中传 统全面 QT 研究可 能不可行。'可被翻译为：6.Special Cases # Date of Approval Questions Answers 6.1 The ICH E14 Guideline states that in certain cases a conventional thorough QT study might not be feasible.\n'当提交文件中包含 ICH Q12中描述的其他生命周期管理要素时，申请人应遵循ICH Q12以及本文件第7章中描述的原则。'可被翻译为：When other lifecycle management elements as described in ICH Q12 are included in the submission, the applicant should follow the principles described in ICH Q12 and Chapter 7 of this document.\n'因此，在所有申请中将不再认可经 Bazett 公式校 正的 QT 间期数据，除非为与历史 Bazett 公式校正的 QT 数据进行对 比而必须使用。'可被翻译为：Therefore, QT interval data corrected using Bazett’s corrections is no longer warranted in all applications unless there is a compelling reason for a comparison to historical Bazett’s corrected QT data.\n'在成人受试者中，已确证 Bazett 公式是校正受试者间和受试者内 心率差异的较差方法。'可被翻译为：The principles set below would be applicable in all clinical studies (thorough QT or other studies). In adults, Bazett’s correction has been clearly shown to be an inferior method of correcting for differences in heart rate among and within subjects.\n\n根据上述已知信息，请将'1.5 2012 年 4 月 依据 ICH E14 指导原则 所述，应在所有申请中， 递交用 Fridericia 公式 和 Bazett 公式校正的 QT 间期；是否仍旧有必 要？'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.5 April 2012 The ICH E14 Guideline states that QT interval corrected by Fridericia’s and Bazett’s correction should be submitted in all applications; is this still necessary?"
    },
    {
        "instruction":"已知信息：\n'质量：产品、系统或工艺的一系列固有特性符合要求的程度。（ICH Q9）'可被翻译为：Quality: The degree to which a set of inherent properties of a product, system or process fulfils requirements. (ICH Q9)\n'质量（Quality）：指原料药或制剂对预期用途的适用性，包括鉴别、规格和纯度等属性（《ICH Q6A质量标准：新原料药和新药制剂的检测方法和可接受标准：化学药物》）。'可被翻译为：Quality: The suitability of either a drug substance or drug product for its intended use. This term includes such attributes as the identity, strength, and purity (from ICH Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances).\n'操作和监管的灵活程度及其切实实施取决于现有的监管框架，对产品以及工艺的理解（ICH Q8（R2）和Q11），对质量 风险管理原则（ICH Q9）的应用和有效的药品质量体系（ICH Q10）。'可被翻译为：The extent of this operational and regulatory flexibility and its adequate implementation is subject to the regulatory framework in place, as well as product and process understanding (ICH Q8(R2) and Q11), application of quality risk management principles (ICH Q9), and an effective pharmaceutical quality system (ICH Q10).\n'本指导原则适用于新制剂（定义见ICHQ6A和Q6B）以及含已有原料药的新制剂。'可被翻译为：The guideline applies to new finished drug products (as defined in ICH Q6A and Q6B) and new drug products containing existing drug substances.\n\n根据上述已知信息，请将'质量： 产品、系统和工艺的一组内在特性满足要求的程度（参见ICHQ6A特别针对原料药和制剂质量的定义）。（ICH Q9）'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Quality: The degree to which a set of inherent properties of a product, system, or process fulfills requirements (see ICH Q6A definition specifically for quality of drug substance and drug products). (ICH Q9)"
    },
    {
        "instruction":"已知信息：\n'DTD 指定了特定文件所需的结构和格式。XML比SGML更灵活，并且允许采纳“格式良好” 数据的内容-满足 XML 的基本词汇和“语法”要求、但不针对一组特定属性或必需元素列表引用元素DTD。XML包含一个称为模式的进一步概念。'可被翻译为：The DTD specifies the required structure and format of a particular document.XML is more flexible than SGML and allows for the concept of ‘well-formed’ data – content that meets the basic vocabulary and ‘grammatical’ requirements of XML but does not reference a DTD for a specific set of attributes or list of required elements.XML contains a further concept called a schema.\n'ICH 选择 XML模式进行 ICSR报告，因为更适合达到预期目的：XML具有便携式和非专有性。'可被翻译为：The ICH chose to adopt an XML schema for the ICSR as it is more suitable for the intended purpose: XML is portable and non-proprietary.\n'在DTD中不符合其规则的SGML\/XML文件视为无效。'可被翻译为：SGML\/XML documents that do not follow the rules in their DTDs are categorised as invalid.\n'因此，此处提及的当前信息标准目前依赖于XML模式。'可被翻译为：As a result, the current messaging standard herein now relies upon XML schemas.\n\n根据上述已知信息，请将'一般而言，DTD 在应用于文件或文本密集型信息时表现良好。XML 模式最适合数据密集型信息5。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In general, DTDs perform well when applied to documents or text-intensive information.XML schema work best for data-intensive information5."
    },
    {
        "instruction":"已知信息：\n'一旦皮肤的水合作用和温度达到平衡(即30分钟后)，应测量皮肤表面温度。在施用剂型之前，皮肤表面温度应在目标温度(32°)的±1°内。受体溶液的温度，或循环水浴的温度，或干热系统的设定点，或系统的任何其他组成部分的温度不应假定与皮肤表面温度相同。而是直接测量皮肤表面温度(使用红外温度计或热电偶)，并根据需要调节VDC系统的热调节机制，使皮肤表面温度达到32°的目标温度。搅拌器可以在平衡期间运行，以加速温度稳定。'可被翻译为：Once the hydration and temperature of the skin has equilibrated (i.e., after 30 min) the skin surface temperature should be measured. The skin surface temperature should be within ±1° of the target temperature (32°) prior to applying the dosage form. The temperature of the receptor solution, or the circulating water bath, or the set point of a dry heat system, or any other component of the system should not be assumed to be the same as the skin surface temperature. Instead, the skin surface temperature should be directly measured (with an infrared thermometer or a thermocouple), and the thermoregulatory mechanism of the VDC system should be adjusted as needed to produce the target temperature of 32° at the skin surface. The stirrers can be run during the duration of the equilibration to speed up temperature stabilization.\n'皮肤表面温度应使用红外温度计测量。加热块的温度必须设置高于所需的膜温度(例如，对于32°的皮肤表面温度设为33°)。'可被翻译为：Skin surface temperature should be measured using an IR thermometer. The temperature of the heating block must be set higher than the desired membrane temperature (e.g., 33° for a 32° skin surface temperature).\n'在IVPT开始运行之前，系统应在预先确定的实验条件下进行适当的平衡。在实验之前和实验过程中，受体溶液(膜下)中不应出现气泡;如果合适，受体溶液可以脱气。系统温度(包括膜表面温度和循环水浴温度，如适用)应稳定且控制良好。冷冻的生物膜应在室温下解冻，然后组装在扩散池上。一旦安装，皮肤切片应该被允许平衡到生理上相关的水合作用和温度状态(例如，在32°的膜表面温度下30分钟)。'可被翻译为：The system should be appropriately equilibrated under the predefined experimental conditions prior to the beginning of the IVPT run. No air bubbles should be present in the receptor solution (under the membrane) immediately prior and during the experiment; if appropriate, the receptor solution can be degassed. The system temperature (including the membrane surface temperature and the circulating water bath temperature, if applicable) should be stable and well controlled. Frozen biological membranes should be thawed at ambient temperature prior to assembling on the diffusion cells. Once mounted, the skin sections should be allowed to equilibrate to a physiologically relevant state of hydration and temperature (e.g., for 30 min at a membrane surface temperature of 32°).\n'在IVRT开始运行之前，系统应在预定的实验条件下适当地平衡。在实验前或实验过程中，受体溶液(膜下)中不应出现气泡;如果合适，受体溶液可以脱气。系统温度(包括膜表面温度和循环水浴温度，如适用)应稳定且控制良好。IVRT膜在装配于扩散池之前可以用受体溶液预浸泡，或者在给药之前用扩散池内的受体溶液原位平衡(例如，在32°的膜温度下30分钟)，具体取决于方法。'可被翻译为：The system should be appropriately equilibrated under the predefined experimental conditions prior to the beginning of the IVRT run. No air bubbles should be present in the receptor solution (under the membrane) immediately prior to, or during the experiment; if appropriate, the receptor solution can be degassed. The system temperature (including the membrane surface temperature and the circulating water bath temperature, if applicable) should be stable and well controlled. IVRT membranes can be presoaked with receptor solution prior to assembling in the diffusion cell or equilibrated with the receptor solution in situ within the diffusion cell prior to dosing (e.g., for 30 min at a membrane temperature of 32°) depending upon the method.\n\n根据上述已知信息，请将'一旦皮肤的水合作用和温度达到平衡(例如，30分钟后)，应测量皮肤表面温度。在施用剂型之前，皮肤表面温度应在目标温度(32°)的±1°内。受体溶液的温度，或循环水浴的温度，或干热系统的设定点，或系统的任何其他组成部分的温度不应假定与皮肤表面温度相同。相反，应直接测量皮肤表面温度(使用红外温度计或热电偶)，并根据需要调整FDC系统的温度调节机制，使皮肤表面温度达到32°的目标温度。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Once the hydration and temperature of the skin has equilibrated (e.g., after 30 min) the skin surface temperature should be measured. The skin surface temperature should be within ±1° of the target temperature (32°) prior to applying the dosage form. The temperature of the receptor solution, or the circulating water bath, or the set point of a dry heat system, or any other component of the system should not be assumed to be the same as the skin surface temperature. Instead, the skin surface temperature should be directly measured (with an infrared thermometer or a thermocouple), and the thermoregulatory mechanism of the FDC system should be adjusted as needed to produce the target temperature of 32° at the skin surface."
    },
    {
        "instruction":"已知信息：\n'5.1. 不良事件 应对临床试验期间所有接受因子 VIII 制品的病人进行包括生命体征在内的安全性评估。'可被翻译为：Adverse events  Safety, including vital signs, should be assessed in all patients receiving the factor VIII product during  clinical trials.\n'在所有临床试验中，安全性和耐受性（见词汇表）的评 价是一个重要方面。'可被翻译为：In all clinical trials evaluation of safety and tolerability (see Glossary) constitutes an important element.\n'所有新的重组因子 IX 产品都需开展 PUP 试验，比如为改变体内特性（如药动学参数）而使用因子 IX 分子的新基因结构或者修饰和使用新工艺（如较少使用的新 细胞系）生产的因子 IX 产品。'可被翻译为：A PUP study needs to be conducted for all novel recombinant factor IX products, such as novel genetic constructs or modification of the factor IX molecule in order to alter its in vivo properties, e.g. pharmacokinetics, and for factor IX products manufactured with novel production methods, e.g. a new cell line where there is limited experience.\n'附录II-因子IX产品的临床试验：新产品'可被翻译为：Annex II – Clinical trials with factor IX products: new products\n\n根据上述已知信息，请将'所有在临床试验期间使用因子 IX 的患者都应该接受安全性评估，包括生命体征。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Safety, including vital signs, should be assessed in all patients receiving the factor IX product during clinical trials."
    },
    {
        "instruction":"已知信息：\n'最终定稿后，将取代1999 年 02 月的指导原则， 并反映FDA关于RA药品开发的最新见解。'可被翻译为：After it has been finalized, this guidance will replace the February 1999  guidance and will reflect the current thinking of the FDA on RA drug product development.\n'本指导原则的目的是表述 FDA 目前对支持治疗类风湿性关节炎（RA）患者 的药物批准的临床开发中， 剂量选择以及疗效和安全性评价的考虑。'可被翻译为：The purpose of this guidance is to outline the FDA’s current thinking on the principles of clinical  development relevant to dose-selection and assessment of efficacy and safety to support the  approval of drug products for the treatment of patients with rheumatoid arthritis (RA).\n'3.4.2 有限的初始临床开发项目的依据'可被翻译为：3.4.2. Justification for a limited initial clinical development programme\n'3.4.3 开发项目的内容'可被翻译为：3.4.3. Content of the development programme\n\n根据上述已知信息，请将'FDA现在的态度，受到自 1999 年版指导原则发表以来的临床项开发项目的影响，以及因为大量有 效的治疗面世， RA标准治疗变化的影响。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The  FDA’s current thinking has been influenced by clinical development programs conducted for RA since the 1999 guidance published, and by changes in the standard of care for RA because of  availability of many effective treatments."
    },
    {
        "instruction":"已知信息：\n'若在对受试者退出的评估 中发现了任何安全性问题，应根据具体情况在DSUR第18节中 进行说明。'可被翻译为：Any safety issues identified from a review of these withdrawals should be addressed in Section 18 of the DSUR as appropriate.\n'全因死亡率通常是有效性评估的一部分，但也应作为安全性评估的一部分纳入，以报告整个研究期间的死亡率。'可被翻译为：All cause mortality is usually part of the efficacy evaluation, but should also be included as part of the safety assessment to inform about mortality throughout the study period.\n'随着新产品、平台和技术的出现，或者在产品测试中发现任何重大的科学差距，将持续对 PMM 进行修订。'可被翻译为：The PMM will continually be revised as newer products, platforms and technologies emerge or any significant scientific gaps are identified with product testing.\n'3.18 整体安全性评估 整体安全性评估是相对于原有对试验药的认识，对报告周期 内新获得的相关的临床、非临床、流行病学信息进行的简明完整 的评估。'可被翻译为：3.18 Overall Safety Assessment The overall safety assessment should be a concise, integrated evaluation of all new relevant clinical, non-clinical, and epidemiologic information obtained during the reporting period relative to previous knowledge of the investigational drug.\n\n根据上述已知信息，请将'若在 对受试者死亡进行的评估中发现任何安全性问题，应根据具体情 况在整体安全性评估一节中进行说明。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Any safety issues identified from a review of these deaths should be addressed in Section 18 of the DSUR as appropriate."
    },
    {
        "instruction":"已知信息：\n'（六）相关生产操作或活动、工艺参数及控制范围，以及所 用主要生产设备的编号；'可被翻译为：6. Any relevant processing operation or event, process parameters and control limits, and the reference number of major equipment used;\n'1.对生产场所和所用设备的说明（如操作间的位置和编号、洁净度级别、必要的温湿度要求、设备型号和编号等）；'可被翻译为：1) A statement of the processing location and the equipment to be used (e.g. operation room's location and reference number, cleanliness level, necessary temperature and humidity requirements, equipment type and reference number);\n'对于工艺参数范围较窄并固定设备的生产操作，仅用现 有的生产数据可能无法论证工艺参数操作范围的放大或了 解多参数之间的相互作用，可能需要进行其他研究来开发设 计空间。'可被翻译为：For manufacturing operations run under narrow operational ranges in fixed equipment, an expanded region of operation and an understanding of multi-parameter interactions may not be achievable from existing manufacturing data alone and additional studies may be needed to develop a design space.\n'1.对生产场所和所用设备的说明（如操作间的位置和编号、 洁净度级别、必要的温湿度要求、设备型号和编号等）；'可被翻译为：1) A statement of the processing location and the equipment to be used (e.g. operation room's location and reference number, cleanliness level, necessary temperature and humidity requirements, equipment type and reference number);\n\n根据上述已知信息，请将'6.相关生产操作或活动、工艺参数及控制范围，以及所用主要生产设备的编号。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"6. Any relevant processing operation or event, process parameters and control limits, and the reference number of major equipment used;"
    },
    {
        "instruction":"已知信息：\n'3. 药品审评质量管理规范办公室'可被翻译为：3. Office of Good Clinical Practice\n'理事办公室，药品临床试验质量管理规范办公室'可被翻译为：Office of the Commissioner, Office of Good Clinical Practice\n'药品临床试验质量管理规范办公室'可被翻译为：Office of Good Clinical Practice\n'药品审评质量管理规范办公室（OGCP）是在FDA监管临床试验中出现的HSP和GCP问题的FDA内部联络点。'可被翻译为：The Office of Good Clinical Practice (OGCP) is the focal point within FDA for HSP and GCP issues arising in clinical trials regulated by FDA.\n\n根据上述已知信息，请将'（3） 药品审评质量管理规范办公室；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(3) Office of Good Clinical Practice;"
    },
    {
        "instruction":"已知信息：\n'制剂和辅料来源可能影响治疗蛋白的免疫原性。'可被翻译为：The formulation and the source of excipients may influence the immunogenicity of therapeutic proteins.\n'SCIg被用作替代疗法，来治疗原发性和继发性免疫缺陷综合症。'可被翻译为：SCIg is used as replacement therapy for the treatment of primary and secondary immunodeficiencies.\n'代表着内源性蛋白对应物的治疗蛋白的免疫应答会导致出现针对内源性蛋白的交叉反应性，如果在内源性蛋白不断合成的情况下。'可被翻译为：An immune response to a therapeutic protein representing a counterpart to an endogenous protein may result in cross-reactivity, directed to the endogenous protein in cases where endogenous protein is still produced.\n'是否畸形PUP临床试验取决于因子VIII制品的类型（如为延长半衰期而进行改造的新重组蛋白）。'可被翻译为：Clinical trials in PUPs are  required depending on the type of factor VIII product (e.g. novel modified recombinant proteins to  extend half-life).\n\n根据上述已知信息，请将'当在患者缺乏天然因子的情况下将治疗蛋白用于替代内源性蛋白时（例如VIII因子；酶替代疗法），生理性抗原可能代表着某种新抗原，免疫系统会将治疗蛋白判读为异物或非自身蛋白。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"When the therapeutic protein is used for substitution of an endogenous protein (e.g. factor VIII; enzyme replacement) where the patient is deficient of the natural counterpart, the physiological antigen may represent a neo-antigen and the immune system will interpret the therapeutic protein as foreign or non-self."
    },
    {
        "instruction":"已知信息：\n'2B类元素丰度较低并且与其他物料共生的可能性较低，因此出现在药品中的概率较低。'可被翻译为：Class 2B elements have a reduced probability of occurrence in the drug product related to their low abundance and low potential to be co-isolated with other materials.\n'除非有意添加这些元素，否则在口服给药途径的风险评估中不需考虑。'可被翻译为：For oral routes of administration, unless these elements are intentionally added, they do not need to be considered during the risk assessment.\n'3 如非有意添加，在风险评估中不需要考虑皮肤给药途径PDE大于500 μg\/day的3类元素 （见ICH Q3D第4章）。'可被翻译为：3 Class 3 elements with a cutaneous PDE above 500 μg\/day do not have to be included in the risk assessment unless intentionally added (see section 4 of ICH Q3D)\n'在风险评估中需要考虑的非有意添加的元素 1,2,3'可被翻译为：Include in Risk Assessment if not intentionally added 1,2,3\n\n根据上述已知信息，请将'2 如非有意添加，2B类元素出现在药品中的概率较低，在口服、注射和吸入药品评估中不 需要考虑（见ICH Q3D第4章）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2 Class 2B elements were excluded from the assessment of oral, parenteral and inhalation products due to the low likelihood that they would be present if not intentionally added (see section 4 of ICH Q3D)."
    },
    {
        "instruction":"已知信息：\n'使用含2 µg\/mL放线菌素D的试验培养基，制备每ml含1x10 6 个细 胞的WEHI-164细胞悬液。'可被翻译为：Prepare a suspension of WEHI-164 cells containing 1x106 cells per millilitre, using assay medium containing 2 µg\/mL of actinomycin D\n'WEHI-164细胞（ATCC）、适当浓度的TNF-α溶液、试验和培养基质 包括组分和浓度 - 放线菌素D、四唑盐WST-8'可被翻译为：WEHI-164 cells (ATCC), TNF-alpha solution of suitable concentration, assay and culture medium including components and concentrations- Actinomycin D, Tetrazolium salt WST-8\n'细胞离心后，立即从细胞沉淀中除去培养基，并通过缓慢添加预冷的冻存培养基轻轻重悬细胞。根据活细胞数量和目标细胞浓度（通常，细胞库活细胞密度大约1×107个细胞\/ mL），立即用适当体积的冷冻保存介质稀释细胞悬液。如上一节所述，冷冻储藏介质是高渗的，应限制暴露时间。将最终的细胞悬浮液转移到一个容器中，在小瓶灌装期间可以在其中轻轻混合细胞，促进细胞库的均匀性。'可被翻译为：Immediately following centrifugation of cells, growth medium is removed from cell pellets,and cells are gently resuspended by slow addition of cryopreservation medium that is often precooled for many cell types. The cell suspension is immediately diluted with an appropriate volume of cryopreservation medium based on viable cell count and targeted cell density (typically, cell banks are produced at aviable cell density of approximately 1 × 107 cells\/mL). As mentionedin the previous section, cryopreservation medium is highly hypertonic, and exposure time should be limited. The\n'在规定培养条件下扩增MCB获得匀质的细胞悬液，并经分装成多个等份制备而成。'可被翻译为：The WCB is prepared from aliquots of a homogeneous suspension of cells obtained from culturing the MCB under defined culture conditions.\n\n根据上述已知信息，请将'使用含2 µg\/mL放线菌素 D的试验培养基制备含 1x10 6 个细胞\/mL的WEHI- 164细胞悬液。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Preparation of a suspension of WEHI-164 cells containing 1x106 cells per millilitre, using assay medium containing 2 µg\/mL of actinomycin D."
    },
    {
        "instruction":"已知信息：\n'一项多中心研究是根据共同研究方案进行的单一试验，涉及到几家研究中心（如诊所、医院），其中收集的数据旨在作为一个整体进行分析（而不是将事后根据将不同研究中 的数据或结果结合在一起得出结论）。'可被翻译为：A multicentre study is a single study under a common protocol, involving several centres (e.g., clinics, practices, hospitals) where the data collected are intended to be analysed as a whole (as opposed to a post-hoc decision to combine data or results from separate studies).\n'多中心试验 是指多个研究者在多个场所按同一个方案实施的临床 试验。'可被翻译为：Multicentre Trial A clinical trial conducted according to a single protocol but at more than one site, and therefore, carried out by more than one investigator.\n'可 是，很多试验会更复杂一些，例如，一个研究者可能从几家 医院招募受试者；一个研究者可能代表一个临床医生团队 （参与研究者），他们或从一家医院所辖的几个诊所，或从几 家相关的医院招募受试者。'可被翻译为：In many trials, however, the situation is more complex. One investigator may recruit subjects from several hospitals; one investigator may represent a team of clinicians (subinvestigators) who all recruit subjects from their own clinics at one hospital or at several associated hospitals.\n'由多位研究者按同一试验方案在不同地点和单位同时进行的临床试验。各中心同期开始与结束试验。多中心试验由一位主要研究者总负责，并作为临床试验各中心间的协调研究者。'可被翻译为：A clinical trial conducted simultaneously by multiple investigators in different locations and units under the same experimental protocol. Each center starts and ends the trial at the same time. Multicenter trials are led by a principal investigator who acts as the coordinating investigator between clinical trial centers.\n\n根据上述已知信息，请将'最简单的多中心试验是每位研究者负责在一家医院招 募受试者，所以，“中心”是由研究者或医院唯一确定的。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In the simplest multicentre trial, each investigator will be responsible for the subjects recruited at one hospital, so that ‘centre’ is identified uniquely by either investigator or hospital."
    },
    {
        "instruction":"已知信息：\n'在这种情况下，在 提交PBRER时，只需要更新包含新信息或新评估的模块。'可被翻译为：In these circumstances, only modules that include new information or new evaluation would need to be updated when submitting the PBRER.\n'如果监管机构允许，部分下列附录无需与报告一同提供， 仅需根据要求提供。'可被翻译为：Where permitted by the regulatory authority, some of the following appendices need not be submitted with the report but need to be provided only on request.\n'特定章节的考虑事项： 章节15：信号概述 MAH应在汇总表中提供在报告期内正在进行和关闭的信号的概述。'可被翻译为：Considerations for Specific Sections: Section 15: Overview of Signals The MAH should provide in a summary table an overview of signals ongoing and closed in the reporting interval.\n'在累积信息的背景下中，PBRER应包含与报告期内MAH可获 得的药品相关新信息的评估，该评估通过以下方式进行：'可被翻译为：The PBRER should contain an evaluation of new information relevant to the medicinal product that became available to the MAH during the reporting interval, in the context of cumulative information by:\n\n根据上述已知信息，请将'在PBRER中需要报告的情况下，应在区域附录中提供在报告期内获得的 仅与该区域相关的评估结果。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"When required for reporting in a PBRER, results of evaluations that are relevant to only one region and that became available during the reporting interval should be provided in regional appendices."
    },
    {
        "instruction":"已知信息：\n'不应提交新的会议申请， 而重新安排的会议不应设定新的时间框。'可被翻译为：A new meeting request should not be submitted and  new time frames should not be set for rescheduled meetings.\n'此时，FDA并不提议在采用电子医疗保健数据的药物流行病学 安全性研究的报告时任何这些文件采用一个特定格式。'可被翻译为：At this time, FDA is not proposing a specific format for any of these documents when reporting on pharmacoepidemiologic safety studies that use electronic healthcare data.\n'然而，若申办方或申请人提供新数据或修改后的或新的建议， FDA或许不能对新数据提出意见， 可能因此需要申办方或申请人提出新的会议申 请。'可被翻译为：If, however, a sponsor or applicant provides new data or a revised or new proposal, the FDA may not be able to provide comments on the new data or it may generate the need for the submission of a new meeting request by the sponsor or  applicant.\n'若演讲所包含的不仅仅是小部分的新数据， 这些新数据有别于以往数据的说明或解释， 而且没有纳入原先提交给 CBERE 或 CDER 评审的会议资料包， FDA 人员或许未能对新数据提出意见。'可被翻译为：If a presentation  contains more than a small amount of new data that are distinct from clarifications or  explanations of previous data and that were not included in the original meeting package submitted to CBER or CDER for review, FDA staff may not be able to provide comments on the  new data.\n\n根据上述已知信息，请将'在会议期间，申办方通常不应询问未包括在会议文件包或以前未提供给FDA或FDA在其初步意见中未要求的现有新数据或信息中的实质性问题。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"During the course of the meeting, sponsors should generally not ask substantive questions that were not included in the meeting package, or present new data or information that was not previously provided to FDA or requested by FDA in their preliminary comments."
    },
    {
        "instruction":"已知信息：\n'标示量的80%或接受 标准下限的80%'可被翻译为：80% of declared content or 80% of lower specification acceptance criterion\n'获得的CV必须小于或等于预设的可接受值'可被翻译为：The CV obtained must be less than or equal to a pre-defined acceptable value\n'CI – 置信区间'可被翻译为：CI – Confidence Interval\n'可报告范围内各水平下平均中间精密度的95%置信区间 上限（95% CI%几何变异系数）不超过20% 1） 。'可被翻译为：Upper 95% confidence interval for the average intermediate precision across levels across the reportable range (95% CI % geometric coefficient of variation) is not more than 20%1)\n\n根据上述已知信息，请将'建议申请人不要舍去置信区间(CI)的有效位数；因此，要达到80%到125%的标准，CI的数值不得低于80.00%，且不超过125.00%。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"We recommend that applicants not round off CI values; therefore, to pass a CI limit of 80 to 125 percent, the value would be at least 80.00 percent and not more than 125.00 percent."
    },
    {
        "instruction":"已知信息：\n'2.原液应提前在适当的条件下分装，包装材料与进口材料一只。应尽量选取小的包装规格，以避免样品的污染，并保证各项实验的进行。'可被翻译为：2.The raw liquid should be sub-packaged in advance, under proper conditions, with packaging materials consistent with those to be imported as applied. Small packaging specifications should be selected as far as possible to avoid sample contamination and ensure the proper progress of each test.\n'（二）应完整保存可追溯的受试物和对照品的接收、配制、分析(如均一性、浓度、稳定性等)、使用、返还等记录，并与申报资料一致。如：'可被翻译为：(2) Records of receipt, formulating, analysis (such as homogeneity, concentration, stability, etc.), use and return of the test\/control articles should be retained completely and traceably and should be consistent with those in the application dossiers. For example:\n'2.所需全部包装材料的完整清单，包括包装材料的名称、数量、规格、类型以及与质量标准有关的每一包装材料的代码；'可被翻译为：2) A complete list of all the packaging materials required for a standard batch size, including name, quantities, sizes and types, with the code or reference number relating to the specifications of each packaging material;\n'第四十二条 药品制剂申请人提出药品注册申请，可以直接选用已登记的化学原料药、辅料及直接接触药品的包装材料和容器；选用未登记的化学原料药、辅料及直接接触药品的包装材料和容器的，相关研究资料应当随药品制剂注册申请一并申报。'可被翻译为：Article 42 When submitting a drug registration application, the drug product applicant may directly select chemical active drug ingredients, excipients and primary packaging materials and containers that have been registered; where chemical active drug ingredients, excipients and primary packaging materials and containers that have not been registered are selected, relevant study data shall be submitted together with the drug registration application.\n\n根据上述已知信息，请将'2.原料药应提前在适当的条件下选用与申报进口包装材料一致的包装材料进行分装后送样，应尽量选取小的包装规格，避免样品污染，保证各项实验的进行。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2.The sample APIs should be sub- packaged in advance, under proper conditions, with packaging materials consistent with those to be imported as applied. Small packaging specifications should be selected as far as possible to avoid sample contamination and ensure the proper progress of each test."
    },
    {
        "instruction":"已知信息：\n'批签发申请人应当立即采取停止销售、使用，召回缺陷产品等措施，并按照有关规定在药品监督管理部门的监督下予以销毁。批签发申请人将销毁记录同时报药品监督管理部门和相应的批签发机构。'可被翻译为：The lot release applicant shall immediately take measures such as stopping the sale and use and recalling the defective products, and destroy them under the supervision of the drug regulatory departments in accordance with relevant provisions. The lot release applicant shall report the destruction records to the drug regulatory departments and the corresponding lot release institution simultaneously.\n'第三十二条    在批签发工作中发现企业产品存在质量问题或者其他安全隐患，涉及已上市流通批次的，批签发机构应当立即通报批签发申请人所在地和生产场地所在地省、自治区、直辖市药品监督管理部门；涉及进口生物制品的应当通报进口口岸所在地省、自治区、直辖市药品监督管理部门。接到通报的药品监督管理部门立即通知批签发申请人。'可被翻译为：Article 32 If the product is identified to have any quality or other potential safety issues, involving the batches already marketed or circulated, the lot release institution shall immediately report to the drug regulatory departments of provinces, autonomous regions or municipalities directly under the Central Government where the lot release applicant is located and where the production site is located; if the imported biological product is involved, the lot release institution shall notify the drug regulatory departments of provinces, autonomous regions or municipalities directly under the Central Government where the import port is located. The drug regulatory departments receiving the notification shall immediately notify the lot release applicant.\n'批签发申请人应当将销毁记录同时报食品药品监督管理部门和相应的批签发机构。'可被翻译为：The lot release applicant shall also report the destruction records to the food and drug regulatory departments and the corresponding lot release institution simultaneously.\n'第三十一条 不予批签发或者撤回批签发的生物制品，由所在地省、自治区、直辖市药品监督管理部门按照有关规定监督批签发申请人销毁。不予批签发或者撤回批签发的进口生物制品由口岸所在地药品监督管理部门监督销毁，或者依法进行其他处理。'可被翻译为：Article 31 Biological products of which lot release is disapproved or withdrawn shall be destroyed by the lot release applicant in accordance with relevant regulations under the supervision of the local drug regulatory departments of  provinces, autonomous regions or municipalities directly under the Central Government. The imported biological product of which lot release is disapproved or withdrawn shall be destroyed under the supervision of the drug regulatory departments in the place where the import port is located or be disposed according to law.\n\n根据上述已知信息，请将'第三十一条 在批签发工作中发现企业产品存在严重缺陷，涉及已上市流通批次的，食品药品监管总局应当立即通知批签发申请人，批签发申请人应当及时采取停止销售、使用、召回缺陷产品等措施，并按照有关规定在省、自治区、直辖市食品药品监督管理部门的监督下予以销毁。批签发申请人应当将销毁记录同时报食品药品监督管理部门和相应的批签发机构。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 31 Where the product of the enterprise is identified to have serious defects in the lot release, involving the batches that have already been marketed and distributed, the CFDA shall immediately notify the lot release applicant. The lot release applicant shall immediately take such measures as stopping the sales and use and recalling the defective products and destruct them in accordance with relevant regulations and under the supervision of the food and drug regulatory departments of the provinces, autonomous regions and municipalities directly under the Central Government. The lot release applicant shall also report the destruction records to the food and drug regulatory departments and the corresponding lot release institution simultaneously."
    },
    {
        "instruction":"已知信息：\n'毒性试验中的给药方案决定了暴露特征，这在风险评估中很重要。'可被翻译为：Dosing schedules used in the toxicity studies determine the exposure profile, which can be important in the risk assessment.\n'安全性数据的收集、分析和报告 应岁所有的毒性（包括蓄积毒性）进行描述。'可被翻译为：Safety data collection, analysis and reporting All toxicity should be described, including cumulative toxicity.\n'毒性安全限度'可被翻译为：Safety Limiting Toxicity\n'依据可获得的数据，吸入途径的PDE值既可以局部毒性（呼吸系统）为基础，也可以全身毒性为基础。'可被翻译为：Depending on available data, inhalation PDEs were based on either local (respiratory system) or systemic toxicity.\n\n根据上述已知信息，请将'以给药途径为基础对数据进行总结来确定毒性安全限度。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The data was reviewed to identify the safety limiting toxicities based on routes of administration."
    },
    {
        "instruction":"已知信息：\n'个例安全报告电子传输的信息传输规范 个例执行指导原则 （ICH ICSR消息版本3.96）'可被翻译为：Electronic Transmission of Individual Case Safety Reports Message Specification Implementation Guide (ICH ICSR Message Version 3.96)\n'个例安全报告个例（ICSRs）电子传输的执行 指导原则 数据元素和信息规范元素'可被翻译为：Electronic Transmission of Individual Case Safety Reports (ICSRs) Implementation Guide Data Elements and Message Specification\n'个例安全报告电子传输的执行指导原则 数据元素和信息规范个例元素'可被翻译为：Electronic Transmission of Individual Case Safety Reports Implementation Guide Data Elements and Message Specification\n'个例安全报告电子传输的信息传输规范个例 （ICH ICSR DTD v2.1）'可被翻译为：Electronic Transmission of Individual Case Safety Reports Message Specification (ICH ICSR DTD v2.1)\n\n根据上述已知信息，请将'个例安全报告（ICSR）电子传输执行指导原则'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Implementation Guide for Electronic Transmission of Individual Case Safety Reports (ICSRs)"
    },
    {
        "instruction":"已知信息：\n'某些情况下，某杂质同时也是原料药的代谢产物。此时对代谢产物的致突变风险评估可作为该杂质限度制订的依据。'可被翻译为：There may be cases when an impurity is also a metabolite of the drug substance. In such cases the risk assessment that addresses mutagenicity of the metabolite can qualify the impurity.\n'• 已鉴定的实际存在的杂质应考虑其潜在致突变性。'可被翻译为：• Actual impurities that have been identified should be considered for their mutagenic potential.\n'o 如果对杂质进行了细菌致突变试验，应提交杂质细 菌致突变试验的研究报告。'可被翻译为：o When bacterial mutagenicity assays were performed on impurities, study reports should be provided for bacterial mutagenicity assays on impurities.\n'本指南是在已建立的风险评估策略的基础上，制订致突变 杂质的可接受摄入量。'可被翻译为：This guideline bases acceptable intakes for mutagenic impurities on established risk assessment strategies.\n\n根据上述已知信息，请将'在这种情况下，对代谢产物的 致突变风险评估可以界定该杂质。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In such cases the risk assessment that addresses mutagenicity of the metabolite can qualify the impurity."
    },
    {
        "instruction":"已知信息：\n'便秘是儿童常见疾病，占普通儿科医生临床应诊的 3%，儿科消化疾病的 25-30%。'可被翻译为：Constipation in childhood is considered to be a common condition, which accounts for 3% of all consultations of general paediatricians, and 25-30% of paediatric gastroenterologists.\n'儿童期便秘被视为是一种常见现象， 占普通儿科就诊的 3%，占儿科胃肠道 疾病就诊的 25-30%75。'可被翻译为：Constipation in childhood is considered to be a common phenomenon, which accounts for 3% of all consultations of general paediatricians, and 25-30% of paediatric gastroenterologists75.\n'然而，最近便秘有了更明确 的定义， 不仅是大便次数减少，还包含了其他的症状， 如大便稠度下降，大便费力以及排便不畅感。'可被翻译为：However, more  recently, constipation is more specifically defined on the basis not only of infrequent stools, but  additional symptoms, such as reduced stool consistency, straining at stool, and sense of incomplete  bowel evacuation.\n'儿童功能性便秘的诊断可参考儿童便秘巴黎共识（PACCT）和罗马 III 标准，包括：必须满足下列至少2项，且诊断前症状持续至少2 个月：'可被翻译为：The definition of childhood functional constipation is based on the “Paris Consensus on Childhood Constipation Terminology (PACCT) Group, and the Rome III criteria , which include both the following: Must include 2 or more of the following criteria for at least 2 months before diagnosis:\n\n根据上述已知信息，请将'儿童器质性便秘很少见，且 95%的儿童便秘是“功能性”的。由于在排便过程 受干扰、憋大便等行为原因引起粪便嵌塞，最后溢出致大便失禁。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"While organic causes for constipation are rare, and usually detected in early childhood, 95% of childhood constipation is thought to be “functional” on the basis of a learned behaviour of interruption of the defecation process with stool-withholding cycles leading to constipation, faecal impaction, and finally overflow faecal incontinence."
    },
    {
        "instruction":"已知信息：\n'将对主要分析进行几项敏感性分析，这些分析并不基于相同的假设。'可被翻译为：The primary analysis will also have to be accompanied by several sensitivity analyses, not all of which should be based on the same assumptions.\n'如果申办方和监管机构 就所关注的主要估计目标达成一致，并预先明确规定了主估计方 法，且敏感性分析也验证了估计值的结果解释是可靠的，则补充 分析在结果评估中通常不被优先考量。'可被翻译为：Where the primary estimand(s) of interest is agreed between sponsor and regulator, the main estimator is pre-specified unambiguously, and the sensitivity analysis verifies that the estimate derived is reliable for interpretation, supplementary analyses should generally be given lower priority in assessment.\n'对应于特定估计目标的缺失数据，以及与特 定估计目标不直接相关的数据，两者之间存在区别，由此在分析 中产生了不同类别的假设，需要通过敏感性分析来检查。'可被翻译为：The distinction between data that are missing in respect of a specific estimand and data that are not directly relevant to a specific estimand gives rise to separate sets of assumptions to be examined in sensitivity analysis.\n'建议采用敏感性分析，通过放松主要分析的假定缺失数据机制检验意向治疗人群中主要分析结果的稳健性。'可被翻译为：Sensitivity analyses are recommended to test the robustness of the primary analysis results in the intent-to-treat population and by relaxing the assumed missing data mechanism of the primary analysis.\n\n根据上述已知信息，请将'应该进行一系列敏感性分析，从而证明主要分析对终止和缺失数据不敏感。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Appropriate sensitivity analyses should be performed to demonstrate that the primary analysis is robust to discontinuation and missing data."
    },
    {
        "instruction":"已知信息：\n'钼以多种形式存在于土壤中，含量为0.1~10 mg\/kg。'可被翻译为：Mo exists in soil in various forms at concentration of 0.1-10 mg\/kg.\n'钼'可被翻译为：MOLYBDENUM\n'锂（Li）是一种广泛存在于动、植物组织中的金属元素。'可被翻译为：Lithium (Li) is a common metal that is present in plant and animal tissues.\n'钼主要以钼 酸根离子（MoO4 2-）的形式存在于土壤及天然水中，MoO4 2-可与多种阳离子如K+、 NH4+和Ca2+形成可溶性的化合物。'可被翻译为：The predominant form of Mo occurring in soils and natural waters is the molybdate ion, MoO4 2- which forms soluble compounds with a variety of cations including K+, NH4 + and Ca2+.\n\n根据上述已知信息，请将'钼广泛存在于蔬菜、乳制品和肉类中。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"It is widely present in vegetables, dairy products and meats."
    },
    {
        "instruction":"已知信息：\n'如果使用假设检验，对多重性的统计调整以量化I类错 误是合适的，但是II类错误通常更值得关注。'可被翻译为：If hypothesis tests are used, statistical adjustments for multiplicity to quantify the type I error are appropriate, but the type II error is usually of more concern.\n'单侧或双侧检验的I类错误选择有所不同。'可被翻译为：The choice of type I error should be a consideration separate from the use of a one-sided or two-sided procedure.\n'因为存在潜在的多重性问题，所以应解释 对I类错误的影响（见第5.6章节），也应在方案中给出控制 I类错误的方法。'可被翻译为：The effect on the type I error should be explained because of the potential for multiplicity problems (see Section 5.6); the method of controlling type I error should be given in the protocol.\n'在层1中，所有零假设按I类错误水平α=0.05来 评估，不会按假设的数量来调整；这遵循关闭检验原则。'可被翻译为：In Tier 1, all the null hypotheses are evaluated at the Type I error level of α-level = 0.05 without adjusting for the number of hypotheses; this follows from the closed testing principle.\n\n根据上述已知信息，请将'通常I类错误概率设 在5%或者更小，或者由多重比较所需要的任何调整来决定； 检验假设的事先合理性以及结果的预期影响可能会影响I类 错误的精确选择。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Conventionally the probability of type I error is set at 5% or less or as dictated by any adjustments made necessary for multiplicity considerations; the precise choice may be influenced by the prior plausibility of the hypothesis under test and the desired impact of the results."
    },
    {
        "instruction":"已知信息：\n'洁净室和洁净空气设备的确认'可被翻译为：Cleanroom and clean air equipment qualification\n'关键的生产工艺和操作规程应当定期进行再验证，确保其能 够达到预期结果。'可被翻译为：Critical manufacturing processes and operation procedures should be revalidated at defined intervals to ensure the intended outcome.\n'洁净室和洁净空气设备的确认是评估分级的洁净室或洁净空气设备与其预期用途的符合程度的整体过程。\n作为附录 15 的确认要求的一部分，洁净室和洁净空气设备的确认应包括（与设施的设计\/运行相关的）：'可被翻译为：Cleanroom and clean air equipment qualification is the overall process of assessing the level of compliance of a classified cleanroom or clean air equipment with its intended use. As part of the qualification requirements of Annex 15, the qualification of cleanrooms and clean air equipment should include (where relevant to the\ndesign\/operation of the installation):\n'应使用符合附录 15 要求的方法对洁净室和洁净空气设备进行确认。洁净室确认（包括分级）应与动态环境监测明确区别开来。'可被翻译为：Cleanrooms and clean air equipment should be qualified using methodology in accordance with the requirements of Annex 15. Cleanroom qualification (including classification) should be clearly differentiated from operational environmental monitoring.\n\n根据上述已知信息，请将'洁净室和洁净空气设备的再确认应按照规定的程序定期执行。再确认应至少包括以下内容：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The requalification of cleanrooms and clean air equipment should be carried out periodically following defined procedures. The requalification should include at a minimum the following:"
    },
    {
        "instruction":"已知信息：\n'基于目视检查的能力，并有充分的清洁研究支持性数据（例如，分析检测来证明清洁有效性）时，对专用设备采用“目测清洁”是可能被接受的【ICHQ7，第12.76章节】。'可被翻译为：‘Visually clean’ may be acceptable for dedicated equipment based on the ability to visually inspect and sufficient supporting data from cleaning studies (e.g., analytical determination to demonstrate cleaning effectiveness) [ICH Q7, Section 12.76].\n'5.5 更换品种时，是否需要同时采用目视检查和分析测试来确认设备是清洁的？（2015年6月）'可被翻译为：5.5 June 2015 At product changeover, are both visual examination and analytical testing necessary to verify that equipment is clean?\n'5.3 是否期望在清洁验证时确认设备清洁时限？（2015年6月）'可被翻译为：5.3 June 2015 Is it expected that equipment cleaning time limits be confirmed in cleaning validation?\n'5.2 专用设备还要规定残留物的可接受标准吗？（2015年6月）'可被翻译为：5.2 June 2015 Should acceptance criteria for residues be defined for dedicated equipment?\n\n根据上述已知信息，请将'5.1对于专用设备，在清洁有效性确认中使用“目测清洁”是否可接受（即无需专属的分析检测）？（2015年6月）'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"5.1 June 2015 For dedicated equipment, is ‘visually clean’ acceptable for verification of cleaning effectiveness, (i.e., no expectation for specific analytical determination)?"
    },
    {
        "instruction":"已知信息：\n'第四条 持有人是药品上市后变更管理的责任主体，应当按照药品监管法律法规和药品生产质量管理规范等有关要求建立药品上市后变更控制体系；根据国家药品监督管理局有关技术指导原则和国际人用药注册协调组织（ICH）有关技术指导原则制定实施持有人内部变更分类原则、变更事项清单、工作程序和风险管理要求，结合产品特点，经充分研究、评估和必要的验证后确定变更管理类别。'可被翻译为：Article 4 MAHs are the main body of responsibility for the management of post-approval changes of drugs. MAHs shall establish a post-approval change control system in accordance with the laws and regulations on drug supervision, the Good Manufacturing Practice for Drugs and other relevant requirements; formulate and implement the principle for internal classification of changes, list of changes, working procedures and risk management requirements of MAH in accordance with the relevant technical guidelines of NMPA and ICH; and determine the change management category after sufficient study, evaluation and necessary verification in combination with product characteristics.\n'各省级药品监管部门应当落实辖区内药品上市后变更监管责任，细化工作要求，制定工作文件，明确工作时限，药品注册管理和生产监管应当加强配合，互为支撑，确保药品上市后变更监管工作平稳有序开展。'可被翻译为：Each provincial drug regulatory department shall implement the responsibility for supervision over change management of post-approval drugs at its administrative area, by specifying requirements, formulating working documents, and clarifying time limits. The cooperation between drug registration administration and production supervision should be consolidated for mutual support, to ensure the smooth and orderly implementation of change management of post-approval drugs.\n'受让方所在地省级药品监管部门应当重点加强对转让药品的监督检查，及时纳入日常监管计划。'可被翻译为：The provincial drug regulatory department where the transferee is located shall focus on strengthening the supervision and inspection on the transferred drugs, and include them in the routine supervision plan in a timely manner.\n'委托双方不在同一个省的，受托方应当通过所在地省级药品监管部门对受托方生产药品的车间和生产线的现场检查，配合持有人提供相关申请材料。持有人所在地省级药品监管部门应当对持有人提交的申请材料进行审查，并结合受托方所在地省级药品监管部门出具的现场检查结论，作出持有人变更生产地址或者生产范围的决定。'可被翻译为：Where the entrusting parties are not in the same province, the trustee shall pass the on-site inspection of the drug production workshop and production line through the local provincial drug administration department, and cooperate with the holder to provide relevant application dossiers. The provincial drug administration department where the holder is located shall review the application dossiers submitted by the holder and make a decision to change the production address or production scope in accordance with the on-site inspection conclusion issued by the provincial department where the trustee is located.\n\n根据上述已知信息，请将'第三十条 持有人和受托生产企业所在地省级药品监管部门应当按照药品生产监管的有关规定加强对药品上市后变更的监督管理，对持有人变更控制体系进行监督检查，督促其履行变更管理的责任。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 30 The provincial drug regulatory department in the place where the MAHs and contract manufacturers are located shall strengthen the supervision and administration of post-approval changes of drugs in accordance with the relevant provisions for drug production supervision, supervise and inspect the MAHs' change control system, and urge them to fulfill their responsibilities for change management."
    },
    {
        "instruction":"已知信息：\n'● 一个身份可识别的患者-几个数据元素中认为足以定义可识别的患者的任何一个元素（例如姓名首字母缩写、年龄、性别）；'可被翻译为：• one identifiable patient - any one of several data elements is considered sufficient to define an identifiable patient (e.g. initials, age, sex);\n'几个数据元素中的任意一个即可定义一个身份可识别的患者几个数据元素中的任意一个即可定义一个身份可识别的患者（例如姓名首字母缩写、年龄和性别）或一个身份可识别的报告者（例如姓名首字母缩写、地址和资格）。'可被翻译为：Any one of several data elements is sufficient to define an identifiable patient (e.g. initials, age, and sex) or an identifiable reporter (e.g. initials, address, and qualification).\n'用户指导原则 根据该数据元素获取报告者街道地址的姓名。'可被翻译为：User Guidance This data element captures the reporter's street name.\n'但是，对于每个主要来源应至少完成一个小节，以确保其为一个可识别的报告者。'可被翻译为：However, at least one subsection for each Primary Source should be completed to ensure that it is an identifiable reporter.\n\n根据上述已知信息，请将'● 一个身份可识别的报告者-几个数据元素中认为足以定义可识别的报告者的任何一个元素（例如姓名、地址、资质）；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"• one identifiable reporter - any one of several data elements is considered sufficient to define an identifiable reporter (e.g. initials, address, qualifications);"
    },
    {
        "instruction":"已知信息：\n'5 采用美国国立癌症研究所的通用不良事件术语标准（CTCAE），U.S.健康与人类服务部门，美国国立卫生 研究院、美国国立癌症研究院描述的分级系统用于癌症试验中的不良事件。4级不良事件是导致需要救生 紧急干预的事件；3级不良事件可导致严重或临床重要但不会立刻危及生命的结果；需要住院或住院期延 长；伤残；导致洗澡、穿衣、脱衣、饮食、上厕所、服药能力受限；和2级事件导致需要中度、最低、或 局部或侵入性干预；导致相应年龄的做饭、在杂货店和\/或服装店购买、使用电话、管理财物的能力受限。'可被翻译为：5 Using the grading system for adverse events in cancer trials described in the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE), U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. A Grade 4 adverse event results in need for life-saving urgent intervention; a Grade 3 adverse event results in severe or clinically significant but not immediately life-threatening consequences; hospitalization or prolonged hospitalization needed; disabling; results in limitations on ability to bathe, dress, undress, feed, use toilet, take medications; and a Grade 2 event results in need for moderate, minimal, or local or invasive intervention; results in limitations on age appropriate ability to prepare meals, grocery, and\/or clothes shop, use the telephone, manage money.\n'应根据 通常的分级系统，例如美国国家癌症研究所（NCI）的不良事件常用术语标准（CTCAE） 对毒性进行分级。'可被翻译为：The toxicity should be graded according to a generally recognised system, e.g. the National Cancer Institute’s (NCI) Common Terminology Criteria for Adverse Events (CTCAE).\n'国立卫生研究院'可被翻译为：National Institute of Health (www.nih.gov)\n'FDA 地区术语集支持U.S.国立癌症研究所（NCI），EVS，和 FDA 内部物质注册系统（SRS）（还包括其他）的控制术语集。'可被翻译为：FDA regional terminology supports the controlled terminology of the U.S. National Cancer Institute (NCI), the EVS, and the FDA internal Substance Registration System (SRS) (among others).\n\n根据上述已知信息，请将'5采用美国国立癌症研究所的通用不良事件术语标准（CTCAE），U.S.健康与人类服务部门，美国国立卫生 研究院、美国国立癌症研究院描述的分级系统用于癌症试验中的不良事件。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"5 The grading system was used for adverse events in cancer trials described in the Common Terminology Criteria for Adverse Events document from the National Cancer Institute (U.S. Department of Health and Human Services’ National Cancer Institute at the National Institutes of Health)."
    },
    {
        "instruction":"已知信息：\n'某些情况下，动物试验可能需要调整以适应人体中的复杂情况，以处理二者的差异性（例如相关基因核酸序列的差异）。'可被翻译为：There might be the situation that the assay of animal studies has to be adapted to the human situation to cope with respective differences, e.g. the nucleic acid sequence differences of the gene of interest.\n'对治疗蛋白产生的免疫应答较为复杂，除形成抗体外，T细胞激活或固有免疫应答对潜在不良作用有所贡献。'可被翻译为：This immunological response to therapeutic proteins is complex and, in addition to antibody formation, T cell activation or innate immune responses could contribute to potential adverse effects.\n'对于离体基因修饰细胞（即离体细胞经转导\/转染方法进 行基因修饰后用于动物\/人受试者）组成的GT产品，BD评价的考虑因素应包括细胞类型、ROA、表达产物或基因修饰 对细胞体内预期分布的潜在影响（例如，新的或改变的细胞粘附分子表达）等。'可被翻译为：Considerations for BD assessment of GT products that consist of ex vivo genetically modified cells (i.e., cells that are transduced\/transfected ex vivo and then administered to the animal\/human subject) should include factors such as the cell type, ROA, and the potential for the expression product or gene modification event to affect the expected distribution of the cells within the body (e.g., new or altered expression of cell adhesion molecules).\n'目前完全承认，机构和地区间的异基因造血干细胞 移植标准（例如患者资格、HLA配型、预处理方案、预防移植物抗宿主病等）是有差 异的。'可被翻译为：It is fully acknowledged that criteria for HSCT (e.g. patient eligibility, HLA matching, conditioning regimen, graft versus host disease prevention, etc) vary between institutions and regions.\n\n根据上述已知信息，请将'此外，动物体内可能出现移植物抗宿主病，会使基因修饰人T细胞的BD分析评价复杂化。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In addition, the occurrence of graft versus host disease in animals can complicate interpretation of BD assessment of genetically modified human T cells."
    },
    {
        "instruction":"已知信息：\n'• 业界指南：E2B（R3）个别病例安全性报告（ICSR）执行指引的电子传递 - 数 据元素和信息规范'可被翻译为：• Guidance for Industry: E2B(R3) Electronic Transmission of Individual Case Safety Reports (ICSRs) Implementation Guide – Data Elements and Message Specification\n'• 业界指南 ICH E2B（R3）ICSR执行指引附件I（B）：前后兼容性 补充ICH E2B（R3）IG，并帮助报告者和接受者执行系统，特殊重点是之前标准（ICH E2B（R2））和这一标准（ICH E2B（R3））转换的建议。'可被翻译为：• The guidance for industry Appendix I (B) to the ICH E2B(R3) ICSRs Implementation Guide: Backwards and Forwards Compatibility supplements the ICH E2B(R3) IG, and assists reporters and recipients in implementing systems with a special focus on the recommendations for conversion between the previous standard (ICH E2B(R2)) and this standard (ICH E2B(R3)).\n'ICHE2B(R3)专家工作组\/执行工作组 ICH E2B(R3)指南: 个例安全报告的电子传输(ICSRs)'可被翻译为：ICH E2B(R3) Expert Working Group \/ Implementation Working Group ICH E2B(R3) Guideline: Electronic Transmission of Individual Case Safety Reports (ICSRs)\n'FDA采纳了该指南，并于2014年2月将其发布为FDA业界指南E2B（R3）个别病例安全性报告执行指引的电子传递 一数据 元素和信息规范（ICH E2B（R3）IG）。'可被翻译为：FDA adopted that guideline and in February of 2014 published it as FDA Guidance for Industry E2B(R3) Electronic Transmission of Individual Case Safety Reports Implementation Guide — Data Elements and Message Specification (ICH E2B(R3) IG).\n\n根据上述已知信息，请将'A. 背景 ICH E2B专家工作组（E2B EWG）发布了修订版ICH ICSR电子提交执行指引： 药物警戒性报告指南的E2B（R3）数据元素和信息规范。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A. Background The ICH E2B Expert Workgroup (E2B EWG) released the revised, ICH Implementation Guide for the Electronic Transmission of ICSRs: E2B(R3) Data Elements and Message Specification for pharmacovigilance reporting guideline."
    },
    {
        "instruction":"已知信息：\n'研究者应该在研究方案和最终报告中 讨论选择某种特殊的研究设计的依据。'可被翻译为：Investigators should discuss their rationale for selecting a particular study design in the study protocol and final report.\n'申办方和申请人在尝试联系研究者时应就适当的努力进行合理的判断， 可以包括考虑该研究者在研究中的作用以及该研究者数据贡献的重要性。'可被翻译为：Sponsors and applicants should exercise reasonable judgment regarding the appropriate amount of effort to expend when attempting to contact investigators, which may include consideration of the role of the investigator in the study and the importance of the investigator’s data contribution.\n'设计方面的考虑'可被翻译为：Design consideration\n'答：在许多情况下， IND\/IDE 申办方、第 54 部分申办方和申请人都是同一方。'可被翻译为：A: In many cases, the IND\/IDE sponsor, the part 54 sponsor, and the applicant will be the same party.\n\n根据上述已知信息，请将'答：IND 申办方将需要根据研究大小、设计和其他方面的考虑， 考虑某项给定研究的潜在作用。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A: The IND sponsor will need to consider the potential role of a particular study based on study size, design, and other considerations."
    },
    {
        "instruction":"已知信息：\n'在与利益-风险评估相关的情况下，本章节还应总结临床试验中用于治疗经 批准的适应症的非危及生命的疾病时缺乏有效性的信息。'可被翻译为：When relevant to the benefit-risk evaluation, information on lack of efficacy from clinical trials for treatments of non-life-threatening diseases in approved indications should also be summarised in this section.\n'在安全性说明中，这一节应当介绍尚未被临床数据充分说明 的非临床安全性发现，例如：'可被翻译为：Within the Specification, this section should present non-clinical safety findings that have not been adequately addressed by clinical data, for example:\n'5. 混杂因素及效应调整因素的发现及处理 既未发现也未充分解决的偏倚可能会影响药物流行病学安全性研究的有效性。'可被翻译为：5.Identification and Handling of Confounders and Effect Modifiers Biases that are either unidentified or inadequately addressed can compromise the validity of pharmacoepidemiologic safety studies.\n'应该承认未解决的问题和不确定性。'可被翻译为：Unresolved concerns and uncertainties should be acknowledged.\n\n根据上述已知信息，请将'在临床研究中未发现或未解决的非临床安全性问题；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Non-clinical safety concerns that have not been observed or resolved in clinical studies;"
    },
    {
        "instruction":"已知信息：\n'CAPA 纠正措施和预防措施-用于调查、理解和纠正偏差， 并预防其再次发生的系统。'可被翻译为：CAPA Corrective Action and Preventive Action – System that focuses on investigating, understanding, and correcting discrepancies while attempting to prevent their occurrence\n'•纠正和预防措施（CAPA）系统；'可被翻译为：• Corrective action and preventive action (CAPA) system;\n'（七）任何重大偏差都要充分记录，调查以确定根本原因并采取适当的纠正和预防措施；'可被翻译为：(vii) Any significant deviations are fully recorded, investigated with the objective of determining the root cause and appropriate corrective and preventive action implemented;\n'应以确定根本原因为目的，采用结构化的调查方法。'可被翻译为：A structured approach to the investigation process should be used with the objective of determining the root cause.\n\n根据上述已知信息，请将'预防机制——趋势分析、详细调查、确定根本原因、纠正和预防措施（CAPA）以及对全面调查工具的需求。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Prevention mechanisms - trend analysis, detailed investigation, root cause determination, corrective and preventive actions (CAPA) and the need for comprehensive investigational tools."
    },
    {
        "instruction":"已知信息：\n'从含有抗凝剂的容器中收集的血液中分离细胞成分后，或在单采过程中通过抗凝血的连续过滤和\/或离心分离，用于进一步生产的人体血液的液体部分。'可被翻译为：The liquid part of human blood remaining after separation of the cellular elements from blood collected in a container containing an anticoagulant, or separated by continuous filtration and\/or centrifugation of anticoagulated blood in an apheresis procedure, intended for further manufacturing.\n'从人类血液中提取的任何治疗物质，包括全血、血液成分和血浆来源的药品。'可被翻译为：Any therapeutic substances derived from human blood, including whole blood, blood components and plasma-derived medicinal products.\n'无菌制备和加工'可被翻译为：Aseptic preparation and processing\n'在指定条件下从选定的细胞克隆制备而得的单批细胞，它被分装到多个容器中，并在规定的条件下贮藏。MCB通常用于制备所有的工作细胞库。新旧MCB(源自同一前代细胞克隆)的检测项目应该一致。'可被翻译为：An aliquot of a single pool of cells which generally has been prepared from the selected cell clone under defined conditions, dispensed into multiple containers and stored under defined conditions. The MCB is used to derive all working cell banks. The testing performed on a new MCB (from a previous initial cell clone, MCB or WCB) should be the same as for the MCB unless justified.\n\n根据上述已知信息，请将'一种血液成分(红细胞、白细胞、血小板、低温沉淀和血浆)，可通过各种分离方法制备，并在可直接用于治疗目的或用于进一步加工\/制造的条件下制备。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A constituent of blood (erythrocytes, leukocytes, platelets, cryoprecipitate and plasma) that can be prepared by various separation methods and under such conditions that it can be used either directly for therapeutic purposes or for further processing\/manufacturing."
    },
    {
        "instruction":"已知信息：\n'选择致癌性试验的剂量和动物种属／品系时，应考虑所有 相关信息，包括人体用药情况、暴露模式和代谢等因素。'可被翻译为：All relevant information should be considered for dose and species\/strain selection for the carcinogenicity study. This information should include knowledge of human use, exposure patterns, and metabolism.\n'致癌性试验所采用的所有动物种属和品系的雄性和雌性动物 均应进行剂量范围研究。'可被翻译为：Dose-ranging studies should be conducted for both males and females for all strains and species to be tested in the carcinogenicity bioassay;\n'对于需要产生的具有生物学意义的作用，在靶部位的暴露量需要足够高，并且该物质的效力需要充分。'可被翻译为：For biologically significant effects to be produced, exposure needs to be sufficiently high at the target site and the substance needs to be of sufficient potency.\n'银没有致突变性，动物毒性研究和人职业暴露量研究均无充分的致癌性证据。'可被翻译为：Silver is not mutagenic. Animal toxicity studies and human occupational studies have not provided sufficient evidence of carcinogenicity.\n\n根据上述已知信息，请将'动物全身药物暴露量应足够高，以确保充分检测致癌性。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The level of animal systemic exposure should be sufficiently great compared to exposure to provide reassurance of an adequate test of carcinogenicity."
    },
    {
        "instruction":"已知信息：\n'如果特定基因组亚群中的获益-风险平衡的影响可通过基因组学BM或一套标志物识别，应在产品标签中考虑药物基因组学相关信息。'可被翻译为：Pharmacogenomics related information should be considered in the product labelling, in case an impact on the benefit-risk balance in a specific genomic subpopulation is identifiable by a genomic BM or set of markers.\n'药物信息中是否纳入药物基因组学信息及其对于药物警戒活动的影响将受到特定 基因组亚群总体受益风险情况、基因组学生物标记物影响程度及证据水平的影响。'可被翻译为：Inclusion of pharmacogenetic information in the product information and its impact on pharmacovigilance activities will be guided by the overall benefit risk balance in specific genomic subpopulations, magnitude of the genetic \/ genomic biomarker effect and the level of evidence.\n'应该提供基于亚群的基因组学BM的获益和风险 的使用数据和特征，包括基因组学BM的临床效用或有用性。'可被翻译为：Usage data and characterisation of benefits and risks in genomic BM based subpopulations should be presented, including the clinical utility or usefulness of the genomic BM.\n'确认基因组学BM的影响，优化获益风险平衡和风险最小化措施：'可被翻译为：to confirm the impact of a genomic BM and optimise benefit-risk balance and risk minimisation measures:\n\n根据上述已知信息，请将'在产品标签中包含和定位基因组学信息，因此，对临床使用和药物警戒活动的影响将受到总体获益-风险平衡、特定基因组亚群中基因组学BM效应的大小以及证据的强度和决定性指导。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Inclusion and positioning of genomic information in the product labelling and therefore impact on clinical use and pharmacovigilance activities will be guided by the overall benefit-risk balance, magnitude of the genomic BM effect in specific genomic subpopulations, and the strength and conclusiveness of evidence."
    },
    {
        "instruction":"已知信息：\n'关于新药评价中使用健康相关生活质量（HRQL）量表的监管指导文件的反思（CHPM\/EWP\/139391\/04）'可被翻译为：Reflection Paper on the regulatory guidance for the use of Health-Related Quality of Life (HRQL) measures in the evaluation of medicinal products (CHPM\/EWP\/139391\/04)\n'更通用的健康相关生活质量（HRQOL）工具正在评估患者对疾病和治疗对日常生活、身体、心理和社会功能以及健康的影响的看法。'可被翻译为：More general Health-related quality of life (HRQOL) tools are assessing the patient’s perception of the impact of disease and treatment on daily life, physical, psychological and social functioning and well-being.\n'药代动力学在药物的儿科人群开发中的作用指南（EMEA\/CHMP\/EWP\/147013\/2004）；'可被翻译为：Guideline on the role of pharmacokinetics in the development of medicinal products in the paediatric population (EMEA\/CHMP\/EWP\/147013\/2004)\n'药代动力学在儿科人群药品的开发中的作用– EMEA\/CHMP\/EWP\/147013\/2004 corr'可被翻译为：Guideline on the role of pharmacokinetics in the development of medicinal products in the paediatric population - EMEA\/CHMP\/EWP\/147013\/2004 corr.\n\n根据上述已知信息，请将'健康相关的生命质量（HRQoL）测量用于药物评估的法规指南（EMEA\/CHMP\/EWP\/139391\/2004）的读后感；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Reflection Paper on the Regulatory Guidance for the Use of Health-Related Quality of Life (HRQL) Measures in the Evaluation of Medicinal Products (EMEA\/CHMP\/EWP\/139391\/2004);"
    },
    {
        "instruction":"已知信息：\n'因此，如果使用HPLC方法确定的Koc在A级中的触发值 （10.000L \/ kg）的2倍内，和\/或在B级中使用SimpleTreat模型，和\/或计算的 沉积物风险评价被触发（在14天时或14天之后>10%的物质转移到沉积物）， 则指示值是不可接受的。'可被翻译为：Thus, if a Koc determined using the HPLC method is within a fac- tor of 2 of the trigger value (10.000 L\/kg) in Tier A and\/or the SimpleTreat model is used in Tier B and\/or calculated sediment risk assessment has been triggered (>10% of substance shifted to sedi- ment at or after 14 days), an indicative value is not acceptable.\n'应用药物后短时间内发生的毒性作用（14天内）。'可被翻译为：Toxic effects that occur within a short period of time after application of the drug (within 14 days).\n'是的，毒性试验的结果应被重新计算为有机碳含量为10%的标准沉积物， 根据公式： 标准沉积物检测标准沉积物 检测请注意，检测得到的效应浓度表示为干重浓度。'可被翻译为：Yes, results from toxicity tests should be recalculated into standard sediment with an organic carbon content of 10% according to: Please note that the resulting effect concentration from a test is expressed as a dry weight concentration.\n'ii）如果在沉积物中代谢物的含量构成≥10％的初始母体化合物浓度，应检测代 谢物的毒性吗？'可被翻译为：ii) Should the toxicity of a metabolite be tested in case it constitutes ≥10% of the initial parent compound concentration in the sediment?\n\n根据上述已知信息，请将'（1）在14天时的任何时间点或者14天之后 转移到沉积物的化合物的量（包括不可提取残渣= NER）- 如果大于10%，则触 发沉积物毒性检测；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(1) the amount of compound (including Non –Extractable Residues = NER) that has shifted to sediment at any time point at or after 14 days – if this is more than 10%, a sediment toxicity test is triggered;"
    },
    {
        "instruction":"已知信息：\n'第四十三条 食品药品监督管理部门应当自受理复审申请之日起30个工作日内作出复审决定，并书面通知申请人。维持原决定的，食品药品监督管理部门不再受理申请人再次提出的复审申请。'可被翻译为：Article 43 The food and drug regulatory department shall make a re-evaluation decision within 30 workdays after accepting the re-evaluation application and inform the applicant. Where the original decision shall be maintained, the food and drug regulatory department shall not accept further application for re-evaluation by the applicant.\n'食品药品监督管理部门应当自受理复审申请之日起30个工作日内作出复审决定，并书面通知申请人。维持原决定的，食品药品监督管理部门不再受理申请人再次提出的复审申请。'可被翻译为：The food and drug regulatory department shall make a re-evaluation decision within 30 workdays after accepting the re-evaluation application and inform the applicant. Where the original decision shall be maintained, the food and drug regulatory department shall not accept further application for re-evaluation by the applicant.\n'第一百五十六条 申请人对国家食品药品监督管理局作出的不予批准决定有异议的，可以在收到不予批准的通知之日起60日内填写《药品注册复审申请表》，向国家食品药品监督管理局提出复审申请并说明复审理由。'可被翻译为：Article 156 If holding any dispute on the unapproval decision made by the State Food and Drug Administration, an applicant may, within 60 days after receiving the decision, fill in the Application Form for Drug Registration Second Review, and submit the application to the State Food and Drug Administration and provide reasons.\n'第三十五条 复审维持原决定的，发给生物制品批签发复审结果通知书，不再受理批签发申请人再次提出的复审申请；复审改变原结论的，收回原生物制品不予批签发通知书，发给生物制品批签发证明。'可被翻译为：Article 35 If the re-review sustains the original decision, a Notice of Re-review Result for Lot Release of Biological Products will be issued to the applicant, and the lot release applicant's further applications for re-review will no longer be accepted; if the re-review changes the original conclusions, the original Notice of Disapproval of Lot Release of Biological Products will be withdrawn, and a Certificate for Lot Release of Biological Products will be issued.\n\n根据上述已知信息，请将'第一百五十七条 国家食品药品监督管理局接到复审申请后，应当在50日内作出复审决定，并通知申请人。维持原决定的，国家食品药品监督管理局不再受理再次的复审申请。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 157 The State Food and Drug Administration shall make a second review decision, and notify the applicant the decision within 50 days after receiving an application for second review. Where the original decision is affirmed, the State Food and Drug Administration shall not accept any further application for second review thereof."
    },
    {
        "instruction":"已知信息：\n'给药370 mg\/m2后的数 据也可获得（Bocci）：Cmax=48.41 µg\/mL，AUC=13.61 µg·h\/mL。'可被翻译为：Data are also available after a 370 mg\/m2 dose (Bocci): Cmax = 48.41 µg\/mL, AUC = 13.61 µg·h\/mL.\n'a：从5 mg\/kg的报告值外推得到（Brouwer）：从曲线图目测得到Cmax=~1.0 µg\/mL，AUC=4.4 µg∙h\/mL。'可被翻译为：a: Extrapolated from reported values at 5 mg\/kg (Brouwer): Cmax = ~1.0 µg\/mL from visual inspection of graph, AUC = 4.4 µg∙h\/mL.\n'b: Wistar大鼠于GD9单次经口给予5 mg\/kg后的外推或实际值（Tzimas 1997）：Cmax = 0.15 µg\/mL，AUC(0-8h) = 0.25 µg·h\/mL。于GD12单次给予6 mg\/kg后的药代动力学数据也可获得（Collins, 1995）：目测曲线图得Cmax=0.320 µg\/mL，AUC(0-8h)=0.820 µg·h\/mL；每天给药6次后的数据也可获得 （Collins 1994，1995）：Cmax = 0.046或0.052 µg\/mL，相应地，AUC(0-24h)=0.098 µg·h\/mL或AUC(0-10h)=0.090 µg·h\/mL。'可被翻译为：b: Extrapolated or actual value after single 5 mg\/kg oral dose on GD9 in Wistar rats (Tzimas 1997): Cmax = 0.15 µg\/mL, AUC(0-8h) = 0.25 µg·h\/mL. Pharmacokinetic data are also available after a single dose of 6 mg\/kg on GD12 (Collins, 1995): Cmax = 0.320 µg\/mL from visual inspection of graph, AUC(0-8h) = 0.820 µg·h\/mL; as well as after 6 daily doses (Collins 1994, 1995): Cmax = 0.046 or 0.052 µg\/mL, and AUC(0-24h) = 0.098 µg·h\/mL or AUC(0-10h) = 0.090 µg·h\/mL, respectively.\n'd：单次静脉注射给予甲氨蝶呤30 mg\/m2后报告值外推至14.7 mg\/m2（Campbell）：目测曲线图得Cmax=4.37 µg\/mL，AUC(0-inf)=6.69 µg·h\/mL。'可被翻译为：d: Extrapolated to 14.7 mg\/m2 f rom reported value after 30 mg\/m2 methotrexate intravenous single dose (Campbell): Cmax = 4.37 µg\/mL from visual inspection of graph, AUC(0-inf) = 6.69 µg·h\/mL.\n\n根据上述已知信息，请将'也可获得口 服给药数据（Campbell）：目测曲线图得Cmax=0.50 µg \/mL，AUC(0-inf) = 2.34µg·h\/mL。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Oral data are also available (Campbell): Cmax = 0.50 µg \/mL from visual inspection of graph, AUC(0-inf) = 2.34µg·h\/mL."
    },
    {
        "instruction":"已知信息：\n'一般而言，若认为遗传药理学特征可影响任一研究药物的药代动力学特征，则建议在药物间相互作用研究中对受试者人群进行基因分型。'可被翻译为：As a general rule, genotyping of the population included in a drug-drug interaction study for a relevant gene is recommended when pharmacogenetics are expected to affect the pharmacokinetics of any of the drugs included in the study.\n'若药物暴露量的个体间差异性较大，有可能具有基因差异性的人群中产生药物安全性和\/有效性的差异，则通常要求开展遗传药理学对活性成分（原代谢产物\/ 活性代谢产物）药代动力学参数及其疗效和安全性影响的研究。可通过以下因素来确定是否符合此要求：'可被翻译为：Studies of the effect o and\/or active metabolites) and its implications for efficacy and safety during development are general required when the magnitude of the interindividual variation in drug exposure is so high as to likely influence the safety and\/or efficacy of the drug in genetically variable populations. Factors that identify such a situation are:\n'对药代动力学研究的原则同样适用于II期和III期研究中不一定能获得完整的药代动力学数据，但应列出与基因型相关的已有药代动力学或群体药代动力学数据，并给出药代动力学参数在各基因亚群中的标准描述性统计数据，包括均值、标准差和范围。'可被翻译为：If appropriate, the same applies here as described for pharmacokinetic studies. It is acknowledged that in Phase II and III studies, full pharmacokinetic data will not always be available. Still, available pharmacokinetic or population pharmacokinetic data in relation to genotypes should be listed, and standard descriptive statistics for each genetic subpopulation, including mean, standard deviation and range should be provided for the pharmacokinetic parameters.\n'在药物研发的哪种情况或阶段下应开展遗传药理学相关的药代动力学研究。'可被翻译为：In which situations and at what stage(s) in the clinical development program should pharmacogenetics related pharmacokinetic studies be performed.\n\n根据上述已知信息，请将'遗传药理学相关的基因问题，若其机制得到已有的体外或药代动力学信息的支持，则可接受对新产生的数据进行的回顾性分析结论。此种情况下建议从I、II、III期研究较大比例的患者中获取DNA。若在回顾性分析中发现的新的遗传相关性信息，则建议开展补充性研究（例如研究并确证该发现的药代动力学结果的体外或药代动力学研究）提供额外的支持信息。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Conclusions from a retrospective analysis carried out in response to emerging data may be acceptable for genetic issues related to pharmacokinetics if mechanistically supported by available in vitro or pharmacokinetic information. In this case, DNA should preferably be available from a large proportion of patients in the Phase I, II and III studies. If a new genetic association is discovered in a retrospective analysis, complementary studies, such as in vitro studies or pharmacokinetic studies investigating the mechanism and confirming pharmacokinetic consequences of this finding, will be expected as additional support."
    },
    {
        "instruction":"已知信息：\n'采用计量学上有效程序测定了一个或多个规定特性的标准样品，并附有证书提供规定特性值及其不确定度和计量溯源性的陈述。'可被翻译为：One or more standard samples with specified characteristics have been determined using a metrologically valid procedure, accompanied by a certificate providing a statement of the specified characteristic values and their uncertainty and metrological traceability.\n'量表测量结果与被测量对象潜在特质的一致性，即量表是否符合假设的理论。'可被翻译为：The consistency of the scale measurement results with the underlying characteristics of the measured object, that is, whether the scale conforms to a hypothesized theory.\n'用标准偏差表示的测量结果的不确定度。'可被翻译为：Uncertainty of the result of a measurement expressed as a standard deviation.\n'在相同的测量条件下，同一测量的连续测量结果之间的一致性(改编自ISO)。'可被翻译为：Closeness of the agreement between the results of successive measurements of the same measure and under the same conditions of measurement (adapted from ISO).\n\n根据上述已知信息，请将'测量结果的特性，即测量结果可以通过记录的、不间断的校准链与参考相关联，每个校准链都对测量不确定度有贡献'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Property of a measurement result whereby the result can be related to a reference through a documented, unbroken chain of calibrations, each contributing to the measurement uncertainty"
    },
    {
        "instruction":"已知信息：\n'2.3：质量综述（QOS）'可被翻译为：2.3 : QUALITY OVERALL SUMMARY (QOS)\n'质量综述应包括各章节的充分信息，为质量审评员提供模块3的综述。质量综述还应重点强调产品的关键参数，如果存在未遵循指导原则的情况，应提供合理性论证。质量综述还应包括需整合质量模块信息与其他模块信息关键问题的讨论（如，通过CTD- S模块中毒理学研究来确定杂质限度），包括交叉引用其他模块的卷号和页码。'可被翻译为：The QOS should include sufficient information from each section to provide the Quality reviewer with an overview of Module 3. The QOS should also emphasise critical key parameters of the product and provide, for instance, justification in cases where guidelines were not followed. The QOS should include a discussion of key issues that integrates information from sections in the Quality Module and supporting information from other Modules (e.g. qualification of impurities via toxicological studies discussed under the CTD-S module), including cross-referencing to volume and page number in other Modules.\n'CTD通用技术文档的组织的图示说明 \n模块 1 \n地区 \n行政管理 \n信息 \n1 \n1.1 目录 \n不属于CTD \nCTD \n模块 2 \nCTD 目录 \n2.1 \nCTD 引言 \n2.2 \n质量综述 \n2.3 \n非临床综述 \n2.4 \n非临床文字总结和 列表总结 \n2.6 \n临床综述 \n2.5 \n临床总结 \n2.7 \n模块3 \n质量 \n3 \n3.1 目录 \n模块 4 \n非临床试验报告 \n4 \n4.1 目录 \n模块 5 \n临床研究报告 \n5 \n5.1 目录'可被翻译为：Diagrammatic Representation of the Organization of the ICH CTD Common Technical Document \nModule 1 \nRegion \nAdministrative \nInformation \n1 \n1.1 Submission\nNot part of the CTD \nT of C \nModule 2 \nCTD Table of Contents \n2.1 \nCTD Introduction \n2.2 \nQuality Overall Sumary \n2.3 \nNonclinical Overview \n2.4 \nNonclinical Written and Tabulated Summaries \n2.6 \nClinical Overview \n2.5 \nClinical Summary \n2.7 \nModule 3 \nQuality \n3 \n3.1 T of C \nModule 4 \nNonclinical Study Reports \n4 \n4.1 T of C \nModule 5 \nClinical Study Reports \n5 \n5.1 T of C\n'人用药品注册通用技术文档：质量 模块2的质量综述 模块3：质量'可被翻译为：THE COMMON TECHNICAL DOCUMENT FOR THE REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE: QUALITY QUALITY OVERALL SUMMARY OF MODULE 2 MODULE 3 : QUALITY\n\n根据上述已知信息，请将'质量综述（QOS）是对模块3中主体数据的总结。质量综述不应包含未出现在CTD模块3或其他部分的信息或数据。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The Quality Overall Summary (QOS) is a summary that follows the scope and the outline of the Body of Data in Module 3. The QOS should not include information, data or justification that was not already included in Module 3 or in other parts of the CTD."
    },
    {
        "instruction":"已知信息：\n'在开发项目过程中的任何时 间均能考虑进行这样的研究。'可被翻译为：Such studies could be considered at any time during the developing programme.\n'总的来说，上市前研究中的所有患者都可以用于上市后研究。'可被翻译为：In general, all patients from pre-authorisation clinical trials could be enrolled in post- marketing investigations.\n'2.3.3 药代动力学资料（WoE因素：已有资料的数量和类型）'可被翻译为：2.3.3 Pharmacokinetic Data (WoE Factors: Amount\/Type of Existing Data)\n'2.3.1 临床信息（WoE因素：拟用患者的最小年龄；已有资料的数量\/类型、临床给药期限）'可被翻译为：2.3.1 Clinical Information (WoE Factors: Youngest Intended Patient Age; Amount\/Type of Existing Data; Clinical Treatment Duration)\n\n根据上述已知信息，请将'随着临床开发的进展，可以根据当时所有已有资料来调整WoE。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"As clinical development progresses, adjustments to the WoE can be made based on all the available data at that time."
    },
    {
        "instruction":"已知信息：\n'由于给予的核酸的持久性和清除很大程度上取决于免疫监视水 平，因此动物模型的免疫状态应尽可能模拟患者的情况。'可被翻译为：The persistence and clearance of administered nucleic acid will largely depend on immune surveillance; therefore the immune status of the animal model should mimic the patient’s situation as closely as possible.\n'预期病毒\/载体感染\/转导以及复制到所选动物物种\/模型的能力。'可被翻译为：The ability of the intended virus\/vector to infect\/transduce, and to replicate in, the chosen animal species\/models.\n'3.2.1.4 产品含质粒、非病毒载体及转基因生物而非病毒或病毒载体时，起始物料应该是产生生产细胞的成分，如质粒、宿主细菌及重组微生物细胞的主细胞库'可被翻译为：3.2.1.4.In the case of products consisting of plasmids, non viral vectors and genetically modified microorganism(s) other than viruses or viral vector, the starting materials shall be the components used to generate the producing cell, i.e. the plasmid, the host bacteria and the master cell bank of recombinant microbial cells.\n'氟（18F）脱氧葡糖的细胞摄取通过组织特异性载体系统进行，其中部分载体是胰岛素依赖型，因此会受到摄入食物、营养状况和本身是否有糖尿病的影响。糖尿病患者的氟（18F）脱氧葡糖细胞摄取减少是由于组织分布的改变和葡萄糖代谢的改变而导致的。'可被翻译为：The cellular uptake of fludeoxyglucose (18F) is performed by tissue-specific carrier systems which are partly insulin-dependent and, thus, can be influenced by eating, nutritional condition and the existence of a diabetes mellitus. In patients with a diabetes mellitus a reduced uptake of fludeoxyglucose (18F) into the cells occurs due to a changed tissue distribution and glucose metabolism.\n\n根据上述已知信息，请将'动物模型中病毒\/细菌的细胞受体表达和组织分布，可能会影响宿主摄取的效率以 及载体细胞和组织的隔离。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The expression and tissue distribution of cellularreceptors for virus\/bacteria in the animal  model that might affect the efficiency of the uptake by the host and the cellular and tissue sequestration of the vector."
    },
    {
        "instruction":"已知信息：\n'当用除掺食给药以外的其他途径给药更适合时，高剂量可能 受限于实际可行性和局部耐受性。'可被翻译为：When routes other than dietary administration are appropriate, the high dose can be limited based on considerations including practicality and local tolerance.\n'对于拟用于晚期肿瘤患者的药物，上述限度可能不适用，论证时应考虑设置更高的杂质限度。'可被翻译为：Such limits are not appropriate for pharmaceuticals intended to treat patients with advanced cancer, and justifications described above should be considered to set higher limits.\n'对于暴露比较，单 次给药剂量250 mg（10 mL）被用于Cmax，口服液剂量625 mg\/day则被用于AUC，因溶液的暴露比缓释胶囊更高（美国FDA 1986）。'可被翻译为：For exposure comparisons, a dose of 250 mg (10 mL) as a single dose was used for Cmax and a dose of 625 mg\/day oral solution was used for AUC since exposure was higher for the solution than for extended release capsules (FDA, United States 1986).\n'银屑病中的静脉给药剂量 25 mg（14.7 mg\/m2）被选择用 于PK倍数比较，因为这是非肿瘤适应症中的最高剂量，且也将能提供比口服给药（蕈样肉芽肿）50 mg（29 mg\/m2）更高的暴露，因为口服生物利用度 仅~40%。'可被翻译为：An intravenous dose of 25 mg (14.7 mg\/m2) in psoriasis was chosen for PK margin comparisons since this was the highest dose in a non-oncology indication and would also provide a higher exposure than a 50 mg (29 mg\/m2) oral dose (mycosis fungoides) since oral bioavailability is only ~40%.\n\n根据上述已知信息，请将'尽管更高的间歇性给药剂量被用于肿瘤适应症，但认为用于镰状细胞性贫血的剂量与发育毒性风险评估更相关。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Although higher intermittent doses are used for oncology indications, the dose for sickle cell anemia is believed to be more relevant for assessing risk of developmental toxicity."
    },
    {
        "instruction":"已知信息：\n'现已有一些在犬和恒河猴上诱导微核的经验（Harper等， 2007；Hotchkiss等，2008）。'可被翻译为：Some experience is now available for micronucleus induction in the dog and rhesus monkey (Harper et al., 2007; Hotchkiss et al., 2008).\n'在遗传毒性试验策略中，体内试验具有重要作用。'可被翻译为：In Vivo Test Results In vivo tests have an important role in genotoxicity test strategies.\n'由于成熟动物的肝脏不是高度有丝分裂的组织，第二种试验通常采用非细胞遗传学终点，但是，当分裂肝细胞存在时，如在部分肝切除术后，或在年轻大鼠上（Hayashi等，2007），采用肝脏进行微核试验也是可能的，并可检测已知的遗传毒性化合物。'可被翻译为：Since liver of mature animals is not a highly mitotic tissue, often a non-cytogenetic endpoint is used for the second assay, but when dividing hepatocytes are present, such as after partial hepatectomy, or in young rats (Hayashi et al., 2007), micronucleus analysis in liver is possible, and detects known genotoxic compounds.\n'肼在体内（参考文献6）可诱导小鼠骨髓微核形成，但不会诱发小鼠骨髓染色体畸变。已有研究报道在体内若干个组织中发现DNA加合物。'可被翻译为：In vivo, (Ref. 6) hydrazine induced micronuclei but not chromosome aberrations in mouse bone marrow. DNA adducts have been reported in several tissues in vivo.\n\n根据上述已知信息，请将'（6）采用皮肤和结肠进行诱导微核的体内试验已有一 些经验（Hayashi等，2007），而且在这些组织中进行DNA 损伤试验也是一种合适的替代方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"6. There is some experience with in vivo assays for micronucleus induction in skin and colon (Hayashi et al., 2007), and DNA damage assays in these tissues can also be an appropriate substitute."
    },
    {
        "instruction":"已知信息：\n'·临床药理学，药效学和药代动力学：应提供儿科用药小节概述的药效学、药代动力学和药物基因组学数据更为详细的讨论。应包括相关的儿科药代动力学和\/或药效学研究数据以及剂量反应信息。'可被翻译为：• CLINICAL PHARMACOLOGY, Pharmacodynamics and Pharmacokinetics: A more detailed discussion of the pharmocodynamic, pharmacokinetic, and pharmacogenomic data summarized in the Pediatric Use subsection should be provided. Relevant pediatric pharmacokinetic and\/or pharmacodynamic study data and dose response information should be included.\n'与儿科用药安全和有效相关的其他信息'可被翻译为：•Other information related to the safe and effective pediatric use of the drug\n'另外，上述说明中概述的数据必须在说明书的适当部分进行更为详细的讨论。儿科和成人应答之间任何有意义的差异、特殊监测的需要、剂量调整以及与儿科患者安全和有效使用该药相关的任何其他资料，必须在儿科用药小节简要引述 （21 CFR 201.57（c）（9）（iv）（D）（2）），并且应在说明书的适当部分更为详细地讨论。'可被翻译为：In addition, data summarized in the above statement must be discussed in more detail in the appropriate section of labeling. Any significant differences between pediatric and adult responses, a need for specific monitoring, dosing adjustments, and any other information related to the safe and effective use of the drug in pediatric patients must be cited briefly in the Pediatric Use subsection (21 CFR 201.57(c)(9)(iv)(D)(2)), and a more detailed discussion should be included in the appropriate section of 417 labeling.\n'儿科用药小节概述的所有数据，当合适时，应在说明书的其他部分进一步详细讨论（21 CFR 201.57（c）（9）（iv）（B））。当儿科数据在说明书某一部分进行概述，在说明书的另一部分进行详细讨论时，应采用适当的交叉参照。当现有数据支持儿科适应症时，根据法规要求说明书中必须有儿科信息（21 CFR 201.57（c）（9）（iv））。更多建议参见第III.A.节“支持儿科适应症安全性和有效性的证据充足”。'可被翻译为：All data summarized in the Pediatric Use subsection should be discussed in further detail in 297 other labeling sections, as appropriate (21 CFR 201.57(c)(9)(iv)(B)). Appropriate labeling cross-references should be used when pediatric data are summarized in one section of labeling and discussed in more detail in another section of labeling. When a pediatric indication is supported by available data, the pediatric information must be placed in the labeling as required by regulation (21 CFR 201.57(c)(9)(iv)). Recommendations are further described in section III.A., Sufficient Evidence to Support Safety and Effectiveness for a Pediatric Indication.\n\n根据上述已知信息，请将'·临床研究：应提供儿科用药小节概述的儿科临床数据更为详细的讨论。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"• CLINICAL STUDIES: A more detailed discussion of the pediatric clinical data summarized in the Pediatric Use subsection should be provided."
    },
    {
        "instruction":"已知信息：\n'最后大型的III期试验往往未能证实疗效。'可被翻译为：Consequently the large Phase 3 trials often failed to be confirmatory.\n'当安慰剂对照试验不合乎伦理，并且活性对照试验 不可信时，新药的研究就有可能非常困难。'可被翻译为：Where a placebo-controlled trial is unethical and an active control trial would not be credible, it may be very difficult to study new drugs at all.\n'然而，如果II期试验中未进行剂量探索，验证性III期试验或许至少可以提供一部分的剂量反应数据。'可被翻译为：However, it is also possible to provide dose-response data at least in part from confirmatory phase III trials where dose finding is lacking from phase II.\n'本指导原则坚持I\/II期探索性临 床试验和III期验证性临床试验是不同的。'可被翻译为：The distinction between Phase I\/II exploratory and Phase III confirmatory trials has been adhered to in this Guideline.\n\n根据上述已知信息，请将'遗憾的是， AD 的药物研发领域遭遇了重重挫折，在一些情况下，探索性试验未能为III期研究提供 “假说验证”的信息。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Unfortunately the field of AD drug development has witnessed many failures and it is noted that in some cases, exploratory trials did not provide ‘proof of concept’ to inform Phase 3."
    },
    {
        "instruction":"已知信息：\n'D.9.2.r.1b 报告的死因（MedDRA编码） 用户指导原则 该数据元素获取报告的死因的元素MedDRA 低位语代码。 一致性 数据类型 2.16.840.1.113883.6.163 可选，但如果填写了D.9.2.r.1a，则为必填项。 8N OID 允许值 数值 业务规则'可被翻译为：D.9.2.r.1b Reported Cause(s) of Death (MedDRA code) User Guidance This data element captures the MedDRA LLT code for the reported cause of death. Conformance Optional, but required if D.9.2.r.1a is populated. Data Type 8N OID 2.16.840.1.113883.6.163 Value Allowed Numeric Business Rule(s)\n'D.9.4.r.1a 用于尸检确定的死因的MedDRA版本 用户指导原则 一致性 4AN 该数据元素为编码元素D.9.4.r.1b所使用的所使用的MedDRA版本。 可选，但如果填写了D.9.4.r.1b，则为必填项。 数据类型 OID 允许值 无 数值和“.”（点） 业务规则 每个ICSR仅允许1个MedDRA版本。 对于MedDRA版本15.1，容许值为“15.1”。'可被翻译为：D.9.4.r.1a MedDRA Version for Autopsy-determined Cause(s) of Death User Guidance This data element captures the MedDRA version for D.9.4.r.1b. Conformance Optional, but required if D.9.4.r.1b is populated. Data Type 4AN OID None Value Allowed Numeric and ‘.‘(dot) Business Rule(s) Only 1 MedDRA version is allowed per ICSR. For MedDRA version 15.1 value allowed is ‘15.1’.\n'D.8.r.6b 适应症（MedDRA编码） 用户指导原则 该数据元素获取药品适应症的MedDRA 低位语代码。 一致性 数据类型 2.16.840.1.113883.6.163 可选，但如果填写了D.8.r.6a，则为必填项。 8N OID 允许值 数值 业务规则'可被翻译为：D.8.r.6b Indication (MedDRA code) User Guidance This data element captures the MedDRA LLT code for the indication of the medicinal product. Conformance Optional, but required if D.8.r.6a is populated. Data Type 8N OID 2.16.840.1.113883.6.163 Value Allowed Numeric Business Rule(s)\n'D.10.8.r.6b 适应症（MedDRA编码） 用户指导原则 该数据元素获取药品适应症的MedDRA 低位语代码。 一致性 数据类型 2.16.840.1.113883.6.163 可选，但如果填写了D.10.8.r.6a，则为必填项。 8N OID 允许许值 数值 业务规则'可被翻译为：D.10.8.r.6b Indication (MedDRA code) User Guidance This data element captures the MedDRA LLT code for the indication of the medicinal product. Conformance Optional, but required if D.10.8.r.6a is populated. Data Type 8N OID 2.16.840.1.113883.6.163 Value Allowed Numeric Business Rule(s)\n\n根据上述已知信息，请将'D.9.4.r.1b 尸检-确定的死因（MedDRA编码） 用户指导原则 一致性 该数据元素获取尸检时确定的死因的MedDRA 低位语代码。 可选，但如果填写了D.9.4.r.1a，则为必填项。 数据类型 OID 允许值 8N 2.16.840.1.113883.6.163 数值 业务规则'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"D.9.4.r.1b Autopsy-determined Cause(s) of Death (MedDRA code) User Guidance This data element captures the MedDRA LLT code for the autopsy- determined cause of death. Conformance Optional, but required if D.9.4.r.1a is populated. Data Type 8N OID 2.16.840.1.113883.6.163 Value Allowed Numeric Business Rule(s)"
    },
    {
        "instruction":"已知信息：\n'如果作用机制得到充分表征（例如常规的NSAID或μ受体激动剂阿片类药物），根据PK\/PD考虑因素，在同一类别的产品中有效性和安全性数据的外推可能是可接受的。'可被翻译为：If the mechanism of action is well characterized (e.g. conventional NSAIDs or µ agonist opioids) extrapolation of efficacy and safety data from products in the same class is likely to be acceptable on a case by case basis subject to PK \/ PD considerations.\n'对于作用机制不同的药物，可能需要对照数据。'可被翻译为：For cases with a different mode of action, controlled data may be required.\n'在阿片类药物引起的便秘的治疗中，尤其当药理作用机制是针对胃肠道中阿片受体时，应该特别关注阿片类戒断症状以及对疼痛症状的影响，因为阿片类拮抗剂可能会影响中枢性镇痛作用。'可被翻译为：Special emphasis in the treatment of opioid-induced constipation – especially if the pharmacological mechanism of action is targeted at the opioid receptors in the gastrointestinal tract – has to be paid on the induction of opioid withdrawal symptoms, and on the impact on pain symptoms reflecting a potential interaction of opioid antagonist on the central analgesic effect.\n'阿片类药物（特别是据称药理学作用机制是针对胃肠道阿片受体的阿片类药 物）药物引起的便秘的治疗应特别强调阿片类药物引起的撤退症状，以及消除的 症状，以及由于理论上对于疼痛药物疗效的妥协而对疼痛症状产生的影响。'可被翻译为：Special emphasis in the treatment of opioid-induced constipation – especially if the pharmacological mechanism of action is allegedly targeted at the opioid receptors in the gastrointestinal tract – has to be paid on the induction of opioid withdrawal symptoms, and on the impact on pain symptoms for theoretically compromising the efficacy of the pain medication.\n\n根据上述已知信息，请将'如果作用机制得到充分表征（例如常规的NSAID或μ受体激动剂阿片类药物），则可以根据具体情况接受由同一类别的产品的数据推断。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"If the mechanism of action is well characterized (e.g. conventional NSAIDs or mu agonist opioids) extrapolation of data from products in the same class can be accepted on a case by case basis."
    },
    {
        "instruction":"已知信息：\n'某些方面的疗效评价可能需要长期对照的临床试验数据。'可被翻译为：Assessment of efficacy in some domains may require long-term controlled clinical trial data.\n'尽管如此，尽可能确定证实的疗效局有临床相关性仍是重要的。'可被翻译为：Nevertheless it remains important to establish that the demonstrated effects of treatment are clinically relevant.\n'3.1.1 平行组设计'可被翻译为：3.1.1 Parallel Group Design\n'对于残疾的明显声称，将需要大规模长期平行组试验，以确 立对疾病进展的临床相关性治有效性应。'可被翻译为：For a distinct claim on disability large-scale long-term parallel group trials will be required to establishclinically relevant treatment effects on disease progression.\n\n根据上述已知信息，请将'因此，在平行组设计中，应定期进行测定从而建立临床相关性的效应。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In consequence clinical outcomes in a parallel group design should be measured at regular intervals to establish a clinically relevant effect."
    },
    {
        "instruction":"已知信息：\n'第十二条 药品注册证书有效期为五年，药品注册证书有效期内持有人应当持续保证上市药品的安全性、有效性和质量可控性，并在有效期届满前六个月申请药品再注册。'可被翻译为：Article 12 The term of validity for the Drug Approval License is 5 years. An MAH shall continually ensure the safety, efficacy and quality of the drug during the term of validity and apply for registration renewal 6 months prior to the expiration date.\n'第八十二条 持有人应当在药品注册证书有效期届满前六个月申请再注册。境内生产药品再注册申请由持有人向其所在地省、自治区、直辖市药品监督管理部门提出，境外生产药品再注册申请由持有人向药品审评中心提出。'可被翻译为：Article 82 MAHs shall apply for registration renewal at least 6 months prior to expiration of the Drug Approval License. The application for registration renewal of a drug manufactured within the territory of the People's Republic of China shall be submitted by the MAH to the drug regulatory departments of the provinces, autonomous regions or municipalities directly under the Central Government where it is located; the application for registration renewal of a drug manufactured overseas shall be submitted by the MAH to the CDE.\n'（六）申请进口药品分包装，应当在该药品《进口药品注册证》或者《医药产品注册证》的有效期届满1年前提出。'可被翻译为：(6) An application for drug repackaging shall be made one year prior to the expiration of the Import Drug License or the Pharmaceutical Product License.\n'第十九条 药品生产许可证有效期届满，需要继续生产药品的，应当在有效期届满前六个月，向原发证机关申请重新发放药品生产许可证。'可被翻译为：Article 19 In the case of continuing the drug manufacturing following the expiration of the Drug Manufacturing Certificate, the company shall apply to the original issuing authority for renewal of the Drug Manufacturing Certificate 6 months ahead of the expiration.\n\n根据上述已知信息，请将'第一百二十条 国家食品药品监督管理局核发的药品批准文号、《进口药品注册证》或者《医药产品注册证》的有效期为5年。有效期届满，需要继续生产或者进口的，申请人应当在有效期届满前6个月申请再注册。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 120 The valid term of a drug approval number, Import Drug License or Pharmaceutical Product License issued by the State Food and Drug Administration is five years. To continue its drug production or importation, the applicant shall submit a re-registration application six months prior to the expiry date."
    },
    {
        "instruction":"已知信息：\n'每日允许摄入量'可被翻译为：acceptable daily intake\n'可接受摄入量'可被翻译为：acceptable intake\n'人体饮食摄入钴的平均值约为11 μg \/天[1]。'可被翻译为：The average person receives about 11 µg Co\/day in the diet (ATSDR, 2004).\n'人体钒总膳食摄入量预计为10~60 μg\/天。'可被翻译为：Estimates of total dietary intake of vanadium in humans range from 10 to 60 µg\/day.\n\n根据上述已知信息，请将'从饮用水摄入的量取决于水源，预计可达140 μg\/天。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Intake from drinking water depends on the water source and estimates are up to 140 µg\/day."
    },
    {
        "instruction":"已知信息：\n'此类研究应包括心电图和持续动态监测，且可能需要由某些电生理学检查进行补充。'可被翻译为：These investigations should include electrocardiography and continuous ambulatory monitoring which may require to be supplemented by some electrophysiological studies.\n'临床心电图评估应该在临床研发较早阶段 进行。'可被翻译为：Clinical electrocardiographic evaluation should be performed early in clinical development.\n'CminSS–稳态时最低浓度或谷浓度。'可被翻译为：CminSS - Minimum or trough concentrations at steady-state.\n'这包括可靠、高质量的心电图（ECG）记录 和分析，足够支持 ECG 间期的有效测定（参见 E14 和问与答#1）。'可被翻译为：This includes robust, high-quality electrocardiogram (ECG) recording and analysis sufficient to support a valid assay for ECG intervals (see ICH E14 and Q&A #1).\n\n根据上述已知信息，请将'除Q&A中早期推荐的评估外，还可能需要进行额外的 ECG评估（例如 24 小时心电图记录、遥测、稳态时多次谷浓度下 的心电图评估）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Additional ECG assessment over and above what is recommended earlier in the Q&A might also be called for (e.g., 24 hour ECG recording, telemetry, multiple trough ECGs through steady state)."
    },
    {
        "instruction":"已知信息：\n'同一原料(如来自同一批次)为均质原料，不同原料为非均质原料。'可被翻译为：A material is regarded as homogeneous when it is all of the same origin (e.g. from the same batch) and as non-homogeneous when it is of differing origins.\n'生产预期产品的一致性是对细胞基质进行评估的主要内容。'可被翻译为：Evaluation of the cell substrate with respect to the consistent production of the intended product of interest should be the primary subject of concern.\n'测定物料稠度的仪器。'可被翻译为：An instrument for determining the consistency of materials.\n'然而，一个注册批次也可以是生产规模的批次。'可被翻译为：However, a primary batch may be a production batch.\n\n根据上述已知信息，请将'在一个批次中具有一致的稠度和组成的材料。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Material of uniform consistency and composition throughout a batch."
    },
    {
        "instruction":"已知信息：\n'在完成治疗之后，应在随访的第4、12和24周测量病毒RNA。'可被翻译为：After completion of treatment, viral RNA should be measured at weeks 4, 12, and 24 of follow up.\n'II期临床试验应表征 作为联合治疗方案部分的DAA的最佳剂量和疗程，同时考虑抗病毒活性和安全 性。'可被翻译为：Phase 2 trials should characterize the optimal dose and treatment duration of the DAA(s) as part of combination regimens with regard to both antiviral activity and safety.\n'是否需要进行耐药性筛选取决于治疗方案、来自在有DAA治疗经历的人群 中进行的其他试验的新兴数据以及患者群的特征，包括HCV DAA暴露史、 peg-IFN\/RBV治疗史以及含peg-IFN\/RBV治疗方案的合适性。'可被翻译为：The need for drug resistance screening depends on the specific drug classes in the regimen, emerging data from other trials in DAA-experienced populations, and the characteristics of the patient population, including HCV DAA exposure history, peg-IFN\/RBV treatment history, and eligibility for a treatment regimen containing peg-IFN\/RBV.\n'多年以来，CHC治疗的标准治疗 是聚乙二醇化干扰素α-2（peg-IFN）和利巴韦林（RBV）联合给药24周（基因型 2和3）或48周（基因型1或其他）。'可被翻译为：For many years, the standard of care for treatment of CHC had been a combination of pegylated interferon alpha-2 (peg-IFN) and ribavirin (RBV) administered for 24 (genotypes 2 and 3) or 48 weeks (genotype 1 and others).\n\n根据上述已知信息，请将'对于 peg-IFN\/RBV加一种DAA治疗方案，治疗过程中的关键测量值可能包括第1、2、 4、8、12和24周或治疗结束时。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Key on-treatment measurements can include weeks 1, 2, 4, 8, 12, and 24, or at the end of therapy."
    },
    {
        "instruction":"已知信息：\n'药物遗传学（药物基因组学（PGx）的子集）：研究DNA序列中与药物反应相关的变异（ICH15）。'可被翻译为：Pharmacogenetics (a subset of pharmacogenomics (PGx)): the study of variations in DNA sequence as related to drug response (ICH15).\n'CIOMs VII（2005）：药物基因组学被更广泛地定义为应用基因组学技术来阐明疾病易感性、药物发现、药理学功能、药物处置和治疗反应。'可被翻译为：CIOMs VII (2005): Pharmacogenomics is defined more broadly as the application of genomic technologies to elucidate disease susceptibility, drug discovery, pharmacological function, drug disposition and therapeutic response.\n'遗传药理学（PGt）是药物基因组学（PGx）的分支，被 定义为: 对药物反应相关的DNA序列变化的研究。'可被翻译为：Pharmacogenetics (PGt) is a subset of pharmacogenomics (PGx) and is defined as: The study of variations in DNA sequence as related to drug response.\n'药物基因组学：与药物反应相关的DNA和RNA特征的差异的研究（ICH15）。'可被翻译为：Pharmacogenomics: the study of variations of DNA and RNA characteristics as related to drug response (ICH15).\n\n根据上述已知信息，请将'药物基因组学（PGx）被定义为： 对药物反应相关的DNA和RNA特征变化的研究。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Pharmacogenomics (PGx) is defined as: The study of variations of DNA and RNA characteristics as related to drug response."
    },
    {
        "instruction":"已知信息：\n'第四条 体外诊断试剂注册是食品药品监督管理部门根据注册申请人的申请，依照法定程序，对其拟上市体外诊断试剂的安全性、有效性研究及其结果进行系统评价，以决定是否同意其申请的过程。'可被翻译为：Article 4 In-vitro diagnostic reagent registration refers to the prescribed procedures conducted by the food and drug regulatory department upon an application submitted by the registration applicant to decide whether the medical device to be marketed can be sold based on a comprehensive evaluation of the research and results of its safety and effectiveness.\n'第十二条 体外诊断试剂产品研制包括：主要原材料的选择、制备，产品生产工艺的确定，产品技术要求的拟订，产品稳定性研究，阳性判断值或者参考区间确定，产品分析性能评估，临床评价等相关工作。'可被翻译为：Article 12 The research and development of in-vitro diagnostic reagents involves main raw materials selection and preparation, manufacturing process determination, product technical requirements drafting, product stability study, positive judgment value or reference range determination, product analysis performance evaluation and clinical evaluation, etc..\n'第二十条 医疗器械临床评价是指申请人或者备案人通过临床文献资料、临床经验数据、临床试验等信息对产品是否满足使用要求或者适用范围进行确认的过程。'可被翻译为：Article 20 Clinical evaluation of medical devices refers to the process that the applicant or filing entity validates whether the products under registration can meet their intended use and indications based on the information of clinical literature, clinical experience data and clinical trials.\n'无需进行临床试验的体外诊断试剂，申请人或者备案人应当通过对涵盖预期用途及干扰因素的临床样本的评估、综合文献资料等非临床试验的方式对体外诊断试剂的临床性能进行评价。申请人或者备案人应当保证评价所用的临床样本具有可追溯性。'可被翻译为：For the clinical trial of in-vitro diagnostic reagents are not required, the applicant shall evaluate the clinical performance of in-vitro diagnostic reagents through non-clinical trial methods such as evaluation on the clinical samples covering intended use and interference factors as well as comprehensive literatures. The applicant or filing entity shall ensure that the clinical samples for evaluation are traceable.\n\n根据上述已知信息，请将'第二十八条 体外诊断试剂临床评价是指申请人或者备案人通过临床文献资料、临床经验数据、临床试验等信息对产品是否满足使用要求或者预期用途进行确认的过程。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 28 Clinical evaluation of in-vitro diagnostic reagents refers to the process that the applicant or filing entity validates whether the products under registration can meet their intended use and indications based on the information of clinical literature, clinical experience data and clinical trials."
    },
    {
        "instruction":"已知信息：\n'因此，对于预先设定的临床重要终点，应通过证明试验药物优于安慰剂或（可能的情况下）活性参比治疗的研究设计来评估疗效。'可被翻译为：Therefore, efficacy should be evaluated in studies that are designed to demonstrate superiority of the test agent compared to placebo or, possibly, compared to active comparative therapy for a pre-specified clinically important endpoint.\n'终点的选择可能会受到试验药物作用机制的影响。'可被翻译为：The choice of endpoint might be influenced by the mechanism of action of the test product.\n'可以考虑替 代设计，例如抢救-镇痛试验，其中患者可以通过患者控制镇痛法或护士控制镇痛法（PCA、NCA） 快速获得镇痛。'可被翻译为：Alternative designs such as rescue-analgesic trials in which patients have rapid access to analgesia, either patient-controlled or nurse-controlled (PCA, NCA), may be considered.\n'抢救药物使用评估 如果允许抢救药物在试验中使用，那么在试验草案中应说明抢救药物的使用在不 同治疗组中如何分析。'可被翻译为：Assessment of Rescue Medication Use If rescue medications are allowed during the trial, the protocol should document how rescue medication use will be analyzed in the different treatment groups.\n\n根据上述已知信息，请将'作为治疗失败指示的抢救药物需要可定义为一些研究设计中的试验终点（例如剂量需求、抢救 时间或至非试验镇痛时间，视情况而定）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Need for rescue medication as indicator of treatment failure may be defined as a trial endpoint in some study designs (e.g. dose requirement, time to rescue or time to non-trial analgesia as appropriate)."
    },
    {
        "instruction":"已知信息：\n'在 研究内确定终点应该是最理想的，以便进展后在对照组和维持组使用一致的下一线治 疗。'可被翻译为：This should ideally be done within the study so that agreed next line therapy(ies) is used after progression in the control and maintenance arms.\n'无论选择了什么样的终点，都必须是充分合理的。'可被翻译为：Whichever endpoints are chosen must be thoroughly justified.\n'最大可行剂量（MFD）终点'可被翻译为：MAXIMUM FEASIBLE DOSE (MFD) ENDPOINT\n'最大可行剂量'可被翻译为：Maximum Feasible Dose\n\n根据上述已知信息，请将'各 方均以最大可行剂量作为合适的终点。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"All regions have used a maximum feasible dose as an appropriate endpoint."
    },
    {
        "instruction":"已知信息：\n'可以将药物警戒计划撰写成一个 独立文件，也可以将其要素整合到 CTD中。'可被翻译为：It can be a stand-alone document but elements could also be incorporated into the CTD.\n'药物警戒计划 应当以安全性说明为基础。'可被翻译为：The Pharmacovigilance Plan should be based on the Safety Specification.\n'本指导原则可被用于指导申办方撰写一份独立的文件（针对有相应法规的地区），或指导申办方将安全性说明和药物警戒计划的要素整合到通用技术文档（CTD）中。'可被翻译为：The guideline can be used by sponsors to develop a stand-alone document for regions that prefer this approach or to provide guidance on incorporation of elements of the Safety Specification and Pharmacovigilance Plan into the Common Technical Document (CTD).\n'如果药物警戒计划与安全性说明是分开的独立文件，这个 摘要非常重要。'可被翻译为：This is important if the Pharmacovigilance Plan is a separate document from the Safety Specification.\n\n根据上述已知信息，请将'安全性说明可以是一个与 药物警戒计划关联的独立文件，也可以将其要素结合到 CTD中。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The Safety Specification can be a stand-alone document, usually in conjunction with the Pharmacovigilance Plan, but elements can also be incorporated into the CTD."
    },
    {
        "instruction":"已知信息：\n'在重复给药毒性试验开始前，通常可获得试验剂量对于重复给药毒性试验是否合适的充分信息，该信息可用于确 定进行一项急性遗传毒性试验合适，还是进行一项结合性试 验合适。'可被翻译为：Often sufficient information on the likely suitability of the doses for the repeat-dose toxicology study is available before the study begins and can be used to determine whether an acute or an integrated test will be suitable.\n'当进行追加试验以阐明任何遗传毒性指征时，或当采用无体外哺乳动物细胞试验的标准组合选择二时，应对多种因素进行评价以确定高剂量是否适用于遗传毒性评价。'可被翻译为：When carrying out follow-up studies to address any indication of genotoxicity, or when using Option 2 with no in vitro mammalian cell assay, several factors should be evaluated to determine whether the top dose is appropriate for genotoxicity evaluation.\n'·稀释样品浓度低于LLOQ；'可被翻译为：• The diluted sample is below the LLOQ\n'以上要求同样适用于大量研究样品的分析浓度高于ULOQ的情况。如果可能，应调整校准曲线范围，并增加质控样品或调整浓度。如无法调整校准曲线范围或浓度超过ULOQ的样品数量不多，则应采用经验证的稀释方法对样品进行稀释。'可被翻译为：The same applies if a large number of the analyte concentrations of the study samples are above the ULOQ. The calibration curve range should be changed, if possible, and QC(s) added or their concentrations modified. If it is not possible to change the calibration curve range or the number of samples with a concentration above the ULOQ is not large, samples should be diluted according to the validated dilution method.\n\n根据上述已知信息，请将'为获得合适的毒性范围，在一个较宽的浓度范围内进行初步的范围探索试验是有益的，但是，在遗传毒性试验中，采用剂距非常接近（低于两倍稀释度）的多个浓度进行试验，通常是非常关键的。可对更多、额外的浓度进行试验，但是不必对所有浓度都进行遗传毒性评价。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"To obtain an appropriate toxicity range, a preliminary range-finding assay over a broad range of concentrations is useful, but in the genotoxicity assay it is often critical to use multiple concentrations that are spaced quite closely (less than two fold dilutions). Extra concentrations can be tested but not all concentrations need be evaluated for genotoxicity."
    },
    {
        "instruction":"已知信息：\n'有时，申办方可能不同意这些决定中的一项，并引起争议。'可被翻译为：Sometimes, a sponsor may disagree with the Agency on a matter, and a dispute arises.\n'通常，下列类型的研究或试验没有满足PMRs的法定目的，但可能经协商认为符合PMCs。'可被翻译为：Generally, the following types of studies or clinical trials would not meet the statutory purposes for PMRs, but might be considered for agreed-upon PMCs:\n'在某些情况下，由于新抗菌剂的特性，申办方可能按照章节3.2中描述的路线， 计划进行标准适应症的随机、对照研究，这将进一步支持给药方案的安全性 和疗效。'可被翻译为：In some cases and subject to the properties of the new antibacterial agent sponsors may plan to conduct randomised controlled studies in standard indications along the lines described in section 3.2, which will further support the safety and efficacy of the dosing regimen.\n'如果利用历史阳性对照 数据来证明试验灵敏度或根据历史对照数据计算统计学把握度，则当前数据的方 差应与历史数据保持一致。'可被翻译为：If historical positive control data are utilized to justify assay sensitivity or statistical power is calculated from historical control data, then the variance of the present data should be consistent with that seen historically.\n\n根据上述已知信息，请将'可能在某些情况下申办方认为执行至少一项有充分把握度的随机、对照临床 试验来支持某个适应症是行不通的。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"There may be instances in which the sponsor considers that it is not feasible to conduct at least one adequately powered randomised and controlled clinical trial to support an indication."
    },
    {
        "instruction":"已知信息：\n'全球数据缺乏种族因素影响相关研究和数据的，应开展必要的PK，和\/或PD，有效性和安全性研究，以支持该药品上市申请。'可被翻译为：In the absence of the study and data related to the impact of racial factors in global data, necessary PK, and\/or PD, effectiveness and safety studies should be conducted to support the marketing application of the drug.\n'对于境外已上市境内未上市的药品，需结合药品具体情况，按照临床评价的基本逻辑对原研药品的临床研究数据进行充分评价，根据评价结果确定临床试验要求。对于不同研发背景的药品，其所需开展的临床试验应具体问题具体分析。'可被翻译为：For the drugs marketed overseas but not marketed in China, full evaluation should be performed for the clinical study data of the originator drugs according to the basic logic of clinical evaluation and in combination with the actual situation of the drugs, and the clinical trial requirements should be determined according to the evaluation results. For drugs with different R & D backgrounds, the clinical trials required to be carried out should be determined case by case.\n'（一）治疗严重危及生命且尚无有效治疗手段的疾病的药品，药物临床试验已有数据证实疗效并能预测其临床价值的；'可被翻译为：(1) Drugs used for treating serious life-threatening diseases for which no effective treatment is available, whose efficacy has been verified by data in drug clinical trials and whose clinical values can be predicted;\n'第五十九条 药物临床试验期间，用于防治严重危及生命或者严重影响生存质量的疾病，且尚无有效防治手段或者与现有治疗手段相比有足够证据表明具有明显临床优势的创新药或者改良型新药等，申请人可以申请适用突破性治疗药物程序。'可被翻译为：Article 59 During clinical trials, for innovative drugs or modified new drugs used for the prevention and treatment of serious life-threatening diseases or diseases that seriously affect the quality of life but no effective means of prevention and treatment is available, or significantly clinically superior over current treatments with sufficient evidence is demonstrated, the applicant may apply for the breakthrough therapy drug procedure.\n\n根据上述已知信息，请将'对于全球数据中没有中国人群相关数据，但有较充分的种族因素相关研究和分析数据且未见明显种族因素影响的药品，应具体问题具体分析：（1）用于严重或危及生命疾病、罕见病且无有效治疗手段的药品，或用于此类疾病且较现有治疗手段具有明显提高疗效或安全性等优势的药品，可考虑在严格风险控制的前提下批准上市，并应开展上市后有效性和安全性临床试验以支持药品全生命周期获益\/风险评估。（2）对于较现有治疗手段未见明显临床优势的药品，应参考“五（一）2”项相关要求进行临床试验。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For drugs with no relevant data of Chinese population in the global data, but there is relatively sufficient racial factor related study and analysis data and no significant impact of racial factors is identified, the analysis should be conducted on a case-by case basis: (1) For a drug used for serious or life-threatening diseases and rare diseases for which there is no effective therapeutic means, or a drug with significantly improved effectiveness or safety and other advantages over existing therapeutic means when being used for such diseases, the approval for marketing can be considered on the premise of strict risk control, and post-marketing effectiveness and safety clinical trial should be conducted to support the whole life cycle benefit\/risk evaluation of the drug. (2) For a drug without significant clinical advantages over existing therapeutic means, the clinical trial should be conducted with reference to the requirements of Section \"V (I) 2\"."
    },
    {
        "instruction":"已知信息：\n'应考虑其他消除途径重要性改变的可能后果。'可被翻译为：Consideration should be given to possible consequences of altered importance of other elimination pathways.\n'应将RRMS复发相关的残疾累积同SPMS或PPMS的残疾进展区分开来。'可被翻译为：A distinction should be made between accumulation of disability in relation to relapses in RMS and progression of disability in SPMS or in PPMS.\n'6.分离柱的功能和再生'可被翻译为：6. Function and Regeneration of Columns\n'适当地保存临床试验期间从患者中分离的所有目标病原体，以备在需要进行其他试验时使用。'可被翻译为：All target pathogens isolated from patients during clinical trials should be appropriately saved in the event that there is a need to do additional trials with the bacteria.\n\n根据上述已知信息，请将'如果膨胀效应是目标之一，应将其从再生的肌肉组织分离，跟进这两种效应。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"If bulking effect is one of the aims, it should be separated from the regeneration of the muscle tissue and both of these effects should be followed."
    },
    {
        "instruction":"已知信息：\n'选择适当的 阴性对照也很重要。'可被翻译为：Selection of appropriate negative controls is important.\n'全部过程都要设置阴性和阳性对照以确保测量结果的可靠性。'可被翻译为：In all cases crucial element to be considered is the choice of positive and negative controls to ensure reliability of the measurements.\n'不同的生物学水平有相应的方法检测PGBM，需要根据PGBM的应用目的和技术的特征及局限性来选择检测方法。'可被翻译为：PGBM measurement can be assessed at different biological levels with different technologies; thus, the appropriate choice of assay depends both on the application of the PGBM and the features and limitations of the respective technology.\n'如果基线检测与随访检测之间的表型出现变化，则这一方法的应用受到限制。'可被翻译为：Limitations of the method apply in case of changes in phenotype or genotype between baseline and follow up investigations.\n\n根据上述已知信息，请将'需要阴性对照来确立检测基线，并且表征\/验证检测方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Negative controls are needed to establish assay baselines and characterize\/validate the assays."
    },
    {
        "instruction":"已知信息：\n'（五）法律、法规规定应当注销行政许可的其他情形。'可被翻译为：(5) other circumstances where administrative licensing shall be canceled as stipulated by laws and regulations.\n'（四）化妆品生产许可依法被撤回、撤销或者化妆品生产许可证依法被吊销的；'可被翻译为：(4) Cosmetics Manufacturing License is withdrawn or canceled according to law, or the license for production of cosmetics is revoked according to law;\n'（八）法律法规规定的不应当批准的其他情形。'可被翻译为：(8) other circumstances in which applications shall not be approved according to laws and regulations.\n'11.法律法规规定的其他不应当通过的情形。'可被翻译为：11. Other circumstances that defined by laws and regulations that shall be deemed “Fail”.\n\n根据上述已知信息，请将'（五）法律法规规定应当注销化妆品生产许可的其他情形。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(5) Other circumstances where the cosmetics manufacturing license shall be cancelled as prescribed by laws and regulations."
    },
    {
        "instruction":"已知信息：\n'终点指标亚组'可被翻译为：endpoint subset\n'在同一剂量组中被分配至相同 终点指 标的个体动物集合。增强的围产期发育毒性试验 （Enhanced Pre - and Postnatal Development'可被翻译为：A set of individual animals within a dose group that are assigned to the same endpoint.\n'3.9 试验组和终点指标亚组的动物分配'可被翻译为：3.9 Allocation of Animals to Study Groups and Endpoint Subsets\n'这可以通过如何构建和标准化试验窝，并结合如何将试验窝分配至不同剂量组，以及 如何将个体幼仔分配至终点指标亚组来实现。'可被翻译为：This can be achieved by how the study litters are constructed and standardised in combination with how the study litters are assigned to dose groups and how the individual pups are assigned to endpoint subsets.\n\n根据上述已知信息，请将'终点指标亚组（Endpoint Subset）：在同一剂量组中被分配至相同终点指标的个体动物集合。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Endpoint Subset: A set of individual animals within a dose group that are assigned to the same endpoint."
    },
    {
        "instruction":"已知信息：\n'L. 快速响应码 快速响应码（QR码）是一种矩阵条码（或二维码），可以通过手机阅读。'可被翻译为：L. Quick Response Code A Quick Response Code (QR code) is a type of matrix bar code (or two-dimensional bar code) that can be read by a mobile phone.\n'它还可以提供支持或驳斥信号的信息。'可被翻译为：It could also provide information that either supports or refutes a signal.\n'FDA尚未设定QR 码在标签上的正式位置。'可被翻译为：FDA has not developed a formal position on the use of QR Codes.\n'申办方上诉联络人姓名、职称和联系信息（即，邮政地址，电子邮箱， 电话号码，传真号码）。'可被翻译为：The name, title, and contact information (i.e., mailing address, email address, telephone number, fax number) for the sponsor contact for the appeal.\n\n根据上述已知信息，请将'QR 码可以提供各种各样的信息（例如，互联网地址，电话号码）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"QR codes may provide various bits of information (e.g., Internet address, phone numbers)."
    },
    {
        "instruction":"已知信息：\n'对于具有抗增殖作用（在快速生长组织中很明显）且预期在不同种属间具有一致性的靶向快速分裂细胞的遗传毒性 药物（例如，核苷类似物，烷化剂，微管抑制剂），在一种 啮齿动物中的3个月毒性试验足以支持后续临床开发和注 册。'可被翻译为：For genotoxic drugs targeting rapidly dividing cells (e.g., nucleoside analogs, alkylating agents, microtubule inhibitors) that have anti-proliferative effects (evident in rapidly growing tissues) and are expected to be consistent across different species, toxicity studies in one rodent species of 3-month duration are considered sufficient for continued clinical development and registration.\n'根据基因治疗药品的性质， 可能需要进行遗传毒性研究。'可被翻译为：Genotoxicity studies might be required depending on the nature of the GTMP.\n'3.4 支持后续临床试验和上市的毒理学研究期限'可被翻译为：3.4 Duration of Toxicology Studies to Support Continued Clinical Development and Marketing\n'对于那些有遗传毒性且在一般毒理学试验中靶向快速分裂细胞（如crypt细胞、骨髓）的药物，或者归属于确定可引起发育毒性的药物类别，这些发育毒性试验在上市时也不是必需的。'可被翻译为：These studies are also not considered essential for the purpose of marketing applications for pharmaceuticals that are genotoxic and target rapidly dividing cells (e.g., crypt cells, bone marrow) in general toxicity studies or belong to a class that has been well characterized as causing developmental toxicity.\n\n根据上述已知信息，请将'3.4 对于靶向快速分裂细胞的遗传毒性药物，推荐何种一般毒理学研究以支持后续的临床开发，包括上市？'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"3.4 What general toxicology studies are recommended for continued clinical development, including marketing, for genotoxic drugs targeting rapidly dividing cells?"
    },
    {
        "instruction":"已知信息：\n'在原料、起始物或中间体的质量标准中包含杂质检查项，或作为过程控制项，采用合适的分析方法将杂质控制在可接受限度以内。'可被翻译为：Include a test for the impurity in the specification for a raw material, starting material or intermediate, or as an in-process control, with an acceptance criterion at or below the acceptable limit using an appropriate analytical procedure.\n'监管部门评估对原料药及原料药生产工艺的控制是否 进行了充分考虑，包括是否对杂质进行了适当的控制。'可被翻译为：Regulatory authorities assess whether the controls on the drug substance and drug substance manufacturing process can be considered adequate, including whether there are appropriate controls for impurities.\n'工艺相关杂质的控制（8.1） 开发原料药控制策略有 4 种可能的方法：方法1 在原料药质量标准中包含对杂质的检测，使用合适的分析规程将可接受标准 设定在可接受限度以内。'可被翻译为：8.1 Control of Process Related Impurities There are 4 potential approaches to development of a control strategy for drug substance: Option 1 Include a test for the impurity in the drug substance specification with an acceptance criterion at or below the acceptable limit using an appropriate analytical procedure.\n'因此，将中间体X中杂质A控制在1.0%的可接受限度是合理的， 无需在原料药标准中对该杂质进行检测。'可被翻译为：Therefore, control of the impurity A in the intermediate X with an acceptance limit of 1.0% is justified and no test is warranted for this impurity in the drug substance specification.\n\n根据上述已知信息，请将'原料药质量标准中包含杂质检查项，采用合适的分析方法将杂质控制在可接受限度以内。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Include a test for the impurity in the drug substance specification with an acceptance criterion at or below the acceptable limit using an appropriate analytical procedure."
    },
    {
        "instruction":"已知信息：\n'第二百一十条 使用切割式标签或在包装线以外单独打印 标签，应当采取专门措施，防止混淆。'可被翻译为：Article 210: Special care should be taken when using cut-labels and when over-printing is carried out off-line, to avoid mixups.\n'切割式标签或其他散装印刷包装材 料应当分别置于密闭容器内储运，以防混淆。'可被翻译为：Cut labels and other loose printed packaging materials should be stored and transported in separate closed containers so as to avoid mixups.\n'9.32 已打印批号或其他批信息的剩余标签均应当销毁。应当采取专门措施保存退回的标签，防止混淆并正确标识。'可被翻译为：9.32 All excess labels bearing batch numbers or other batch-related printing should be destroyed. Returned labels should be maintained and stored in a manner that prevents mix-ups and provides proper identification.\n'第二百零六条 有数条包装线同时进行包装时，应当采取隔离或其他有效防止污染、交叉污染或混淆的措施。'可被翻译为：Article 206 Appropriate segregation or other precautions to effectively prevent contamination, cross-contamination or mixups should be adopted if several packaging lines are working simultaneously.\n\n根据上述已知信息，请将'第二百一十条 使用切割式标签或在包装线以外单独打印标签，应当采取专门措施，防止混淆。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 210 Special care should be taken when using cut-labels and when over-printing is carried out off-line, to avoid mixups."
    },
    {
        "instruction":"已知信息：\n'Q8 本指导原则由指导委员会批准进入第四阶段，并推荐给ICH三方管理机构采纳。 2005年 11月10 日'可被翻译为：Q8 Approval of the Guideline by the Steering Committee under Step 4 and recommendation for adoption to the three ICH regulatory bodies. 10 November 2005\n'在2000年11月8日召开的ICH指导委员会会议上，ICH进程进入第四阶段， 本指导原则被推荐给ICH三方监管机构采纳'可被翻译为：Having reached Step 4 of the ICH Process at the ICH Steering Committee meeting on 8 November 2000, this guideline is recommended for adoption to the three regulatory parties to ICH\n'Q11 在增本指导原则由指导委员会批准进入第四阶段，并推荐给ICH三方监管机构采纳。'可被翻译为：Q11 Approval by the Steering Committee under Step 4 and recommendation for adoption to the three ICH regulatory bodies.\n'Q11 本指导原则由指导委员会批准进入第二阶段，并发布以公开征求意见。'可被翻译为：Q11 Approval by the Steering Committee under Step 2 and release for public consultation.\n\n根据上述已知信息，请将'本指导原则由ICH委员会批准进入第4阶段'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Approval by the ICH Assembly under Step 4"
    },
    {
        "instruction":"已知信息：\n'ICH Q7并未期望企业聘用顾问。'可被翻译为：ICH Q7 does not expect the use of a consultant.\n'ICH Q7并未专门说明应该由谁来取样【ICHQ7，第2.22章节】。'可被翻译为：ICH Q7 does not prescribe specifically who should perform the sampling [ICH Q7, Section 2.22].\n'14.1 不合格物料应该采用物理和安全隔离的方式贮存吗？'可被翻译为：14.1 June 2015 Should rejected materials be stored under physical and secure segregation?\n'如果采用其他方法替代物理隔离，则该方法应当具有同等的安全性。'可被翻译为：Any system replacing the physical quarantine should give equivalent security.\n\n根据上述已知信息，请将'ICH Q7并未明确要求采用物理和安全隔离。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"ICH Q7 does not specify a need for physical and secure segregation."
    },
    {
        "instruction":"已知信息：\n'使用肯定句有助于确保终端用户即使没有逐字逐句读说明依然能够理解预期 的给药途径22,23,24'可被翻译为：Using affirmative statements will help to ensure that end users understand the intended route of administration, even if they do not read every word.22,23,24\n'例如，“不用于鞘内”常被混淆为“用于鞘内”。肯定表达，如“仅 静脉使用”，“其他途径给药会产生致命后果”或“使用前必须稀释”更易理解。'可被翻译为：For example, the warning “Not for intrathecal use” has been confused as “For intrathecal use.” Affirmative statements such as “For Intravenous Use Only,” “Fatal if given by any other route,” or “Must Dilute Before Use” are more easily understood.\n'如推荐，当由于狭窄的治疗指数，通过使用基因组学BM调整给药，以仔细监测患者。'可被翻译为：as recommended when, because of narrow therapeutic index, dosing is adjusted by the use of a genomic BM, to carefully monitor the patients.\n'因静脉给药和腹腔注射给药的PK有本质差别（Sekiya, et al., 1985），故未使用静脉给药的数据。'可被翻译为：There are substantial differences in PK between the intravenous and intraperitoneal routes (Sekiya, et al., 1985), so intravenous data were not used.\n\n根据上述已知信息，请将'我们推荐使用肯定句，如“静脉使用”， “ 通过皮下注射给药”，”或“仅局部使用”。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"We recommend using positive statements such as “for intravenous use,” “give by subcutaneous injection,” or “topical use only.”"
    },
    {
        "instruction":"已知信息：\n'用户指导原则 该数据元素提供了元素D.7.1.r.1b 中的“医疗状况医疗状况”的其他相关信息，这些信息在结构化数据元素中无法被获取元素。例如在早产的情况下，出生体重应记录在此处；或者在缺乏精确日期的情况下，也可在此处提供有助于理解病史的文本说明（例如“自童年时期开始”）。'可被翻译为：User Guidance This data element provides additional relevant information about the ‘medical condition’ in D.7.1.r.1b that could not be captured otherwise in a structured data element. For example, in case of prematurity, the birth weight should be recorded here; or in the absence of imprecise dates, a text description that would aid in understanding the medical history (e.g. ‘since childhood’) can also be provided here.\n'D.10.3 母亲末次月经日期 用户指导原则 该数据元素获取母亲的末次月经日期。元素 一致性 可选择 数据类型 日期\/时间 OID 无 允许值 更多信息见附录II。 不完整信息：MSK、ASKU、NASK 业务规则 所需的最低精准度为年（即：“CCYY”）。 指定日期无法查阅未来日期。 关于使用不完整信息描述缺失或未传输的信息的进一步指导原则，请参见第 3.3.6 节。'可被翻译为：D.10.3 Last Menstrual Period Date of Parent User Guidance This data element captures the date of the last menstrual period for the parent. Conformance Optional Data Type Date \/ Time OID None Value Allowed See Appendix II for further information. nullFlavor: MSK, ASKU, NASK Business Rule(s) Minimum precision required is the year (i.e. ‘CCYY’). The date specified cannot refer to a future date. Please see Section 3.3.6 for further guidance on the use of nullFlavor to describe missing or non-transmitted information.\n'D.10.3母亲末次月经日期'可被翻译为：D.10.3 Last Menstrual Period Date of Parent\n'用户指导原则 该数据元素获取患者的末次月经日期元素（如相关）。'可被翻译为：User Guidance This data element captures the date of the last menstrual period of the patient when it is relevant.\n\n根据上述已知信息，请将'可包括不精确的日期（例如年份和月份或仅年份）。应在数据元素元素D.7.1.r中记录关于更年期或更年期相关疾病的其他信息。如此报告是针对儿童\/胎儿的，应在数据元素D.10.3中记录母亲的末次月经日期。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Imprecise dates can be included (e.g. month and year, or year only).Other information on menopause or conditions related to menopause should be captured in the data element D.7.1.r. If this report is for a child\/foetus, then the mother’s last menstrual period is captured in the data element D.10.3."
    },
    {
        "instruction":"已知信息：\n'可以评价各区域间处理效应的一 致性，如果观察到临床相关差异，则应进一步研究并确定这些差异 是否由内在或外在因素差异所致（参见第2.2.7节）。'可被翻译为：Consistency of treatment effects across regions is evaluated, and if clinically relevant differences are observed, there should be further exploration to determine if these differences can be at- tributed to differences in intrinsic or extrinsic factors (see Section 2.2.7).\n'分析应该显示临床治疗之间差异 的大小（点估计）、相关的置信区间以及假设检验的结果。'可被翻译为：The analysis should show the size (point estimate) of the difference between the treatments, the associated confidence interval, and where utilised, the results of hypothesis testing.\n'不应仅针对完成研究的患者子集评估临床试验的结果， 而且还应对整个随机患者群体进行评估，或至少对所有具有 任意一次研究测量结果的患者进行评估。'可被翻译为：The results of a clinical trial should be assessed not only for the subset of patients who completed the study, but also for the entire patient population as randomised or at least for all those with any on-study measurements.\n'对于每隔一段时间重复进行关键疗效变量测量或评估 （例如血液或尿液培养，肺功能测试，心绞痛频率或整体评估）的对照试验，报告附带的数据列表应包括每位试验患者 的识别码，关键变量的所有测量值或观察值（包括基线测量 值），并标注试验期间的测量时间（例如，治疗日和治疗时 间，如相关），该时间点的药物\/剂量（如需要，以mg \/ kg表 示），任何依从性的评估结果、进行测量和评估时或临近时 间内使用的任何伴随用药。'可被翻译为：For a controlled study in which critical efficacy measurements or assessments (e.g., blood or urine cultures, pulmonary function tests, angina frequency, or global evaluations) are repeated at intervals, the data listings accompanying the report should include, for each patient, a patient identifier, all measured or observed values of critical measurements, including baseline measurements, with notation of the time during the study (e.g., days on therapy and time of day, if relevant) when the measurements were made, the drug\/dose at the time (if useful, given as mg\/kg), any measurements of compliance, and any concomitant medications at the time of, or close to the time of, measurement or assessment.\n\n根据上述已知信息，请将'如果任何疗效或安全性结果的关键测量或评估是由多 方（例如，研究者和专业委员会可提供关于患者是否发生急 性梗塞的意见）合作完成的，应该显示各方评定尺度的整体 差异，并且应识别具有不同评价结果的个体患者。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"If any critical measurements or assessments of efficacy or safety outcomes were made by more than one party (e.g., both the investigator and an expert committee may offer an opinion on whether a patient had an acute infarction), overall differences between the ratings should be shown, and each patient having disparate assessments should be identified."
    },
    {
        "instruction":"已知信息：\n'需要进行药物的剂量探索研究。'可被翻译为：Appropriate dose finding study (studies) needs to be undertaken.\n'探索性研究旨在考察药物在特定患者群体中的安全性 和有效性。'可被翻译为：Exploratory studies are designed to investigate safety and efficacy in a selected population of patients for whom the drug is intended.\n'在药物开发过 程中，该研究是否为浓 度-反应建模提供了一 个合理的方法?'可被翻译为：Has this investigation yielded a reasonable approach to concentration-response modeling during drug development?\n'治疗探索性研究'可被翻译为：Therapeutic exploratory studies\n\n根据上述已知信息，请将'在合理的药物开发中，探索性研究是必不可少的。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Exploratory studies are essential in rational drug development."
    },
    {
        "instruction":"已知信息：\n'二、申请豁免进行人体生物等效性试验，须在申请表中注明。经评审不能豁免，实质缺陷不能纠正的，不要求申请人提供补充材料，不予批准注册申请。'可被翻译为：II. Applying for exemption from human bio equivalence tests shall be indicated in the application form. If the exemption cannot be made after evaluation, and the substantial defects cannot be corrected, the applicant will not be required to provide supplementary materials, and the registration application shall be disapproved.\n'若满足以下条件，其它规格的体内生物等效性试验可豁免：（i）规定的规格生物等效性试验结果可接受；（ii）所有规格体外溶解试验结果可接受，或者（iii） 所有规格制剂的处方比例相似18'可被翻译为：An in vivo BE requirement for one or more strength(s) can be waived based on (i) acceptable BE study on the designated strength, (ii) acceptable in vitro dissolution testing of all the strengths, and (iii) proportional similarity of the formulations across all strengths.18\n'三、如果先前发布的《人类生物等效性试验豁免指南》与M9指南不一致，应以M9指南为准。'可被翻译为：III. In case of inconsistency between the previously issued Guideline for Exemption from Human Bio equivalence Tests and the M9 Guideline, the M9 Guideline shall prevail.\n'（一）开展生物等效性试验未备案；'可被翻译为：(1) conduct bioequivalence trial without filing;\n\n根据上述已知信息，请将'一、如果经申报人评估符合M9要求，申报人可直接在药品注册申请中提出免除人体生物等效性试验。国家药监局不会单独发布免人生物等效性试验或简化人生物等效性试验的品种目录。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"I. If M9 requirements are met according to the assessment by the applicant, the applicant can directly propose exemption of human bio equivalence test in the drug registration application. NMPA will not issue a separate catalogue of varieties exempted from human bioequivalence test or subject to simplified human bio equivalence test."
    },
    {
        "instruction":"已知信息：\n'在这些情况下， 需要针对不同年龄组的儿童患 者进行验证性随机、对照研究以支持疗效和安全性。'可被翻译为：In these instances, confirmatory randomised and controlled studies in children of different age groups will be required to support efficacy and safety\n'如果产品预期应用于儿童，则通常希望在该年龄组中开展临床研究。'可被翻译为：If the product is indicated for children, clinical studies are usually expected to be carried out in this age group.\n'变应原免疫治疗药物的有效性应在专门的儿童人群试验中进行评估，而非既包括儿童人群又包括成人的综合性试验。'可被翻译为：The efficacy of products for allergen immunotherapy should be evaluated in special trials in the paediatric population and not in combined trials including children and adults.\n'通常在成人研究中的建议也适用于在儿童人群中的研究。'可被翻译为：The recommendations for studies in adults are also valid for studies in paediatric populations.\n\n根据上述已知信息，请将'儿童试验常在成人试验后进行，对儿童的研究会主要设立适用于这一组患者的具体问题，'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"As paediatric development usually follows studies in adults, studies in children will be mainly to establish specific questions as applicable to this group of patients."
    },
    {
        "instruction":"已知信息：\n'国家医疗器械不良事件监测年度报告'可被翻译为：Release of Annual Report for National Medical Device Adverse Event Monitoring (2018)\n'2018年，在全国医疗器械不良事件监测工作人员的开拓努力下，全国医疗器械不良事件监测工作持续推进，监测范围不断扩大，报告收集能力明显提升，报告数量继续增加。监测人员不良事件分析评价能力不断提高，有效提高了风险的发现和处置能力，生产企业不良事件监测主体责任逐步得到落实，医疗器械不良事件监测工作取得了新的进展︰'可被翻译为：In 2018, with the pioneering efforts of our staff, the national medical device adverse event monitoring has continued to advance, the monitoring scope continued to expand, the report collection capability was significantly improved, and the number of reports saw a persistent increase. The ability of monitoring personnel to analyze and evaluate adverse events has been continuously improved to effectively detect and deal with risks, the principal responsibility of manufacturers' monitoring of adverse events has been gradually implemented, and new progress has been made in this field.\n'为全面反映2019年我国医疗器械不良事件监测情况，国家药品不良反应监测中心编撰了《国家医疗器械不良事件监测年度报告（2019年）》。'可被翻译为：To fully reflect the monitoring of adverse events in relation to China's medical devices in 2019, the National Center for Adverse Drug Reaction Monitoring has compiled and released the Annual Report for National Medical Device Adverse Event Monitoring (2019).\n'为全面反映2019年我国药品不良反应监测情况，提高安全用药水平，更好地保障公众用药安全，国家药品不良反应监测中心组织编撰《国家药品不良反应监测年度报告（2019年）》。'可被翻译为：To fully reflect the status of China's adverse drug reaction (ADR) monitoring in 2019, improve the level of safe drug use, and better ensure drug safety for the public, the National Center for ADR Monitoring has organized the compilation of the Annual Report for National Adverse Drug Reaction Monitoring (2019)\n\n根据上述已知信息，请将'为全面反映2018年我国医疗器械不良事件监测情况，国家药品不良反应监测中心编撰了《国家医疗器械不良事件监测年度报告(2018年)》。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"To fully reflect the monitoring of adverse events in China's medical devices in 2018,the National Center for Adverse Drug Reaction Monitoring has compiled and released on October 30, 2019 the Annual Report for National Medical Device Adverse Event Monitoring (2018), which is excerpted as follows:"
    },
    {
        "instruction":"已知信息：\n'筛选抗菌药物及评价其药效的各种模型。'可被翻译为：Models for the screening of antimicrobial agents and the evaluation of their efficacy.\n'在药物筛选中所应用的分子、细胞、组织、器官或整体的实验模型。'可被翻译为：An experimental model of a molecule, cell, tissue, organ, or whole body used in drug screening.\n'筛选抗病毒化合物及评价抗病毒药效的人工感染模型。'可被翻译为：Artificial infection models for screening antiviral compounds and evaluating antiviral efficacy.\n'利用临床上有致病力的寄生虫在动物体内复制出与临床病理变化相似感染模型。用于相应抗寄生药物的筛选及药效评价。'可被翻译为：Infection models similar to clinicopathological changes were replicated in animals using clinically pathogenic parasites. It is used for screening and pharmacodynamic evaluation of corresponding anti-parasitic drugs.\n\n根据上述已知信息，请将'筛选抗肿瘤药物及评价其药效的体内外模型。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"An in vivo and in vitro model for screening antitumor drugs and evaluating their efficacy."
    },
    {
        "instruction":"已知信息：\n'如何护理这样的个体尚无足够的科学证据，因为多病在老年个体的临床试验中常作为排除标准（1，69）。'可被翻译为：There is still little scientific evidence on how to care for such individuals, as multimorbidity is frequently used as an exclusion criterion for clinical trials in older people (1, 69).\n'这些常常发生的排除导致一种“偏证”情形，正好与老年人的循证医学相对立。'可被翻译为：Such frequent exclusion has generated a situation of \"evidence biased\", as opposed to evidence based medicine for older adults.\n'此外，老年人更常使用各种伴随用药。'可被翻译为：Moreover, older people do more frequently receive a variety of concomitant medication.\n'哮喘治疗药物临床研究指导原则 目录 执行摘要'可被翻译为：Guideline on the clinical investigation of medicinal products for the treatment of asthma Table of contents Executive summary\n\n根据上述已知信息，请将'执行摘要 因大量慢性病，老年人是药物的大客户；尽管这样，临床试验常将其排除。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Executive summary Older persons are large drugs consumers for a number of chronic diseases, but despite this they have often been excluded from clinical trials."
    },
    {
        "instruction":"已知信息：\n'4 2009年4 月 是否有针对PQS 是否符合ICH Q10要求 的认证？'可被翻译为：4 April 2009 Will there be certification that the PQS is in accordance with ICH Q10?\n'Q10. \tHIPAA授权（常与知情同意文件结合）是否可通过电子方式获得？'可被翻译为：Q10. Can HIPAA authorizations for research, which are frequently combined with informed consent documents, be obtained electronically?\n'可提供方法以实现目标的一种工具或程序。 (ICH Q10)'可被翻译为：A tool or process which provides the means to achieve an objective. (ICH Q10)\n'如没有合适的ICH或ISO定义，则拟定ICH Q10的定义。'可被翻译为：Where no appropriate ICH or ISO definition was available, an ICH Q10 definition was developed.\n\n根据上述已知信息，请将'没有。不会有特殊的ICH Q10认证程序。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"No. There will not be a specific ICH Q10 certification programme."
    },
    {
        "instruction":"已知信息：\n'如果得不到“相关”病毒，或它不太适用于病毒清除的工艺评价研究（如不能离体培养到足够的滴度）， 应使用特异“模型”病毒代替。'可被翻译为：When a “relevant” virus is not available or when it is not well adapted to process evaluation of viral clearance studies (e.g., it cannot be grown in vitro to sufficiently high titers), a specific “model” virus should be used as a substitute.\n'如果不能使用已鉴定的病毒，应使用相关模型 病毒或特异模型病毒来评估其工艺清除效果是否可被接受。'可被翻译为：If it is not possible to use the identified virus, “relevant” or specific “model” viruses should be used to demonstrate acceptable clearance.\n'在灭活的关键步骤，应对已鉴定的病毒（或相关模型病毒或 特异模型病毒）进行时效性灭活，作为对这些病毒工艺评价 的一部分。'可被翻译为：Time-dependent inactivation for identified (or “relevant” or specific “model”) viruses at the critical inactivation step(s) should be obtained as part of process evaluation for these viruses.\n'在选择清除研究用病毒时，首先要明确对已知病毒清除的工艺评价和对用非特异模型病毒（后文叙述）进行的工艺病毒去除验证的评估之间的区别。'可被翻译为：In selecting viruses to use for a clearance study, it is useful to distinguish between the need to evaluate processes for their ability to clear viruses that are known to be present and the desire to estimate the robustness of the process by characterising the clearance of non-specific “model” viruses (described later).\n\n根据上述已知信息，请将'如无法使用该病毒，应使用“相关”和\/或特异模型病毒（后文叙述）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"If it is not possible to use the identified virus, “relevant” and\/or specific “model” viruses (described later) should be used."
    },
    {
        "instruction":"已知信息：\n'章节16.1：安全性问题的总结 对于这一课题的讨论，请参见疑问13.4的解答。'可被翻译为：Section 16.1: Summary of Safety Concerns For a discussion on this topic, please refer to the answer for Question 13.4.\n'3.16 信号和风险评估 PBRER的章节16的目的是提供： 简要介绍在报告覆盖的时间段开始时重要的已确定和潜在风险以及重 要的缺失信息*（16.1）；'可被翻译为：3.16 Signal and Risk Evaluation The purpose of Section 16 of the PBRER is to provide: A succinct summary of what is known about important identified and potential risks and important missing information* at the beginning of the reporting interval covered by the report (16.1);\n'在PBRER的章节16.4中，MAH应对风险的公众健康影响进行评估，作为对PBRER 目的的重要风险的表征的一部分。'可被翻译为：In Section 16.4 of the PBRER, the MAH should present its evaluation of the public health impact of the risk as part of the characterisation of important risk(s) for the purposes of the PBRER.\n'信号评估的描述可以包括在PBRER的这一章节或附录中。'可被翻译为：The description(s) of the signal evaluations can be included in this section of the PBRER, or in an appendix.\n\n根据上述已知信息，请将'如果使用这一方法，在章节16.1中列出的所有安全性问题应在PBRER章节16.4中 表征，包括对重要缺失信息进行描述。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"If this method is used, all the safety concerns listed in Section 16.1 should be characterised in Section 16.4 of the PBRER, including a description of the important missing information."
    },
    {
        "instruction":"已知信息：\n'鼓励申办方探索另外的、新出现的方法来估计不治疗 的作用，例如使用基于药物计量学的方法。'可被翻译为：Sponsors are encouraged to explore alternative and emerging methods for estimating the no-treatment effect (e.g. using pharmacometric-based approaches).\n'选择的种属和模型应与正在开发的药物的特定临床适应症相关。'可被翻译为：Species and models selected should be relevant to the specific clinical indication for which the drug is being developed.\n'对于血液学恶性肿瘤而言，在许多情况下疾病特定缓解标准往往无法避免，并且某些病种还未实现完全协调。因此，及时跟进国际工作组在这些问题上取得的进展就显得十分重要。特别是，当在新的临床指导原则中引入更为开放的疾病特定缓解标准时，希望申办者能重点对药物开发方面进行解释。'可被翻译为：The use of tumour biomarkers and other dynamic measures of activity is encouraged. In haematological malignancies, disease specific response criteria are unavoidable in many cases and full harmonization has not yet been accomplished for some disease entities. Therefore it is of importance to follow the progress made by international working groups on these issues. Especially if less conservative disease specific response criteria are introduced in new clinical guidelines, a justification with focus on aspects of drug development is expected from the sponsor.\n'该附录引入了疾病特异性指导，而且重构了以治疗和相对毒性目 的为基础的验证性研究章节。'可被翻译为：In this appendix disease specific guidance was introduced and the section on confirmatory studies based on aims of therapy and relative toxicity was restructured.\n\n根据上述已知信息，请将'特别是如果在新的临床指导原则中引入了不太保守的疾病特异 性缓解标准时，期望获得申办方的关于药物开发的理由。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Especially if less conservative disease specific response criteria are introduced in new clinical guidelines, a justification with focus on aspects of drug development is expected from the sponsor."
    },
    {
        "instruction":"已知信息：\n'基因嵌入'可被翻译为：gene intercalation\n'DNA或RNA的一种突变形式，在多核昔酸链内插入了一个或多个额外核昔酸的过程。（2）在DNA或RNA链中增加一个或多个额外核昔酸的过程。'可被翻译为：A mutated form of DNA or RNA in which one or more additional nucleotides are inserted into a polynucleoxylic acid chain. (2) A process by which one or more additional nucleotides are added to a strand of DNA or RNA.\n'抗原与抗体、配体与受体等分子之间的结合是一对一的关系，这种一对一的反应称特异性反应。'可被翻译为：The binding between antigens and antibodies, ligand and receptors and other molecules is a one-to-one relationship, and this one-to-one reaction is called a specific reaction.\n'计算被设计的药物分子与受体结合的空间和电性的互补性，修饰并优化药物分子的取代基和分子构象，优化受体与配体间相互作用的过程。'可被翻译为：Calculate the spatial and electrical complementarity of the binding of the designed drug molecule with the receptor, modify and optimize the substitution group and molecular conformation of the drug molecule, and optimize the interaction process between the receptor and ligand.\n\n根据上述已知信息，请将'化学上指在两个分子或基团之间加入一个分子，过程可逆。DNA嵌入时有许多分子可与生物体内的DNA发生交互作用，以配体为例，嵌入是配体分子与DNA的一种结合方式，当配体大小符合碱基对之间的空隙 时，就有可能插入其中，从而造成DNA分 子结构的扭曲变形。通常嵌入DNA的配体 是多环类、芳香类，或是平面分子。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Chemically, the insertion of a molecule between two molecules or groups in a reversible process. When DNA is embedded, many molecules can interact with DNA in living organisms. Take ligand as an example, embedding is a way of binding ligand molecules to DNA. When the size of ligand meets the gap between the base pairs, it is possible to insert it, resulting in the distortion of the DNA substructure. Usually ligands embedded in DNA are polycyclic, aromatic, or planar molecules."
    },
    {
        "instruction":"已知信息：\n'此类差异可 能影响试验结果和\/或对试验结果的解释。'可被翻译为：Such differences may have an impact on the trial results and\/or their interpretation.\n'（1）比较个别研究以更好地理解整体结果（见第III.C.1节，个别研究的结果 的比较）；和'可被翻译为：(1) comparing the individual studies to better understand the overall results (see section III.C.1., Comparison of Results of Individual Studies); and\n'在大多数情况下，跨研究汇总的数据的亚群效应的分析比个别研究中的分析更有可能具有足够的功效来评价差异。'可被翻译为：In most cases, analyses of subpopulation effects in data pooled across studies are more likely than analyses in individual studies to have adequate power to assess differences.\n'如上所述，综合亚群分析应包括个别研究（在个别研究中的亚群足够大以使其有用）和汇总分析。'可被翻译为：As noted, the integrated subpopulation analyses should include both individual studies (where subpopulations are large enough for this to be useful) and pooled analyses.\n\n根据上述已知信息，请将'个别研究之间的差异可影响汇总分析的有效性和可解释性。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Differences among individual studies can affect the validity and interpretability of pooled analyses."
    },
    {
        "instruction":"已知信息：\n'压缩正常时出现异常CUS，或是，在筛选期间不可压缩，在完全压缩期间血栓直径大幅增加（4毫米或以上）；'可被翻译为：Abnormal CUS where compression had been normal or, if non-compressible during screening, a substantial increase (4 mm or more) in diameter of the thrombus during full compression;\n'一些可能有用的成像技术可能不会被常规性地使用（如新引 进的或者已有的影像诊断学）和\/或可能难以解读（如幼儿的胸片） 。'可被翻译为：Some potentially useful imaging techniques may not be in routine use (e.g. newly-introduced or experimental diagnostic imaging) and\/or may be difficult to interpret (e.g. chest radiographs in young children).\n'血栓形成'可被翻译为：Thrombogenicity\n'（例如：血栓形成后综合征和慢性血栓栓塞性肺动脉高压）。'可被翻译为：(i.e.: the post-thrombotic syndrome and chronic thromboembolic pulmonary hypertension).\n\n根据上述已知信息，请将'CUS成像可能产生技术上的困难，或异常更多的提示既往血栓而不是最近形成的血栓，这些情况并不少见。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Not infrequently, CUS imaging may be technically difficult, or the abnormality is more suggestive of old rather than recent thrombosis."
    },
    {
        "instruction":"已知信息：\n'可重复性'可被翻译为：repeatability\n'宿主细胞 见母细胞。'可被翻译为：Host cells See Parental cells.\n'CHO细胞hprt试验：（有或无代谢活化条件下）。'可被翻译为：CHO cell hprt assay with and without metabolic activation.\n'细菌回复突变试验（Ames）：有或无代谢活化条件下，鼠伤寒沙门氏菌TA1535、TA102、TA98和TA100以及大肠杆菌WP2 uvrA表现出致突变性；可在体外导致小鼠淋巴瘤L5178Y细胞的Tk和hprt基因发生突变。'可被翻译为：Microbial reverse mutation assay (Ames), Salmonella typhimurium strains TA 1535, TA 102, TA 98 and TA 100, and in Escherichia coli strain WP2 uvrA, with and without activation; In vitro mouse lymphoma L5178Y cells, in tk and hprt genes.\n\n根据上述已知信息，请将'人淋巴母细胞和小鼠淋巴瘤细胞（有或无代谢活化条件下）中的可重复性；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Human lymphoblasts and mouse lymphoma cells, reproducibly with S9, in some cases without S9;"
    },
    {
        "instruction":"已知信息：\n'由肾上腺皮质所分泌的，可以调节体内糖和水盐代谢的类固醇激素。'可被翻译为：A steroid hormone secreted by the adrenal cortex that regulates the metabolism of sugars and salts in the body.\n'调节性腺分泌或对性功能进行干扰类药物的总称。如雌激素、雄激素、孕激素等。'可被翻译为：A general term for drugs that regulate gonadal secretion or interfere with sexual function. Such as estrogen, androgen, progesterone, etc.\n'由活细胞合成的、对其特异底物起高效催化作用的蛋白质或结合蛋白。'可被翻译为：A protein or binding protein synthesized by living cells that acts as an efficient catalyst for their specific substrates.\n'一般为肽类，能增强或减弱神经元对神经递质反应，起调节作用。'可被翻译为：Usually peptides, which can enhance or weaken the response of neurons to neurotransmitters and play a regulatory role.\n\n根据上述已知信息，请将'由内分泌腺或内分泌细胞分泌的高效生物活性物质。在体内作为信使传递信息，对机体生理过程起调节作用。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A highly bioactive substance secreted by endocrine glands or endocrine cells. It acts as a messenger in the body to carry information and regulate physiological processes."
    },
    {
        "instruction":"已知信息：\n'主要分析应使用由中心实验室进行的血清学研究的结果。'可被翻译为：The results of serology performed at centralised laboratories should be used in the primary analysis.\n'其他检测应该在中心实验室完成。'可被翻译为：Other assessments should be done in central laboratories.\n'临床研究中，建议由配备适当的专业人员的中心实验室对从认可的当地实验室获 得的鉴定和药敏试验结果进行确认， 独立分型以区别于新感染的复发， 并进行血清学研究。'可被翻译为：During clinical studies it is recommended that the confirmation of identification and susceptibility test results obtained from accredited local laboratories, isolate typing to distinguish relapses from new infections and serological studies should be conducted at designated centralised laboratories with appropriate expertise.\n'最好是临床开发项目中的所有研究都通过指定中心实验室对分离株鉴定和药敏试验的结果进行再确认。'可被翻译为：It is preferable that all studies in the clinical development programme should employ re-confirmation of isolate identity and susceptibility testing at designated central laboratories.\n\n根据上述已知信息，请将'应该主要由有相应专长的中心实验室进行血清学研究或确认结果。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Central laboratories with appropriate expertise should be used for the primary conduct of serological studies or for the confirmation of results."
    },
    {
        "instruction":"已知信息：\n'用户指导原则 根据该数据元素获取发送者的职称。'可被翻译为：User Guidance This data element captures the sender’s title.\n'用户指导原则 该数据元素获取报告者的资格。'可被翻译为：User Guidance This data element captures the reporter qualification.\n'用户指导原则 根据该数据元素获取报告者的姓氏。元素'可被翻译为：User Guidance This data element captures the reporter's family name.\n'用户指导原则  根据该数据元素获取报告者所在城市的名称。'可被翻译为：User Guidance This data element captures the reporter's city name.\n\n根据上述已知信息，请将'用户指导原则 根据该数据元素获取报告者的职称。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"User Guidance This data element captures the reporter's title."
    },
    {
        "instruction":"已知信息：\n'表A-1：用于病毒清除研究的病毒举例'可被翻译为：Table A-1 : Examples of Viruses Which Have Been Used in Viral Clearance Studies\n'C.病毒清除研究的说明'可被翻译为：C. Interpretation of Viral Clearance Studies\n'附录2和表A-1例举了代表不同物理化学结构的“模型” 病毒以及已用于病毒清除研究的一些病毒。'可被翻译为：Examples of useful “model” viruses representing a range of physico-chemical structures and examples of viruses which have been used in viral clearance studies are given in Appendix 2 and Table A-1. 2.\n'附录2病毒清除研究中病毒的选择'可被翻译为：APPENDIX 2 The Choice of Viruses for Viral Clearance Studies\n\n根据上述已知信息，请将'B. 已应用于病毒清除研究的病毒举例 表A-1列举了已用于病毒清除研究的病毒。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"B. Examples of viruses which have been used in viral clearance studies Several viruses which have been used in viral clearance studies are listed in Table A-1."
    },
    {
        "instruction":"已知信息：\n'目前实际的诊断方法是在出现痴呆症状之前，需要具有至少一年以上的帕金森病主要运动症状。'可被翻译为：A current pragmatic approach requires at least one year of major parkinsonian motor symptoms before the onset of dementia symptoms appears.\n'对于症状治疗，可能需要至少 12 个月的长期有效性研究，因为症状随时间的变化可能较为缓慢。'可被翻译为：Longer efficacy studies of at least 12 months for symptomatic treatments might be needed since changes of symptoms over time evolve more slowly.\n'提示预后不良的因素为症状出现时年龄较大、从初次出现症状到作出诊断的时间短、延髓 起病及呼吸功能恶化。'可被翻译为：Prognostically unfavourable factors are older age at time of onset of symptoms, short time from first symptoms to diagnosis, bulbar onset and worsening respiratory function.\n'已鉴定出数个候选的蛋白水平、神经生理学和神经影像学ALS生物标志物，但到 目前为止仍没有一个可经充分验证来用作临床结局的诊断或替代参数（Turner 2009; Bowser 2011）。'可被翻译为：Several candidate protein-based, neurophysiological and neuroimaging biomarkers for ALS have been identified but until now none has been sufficiently validated for use as a diagnostic or surrogate parameter for clinical outcome (Turner 2009; Bowser 2011).\n\n根据上述已知信息，请将'其症状往往要到出现明显的运动功能丧失时才会被辨认出，并且从发病到确诊之 间的平均诊断延迟时间仍有约1年（Mitchell 2010; Bowser 2011）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Symptoms are often not recognised until considerable motor function has been lost and the mean delay from presentation to diagnosis is approximately 1 year (Mitchell 2010; Bowser 2011)."
    },
    {
        "instruction":"已知信息：\n'第二十四条 核查组应当由2名以上具备药品检查员资格的人员组成，实行组长负责制。根据核查品种的具体情况，可有相关领域专家参与注册核查。对药品审评中心启动的有因检查，药品审评中心原则上应当派员参加。'可被翻译为：Article 24 The inspection team shall be composed of two or more persons who are qualified as drug inspectors, and the team leader shall assume overall responsibility. According to the specific conditions of the inspected varieties, experts in related fields may participate in the registration inspection. The CDE shall, in principle, send personnel to participate in cause-related inspections initiated by it.\n'核查中心和省级局可分别组建检查组， 或共同组建一个检查组。原则上注册核查与上市前 GMP 检查选择在同一生产周期内开展。'可被翻译为：The CFDI and the provincial authority may form separate inspection teams or jointly form an inspection team. In principle, the registration inspection, and the Pre-market GMP inspection should be carried out in the same production period.\n'第六条 根据法规要求和职能， 核查中心和省级局按程序组建检查组，完成药品注册现场核查和上市前 GMP 检查工作。'可被翻译为：Article 6 In accordance with the requirements and functions of laws and regulations, the CFDI and provincial authorities shall form inspection team in accordance with procedures to complete the drug registration inspection and Pre-market GMP inspection.\n'第三条 核查中心协调省级局同步实施检查工作时，双方应当根据法规要求和各自职能，遵循风险管理的理念，共同合作，保证注册核查与上市前GMP 检查的有机衔接。'可被翻译为：Article 3 When the CFDI coordinates the collaborative inspections with provincial authorities, both parties shall, in accordance with the regulatory requirements and their respective functions, follow the concept of risk management and work together to ensure the smooth collaboration between registration inspection and Pre-market GMP inspection.\n\n根据上述已知信息，请将'如共同组建检查组，检查组长和组员均应为国家药品GMP 检查员。检查组长由核查中心和省级局共同协商确定。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"If an inspection team is formed together, the inspection team leader and team members should be qualified national GMP inspectors. The inspection team leader shall be determined by the CFDI and the provincial authority through joint discussion."
    },
    {
        "instruction":"已知信息：\n'是否属于重要风 险将取决于多个因素，包括对个人的影响、风险的严 重性以及对公众健康的影响。'可被翻译为：What constitutes an important risk will depend upon several factors, including the impact on the individual, the seriousness of the risk, and the impact on public health.\n'关于风险，请考虑其临床重要性，例如毒性的性质、严重性、频率、 可预测性、可预防性、可逆性、对患者的影响、以及它是否源于标签 外使用、新用途或误用。'可被翻译为：With respect to risk, consider its clinical importance, e.g., nature of toxicity, seriousness, frequency, predictability, preventability, reversibility, impact on patients, and whether it arose from off-label use, a new use, or misuse.\n'在评估个体风险的公众健康影响时，MAH应考虑 以下要点（其目的只是说明而不是综合性的）：产品使用的程度（治疗人群的大小），频率和健康后果（包括严重性、可预防性和可逆性的考虑）。'可被翻译为：In assessing the public health impact of individual risks, the MAH should consider the following points that are intended to be illustrative rather than comprehensive: extent of product use (size of treated population), frequency, and health consequences (including consideration of seriousness, preventability, and reversibility).\n'可能会影响产品的风险-利益特征或对公众健康产生影响的已确定风险或潜在风险。是否属于重要风险将取决于多个因素，包括对个人的影响、风险的严重性以及对公众健康的影响。通常，有可能被纳入产品标签中的禁忌，警告和注意事项章节的任何风险都应该被认为是重要的风险。'可被翻译为：An identified risk or potential risk that could impact on the risk-benefit profile of the product or have implications for public health. What constitutes an important risk will depend upon several factors, including the impact on the individual, the seriousness of the risk, and the impact on public health. Normally, any risk that is likely to be included in the contraindications or warnings and precautions section of the product labelling should be considered important.\n\n根据上述已知信息，请将'在确定风险是否重要时应考虑以下因素： 风险的医学严重性，包括对个体患者的影响； 其频率、可预测性、可预防性和可逆性； 对公众健康的潜在影响（频率，治疗人群的大小）；和 由于公众对风险的认识，避免使用具有预防作用的医疗产品的可能性。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The following factors should be considered when determining whether or not a risk is important: Medical seriousness of the risk, including the impact on individual patients; Its frequency, predictability, preventability, and reversibility; Potential impact on public health (frequency; size of treated population); and Potential for avoidance of a medical product with a preventive benefit as a result of public perception of risk."
    },
    {
        "instruction":"已知信息：\n'这样才能评估抗体发生的临床意义，以及抗体效应是否随时间变化，这种变化可能是因为滴度变化和\/或抗体反应的同种型变化\/亲和性成熟导致的。'可被翻译为：This allows assessment of the clinical significance of antibody development, and also whether the antibody effect changes over time, which could occur as a result of increase in titre and\/or isotype switching\/affinity maturation of the antibody response.\n'在这种情况下，要考虑更广泛地监 测与治疗结果有关的抗-单抗反应动力学。'可被翻译为：In such cases, more extensive monitoring of the anti-mAb response dynamics relative to therapeutic outcome may have to be considered.\n'这适用于抗体测定和表征所采用的测定法以及评价对抗体的临床应答（如果诱导出临床应答）所采用的方法。'可被翻译为：This applies to assays used to measure and characterise antibodies and to methods employed for assessing clinical responses to antibodies if they are induced.\n'8.1. 抽样计划的依据和抗体应答的动力学'可被翻译为：8.1. Rationale for sampling schedule and kinetics of the antibody response\n\n根据上述已知信息，请将'抗体生成和持续时间的动力学以及抗体应答程度的评价较为重要，因为这与临床后果相关。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Evaluation of the kinetics of antibody development and the duration as well as the magnitude of the antibody response is important as it may correlate with clinical consequences."
    },
    {
        "instruction":"已知信息：\n'在下文中讨论在不同类别的长持续时间疼痛中的合适的疼痛模型示例。'可被翻译为：Examples for suitable pain models in the different categories of pain of long duration are discussed in the following.\n'为了证明治疗急性疼痛的一般适应症是合理的，需要在躯体和内脏疼痛模型中或在躯体疼痛和躯体\/内脏混合疼痛模型中独立证明有效性。'可被翻译为：To justify a general indication for the treatment of acute pain, efficacy needs to be demonstrated independently in models of both somatic and visceral pain, or in models of somatic pain and mixed somatic\/visceral pain.\n'在急性疼痛试验中，研究持续时间可以从几小时到几周不等，取决于所研究的疼痛模型或临床情况。'可被翻译为：Study duration may vary from hours to weeks in acute pain trials, depending on the pain model or clinical situation being studied.\n'在突破性疼痛的情况下，来自更普遍疼痛模型的临床数据将适合于此目的。'可被翻译为：In the case of breakthrough pain clinical data from more general pain models will be appropriate for this purpose.\n\n根据上述已知信息，请将'表1：适合用于急性疼痛的有效性研究的疼痛模型示例'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Table 1: Examples of pain models appropriate to be used in efficacy studies in acute pain Pain"
    },
    {
        "instruction":"已知信息：\n'未测量的混杂因素可能会影响研究的有效性。'可被翻译为：Unmeasured confounders can affect the study validity.\n'对未测量的混杂因素及其它相关来源的偏倚的可能影响应进行讨论，可能的话，还应进行分析性的评估。'可被翻译为：The potential impact of unmeasured confounders and other relevant sources of bias should be discussed and, when possible, evaluated analytically.\n'C. 特定统计学技术的使用（如为了减少混杂因素） 研究者应确保采用适当的统计学技术来解决混杂因素和评估效应调整。'可被翻译为：C. Use of Specific Statistical Techniques (e.g., To Minimize Confounding) Investigators should ensure that appropriate statistical techniques are used to address confounding and assess effect modification.\n'5. 混杂因素及效应调整因素的发现及处理 既未发现也未充分解决的偏倚可能会影响药物流行病学安全性研究的有效性。'可被翻译为：5.Identification and Handling of Confounders and Effect Modifiers Biases that are either unidentified or inadequately addressed can compromise the validity of pharmacoepidemiologic safety studies.\n\n根据上述已知信息，请将'但是由于未测量的混杂因素以及较小的效应可能也具有统计学显著性，导致结果有偏倚。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"However, results might be biased because of unmeasured confounding and small effects can be statistically significant."
    },
    {
        "instruction":"已知信息：\n'在啮齿类动物重复给药毒性试验期间也可评估雄性生育力。'可被翻译为：It is also possible to evaluate male fertility during a rodent repeated-dose toxicity study.\n'首选已有成年动物重复给药毒性资料的种属和品系，以便于比较幼龄动物和成年动物之间的毒性和系统暴露特性。'可被翻译为：Preference for a species and strain for which adult repeated-dose toxicity data are available to facilitate a comparison of the toxicity and systemic exposure profiles between juvenile and adult animals\n'在预期对雄性或雌性生育力无影响，或者由于在重复给药毒性试验中观察到 的生殖器官毒性而延长给药期限是合适时，可以考虑重复给药试验与生育力试验 的组合设计。'可被翻译为：In cases where no effects on male or female fertility are anticipated, or where extending the dosing period is appropriate due to observation of reproductive organ toxicity in a repeated- dose toxicity study, a combination design of repeated-dose and fertility studies can be considered.\n'对于重复给药的组织分布试验尚无统一的要求。但可能存在重复给药后的评估可提供重要信息的情况。'可被翻译为：There has been no consistent requirement for repeated dose tissue distribution studies. However, there may be circumstances when assessments after repeated dosing may yield important information.\n\n根据上述已知信息，请将'采用性成熟动物进行的重复给药毒性试验可提供生殖器官毒性的重要信息， 其可影响DART试验的设计。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Repeated–dose toxicity studies with sexually mature animals can provide important information on toxicity to reproductive organs that can affect the design of a DART study."
    },
    {
        "instruction":"已知信息：\n'在小规模人群、非常罕见的肿瘤的研究 对于一些真正罕见的肿瘤或者非常窄的适应症（究竟是由于肿瘤表型还是由于与靶 点表达有关的限制所致），为了检测抗肿瘤活性的明显相关性差异根本不可能招募到足 够数量的患者进行合理效力的随机研究。'可被翻译为：Studies in small study populations, very rare tumours For some truly rare tumours or very narrow indications, whether due to tumour phenotype or restrictions related to target expression, it is simply not possible to recruit a sufficiently large number of patients to conduct reasonably powered, randomised studies in order to detect clearly relevant differences in anti-tumour activity.\n'如果探索性研究基于肿瘤表型\/基因型为纳入\/排除特定的患者提供基础，那么这将 在说明书中显示出来。作为一种推论，如果患有未表现活性靶向的肿瘤的患者符合资格，那么若其未通过亚组分析等证明目标表现与抗肿瘤活性无关，那么受限说明书仍适用。'可被翻译为：If exploratory studies provide a basis for including\/excluding certain patients based on tumour phenotype\/genotype, this will be reflected in the labelling. As a corollary, if patients with tumours not expressing the target for activity are eligible, a restricted labelling may still be appropriate if it has not been demonstrated, e.g. by subgroup analyses, that target expression is irrelevant for anti-tumour activity.\n'与靶抗原结合：应筛选（过）表达靶抗原的肿瘤细胞或血浆，并应研究靶抗原表达 与活性的关系。'可被翻译为：Binding to target antigen(s): tumour cells or plasma should be screened for (over)-expression of the target and the relationship between target expression and activity should be investigated.\n'性别 对于一些肿瘤和\/或治疗，已经报道了与性别相关的抗肿瘤活性差异。'可被翻译为：Gender For some tumours and\/or therapies, a difference in antitumour activity related to gender has been reported.\n\n根据上述已知信息，请将'对于一些罕见肿瘤或非常有限的适应症，无论是由于肿瘤显型还是相关靶基因的表达限制，几乎就不可能招蓦足够大样本量的患者进行更有说服力的试验，为发现明显相关的抗肿瘤方面的差异应进行随机研究。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For some truly rare tumours or very narrow indications, whether due to tumour phenotype or restrictions related to target expression, it is simply not possible to recruit a sufficiently large number of patients to conduct reasonably powered, randomised studies in order to detect clearly relevant differences in anti-tumour activity."
    },
    {
        "instruction":"已知信息：\n'基于上述这些原因，任何暴露在一个后来被鉴定 为致突变的杂质下的情况，不一定与已暴露于该杂质的患者的患癌风险增加相关。'可被翻译为：Based on all the above considerations, any exposure to an impurity that is later identified as a mutagen is not necessarily associated with an increased cancer risk for patients already exposed to the impurity.\n'例如，工艺相关杂质和基 质组分不会对剂量反应曲 线的特征造成显著影响。'可被翻译为：For example, process related and matrix components do not significantly affect the characteristics of the dose response curve\n'本指导原则不适用于ICH S9（参考文献4）所定义的拟用于晚期癌症适应症的原料药和制剂。另外，某些情况下拟用于其它适应症的原料药本身在治疗浓度下就存在遗传毒性，且预测可能会增加致癌风险。在这些情况下，暴露于致突变杂质不会显著增加原料药的致癌风险。因此，杂质可以按非致突变性杂质进行控制。'可被翻译为：This guideline does not apply to drug substances and drug products intended for advanced cancer indications as defined in the scope of ICH S9 (Ref. 4). Additionally, there may be some cases where a drug substance intended for other indications is itself genotoxic at therapeutic concentrations and may be expected to be associated with an increased cancer risk. Exposure to a mutagenic impurity in these cases would not significantly add to the cancer risk of the drug substance. Therefore, impurities could be controlled at acceptable levels for non-mutagenic impurities.\n'本指导原则不适用于ICH S9（参考文献4）所定义的拟用于晚期癌症适应症的原料药和制剂。另外，某些情况下，拟用于其它适应症的原料药本身在治疗浓度下就存在遗传毒性，且预期可能会增加致癌风险。在这些情况下，暴露于致突变杂质不会显著增加原料药的致癌风险。因此，杂质可以按非致突变性杂质进行控制。 本指导原则所述对杂质潜在致突变性的评估不适用于矫味剂、着色剂和香料，以及已上市药物中使用的辅料。本指导原则不适用于药物包材相关的可浸出物，但如有必要，可使用本指导原则中描述的限制潜在致癌风险的安全风险评估原则。如有必要，首次在药品中使用的化学合成辅料中的杂质，可采用本指导原则的安全风险评估原则。'可被翻译为：This guideline does not apply to drug substances and drug products intended for advanced cancer indications as defined in the scope of ICH S9 (Ref. 4). Additionally, there may be some cases where a drug substance intended for other indications is itself genotoxic at therapeutic concentrations and may be expected to be associated with an increased cancer risk. Exposure to a mutagenic impurity in these cases would not significantly add to the cancer risk of the drug substance. Therefore, impurities could be controlled at acceptable levels for non-mutagenic impurities. Assessment of the mutagenic potential of impurities as described in this guideline is not intended for excipients used in existing marketed products, flavoring agents, colorants, and perfumes. Application of this guideline to leachables associated with drug product packaging is not intended, but the safety risk assessment principles outlined in this guideline for limiting potential carcinogenic risk can be used if warranted. The safety risk assessment principles of this guideline can be used if warranted for impurities in excipients that are used for the first time in a drug product and are chemically synthesized.\n\n根据上述已知信息，请将'在这些情况下，暴露 在致突变杂质下不会显著增加原料药的癌症风险。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Exposure to a mutagenic impurity in these cases would not significantly add to the cancer risk of the drug substance."
    },
    {
        "instruction":"已知信息：\n'清洁验证确认清洁工艺是有效的。'可被翻译为：Appropriate cleaning validation verifies that the cleaning process is effective.\n'允许在必要时进行清洁程序。'可被翻译为：Allow cleaning procedures to be conducted as necessary.\n'例如在HIV\/AIDS领域以及对于某些抗菌治疗，由于快速产生的抗药性，单药疗法并不是一种可接受的方法。'可被翻译为：For example, in the field of HIV\/AIDS and for some anti-microbials, monotherapy is not an acceptable comparator, due to rapidly evolving drug resistance.\n'对于无菌灌装的产品，样品应包括在本批次灌装开始和结束时的容器。额外取样应根据风险进行考虑，例如在关键干预之后取样。'可被翻译为：For products which have been filled aseptically, samples should include containers filled at the beginning and end of the batch. Additional samples, e.g. taken after critical interventions should be considered based on risk.\n\n根据上述已知信息，请将'证明清洗已达到可接受水平的行为，例如在两个批次之间。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The act of demonstrating that cleaning was done to an acceptable level, for example, between two batches."
    },
    {
        "instruction":"已知信息：\n'假设以后的治疗将是在现有 PPI 治疗的基础上加一个“附加”治疗。'可被翻译为：It is assumed that the treatment will be an “add-on” to existing PPI therapy.\n'如果该药物并不被预期用于替代吸入性皮质类固醇，则可使用附加治疗设计 方案，即在标准背景药物的基础上将新药与安慰剂进行比较。'可被翻译为：If the drug is not intended to be substituted for inhaled corticosteroids, add-on designs where the new drug is compared with placebo on top of standard background medication are required.\n'疗效不足患者的治疗（‘附加适应症’）'可被翻译为：Treatment of insufficiently responding patients (‘add-on indication’)\n'对于单药一线治疗的适应症而言，安慰剂对照试验是可以接受的。'可被翻译为：For a first-line, monotherapy indication, placebo controlled trials are acceptable.\n\n根据上述已知信息，请将'对于附加的适应症而言，建议把 PPI 设计作为背景治疗。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For ‘add on’ indication, design with PPI’s as the background treatment is recommended."
    },
    {
        "instruction":"已知信息：\n'（二）生产用原辅材料、菌种、毒种、细胞等是否与国家药品监督管理局批准的一致；'可被翻译为：(II) Whether the raw materials and auxiliaries, bacterial strains\/seeds, viral strains\/seeds and cells used for production are consistent with those approved by the NMPA;\n'（三）生产工艺和过程控制是否与食品药品监管总局批准的一致并符合药典要求；'可被翻译为：(III) Whether the production process and process control are consistent with those approved by the CFDA and meet the requirements in the ChP;\n'（六）产品包装、标签及说明书是否与食品药品监管总局核准的内容一致；'可被翻译为：(VI) Whether the product package, label and package inserts are consistent with those approved by the CFDA;\n'（三）药品质量是否符合国家标准，药品生产过程是否符合GMP等规定，药品生产与批准的工艺是否一致；'可被翻译为：(Ⅲ) Whether the drug quality meets the national standard, whether the production of the drug meets the regulations such as GMP, whether the drug is manufactured in accordance with the approved manufacturing process;\n\n根据上述已知信息，请将'（二）生产用原辅材料、菌种、毒种、细胞等是否与食品药品监管总局批准的一致；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(II) Whether the raw materials and subsidiary, bacterial strains\/seeds, viral strains\/seeds and cells used for production are consistent with those approved by the CFDA;"
    },
    {
        "instruction":"已知信息：\n'TLV： 阈值限度值：多数工人能每天暴露而无不良反应的空气中的浓度（即，有效的，安全和危险浓度之间的阈值）。该值由ACGIH确立（且每年进行修订），是以每日工作7或8小时，每周工作40小时计算的时间加权浓度（TWA），其与长期影响有关。（IUPAC）'可被翻译为：TLV: Threshold Limit Value: The concentration in air to which it is believed that most workers can be exposed daily without an adverse effect (i.e., effectively, the threshold between safe and dangerous concentrations). The values were established (and are revised annually) by the ACGIH and are time weighted concentrations (TWA) for a 7- or 8-hour workday and 40-hour workweek, and thus related to chronic effects. (IUPAC）\n'对大多数健康工人不会造成不良影响的空气中物质浓度，每天暴露8小时，每周暴露40小时。'可被翻译为：Airborne concentration of substances that will not result in adverse effects to most healthy workers, exposed for 8 hours\/day, 40 hours\/week.\n'TWA： 时间加权平均值：如ACGIH定义，以常规的每日工作8小时和每周工作40小时计算的时间加权平均浓度。(IUPAC)'可被翻译为：TWA: Time Weighted Average: As defined by ACGIH, time-weighted average concentration for a conventional 8-hour workday and a 40-hour workweek. (IUPAC)\n'时间加权平均值：如 ACGIH 定义，以常规的每日工作 8 小时和每周工作40小时计算的时间加权平均浓度。（IUPAC）'可被翻译为：Time Weighted Average: As defined by ACGIH, time-weighted average concentration for a conventional 8-hour workday and a 40-hour workweek. (IUPAC)\n\n根据上述已知信息，请将'多数工人能每天暴露而无不良反应的空气中的浓度（即，有效的，安全和危险浓度之间的阈值）。该值由 ACGIH 确立（且每年进行修正），是以每日工作7或8小时，每周工作40小时计算的时间加权浓度（TWA），其与长期影响有关。（IUPAC）'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Threshold Limit Value: The concentration in air to which it is believed that most workers can be exposed daily without an adverse effect (i.e., effectively, the threshold between safe and dangerous concentrations). The values were established (and are revised annually) by the ACGIH and are time_x0002_weighted concentrations (TWA) for a 7- or 8-hour workday and 40-hour workweek, and thus related to chronic effects. (IUPAC）"
    },
    {
        "instruction":"已知信息：\n'一个有用的设计是寻求联合比单药治疗的产品优势的一个三臂试验。'可被翻译为：A useful design is a 3-arm trial seeking superiority of the combination versus both products in monotherapy.\n'安慰剂对照研究最好加入第3个研究臂， 即随机接受活性参比药物的治疗臂。'可被翻译为：It is preferred that placebo-controlled studies should incorporate a third study arm that is randomised to an active comparator.\n'活性对照加安慰剂对照（3臂研究，见 2.1.5.1.1)'可被翻译为：• Active and placebo controls (3-arm study; see 2.1.5.1.1)\n'在活性对照和安慰剂对照的临床试验中，一个有用的评 估敏感度的方法是三臂试验，包括安慰剂和一个已知的活性 对照治疗，一种有许多优点的试验设计。'可被翻译为：A useful approach to the assessment of assay sensitivity in active control trials and in placebo-controlled trials is the three-arm trial, including both placebo and a known active treatment, a trial design with several advantages.\n\n根据上述已知信息，请将'一个可能的办法是设计3臂的研究，将研究产品和安慰剂组以及一个活性药物进行比较（见第7.2节）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A possible approach is a 3 arm study comparing the investigational product to placebo and an active comparator (see section 7.2)."
    },
    {
        "instruction":"已知信息：\n'如上所述，骨质量不是通过测量一个特定骨参数来捕获的，而是部分地通过特定骨强度和密度测量参数之间的关系反映。'可被翻译为：As described above, bone quality is not captured by the measurement of one particular bone parameter but is, in part, reflected by the relationship between specific bone strength and densitometric parameters.\n'b. 骨量和骨密度'可被翻译为：b. Bone mass and density\n'虽然骨质量不易直接评估，非临床研究提供了通过测量由骨量和骨质量确定的骨强度来提供关于骨质量的间 接信息的机会。'可被翻译为：Although bone quality cannot be easily assessed directly, nonclinical studies offer the opportunity to provide indirect information about bone quality through the measurement of bone strength, which is determined by both bone mass and bone quality.\n'骨质量指以不以骨量或骨质量方式 确定的骨生物力学行为的骨结构和材料性质（Hernandez and Keaveny 2006）。'可被翻译为：Bone quality refers to those structural and material properties of bone that determine its biomechanical behavior in ways that are not accounted for by bone quantity or mass (Hernandez and Keaveny 2006).\n\n根据上述已知信息，请将'可以通过骨量（即骨矿物质密度（BMD）或骨矿物质含量（BMC））和骨强度之间的相关性的变化来识别对骨质量的不良影响。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"An adverse effect on bone quality can be identified by a change in the correlation between bone mass (i.e., bone mineral density (BMD) or bone mineral content (BMC)) and bone strength."
    },
    {
        "instruction":"已知信息：\n'此外，如果适用，也应该进行下列考察：'可被翻译为：In addition, the following test should be performed if applicable:\n'如适用，可使用PCR试验 或其他适当的方法。'可被翻译为：If appropriate, a PCR test or other suitable methods may be used.\n'这种情况下，应定义AUC(0-T) 为主要终点，并检测部分AUC，如AUC(0-T50%) 和AUC(T50%-T) 作为次要终点。'可被翻译为：In such instances, AUC(0-τ) should be the primary endpoint and measures of partial AUCs, e.g. AUC(0-τ50%) and AUC(τ50%- τ) the secondary endpoints.\n'中效胰岛素，应定义AUC(0-T) 和Cmax为主要终点，AUC(0-t) 和AUC(0-∞) 、有意义部分的AUC、tmax和t1\/2为次要终点。'可被翻译为：In case of intermediate-acting insulins, AUC(0-τ) and Cmax should be defined as primary endpoints and AUC(0-t), AUC(0-∞), meaningful partial AUCs, tmax and t1\/2 as secondary endpoints.\n\n根据上述已知信息，请将'如果适用，还应测定部分AUC（p-AUC）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"When applicable, partial AUCs (p-AUCs) should also be determined."
    },
    {
        "instruction":"已知信息：\n'分层可以用来保证治疗组间协变量的平衡性，'可被翻译为：Stratification may be used to ensure balance of treatments across covariates;\n'随机化应该相应地分层。'可被翻译为：Randomisation should be stratified accordingly.\n'这包括随机化中不用于分层的协变量。'可被翻译为：This includes the use of covariates not stratified for in the randomisation.\n'随机化可以在协变量水平对治疗组进行平衡，但在实践中，事后观察到不平衡的情况并不少见。'可被翻译为：Randomisation is expected to balance treatment groups among the covariate levels on average but, in practice, it is not unusual to observe imbalances post hoc.\n\n根据上述已知信息，请将'分层随机化常常用于在指定的协变量（一般为定性协变量或分类定量协变量）水平内减少治疗组间这种不平衡的概率。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Stratified randomisation is often used to reduce the likelihood of such imbalances between treatment groups within the levels of specified covariates (generally qualitative covariates or categorised quantitative covariates)."
    },
    {
        "instruction":"已知信息：\n'3. 泡罩板标签材料和可读性'可被翻译为：3. Blister Cell Label Material and Readability\n'1.泡罩板的标签'可被翻译为：1. Blister Cell Label\n'4. 泡罩包装标签设计'可被翻译为：4. Blister Pack Label Design\n'4. 泡罩包装标签设计 应谨慎考虑泡罩包装标签的整个设计，以免造成混淆和错误。'可被翻译为：4.Blister Pack Label Design Careful consideration should be given to the overall design of a blister pack label so that it does 604 not lead to confusion and error.\n\n根据上述已知信息，请将'3. 泡罩板标签材料和可读性 应根据泡罩底板所用材料，仔细选择颜色、字体大小和字型。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"3.Blister Cell Label Material and Readability Color, type size, and font style should be carefully chosen based on the material used for the blister cell backing."
    },
    {
        "instruction":"已知信息：\n'84 从IRB收到信息后，申办方如何处理公开披露的信息？'可被翻译为：84. What does the sponsor do, upon receiving from the IRB the information that has been publicly disclosed?\n'83 IRB如何处理公开披露的信息？'可被翻译为：83. What does the IRB do with the information that has been publicly disclosed?\n'也可能存在信息流不同的情况，例如，如果申办方向IRB提供这些信息，同时申办方将这些已经披露的信息提交到FDA 备案文件管理处。'可被翻译为：There may also be situations in which flow of information could vary, for example, if the sponsor provides the information to the IRB, at the same time that the sponsor submits the information that has been disclosed to the FDA docket.\n'申办方必须及时向IND或IDE档案提交已公开披露的信息。'可被翻译为：The sponsor must promptly submit to the IND or IDE file copies of the information that was publicly disclosed.\n\n根据上述已知信息，请将'84 从IRB收到信息后，申办方如何处理公开披露的信息？ 从IRB收到已公开披露的信息的副本后，申办方必须按照下列地址将资料递 交给FDA IND\/IDE和备案文件管理处：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"84.What does the sponsor do, upon receiving from the IRB the information that has been publicly disclosed? Upon receiving copies of the information that has been publicly disclosed from the IRB, the sponsor must submit the information to FDA, i.e., to the IND\/IDE and to FDA’s Dockets Management at the following address:"
    },
    {
        "instruction":"已知信息：\n'ICH ICSR执行指导原则 2016年11月10日 -161- 进一步说明日期和时间：2009年6月1日下午3：31：15：05：5太平洋时区：'可被翻译为：To further illustrate date and time: June 1, 2009, at 3:31:15:05:5 pm Pacific Time Zone:\n'研究的时间安排需遵循ICH S9。'可被翻译为：The timing of the studies should follow ICH S9.\n'中间放置条件可从30°C±2°C\/60%RH±5%RH切换为30°C±2°C \/65%RH±5%RH，但必须清楚记录切换前后的放置条件和切换日期，并在注册申请中进行说明。'可被翻译为：Mid-stream switch of the intermediate storage condition from 30°C ± 2°C\/60% RH ± 5% RH to 30°C ± 2°C\/65% RH ± 5% RH can be appropriate provided that the respective storage conditions and the date of the switch are clearly documented and stated in the registration application.\n'协调世界时（UTC）在1972年之前称 为格林威治标准时间（GMT，也称为“祖鲁时间”）；但是，不应再使用GMT。'可被翻译为：Coordinated Universal Time (UTC) was called Greenwich Mean Time (GMT, also known as ‘Zulu Time’) prior to 1972; however, GMT should no longer be used.\n\n根据上述已知信息，请将'为了在 ICH 各区域同步切换，MSSO 建议切换日期为格林威治标准时间星期日24时（即星期一0 时）。例如：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"To synchronize this event over the three ICH regions, the MSSO recommends midnight GMT, Sunday to Monday, for the switchover. For example :"
    },
    {
        "instruction":"已知信息：\n'对于安全性参数，参考人口暴露的指导方针ICHE1A 。'可被翻译为：For safety parameters, reference is given to the guideline on population exposure, ICH E1A.\n'安全性评价 一般来说，应该考虑 ICH E1 的内容。'可被翻译为：Safety evaluations  In general the content of ICH E1 should be taken into consideration.\n'13.2 2014年3月 该指南指出，PBRER应在章节6至14 中提供与安全性相关的数据和发现。'可被翻译为：13.2 March 2014 The Guideline states that the PBRER should present safety-related data and findings in Sections 6 through 14.\n'多数情况下，根据研究者定义中心较为可行，ICH E6在这方 面提供了相关指南。'可被翻译为：In most instances centres can be satisfactorily defined through the investigators and ICH E6 provides relevant guidance in this respect.\n\n根据上述已知信息，请将'必须根据ICHE11和其他相关指南提供安全性数据。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Safety data have to be provided in accordance with ICH E11 and other relevant guidance."
    },
    {
        "instruction":"已知信息：\n'8.监督厂房和设备的维护，以保持其良好的运行状态；'可被翻译为：8) To check the maintenance of premises and equipment for the purpose of maintaining a sound operating state;\n'4.确保厂房和设备的维护保养，以保持其良好的运行状态；'可被翻译为：4) To ensure that the premises and equipment are maintained and serviced to function in a sound operating state;\n'3.厂房和设备的维护、清洁和消毒；'可被翻译为：3. Maintenance, cleaning and sanitation of premises and equipment;\n'（三）厂房和设备的维护、清洁和消毒；'可被翻译为：3. Maintenance, cleaning and sanitation of premises and equipment;\n\n根据上述已知信息，请将'8.监督厂房和设备的维护，以保持其良好的运行状态；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"8) To check the maintenance of premises and equipment for the purpose of maintaining a sound operating state;"
    },
    {
        "instruction":"已知信息：\n'第三方平台应当加强检查，对入驻平台的药品网络销售企业的药品信息展示、处方审核、药品销售和配送等行为进行管理，督促其严格履行法定义务。'可被翻译为：The third-party platform shall strengthen the examination, manage the drug information display, prescription examination, drug sales and delivery, and other behaviors of the online drug sales enterprises settled on the platform, and urge them to strictly perform their legal obligations.\n'第三方平台提供者应当依法对申请进入平台经营的药品上市许可持有人、药品经营企业的资质等进行审核，保证其符合法定要求，并对发生在平台的药品经营行为进行管理。'可被翻译为：Third party platform providers shall, in accordance with the law, examine the qualifications of MAHs and drug distributors requesting to operate on their platform to ensure that they comply with statutory requirements, and manage drug distribution activities carried out on their platform.\n'药品上市许可持有人依法召回药品的，第三方平台、药品网络销售企业应当积极予以配合。'可被翻译为：If the drug MAH recalls the drug according to law, the third-party platform and online drug sales enterprises shall cooperate actively.\n'第二十条 第三方平台应当对申请入驻的药品网络销售企业资质、质量安全保证能力等进行审核，对药品网络销售企业建立登记档案，至少每六个月核验更新一次，确保入驻的药品网络销售企业符合法定要求。'可被翻译为：Article 20 The third-party platform shall audit the qualifications, and the quality and safety assurance capabilities of the online drug sales enterprises that apply for settlement, establish registration record for online drug sales enterprises, and check and update such information at least every six months to ensure that the settled online drug sales enterprises meet the legal requirements.\n\n根据上述已知信息，请将'第三方平台应当与药品网络销售企业签订协议，明确双方药品质量安全责任。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The third-party platform shall sign an agreement with the online drug sales enterprise to clarify the drug quality and safety responsibilities of both parties."
    },
    {
        "instruction":"已知信息：\n'显示优效性的分 析应包括直至研究结束时发生的所有主要终点事件（从每名患者随机日期至达到 主要终点事件的研究目标的估测日期）。'可被翻译为：The analysis to show superiority should include all primary endpoint events occurring through end of study (from each patient’s date of randomization to the estimated date of attainment of the study’s target of primary endpoint events).\n'尽管单纯的这些分析通常不能提供临床研究前的充分毒理学评价，但是该信息可以补充着重于毒理学的研究。非临床研究的时间和特定设计会随所研究的药物或生物制品种类、支持在最初人类研究和后期药物研发阶段给药所需的信息、以及预期临床用途而变化。'可被翻译为：Although these analyses alone usually do not provide a sufficient toxicological evaluation before clinical studies, this information might supplement toxicology-focused studies. The timing and specific design of nonclinical studies vary with the type of drug or biological product being studied, the information needed to support administration in the initial human studies and later stages of drug development, and the intended clinical use.\n'显示优效性的分析应包括直至研究结束时发生的所有主要终点事件'可被翻译为：The analysis to show superiority should include all primary endpoint events occurring through end of study\n'非劣效性和优效性分析应遵循一般统计学指导原则（ICH E9）。'可被翻译为：The analysis of non-inferiority and superiority should follow general statistical guidelines (ICH E9).\n\n根据上述已知信息，请将'显示非劣效性的分析应包括在研究药物使用期间（包括停用研究药物后 3 天）的主要终点事件（治疗中分析）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The analysis to show non-inferiority should include the primary endpoint events while taking study drug including a period of 3 days after study drug discontinuation (on-treatment analysis)."
    },
    {
        "instruction":"已知信息：\n'在这些情况下，我们强烈建议申办方在动物研究开始前与FDA会面，以便实现与可支持拟定临床试验的简化非临床计划同步。当动物疾病模型可获得后，药理学研究有助于理解药物对疾病病理生理学的作用，并且指导患者中的生物学作用测定计划。'可被翻译为：In these circumstances, we strongly recommend that sponsors meet with FDA before starting animal studies to obtain concurrence with an abbreviated nonclinical program that can support the proposed clinical trials. When an animal model of the disease is available, pharmacology studies may contribute to understanding the actions of the drug on disease pathophysiology and guide plans for measuring biological effects in patients.\n'非临床研究应在临床开发开始前进行。'可被翻译为：Non-clinical studies should be performed before initiating clinical development.\n'如果药品没有IND，FDA将分 配一个IND前编号，以便可以安排一次会议充分通知FDA该药品的整体开发计 划（见第III节B.1部分“递交请求前与FDA召开会议”）。'可被翻译为：If there is no IND for the product, FDA will assign a pre-IND number so that a meeting to fully inform FDA of the overall development plan for the product can be scheduled (see section III.B.1., Meeting With FDA Before Submission of a Request).\n'如第III.B.1节“递交请求前与FDA召 开会议”所述，FDA鼓励申办方在递交“请求”之前请求召开会议。'可被翻译为：As noted in section III.B.1., Meeting With FDA Before Submission of a Request, FDA encourages sponsors to request a meeting before submitting the Request.\n\n根据上述已知信息，请将'与FDA关于开发适当的动物模型的讨论应 在药品开发过程的早期开始，以便“请求”递交前的会议着重于对动物模型的最 终共识，而不是对该议题的介绍。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Discussions with FDA regarding the development of an appropriate animal model should begin early in the product development process so that the meeting before submission of a Request focuses on final consensus on the animal model, not an introduction of this topic."
    },
    {
        "instruction":"已知信息：\n'国家监测机构应当对国家药品监督管理局批准注册或者备案的医疗器械的不良事件报告和各省、自治区、直辖市药品监督管理部门的季度报告进行综合分析，必要时向国家药品监督管理局提出监管措施建议。'可被翻译为：National monitoring agencies shall carry out comprehensive analysis on adverse event reports of the medical devices approved by the NMPA to be registered or filed and quarterly reports submitted by all the provinces, autonomous regions and municipalities directly under the central government, and if necessary, propose recommendations on supervisory measures to the NMPA.\n'国家医疗器械不良事件监测年度报告'可被翻译为：Release of Annual Report for National Medical Device Adverse Event Monitoring (2018)\n'第三十三条  批签发机构应当对批签发工作情况进行年度总结，由中检院汇总分析后，于每年3月底前向国家药品监督管理局报告。'可被翻译为：Article 33 Lot release institutions shall summarize their annual lot release work. The NIFDC, after summarization and analysis, shall report to the NMPA before the end of March each year.\n'创新医疗器械持有人应当在首个注册周期内，每半年向国家监测机构提交产品不良事件监测分析评价汇总报告。国家监测机构发现医疗器械可能存在严重缺陷的信息，应当及时报国家药品监督管理局。'可被翻译为：MAHs of innovative medical devices shall, within the first registration cycle, submit analysis, evaluation and summary report of product adverse event monitoring to national monitoring agency every half a year. In case of identifying any possible serious defects of a medical device, national monitoring agency shall promptly report to National Medical Products Administration.\n\n根据上述已知信息，请将'国家监测机构应当对全国医疗器械不良事件年度监测情况进行汇总分析，形成年度报告，于每年3月底前报国家药品监督管理局。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"National monitoring agencies shall carry out Meta-analysis on the annual monitoring information of medical device adverse events nationwide, complete annual report and submit it to the NMPA by the end of March each year."
    },
    {
        "instruction":"已知信息：\n'应通过与此新的基线检查结果比较来确定扩展治疗期间的复发。'可被翻译为：A recurrence during the extended treatment should be defined in comparison to this new baseline test.\n'VTE“急性”复发（例如在治疗的前 3~6 个月内）的诊断应基于与急性 VTE 最初诊断的基线检查进行客观的比较。'可被翻译为：The diagnosis of “acute” recurrent VTE (i.e. during the first 3-6 months of treatment) should be based on the comparison of objective tests compared to baseline test performed for the initial diagnosis of acute VTE.\n'如果已证明患有DVT患者存在提示为PE的症状，VPLS上“非诊断性”的发现足以诊断PE。'可被翻译为：In the presence of symptoms indicative of PE in a patient with demonstrated DVT, nondiagnostic” findings on VPLS are sufficient for a diagnosis of PE.\n'区别VTE的初始治疗（通常为3-6个月）和VTE的扩展治疗（复发的二级预防）（一旦初始治疗结束后，无限期的）是很重要的。'可被翻译为：It is important to distinguish between initial treatment of VTE (usually 3-6 months), and extended treatment (secondary prevention of recurrences) of VTE (once initial treatment has finished, to indefinite).\n\n根据上述已知信息，请将'在治疗的最初3~6个月后的扩展治疗期间复发的诊断应与在初期治疗结束之后进行的新基线检查（例如用 CUS 诊断 VTE 或 sTE 或用 VPLS 诊断 PE）进行比较。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The diagnosis of recurrences during an extended study after the initial 3 to 6 months of treatment should be compared to a new baseline test (i.e. CUS for VTE or sCT or VPLS for PE) performed at the end of the initial treatment."
    },
    {
        "instruction":"已知信息：\n'国家药监局关于发布应用纳米材料的医疗器械安全性和有效性评价指导原则第一部分：体系框架的通告'可被翻译为：NMPA Announcement on Issuing the Guidance for Evaluation of the Safety and Efficacy of Medical Devices Using Nano Materials-Part 1: System Framework\n'14见FDA指导原则：源于设计，医疗器械中人为因素的介绍，1996年12月；为行业和FDA上市前和设计 控制审评人员制定的指导原则：医疗器械使用-安全：把人为因素工程学整合到风险管理中，2000年7月18日；为行业和食品药品监督管理局工作人员制定的指导原则草稿-应用人为因素和使用工程学以便优化医疗器械设计，2011年6月22日；FDA医疗器械指导原则网址： http:\/\/www.fda.gov\/MedicalDevices\/DeviceRegulationandGuidance\/GuidanceDocuments\/default.htm（一经定稿，本指导原则将代表FDA关于这一主题的最新见解）'可被翻译为：14 See FDA guidances: Do it by Design, An Introduction to Human Factors in Medical Devices, December 1996; guidance for industry and FDA Premarket and Design Control Reviewers: Medical Device Use-Safety: Incorporating Human Factors Engineering into Risk Management, July 18, 2000; and draft guidance for industry and Food and Drug Administration staff - Applying Human Factors and Usability Engineering to Optimize Medical Device Design, June 22, 2011; available on FDA Medical Devices guidance Web page at http:\/\/www.fda.gov\/MedicalDevices\/DeviceRegulationandGuidance\/GuidanceDocuments\/default.htm (when final, this guidance will represent FDA’s current thinking on this topic).\n'为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局组织制定，并于2020年3月10日发布了《医疗器械安全和性能的基本原则》。'可被翻译为：To strengthen the supervision and guidance over the registration of medical device products and further improve the quality of registration review, NMPA has organized the formulation of and released on March 10, 2020 the Fundamental Principles for Medical Device Safety and Performance.\n'为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局组织制定并于2020年5月14日发布了《登革病毒核酸检测试剂注册技术审查指导原则》。'可被翻译为：To strengthen the supervision and guidance over medical device registration and further improve the quality of registration review ,NMPA organized to formulate and released on May 14, 2020 the Technical Review Guidance for the Registration of Dengue Virus Nucleic Acid Detection Reagents.\n\n根据上述已知信息，请将'为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局组织制定了《应用纳米材料的医疗器械安全性和有效性评价指导原则第一部分：体系框架》，并于2021年8月26日发布。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"To strengthen the supervision and guidance over the registration of medical device products and further improve the quality of registration review, the NMPA has organized to formulate the Guidance for Evaluation of the Safety and Efficacy of Medical Devices Using Nano Materials-Part 1: System Framework, which was issued on August 26, 2021."
    },
    {
        "instruction":"已知信息：\n'第一百四十八条 确认或验证应当按照预先确定和批准的方案实施，并有记录。确认或验证工作完成后，应当写出报告，并经审核、批准。确认或验证的结果和结论（包括评价和建议）应当有记录并存档。'可被翻译为：Article 148 Qualification or validation should be implemented in accordance with a predefined and approved protocol, and be recorded. Upon completion of qualification or validation, a report should be prepared, reviewed and approved. The qualification or validation result and conclusion (including comments and suggestions) should be recorded and archived.\n'第一百四十八条 确认或验证应当按照预先确定和批准的 方案实施，并有记录。'可被翻译为：Article 148: Qualification or validation should be implemented in accordance with a predefined and approved protocol, and be recorded.\n'确认或验证工作完成后，应当写出报告， 并经审核、批准。'可被翻译为：Upon completion of qualification or validation, a report should be prepared, reviewed and approved.\n'第五十五条 申办者若采用电子临床数据库或者远程电子临床数据系统，应当确保临床数据的受控、真实，并形成完整的验证文件。'可被翻译为：Article 55 If the sponsor adopts an electronic clinical database or a remote electronic clinical data system, the sponsor shall ensure that the clinical data is under control and integrity and that a complete verification document is formed.\n\n根据上述已知信息，请将'第五十五条 验证应当按照预先确定和批准的方案实施，验证报告应当经过审核和批准，验证文件应当存档。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 55 Validation shall be carried out in accordance with the pre-determined and approved scheme; the validation report shall be reviewed and approved. Validation documents shall be archived."
    },
    {
        "instruction":"已知信息：\n'随后，试验在没有安慰剂对照的情况 下继续进行。'可被翻译为：The trial would then continue without the placebo group.\n'即使后期研究未使用阳性对照，但是可在其他研究（例如全面QT研究）中验证 新技术。'可被翻译为：Even though a positive control is not used in late stage studies, the new technology could be validated in other studies (such as the thorough QT study).\n'样本量和检验效能的 计算通常基于各中心的处理间差异是相同的无偏估计的假 设，因此，制定共同研究方案并给予实施很重要。'可被翻译为：Furthermore the usual sample size and power calculations depend upon the assumption that the differences between the compared treatments in the centres are unbiased estimates of the same quantity. It is important to design the common protocol and to conduct the trial with this background in mind.\n'在这方面，改变传统非临床计划的设计和\/或时间安排是阐述儿科患者潜在安全性问题的一种方法'可被翻译为：In this respect, changing the design and\/or timing of the traditional nonclinical program is one way to address potential safety concerns for the paediatric patient.\n\n根据上述已知信息，请将'后期阶段的对照试验代表了以无偏的方式探索任何新的 潜在不良反应的重要方法，即使这些试验在这方面通常缺乏 检验效能。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Later phase controlled trials represent an important means of exploring in an unbiased manner any new potential adverse effects, even if such trials generally lack power in this respect."
    },
    {
        "instruction":"已知信息：\n'无需使用相同的策略来处理所有的 伴发事件。'可被翻译为：It is not necessary to use the same strategy to address all intercurrent events.\n'无需对T产品与R产品进行信息充分的检测。 对比R和T产品。'可被翻译为：No comparative testing of T product to R product is needed. Compare R and T products.\n'基于这些 讨论，FDA建议如下： a. 颜色差异化 颜色差异化是一个非常有效的工具，它可以：（1）在生产商产品线内区别产 品，（2）在生产商产品线内区别规格，（3）突出显示标签的某些部分，如重要警告。'可被翻译为：Based on these  discussions, FDA recommends the following:  a. Color Differentiation  Color differentiation is an effective tool that can (1) differentiate products within a  manufacturer’s product line; (2) differentiate strengths within a manufacturer’s product line; and  (3) highlight certain aspects of the label, such as important warning statements.\n'当申办者考虑用颜色来把注意力吸引到药品名称，规格和重要警告上时，我们建议谨慎使用颜色。'可被翻译为：We recommend that sponsors use color prudently to bring attention to  the product name, strength, and important warning(s).\n\n根据上述已知信息，请将'当所用颜色不与任何一特征有关联，且色彩设计的应用没有格式时，颜色差异化的方法是最有效的。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Color differentiation is most effective when the color used has no  association with a particular feature and there is no pattern in the application of the color scheme."
    },
    {
        "instruction":"已知信息：\n'一种药物的不同制剂在相同的实验条件下，给予相同剂量，反映其吸收速度和程度的主要药动学参数没有统计学差异。'可被翻译为：Different preparations of a drug are given the same dose under the same experimental conditions, and there is no statistical difference in the main pharmacokinetic parameters reflecting the rate and degree of absorption.\n'终止随机分配的治疗或因各种原因使用另 一种药物，两个治疗组的应答情况可以表现得更相近，而这与最 初的随机分配的治疗组间的相似度无关。'可被翻译为：Responses in both treatment groups can appear more similar following discontinuation of randomised treatment or use of another medication for reasons that are unrelated to the similarity of the initially randomised treatments.\n'•对适宜数量空腹状态的受试者，用8盎司（240mL）水送服受试制剂和参比制 剂，餐后等效性试验除外。'可被翻译为：·The test or RLD products can be administered with about 8 ounces (240 mL) of water to an appropriate number of subjects under fasting conditions, unless the study is a fed BE study.\n'•应说明受试制剂和参比制剂的批号、参比制剂的有效期等信息。建议受试制剂药物含量与参比制剂药物含量差值小于5%。申请人应提供受试制剂和参比制剂 的组成说明，尽可能提供二者成分一一对比的资料。根据21 CFR 320.63，试验资料等应保存至试验后5年。关于额外的信息，请参见行业指导原则《生物利用度和生物等效性研究样品的处理和保存》。29'可被翻译为：·The lot numbers of both test and RLD products and the expiration date for the RLD product should be stated. We recommend that the assayed drug content of the test product batch not differ from the RLD product by more than +\/- 5 percent. The applicant should include a statement of the composition of the test product and, if possible, a side- by-side comparison of the compositions of test and RLD products. In accordance with 21 CFR 320.63, study drug test article of the test and RLD products must be retained for five years. For additional information, please refer to the guidance for industry Handling and Retention of Bioavailability and Bioequivalence Testing Samples.29\n\n根据上述已知信息，请将'在相似的试验条件下单剂或多剂服用相同摩尔数的治疗组份后，受试制剂的吸收速度和程度与参比制剂相比没有显著差异 6'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The rate and extent of absorption of the drug do not show a significant difference from the rate and extent of absorption of the listed drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses....6"
    },
    {
        "instruction":"已知信息：\n'44 - 关于该项研究主要结局的信息； FDA建议申办方在披露之前，向IRB提供这些信息。'可被翻译为：44 FDA recommends that the sponsor provide the information to the IRB(s) for review prior to disclosure.\n'注意，在某项研究被终止或中止时，申办方必须上报FDA（21 CFR 312.31（a）（2），812.150 （b）（7）），并且FDA期望也告知公众终止\/中止的情况。'可被翻译为：Note that sponsors must report to FDA when a study is terminated or discontinued (21 CFR 312.31(a)(2), 812.150(b)(7)), and it is FDA’s expectation that the public also be informed of terminations\/discontinuances.\n'89 研究完成或终止后谁负责披露该项研究的信息？'可被翻译为：89.Who is responsible for disclosing information about the study after it is completed or terminated?\n'如公众希望查阅提交到备案文件管理处的公开披露信息，可亲自到FDA备 案文件管理处分支，在线阅读这些材料 （http:\/\/www.regulations.gov\/search\/Regs\/home.html#docketDetail?R=FDA-1995-S- 0036），或者按下列地址向FDA发送信息法自由权请求，索取副本（21 CFR 312.130（d）和 812.38）: 食品药品监督管理局 信息自由室 （HFI-35） 5600 Fishers Lane Rockville，MD 20857 电话：（301）827-6500 B. 研究完成或终止后的公开披露'可被翻译为：Members of the public wishing to examine public disclosure information submitted to the docket may visit the FDA's Dockets Management Branch in person, view the materials on-line (http:\/\/www.regulations.gov\/search\/Regs\/home.html#docketDetail?R=FDA-1995-S-0036), or request a copy by sending a Freedom of Information Act request to FDA at the address shown below (21 CFR 312.130(d) and 812.38): Food and Drug Administration Division of Freedom of Information (HFI-35) 5600 Fishers Lane Rockville, MD 20857 Telephone: (301) 827-6500 B. PUBLIC DISCLOSURE AFTER THE STUDY IS COMPLETED OR TERMINATED\n\n根据上述已知信息，请将'94 研究完成或终止后披露的信息必须提交至FDA的备案文件管理处 吗？'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"94. Must information that is disclosed after the study is completed or terminated be submitted to FDA’s Public Docket?"
    },
    {
        "instruction":"已知信息：\n'一些改变只有在适当的停药后时期以使器官系统成熟并表达出改变后才能确定。因此，一些评估只有在达到一定程度的成熟后进行才有意义（例如学习和记忆、免疫功能）。这些评估可以在暴露涵盖与临床使用相关的所有发育窗口之后的停药后时期进行。当JAS给药期在未成熟年龄时停止的情况下，这一点尤为重要，动物将在停药后时期继续成熟至可进行合适评估的年龄。'可被翻译为：Some alterations can only be identified following an appropriate post-treatment period to allow maturation of an organ system and expression of the alteration. Therefore, some assessments can only be meaningfully performed after a certain level of maturity is reached (e.g., learning and memory, immunological function). These assessments can be conducted in post-treatment periods after exposure has covered all developmental windows relevant to the clinical use. This is especially relevant in cases when the JAS dosing duration would cease at an immature age and the animals will continue to mature during the post-treatment period to an age at which an appropriate assessment can be conducted.\n'需要对在治疗停止后药品对免疫系统影响的可逆性进行评价。'可被翻译为：Reversibility of the drug-effect on the immune-system after treatment withdrawal needs to be evaluated.\n'3.5 停药后时期评估'可被翻译为：3.5 Post-Treatment Period Assessments\n'使用TPO 受体激动剂而引发的网硬蛋白增加已被证实，并且在停药后呈现可逆性。'可被翻译为：An increased bone marrow reticulin has been demonstrated with the use of TPO-R agonists and it appears to be reversible when treatment is discontinued.\n\n根据上述已知信息，请将'是否需进行停药后时期评估，取决于WoE评价的结果和试验中所评估的终点指标。ICHM3中的评价潜在的可逆性的原则适用。停药后时期的期限应足以使影响可能恢复，并应考虑到药物的清除。但是，证明完全可逆性并非是必要的。可逆性的趋势（如发生率和\/或严重程度降低）以及对最终将达到完全可逆性的科学评估可能足够。同样，如果某一特定影响的不可逆性在成年动物中已充分表征，则通常没有必要在JAS中证实这一点。JAS的一些终点指标不适用于可逆性评估的经典方法，例如青春期开始的时间。此外，应考虑与动物生命阶段相关的停药后时期的时间选择。如果停药后时期开始于成熟之前，可逆性的能力可能受到某些器官系统持续生长和发育的影响，应谨慎解释。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Whether a post-treatment period is advisable is dependent on the outcome of the WoE assessment and the endpoints to be evaluated in the study. The principles of evaluation of the potential for reversibility in ICH M3 apply. The duration of the post-treatment period should be sufficient to allow the potential recovery of the effect and should take into account the elimination of the pharmaceutical. However, the demonstration of full reversibility is not considered essential. A trend towards reversibility (e.g., decreased incidence and\/or severity) and a scientific assessment that this would eventually progress to full reversibility could be sufficient. Likewise, if irreversibility of a specific effect is well characterised in adult animals, it is generally not necessary to confirm this in a JAS. There are endpoints in a JAS that are not amenable to the classic approach of reversibility assessment, such as the timing of onset of puberty. Additionally, the timing of the post-treatment period in relation to the life stage of the animals should be considered. If the post-treatment period begins prior to maturity, the capacity for recovery can be influenced by the continued growth and development of some organ systems and should be carefully interpreted."
    },
    {
        "instruction":"已知信息：\n'除IOM的建议外，公共与卫生服务部部长公布了一份报告，名为“把常识带到医疗监管:监管改革咨询委员会部长报告（2002年11月）”。这份报告建议FDA对于所有FDA监管药品采用安全的标签，以改善患者安全性，并减少可预防的不良事件。'可被翻译为：In addition to the IOM recommendations, the Secretary of Health and Human Services published a report entitled Bringing Common Sense to Health Care Regulation: Report of the Secretary’s Advisory Committee on Regulatory Reform (November 2002). This report recommended that FDA adopt safe labeling practices for all FDA-regulated products to improve patient safety and decrease preventable adverse drug events.\n'因此，在开发这种盒子的容器标签和纸盒标识时，FDA 给出下列建议。'可被翻译为：Therefore, FDA recommends the following when developing the container label and carton labeling for these packs:\n'2010年4月'可被翻译为：April 2010\n'2010年11月'可被翻译为：November 2010\n\n根据上述已知信息，请将'13健康素养和处方容器标签顾问组对安全药物使用专家委员会的建议，2009年5月和11月，美国药典 （USP），2010年4月发表。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"13Recommendations to the Safe Medication Use Expert Committee by the Health Literacy and Prescription Container Labeling Advisory Panel, May and November 2009, United States Pharmacopia (USP), posted April 2010."
    },
    {
        "instruction":"已知信息：\n'注意，一个监管机构接受某项试验并不意味着其他卫生监管机构也接受该 试验。'可被翻译为：Note that acceptance of an assay by one regulatory authority does not bind other health authorities to accept the assay.\n'但是，不是所有的不良事件均需要报告的如此详细。'可被翻译为：Not all AEs may need to be reported in such detail, however.\n'FDA建议，如果可能的话，应与受试者的法定授权代表或家庭进行亲自接触传达信息，并在入组后尽快传达。'可被翻译为：FDA recommends that the information be communicated through personal contact with the subject’s LAR or family if at all possible, and as soon as feasible after the enrollment has taken place.\n'FDA并不要求申办方研究疾病的生物化学基础，但是申办方应在药物研发开始时尽可能全面地理解疾病的病理生理学。'可被翻译为：FDA does not require sponsors to study the biochemical basis of a disease, but sponsors should seek to understand the pathophysiology of a disease as fully as possible at the outset of drug development.\n\n根据上述已知信息，请将'不过，FDA理解亲自接触并不总是可能的。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"However, FDA recognizes that personal contact is not always possible."
    },
    {
        "instruction":"已知信息：\n'很重要的一点是研究者应确保数据来源的患者人数充分或是，基于假设的暴露风 险窗，患者随访时间足以确认所关注的结局。'可被翻译为：It is important for investigators to ensure that the data source(s) contain a sufficient number of patients or patient follow-up time to ascertain outcomes of interest based on the hypothesized exposure risk window.\n'此外，对整合的安全性数据的分析方法应考 虑（可能）不同的患者人群和\/或多项研究不同的研究设计。'可被翻译为：In addition, the approach to the analyses of integrated safety data should take into account (possible) differing  patient populations and\/or differing study designs from multiple studies.\n'6.1.4 访问期中数据'可被翻译为：6.1.4 Access to Interim Data\n'即 使在没有计划期中分析的研究中，也应特别注意对非盲态数 据的任何持续监测，以避免不适当的访问。'可被翻译为：Even in studies without planned interim analyses, special attention should be paid to any ongoing monitoring of unblinded data to avoid inappropriate access.\n\n根据上述已知信息，请将'在有计划期中 分析的研究中，应特别注意哪些人可以访问数据和结果。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In studies with planned interim analyses, special attention should be given to which individuals have access to the data and results."
    },
    {
        "instruction":"已知信息：\n'日剂量： 患者每天使用的药品总量。'可被翻译为：Daily Dose: The total mass of drug product that is consumed by a patient on a daily basis.\n'对于成人来说，超过 30 ml 的剂量可根据患者偏好分次给药。'可被翻译为：In adults doses over 30 ml may be divided according to patient preference.\n'用于预防、治疗、诊断人的疾病，有目的地调节人的生理机能并规定有适应证或者功能主治、用法和用量的物质。包括中药材、中药饮片、中成药、化学原料药及其制剂、抗生素、生化药品、放射性药品、血清、疫苗、血液制品和诊断药品等。'可被翻译为：Substances used for the prevention, treatment and diagnosis of human diseases, the purposeful regulation of human physiological functions, and the regulation of indications or functional indications, usage and dosage. Including Chinese medicinal materials, Chinese herbal decoction pieces, proprietary Chinese medicines, chemical raw materials and their preparations, antibiotics, biochemical drugs, radiopharmaceuticals, serum, vaccines, blood products and diagnostic drugs.\n'根据相关法规、技术规范，对处方书写的规范性及药物临床使用的适宜性（用药适应证、药物选择、给药途径、用法用量、药物相互作用、配伍禁忌等）进行评价，发现存在或潜在的问题，制定并实施干预和改进措施，促进临床药物合理应用的过程。'可被翻译为：In accordance with relevant regulations and technical specifications, the evaluation of the standardization of prescription writing and the appropriateness of clinical drug use (indications, drug selection, administration route, dosage, drug interactions, compatibility contraindications, etc.) is conducted. This process involves identifying existing or potential issues, formulating and implementing interventions and improvement measures to promote the rational application of clinical drugs.\n\n根据上述已知信息，请将'药品用于治疗其主要临床适应证时的成人平均日用量。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The average daily adult dosage of a drug product at the time it is used to treat its primary clinical indication."
    },
    {
        "instruction":"已知信息：\n'药品说明书和标签管理规定'可被翻译为：Provisions for Drug Insert Sheets and Labels\n'《药品说明书和标签管理规定》于2006年3月10日经国家食品药品监督管理局局务会审议通过，现予公布，自2006年6月1日起施行。'可被翻译为：The Provisions for Drug Insert Sheets and Labels, adopted at the executive meeting of the State Food and Drug Administration on March 10, 2006, is hereby promulgated and shall go into effect as of June 1, 2006.\n'第一条 为规范药品生产质量管理，根据《中华人民共和国药品管理法》、《中华人民共和国药品管理法实施条例》，制定本规范。'可被翻译为：Article 1 These provisions of Good Manufacturing Practice (GMP) for Drugs, in accordance with the Drug Administration Law of the People's Republic of China and the Regulations for Implementation of the Drug Administration Law of the People's Republic of China, are enacted to regulate the manufacturing and quality management of Drugs.\n'第一条 为加强药品经营质量管理，规范药品经营行为，保障人体用药安全、有效，根据《中华人民共和国药品管理法》、《中华人民共和国药品管理法实施条例》，制定本规范。'可被翻译为：Article 1 To strengthen quality management of drug distribution, standardize drug distribution activities, and guarantee safe and effective use of drugs on human body, the Good Supply Practice for Drugs (GSP) is formulated in accordance with the Drug Administration Law of the People's Republic of China and the Regulations for Implementation of the Drug Administration Law of the People's Republic of China.\n\n根据上述已知信息，请将'第一条 为规范药品说明书和标签的管理，根据《中华人民共和国药品管理法》和《中华人民共和国药品管理法实施条例》制定本规定。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 1 The Provisions are enacted with a view to regulating drug insert sheets and labels in accordance with the Drug Administration Law of the People's Republic of China and the Regulations for Implementation of the Drug Administration Law of the People's Republic of China."
    },
    {
        "instruction":"已知信息：\n'如ICH Q14第4章所述，QRM可用于评价分析方法预期变更的影响。'可被翻译为：As described in Chapter 4 of ICH Q14, QRM can be used to evaluate the impact of prospective changes for analytical procedures.\n'评价了分析方法属 性，变更后符合标准 和，如适用 变更后结果仍然相 当或差异可接受， 并且对质量标准的潜在影响进行了评 价'可被翻译为：Analytical procedure attributes are evaluated and criteria are met after change And, as appropriate Results are comparable after change or differences are acceptable and potential impact on specification evaluated\n'报告类别 当既定条件发生变更时'可被翻译为：Reporting Category when making a change to the Established Condition\n'在实施变更时（与附录2保持一致），MAH应考虑计划内变更的影响、是否计划同步变更以及是否修订最初拟定的报告类别。'可被翻译为：When implementing the change, and consistent with Appendix 2, an MAH should consider the impact of the planned change, whether concurrent changes are planned, and if the originally proposed reporting category should be revised.\n\n根据上述已知信息，请将'当启动分析方法的变更时，QRM可用于评价变更的影响，以及用于重新确认最初商定的报告类别仍然适当。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"When initiating changes to analytical procedures, QRM can be used to evaluate the impact of the changes and reconfirm that the originally agreed reporting category is still appropriate."
    },
    {
        "instruction":"已知信息：\n'在器官发生期早期至少应有一次给药，以评估疫苗制剂组分潜在的直接胚胎 毒性作用，并在妊娠期的其余时间内维持高抗体应答。'可被翻译为：At least one dose should be administered during early organogenesis to evaluate potential direct embryotoxic effects of the components of the vaccine formulation and to maintain a high antibody response throughout the remainder of gestation.\n'当正在开发的疫苗拟用于妊娠期间时，应基于其拟定用途（例如，在妊娠 期间保护母亲或在出生后早期保护儿童）提供该特异性试验设计的合理性。'可被翻译为：When developing vaccines to be given during pregnancy, a justification should be provided for the specific study design, based upon its intended use (e.g., protecting the mother during pregnancy or protecting the child early postnatally).\n'最常选用的研究设计应该相当于对下述各阶段影响的联合研究：\n-生育力和早期胚胎发育\n-围产期发育，包括母体的功能\n-胚胎-胎仔发育'可被翻译为：The most probable option can be equated to a combination of studies for effects on\n- Fertility and early embryonic development\n- Pre- and postnatal development, including maternal function\n- Embryo-fetal development\n'如ICH S6所述，NHP最常用于评价仅在灵 长类中具有药理学活性的生物制品对胚胎-胎仔发育和出生后早期发育的影响。'可被翻译为：They are most typically used for evaluating effects on embryo-fetal development and early postnatal development for biopharmaceuticals that are only pharmacologically active in primates, as described in ICH S6.\n\n根据上述已知信息，请将'疫苗接种方案应使在整个胚胎、胎仔和出生后早期阶段尽可能提高母体抗体 滴度和\/或免疫应答。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The vaccination regimen should maximize maternal antibody titers and\/or immune response throughout the embryonic, fetal, and early postnatal periods."
    },
    {
        "instruction":"已知信息：\n'静脉血栓栓塞症临床表现为深静脉血栓（DVT）和肺栓塞（PE）。'可被翻译为：VTE clinically manifests as deep vein thrombosis (DVT) and pulmonary embolism (PE).\n'VTE 术中和术后高患病率（未预防情况下，骨科大手术后医院获得性无症状的 DVT 的发生率[由静脉造影术评估]大约为 40-60%；多达 1\/3 的血栓与近端深静脉相关）\n在深静脉中血栓的形成使得患者易于出现有症状的 DVT 和 PE（DVT 的最初临床 表现）和致命性 PE \n血栓预防在防止 DVT、近端 DVT、PE 和致命 PE 中得以证明的疗效 \n手术相关的 VTE 风险水平分为高-中-低三级，以便在各风险水平进行组特异的 VTE 预防：\nVTE高危手术如下肢骨科大手术（如髋关节、膝盖、髋部骨折择期手术）或腹部和癌症大手术（如结肠、子宫、卵巢手术）\nVTE 中危手术如良性疾病、创伤或下肢骨折的软组织大手术 \nVTE 低危手术如腹部小手术、静脉曲张手术、膝关节镜检查、膝盖韧带重建'可被翻译为：-high prevalence of VTE intra- and post-operatively (without prophylaxis, the incidence of hospital-acquired asymptomatic DVT [assessed by venography] is approximately 40 – 60% following major orthopaedic surgery; up to one third of these thrombi involve the proximal deep veins) \n-the formation of a thrombus in a deep vein predisposes patient to symptomatic DVT and PE (which may be the initial clinical manifestation of a DVT) and fatal PE \n-proven efficacy of thromboprophylaxis at preventing DVT, proximal DVT, PE and fatal PE The risk stratification to three (high-moderate-low)surgery\n-relatedVTE risk levels allows for the implementation of group-specific VTE prophylaxis at each risk level: \n-surgery with high VTE risk such as major orthopaedic surgery of the lower limbs (e.g. elective hip or knee surgery, hip fracture) or major abdominal and cancer surgery (e.g. colorectal, uterine, ovarian surgery) \n-surgery with moderate VTE risk such as major soft tissue surgery of benign disease, trauma or fracture of lower extremities \n-surgery with low VTE risk such as minor abdominal surgery, varicose veins surgery, knee arthroscopy, knee ligament reconstruction\n'非常罕见的不良反应：血栓栓塞反应如心肌梗死、中风、肺栓塞、深静脉血栓 形成。'可被翻译为：Very rarely: Thromboembolic reactions such as myocardial infarction, stroke, pulmonary embolism, deep vein thromboses.\n'手术患者的静脉血栓栓塞（VTE）的发病率最高。'可被翻译为：Surgical patients have the highest prevalence of venous thromboembolism (VTE).\n\n根据上述已知信息，请将'静脉血栓栓塞（VTE）是由于循环系统疾病致死的第三位诱因，仅次于心肌梗死和中风[1]。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Venous thromboembolism (VTE) is the third leading cause of death due to circulatory diseases, only behind of myocardial infarction and stroke [1]."
    },
    {
        "instruction":"已知信息：\n'在同步DSUR和PBRER的DLP时，下一个DSUR所覆盖的时间段不 得超过一年。'可被翻译为：In synchronising the DLPs for the DSUR and PBRER, the period covered by the next DSUR should be no longer than one year.\n'申办者不得因撰写DSUR而揭盲数据。'可被翻译为：Sponsors should not unblind data for the specific purpose of preparing the DSUR.\n'数据锁定点应是DSUR一年报告周期的最后一天。'可被翻译为：The data lock point of the DSUR should be the last day of the one-year reporting period.\n'报告周期及DSUR数据锁定点'可被翻译为：Periodicity and DSUR Data Lock Point\n\n根据上述已知信息，请将'两份报告数据锁定点同步后，下一次DSUR 递交周期不应超过一年。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In synchronising the data lock points for the DSUR and PSUR, the period covered by the next DSUR should be no longer than one year."
    },
    {
        "instruction":"已知信息：\n'目录中给出定位申请书中资料的路径图。如果以纸质格式进行提交，应通过分隔栏和标签来分隔申请书的各个部分，同时应从第1卷的第1页到末卷的末页对页面按顺序编号（即各卷不应从第1页开始）。'可被翻译为：The table of contents provides a road map to locate information in the application. Each section of the application should be delineated by dividers and tabbed when submitted in paper, and the pages should be numbered sequentially from the first page in volume one to the last page in the last volume (i.e., each volume should not start with page 1).\n'- 申办方应在会议请求中陈述召开会议的目的。'可被翻译为：‒ Sponsors should outline the purpose of the meeting in the meeting request.\n'C. 来自申办方的提案'可被翻译为：C. Submissions From Sponsors\n'这些后一类提案 类型包括一些与安全性相关的提案、与申办方的沟通往往至关重要并被 推荐进行但无监管时间限的药物开发提案（例如，新的方案或方案修订） 以及其他可能需要与申办方进行沟通的提案。'可被翻译为：These latter submission types include some safety-related submissions, drug development submissions without regulatory timelines where communication to the sponsor is often critical and recommended (e.g., a new protocol or protocol amendment), and other submissions where communication with the sponsor may be needed.\n\n根据上述已知信息，请将'概要通常位于提案的第一页，应列出提案的目的，并包括申办方希望以书面形式提出的任何问题。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The summary, which usually comprises the first page of the submission, should list the objectives of the submission, and include any questions the sponsor would like addressed in writing."
    },
    {
        "instruction":"已知信息：\n'在某些情况下，对于一项特定研究，并非所有相关的灵敏度分析都能在方案中考虑到。'可被翻译为：In some cases, not all of the relevant sensitivity analyses for a particular study can be anticipated in the protocol.\n'应以综合、整体的方式考虑和使用指南，而不是仅关 注一个指南或子章节。'可被翻译为：The guidelines should be considered and used in an integrated, holistic way rather than focusing on only one guideline or subsection.\n'26 申办方在紧急临床研究的研究计划（方案）中应包括哪些信息？'可被翻译为：26. What information should sponsors include in the proposed investigational plan (protocol) for an emergency research study?\n'研究报告应说明哪些材料作为附录，哪些在更全面 的归档案例报告表中、以及哪些可以根据监管机构要求提供。'可被翻译为：The study report should indicate what material is included as an appendix, what is in the more extensive archival case report tabulations, if required by the regulatory authority, and what is available on request.\n\n根据上述已知信息，请将'在本章节中，应侧重于计划进行哪些分 析、比较和统计学检验，而不是实际使用哪些。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In this section emphasis should be on which analyses, comparisons and statistical tests were planned, not on which ones were actually used."
    },
    {
        "instruction":"已知信息：\n'申办者如果想利用一个相对于标准治疗 药物的非劣效性试验来说明试验药物的有效性，就应如1.5 中所讨论的那样，解决试验检测灵敏度问题。'可被翻译为：A sponsor intending to demonstrate effectiveness by means of a trial showing non- inferiority of the test drug to a standard agent needs to address the issue of the assay sensitivity of the trial, as discussed in section 1.5.\n'当活性对照试验是用于说明试验药物的非劣 效性时，那么就应该特别考虑在1.5讨论过的检测灵敏度。'可被翻译为：When an active control trial is used to show efficacy by demonstrating non-inferiority, there is the special consideration of assay sensitivity, which is considered above in section 1.5.\n'1.5.1 非劣效\/等效性试验的检测灵敏度'可被翻译为：1.5.1 Assay Sensitivity in Non-inferiority or Equivalence Trials\n'反之，若试验想要通过显示试 验治疗与活性对照相比的非劣效性来证明其有效性，而缺少 检测灵敏度，则可能会得到一个显示非劣效性的无效治疗， 由此导致错误的有效性结论。'可被翻译为：In contrast, if a trial is intended to demonstrate efficacy by showing a test treatment to be non-inferior to an active control, but lacks assay sensitivity, the trial may find an ineffective treatment to be non-inferior and could lead to an erroneous conclusion of efficacy.\n\n根据上述已知信息，请将'1.5中讨论了非劣效性或等效性试验中检测灵敏度的问 题以及试验对得出有效性结论的能力。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"See section 1.5 for discussion of the problem of assay sensitivity and the ability of the trial to support an efficacy conclusion in non-inferiority or equivalence trials."
    },
    {
        "instruction":"已知信息：\n'必要时，应当采用适当的统计学方法；'可被翻译为：when necessary, statistical approaches should be employed;\n'一 般应采用两种性别的动物，如果采用特定的单性别应证明其合理 性。'可被翻译为：Both sexes should generally be used, or justification should be given for specific omissions.\n'“显著性”检验（为推理性统计方法）只是被用于帮助解释结果。结果解释本身必须以生物学的合理性为依据。仅仅因为没有“统计学意义”而认为与对照组结果的差别没有生物学意义的推论是轻率的。从某种程度上讲，认为有“统计学意义”的差别一定有生物学意义也是不慎重的。特别是对那些呈偏态分布的低发生率的事件（例如胚胎死亡、畸形），统计学在研究中所占权重很低。相关各变量的可信区间可提示可能的作用大小。应用统计学程序时，应考虑组间比较所采用的指标单位：采用窝而不是胎仔个体为单位，若亲代两种性别动物均给药处理，则用交配对（也即两代研究中亲代的配对）为单位。'可被翻译为：\"Significance\" tests (inferential statistics) can be used only as a support for the interpretation of results. The interpretation itself must be based on biological plausibility. It is unwise to assume that a difference from control values is not biologically relevant simply because it is not \"statistically significant\". To a lesser extent it can be unwise to assume that a \"statistically significant\" difference must be biologically relevant. Particularly for low frequency events (e.g. embryonic death, malformations) with one sided distributions, the statistical power of studies is low. Confidence intervals for relevant quantities can indicate the likely size of the effect. When using statistical procedures, experimental units of comparison should be considered: the litter, not the individual conceptus, the mating pair, when both sexes are treated, the mating pair of the parent generation in a two generation study.\n'交配时间的准确性应予详细说明，因为它会影响胎仔和幼仔相关参数的变异性。'可被翻译为：The accuracy of the time of mating should be specified since this will affect the variability of fetal and neonatal parameters.\n\n根据上述已知信息，请将'当采用推理性统计方法（判断统计学意义）时，应该以交配（动物）对或窝作为组间比较的基本单位，而不是用胎仔或幼仔个体。应说明检验方法的合理性（注释 23）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"When employing inferential statistics (determination of statistical significance) the mating pair or litter, not the foetus or neonate, should be used as the basic unit of comparison. The tests used should be justified (Note 23)."
    },
    {
        "instruction":"已知信息：\n'a：雄性大鼠单次经口给予他克莫司1.0 mg\/kg后血浆实际值（美国FDA，p. 25）：Cmax=2.9 ng\/mL，AUC(0-inf)=10.9 ng·h\/mL。'可被翻译为：a: Actual values in plasma after 1.0 mg\/kg tacrolimus oral single dose in male rats (FDA, United States, p. 25): Cmax = 2.9 ng\/mL, AUC(0-inf) = 10.9 ng·h\/mL.\n'b：雄性大鼠单次经口给予他克莫司3.2 mg\/kg后血浆实际值（美国FDA，p. 25）：Cmax=20 ng\/mL，AUC(0-inf)=68.9 ng·h\/mL。'可被翻译为：b: Actual values in plasma after 3.2 mg\/kg tacrolimus oral single dose in male rats (FDA, United States, p. 25): Cmax = 20 ng\/mL, AUC(0-inf) = 68.9 ng·h\/mL.\n'利巴韦林 CAS号：36791-04-5 大鼠NOAEL 剂量 Cmax AUC 大鼠LOAEL 剂量 Cmax AUC 大鼠 发现 兔NOAEL 剂量 Cmax AUC 兔LOAEL 剂量 Cmax AUC 兔 发现 注释 0.3 mg\/kg 经口 GD6-15（美国 FDA，p. 64） Cmax=3.8 ng\/mLa AUC=8.28 ng∙h\/mLa 1.0 mg\/kg 经口 GD6-15（美国 FDA，p. 64） Cmax=12.7 ng\/mLa AUC=27.6 ng∙h\/mLa 脑积水，视网膜襞， 膈疝，肾上腺移位， 食道移位，血管缺 陷；移行椎，脊柱侧 凸，肋骨和椎骨融 合，胸骨分裂，缺趾 畸形，后肢旋转不 良；着床后丢失增加 0.3 mg\/kg 经口 GD6-18（美国 FDA，p. 68） 未发现兔PK数 据 1.0 mg\/kg 经口 GD6-18（美国 FDA，p. 68）'可被翻译为：Ribavirin CAS No.: 36791-04-5 Rat NOAEL Dose Cmax AUC Rat LOAEL Dose Cmax AUC Rat Findings Rabbit NOAEL Dose Cmax AUC Rabbit LOAEL Dose Cmax AUC Rabbit Findings Notes 0.3 mg\/kg oral GD6-15 (FDA, United States, p. 64) Cmax = 3.8 ng\/mLa AUC = 8.28 ng∙h\/mLa 1.0 mg\/kg oral GD6-15 (FDA, United States, p. 64) Cmax = 12.7 ng\/mLa AUC = 27.6 ng∙h\/mLa hydrocephaly, retinal folds, diaphragmic hernia, displaced adrenal, displaced oesophagus, vascular defects; extra vertabra, scoliosis, fused ribs and vertebrae, split sternum, ectrodactyly, malrotated hind limbs; increased post- implantation loss 0.3 mg\/kg oral GD6-18 (FDA, United States, p. 68) No rabbit PK data found 1.0 mg\/kg oral GD6-18 (FDA, United States, p. 68)\n'帕唑帕尼 CAS号：444731-52-6 大鼠NOAEL 剂量 Cmax AUC 大鼠LOAEL 剂量 Cmax AUC 大鼠 发现 兔NOAEL 剂量 Cmax AUC 兔LOAEL 剂量 Cmax AUC 兔 发现 注释 1 mg\/kg 经口 GD6-17（美国 FDA，p. 218） Cmax=3.47 μg\/mLa AUC=0.028 μg∙h\/mLa 3 mg\/kg 经口 GD6-17（美国 FDA，p.218） Cmax=10.4 µg\/mLa AUC=0.083 µg∙h\/mLa 大血管畸形，无名动 脉缺失 3 mg\/kg 经口GD7- 19（美国FDA，p. 225） Cmax = 0.130 µg\/mLb AUC(0-t)=0.517 µg∙h\/mLc 10 mg\/kg经口GD7- 19（美国FDA， p. 225） Cmax=1.063 µg\/mLd AUC(0-t)=1.723 µg∙h\/mLd 着床后丢失增 加'可被翻译为：Pazopanib CAS No.: 444731-52-6 Rat NOAEL Dose Cmax AUC Rat LOAEL Dose Cmax AUC Rat Findings Rabbit NOAEL Dose Cmax AUC Rabbit LOAEL Dose Cmax AUC Rabbit Findings Notes 1 mg\/kg oral GD6- 17 (FDA, United States, p. 218) Cmax = 3.47 μg\/mLa AUC = 0.028 μg∙h\/mLa 3 mg\/kg oral GD6- 17 (FDA, United States, p.218) Cmax = 10.4 µg\/mLa AUC = 0.083 µg∙h\/mLa malformations in the great vessels, missing innominate artery 3 mg\/kg oral GD7-19 (FDA, United States, p. 225) Cmax = 0.130 µg\/mLb AUC(0-t) = 0.517 µg∙h\/mLc 10 mg\/kg oral GD7- 19 (FDA, United States, p. 225) Cmax = 1.063 µg\/mLd AUC(0-t) = 1.723 µg∙h\/mLd increased post- implantation loss\n\n根据上述已知信息，请将'他克莫司 CAS号：104987-11-3 大鼠NOAEL 剂量 Cmax AUC 大鼠LOAEL 剂量 Cmax AUC 大鼠 发现 兔NOAEL 剂量 Cmax AUC 兔LOAEL 剂量 Cmax AUC 兔 发现 注释 1.0 mg\/kg经口 GD7-17（美国 FDA，p. 18） Cmax=2.9 ng\/mLa AUC(0-inf)=10.9 ng∙h\/mLa 3.2 mg\/kg 经口 GD7-17（美国 FDA，p. 18） Cmax=20 ng\/mLb AUC(0-inf)=68.9 ng∙h\/mLb 着床后丢失轻微 增加（晚期吸 收） 0.32 mg\/kg 经口 GD6-18（美国 FDA，p. 19） Cmax=0.93 ng\/mLc AUC=17.6 µg∙h\/mLc 1.0 mg\/kg 经口 GD6-18（美国 FDA，p. 19） Cmax=2.9 ng\/mLc AUC=55 ng∙h\/mLc 心室发育不良，室间 隔缺损，球茎主动脉 弓和动脉弓和导管狭 窄，脐膨出，胆囊发 育不全，骨骼畸形；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"TACROLIMUS CAS No.: 104987-11-3 Rat NOAEL Dose Cmax AUC Rat LOAEL Dose Cmax AUC Rat Findings Rabbit NOAEL Dose Cmax AUC Rabbit LOAEL Dose Cmax AUC Rabbit Findings Notes 1.0 mg\/kg oral GD7-17 (FDA, United States, p. 18) Cmax = 2.9 ng\/mLa AUC(0-inf) = 10.9 ng∙h\/mLa 3.2 mg\/kg oral GD7-17 (FDA, United States, p. 18) Cmax = 20 ng\/mLb AUC(0-inf) = 68.9 ng∙h\/mLb slight increase in post implantation loss (late resorptions) 0.32 mg\/kg oral GD6-18 (FDA, United States, p. 19) Cmax = 0.93 ng\/mLc AUC = 17.6 µg∙h\/mLc 1.0 mg\/kg oral GD6-18 (FDA, United States, p. 19) Cmax = 2.9 ng\/mLc AUC = 55 ng∙h\/mLc ventricular hypoplasia, interventricular septal defect, bulbous aortic arch and stenosis of arch and ductus arteriosus, omphalocele, gallbladder agenesis, skeletal malformations;"
    },
    {
        "instruction":"已知信息：\n'强烈建议在开发计划中纳入对生物标志物的研究，预测反应并确定在治疗停药后不 复发的患者。'可被翻译为：It is strongly recommended to include studies on biomarkers in the development program, to predict response and to identify patients who will not relapse after treatment withdrawal.\n'鼓励申办方进行生物标志物的开发和验证以作为其开发策略的一部分，并在适当时将其用作临床试验中的探索性有效性指标。'可被翻译为：Sponsors are encouraged to engage in the development and validation of biomarkers as part of their development strategy and to use them as exploratory efficacy measures in clinical trials as appropriate.\n'可以将两项研究的死亡率的前瞻性计划分析作为开发计划的一部分。'可被翻译为：A prospectively planned analysis of mortality across both studies can be specified as part of the development plan.\n'纳入一个对照组以及按基因组生物标志物状态（即 基因组生物标志物阳性或基因组生物标志物阴性）对随机化进行分层将允许估算灵敏度、特异性和预测值。'可被翻译为：The inclusion of a control arm and stratification of randomisation by genomic biomarker status (i.e. genomic biomarker positive or genomic biomarker negative) will permit estimation of sensitivity, specificity, and predictive value.\n\n根据上述已知信息，请将'因此建议将发现和纳入生物标志物作为药物开发计划的一部分。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"It is therefore advised that identification and inclusion of biomarkers is incorporated as an integral part of the drug development programme."
    },
    {
        "instruction":"已知信息：\n'4.批准质量标准、取样方法、检验方法和其他质量管理的操作规程；'可被翻译为：4) To approve specifications, sampling instructions, testing methods and other quality management procedures;\n'4.取样、检验方法或相关操作规程编号；'可被翻译为：4. Sampling and testing procedures or references to relevant operation procedures;\n'11.12 质量标准、取样计划和检验规程应当科学合理，以确保原料、中间体、原料药、标签和包装材料符合预定的质量与纯度要求。质量标准和检验规程应当与注册申报一致。此外，可建立附加的质量标准。质量标准、取样计划、检验规程及其变更应当由适宜的部门起草并经质量管理部门审核和批准。'可被翻译为：11.12 All specifications, sampling plans, and test procedures should be scientifically sound and appropriate to ensure that raw materials, intermediates, APIs, and labels and packaging materials conform to established standards of quality and\/or purity. Specifications and test procedures should be consistent with those included in the registration\/filing. There can be specifications in addition to those in the registration\/filing. Specifications, sampling plans, and test procedures, including changes to them, should be drafted by the appropriate organizational unit and reviewed and approved by the quality unit(s).\n'4.法规规定的其他需要验证的检验方法。'可被翻译为：4) Other testing methods requested by regulations for validation.\n\n根据上述已知信息，请将'4.批准质量标准、取样方法、检验方法和其他质量管理的操 作规程；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"4) To approve specifications, sampling instructions, testing methods and other quality management procedures;"
    },
    {
        "instruction":"已知信息：\n'2万支（瓶）以下（含2万支），抽样1件；5万支（瓶）以下（含5万支），抽样2件；10万支（瓶）以下（含10万支），抽样3件；10万支（瓶）以上，每增加10万支（瓶）加抽1件，不足10万支（瓶）以10万支（瓶）计。'可被翻译为：If the quantity is below 20,000 vials (including), take 1 product for sampling; if the quantity is below 50,000 vials (including), take 2 products for sampling; if the quantity is below 100,000 vials (including), take 3 products for sampling; if the quantity is more than 100,000 vials, take additional 1 product for sampling for every additional 100,000 vials, and the odd less than 100,000 shall be counted as 100,000.\n'每2万盒（瓶），抽样一件，不足2万盒（瓶）的按2万盒（瓶）计。'可被翻译为：Take 1 product for sampling for every 20,000 boxes (vials), and the odd less than 20,000 boxes (vials) shall be counted as 20,000.\n'10件以内，抽样1件；11件－50件，每增加10件加抽1件，不足10件者以10件计；51件－100件，每增加20件加抽1件，不足20件者以20件计；101件以上，每增加50件加抽1件，不足50件者以50件计；1001件以上，每增加100件加抽1件，不足100件者以100件计；'可被翻译为：If the quantity is less than 10, take 1 product for sampling; if the quantity is 11 to 50, take additional 1 product for sampling for every additional 10, and the odd less than 10 shall be counted as 10; if the quantity is 51 to 100, take additional 1 product for sampling for every additional 20, and the odd less than 20 shall be counted as 20; if the quantity is more than 101, take additional 1 product for sampling for every additional 50, and the odd less than 50 shall be counted as 50; if the quantity is more than 1001, take additional 1 product for sampling for every additional 100, and the odd less than 100 shall be counted as 100;\n'4．1公斤以下的，每20公斤抽样1件，不足20公斤者以20公斤计（原装抽样）。'可被翻译为：4. If the products within one package are less than 1 kg, take 1 product for sampling for every 20 kg, and the odd less than 20 kg shall be counted as 20 kg (taking samples from original package).\n\n根据上述已知信息，请将'100－1000毫升（含1000毫升）的注射液，每1万瓶抽样1件，不足1万瓶的按1万瓶计。1000毫升以上的注射液（含透析液），每5000瓶（袋）抽样1件，不足5000瓶（袋）的按5000瓶计。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"If the injection is 100 ml to 1000 ml (including), take 1 product for sampling for every 10,000 vials, and the odd less than 10,000 vials shall be counted as 10,000. If the injection (including dialysate) is more than 1000 ml, take 1 product for sampling for every 5,000 vials (bags), and the odd less than 5,000 vials (bags)shall be counted as 5,000."
    },
    {
        "instruction":"已知信息：\n'本指导原则是为CTD（ICH M4）模块3中所定义的制 剂在药品研发章节（3.2.P.2）中所申报内容提供指导。本原则不适用于指导药品研发中临床研究阶段的申报内容，但是其中的一些基本原则在该阶段也是非常值得考虑的。本原则也可能适用于其他类型的产品，申报者可以咨询相关管理机构来确定是否适用。'可被翻译为：This guideline is intended to provide guidance on the contents of Section 3.2.P.2 (Pharmaceutical Development) for drug products as defined in the scope of Module 3 of the Common Technical Document (ICH guideline M4). The guideline does not apply to contents of submissions for drug products during the clinical research stages of drug development. However, the principles in this guideline are important to consider during those stages as well. This guideline might also be appropriate for other types of products. To determine the applicability of this guideline to a particular type of product, applicants can consult with the appropriate regulatory authorities.\n'药品研发信息应在CTD的P2章节中提交，而从药品研发过程得到的其它信息，则可以根据CTD的格式，以各种不同的方式提供（参见以下具体建议）。但是，申报者应清楚的标明各种信息在申报资料中所处的章节。除了在申报资料中已递交的内容外，本指导原则的部分内容（如产品生命周期管理，持续改进）涉及申报者的药品质量体系（见ICH Q10）。'可被翻译为：Pharmaceutical development information is submitted in Section P.2 of the CTD. Other information resulting from pharmaceutical development studies could be accommodated by the CTD format in a number of different ways and some specific suggestions are provided below. However, the applicant should clearly indicate where the different information is located. In addition to what is submitted in the application, certain aspects (e.g., product lifecycle management, continual improvement) of this guideline are handled under the applicant’s pharmaceutical quality system (see ICH Q10).\n'为了促进CTD 通用指导原则(M4)的实施, ICH 专家组拟定了一系列问答: M4 问答'可被翻译为：In order to facilitate the implementation of the CTD General (M4) guideline, the ICH Experts have developed a series of Q&As: M4 Q&As\n'在通用技术文件（CTD）中提交的药品研发及相信息'可被翻译为：SUBMISSION OF PHARMACEUTICAL DEVELOPMENT AND RELATED INFORMATION IN COMMON TECHNICAL DOCUMENTS (CTD) FORMAT\n\n根据上述已知信息，请将'本指导原则介绍了在ICH M4通用技术文件（CTD）中药品研发章节（3.2.P.2）中应注册申报的内容。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"This guideline describes the suggested contents for the 3.2.P.2 (Pharmaceutical Development) section of a regulatory submission in the ICH M4 Common Technical Document (CTD) format."
    },
    {
        "instruction":"已知信息：\n'可根据数据类型、仪器或样品、模型预期目的和\/或先验知识 选择数据转换方法。'可被翻译为：The selection of the data transformation method(s) can be driven by the type of data, instrument or sample, the intended purpose of the model and\/or prior knowledge.\n'在某些情况下，可能需要关联或换算以提供相同的测量单位。'可被翻译为：In some cases, a correlation or conversion may be needed to provide the same unit of measure.\n'数据转换（DATA TRANSFORMATION） 为获得与输出数据更好的相关性并简化模型结构，而对模型输 入数据进行的数学处理。（ICH Q14）'可被翻译为：ICH Q14 Guideline 21 DATA TRANSFORMATION Mathematical operation on model input data to assume better correlation with the output data and to simplify the model structure. (ICH Q14)\n'如有必要，可对受变更影响的分析方法性能特征进行全面或部分再验证，和\/或进行代表性样品和参比物质的比较分析。'可被翻译为：These can include, if necessary, full or partial revalidation of the analytical procedure performance characteristics affected by the change and\/or comparative analysis of representative samples and reference material.\n\n根据上述已知信息，请将'如有必要，可对测量数据进行数学转换（例如，通过使用对数函数）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The measured data can be mathematically transformed if necessary (e.g., through the use of a log function)."
    },
    {
        "instruction":"已知信息：\n'指南主要集中于旨在改变疾病进展的治疗。'可被翻译为：The guideline primarily focuses on treatments aimed to modify disease progression.\n'疾病修饰治疗的首要目标是延缓或甚至逆转疾病进展。'可被翻译为：For disease-modifying treatments the primary goal is the slowing or even reversal of disease progression.\n'旨在降低疾病进展风险的治疗'可被翻译为：Treatments aiming at reducing risk for disease progression\n'疾病修饰治疗 如果药物治疗能使基础病例或病理生理的疾病进展得以延缓，那么可以认为药物具  有疾病修饰的效应。'可被翻译为：Disease modifying treatments  A medicinal product can be considered to be disease modifying when the pharmacologic treatment delays the underlying pathological or pathophysiological disease processes.\n\n根据上述已知信息，请将'本指导原则主要关注旨在修饰疾病进展的治疗。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The guideline focuses on treatment aimed to modify disease progression."
    },
    {
        "instruction":"已知信息：\n'然后，当获得 10 名 12 岁以上 PTP 关于至少 50ED 的药动学和疗效\/安全性数据后，可以开始开展 0-<12 岁儿童的临床试验。'可被翻译为：Subsequently, when PK and efficacy\/safety in 10 PTPs ≥12 years for at least 50 EDs are available, the clinical trial(s) in children 0 - <12 years can be initiated.\n'除了要求对某些药物进行儿科评估外，PREA还要求使用适合每个研究年龄组的药物制剂来进行评估。'可被翻译为：In addition to requiring pediatric assessments of certain drugs, PREA also requires that those assessments be conducted using a formulation of the drug that is appropriate for each age group being studied.\n'在申请上市时，须递交 50 名儿童（0 至 12 岁）服药 50 天后的药动学参数（增量回收率、体内半衰期、药时曲线下面积和清除率）以及完整的疗效及安全性试验资料。'可被翻译为：Within the application for marketing authorisation, pharmacokinetic data (incremental recovery, in vivo  half-life, AUC and clearance) as well as the completed efficacy and safety trial in 50 children ( to 0 <12 y) followed for  EDs should be submitted.\n'随后，在从年龄≥12 岁的 20 个 PTP 获得关于至少50ED 的药动学和疗效\/安全性数据后，对 0-<12 岁儿童的临床研究才可以开始。'可被翻译为：Subsequently, when PK and  efficacy\/safety data from  PTPs ≥12 years for at least  50 EDs are available, the clinical trial(s) in  children  0-<12 years can be initiated.\n\n根据上述已知信息，请将'可以入组每个年龄组的PTP，条件是完成儿童试验（药动学参数、疗效和安全性）并递交报告供相关主管部门评估。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"PTPs of every age group could be included, provided that trial in children is completed (PK and efficacy and safety) and report is submitted and evaluated by the relevant Competent Authority(ies)."
    },
    {
        "instruction":"已知信息：\n'（一）医疗器械的名称、型号、规格、数量；'可被翻译为：(1) name, model, specification, and quantity of the medical device;\n'（八）安装和使用说明或者图示，由消费者个人自行使用的医疗器械还应当具有安全使用的特别说明；'可被翻译为：(8) Installation and use instructions or illustrations; medical devices intended for personal use shall also be attached with special instructions for safe use.\n'医疗器械停止销售、使用的，其产品标识不得用于其他医疗器械；重新销售、使用时，可使用原产品标识。'可被翻译为：Where the sale or use of any medical device is suspended, its UDI-DI can no longer be applied for use on other medical devices; if the sale or use thereof is restarted, the original UDI-DI can be used again.\n'药物联合应用时需进行一般毒理学、安全药理学和生殖毒性评估。'可被翻译为：General toxicology, safety pharmacology, and reproductive toxicology assessments should be done for the combination.\n\n根据上述已知信息，请将'（六）产品需要同其他医疗器械一起安装或者联合使用时，应当注明联合使用器械的要求、使用方法、注意事项；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(6) For a product needs to be installed or used in combination with other medical devices, requirements, use methods and precautions of the combining medical devices shall be provided."
    },
    {
        "instruction":"已知信息：\n'申请人获准开展药物临床试验的为药物临床试验申办者（以下简称申办者）。'可被翻译为：An applicant who is approved to carry out clinical trials of drugs shall be the sponsor of drug clinical trials (hereinafter referred to as the sponsor).\n'1.54 申办者-研究者 单独或与其他人一起，发起并实施一个临床试验的个人。 在他(们)的直接指示下，给对象服用、发给对象或由对象使用 试验用药品。该术语并不包括除了个人以外的任何人(如不包括 一个公司和一个机构)。一个申办者-研究者的义务包括一个申 办者和一个研究者两者的义务。'可被翻译为：1.54 Sponsor-Investigator An individual who both initiates and conducts, alone or with others, a clinical trial, and under whose immediate direction the investigational product is administered to, dispensed to, or used by a subject. The term does not include any person other than an individual (e.g., it does not include a corporation or an agency). The obligations of a sponsor-investigator include both those of a sponsor and those of an investigator.\n'1.53 申办者 发起一项临床试验的，并对该试验的管理和财务负责的个 人、公司、机构或组织。'可被翻译为：1.53 Sponsor An individual, company, institution, or organization which takes responsibility for the initiation, management, and\/or financing of a clinical trial.\n'17. 申办者 ICH E6（R1） 负责发起、管理和\/或资助临床试验的个人、公司、机构或组织。'可被翻译为：17.Sponsor ICH E6 (R1) An individual, company, institution, or organisation which takes responsibility for the initiation, management, and\/or financing of a clinical trial.\n\n根据上述已知信息，请将'申办者，是指临床试验的发起、管理和提供财务支持的机构或者组织。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The sponsor refers to the institution or organization that launches, manages and provides financial support for the clinical trial."
    },
    {
        "instruction":"已知信息：\n'适当时，法规申报资料应包括更新的控制策略。'可被翻译为：If appropriate, the regulatory submission would include an updated control strategy.\n'如果申报资料里包括已注册替代RTRT控制策略（例如，当无法进行过程分析时进行的传统终产品检测），则相关分析方法以及何时应用这些方法也应包含在产品质量标准中。'可被翻译为：If the dossier includes a registered alternative control strategy to RTRT (e.g., traditional end-product testing when process analytics are unavailable), the related analytical procedures and when they would be applied should also be included in the product specifications.\n'采用增强方式时，不应导致在注册申报资料中提供更不详细的分析方法描述。'可被翻译为：The use of the enhanced approach should not lead to providing a less detailed description of analytical procedures in a regulatory submission.\n'4 2009年6 月 当在线检测或者 监测设备出现故障时， 可以采取哪些措施？'可被翻译为：4 June 2009 What approaches can be taken in the event of on-line\/in- line\/at-line testing or monitoring equipment breakdown?\n\n根据上述已知信息，请将'注册申报资料中提供的控制策略应包括设备故障时可 采用的替代检测或者监测方法的建议。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The control strategy provided in the application should include a proposal for use of alternative testing or monitoring approaches in cases of equipment failure."
    },
    {
        "instruction":"已知信息：\n'验证集 (VALIDATION SET)'可被翻译为：VALIDATION SET\n'独立样本的验证集的描述；'可被翻译为：• Description of the validation set with independent samples;\n'用于对校正模型的性能进行独立评估的一组数据。（ICH Q2）'可被翻译为：A set of data used to give an independent assessment of the performance of the calibration model. (ICH Q2)\n'内部测试集（INTERNAL TEST SET） 从样品中获得的一组数据，这些样品涵盖的物理化学特性变异 范围与用于构建校正集样品类似。（ICH Q14）'可被翻译为：INTERNAL TEST SET A set of data obtained from samples that have physical and chemical characteristics that span a range of variabilities similar to the samples used to construct the calibration set. (ICH Q14)\n\n根据上述已知信息，请将'验证集（VALIDATION SET） 用于对校正模型的性能进行独立评估的一组数据。（ICH Q2）'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"VALIDATION SET A set of data used to give an independent assessment of the performance of the calibration model. (ICH Q2)"
    },
    {
        "instruction":"已知信息：\n'D -患者特征 1„1 D -患者特征 D.1 -患者（姓名或姓名首字母缩写） D.1.1.1 -患者医疗记录编号和记录编号的来源（GP医疗记录编号） D.1.1.2 -患者医疗记录编号和记录编号的来源（专家记录编号） D.1.1.3 -患者医疗记录编号和记录编号的来源（医院记录编号） D.1.1.4 -患者医疗记录编号和记录编号的来源（研究编号） D.3 -体重（kg） D.4 -身高（cm） D.5 -性别 D.6 -末次月经日期 D.7.2 -相关病史及并发疾病的文本说明（不包括反应\/事件） D.7.3 -合并治疗 D.9.1 -死亡日期 D.9.3 -是否进行尸检？ D.2 -年龄信息 0 „ 1 0 „ n 0 „ n 0 „ n D.2.1 -出生日期 D.2.2a -反应\/事件发生时的年龄（数） D.2.2b -反应\/事件发生时的年龄（单位） D.2.2.1a -当胎儿的反应当胎儿的反应\/事件被观察到时的妊娠期（数） D.2.2.1b -当胎儿的反应当胎儿的反应\/事件被观察到时的妊娠期（单位） D.2.3 -患者年龄段年龄段（按报告者） D.7.1.r -相关病史的结构化信息（必要时重复） D.7.1.r.1a -用于病史的 MedDRA 版本 D.7.1.r.1b -病史（疾病\/外科手术\/等）（MedDRA编码） D.7.1.r.2 -开始日期 D.7.1.r.3 -持续时间 D.7.1.r.4 -结束日期 D.7.1.r.5 -评论 D.7.1.r.6 -家族史 D.8.r -相关既往用药史（必要时重复） D.8.r.1 -报告所用药物的名称 D.8.r.2a - MPID 版本日期\/编号 D.8.r.2b -药品标识符（MPID） D.8.r.3a - PhPID 版本日期\/编号 D.8.r.3b -药剂标识符（PhPID） D.8.r.4 -开始日期 D.8.r.5 -结束日期 D.8.r.6a -针对适应症的 MedDRA版本 D.8.r.6b -适应症（MedDRA编码） D.8.r.7a -针对反应的 MedDRA版本 D.8.r.7b -反应（MedDRA编码） D.9.2.r -报告的死因（必要时重复） D.9.2.r.1a -用于报告死因的 MedDRA版本 D.9.2.r.1b -报告的死因（MedDRA编码） D.9.2.r.2 -报告的死因（自定义文本） 接下页'可被翻译为：D - Patient Characteristics D.1 - Patient (name or initials) D.1.1.1 - Patient Medical Record Number(s) and the Source(s) of the Record Number (GP Medical Record Number) D.1.1.2 - Patient Medical Record Number(s) and the Source(s) of the Record Number (Specialist Record Number) D.1.1.3 - Patient Medical Record Number(s) and the Source(s) of the Record Number (Hospital Record Number) D.1.1.4 - Patient Medical Record Number(s) and the Source(s) of the Record Number (Investigation Number) D.3 - Body Weight (kg) D.4 - Height (cm) D.5 - Sex D.6 - Last Menstrual Period Date D.7.2 - Text for Relevant Medical History and Concurrent Conditions (not including reaction \/ event) D.7.3 - Concomitant Therapies D.9.1 - Date of Death D.9.3 - Was Autopsy Done? D - Patient Characteristics D.2.1 - Date of Birth D.2.2a - Age at Time of Onset of Reaction \/ Event (number) D.2.2b - Age at Time of Onset of Reaction \/ Event (unit) D.2.2.1a - Gestation Period When Reaction \/ Event Was Observed in the Foetus (number) D.2.2.1b - Gestation Period When Reaction \/ Event Was Observed in the Foetus (unit) D.2.3 - Patient Age Group (as per reporter) D.2 - Age Information D.8.r.1 - Name of Drug as Reported D.8.r.2a - MPID Version Date \/ Number D.8.r.2b - Medicinal Product Identifier (MPID) D.8.r.3a - PhPID Version Date \/ Number D.8.r.3b - Pharmaceutical Product Identifier (PhPID) D.8.r.4 - Start Date D.8.r.5 - End Date D.8.r.6a - MedDRA Version for Indication D.8.r.6b - Indication (MedDRA code) D.8.r.7a - MedDRA Version for Reaction D.8.r.7b - Reaction (MedDRA code) D.8.r - Relevant Past Drug History (repeat as necessary) D.7.1.r.1a - MedDRA Version for Medical History D.7.1.r.1b - Medical history (disease \/ surgical procedure \/ etc.) (MedDRA code) D.7.1.r.2 - Start Date D.7.1.r.3 - Continuing D.7.1.r.4 - End Date D.7.1.r.5 - Comments D.7.1.r.6 - Family History D.7.1.r - Structured Information on Relevant Medical History (repeat as necessary) 0 ... 1 0 ... n 0 ... n 1 ... 1 D.9.2.r.1a - MedDRA Version for Reported Cause(s) of Death D.9.2.r.1b - Reported Cause(s) of Death (MedDRA code) D.9.2.r.2 - Reported Cause(s) of Death (free text) D.9.2.r - Reported Cause(s) of Death (repeat as necessary) 0 ... n Continued on Next Page\n'D.10.7.2 相关病史及并发疾病的文本说明 用户指导原则 此数据元素获取有关元素D.10.7.1.r中父母的无法编码的任何其他病史的信息。 一致性 可选择 数据类型 10000AN OID 无 允许值 自定义文本 业务规则'可被翻译为：D.10.7.2 Text for Relevant Medical History and Concurrent Conditions of Parent User Guidance This data element captures information about any other medical history for the parent that could not be coded in D.10.7.1.r. Conformance Optional Data Type 10000AN OID None Value Allowed Free text Business Rule(s)\n'表2：E2B（R3）数据元素和元素MedDRA OID 元素元素ID 元素名称元素 D.7.1.r.1b OID 文献参考文献参考 病史（疾病\/外科手术\/等）（MedDRA编码） 2.16.840.1.113883.6.163 D.8.r.6b 适应症（MedDRA编码） D.8.r.7b 2.16.840.1.113883.6.163 反应（MedDRA编码） D.9.2.r.1b 2.16.840.1.113883.6.163 报告的死因（MedDRA编码） D.9.4.r.1b 2.16.840.1.113883.6.163 尸检确定的死因（MedDRA编码） D.10.7.1.r.1b 2.16.840.1.113883.6.163 病史（疾病\/外科手术\/等）（MedDRA编码） 2.16.840.1.113883.6.163 D.10.8.r.6b 适应症（MedDRA编码） D.10.8.r.7b 2.16.840.1.113883.6.163 反应（MedDRA编码） E.i.2.1b 2.16.840.1.113883.6.163 反应\/事件（MedDRA编码） F.r.2.2b 2.16.840.1.113883.6.163 检测名称检测（MedDRA编码） G.k.7.r.2b 2.16.840.1.113883.6.163 适应症（MedDRA编码） 2.16.840.1.113883.6.163 H.3.r.1b 发送者的诊断\/综合征和（或）对不良反应\/事件的重新分类（MedDRA编码） 2.16.840.1.113883.6.163'可被翻译为：Table 2: E2B (R3) data elements and MedDRA OIDs Element id Element Name OID Reference D.7.1.r.1b Medical History (disease \/ surgical procedure \/ etc.) (MedDRA code) 2.16.840.1.113883.6.163 D.8.r.6b Indication (MedDRA code) 2.16.840.1.113883.6.163 D.8.r.7b Reaction (MedDRA code) 2.16.840.1.113883.6.163 D.9.2.r.1b Reported Cause(s) of Death (MedDRA code) 2.16.840.1.113883.6.163 D.9.4.r.1b Autopsy-determined Cause(s) of Death (MedDRA code) 2.16.840.1.113883.6.163 D.10.7.1.r.1b Medical History (disease \/ surgical procedure \/ etc.) (MedDRA code) 2.16.840.1.113883.6.163 D.10.8.r.6b Indication (MedDRA code) 2.16.840.1.113883.6.163 D.10.8.r.7b Reactions (MedDRA code) 2.16.840.1.113883.6.163 E.i.2.1b Reactions \/ Event (MedDRA code) 2.16.840.1.113883.6.163 F.r.2.2b Test Name (MedDRA code) 2.16.840.1.113883.6.163 G.k.7.r.2b Indication (MedDRA code) 2.16.840.1.113883.6.163 H.3.r.1b Sender's Diagnosis \/ Syndrome and \/ or Reclassification of Reaction \/ Event (MedDRA code) 2.16.840.1.113883.6.163\n'D.10.7父母的相关病史及并发疾病'可被翻译为：D.10.7 Relevant Medical History and Concurrent Conditions of Parent\n\n根据上述已知信息，请将'D -患者特征 续上页 D.9.4.r -尸检-确定的死因（必要时重复） 0„n D.9.4.r.1a -用于尸检确定的死因的 MedDRA版本 D.9.4.r.1b -尸检-确定的死因（MedDRA编码） D.9.4.r.2 -尸检-确定的死因（自定义文本） D.10 -父母-儿童\/胎儿的报告，关于父母的信息 0„1 D.10.1 -研究识别 D.10.2.1 -父母的出生日期 D.10.2.2 -父母的年龄 D.10.2.2a -父母的年龄（数） D.10.2.2b -父母的年龄（单位） D.10.3 –母亲末次月经日期 D.10.4 -父母的体重（kg） D.10.5 -父母的身高（cm） D.10.6 -父母的性别 0„1 D.10.7.2 -相关病史及并发疾病的文本说明 D.10.7 -父母的相关病史及并发疾病 D.10.7.1.r -父母的结构化信息（必要时重复） 0„n D.10.7.1.r.1a -用于编码病史的 MedDRA版本 D.10.7.1.r.1b -病史（疾病\/外科手术\/等）（MedDRA编码） D.10.7.1.r.2 -开始日期 D.10.7.1.r.3 -持续时间 D.10.7.1.r.4 -结束日期 D.10.7.1.r.5 -评论 D.10.8.r -父母的相关既往药物史（必要时重复） 0„n D.10.8.r.1 -报告所用药物的名称 D.10.8.r.2a - MPID 版本日期\/编号 D.10.8.r.2b -药品标识符（MPID） D.10.8.r.3a - PhPID 版本日期\/编号 D.10.8.r.3b –药物制剂标识符（PhPID） D.10.8.r.4 -开始日期 D.10.8.r.5 -结束日期 D.10.8.r.6a -针对适应症的 MedDRA版本 D.10.8.r.6b -适应症（MedDRA编码） D.10.8.r.7a -针对反应的 MedDRA版本 D.10.8.r.7b -反应（MedDRA编码）'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"D - Patient Characteristics Continued from Previous Page D.10.1 - Parent Identification D.10.2.1 - Date of Birth of Parent D.10.2.2 - Age of Parent D.10.2.2a - Age of Parent (number) D.10.2.2b - Age of Parent (unit) D.10.3 - Last Menstrual Period Date of Parent D.10.4 - Body Weight (kg) of Parent D.10.5 - Height (cm) of Parent D.10.6 - Sex of Parent D.10 - For a Parent-Child \/ Foetus Report, Information Concerning the Parent D.10.7.2 - Text for Relevant Medical History and Concurrent Conditions of Parent D.10.7 - Relevant Medical History and Concurrent Conditions of Parent 0 ... 1 0 ... 1 D.10.7.1.r.1a - MedDRA Version for Medical History D.10.7.1.r.1b - Medical History (disease \/ surgical procedure\/ etc.) (MedDRA code) D.10.7.1.r.2 - Start Date D.10.7.1.r.3 - Continuing D.10.7.1.r.4 - End Date D.10.7.1.r.5 - Comments D.10.7.1.r - Structured Information of Parent (repeat as necessary) 0 ... n D.10.8.r.1 - Name of Drug as Reported D.10.8.r.2a - MPID Version Date \/ Number D.10.8.r.2b - Medicinal Product Identifier (MPID) D.10.8.r.3a - PhPID Version Date \/ Number D.10.8.r.3b - Pharmaceutical Product Identifier (PhPID) D.10.8.r.4 - Start Date D.10.8.r.5 - End Date D.10.8.r.6a - MedDRA Version for Indication D.10.8.r.6b - Indication (MedDRA code) D.10.8.r.7a - MedDRA Version for Reaction D.10.8.r.7b - Reactions (MedDRA code) D.10.8.r - Relevant Past Drug History of Parent (repeat as necessary) 0 ... n D.9.4.r.1a - MedDRA Version for Autopsy-determined Cause(s) of Death D.9.4.r.1b - Autopsy-determined Cause(s) of Death (MedDRA code) D.9.4.r.2 - Autopsy-determined Cause(s) of Death (free text) D.9.4.r - Autopsy-determined Cause(s) of Death (repeat as necessary) 0 ... n"
    },
    {
        "instruction":"已知信息：\n'生产工艺性能，包括控制策略的有效性，应定期进行评估。'可被翻译为：Manufacturing process performance, including the effectiveness of the control strategy, should be periodically evaluated.\n'应通过一定频次的分析测试来确认经验证的清洁工艺持续有效，该频率应由原料药生产商采用基于风险的方法来决定。'可被翻译为：Frequency of analytical testing to verify ongoing effectiveness of the validated cleaning process is determined by the API manufacturer using a risk-based approach.\n'f. 残留溶剂，如果脂质体生产过程中使用了有机溶剂，残留溶剂的可接受标准应基于脂质体药品的性能和安全性。'可被翻译为：f. Residual solvent(s), if any organic solvent(s) are used in the manufacture of the liposome product The residual solvents acceptance criteria should be based on the performance of the liposome drug product as well as safety concerns.\n'病毒清除工艺鉴定：用非特异“模型”病毒评价生产过程 去除和\/或灭活病毒可靠性的研究。'可被翻译为：Viral clearance studies in which non-specific “model” viruses are used to assess the robustness of the manufacturing process to remove and\/or inactivate viruses.\n\n根据上述已知信息，请将'生产过程应该在公司的质量体系下被定期评估以核实溶剂的去除情况。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The manufacturing process should be periodically evaluated under the firm's quality system to verify removal of the solvent."
    },
    {
        "instruction":"已知信息：\n'> [含果糖产品的产品特性：]<毎毫升此药品含有{XX}mg果糖作为辅料。'可被翻译为：For acute renal failure see below.> [Product specific for products containing sucrose:] <This medicinal product contains {XX} mg of sucrose per ml as an excipient.\n'[除了以下内容，还要包括任何附加的产品特有注意事项和预防措施（比如：有 关本产品辅料的注意事项）。] [含果糖\/山梨糖醇产品的产品特性]<每毫升此药品含有{ XX }毫克<果糖> <山 梨醇>作为辅料。'可被翻译为：[In addition to the text below, include any additional product specific precautions and warnings (e.g. those relating to excipients present in the product).] [Product specific for products containing fructose\/sorbitol]<This medicinal product contains {xx} mg of <sorbitol><fructose> per ml as an excipient.\n'急性肾衰竭情况见下文。> [含葡萄糖产品的产品特性：]<毎毫升此药品含有{XX}mg葡萄糖作为辅料。'可被翻译为：For acute renal failure see below.> [Product specific for products containing glucose:] <This medicinal product contains {XX} mg of glucose per ml as an excipient.\n'这些肾功能障碍和急性肾功能 衰竭的报道虽然与许多含有各种辅料如蔗糖、葡萄糖和麦芽糖的已上市IVIg的使用 有关，但其中以蔗糖作为稳定剂的产品占了较大的比例。'可被翻译为：While these reports of renal dysfunction and acute renal failure have been associated with the use of many of the licensed IVIg products containing various excipients such as sucrose, glucose and maltose, those containing sucrose as a stabiliser accounted for a disproportionate share of the total number.\n\n根据上述已知信息，请将'[含麦芽糖产品的产品特性：]<每毫升此药品含有{ XX }mg<麦芽糖>作为辅料。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"[Product specific for products containing maltose:] <This medicinal product contains {xx} mg of maltose per ml as an excipient."
    },
    {
        "instruction":"已知信息：\n'相比之 下，活性对照试验或剂量比较试验检测的是相对于其他治疗 的效果。'可被翻译为：In contrast, an active control trial or a dose-comparison trial measures the effect relative to another treatment.\n'因此，假如在一项临床试验中 对它们进行比较，不同的终点选择和时间确定就可能对其中 某种治疗有利。'可被翻译为：Therefore, when comparing them in a clinical trial, the choice and timing of endpoints may favor one treatment or the other.\n'8.4.作为可比性研究一部分的免疫原性可比性评价之方法学层面'可被翻译为：8.4. Methodological aspects to assess comparability of immunogenicity potential as part of a comparability exercise\n'在可更加快捷地确立疗效的证据并使得在更早时间点与安慰剂进行比较变得可行的试验中，参照既定治疗选择评估疗效和安全性数据仍然很重要，尤其是在更晚的时间点，进行这些比较的精密度应作为试验样本量计划的一部分。'可被翻译为：For trials in which evidence of efficacy may be established more rapidly such that a comparison versus placebo at an earlier time- point is feasible, it remains important to contextualise efficacy and safety data against an established treatment option, in particular at later time periods, and the precision with which these comparisons can be made should be part of planning the sample size for the trial.\n\n根据上述已知信息，请将'临床疗效的比较试验通常作为可比性工作的一部分。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A comparative clinical efficacy trial will usually be required as part of the comparability exercise."
    },
    {
        "instruction":"已知信息：\n'第七十三条 依法经过资格认定的药师或者其他药学技术人员调配处方，应当进行核对，对处方所列药品不得擅自更改或者代用。对有配伍禁忌或者超剂量的处方，应当拒绝调配；必要时，经处方医师更正或者重新签字，方可调配。'可被翻译为：Article 73 Prescriptions dispensed by pharmacists or other drug professionals who are qualified in accordance with the law shall be checked, and no drugs listed in the prescriptions may be changed or substituted without authorization. The pharmacists shall refuse to dispense incompatible or over-dosage prescriptions and prescriptions may be dispensed only after the prescribing physician makes corrections or re-signs the order.\n'第五十八条 药品经营企业零售药品应当准确无误，并正确说明用法、用量和注意事项；调配处方应当经过核对，对处方所列药品不得擅自更改或者代用。对有配伍禁忌或者超剂量的处方，应当拒绝调配；必要时，经处方医师更正或者重新签字，方可调配。'可被翻译为：Article 58 Drug distributors shall retail drugs properly and include an accurate description of dosage and administration and precautions. Prescriptions for dispensing shall be checked, and no drugs listed in the prescription may be changed or substituted without authorization. Requests to dispense incompatible or over-dosage prescriptions and prescriptions may be dispensed only after the prescribing physician makes corrections or re-signs the order.\n'凭执业医师和执业助理医师处方方可购买、调配和使用的药品。'可被翻译为：Drugs that can be purchased, dispensed and used only on the prescription of a medical practitioner or assistant medical practitioner.\n'处方调配费'可被翻译为：dispensing fee\n\n根据上述已知信息，请将'（一）处方经执业药师审核后方可调配；对处方所列药品不得擅自更改或者代用，对有配伍禁忌或者超剂量的处方，应当拒绝调配，但经处方医师更正或者重新签字确认的，可以调配；调配处方后经过核对方可销售。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(I) Prescription can be dispensed only after being audited by licensed pharmacists. The drugs listed in the prescription shall not be altered or substituted without authorization. The dispensing of prescriptions with incompatibility or overdose shall be refused; however, those may be dispensed after being corrected or re-signed by the prescriber. After the dispensing of prescription, the drugs can be sold only after being checked;"
    },
    {
        "instruction":"已知信息：\n'目前，尚无数据表明低于 10-4阀值的MRD水平会产生额外的临床利益。'可被翻译为：There is no data currently available to support a MRD level below the 10 -4 threshold would provide  added clinical benefit.\n'可能必须通过其他项目来证明患者获得了有临床意义的获益，即使这些额外的项目平均 而言随时间的变化并不大。'可被翻译为：It may be that other items are necessary to demonstrate a clinically meaningful benefit for patients, even if those additional items on average do not change as much over time.\n'目前的证据表明，在未选择的患者队列中，MRD水平≥10-4的患者的中位PFS大约2年，而MRD水平 <10-4的患者的预测中位PFS大约为6年。'可被翻译为：Current evidence suggests that in unselected patient cohorts an MRD level ≥ 10 -4is associated to a  median PFS of about 2 years, whereas a MRD level < 10 -4predicts a median PFS of around 6 years.\n'目前的证据表明，MRD 水平≥10-2 的患者的中位PFS 大约 2 年，而 MRD 水平<10-4的患者的预测中位PFS 大约为 6 年。'可被翻译为：Current evidence suggests that an MRD level ≥ 10 -2 is associated to a median PFS of about 2 years, whereas a MRD level < 10 -4 predicts a median PFS of around 6 years.\n\n根据上述已知信息，请将'目前，尚无前瞻性的数据表明MRD 低于 10-4 阀值会产生额外的临床利益。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"There is no prospective data currently available to support that a further reduction of MRD level below the 10 -4 threshold would provide added clinical benefit."
    },
    {
        "instruction":"已知信息：\n'在研究产品的开发过程中，特别是在上市申请时，通常 会将不同试验的药物安全性与耐受性的特性进行汇总。'可被翻译为：The safety and tolerability properties of a drug are commonly summarised across trials continuously during an investigational product’s development and in particular at the time of a marketing application.\n'为了揭示原料药内在稳定性而进行的研究，它是开发研究的一部分。'可被翻译为：Studies undertaken to elucidate the intrinsic stability of the drug substance.\n'使用适当的工具来评估拟变更的影响，可以包括： o 对代表性物料（可以是中试规模或实验室规模，而不 是商业规模）进行的原料药和\/或制剂的加速和\/或影 响因素稳定性研究。 o 对代表性物料进行的变更前后的对比研究 o 相关数据的统计学评价，包括现有的稳定性研究 o 根据经验或一级动力学模型预测降解情况 o 利用先验知识，包括相关公司知识和科学文献'可被翻译为：Use of appropriate tools to evaluate the impact of the intended change. These may include: o Drug substance and\/or drug product accelerated and\/or stress studies on representative material (which may be pilot or laboratory scale rather than full scale) o Pre-and post-change comparability studies on representative material o Statistical evaluation of relevant data including existing stability studies o Predictive degradation and other empirical or first-principles kinetic models o Utilisation of prior knowledge including relevant company knowledge and the scientific literature\n'拟定的验证批的数量应根据工艺变异性、工艺\/产品的复杂性、 开发过程中获得的工艺知识、技术转移期间商业规模的支持性数据 以及MAH的整体经验确定。'可被翻译为：The number of proposed validation batches should be based on the variability of the process, the complexity of the process\/product, process knowledge gained during development, supportive data at commercial scale during the technology transfer and the overall experience of the MAH.\n\n根据上述已知信息，请将'通过药品或原料药上市后获得的知识和经验来确定此类型稳定性研究的规模和设计。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The scope and design of such stability studies are informed by the knowledge and experience of the drug product and drug substance acquired since authorisation."
    },
    {
        "instruction":"已知信息：\n'非临床研究应在临床试验开始前进行。'可被翻译为：Non-clinical studies should be performed before initiating clinical trials.\n'非临床研究应在临床开发开始前进行。'可被翻译为：Non-clinical studies should be performed before initiating clinical development.\n'申办方通常开展非临床研究来评估预期的药理学作用，包括在体外和体内疾 病模型中药物作用的研究。'可被翻译为：Sponsors typically conduct nonclinical studies to assess intended pharmacologic effects, including studies on the effects of the drug in in vitro and in vivo models of disease.\n'1.非临床研究：体外和体内数据可以提供医药产品可能的药物遗传学影响的 直接和间接指示。'可被翻译为：1. Non-clinical studies: in vitro and in vivo data may provide direct and indirect indications of possible pharmacogenetic implications for the medicinal product.\n\n根据上述已知信息，请将'非临床体内研究和临床研究的开展程度和性质取决于前一步获得的证据，包括理 化、生物学和非临床体外数据的稳健性。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The extent and nature of the non- clinical in vivo studies and clinical studies to be performed depend on the level of evidence obtained in the previous step(s) including the robustness of the physicochemical, biological and non-clinical in vitro data."
    },
    {
        "instruction":"已知信息：\n'在可能的范围内，用来分析对照研究结果的旨在支持有效性的重要设计特征和统计方法应作为研究的一个整体提交。'可被翻译为：To the extent possible, the important design features and the statistical methodologies used to analyze the results of the controlled studies that were intended to support effectiveness should be presented for the studies as a group.\n'申办者应提供开发所选择指标的支持性证据。'可被翻译为：Sponsors should provide supportive evidence on the development of the selected measure.\n'支持有效性的个体研究的估计的效应大小、置信区间和p值。'可被翻译为：The estimated effect sizes, confidence intervals, and p-values for the individual studies supporting effectiveness.\n'这些图可以显示个体研究的p值和置信区间。'可被翻译为：These plots can show individual study p-values and confidence intervals.\n\n根据上述已知信息，请将'应根据统计证据的强度来描述对提出的申请的支持，包括结果的一致性、个体研究强度、p值和置信区间。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Support for the proposed claim should be described in terms of the strength of statistical evidence, including consistency of findings, individual study strength, p-values, and confidence intervals."
    },
    {
        "instruction":"已知信息：\n'除非 靶点活性的表达仅见于这些罕见的情况，通常建议申办方平行或者在允许进行更全面评 估的适应症中确定了获益-风险时在这些小规模患者人群进行研究，特别是关于安全性的。'可被翻译为：Unless the target for activity is expressed only in these rare conditions, Sponsors are in general advised to undertake studies in these small patient groups in parallel to or when benefit – risk is established in indications allowing a more comprehensive evaluation, especially with respect to safety.\n'一些可能的靶向适应症所包括的患者群体非常小，小到可能是“特殊情况”。'可被翻译为：Some possible target indications comprise very small groups of patients, so small that “exceptional circumstances” might apply.\n'在某些情况下可能需要在ALS患者中开展I期研究，比如当在健康受试者中不表达目标机制时。'可被翻译为：In certain circumstances it may be appropriate to conduct phase I studies in ALS patients, such as when the target mechanism is not expressed in healthy subjects.\n'申请人应根据药品的预期患者人群和拟定治疗适应症，考虑开展药物相互作用和\/或特殊用药人群的研究。 如果申请人具有设计和开展这些研究方面的疑问，可咨询CDER审评小组 获取建议。'可被翻译为：Depending on the target patient population and the proposed therapeutic indication for the drug, you should consider conducting drug interactions and\/or studies in specific populations. You should consult the appropriate CDER review division regarding the conduct and design of these studies if you have questions.\n\n根据上述已知信息，请将'某些潜在目标适应症包括非常小组的患者，小到可以适用“例外情况”。除非在这些 少数情况下表现出目标活性，否则当在适应症确定获益-风险并允许开展与安全 有关的更为全面的评估时，一般建议申办者在这些患者小组中展开研究。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Some possible target indications comprise very small groups of patients, so small that “exceptional circumstances” might apply. Unless the target for activity is expressed only in these rare conditions, Sponsors are in general advised to undertake studies in these small patient groups in parallel to or when benefit – risk is established in indications allowing a more comprehensive evaluation, especially with respect to safety."
    },
    {
        "instruction":"已知信息：\n'对于仅在显著超出（例如，超过50倍）人体暴露量时才发生的这些内分泌 活性，通常不需要进行附加的考察。'可被翻译为：Those endocrine activities that occur in animals only at exposures substantially above (e.g., greater than 50 times) the human exposure usually do not warrant additional investigation.\n'如果上述机制信息和证据权重分析支持不具有相关的遗传毒性，仅需要单独一个具有合适暴露证据的体内试验，来确定受试物缺乏遗传毒性作用。'可被翻译为：If the above mechanistic information and weight of evidence supports the lack of relevant genotoxicity, only a single in vivo test with appropriate evidence of exposure is called for in order to establish the lack of genotoxic activity.\n'与之相反，母体化合物随给药时间增加而 暴露量明显减少（如比起始暴露量减少≥50%），使得该试验不合适（除非可获得开始给药后较短几天内的血样）。'可被翻译为：In contrast, substantial reduction in exposure to parent drug with time (e.g., ≥ 50% reduction from initial exposure) can disqualify the study (unless a blood sample taken in the first few days is available).\n'如果该试验确定了对生育力有 影响，则应确定受影响的性别。'可被翻译为：If effects on fertility are identified in the study, the affected sex should then be determined.\n\n根据上述已知信息，请将'如果这种现象发生于单性别，通常在试验结束时不对暴露量减少的该性别进行评价，除非该性别中令人关注的代谢物的暴露量增加。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"If this is seen in one sex, generally the sex with reduced exposure would not be scored at the end of the study, unless there is enhanced exposure to a metabolite of interest."
    },
    {
        "instruction":"已知信息：\n'到目前为止，只有有限的数据是可用的。'可被翻译为：So far limited data are available.\n'铱、锇、铑、钌公开的安全性数据很少。'可被翻译为：There are very few published data on the safety of Iridium, Osmium, Rhodium and Ruthenium.\n'19数据元素是与临床研究中一个项目有关的单次观察结果。'可被翻译为：19 Data element is a single observation associated with a subject in a clinical study.\n'然而，关于这个新定义的人群的临床经验是相当有限的，有待在未来几年中实现。'可被翻译为：However, the clinical experience with this new defined group is fairly limited and will be achieved the coming years.\n\n根据上述已知信息，请将'仅在有限的几 个项目提供了一些人类数据[4]。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Some human data are available but only in a limited number of subjects (ATSDR, 2003)."
    },
    {
        "instruction":"已知信息：\n'待包装产品变成成品所需的所有操作步骤，包括分装、贴签等。但无菌生产工艺中产品的无菌灌装，以及最终灭菌产品的灌装等不视为包装。'可被翻译为：All operations, including filling and labeling, which a bulk product has to undergo in order to become a finished product. Aseptic filling, filling of products for terminal sterilization, and etc., are not regarded as packaging.\n'散装产品为成为成品而必须经历的所有操作，包括灌装和贴标。'可被翻译为：All operations, including filling and labelling, that a bulk product has to undergo in order to become a finished product.\n'但无菌生产工艺中产品的无菌灌装，以及最终灭菌产品的灌装等不视为包装。'可被翻译为：Aseptic filling, filling of products for terminal sterilization, and etc., are not regarded as packaging.\n'药品生产过程中涉及的所有操作，包括加工、配制、配方、灌装、包装和标签。'可被翻译为：All operations involved in the production of a drug, including processing, compounding, formulating, filling, packaging, and labelling.\n\n根据上述已知信息，请将'1.散装产品为成为成品而必须经历的所有操作，包括灌装和贴标签。无菌灌装通常不被视为包装的一部分，散装产品是被灌装的，但不是最终包装的主要容器。\n2.散装产品为成为成品而必须经历的所有操作，包括灌装和贴标签。在无菌条件下灌装无菌产品或打算最终灭菌的产品，通常不被视为包装的一部分。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.All operations, including filling and labelling, that a bulk product has to undergo in order to become a finished product. Sterile filling would not normally be regarded as part of packaging, the bulk product being the filled, but not the finally packaged, primary container.\n2.All operations, including filling and labelling, that a bulk product has to undergo in order to become a finished product. Filling of a sterile product under aseptic conditions or a product intended to be terminally sterilized, would not normally be regarded as part of packaging."
    },
    {
        "instruction":"已知信息：\n'预测性基因生物标记物可能是疗效（例如EGFR基因突变状态和使用易瑞沙）或者安全性的指标（例如HLA B* 5701阿巴卡韦过敏）。在一些特定的情况下这种区别可能会被混淆，并且数据也可能提供一些其他的解释。例如，帕尼单抗（维克替比）在晚期结直肠癌的三线治疗中的作用容易被解释为有效性标记物，而与FOLFOX化疗方案联用作为2线治疗表明，KRAS位点的突变可以作为安全性的一个标记物（KRAS突变的患者使用维克替比+FOLFOX方案可能会有潜在损害）。基因生物标记物也可能作为药物的分子靶点（Her-2受体和曲妥珠单抗）。因此在任何研发项目（包括所需的试验设计）中选择和评估基因生物标记物都应依据研究中的基因生物标记物预计的主要作用、疾病和标记物的复杂关系和药物的作用机制。例如，由 于Her-2受体的超表达是乳腺癌4的一个指标性结果，因此曲妥珠单抗（一种拮抗Her-2受体的单克隆抗体）5的研发就必然要求通过调整试验设计来评估这一效应。另外还要考虑到多种标记物会独立地或同时的与一种特定疾病相关联，由此影响到药物反应的预测效果（例如 乳腺癌6中的ER和Her-2受体、 Her-2和EGFR）。因此在探索性研究中可评估多个生物标记物（或基因生物标记物），并可按照实际情况、相关药物、作用的机制或途径，从中选择一个或多个标记物进行进一步评估。此种情况下每一个标记物和相关临床终点的关联强度将会影响其后续的研发、该生物标记物的临床应用情况[7]以及为临床和法规采用该基因生物标记物所要求的证据标准。在一项或多项探索性研究中研究一个基因生物标记物或一组基因生物标记物（多个标记物标记物\/基因标记物）时，有必要认识到这类研究会产生假设，并且应包含一系列的分类标准8，可通过这些标准将一个或一组生物标记物转译成可预测临床转归的标记物。'可被翻译为：Predictive GBMs may be indicators of efficacy (e.g. EGFR mutation status and use of geftinib) or safety (e.g., HLA B* 5701 and abacavir hypersensitivity). This distinction may blur in certain situation and the data may provide opportunities for alternative interpretations. For example, the role of panitumumab (Vectibix) monotherapy in the third line indication in metastatic colorectal carcinoma is liable to interpretation as an efficacy marker while the combination with FOLFOX chemotherapy in the 2nd line indication suggests that mutant KRAS status may serve as a safety marker (potential for harm with the use of Vectibix + FOLFOX in those with mutated KRAS). GBMs may also serve as molecular targets for drug therapy (Her-2 receptor and trastuzumab). Therefore, the selection and evaluation of the GBM in any development programme (including design of the trials needed) will be dependent on the expected primary role of the GBM under consideration, the complexity of the relationship of the marker to the disease and, the mechanism of drug action. For example, while Her-2 receptor overexpression is an bindicator of outcome in breast cancer4, development of trastuzumab5, a monoclonal antibody against HER-2 necessarily required modification of the trial designs that permitted evaluation of this intervention. It is important to consider that more than one marker may be linked to a particular disease and also influence the predictability of drug response either independently or simultaneously (e.g. ER and Her-2 in breast cancer6, Her-2 and EGFR). Therefore, in exploratory studies, it is possible to evaluate a number of markers (or GBMs) among which one or more might eventually be selected for further evaluation depending on the situation, the drug in question and the mechanism or pathway of action. In such cases, the strength of association between each marker(s) and the relevant clinical endpoint will influence its subsequent development, clinical utility of the marker(s)7 and the evidentiary standards needed to achieve clinical and regulatory adoption of the GBM. When a GBM or a panel of GBMs (“multimarker signatures\/ gene signatures”) are investigated within one or more exploratory studies, it is necessary to recognise that such studies are hypothesis generating and should include a set of classifiers8 that translate the biomarker or the panel into a set of markers that predict clinical outcome.\n'基因生物标记物信号的产生可能基于理论合理性也可能基于初步研究中发现的关系，之后在基因生物标记物研发的探索阶段以经验方式加以确认。或者可在药物临床研发阶段期间、刚刚结束后或结束很长一段时间后提出假设。在某些情况下，潜在的生物标记物可能属于已 有的知识范畴（CYP450多态性或其他药物代谢酶），但在另一些情况下新的基因生物标记物可能在药物研发阶段或之外被研究（或产生）。经管需要的证据水平视情况而不同，但期望所有良好的临床和统计原则都能在这些情况中遵循。总的来说，早期信号生成研究的结果， 建议在前瞻性关键性临床研究中进行确认，对于有效性标记物而言更应如此。该前瞻性临床试验应能为标记物关系的机制、关治疗干预的相互作用标记物的预测价值及其临床使用提供详细的分析。少数情况下，可能在关键性临床试验期间完或成后通过III期试验的回顾性或 探索性分析来发现某一基因生物标记物，原因是关键性试验的大样本量更有助于明确定义受益或识别低发生率的药物不良反应，此种不良反应在探索性研究可能并不明显（例如帕尼单抗与KRAS的关系研究）。第二中情况更易发生于对安全性相关的基因生物标记物。安全性相关生物标记物（基因生物标记物）可能在药物上市后才可被发现，此时要求更新药品文献综述。此种更新有时被称为”翻新（retrofit）”,即一旦在上市后研究或观察中新增基因生物标记物的相关数据，则可在原有批准内容的基础上对产品文献综述和临床使用说明进行修改。这种补救措施并非最理想的策略。对阿巴卡韦的过敏症评估正是其中一例。更新时可能包含 回顾性分析，但并非强制要求。'可被翻译为：GBM signals may be generated based on theoretical plausibility or based on an association noted in preliminary studies, and then confirmed empirically during the exploratory phase of development of the GBM. Alternatively, hypotheses may be generated during, immediately after, or a long time after the clinical development programme for a medicinal product. In some instances, a candidate biomarker may fit in to an existing body of knowledge (CYP450 polymorphisms or other drug metabolising enzymes) but in other cases novel GBMs may be investigated (or generated) within or outside of a drug development programme. While the evidentiary burden will differ between circumstances, it is expected that sound clinical and statistical principles are followed in all of these situations. In general, confirmation of findings obtained from early signal generating studies in a prospective pivotal clinical trial is expected and this more likely to be the expectation for markers of efficacy. The prospective clinical trials should provide a detailed analysis of the basis of the association, the interaction with the relevant therapeutic intervention, the predictive value of the marker and then its clinical utility. Occasionally, a GBM may be identified during or after the pivotal trials are completed through a retrospective or an exploratory analysis of the phase III trial due to the fact that the larger sample size in the pivotal trials provide greater opportunity both for defining the benefit more clearly or for identifying the low frequency ADRs, not evident in the exploratory clinical studies (for example Panitumumab & KRAS). The second scenario is more frequently true for GBMs related to safety. Indeed, markers (GBMs) related to safety may be identified after the medicinal product has been marketed, necessitating updates to the product literature. This sometimes is referred to as “retrofit” i.e., the product literature and clinical use may be modified from the original authorisation, once data relating to the GBM become available from post marketing studies or observations. This type of rescue strategy is not optimal. Evaluation of hypersensitivity reactions to abacavir serves as the exemplar of such a situation. Retrofit does not invariably imply retrospective analysis but may include such evaluation.\n'预测性基因生物标记物'可被翻译为：Predictive GBMs\n'预后基因生物标记物（标记物）指与未治疗的或接受不同治疗的患者转归相关的标记物。研发和评估这类预后基因生物标记物通常采样一些便捷的患者或受试者样本（根据可用的生物样本情况）进行基因生物标记物（血样或组织）检测。因此预后生物标记物可能可以或不能为临床决策或者影响治疗或干预的决策流程提供依据。但研究评估预后基因生物标记物或可能提供自然病程的科学背景，也可能促进其他生物标记物（基因或非基因）的研发和间接 促进药物的研发。'可被翻译为：Prognostic GBMs (or markers) are those that correlate with outcome of disease in either untreated or heterogeneously treated patients. Development and evaluation of such GBMs are often based on a convenience sample of patients or subjects based on the availability of biological sample for assay of the GBM (blood or tissue). Thus prognostic BMs may or may not provide the basis for a clinical decision or influence the decision algorithm for treatment or intervention. However, studies evaluating prognostic GBMs may provide a scientific background of the natural history of the disease, facilitate development of additional other biomarkers (genomic or non-genomic) and contribute to drug development indirectly.\n\n根据上述已知信息，请将'预测性基因生物标记物在药物研中是最为重要的领域，这些预测性基因生物标记物应当包括某些治疗前特征，以判定某一受试者是否适合接受这一受试药物。通常来说这些预测性基因生物标记物采用两分法或按特定的分类程序来分类（见3.2章）。需注意这些基因生物标记物最简单的形式可能是一个基因或一个点突变，或者可能基于许多基因的表达水平，其表达模式以一种既定的方式进行结合和评估。如果这些不同的基因或者表达水平的关系不是预先确定，而是按照一项试验中的受试者工作特征来确定相关临界值的，则需要另外一项试验来确认这种关系。通过在一些根据标记物选择和分组的明确患者人群中进行关键性临床试验有助于对这类预测性标记物的临床使用情况进行评估。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For the purposes of drug development, predictive GBMs occupy the highest area of interest. These should be pre-treatment characteristics that enable to determine whether a particular subject is a good candidate for treatment with a test agent. Commonly these tend to be binary or depend on classifiers (see section 3.2). Of note, these GBMs, in their simplest form could be a gene or point mutation. Alternatively, they could be based on expression levels of many genes where expression profiles of these genes are combined and evaluated in a predefined fashion. If the relationship between different genes or their expression levels are not predefined, but cut off points are generated using ROCs from one trial, then confirmation in a second trial would be expected. Evaluation of clinical utility of such predictive markers is facilitated by pivotal trials conducted in defined patient populations, selected and grouped based on the marker(s)."
    },
    {
        "instruction":"已知信息：\n'已经报告了用药错误，当以毫克标记口服给药装置但是剂量以毫升计时，导致患者不能测量特定体积的口服溶液。'可被翻译为：Medication dosing errors have been reported when an oral dosing device is labeled in milligrams but the dose is prescribed in milliliters, leading to patients being unable to measure a specific volume of oral solution.\n'检查药品规格和剂量的一致性。曾因开发的药品规格或表达的药品规格，与药品的剂量和用法用量不一致，使用剂量计算变得复杂化，而导致剂量错误。例如，说明书中药品规格按百分比表示，但药品的剂量和用法用量是按毫克来描述。这类问题的另一个例子为，一个药品的常用剂量是300mg，但只有每瓶100ml的包装。如果每次服用全部剂量需要3瓶，而不是1瓶时，则很容易发生剂量和用法用量的错误。服用多个单位（如，片、胶囊、瓶、注射器）才达到全部剂量，已经导致剂量错误，因为用药者可以计算错误或每次忘记服用了几个单位的药物。'可被翻译为：Check for consistency between the drug product strength and dosing. Developing a product strength or expressing the strength in a manner that is incongruent with the dosage and administration of the product complicates the calculation of dosage and has led to dosing errors. For example, the strength may be expressed on the label in percentage, but the dosage and administration of the drug is described in milligrams. Another example of this type of problem would include a product with a usual dosage of 300 mg when the product is only available as a 100 mg vial. If 3 vials are needed to make up the full dose rather than a single vial, the product may be prone to dosing and administration errors. Multiple units (e.g., tablets, capsules, vials, syringes) required to achieve a usual single dose have led to dosing errors because of users making miscalculations or forgetting how many units have already been administered.\n'7. 公制计量 计量或规格的表述应该使用公制计量单位如毫升，毫克和微克，而不是药剂师 或家用的计量单位（例如，茶匙、汤匙、打兰和格令）或比例（例如，1： 1000）。'可被翻译为：7.Metric Measurements The dose or expression of strength should appear in metric units of measure such as mL, mg, and mcg, rather than apothecary or household measurements (e.g., tsp for teaspoon, TBSP for tablespoon, drams, and grains) or ratios (e.g., 1:1000).\n'E.避免使用外形相似的容器标签和纸盒标识 。 外观相似的容器标签和纸盒标识经常导致药品选择错误，从而又导致分发和配 给了错误的药品，错误的规格和\/或错误的剂量。'可被翻译为：E. Avoid Look-alike Container Labels and Carton Labeling  Look-alike container labels and carton labeling have frequently contributed to product selection  errors leading to the dispensing and administration of the wrong drug, wrong strength and\/or  wrong dose.\n\n根据上述已知信息，请将'如果产品的规格在容器标签 上显示地不清楚，或表述用的计量单位与计量说明上所使用的计量单位不一致，就 有可能会导致选择和配给错误的剂量（即，用药过量或用药不足）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"If the product strength is not clearly displayed on the container label, or is expressed in units of measure that are incongruent with those used in the dosing instructions, the wrong strength can be selected or the wrong dose administered (i.e., over- or under-dosing)."
    },
    {
        "instruction":"已知信息：\n'如果研究仅仅中枢神经性疼痛或仅仅周围神经性疼痛的模型，通常会相应地限制适应症。合适的中枢神经病模型包括脊髓损伤和中风后疼痛。'可被翻译为：If models of just central neuropathic pain or of just peripheral neuropathic pain are studied, 569 the indication will normally be restricted accordingly. Suitable central neuropathic models include spinal cord injury and post-stroke pain.\n'中枢机制可能参与外周和中枢神经性疼痛，但外周机制通常不参与中枢神经性疼痛。'可被翻译为：Central mechanisms may be involved in both peripheral and central neuropathic pain, but peripheral mechanisms are not generally involved in central neuropathic pain.\n'应尽可能表征神经性疼痛的外周或中枢起源以及相关的阴性和阳性现象（感觉发现）。'可被翻译为：The peripheral or central origin of neuropathic pain should be characterised as far as 620 possible as well as associated negative and positive phenomena (sensory findings).\n'为了证明治疗神经性疼痛的一般适应症是合理的，需要单独证明在中枢和周围神经性疼痛中的有效性。'可被翻译为：To justify a general indication for the treatment of neuropathic pain, efficacy needs to be demonstrated independently in models of both central and peripheral neuropathic pain.\n\n根据上述已知信息，请将'中枢神经性疼痛的示例是中风后或脊髓损伤神经性疼痛，而糖尿病痛性周围神经病变 （DPNP）或带状疱疹后神经痛（PHN）是常见的外周神经性疼痛病症。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Examples of central neuropathic pain are post-stroke or spinal cord injury neuropathic pain, while diabetic peripheral neuropathy (DPNP) or post-herpetic neuralgia (PHN) are common peripheral neuropathic pain conditions."
    },
    {
        "instruction":"已知信息：\n'方案及后续修 订应获得包括试验统计师在内的责任人员的批准。'可被翻译为：The protocol and subsequent amendments should be approved by the responsible personnel, including the trial statistician.\n'试验统计 师（见词汇表）在与其他临床试验专家合作时，其作用和职 责是确保在支持药物研发的临床试验中恰当地应用统计学 原则。'可被翻译为：The role and responsibility of the trial statistician (see Glossary), in collaboration with other clinical trial professionals, is to ensure that statistical principles are applied appropriately in clinical trials supporting drug development.\n'一项研究的 综合性完整报告不应是临床报告和统计报告的简单合并。'可被翻译为：The integrated full report of a study should not be derived by simply joining a separate clinical and statistical report.\n'试验统计师'可被翻译为：trial statistician\n\n根据上述已知信息，请将'为此，试验统计师应是负责临床研究报告的小组成 员之一，还应批准临床报告。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"To this end the trial statistician should be a member of the team responsible for the clinical study report, and should approve the clinical report."
    },
    {
        "instruction":"已知信息：\n'Zoboryn是ZB3579临床试验的唯一申办者。'可被翻译为：Zoboryn is the sole sponsor of ZB3579 clinical trials.\n'每批药品均应当编制唯一的批号。'可被翻译为：Each batch of product should have a unique batch number.\n'试验编号（例如：方案编号或其他试验识别码）；'可被翻译为：Study ID (e.g., protocol number or other identifier);\n'申请人获准开展药物临床试验的为药物临床试验申办者（以下简称申办者）。'可被翻译为：An applicant who is approved to carry out clinical trials of drugs shall be the sponsor of drug clinical trials (hereinafter referred to as the sponsor).\n\n根据上述已知信息，请将'11 EudraCT编号是欧洲经济区内获准的临床试验的唯一识别码。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"11 The EudraCT number is the unique identifier for trials authorised in the European Economic Area."
    },
    {
        "instruction":"已知信息：\n'如章节IV中所讨论的，FDA建议潜在ANDA申请者按照基于层次的方法，它可以有效地对比T产品与R产品之间的防止滥用的措施。'可被翻译为：As discussed in Section IV, FDA recommends that potential ANDA applicants follow a tier-based approach to efficiently compare the abuse deterrence of T product to R product.\n'FDA建议潜在ANDA申请者遵循基于层次的方法，它可以 有效地对比T产品及其R产品，并限制评估T产品的防止滥用的措施所需的检验 数量。'可被翻译为：FDA recommends that potential ANDA applicants follow a tier-based approach to efficiently compare a T product to its R product and limit the number of tests required for evaluating the abuse deterrence of T product.\n'如果可用的体外检测方法过度敏感或者不能充分地评估和 对比T产品与R产品的防止滥用的措施，潜在ANDA申请者还可以提议进行PK研究。'可被翻译为：Potential ANDA applicants may also propose to conduct PK studies in cases where available in vitro testing methodology is overly sensitive or cannot adequately assess the abuse deterrence of the T product relative to the R product.\n'对T产品的防止滥用的措施评估应基于潜在 申请者对R产品的防止滥用的措施、可能的滥用途径、以及对通过这些途径滥用 的评估有意义的特定措施的最大理解。'可被翻译为：The evaluation of the abuse deterrence of T product should be based on the potential applicant’s best understanding of the abuse deterrence of R product, the potential routes of abuse, and specific measures meaningful to the evaluation of abuse by those routes.\n\n根据上述已知信息，请将'为了充分地对比R产品与T产品，潜在ANDA申请者应采用在本指南描述的基于层次的方法，鉴定R产品在所 有滥用途径方面的防止滥用的措施。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In order to adequately compare R and T products, a potential ANDA applicant should identify the R product’s abuse deterrence for all routes of abuse using the tier-based approach described in this guidance."
    },
    {
        "instruction":"已知信息：\n'肿瘤预防 法规经验是有限的，但是在概念上情形与辅助治疗是相当类似的。'可被翻译为：Tumour Prevention Regulatory experience is limited, but conceptually the situation is rather similar to the adjuvant setting.\n'对照治疗方案应根据主要抗癌指南中列出的标准来选择。'可被翻译为：The control regimen should be selected according to the criteria set out in the main anticancer guideline.\n'方案应该定义出用于排除远端转移的方法。直肠指检仍然被认为是最适合评估局部进展的方法。如果研究无法在双盲情况下进行，建议由两个独立的泌尿科医生进行检查。其它疗效标准与下文描述的远端转移瘤的标准类似。'可被翻译为：The protocol should define methods to be used to exclude distant metastases. Digital rectal examination is still considered the most appropriate method to assess local progression. If studies cannot be conducted under proper double blind conditions, examination by two independent urologists is recommended. Response criteria are otherwise similar to those for metastatic disease presented below.\n'远端转移瘤的治疗'可被翻译为：Therapy for metastatic disease\n\n根据上述已知信息，请将'其它疗效标准与下文描述的远端转移瘤的标准类似。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Response criteria are otherwise similar to those for metastatic disease presented below."
    },
    {
        "instruction":"已知信息：\n'部分缓解（即未达到完全缓解，但是肾脏缓解程度能维持eGFR处于相对于基线值的预定边界内）'可被翻译为：A partial response, i.e. not full recovery but renal response able to maintain an eGFR within pre- specified margins with respect to baseline values,\n'主要终点应该是LDA（最低限度）或者病情缓解。'可被翻译为：The primary endpoint should be LDA, at a minimum, or remission.\n'部分缓解，其定义为GFR出现有临床意义的改善或稳定，但没有完全恢复到正常水平或基线值。'可被翻译为：Partial response, defined as a clinically meaningful improvement or stabilisation of GFR without full recovery to normal or baseline values.\n'b） 主要\/完全肾脏缓解的维持和肾脏疾病发作的预防（依据发生比例和严重程度的下降，说明肾脏疾病发作的类型[肾脏和\/或尿蛋白的类型均应说明]并根据对应的基线情况进行分类）。'可被翻译为：b) Maintenance of major\/complete renal response and prevention of renal flares [in terms of both decreased incidence proportions and their severity grades, specifying the type of renal flares (both nephritic and\/or proteinuric ones) and classified correspondingly to the baseline conditions]\n\n根据上述已知信息，请将'预期主要终点应参考主要\/完全肾脏缓解的有临床意义的数值，如GFR恢复正常或恢复到基线水平，或 24 小时尿蛋白低于 0.5 g。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"It is expected that primary endpoints should be contextualised by reference to clinically meaningful values for major\/complete response, such as normalisation\/return to baseline of measured GFR or proteinuria of <0.5 g\/24-h."
    },
    {
        "instruction":"已知信息：\n'研究设计在某种程度上依赖于所评价的结果。'可被翻译为：The study design is to some extent dependent on the outcome being evaluated.\n'多地区研究还具有其他用途。'可被翻译为：There are other possible uses of multi-regional studies.\n'以多地区临床试验来作为特定地区的桥接研究，需要获得该地区有说服力的研究结果。这是因为该地区研究结果可以使该地区监管者确认药物的有效性，且可以“桥接”注册申报中其他地 区的研究结果。'可被翻译为：For a multi-regional trial to serve as a bridging study for a particular region, it would need to have persuasive results in that region, because it is these regional results that can convince the regulators in that region that the drug is effective, and can \"bridge\" the results of trials in other regions in the registration application.\n'对于一个预期可以作为桥接研究的试验，应考虑以下几点： 计划多地区试验需满足申报地区在研究设计和分析方面的监管要求（见Q1 答复）。'可被翻译为：For a study intended to serve as a bridging study, the following points should be considered: Planning The multi-regional trial would have to satisfy requirements of the region where the application is to be filed with respect to design and analysis (see answer to Q1).\n\n根据上述已知信息，请将'一项研究的结果通常用于多个地区的监管 申请，设计还应考虑研究结果与进行研究地区以外地区的相 关性。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The results of a study are often used in regulatory submissions in multiple regions, and the design should also consider the relevance of the study results for regions other than the one(s) in which the study is conducted."
    },
    {
        "instruction":"已知信息：\n'对于社区代表的 “代表性”如何，以及如何解读参与该项研究的不同社区的意见，尤其是在 它们不同时，和如何进行适当的回应，都不可避免的存在疑问。'可被翻译为：There are inevitably questions of how “representative” community representatives are, and how to interpret the views of the various communities involved in the research, particularly if they differ, and what constitutes an appropriate response.\n'不同的IRB可能认为需要开展更多或更少的社区咨询，取决于特定研究和社区的独特环境。'可被翻译为：Different IRBs may consider more or less community consultation necessary, depending on the unique circumstances of a particular study and the community.\n'采用不同的社区咨询活动将扩大社区参与的机会。'可被翻译为：Using a variety of community consultation activities will broaden the opportunity for community involvement.\n'在开展社区咨询活动时，申办方和临床研究者应确保参与该项研究的社区代表具有参与该咨询过程的机会。'可被翻译为：In conducting community consultation activities, sponsors and clinical investigators should ensure that representatives from the community(ies) involved in the research have an opportunity to participate in the consultation process.\n\n根据上述已知信息，请将'参与社区咨询活动的代表的类型和数量可以因研 究而不同，甚至同一项研究不同中心也可以不同。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The types and number of representatives who participate in community consultation activities may vary by study or even across sites within the same study."
    },
    {
        "instruction":"已知信息：\n'生存率 应尽量明确研究中发生的心源性死亡的具体模式（如心源性猝死、泵功能衰竭、急性冠状动脉事件）。'可被翻译为：Survival  Efforts should be made to define the specific mode of cardiac death occurring in the studies (e.g. sudden cardiac death, pump failure, acute coronary events).\n'应集中数据，从而能够评估死亡率下降的临床诱因（如心律失常、中风、心肌梗塞、非心血管性等）。'可被翻译为：Data should be gathered so as to enable evaluation of the clinical causes of reduction in mortality (such as arrhythmias, stroke, myocardial infarction, non-cardiovascular, etc.).\n'心血管死亡：急性心肌梗死造成的死亡、心源性猝死，心脏衰竭导致的死亡、卒 中死亡和其他心血管疾病导致的死亡。'可被翻译为：Cardiovascular death: death resulting from an acute myocardial infarction, sudden cardiac death, death due to heart failure, death due to stroke, and death due to other cardiovascular causes.\n'血管性死亡应该包括血栓栓塞事件(PE、中风)导致的死亡、所有心血管原因死亡(例如:由于心肌梗塞、心力衰竭或心律失常)和出血引起的死亡。'可被翻译为：Vascular deaths should include deaths caused by thromboembolic events (PE, stroke), all cardiac deaths (e.g.: due to myocardial infarction, heart failure or arrhythmia) and bleeding.\n\n根据上述已知信息，请将'评估死亡率的时候应把猝死（或有证明的心律失常导致的死亡）包括在内，这是非常重要的，'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"It is important to include sudden death (or death due to arrhythmia when documented) in evaluating mortality."
    },
    {
        "instruction":"已知信息：\n'定义为至少出现一次严重出血和\/或临床相关非严重出血的患者比例。'可被翻译为：defined as the rate of patients experiencing at least one major bleeding and\/or a clinically relevant non-major bleeding.\n'- 临床相关出血：定义为至少出现一次严重出血和\/或临床相关非严重出血的患者比例。'可被翻译为：- Clinically relevant bleeding: defined as the rate of patients experiencing at least one major bleeding and\/or a clinically relevant non-major bleeding.\n'- 非严重出血：定义为至少出现一次临床相关非严重出血或其他非严重出血的患者比例。'可被翻译为：- Non-major bleeding: defined as the rate of patients experiencing at least one clinically relevant non-major bleeding or other non-major bleeding.\n'- 总出血：定义为至少出现一次严重出血、临床相关非严重出血或其他非 严重出血的患者比例。'可被翻译为：- Total bleeding: defined as the rate of patients experiencing at least one major bleeding, clinically relevant non-major bleeding or other non-major bleeding.\n\n根据上述已知信息，请将'定义为至少出现一次严重出血、临床相关非严重出血或其他非严重出血的患者比例。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"defined as the rate of patients experiencing at least one major bleeding, clinically relevant non-major bleeding or other non-major bleeding."
    },
    {
        "instruction":"已知信息：\n'5.包装操作步骤的说明，包括重要的辅助性操作和所用设备的注意事项、包装材料使用前的核对；'可被翻译为：5) A description of the packaging operation, including any significant subsidiary operations, any precaution for equipment to be used and checks on packaging materials prior to use;\n'7.包装操作的详细情况，包括所用设备及包装生产线的编号。'可被翻译为：7. Details of the packaging operations carried out, including reference numbers to equipment and the packaging lines used;\n'4.需要说明的注意事项，包括对生产区和设备进行的检查，在包装操作开始前，确认包装生产线的清场已经完成等；'可被翻译为：4) Special precautions to be observed, including an examination of the area and equipment in order to ascertain the line clearance before packaging operations begin;\n'第二百零四条 包装操作前，还应当检查所领用的包装材料正确无误，核对待包装产品和所用包装材料的名称、规格、数量、质量状态，且与工艺规程相符。'可被翻译为：Article 204 Before the packaging operation, all packaging materials drawn for use should also be checked for correctness, and the name, strength, quantity, and quality status of bulk products and all packaging materials should be checked to ensure the conformity with master manufacturing documents.\n\n根据上述已知信息，请将'5.包装操作步骤的说明，包括重要的辅助性操作和所用设备 的注意事项、包装材料使用前的核对；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"5) A description of the packaging operation, including any significant subsidiary operations, any precaution for equipment to be used and checks on packaging materials prior to use;"
    },
    {
        "instruction":"已知信息：\n'1.拭子处理必须在 HEPA 过滤 II 级生物安全柜（BSC）或 HEPA 过滤层流罩（LFH）内无菌操作，其中的空气级别应该等于或优于擦拭取样点。'可被翻译为：1. All processing of swabs must be aseptically performed within a HEPA Filtered II Biological Safety Cabinet (BSC) or HEPA Filtered Laminar Flow Hood (LFH) with an air classification at the same rating or better than that from which the swab was collected\n'用合适的消毒剂擦拭所有外部取样容器，然后放入 LFH\/BSC'可被翻译为：Wipe down all outer sampling containers with a suitable sanitizing agent before placement in the LFH\/BSC\n'1.用适合的消毒剂对套好手套的手消毒（即，杀孢子剂或 70%无菌乙醇）'可被翻译为：1. Disinfect gloved hands with a suitable sanitizing agent (i.e. sporicidal agent or sterile 70% alcohol).\n'无菌 70%乙醇（ETOH）或异丙醇（IPA）'可被翻译为：Sterile 70% ethanol (ETOH) or Isopropyl Alcohol (IPA)\n\n根据上述已知信息，请将'2.将拭子放进层流罩开始分析之前，BSC 或 LFH 的所有表面必须用杀孢子剂和过滤器无菌 70%乙醇或 IPA 彻底消毒'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2. All surfaces within the BSC or LFH must be thoroughly disinfected with a sporicidal disinfectant followed by filter sterile 70% ethanol or IPA prior to placing swabs under the hood and beginning analysis."
    },
    {
        "instruction":"已知信息：\n'本节对药物警戒计划的结构提供指导意见。'可被翻译为：This section gives guidance on the structure of a Pharmacovigilance Plan.\n'药物警戒计划；'可被翻译为：• Pharmacovigilance Plan;\n'ICH指南（E2E药物警戒规划）正在编制中，有助于进一步解决如何 描述安全性数据及其局限性以及如何描述计划的上市后活动和研究的 问题。'可被翻译为：An ICH guideline (E2E Pharmacovigilance Planning) is being developed to further address the question of how to describe the safety data and its limitations and how to describe planned postmarketing activities and studies.\n'生物技术产品可比性指导原则（ICH Q5E, CPMP\/ICH\/5721\/03）。'可被翻译为：Guideline on \"Comparability of Biotechnological Products (ICH Q5E, CPMP\/ICH\/5721\/03).\n\n根据上述已知信息，请将'ICH E2E有关规划药物警戒活动的指导（CPMP\/ ICH\/5716\/03）'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"ICH E2E Note for guidance on Planning Pharmacovigilance Activities (CPMP\/ICH\/5716\/03)"
    },
    {
        "instruction":"已知信息：\n'人血清白蛋白手性固定相'可被翻译为：human serum albumin chiral stationary phase\n'由N,V-二琥珀酰亚胺酯将胃蛋白酶结合在胺丙基硅胶上制备的一种蛋白质手性固定相。'可被翻译为：A chiral stationary phase of protein prepared by N, v-dissuccinimide binding pepsin to aminopropyl silica gel.\n'又称“C8柱二一种常用的高效液相色谱键合硅胶填料，是一种化学键合硅胶固定相。'可被翻译为：Also known as \"C8 column two, a commonly used high performance liquid chromatography bonded silica gel filler, is a chemically bonded silica gel stationary phase.\n'亲硅醇基效应，极性溶质在硅胶基质固定相上因静电作用或氢键作用而与硅胶表面残余硅醇基发生相互作用的现象。'可被翻译为：Silanophile effect, the phenomenon that the polar solute interacts with the residual silanol group on the surface of the silica gel due to electrostatic action or hydrogen bonding on the stationary phase of the silica gel matrix.\n\n根据上述已知信息，请将'以硅胶为载体，由人血清白蛋白与双醇激活硅胶担体共价键合的一种蛋白质手性固定相。用于蛋白质分析。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A protein chiral stationary phase covalently bonded by human serum albumin to a diol activated silica gel support using silica gel as a carrier. Used in protein analysis."
    },
    {
        "instruction":"已知信息：\n'第二十六条 核查中心实施注册核查前，根据《药品注册核查要点与判定原则》,基于风险原则，并结合药品审评中心提出的核查对象和核查关注点(如有),制定核查方案。核查方案内容包括：被核查单位基本情况、核查品种、核查目的、核查依据、现场核查时间、核查内容、核查组成员等。'可被翻译为：Article 26 Before CFDI implements registration inspection, it shall formulate an inspection protocol in accordance with the Key Points and Determination Principles of Drug Registration Inspection, based on the risk principle, and in combination with the inspection objects and inspection concerns (if any) proposed by CDE. The content of the inspection protocol includes: the basic information of the inspected institution, the type of inspection, the purpose of the inspection, the basis of the inspection, the time of the on-site inspection, the content of the inspection, the members of the inspection team, etc.\n'第二十四条 核查组应当由2名以上具备药品检查员资格的人员组成，实行组长负责制。根据核查品种的具体情况，可有相关领域专家参与注册核查。对药品审评中心启动的有因检查，药品审评中心原则上应当派员参加。'可被翻译为：Article 24 The inspection team shall be composed of two or more persons who are qualified as drug inspectors, and the team leader shall assume overall responsibility. According to the specific conditions of the inspected varieties, experts in related fields may participate in the registration inspection. The CDE shall, in principle, send personnel to participate in cause-related inspections initiated by it.\n'注册核查组织实施期间，核查中心可与药品审评中心就核查对象、核查内容和核查关注点进行沟通和调整。特殊情况下，基于风险评估分析，核查中心可向药品审评中心提出是否进行现场核查的意见。'可被翻译为：During the organization and implementation of the registration inspection, CFDI can communicate and adjust the inspection object, inspection content, and inspection focus with CDE. Under special circumstances, based on the risk assessment analysis, CFDI may provide an opinion on whether to conduct on-site inspection to CDE.\n'药品注册核查要点与判定原则'可被翻译为：Key Points and Determination Principles of Drug Registration Inspection\n\n根据上述已知信息，请将'第二十二条 核查中心根据《药品注册核查要点与判定原则》,基于风险原则，并结合药品审评中心提出的核查对象和核查关注点(如有),确定核查地点，结合核查资源等，制定核查计划。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 22 In accordance with the Key Points and Determination Principles of Drug Registration Inspection, based on the risk principle, and combined with the inspection objects and inspection concerns (if any) proposed by CDE, CFDI determines the inspection location and formulates an inspection plan in combination with the inspection resources, etc."
    },
    {
        "instruction":"已知信息：\n'2.2.10 说明\/标签 应按照相应的国家\/地区的要求，在标签上说明贮藏条件。'可被翻译为：2.2.10.Statements\/Labeling A storage statement should be established for the labeling in accordance with relevant national\/regional requirements.\n'如果有特定的储藏要求，报告中应当说明。'可被翻译为：If there were specific storage requirements, these should also be described.\n'在容器、包装和\/或使用说明书上应注明冻干制品溶解后的稳定性，其中应包括溶解后的贮藏条件和最长贮藏期，这些标签均应符合当地有关国家\/地区规定。'可被翻译为：The stability of freeze-dried products after their reconstitution should be demonstrated for the conditions and the maximum storage period specified on containers, packages, and\/or package inserts. Such labelling should be in accordance with relevant national\/regional requirements.\n'光敏性原料药和制剂的正式标签要求是根据国家\/地区的要求制定的。'可被翻译为：The formal labeling requirements for photolabile drug substances and drug products are established by national\/regional requirements.\n\n根据上述已知信息，请将'应按照相应的国家\/地区的要求，在标签上说明贮藏条件。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A storage statement should be established for the labeling in accordance with relevant national\/regional requirements."
    },
    {
        "instruction":"已知信息：\n'微量采样技术适用的基质包括血液及其来源的血浆或血清，可以使用液体或干燥形式进行运输、储存和后续分析。'可被翻译为：The appropriate matrices used for microsampling techniques include blood and its derived plasma or serum, which can be used in liquid or dried form for transportation, storage and subsequent analysis.\n'回答1：在本文件中，微量采样是采集极少量血液（通常≤50μL） 的一种方法，通常用于测定药物和\/或其代谢物的浓度以及后续计 算合适的毒代动力学参数。'可被翻译为：A1 For the purpose of this document, microsampling is a method to collect a very small amount of blood (typically ≤50 µL) that is generally used to measure concentrations of a drug and\/or its metabolites, and subsequently calculate the appropriate TK parameters.\n'干基质法（DMM）是一种采样技术，其优点包括作为药物分析的微量采样技术，针对药物分析可减少血液样品的采集量，以及易于收集、储存和运输等。 除LC-MS或LBA的典型方法学验证外，在支持申报的研究中使用DMM之前，需要进一步验证该采样方法，例如：'可被翻译为：Dried matrix methods (DMM) is a sampling methodology that offers benefits such as collection of reduced blood sample volumes as a microsampling technique for drug analysis and ease of collection, storage and transportation. In addition to the typical methodological validation for LC-MS or LBA, use of DMM necessitates further validation of this sampling approach before using DMM in studies that support a regulatory application, such as:\n'回答4：正如动力学采样的其他方法，为了适当地采用微量采样技术，应开发并验证一种生物分析方法（或按照各地区的法规指导原则\/指南，经验证可用于GLP研究）以确保分析结果的可靠性。'可被翻译为：A4 As with other approaches to kinetic sampling, in order to adopt a microsampling technique appropriately, a bioanalytical method should be developed and qualified (or validated for Good Laboratory Practice studies, in accordance with regulatory guideline\/guidance in each region) to ensure the reliability of analytical results.\n\n根据上述已知信息，请将'将推挽灌流和透析技术结合起来的一种微量生物采样技术。可在麻醉或清醒的生物体上使用，尤其适合于深部组织和重要器官的活体生化研究。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A microbiosampling technique that combines push-pull perfusion and dialysis techniques. It can be used on anesthetized or awake organisms and is especially suitable for in vivo biochemical studies of deep tissues and vital organs."
    },
    {
        "instruction":"已知信息：\n'第二百六十条 质量管理部门对物料供应商的评估至少应当包括：供应商的资质证明文件、质量标准、检验报告、企业对物料样品的检验数据和报告。如进行现场质量审计和样品小批量试生产的，还应当包括现场质量审计报告，以及小试产品的质量检验报告和稳定性考察报告。'可被翻译为：Article 260 Assessment of material suppliers by the quality management department should at least include: the supplier's qualification certificates, specifications and certificates of analysis, the manufacturer's testing data and reports of material samples. Where on-site audit and small scale pilot production are performed, the assessment should also include on-site audit report, certificates of analysis and stability study report of small scale pilot products.\n'第二百六十条质 量管理部门对物料供应商的评估至少应当包括：供应商的资质证明文件、质量标准、检验报告、企业对 物料样品的检验数据和报告。'可被翻译为：Article 260: Assessment of material suppliers by the quality management department should at least include: the supplier's qualification certificates, specifications and certificates of analysis, the manufacturer's testing data and reports of material samples.\n'11.评估和批准物料供应商；'可被翻译为：11) To assess and approve material suppliers;\n'第二百五十六条 应当建立物料供应商评估和批准的操作规程，明确供应商的资质、选择的原则、质量评估方式、评估标准、物料供应商批准的程序。'可被翻译为：Article 256 Operation procedures for assessment and approval of materials suppliers should be established to define the suppliers' qualifications, selection criteria, quality assessment methods, assessment criteria, and approval procedures of material suppliers.\n\n根据上述已知信息，请将'7.2 关于物料供应商评估的具体要求是什么？'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"7.2 June 2015 What is expected in terms of evaluation of suppliers of materials?"
    },
    {
        "instruction":"已知信息：\n'这些研究可能需要独特的设计特征。'可被翻译为：These studies may entail unique design features.\n'研究设计的讨论，包括对照组的选择'可被翻译为：DISCUSSION OF STUDY DESIGN, INCLUDING THE CHOICE OF CONTROL GROUPS\n'因此，应该在研究开始之前与骨骼、生殖系统和泌尿系 统产品处讨论研究方案。'可被翻译为：Therefore, study protocols should be discussed with the division before study initiation.\n'研究者应预先定义与研究的设计、分析、执行和报告有关的方面，将其整理形成研究方案和最终报告，附上与研究的这些方面有关的科学研究选择的科学依据；关于这些方面的更多信息在本指导原则的章节IV、V和VI中提供。'可被翻译为：Investigators should predefine aspects of the study related to the design, analysis, conduct, and reporting of the study and articulate them in the study protocol and final reports, along with a science-based rationale for the scientific study choices pertaining to these aspects of the study; more information regarding these aspects is provided in sections IV, V, and VI of this guidance.\n\n根据上述已知信息，请将'研究者应该在研究方案和最终报告中 讨论选择某种特殊的研究设计的依据。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Investigators should discuss their rationale for selecting a particular study design in the study protocol and final report."
    },
    {
        "instruction":"已知信息：\n'根据已实施的 26 项研究，估计女性便秘的发病率比男性高两倍89 。但通常 来说，之前慢性特发性便秘的临床试验中招募的患者主要为女性，约占 80%以上。'可被翻译为：On the basis of 26 studies, it has been estimated that the prevalence of constipation is about two 688 times higher in women than in men89.\n'便秘更常影响女性、老年人和社会经济地位较低的患者。'可被翻译为：Constipation more frequently affects women, older people, and patients with a low socioeconomic status.\n'例如, 中年女性的ITP患病率高于中年男性。如果招募的健康志愿者中中年女性少于中 年男性，这将限制健康志愿者的相关研究结果与受试患者之间进行比较。'可被翻译为：For example, as the prevalence of ITP is higher in female than male patients of mid adult age recruiting fewer female healthy volunteers than male may limit data comparison.\n'尽管SALS患者中女性患病率随年龄增长有升高趋势，但男性比女性患病率要更高 （1.4-2.5:1）。'可被翻译为：In sporadic ALS men are more commonly affected than women (1.4-2.5:1) although the number of women affected increases with increasing age.\n\n根据上述已知信息，请将'基于26项研究，得出女性便秘的患病率高于男性两倍。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"On the basis of 26 studies, it has been estimated that the prevalence of constipation is about two times higher in women than in men."
    },
    {
        "instruction":"已知信息：\n'应包括目标产品及产品相关物质的说明，以及基本性质、特征和表征数据（例如，一级、高级结构和生物活性）总结，参见3.2.S.3.1。'可被翻译为：A description of the desired product and product-related substances and a summary of general properties, characteristic features and characterisation data (for example, primary and higher order structure and biological activity), as described in 3.2.S.3.1, should be included.\n'ECs（参见第3章）：产品的ECs应列在PLCM文件中。'可被翻译为：ECs (refer to Chapter 3): The ECs for the product should be listed in the PLCM document.\n'5.3.3 药物信息中包含的内容和建议'可被翻译为：5.3.3. Inclusion of information and recommendation in the product information\n'在产品标签中包含和定位基因组学信息，因此，对临床使用和药物警戒活动的影响将受到总体获益-风险平衡、特定基因组亚群中基因组学BM效应的大小以及证据的强度和决定性指导。'可被翻译为：Inclusion and positioning of genomic information in the product labelling and therefore impact on clinical use and pharmacovigilance activities will be guided by the overall benefit-risk balance, magnitude of the genomic BM effect in specific genomic subpopulations, and the strength and conclusiveness of evidence.\n\n根据上述已知信息，请将'5.3.3. 在产品标签中包含信息和建议'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"5.3.3. Inclusion of information and recommendation in the product labelling"
    },
    {
        "instruction":"已知信息：\n'无法使用热法终端灭菌的，可以考虑应用终端灭菌 的替代方法、除菌过滤和\/或无菌生产工艺。'可被翻译为：When terminal sterilisation by heat is 304 not possible, the application of an alternative method of terminal sterilisation, sterilising filtration 305 and\/or aseptic processing may be considered.\n'终端灭菌工艺引起的货架期或贮存条件的变化其本身不能成为采用无菌生 产工艺的理由，除非新的贮存条件或货架期会导致产品使用问题。 在不提供进一步证据的情况下，无菌生产工艺是不会仅基于终端灭菌后杂 质水平升高而被认可的。'可被翻译为：A change in shelf-life or storage conditions caused by a terminal sterilisation process is not in itself a  reason to allow aseptic processing, unless the new storage condition or shelf-life would cause problems  in the use of the product.  Aseptic processing cannot be accepted based solely on an increase in impurity levels upon terminal sterilisation without further justification.\n'虽然，只要可能，使用 欧洲药典 (Ph. Eur.) 的参考条件的终端灭菌是首选方法，本指导原则提供了什么 时候其他终端灭菌工艺、除菌过滤或无菌生产工艺（无论是单独的或与其他终 端微生物消减工艺结合）可以接受为参考终端灭菌工艺的替代方法的信息。 本指导原则代替以前的《药物开发》的附件“灭菌方法选择决策树”（人 用和兽用）。'可被翻译为：Although, terminal sterilisation using a reference condition of the European Pharmacopoeia (Ph. Eur) is the method of choice whenever possible, this guideline provides   information on when other terminal sterilisation processes, sterilising filtration or aseptic processing,   (either alone or when combined with an additional terminal microbial reduction process), could be   accepted as an alternative to a reference terminal sterilisation process.   This guideline replaces the previous Annexes to Pharmaceutical development Decision trees for the  selection of sterilisation methods, (human and veterinary).\n'药物对热的敏感程度。'可被翻译为：How sensitive the drug is to heat.\n\n根据上述已知信息，请将'选择使用热不稳定包装材料本身并不能作为不使用终端灭菌工艺的唯一理 由，可以考察替代材料；例如，聚丙烯对热不如聚乙烯那么敏感，可以进行终 端灭菌。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The choice to use a heat-labile packaging material cannot in itself be the sole reason for not using aterminal sterilisation process and alternative materials could be examined; for instance, polypropylene is not as sensitive to heat as polyethylene and could allow terminal sterilisation."
    },
    {
        "instruction":"已知信息：\n'生产相关信息的转移，包括但不仅限于工艺、包装和分析方法；'可被翻译为：transfer of relevant information in production, including but not limited to processing and packaging and analytical procedure;\n'设施\/设备的差异和适用性验证总结；验证数据支持工艺、 设施\/设备和方法的转移'可被翻译为：Summary of facility\/equipment differences and applicable validation; validation summary data support the process, facility\/equipment, and method transfer\n'11.1. 在计划和执行转移时，应考虑准备转移的设施、设备、仪器、公用系统、产品、工艺和程序的生命周期相关阶段。此要求亦适用于控制策略和工艺验证。'可被翻译为：11.1. The relevant stage of the life cycle of the facility, equipment, instrument, utility, product, process or procedure to be transferred should be taken into consideration when the transfer is planned and executed. This also applies to the control strategy and process validation.\n'控制方法可包括与原料药、制剂物料和组成 相关的参数和属性，设施和设备的操作条件，过程控制，终产品质量标准，监测 和控制的相关方法和频率。'可被翻译为：The controls can include parameters and attributes related to drug substance and drug product materials and components, facility and equipment operating conditions, in-process controls, finished product specifications, and the associated methods and frequency of monitoring and control.\n\n根据上述已知信息，请将'转移涉及的设施、设备、仪器、物料、程序与方法的平行比较；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"a parallel comparison of premises, equipment, instruments, materials, procedures, and methods for transfer under consideration;"
    },
    {
        "instruction":"已知信息：\n'以治愈为目的的治疗方法包括手术和\/或放疗，但积极的监测也是一种替代方法，它可以降低过度治疗和放疗相关副作用的风险。'可被翻译为：Treatments with curative intent include surgery and\/or radiotherapy but active surveillance is an alternative and reduces the risk for overtreatment and side effects related to radical therapy.\n'（新）辅助治疗 辅助治疗的最终目的是提高治愈率。'可被翻译为：(Neo)adjuvant therapy In the adjuvant setting, the ultimate aim is to increase cure rate.\n'在患有高恶性淋巴瘤、生殖细胞肿瘤或在佐药设置中制定新的疗法的最终目的是为了提高治愈率和生存率或在不损失疗效的情况下相应地减少毒性。然而，在某些情况下，由于服药疗法的复杂性，如在急性髓系白血病(AML)中，相对活性试验化合物对这些终点 的影响可能难以界定。'可被翻译为：The ultimate aim of developing new therapies, e.g., in patients with high grade lymphoma, germ cell tumours or in the adjuvant setting, is to improve cure rate and survival or to relevantly decrease toxicity without loss of efficacy. Nevertheless, in some cases and due to the complexity of administered therapies, e.g. in AML, the impact of a relevantly active experimental compound on these endpoints may be hard to demonstrate.\n'以治愈为目的给予治疗'可被翻译为：Treatment administered with curative intent\n\n根据上述已知信息，请将'特别是在姑息性治疗，使用广泛公认仪器的HRQoL\/PRO可能是有用的（附录2） 7.2 以治愈为目的给予治疗 开发新的治疗方法（例如在高分级的淋巴瘤、生殖细胞肿瘤患者或辅助性治疗）的 最终目的是提高治愈率和生存率或相对降低毒性而不损失疗效。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Especially in the palliative setting, HRQoL\/PRO using generally accepted instruments might be informative (Appendix 2) 7.2. Treatment administered with curative intent The ultimate aim of developing new therapies, e.g., in patients with high grade lymphoma, germ cell tumours or in the adjuvant setting, is to improve cure rate and survival or to relevantly decrease toxicity without loss of efficacy."
    },
    {
        "instruction":"已知信息：\n'在rasH2-Tg小鼠模型中，ICH S1C(R2)中列出的在剂量限制性毒性或其他标准不适用时，采用血浆暴露量（AUC）比值选择高剂量尚未被全球接受。对该模型中测试的53种化合物的已有数据的回顾性分析确定，在所有案例中，化合物相关的肿瘤检测均出现在啮齿类动物与人体系统暴露量比50倍的范围内（15）。基于此分析，得出的结论是50倍的血浆暴露量比值（啮齿类动物:人）足以作为高剂量选择的标准。因此，S1C(R2)中规定的2年啮齿类动物致癌性试验高剂量选择的所有标准均适用于rasH2-Tg小鼠致癌性试验，包括血浆暴露量比值，但rasH2-Tg小鼠暴露量比值要求为50倍，而不是在标准品系啮齿类动物2年试验中的25倍。'可被翻译为：A plasma exposure (AUC) ratio for high dose selection in the absence of dose limiting toxicity or other criteria as outlined in ICH S1C(R2) has not been globally accepted as a dose-setting criterion in the rasH2-Tg mouse model. A retrospective evaluation of available data from 53 compounds tested in this model determined that detection of compound-related tumors emerged in all cases within a systemic rodent-to-human exposure ratio up to 50-fold (15). Based on this analysis, it was concluded that a 50-fold plasma exposure ratio (rodent:human) is an adequate criterion for high dose selection. Therefore, all criteria for selection of the high dose as specified in S1C(R2) for 2-year rodent carcinogenicity studies are applicable to rasH2-Tg mice, including a plasma exposure ratio, except that the plasma exposure ratio will be 50-fold in rasH2-Tg mice rather than 25-fold as for 2-year studies conducted in standard strains of rodents.\n'然而，目前基于对采用MTD选择高剂量开展的致癌性试验数据库的分析，按照人血浆中原形药物和／或代谢物 AUC 25倍选择啮齿类动物致癌性试验的高剂量被认为是实用的 （参见注释3）。'可被翻译为：However, for the present, and based on an analysis of a database of carcinogenicity studies performed at the MTD, the selection of a high dose for carcinogenicity studies which represents a 25- to-1 exposure ratio of rodent to human plasma AUC of parent compound and\/or metabolites is considered pragmatic (Note 3).\n'3. 澄清rasH2-Tg小鼠致癌性试验中基于暴露量的高剂量选 择标准'可被翻译为：3. CLARIFICATION ON CRITERIA FOR HIGH DOSE SELECTION BASED ON EXPOSURE FOR RASH2-TG MOUSE CARCINOGENICITY STUDIES\n'1.3 高剂量选择的药代动力学终点 对于在人和啮齿类动物中有相似的代谢特征、并在啮齿类动 物中器官毒性较低的（即：啮齿类动物在高剂量下耐受性良好）的 药物，能达到人体每日最大推荐剂量下药物暴露曲线下面积（AUC） 很多倍的系统暴露量，可作为药物致癌性试验剂量选择的合适终点。'可被翻译为：1.3 Pharmacokinetic Endpoints in High Dose Selection A systemic exposure representing a large multiple of the human area under the exposure curve (AUC) (at the maximum recommended daily dose) can be an appropriate endpoint for dose selection for carcinogenicity studies for pharmaceuticals which have similar metabolic profiles in humans and rodents and low organ toxicity in rodents (i.e., high doses are well tolerated in rodents).\n\n根据上述已知信息，请将'此外，按照ICH S1C(R2)，在2年啮齿类动物试验中基于动物与人血浆的曲线下面积（AUC）的暴露量比值终点选择高剂量的方法，尚未被全球接受用于rasH2-Tg小鼠试验中。因此，应用现有信息对rasH2-Tg小鼠试验中的血浆暴露量和试验结果进行了全面分析（15）。如第3章节所述，分析结果显示，50倍的血浆AUC暴露比值（啮齿类动物：人）足以作为标准用于高剂量的选择。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In addition, an exposure ratio endpoint based on animal to human plasma Area Under the Curve (AUC) for high dose selection in 2-year rodent studies as per ICH S1C(R2) has not been globally accepted for use in the rasH2-Tg mouse study. Therefore, a comprehensive analysis was conducted to assess exposures and outcomes in rasH2-Tg mouse studies from available information (15). As described in Section 3, the results of this analysis indicate that a 50-fold plasma AUC exposure ratio (rodent:human) is an adequate criterion for high dose selection."
    },
    {
        "instruction":"已知信息：\n'液体原料药应暴露 于化学惰性的透明容器内。'可被翻译为：Drug substances that are liquids should be exposed in chemically inert and transparent containers.\n'药物分散于熔融的材料中，再喷于冷气流中凝聚而成球或成囊的方法。'可被翻译为：The method in which the drug is dispersed in a molten material and then sprayed in a cold air stream to condense into a ball or capsule.\n'药物溶解于熔融的载体中，药物主要以分子状态分散在固体分散体中所形成的均相体系。'可被翻译为：The drug is dissolved in the molten carrier, and the drug is mainly dispersed in the molecular state in the homogeneous system formed by the solid dispersion.\n'透明、无色或微黄色的溶液。'可被翻译为：Clear, colourless or slightly yellow solution.\n\n根据上述已知信息，请将'药物分散于熔融的透明状无定形载体中，骤然冷却，得到质脆透明状态的固体溶液。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The drug is dispersed in a molten transparent amorphous carrier, which cools abruptly to obtain a solid solution in a brittle and transparent state."
    },
    {
        "instruction":"已知信息：\n'10.检验、计算复核人员的签名和日期。'可被翻译为：10) Dates and signatures of the persons who verified the testing and the calculations.\n'9.检验人员的签名和日期；'可被翻译为：9) Dates and signatures of the persons who performed the testing;\n'4.生产步骤操作人员的签名；必要时，还应当有操作（如称量）复核人员的签名。'可被翻译为：4. Signatures of the operator of different steps of production and, where appropriate, of the person who checked each of these operations (e.g. weighing);\n'（四）生产步骤操作人员的签名；必要时，还应当有操作（如 称量）复核人员的签名；'可被翻译为：4. Signatures of the operator of different steps of production and, where appropriate, of the person who checked each of these operations (e.g. weighing);\n\n根据上述已知信息，请将'10.检验、计算复核人员的签名和日期。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"10) Dates and signatures of the persons who verified the testing and the calculations."
    },
    {
        "instruction":"已知信息：\n'大家都认识到了这种尴尬的现状；然而，在研究方案中应定义出需进行放疗的明确标准，尤其是如果该研究不能按双盲进行的情况下。'可被翻译为：This unfortunate situation is acknowledged; nevertheless clear criteria defining need for radical therapy should be in place in study protocols, especially if the study cannot be conducted under double-blind conditions.\n'尚未确定哪套标准在临床上更为敏感更具特异性。'可被翻译为：It is not settled yet which criteria are the most sensitive and specific in the clinical setting.\n'对于验证性试验，可接受的主要终点是至需要进行放疗的时间，或是在某个预定时间需要进行放疗的患者比例。然而，直到现在尚无统一的需进行放疗的标准。欧洲泌尿科学会（EAU）、美国国家综合癌症网络（NCCN）、英国卫生质量标准署（NICE）开发的临床指南中提出了多种选择。大家都认识到了这种尴尬的现状；然而，在研究方案中应定义出需进行放疗的明确标准，尤其是如果该研究不能按双盲进行的情况下。建议采用独立的裁决程序。'可被翻译为：For confirmatory trials, an acceptable primary end point is time to need for radical therapy, or proportion of patients in need for such therapy at a predefined point in time. Until now, however, there is no consensus as regards criteria defining need for radical therapy. Clinical guidelines developed by European Urology Association (EAU), National Cancer Comprehensive Network (NCCN) and National Institute for health and clinical excellence (NICE) suggest several options. This unfortunate situation is acknowledged; nevertheless clear criteria defining need for radical therapy should be in place in study protocols, especially if the study cannot be conducted under double-blind conditions. Independent adjudication is recommended.\n'如果尚无此类标准，则可以配制适当的内部制剂。'可被翻译为：If such standards are not available, appropriate in-house preparations can be established.\n\n根据上述已知信息，请将'然而，直到现在尚无统一的需进行放疗的标准。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Until now, however, there is no consensus as regards criteria defining need for radical therapy."
    },
    {
        "instruction":"已知信息：\n'因此，根据最低NOAEL值，如 150 ppm（相当于32 mg Sn\/kg\/天）[3]确定口服PDE值。'可被翻译为：Thus, the PDE for oral exposure was determined on the basis of the lowest NOAEL, i.e., 150 ppm (equivalent to 32 mg Sn\/kg\/day; ATSDR, 2005).\n'本文中PDE值代表每日最大给药剂量的药品中每个元素的最大日允许摄入量，以µg\/天表示。'可被翻译为：The PDEs, reported in micrograms per day (µg\/day) provided in this document give the maximum permitted quantity of each element that may be contained in the maximum daily intake of a drug product.\n'使用最小风险水平（MRL）0.02 mg\/kg\/天推算元素Z的口服PDE值。'可被翻译为：For element Z, a Minimal Risk Level (MRL) of 0.02 mg\/kg\/day was used to derive the oral PDE.\n'基于血液和血压效应结果设定钒的口服NOAEL值为0.12 mg\/kg\/天，以调整因子（F1-F5参见附录1） 计算口服PDE值如下： PDE=0.12 mg\/kg\/天×50 kg\/（1×10×5×1×1）=0.12 mg\/天=120 µg\/天'可被翻译为：The oral NOAEL of 0.12 mg vanadium\/kg\/day for hematological and blood pressure effects was used to calculate the oral PDE. Taking into account the modifying factors (F1-F5 as discussed in Appendix 1), the oral PDE is calculated as below. PDE = 0.12 mg\/kg\/d x 50 kg \/ (1 x 10 x 5 x 1 x 1) = 0.12 mg\/d = 120 µg\/day\n\n根据上述已知信息，请将'口服PDE值是以砷对皮肤的长期效应为基础，并基于有毒物质和疾病登记处（ATSDR）的MRL值以及US EPA0.0003 mg\/kg\/天的限度，确定其限度为15 μg\/天[4,5,8]。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The oral PDE is based on the chronic effects of arsenic to skin and sets the limit at 15 µg\/day based on Agency for Toxic Substances and Disease Registry (ATSDR) MRL and US EPA limit of 0.0003 mg\/kg\/day (ATSDR, 2007; US EPA 2007; EU EFSA, 2009)."
    },
    {
        "instruction":"已知信息：\n'ICH的主要职责是便于制药行业与监管机构之间及内部交换药物警戒信息。'可被翻译为：The primary ICH application is for the exchange of pharmacovigilance information between and among the pharmaceutical industry and regulatory authorities.\n'a) 与ISO药品识别（IDMP）标准融合 ICH 支持药品信息的协调一致，向ISO 工作组健康信息学，医药商业，以及 E2B（R3）ICSR IG电子传递通过其多学科专家工作组5（M5）提供意见。'可被翻译为：a. Integration with ISO Identification of Medicinal Product (IDMP) Standards ICH supports harmonization of medicinal product information and provides input to the ISO workgroups Health Informatics, and the Pharmacy and Medicine Business, and the E2B(R3) Electronic Transmission of ICSR IG through its Multidisciplinary Expert Workgroup 5 (M5).\n'协调统一的生命周期管理的技术和法 规考虑将促进制药行业的创新及持续改进、加强质量保证和改善药 品供应，从而使患者、行业和监管机构从中受益。'可被翻译为：A harmonised approach regarding technical and regulatory considerations for lifecycle management will benefit patients, industry, and regulatory authorities by promoting innovation and continual improvement in the pharmaceutical sector, strengthening quality assurance and improving supply of medicinal products.\n'监管机构可以与受监管行业协商解决监管、科学或行政性问题。'可被翻译为：The Ombudsman may be engaged by the regulated industry to address issues of a regulatory, scientific, or administrative nature.\n\n根据上述已知信息，请将'ICH将监管机构与制药行业连接在一起，以协调药物注册在科学和技术方面的问题。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The ICH brings together regulatory authorities and the pharmaceutical industry to harmonise scientific and technical aspects of drug registration."
    },
    {
        "instruction":"已知信息：\n'本指导原则的部分内容也可 能与临床早期研发或后期研究相关。'可被翻译为：Certain aspects of this guideline may also be relevant to studies con- ducted early in clinical development or in later phases.\n'申办方在药物研发早期即已经开始考虑现有的患者评价手段，并且评价其适用性。'可被翻译为：Early in drug development, sponsors should begin to consider the available patient assessment tools and assess their suitability.\n'7.3.1 临床研发阶段'可被翻译为：7.3.1 Clinical Development\n'临床研发的注意事项（8.6） 众所周知，人们对产品和工艺的认识在研发过程中不断增长，因此，在临床 研发试验阶段用于支持控制策略的数据肯定会比上市注册阶段少。'可被翻译为：8.6 Considerations for Clinical Development It is recognized that product and process knowledge increases over the course of development and therefore it is expected that data to support control strategies in the clinical development trial phases will be less than at the marketing registration phase.\n\n根据上述已知信息，请将'临床心电图评估应该在临床研发较早阶段 进行。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Clinical electrocardiographic evaluation should be performed early in clinical development."
    },
    {
        "instruction":"已知信息：\n'行业指导原则研究者职责-保护研究受试者的权利、安全性和福利行业指导原则\n药品 或者生物制品组合的非临床安全性评价'可被翻译为：Guidance for industry Investigator Responsibilities — Protecting the Rights, Safety, and Welfareof Study Subjects\nGuidance for industry Nonclinical Safety Evaluation of Drug or Biologic Combinations\n'关于使用助理研究者的更多信息，请参见行业指南研究者职责-保护研究受试者的权利、安全性和福利。'可被翻译为：For more information about the use of subinvestigators, see the guidance for industry Investigator Responsibilities — Protecting the Rights, Safety, and Welfare of Study Subjects.\n'更多信息，请参见申办方、临床研究者和 IRB 指南常见问题-研究者声明第 VII 部分 31-33 的信息表（表格 FDA 1572）和行业指南研究者职责-保护研究受试者的 权利、安全性和福利，第 III 节。'可被翻译为：For more information, see the information sheet guidance for sponsors, clinical investigators, and IRBs Frequently Asked Questions — Statement of Investigator (Form FDA 1572), section VII., 31-33, and the guidance for industry Investigator Responsibilities — Protecting the Rights, Safety, and Welfare of Study Subjects, section III.\n'IRB这一职责的关键部分是确保知情同意过程足以保护参与临床研究的受试者的权利和福利（§§ 56.109(b)和 56.111(a)(4)）。'可被翻译为：A critical part of this responsibility is for the IRB to ensure there is an adequate informed consent process that protects the rights and welfare of subjects participating in clinical investigations (§§ 56.109(b) and 56.111(a)(4)).\n\n根据上述已知信息，请将'见行业指导原则研究者职责–保护研究受试者的权利、安全和福利。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"See the guidance for industry Investigator Responsibilities – Protecting the Rights, Safety, and Welfare of Study Subjects."
    },
    {
        "instruction":"已知信息：\n'2. 公司核心数据表 (CCDS) ICH指导原 则E2C 由MAH编写的文件，除了安全性信息外，还包含与 适应症相关的材料、剂量、药理学和其它有关该产品 的信息。'可被翻译为：2.Company Core Data Sheet (CCDS) ICH Guideline E2C A document prepared by the MAH containing, in addition to safety information, material related to indications, dosing, pharmacology and other information concerning the product.\n'PBRER的参考产品信息将包括“核心安全性”和“批准的适应症”章节。'可被翻译为：The reference product information for the PBRER would include “core safety” and “approved indications” components.\n'CCDS 中包含的核心安全信息被称为CCSI。'可被翻译为：The core safety information contained within the CCDS is referred to as the CCSI.\n'参考产品信息为公司核心数据表 （CCDS）时，参考安全性信息为公司核心安全性信 息（CCSI）。'可被翻译为：Where the reference product information is the Company Core Data Sheet (CCDS), the reference safety information is the Company Core Safety Information (CCSI).\n\n根据上述已知信息，请将'这些提议包含对参考安全性信息的原始ICH E2C 概念（如公司核心安全信息* [CCSI]），并添加了已批准的产品适应症。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"These proposals incorporate the original ICH E2C concept of reference safety information (e.g., Company Core Safety Information* [CCSI]), with the addition of the approved indications for the product."
    },
    {
        "instruction":"已知信息：\n'14天取样点计数比初始计数不少于2.0个对数，并且在28天取样点的 计数从14天后不增加。'可被翻译为：Not less than a 2.0 log reduction from the initial count at 14 days, and no increase from the 14-day count at 28 days.\n'7天取样点计数比初始计数减少不少于1.0个对数，14天取样点计数比 初始计数不少于3.0个对数，并且在28天取样点的计数从14天后不增 加。'可被翻译为：Not less than 1.0 log reduction from the initial calculated count at 7 days, not less than 3.0 log reduction from the initial count at 14 days, and no increase from the 14-day count at 28 days.\n'在14和28天取样点的计数从初始计数开始没有增加。'可被翻译为：No increase from the initial calculated count at 14 and 28 days.\n'在7，14和28天取样点的计数从初始计数开始没有增加。'可被翻译为：No increase from the initial calculated count at 7, 14, and 28 days.\n\n根据上述已知信息，请将'14天取样点计数比初始计数不少于1.0个对数，并且在28天取样点的 计数从14天后不增加。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Not less than a 1.0 log reduction from the initial count at 14 days, and no increase from the 14-day count at 28 days."
    },
    {
        "instruction":"已知信息：\n'例如，如果预期试验药物对MDR 革兰氏阴性需氧菌\/兼性厌氧菌有活性， 可以研究用于治疗HAP\/ VAP或IAI的疗效，因为许多这些患者将被相关属种的 生物体感染。'可被翻译为：For example, if the test agent is expected to be active against MDR Gram-negative aerobes\/facultative anaerobes it could be studied for efficacy in HAP\/VAP or IAI since many of the patients will be infected by organisms of relevant genera\/species.\n'例如， 预测试验性抗菌剂在治疗限定或不限 定于特定病原体的、相对罕见类型的感染（如感染性心内膜炎和细菌性脑膜炎） 有临床疗效时。'可被翻译为：For example, this may apply when the test antibacterial agent is predicted to be clinically efficacious in the treatment of relatively rare types of infections (e.g. infective endocarditis and bacterial meningitis), with or without restriction to specific pathogens.\n'. 如果试验性抗菌剂显示对于对一种或多种同类（或很接受的相关类别）药物 耐药的病原体有临床疗效（例如某个脂糖肽类药物显示对万古霉素不敏感的 肠球菌有疗效），则应该声明。'可被翻译为：If the test antibacterial agent showed convincing clinical efficacy against pathogens that were resistant to one or more agents of the same (or very closely-related) drug class (e.g. a lipoglycopeptide showed efficacy against vancomycin-insusceptible enterococci) then this should be stated.\n'例如，应考虑到对于一个药物对某特定病原体的预期疗效可能有重要意义的耐药 发生率估计。'可被翻译为：For example, it should take into account estimates of the prevalence of resistance that might have important implications for the anticipated efficacy of an agent against a particular pathogen.\n\n根据上述已知信息，请将'如果预期试验药物对MDR革兰氏阳性病原体（例如糖肽类药物耐药的葡萄球菌）有效，可以研究用于治疗 HAP\/VAP或SSTI的疗效。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"If the test agent is expected to be active against MDR Gram- positive pathogens such as glycopeptide-resistant staphylococci it could be studied for efficacy in HAP\/VAP or SSTI."
    },
    {
        "instruction":"已知信息：\n'还应介绍研究之间的重要相似性和差异（例如设计、人群、剂量、持续时间、 终点）。'可被翻译为：Important similarities and differences among studies should also be presented (e.g., design, population, dose, duration, endpoints).\n'如果发现这样的差异，则可能是重要的。'可被翻译为：Such differences, if found, may be important.\n'对于旨在显示治疗差异的研究，应指定研究 设计用于检测的差异大小。'可被翻译为：For a study intended to show a difference between treatments, the difference the study is designed to detect should be specified.\n'不论怎样，必须明确，在要证明不同治疗的组间差异 的试验中，很有必要采用良好的研究设计并尽量减少研究的 误差，因为不完善的试验会增加不同治疗之间的差异存在时 不能显示的可能性。。'可被翻译为：Nonetheless, it should be appreciated that in trials intended to show a difference between treatments there is a strong imperative to use a good trial design and minimize trial errors because many trial imperfections increase the likelihood of failing to show a difference between treatments when one exists.\n\n根据上述已知信息，请将'如果设计大致类似的研究间结果存在重要差异，应当显示和讨论这些差异。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"If there are important differences in outcome among studies of generally similar design, these differences should be displayed and discussed."
    },
    {
        "instruction":"已知信息：\n'第一百三十一条 企业应当对直接接触药品岗位的人员进行岗前及年度健康检查，并建立健康档案。患有传染病或者其他可能污染药品的疾病的，不得从事直接接触药品的工作。'可被翻译为：Article 131 Enterprises shall request pre-post and annual health examinations for personnel at the posts in direct contact with drugs, and have health records established. Personnel suffering from infectious diseases or other diseases that could contaminate drugs shall not engage in the work in which they could directly contact the drugs.\n'第三十一条 企业应当对人员健康进行管理，并建立健康档 案。'可被翻译为：Article 31: The manufacturer should have management on the employee's health and establish health archives.\n'直接接触药品的生产人员上岗前应当接受健康检查，以后每 年至少进行一次健康检查。'可被翻译为：Personnel engaged in manufacturing who is in direct contact with drugs should receive medical examination before being assigned to work, and the examination should be carried out at least annually afterward.\n'（二）未按照规定每年对直接接触药品的工作人员进行健康检查并建立健康档案；'可被翻译为：(2) failing to carry out health examination of personnel in direct contact with drugs each year and establish health achieves; or\n\n根据上述已知信息，请将'第三十一条 企业应当对人员健康进行管理，并建立健康档案。直接接触药品的生产人员上岗前应当接受健康检查，以后每年至少进行一次健康检查。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 31 The manufacturer should have management on the employee's health and establish health archives. Personnel engaged in manufacturing who is in direct contact with drugs should receive medical examination before being assigned to work, and the examination should be carried out at least annually afterward."
    },
    {
        "instruction":"已知信息：\n'本指导原则（1）提供简要背景信息、（2）提供建议帮助你决定应该提交NDA 或ANDA，（3）包括NDA和ANDA中需要的内容和格式的说明以及（4）提供可 复制或截图、并可粘贴到申请书中的方框文本。内容和格式章节提供要求的资料 以提交这些PET药物的NDA或ANDA。最后，我们建立了F 18 脱氧葡萄糖注射 液、N 13 氨注射液和F18氟化钠注射液的化学部分以及拟议标签的示例格式以 及356h示例表格。这些格式在FDA网站的独立文件中给出。4'可被翻译为：The guidance (1) provides brief background information, (2) makes recommendations to help you decide whether you should submit an NDA or an ANDA, (3) includes a description of the content and format needed in an NDA and an ANDA, and (4) provides boxed text that you can copy or cut and paste into your application. The content and format sections provide information required to submit an NDA or an ANDA for these PET drugs. Finally, we have developed sample formats for the chemistry sections and for the proposed labeling for fludeoxyglucose F 18 injection, ammonia N 13 injection, and sodium fluoride F 18 injection as well as 356h sample forms. These formats are supplied as separate documents on FDA’s web site.4\n'这部分的指导原则讨论ANDA的内容和格式。如果你申请的药品与上述药 品相同（例如F 18 脱氧葡萄糖注射液、F 18 氟化钠注射液和N 13 氨注射液），你将提交ANDA。在提供一般资料后，我们将逐步展示应在ANDA各个部分中输入内容的说明。各个PET药品化学部分的内容和格式的示例格式在单独附录中给出。'可被翻译为：This section of the guidance discusses the content and format of an ANDA. If your drug is the same as a listed drug (e.g., fludeoxyglucose F 18 injection, sodium fluoride F 18 injection, or ammonia N 13 injection), you should submit an ANDA. After providing general information, we will present a step-by-step description of what you should put in each section of the ANDA. Sample formats for the content and format of the chemistry sections for each PET drug are provided as separate attachments.\n'寻求F 18 脱氧葡萄糖注射液、N 13 氨注射液和F 18 氟化钠注射液许可的申请人可提交NDA或ANDA，这取决于特定药品是否与批准的药物剂型相同以及需申报的适应症。'可被翻译为：An applicant seeking approval for fludeoxyglucose F 18 injection, ammonia N 13 injection, or sodium fluoride F 18 injection may submit an NDA or an ANDA, depending whether or not the specific drug product is the same as an already approved drug formulation and the indications for which approval is sought.\n'在N 13 氨注射液、F 18 氟化钠注射液和F 18 脱氧葡萄糖注射液（神经学 适应症）的NDA内：'可被翻译为：Within an NDA for ammonia N 13 injection, sodium fluoride F 18 or fludeoxyglucose F 18 injection (neurologic indication):\n\n根据上述已知信息，请将'本指导原则旨在辅助申请人撰写第III节（下文）中引用适应症的PET成像中使用的F 18 脱氧葡萄糖注射液、N 13 氨注射液和F18氟化钠注射液的新药申请（NDA）或简略新药申请（ANDA）。根据联邦食品、药品和化妆品法案（法案），FDA批准的NDA或ANDA将使这些PET药物上市用于临床应用成为可能。3'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"This guidance is intended to assist applicants in preparing new drug applications (NDAs) or abbreviated new drug applications (ANDAs) for fludeoxyglucose F 18 injection, ammonia N 13 injection, and sodium fluoride F 18 injection used in PET imaging for the indications cited in Section III (below). FDA approval of an NDA or ANDA will make it possible to market these PET drugs for clinical use according to the requirements of the Federal Food, Drug, and Cosmetic Act (the Act).3"
    },
    {
        "instruction":"已知信息：\n'对于MDS患者，减轻与血细胞减少相关的症状是一个可接受的治疗目的。大多数情况下这是指减少贫血相关症状。由于在老年患者群中，并存疾病相当普遍，症状量表即使经过正确验证，也对捕捉治疗组之间的相关差异太不敏感，特别是红细胞输血必须个体化时（如由于伴随心血管疾病）。因此在规定时限内不再需要输血（伴有血红蛋白水平提高）也被认为是一个可接受的结局测量指标。'可被翻译为：Alleviation of symptoms related to cytopenia is an acceptable aim of treatment in patients with MDS. In most cases this means reduction of anaemia-related symptoms. Due to prevalent co- morbidities in this elderly population, symptom scales, even if properly validated, may be too insensitive to capture also relevant differences between treatment groups especially as transfusion of red blood cells must be individualised due to e.g. concomitant cardiovascular disorders. Loss of need for transfusion for a defined period of time (in combination with improved haemoglobin levels) is therefore considered an acceptable outcome measure.\n'大多数情况下这是指减少贫血相关症状。'可被翻译为：In most cases this means reduction of anaemia-related symptoms.\n'很多MDS 患者在诊断时没有症状，但是最终会发展成有症状的贫血，单纯的血小板减少和单纯的嗜中性白血球减少症或者是两者结合。'可被翻译为：Many patients with MDS are asymptomatic at the time of diagnosis, but eventually develop symptomatic anaemia, thrombocytopenia and neutropenia alone or in combination.\n'慢性 ITP相关变量包括出血症状\/体征、响应时间、响应持续时间、伴随治疗减少、 急救治疗需求与安全(如可以把血小板减少反弹或一个预设的高血小板计数列为 不良事件(AE))。'可被翻译为：Relevant variables in chronic ITP include bleeding signs\/symptoms, time to response, duration of response, concomitant treatment reduction, need for rescue treatment and safety (e.g. rebound thrombocytopenia or a predefined exceedingly high platelet count may be considered an adverse event (AE)).\n\n根据上述已知信息，请将'对于MDS 患者，减轻与血细胞减少相关的症状是一个可接受的治疗目的。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Alleviation of symptoms related to cytopenia is an acceptable aim of treatment in patients with MDS."
    },
    {
        "instruction":"已知信息：\n'E. FDA回应延迟的可能性 有时，FDA部门决定，从咨询委员会审核或顾问（内部，包括内部监管会议， 或者外部）得到的意见对于SPA递交内容的审核至关重要。'可被翻译为：E. Potential for Delay of FDA Response Occasionally, FDA divisions determine that input obtained from advisory committee review or consultants (internal, including internal regulatory meetings, or external) is critical to the review of an SPA submission.\n'告知申办方其问题涉及与其他FDA各方的磋商（例如，需要法律意见的政策问题，关于其他中心参与的组合产品的问题），因此估计的回复时间段即将到来；'可被翻译为：• Inform the sponsor that its question(s) involve consultation with other FDA parties (e.g., policy questions where legal input is necessary, questions about combination products where other centers are involved) and therefore an estimated response time frame will be forthcoming;\n'SPA审核可能不总是在45天内完成的，进一 步描述见第VI节E部分“FDA回应延迟的可能性”。'可被翻译为：SPA reviews may not always be completed within 45 days, as further described in section VI.E., Potential for Delay of FDA Response.\n'D. FDA给申办方的回应 在PDUFA V（90%的SPA）和BsUFA（80%到90%的SPA）目标下，FDA 承诺在收到SPA递交内容后45个日历日内给申办方发送SPA函（见第VIII节 “文件”和第VI.E.节“FDA回应延迟的可能性”）。'可被翻译为：D. FDA Response to Sponsor Under PDUFA V (90 percent of SPAs) and BsUFA (80 to 90 percent of SPAs) goals, FDA committed to sending an SPA Letter (see sections VIII., Documentation, and VI.E., Potential for Delay of FDA Response) to the sponsor within 45 calendar days of receipt of the SPA submission.\n\n根据上述已知信息，请将'在SPA审核期间（例如，由特殊政府雇员或不同的FDA办公室或中心）进 行磋商的需要描述在第VI.E.节“FDA回应延迟的可能性”中，也应该在会上进行考虑和讨论。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The need for consultation during an SPA review (e.g., by special government employees or by a different FDA office or center), described in section VI.E., Potential for Delay of FDA Response, also should be considered and discussed at the meeting."
    },
    {
        "instruction":"已知信息：\n'此外，还应当考虑对贮存时间较长的中间产品进行考察。'可被翻译为：In addition, consideration should be given to intermediate products that are stored and used over prolonged periods.\n'这种情况下， 除另有论述外，应监控拟定存贮条件下（拟定的商业包装）长期主要稳定性试验 中原料药或制剂中的降解。'可被翻译为：In these cases, monitoring for the drug substance or drug product degradation product in long term primary stability studies at the proposed storage conditions (in the proposed commercial pack) is expected unless otherwise justified.\n'虽然生物技术产品\/生物制品在贮藏期内易于发生明显的活性降低、物理化学变化或降解，但国际和国家法规很少有指导原则提供放行标准和有效期末质量标准的区别。'可被翻译为：Although biotechnological\/biological products may be subject to significant losses of activity, physicochemical changes, or degradation during storage, international and national regulations have provided little guidance with respect to distinct release and end of shelf-life specifications.\n'生物技术产品及生物制品通常应密封防湿贮藏。'可被翻译为：Biotechnological\/biological products are generally distributed in containers protecting them against humidity.\n\n根据上述已知信息，请将'另外，还应考虑到在较长贮藏期内的不同时段，生物技术产品\/生物制品的降解可能受不同因素的影响。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"This takes into account the fact that degradation of biotechnological\/biological products may not be governed by the same factors during different intervals of a long storage period."
    },
    {
        "instruction":"已知信息：\n'用户指导原则 此数据元素获取发送者的机构名称（例如：公司名称或监管机构名称）。'可被翻译为：User Guidance This data element captures the sender’s organisation name (e.g. company name or regulatory authority name).\n'用户指导原则 根据该数据元素获取发送者的给定名。'可被翻译为：User Guidance This data element captures the sender’s given name.\n'用户指导原则 根据该数据元素获取发送者的姓氏。'可被翻译为：User Guidance This data element captures sender's family name.\n'用户指导原则 根据该数据元素获取发送者的职称。'可被翻译为：User Guidance This data element captures the sender’s title.\n\n根据上述已知信息，请将'用户指导原则 根据该数据元素获取发送者的机构或个体的类型。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"User Guidance This data element captures the type of sender organisation or individual."
    },
    {
        "instruction":"已知信息：\n'当药事管理的医学术语集（MedDRA）术语用于编码不良事件\/反应的 术语时，在总结表中应显示首选术语（PT）分组和SOC。'可被翻译为：When the Medical Dictionary for Regulatory Activities (MedDRA) terminology is used for coding the adverse event\/reaction terms, the Preferred Term (PT) level and SOC should be presented in the summary tabulations.\n'具体来说，MedDRA 可以用于：'可被翻译为：Specifically, some of the applications for MedDRA are:\n'在大多数情况下，PT 的主 SOC 是有关疾病、症状和体征的主要发病部位。所以，PT 呼吸困难的主 SOC 是 SOC 呼吸系统、胸及纵隔疾病。但是有以下三种例外术语：'可被翻译为：In most instances, PTs relating to diseases or signs and symptoms are assigned to the prime manifestation site SOC. So, for PT Dyspnoea, the primary SOC is SOC Respiratory, thoracic and mediastinal disorders. However, there are exceptions for three types of terms:\n'• 感染词条的主 SOC 是 SOC 感染及侵染类疾病。'可被翻译为：• Terms for infections are assigned to SOC Infections and infestations as the primary SOC.\n\n根据上述已知信息，请将'MedDRA是一种多轴性术语，每个首选语（PT）可与一个以上的SOC 相连。例如，PT 呼吸困难链接到两个 SOC：SOC 呼吸系统、胸及纵隔疾病（其发病器官系统）和 SOC心脏器官疾病（因为其与心脏疾病有关）。每个 PT 被分配一个主 SOC，从而在用所有 的SOC（即累计各个 SOC 数据输出）检索信息时，可避免“双重计算”。多轴 PT 链接的 其他 SOC 被称为“次” SOC。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"MedDRA is a multi-axial terminology meaning that a Preferred Term (PT) may be linked to more than one SOC. For example, PT Dyspnoea has a link to both SOC Respiratory, thoracic and mediastinal disorders (its organ system of manifestation) and to SOC Cardiac disorders (because of its connection to heart disease). Each PT is assigned a primary SOC to avoid “double counting” while retrieving information from all SOCs (i.e., a cumulative SOC-by-SOC data output). The other SOCs to which a multi-axial PT is linked are called “secondary” SOCs."
    },
    {
        "instruction":"已知信息：\n'只要任何有意义的尿动态测量数据是可用的，这些都可以用来支持临床研究结果。'可被翻译为：Wherever meaningful urodynamic measures are available, these can be used to support clinical findings.\n'尿动力学研究的目的是采用监测设备重现患者的症状。'可被翻译为：Urodynamic studies aim to reproduce patient symptoms in a monitored setting.\n'可使用几种参数评估疗效，从血脂水平的改善至对临床结局影响的证明。'可被翻译为：Efficacy may be evaluated using a number of parameters ranging from modification of lipid levels to demonstration of effect on clinical outcomes.\n'在患有MNE的健康儿童中，通常不要求进行诊断性检查如超声、尿流动力学检查和验血。'可被翻译为：Diagnostic investigations such as ultrasound, urodynamic testing and blood tests are normally not required in an otherwise healthy child with MNE.\n\n根据上述已知信息，请将'尿动力学检查也是有用的评估研究结局的支持性参数，例如患者临床改善可证明尿流动力学参数改善。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Urodynamic studies are also considered useful as supportive parameters in the evaluation of the study outcome, e.g. where patients with clinical improvement can be demonstrated to have improved urodynamic parameters."
    },
    {
        "instruction":"已知信息：\n'5.5.9 如果申办者停止一个试验用药品的临床研究，申办者应 当通报所有研究者\/研究机构和所有管理部门。'可被翻译为：5.5.9 If the sponsor discontinues the clinical development of an investigational product, the sponsor should notify all the trial investigators\/institutions and all the regulatory authorities.\n'脱落 是指临床试验的受试者由于任何原因不能继续按研究 方案进行到所要求的最后一次随访。'可被翻译为：Dropout A subject in a clinical trial who for any reason fails to continue in the trial until the last visit required of him\/her by the study protocol.\n'在有些情况下，FDA可以终止IND。如果IND被终止，申办方-研究者必须结束 根据IND实施的所有临床研究，通知IRB ，并召回所有未使用的药物供应 或者提供所有未使用药物供应的处置措施。终止行动可能是基于IND中的缺陷或者根据IND实施研究中的缺陷。'可被翻译为：Under certain circumstances, the FDA may terminate an IND. If an IND is terminated, the sponsor-investigator must end all clinical investigations conducted under the IND, notify the IRB, and recall or otherwise provide for the disposition of all unused supplies of the drug. A termination action may be based on deficiencies in the IND or in the conduct of an investigation under an IND.\n'如果一个报告被提交给多个IND，则每个IND安全性报告都应说明报告提交的所有IND。'可被翻译为：If a report is submitted to multiple INDs, each IND safety report should identify all INDs to which the report is submitted.\n\n根据上述已知信息，请将'如果 IND 被撤回，必须结束所有根据 IND 实施的临床试验。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"If an IND is withdrawn, all clinical trials conducted\tunder the IND must be ended."
    },
    {
        "instruction":"已知信息：\n'实时诊断-实施常规诊断， 以实时确认模型性能。'可被翻译为：Real-time diagnostics - implement routine diagnostics to confirm model performance in real-time\n'在临床开发的早期应考虑制定生物标记物诊断方法，以将技术的临床应用实现最大化。'可被翻译为：The development of biomarker diagnostic methods should be considered early in clinical development, maximising the clinical application of the technology.\n'和成年人ITP诊断一样，儿童ITP诊 断也是基于排除其他潜在病因的过程。'可被翻译为：As for adults, a diagnosis of ITP in children is based on a process of exclusion of any potential cause.\n'某些疾病通常仅在晚年才被诊断出来，但尽管如此，在有生育能力妇女中还 是可能以低的发病率被诊断出来（例如，大疱性类天疱疮，通常在60岁后被诊 断）。'可被翻译为：Some diseases are typically only diagnosed at a later age, but may nonetheless be diagnosed in reproductively capable women at a low incidence (e.g., bullous pemphigoid, which is typically diagnosed after age 60).\n\n根据上述已知信息，请将'实时诊断-实施初始诊 断，以实时确认模型性 能。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Real-time diagnostics - implement initial diagnostics to confirm model performance in real-time"
    },
    {
        "instruction":"已知信息：\n'此类差异可 能影响试验结果和\/或对试验结果的解释。'可被翻译为：Such differences may have an impact on the trial results and\/or their interpretation.\n'在部分情况下，可能需要包括其它临 床试验数据在内的其它数据，或其它来源的支持性证据，来 了解观察到的区域差异。'可被翻译为：In some cases, addi- tional data, including data from other clinical trials, or supportive evidence from other sources, may be needed to understand the regional differences observed.\n'在图2a中，处理反应 随疾病严重程度的增加而增加，同时疾病严重程度因地而异。'可被翻译为：In Figure 2a, response to treatment increases with dis- ease severity, and disease severity differs by region.\n'在计划和设计确证性MRCT前，可在探索性研 究中考察这些差异的程度。'可被翻译为：The magni- tude of such variability could be examined in exploratory studies before the planning and design of confirmatory MRCTs.\n\n根据上述已知信息，请将'即便如此，症状报告可能因地而异，而且可能导致纳入研 究的受试者类型存在差异。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Even so, reporting of symptoms may vary by region and may lead to differences in the types of subjects included in the studies."
    },
    {
        "instruction":"已知信息：\n'布洛芬 CAS 号：15687-27-1 大鼠NOAEL 剂量 Cmax AUC 大鼠LOAEL 剂量 Cmax AUC 大鼠 发现 兔NOAELc 剂量 Cmax AUC 兔LOAEL 剂量 Cmax AUC 兔 发现 人剂量 Cmax AUC 暴露倍数 NOAEL\/人 LOAEL\/人 注释 180 mg\/kg 经口 GD1-20 [Adams] Cmax = 205 µg\/mLa AUC = 597 µg∙h\/mLa 经口GD1-20: 未确定 LOAEL [Adams] 经口GD9-10: 300 mg\/kg [Cappon 2003]b 300 mg\/kg时 Cmax=341 µg\/mLa AUC=995 µg∙h\/mLa GD1-20: 无 GD9-10: 室间隔缺 损 60 mg\/kg 经口 GD1-29 [Adams] Cmax=26.6 µg\/mLd AUC(0-inf)=80.5 µg∙h\/mLd 500 mg\/kg 经口 GD9-11 [Cappon 2003]b Cmax=222 µg\/mLd AUC(0-inf)=671 µg∙h\/mLd 未确定 LOAEL 无 最大剂量为800 mg QID，3200 mg\/天 (13.3 mg\/kg\/次, 53 mg\/kg\/天) [美国说明书] Cmax=59 µg\/mLe AUC=839 µg∙h\/mLe'可被翻译为：Ibuprofen CAS No.: 15687-27-1 Rat NOAEL Dose Cmax AUC Rat LOAEL Dose Cmax AUC Rat Findings Rabbit NOAELc Dose Cmax AUC Rabbit LOAEL Dose Cmax AUC Rabbit Findings Human Dose Cmax AUC Margins NOAEL\/Human LOAEL\/Human Notes 180 mg\/kg oral GD1-20 [Adams] Cmax = 205 µg\/mLa AUC = 597 µg∙h\/mLa oral GD1-20: No LOAEL idenitifed [Adams] oral GD9-10: 300 mg\/kg [Cappon 2003]b at 300 mg\/kg Cmax = 341 µg\/mLa AUC = 995 µg∙h\/mLa GD1-20: None GD9-10: ventricular septal defects 60 mg\/kg oral GD1-29 [Adams] Cmax = 26.6 µg\/mLd AUC(0-inf) = 80.5 µg∙h\/mLd 500 mg\/kg oral GD9-11 [Cappon 2003]b Cmax = 222 µg\/mLd AUC(0-inf) = 671 µg∙h\/mLd No LOAEL identified None Maximum dose is 800 mg QID, 3200 mg\/day (13.3 mg\/kg\/dose, 53 mg\/kg\/day) [US label] Cmax = 59 µg\/mLe AUC = 839 µg∙h\/mLe\n'NOAEL: 大鼠（75mg\/kg\/ 天） Cmax: 136 (45\/0.33) AUC: 111 (334\/3.02) 兔（135 mg\/kg\/ 天） Cmax: 415 (137\/0.33) AUC: 213 (642\/3.02) LOAEL: 无'可被翻译为：NOAEL: rat (75 mg\/kg\/day) Cmax: 136 (45\/0.33) AUC: 111 (334\/3.02) Rabbit (135 mg\/kg\/day) Cmax: 415 (137\/0.33) AUC: 213 (642\/3.02) LOAEL: Rat (225 mg\/kg\/day) Not applicable None\n'大鼠NOAEL 剂量 Cmax AUC 大鼠LOAEL 剂量 Cmax AUC 大鼠 发现 兔NOAEL 剂量 Cmax AUC 兔LOAEL 剂量 Cmax AUC 兔 发现 人剂量 Cmax AUC 暴露倍数 NOAEL\/人 LOAEL\/人 注释 AUC=6.5 (49.1\/7.52) a：Wistar大鼠单次经口给予异维甲酸500 mg\/kg后报告值的外推（Tembe）：Cmax=9.07 µg\/mL，AUC(0-10h)=47.9 µg·h\/mL。'可被翻译为：Rat NOAEL Dose Cmax AUC Rat LOAEL Dose Cmax AUC Rat Findings Rabbit NOAEL Dose Cmax AUC Rabbit LOAEL Dose Cmax AUC Rabbit Findings Human Dose Cmax AUC Margins NOAEL\/Human LOAEL\/Human Notes AUC = 6.5 (49.1\/7.52) a: Extrapolated from reported value after 500 mg\/kg isotretinoin oral single dose in Wistar rats (Tembe): Cmax = 9.07 µg\/mL, AUC(0-10h) = 47.9 µg·h\/mL.\n'5-氟尿嘧啶 CAS号：51-21-8 大鼠NOAEL 剂量 Cmax AUC 大鼠LOAEL 剂量 Cmax AUC 大鼠 发现 兔NOAEL 剂量 Cmax AUC 兔LOAEL 剂量 Cmax AUC 兔 发现 人剂量 Cmax AUC 暴露倍数 NOAEL\/人 LOAEL\/人 注释 10 mg\/kg 单次IP给药 GD9 [Wilson]'可被翻译为：5-FLUOROURACIL CAS No.: 51-21-8 Rat NOAEL Dose Cmax AUC Rat LOAEL Dose Cmax AUC Rat Findings Rabbit NOAEL Dose Cmax AUC Rabbit LOAEL Dose Cmax AUC Rabbit Findings Human Dose Cmax AUC Margins NOAEL\/Huma LOAEL\/Human Notes 10 mg\/kg single dose IP GD9 [Wilson]\n\n根据上述已知信息，请将'NOAEL:大鼠 Cmax=3.4 (205\/59.7) AUC=0.7 (597\/839) 兔c 60 mg\/kg NOAEL Cmax=0.5 (26.6\/59) AUC=0.1 (80.5\/839) 500 mg\/kg NOAEL Cmax=3.8 (222\/59) AUC=0.8 (671\/839) LOAEL: 大鼠 Cmax = 5.8 (341\/59) AUC = 1.2 (995\/839)大鼠NOAEL 剂量 Cmax AUC 大鼠LOAEL 剂量 Cmax AUC 大鼠 发现 兔NOAELc 剂量 Cmax AUC 兔LOAEL 剂量 Cmax AUC 兔 发现 人剂量 Cmax AUC 暴露倍数 NOAEL\/人 LOAEL\/人 注释 兔 无LOAEL a：Sprague Dawley大鼠单次经口给予布洛芬25 mg\/kg（混悬液）后报告值的外推（You）：Cmax=28.4 µg\/mL，AUC(0-inf)=4971.3 µg·min\/mL（82.9 µg∙h\/mL）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"NOAEL: rat Cmax = 3.4 (205\/59.7) AUC = 0.7 (597\/839) rabbitc 60 mg\/kg NOAEL Cmax = 0.5 (26.6\/59) AUC = 0.1 (80.5\/839) 500 mg\/kg NOAEL Cmax = 3.8 (222\/59) AUC = 0.8 (671\/839) LOAEL: rat Cmax = 5.8 (341\/59)Rat NOAEL Dose Cmax AUC Rat LOAEL Dose Cmax AUC Rat Findings Rabbit NOAELc Dose Cmax AUC Rabbit LOAEL Dose Cmax AUC Rabbit Findings Human Dose Cmax AUC Margins NOAEL\/Human LOAEL\/Human Notes AUC = 1.2 (995\/839) rabbit no LOAEL a: Extrapolated from reported value after 25 mg\/kg ibuprofen (suspension) single oral dose in Sprague Dawley rats (You): Cmax = 28.4 µg\/mL, AUC(0-inf)= 4971.3 µg·min\/mL (82.9 µg∙h\/mL)."
    },
    {
        "instruction":"已知信息：\n'CCDS 中包含的核心安全信息被称为CCSI。'可被翻译为：The core safety information contained within the CCDS is referred to as the CCSI.\n'参考产品信息（CCDS）中包含的由 MAH 编写并要求在公司销售该药物的所有国家\/区域列出的所有相关的安全性信息，除非当地监管机构具体要求修改。它是 MAH用于 PBRER 的参考产品信息中包含的信息的一个子集。参考产品信息为公司核心数据表（CCDS）时，参考安全性信息为公司核心安全性信息（CCSI）。'可被翻译为：All relevant safety information contained in the reference product information (e.g., CCDS) prepared by the MAH and which the MAH requires to be listed in all countries where the company markets the drug, except when the local regulatory authority specifically requires a modification. It is a subset of information contained within the MAH’s reference product information for the PBRER. Where the reference product information is the Company Core Data Sheet (CCDS), the reference safety information is the Company Core Safety Information (CCSI).\n'3. 公司核心安全性信 息(CCSI) ICH指导原 则E2C CCDS中包含的由MAH编写并要求在公司销售该 药物的所有国家\/区域列出的所有相关的安全性信 息，除非当地监管机构具体要求修改。'可被翻译为：3.Company Core Safety Information (CCSI) ICH Guideline E2C All relevant safety information contained in the CCDS prepared by the MAH and which the MAH requires to be listed in all countries where the company markets the drug, except when the local regulatory authority specifically requires a modification.\n'该参考 产品信息可能是公司核心数据表*（CCDS）或MAH提出的其它文件（见章节 2.4）。'可被翻译为：This reference product information may be the Company Core Data Sheet* (CCDS) or another document proposed by the MAH (see Section 2.4).\n\n根据上述已知信息，请将'参考产品信息为公司核心数据表 （CCDS）时，参考安全性信息为公司核心安全性信 息（CCSI）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Where the reference product information is the Company Core Data Sheet (CCDS), the reference safety information is the Company Core Safety Information (CCSI)."
    },
    {
        "instruction":"已知信息：\n'在含有OTC防晒活性成分的情况下，FDA权衡了其重要作用、获益与风险，如按照说明与其他防晒措施一起使用，防晒指数（SPF）值为15或以上的广谱防晒药品在降低皮肤癌风险和早期皮肤老化方面可发挥重要作用，应该提供一种为对公众健康具有重要作用的OTC防晒活性成分和防晒成品的安全限度。当确定特定检测和充分证明一种OTC防晒活性成分安全性所需的其他数据时，FDA认为当OTC防晒药品需要同时满足用于消费者和最新科学理论和评价技术的两种条件。为了确保充分讨论了证明防晒药品安全性所需的数据，FDA在2014年9月4-5日举办了一个为期2天非处方药品咨询委员会会议，会议中FDA也提出了多数与本指导原则推荐相同的方法。'可被翻译为：In the case of OTC sunscreen active ingredients, FDA balances the important role that broad spectrum sunscreens with a sun protection factor (SPF) value of 15 or higher play in decreasing the risk of skin cancer and early skin aging caused by the sun, if used as directed with other sun protection measures; the benefits, with the public health importance of providing an adequate safety margin for OTC sunscreen active ingredients and finished sunscreen products, versus the risks. When determining the specific testing and other data needed to adequately demonstrate that an OTC sunscreen active ingredient is safe, FDA considers both the circumstances under which OTC sunscreen products are intended to be used by consumers and current scientific knowledge and assessment technology. To ensure full discussion of the kinds of data needed to address sunscreen safety, FDA held a 2- 112 day meeting of the Nonprescription Drugs Advisory Committee on September 4-5, 2014, at which FDA presented much of the same approach that is recommended in this guidance.\n'FDA要求这些仅防晒伤的产品突出标识警告说明： “皮肤癌\/皮肤老化警告： 晒太阳增加了您皮肤癌和皮肤老化的风险。'可被翻译为：FDA requires these sunburn only products to bear a prominent warning stating: “Skin Cancer\/Skin Aging Alert: Spending time in the sun increases your risk of skin cancer and early skin aging.\n'本品仅有助于防止晒伤，并不能防止皮肤癌和皮肤老化”（21 CFR 201.327（d）（2））'可被翻译为：This product has been shown only to help prevent sunburn, not skin cancer or early skin aging” (21 CFR 201.327(d)(2)).\n'为了处理含有相同活性成分的防晒产品中的差异性，FDA要求对非处方防晒产品进行最终处方测试，以确保其有效性，即测试SPF值以及广谱保护和耐水性，其中这些属性将会在产品标签中声明。'可被翻译为：To address this variability among sunscreen formulations containing the same active ingredient(s), FDA requires final formulation testing of nonprescription sunscreen products to ensure their effectiveness — namely testing for SPF value as well as broad spectrum protection and water resistance, where those attributes are claimed in product labels.\n\n根据上述已知信息，请将'31FDA强烈建议生产商研发具有广谱防辐射和SPF值在15或者更高的OTC防晒产品，原因是如果消费者使用了防止晒伤的防晒产品而增加其全身的日光暴露，而这些产品不能提供充分保护以降低日光导致的皮肤癌和皮肤提前老化的风险，这种情况就会有害于健康。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"31 FDA strongly encourages manufacturers to develop OTC sunscreen products that provide broad spectrum protection and have an SPF value of 15 or higher because of the deleterious health effects that may result if consumers increase their overall sun exposure through use of sunscreen products that help prevent sunburn, but do not provide sufficient protection to help reduce the risk of skin cancer and early skin aging caused by the sun."
    },
    {
        "instruction":"已知信息：\n'6.检验过程，包括对照品溶液的配制、各项具体的检验操作、必要的环境温湿度；'可被翻译为：6) Testing process, including preparation of reference solution, operation of individual tests, necessary data of environment temperature and humidity;\n'4.检验所用的试液和培养基的配制批号、对照品或标准品的来源和批号；'可被翻译为：4) Preparation batch numbers of solutions and culture media, the source and lot number of reference standards;\n'6.必要的检验方法验证报告和记录；'可被翻译为：6) Validation reports and records of testing methods, where applicable;\n'4.检验所用的试液和培养基的配制批号、对照品或标准品的 来源和批号；'可被翻译为：4) Preparation batch numbers of solutions and culture media, the source and lot number of reference standards;\n\n根据上述已知信息，请将'6.检验过程，包括对照品溶液的配制、各项具体的检验操作、 必要的环境温湿度；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"6) Testing process, including preparation of reference solution, operation of individual tests, necessary data of environment temperature and humidity;"
    },
    {
        "instruction":"已知信息：\n'[产品特性：可以在这里简要总结临床研究结果]'可被翻译为：[Product specific: Clinical study results can be briefly summarised here]\n'5.3 临床前安全性数据 [产品特有信息]'可被翻译为：5.3 Preclinical safety data [Product specific]\n'[要求进行PUP研究但仍未获得结果的产品的产品特性-更详细内容见临床指导 原则：]'可被翻译为：[Product specific for products where a study in PUPs is required but results are not yet available – see clinical guideline for further details:]\n'5.4.2 进一步的指导原则：《临床试验方案和方案修改》(见6.)， 《ICH 临床试验报告的结构和内容指导原则》和关于试验设 计、方案和执行的其他ICH指导原则。'可被翻译为：5.4.2 For further guidance: Clinical Trial Protocol and Protocol Amendment(s) (see 6.), the ICH Guideline for Structure and Content of Clinical Study Reports, and other appropriate ICH guidance on trial design, protocol and conduct.\n\n根据上述已知信息，请将'[产品特性—更详细内容见临床指导原则]'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"[Product specific – see clinical guideline for further details]"
    },
    {
        "instruction":"已知信息：\n'潜在风险包括：'可被翻译为：Examples of potential risks include:\n'已确认的风险包括：'可被翻译为：Examples of identified risks include:\n'报告周期内正在进行和已完成的临床试验清单'可被翻译为：Inventory of Clinical Trials Ongoing and Completed during the Reporting Period\n'报告周期内严重不良反应的行列表'可被翻译为：Line Listings of Serious Adverse Reactions during the Reporting Period\n\n根据上述已知信息，请将'下列各项已被确认为报告周期内的重要潜 在风险：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The following have been recognised as important potential risks during the reporting period:"
    },
    {
        "instruction":"已知信息：\n'但如果可提供综合测量，则可以使用这些数据来形成与接受治疗的受试者进行比较的基础，以估计药物疗效并 检验关于此疗效的假设。'可被翻译为：Summary measures may be available to form the basis of comparisons with treated participants to estimate drug effects and test hypotheses about those effects.\n'还可能会对比试验性抗菌剂的合并安全性数据与参比药物的合并数据。'可被翻译为：A comparison of pooled safety data for the test antibacterial agent versus pooled data for the comparative agents may also be performed.\n'SVR12同历史数据进行比较的单组试验设计应在方案中事先规定疗效比较 的历史比率。'可被翻译为：Single-arm trial designs where the SVR12 is compared to historical rates should prespecify the historical rate in the protocol for efficacy comparisons.\n'是指正式完成临床试验前，比较处理组间的有效性或安全性所做的任何分析。'可被翻译为：Any analysis intended to compare treatment arms with respect to efficacy or safety at any time prior to the formal completion of a trial.\n\n根据上述已知信息，请将'然而，安全性和有效性 数据可能来自剂量或疗程比较或单组历史对照试验。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"However, safety and efficacy data can be derived from dose or treatment duration comparison or single-arm, historical control trials."
    },
    {
        "instruction":"已知信息：\n'这些做法导致不正确的剂量 和错误药物错误。'可被翻译为：These practices have led to incorrect doses and wrong-drug errors.\n'如果产品的规格在容器标签 上显示地不清楚，或表述用的计量单位与计量说明上所使用的计量单位不一致，就 有可能会导致选择和配给错误的剂量（即，用药过量或用药不足）。'可被翻译为：If the product strength is not clearly displayed on the container label, or is expressed in units of measure that are incongruent with those used in the dosing instructions, the wrong strength can be selected or the wrong dose administered (i.e., over- or under-dosing).\n'产生与药物的剂量和给药不一致的剂量的刻 痕可导致用药错误，应该避免。'可被翻译为：Scores that produce doses that are incongruent with the dosage and administration of a drug have led to medication dosing errors and should be avoided.\n'3. 剂量与给药'可被翻译为：3. Dosage and Administration\n\n根据上述已知信息，请将'开发与产品的剂量和给药不一致的产 品规格使得剂量的计算、制备和给药复杂化并且导致用药错误。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Developing a product strength that is incongruent with the dosage and administration of the product complicates the calculation, preparation, and administration of a dose and has led to medication dosing errors."
    },
    {
        "instruction":"已知信息：\n'在评价光稳定性结果以确定光暴露引起的变化是否可以接受时，要综合考虑其他正式的稳定性研究结果，以确保药品在货架期内符合其质量标准的规定（见ICH稳定性和杂质指导原则）。'可被翻译为：When evaluating the results of photostability studies to determine whether change due to exposure to light is acceptable, it is important to consider the results obtained from other formal stability studies in order to assure that the product will be within proposed specifications during the shelf life (see the relevant ICH Stability and Impurity Guidelines).\n'有些制剂如输液、皮肤乳膏等，还应进行一些附加试验以证明其使用时的光稳定性；试验的设计取决于制剂的使用方式，申请者可自行考虑。'可被翻译为：It may be appropriate to test certain products such as infusion liquids, dermal creams, etc., to support their photostability in-use. The extent of this testing should depend on and relate to the directions for use, and is left to the applicant’s discretion.\n'制剂光稳定性试验决策流程图 \n测试开始 \n直接暴露在光线下 \n可接受的改变 \n是 \n制剂成分改变？ \n否 \n内包装发生改变？ \n否 \n是 \n是 \n内包装 \n可接受的改变 \n上市销售时的包装 \n可接受的改变 \n上市销售时的包装发生改变 \n重新设计包装或者重新研究制剂组成 \n否 \n测试结束 \n是 \n测试结束 \n是 \n测试结束 \n否 \n否'可被翻译为：DECISION FLOW CHART FOR PHOTOSTABILITY TESTING OF DRUG PRODUCTS \nSTART \nDIRECTLY EXPOSED \nACCEPTANCE CHANGE \nYES \nFORMULATION CHANGE? \nNO \nIMMEDIATE PACK CHANGE? \nNO \nYES \nYES \nIMMEDIATE PACK \nACCEPTANCE CHANGE? \nMARKETING PACK \nACCEPTANCE CHANGE \nMARKETING PACK CHANGE? \nREDESIGN PACKAGE OR REFORMULATION \nNO \nTEST END \nYES \nTEST END \nYES \nTEST END \nNO \nNO\n'通常，制剂的光稳定性研究应进行一系列的试验。首先，制剂应完全暴露进行试验；如有必要，以内包装进行试验； 如再有必要，以上市包装进行试验。'可被翻译为：Normally, the studies on drug products should be carried out in a sequential manner starting with testing the fully exposed product then progressing as necessary to the product in the immediate pack and then in the marketing pack.\n\n根据上述已知信息，请将'制剂测试范围应依据“制剂光稳定性决策流程图”，通过评估光暴露试验结束时是否产生了可接受的变化来进行设计。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The extent of drug product testing should be established by assessing whether or not acceptable change has occurred at the end of the light exposure testing as described in the Decision Flow Chart for Photostability Testing of Drug Products."
    },
    {
        "instruction":"已知信息：\n'这个附录大多是基于法案第505(b)条和21 CFR部分314中的条例。因此，这个部分含有广泛的强制性语言。当FDA法规要求提交特定资料时使用这种强制性语言。与其他指导原则文件不同（其中强制性语言通常附带相关引用，以使指导原则更加用户友好和不那么繁琐），每次进行要求讨论时我们没有列举各项规章制度。'可被翻译为：This Appendix is based extensively on section 505(b) of the Act and regulations in 21 CFR part 314. As a result, this section contains extensive mandatory language. This mandatory language is used whenever FDA regulations require the submission of certain information. Unlike other guidance documents in which mandatory language is typically accompanied by the related cite, to make the guidance more user friendly and less cumbersome, we do not cite each regulation each time we discuss a requirement.\n'因为本指导原则非常详细的讨论了NDA（尤其是5059(b)(2)NDA）或ANDA （505(j)）必须提交的内容，所以本指导原则不同于大部分指导原则，其中包含广泛的强制语言，尤其是附录中。当法案和\/或FDA法规要求提交某些信息时使用这种强制性语言。与其他文件不同（其中强制性语言附带相关引用，以使指导原则更加用户友好和不那么繁琐），每次进行要求讨论时我们没有列举各项规章制度。'可被翻译为：Because this guidance discusses in great detail what must be submitted in an NDA (particularly a 505(b)(2) NDA) or an ANDA (505(j)), the guidance differs from most guidances in that it contains extensive mandatory language, especially in the Appendices. This mandatory language is used whenever the Act and\/or FDA regulations require the submission of certain information. Unlike other documents in which mandatory language is accompanied by the related cite, to make the guidance more user friendly and less cumbersome, we do not cite each regulation each time we discuss a requirement.\n'参见FD&C Act的506(c)部分；21 CFR第314部分，第H分部分。'可被翻译为：See section 506(c) of the FD&C Act; 21 CFR part 314, subpart H.\n'新修订的法案赋予FDA 执行505(o)(3)(E)(ii)部分要求上市后研究和临床试验的权利22。申请人未能遵守时间表、提交定期报告以及法案505(o)(3)(E)(ii)部分的其他规定，除非申请人能够证实不一致行为有很好的理由，否则将被视为违规。依 据法案第505(o)(3)(E)(ii)部分，授权FDA确定什么构成正当理由。此外，依据第 505(p)(2)部分，未进行H和E分章（21 CFR 314.510和601.41）要求的上市后研究或试验可采用强制性措施。'可被翻译为：The new amendments to the Act give FDA authority to enforce the section 505(o)(3)(E)(ii) requirements for postmarketing studies and clinical trials.22 An applicant’s failure to comply with the timetable, periodic report submissions, and other requirements of section 505(o)(3)(E)(ii) will be considered a violation unless the applicant demonstrates good cause for the noncompliance. Under section 505(o)(3)(E)(ii) of the Act, FDA is authorized to determine what constitutes good cause. In addition, under section 505(p)(2), failure to conduct a postmarketing study or trial required under subparts H and E (21 CFR 314.510 and 601.41) may result in enforcement action.\n\n根据上述已知信息，请将'这部分的指导原则大多是基于法案第505(j)条和21 CFR部分314，子部分C 中的法规。因此，这个部分含有广泛的强制性语言。当FDA法规要求提交特定资料时使用这种强制性语言。不同于其他指导原则文件（其中强制性语言通常附带相关引用，以使指导原则更加用户友好和不那么繁琐），每次进行要求讨论时我们没有列举各项规章制度。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"This section of the guidance is based largely on section 505(j) of the Act and regulations in 21 CFR part 314, subpart C. As a result, this section contains extensive mandatory language. This mandatory language is used whenever the Act and\/or FDA regulations require the submission of certain information. Unlike other guidance documents in which mandatory language is typically accompanied by the related cite, to make the guidance more user friendly and less cumbersome, we do not cite each regulation each time we discuss a requirement."
    },
    {
        "instruction":"已知信息：\n'所有PBRER应使用完整的ICH指导原则E2C（R2）格式。'可被翻译为：The full ICH Guideline E2C(R2) format should be used for all PBRERs.\n'本 IG 中的信息传递规范是由 ICH 各方使用并认可的统一规则。'可被翻译为：The messaging specifications in this IG are the agreed, harmonised rules used by the ICH parties.\n'个例安全报告电子传输的信息传输规范 个例执行指导原则 （ICH ICSR消息版本3.96）'可被翻译为：Electronic Transmission of Individual Case Safety Reports Message Specification Implementation Guide (ICH ICSR Message Version 3.96)\n'本 IG 中提供的OID应用于ICH ICSR的XML消息传输；'可被翻译为：The OIDs provided in this IG should be used in XML messages for the ICH ICSR;\n\n根据上述已知信息，请将'本指导原则所依据的信息标准完全有能力传输全面的所依据的 ICSR消息。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The message standard from which this guidance is derived is fully capable of conveying a comprehensive ICSR."
    },
    {
        "instruction":"已知信息：\n'第三十六条 供儿童使用的化妆品应当符合法律、法规、强制性国家标准、技术规范以及化妆品生产质量管理规范等关于儿童化妆品质量安全的要求，并按照国家药品监督管理局的规定在产品标签上进行标注。'可被翻译为：Article 36 Cosmetics for children shall comply with requirements for quality and safety of cosmetics for children in laws, regulations, mandatory national standards, technical specifications, and Good Manufacturing Practice for Cosmetics, etc., and shall be indicated on the product label as specified by the NMPA.\n'二、自2022年5月1日起，申请注册或者进行备案的儿童化妆品，必须按照《规定》进行标签标识；此前申请注册或者进行备案的儿童化妆品，未按照《规定》进行标签标识的，化妆品注册人、备案人应当在2023年5月1日前完成产品标签的更新，使其符合《规定》。'可被翻译为：II. As of May 1, 2022, children's cosmetics under application for registration profiling must be labeled according to the Provisions; as for the children's cosmetics for which registration or filing application has been previously made and labeling and identification fails to comply with the Provisions, the cosmetics registrants and filing applicants must complete the update of product labels prior to May 1,2023, so as to make them comply with the Provisions.\n'第二十六条 化妆品注册人、备案人委托生产化妆品的，应当委托取得相应化妆品生产许可的生产企业生产，并对其生产活动全过程进行监督，对委托生产的化妆品的质量安全负责。受托生产企业应当具备相应的生产条件，并依照法律、法规、强制性国家标准、技术规范和合同约定组织生产，对生产活动负责，接受委托方的监督。'可被翻译为：Article 26 If the registrant or the filing entity of cosmetics entrusts manufacturing of cosmetics, it shall entrust one that has obtained the manufacturing license for the relevant cosmetics, and shall supervise the whole manufacturing process of the entrusted enterprise, and be responsible for quality and safety of the cosmetics entrusted with manufacturing. The contract manufacturer shall have the corresponding manufacturing conditions, and organize manufacturing in accordance with the laws, regulations, mandatory national standards, technical specifications and contractual agreements, be responsible for the manufacturing and be supervised by the entrusting party.\n'特别需要注意的是，事实上，儿童和成人的不良反应谱可能不同（如非甾体类抗炎药胃肠道不良事 件较少但是中枢神经系统的不良事件较多）。'可被翻译为：Special attention should be paid to the fact that the spectrum of adverse reactions might differ in children in comparison to adults (e.g. with NSAIDs less gastrointestinal but more central nervous system adverse events).\n\n根据上述已知信息，请将'具备儿童护肤类、眼部护肤类化妆品生产条件的，应当在生产许可项目中特别标注。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For those who have the manufacturing conditions of children's skin care and eye care cosmetics shall be specially indicated in the manufacturing licensed items."
    },
    {
        "instruction":"已知信息：\n'C ABECB-COPD门诊患者的安慰剂对照试验'可被翻译为：C. Placebo-controlled trials enrolling outpatients with ABECB-COPD:\n'附录A：在安慰剂对照试验中鉴定ABECB-COPD患者的分层方法'可被翻译为：APPENDIX A: STRATIFIED APPROACH FOR CHARACTERIZING PATIENTS WITH ABECB-COPD IN PLACEBO-CONTROLLED TRIALS\n'21 见参考文献章节A治疗指导方针和ABECB-COPD的审核'可被翻译为：21 See References, section A., Treatment guidelines and reviews of ABECB-COPD.\n'我们确定了8项入选了ABECB-COPD门诊患者的安慰剂对照试验。24在这些试验中，三项使用了以下未整合患者症状信息的结局指标：（1）ABECB-COPD 平均持续时间；（2）对所见临床体征的评估；（3）肺功能检测。这三项试验采用这些不同的结局指标都未能证明抗菌药和安慰剂之间存在差异。'可被翻译为：We identified eight placebo-controlled trials that enrolled outpatients with ABECB-COPD.24 Among these trials, three used the following outcome measures that did not incorporate information about patient symptoms: (1) mean duration of ABECB-COPD; (2) assessments of observed clinical signs; and (3) pulmonary function testing. None of these three trials demonstrated a difference between antibacterial drugs and placebo with the use of these different outcome measures.\n\n根据上述已知信息，请将'24 见参考文献章节CABECB-COPD门诊患者的安慰剂对照试验'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"24 See References, section C., Placebo-controlled trials enrolling outpatients with ABECB-COPD."
    },
    {
        "instruction":"已知信息：\n'重复使用NDC号数易导致错误药物或错误规格 的分发或给药。'可被翻译为：The reuse of NDC numbers has led to the dispensing and administration of the wrong drug or wrong strength.\n'在“公司或监管机构名称”中应避免使用“-”（破折号\/连字符）。'可被翻译为：The use of a ‘-’ (dash\/hyphen) should be avoided in the ‘company or regulator name’.\n'我们也强烈鼓励包括到期日期和NDC号码。'可被翻译为：We also strongly encourage including the expiration date and NDC number.\n'重复使用的，过滤器应专用于单个产 品，并在重复使用之前灭菌。'可被翻译为：If re-258 used, the filter should be dedicated to a single product and sterilised before re-use.\n\n根据上述已知信息，请将'例如：xxxx-xxxx-xx。 应避免重复使用NDC号码。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For example: XXXX-XXXX-XX.  Avoid the reuse of NDC numbers."
    },
    {
        "instruction":"已知信息：\n'第五十九条 高活性的物料或产品以及印刷包装材料应当贮存于安全的区域。'可被翻译为：Article 59 Highly active materials or products and printed packaging materials should be stored in safe and secure areas.\n'应按照相应的国家\/地区的要求，在标签上说明贮藏条件。'可被翻译为：A storage statement should be established for the labeling in accordance with relevant national\/regional requirements.\n'第二百二十九条 物料的放行应当至少符合以下要求：'可被翻译为：Article 229 The following requirements should at least be met in materials release:\n'第二百二十九条 物料的放行应当至少符合以下要求：'可被翻译为：Article 229: The following requirements should at least be met in materials release:\n\n根据上述已知信息，请将'第五十九条 高活性的物料或产品以及印刷包装材料应当 贮存于安全的区域。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 59: Highly active materials or products and printed packaging materials should be stored in safe and secure areas."
    },
    {
        "instruction":"已知信息：\n'应该根据产品的描述和目标适应症评估特殊人群。'可被翻译为：This should be assessed as dictated by the product and the target indication.\n'为了优化获益-风险，确定治疗的合适目标人群是必不可少的。'可被翻译为：In order to optimise benefit – risk, it is essential to identify the proper target population for therapy.\n'如果适应症中的人群 之间的利益 - 风险特征存在重大差异，则尽可能由按人群展示利益 - 风险评 估。'可被翻译为：If there are important differences in the benefit-risk profiles among populations within an indication, benefit-risk evaluation should be presented by population, if possible.\n'利益-风险分析评估'可被翻译为：Benefit-Risk Analysis Evaluation\n\n根据上述已知信息，请将'3.18.2 利益-风险分析评估 利益-风险特征是根据适应症和人群特定的。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"3.18.2 Benefit-Risk Analysis Evaluation A benefit-risk profile is specific to an indication and population."
    },
    {
        "instruction":"已知信息：\n'（四）除试验方案或者其他文件中规定不需立即报告的 SAE外，研究者立即向申办者书面报告所有 SAE， 随后及时提供详尽、书面的随访报告。'可被翻译为：(4) Except for SAEs that do not require immediate reporting as specified in the trial protocol or other documents, the investigator shall immediately report all SAEs to the sponsor in writing, and then provide a detailed and written follow-up report in a timely manner.\n'因此，早期治疗的结果(识 别对治疗有反应的受试者并继续接受治疗)可通过一个严格 的基本无假设、无偏倚的研究来证实。'可被翻译为：The results of the initial period of treatment, in which subjects who appear to respond are identified and maintained on therapy, are thus \"validated\" by a rigorous, largely assumption- and bias-free study.\n'退出试验的受试者在退出前可能已经发生了伴发 事件。'可被翻译为：Subjects who withdraw from the trial may have experienced an intercurrent event before withdrawal.\n'重要的是，应提交一份风险管理计划，其中包括对批准后的长期数据的规定的测量，用于评估是否发生了相关的恶性肿瘤。'可被翻译为：Importantly, a risk management plan should be submitted that includes measures for provision of long term data post authorisation to assess the development of related malignancies.\n\n根据上述已知信息，请将'在批准后 6个月内 发生了4 例明显无 混杂因素 的报告； 至事件发 生的时间 合理 对一家医 院进行研 究中心访 视得出的 定向随访 报告。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"4 apparently unconfounded reports within 6 months of approval; plausible time to onset. targeted follow up of reports with site visit to one hospital."
    },
    {
        "instruction":"已知信息：\n'固定化酶'可被翻译为：immobilized enzyme\n'凝固酶'可被翻译为：coagulase\n'一种酶的电极，酶常被放在电极周围的凝胶基质中或电极周围玻璃纸膜中的液膜内。这类电极可特异性地测定该酶所催化反应中反应物或反应产物的浓度。'可被翻译为：The electrode of an enzyme, the enzyme is often placed in a gel matrix around the electrode or in a liquid film in the cellophane film around the electrode. These electrodes can specifically determine the concentration of the reactant or reaction product in the reaction catalyzed by the enzyme.\n'一种特殊类型的酶的不可逆抑制剂。与酶活性中心结合前无活性,经过几步正常的酶促反应后转变为反应性极强的化合物,能与催化其反应的酶发生不可逆共价结合而抑制酶活性。'可被翻译为：An irreversible inhibitor of a particular type of enzyme. Inactive before binding to the active center of the enzyme, it is transformed after a few normal enzymatic reactions into a highly reactive compound that can irreversibly covalently bind to the enzyme that catalyzes the reaction and inhibit enzyme activity.\n\n根据上述已知信息，请将'用物理的或化学的方法使酶与水不溶性大分子载体结合或把酶包埋在水不溶性凝胶或半透膜的微囊体中制成的酶。酶固定化后一般稳定性增加，易从反应系统中分离，且易于控制，能反复多次使用。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Enzymes made by physically or chemically binding enzymes to water-insoluble macromolecular carriers or by embedding enzymes in microcapsules of water-insoluble gels or semi-permeable membranes. The general stability of the enzyme after immobilization is increased, it is easy to be separated from the reaction system, and it is easy to control and can be used repeatedly."
    },
    {
        "instruction":"已知信息：\n'本节包含与本IG相关的代码集和OID，但并非由或为ICH专门创建。'可被翻译为：This section contains information on Code Sets and OIDs relevant to this IG but not specifically created by or for ICH.\n'IG 这一章节的表1至表7列出了用于编码ICH ICSR数据元素的所有元素OID。'可被翻译为：Tables 1 through 7 in this section of the IG list all the OIDs used to code the data elements of the ICH ICSR.\n'3.2 E2B（R3）的代码集、术语和词汇'可被翻译为：3.2 Code Sets, Terminologies and Vocabularies for E2B(R3)\n'3.2.1 ICSR消息使用的术语和词汇'可被翻译为：3.2.1 Terminologies and Vocabularies Employed by the ICSR Message\n\n根据上述已知信息，请将'本节将介绍该 IG 中使用的代码集、术语和词汇。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"This section will address the code sets, terminologies and vocabularies used in this IG."
    },
    {
        "instruction":"已知信息：\n'改换时的患者情况的综合数据 必须在病例报告表中记录， 并在研究报告中展示。'可被翻译为：Comprehensive data on the condition of patients at the time of switch must be captured in the case report forms and presented in the study report.\n'入组时，研究者应考察患者的病史并进行体格检查，进而评估患者。入组检查过程中记录在病例报告表中的信息应包括以下：'可被翻译为：At entry, the investigator should evaluate the patient by performing an appropriate history and physical examination. The following information should be recorded on the case report form during the entry examination.\n'正如对当前烟草使用情况的记录一样，应在病例报告表中记录所有可能出现 在ABECB-COPD患者中的症状与体征（症状和患者报告的体征应通过PRO量 表记录）：'可被翻译为：All signs and symptoms that may be present in patients with ABECB-COPD should be captured on the case report form (symptoms and patient-reported signs should be captured by a PRO instrument), as should current tobacco use.\n'（一）病例报告表中入组、知情同意、病史或伴随疾病、访视、给药记录、病情记录等信息与试验源数据和\/或 HIS 系统一致。'可被翻译为：(1) The enrollment, informed consent, medical history or concomitant disease, visit, drug administration, disease record and other information in the case report form are consist with the source data and\/or and HIS system.\n\n根据上述已知信息，请将'研究者应在病例报告表中记录从治疗过程中诊室访视得来的结果（例如，病史，体格检查和实验室检查结果）。如果研究者通过电话或通过其他交互式技术联系患者，则应在病例报告中记录具体的提问、提问的方式和回答。用良好定义且可靠的日记在这次访视中记录患者症状，也应在病例报告表中记录该信息。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Investigators should document findings from on-therapy office visits on the case report form (e.g., history, physical examination, and laboratory test results). If the investigator contacts the patient by telephone or by another interactive technology, documentation of the specific questions asked, how they were asked, and the responses given should be captured on the case report form. If a well-defined and reliable diary is used to capture patient symptoms during this visit, this information also should be recorded on the case report form."
    },
    {
        "instruction":"已知信息：\n'当活性对照研究显示出试验治疗优效于活性治疗时，更 易于解读为有效性的证据。'可被翻译为：Where superiority to an active treatment is shown, active control studies are readily interpretable regarding evidence of efficacy.\n'相比之 下，活性对照试验或剂量比较试验检测的是相对于其他治疗 的效果。'可被翻译为：In contrast, an active control trial or a dose-comparison trial measures the effect relative to another treatment.\n'随后安慰剂组的患者可以转到生物仿制品组，试验继续以两个活性组进行。'可被翻译为：Patients in the placebo arm could be subsequently switched to the biosimilar product and the trial continued with the two active arms.\n'试验组与 安慰剂组之间结果的差异用来评价在该试验条件下所研究 药物的有效性。'可被翻译为：The difference in outcome between the active treatment and placebo groups is the measure of treatment effect under the conditions of the trial.\n\n根据上述已知信息，请将'继续治疗的试验组与随机接受安慰剂的试验组之间出现 的任何差异都可以证明活性治疗的效应。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Any difference that emerges between the group receiving continued treatment and the group randomized to placebo would demonstrate the effect of the active treatment."
    },
    {
        "instruction":"已知信息：\n'如果选择了一种旨在证明检测灵敏度，而不验证非劣效性的方法，尤其是对于与已上市药品有关的特定适应症，那么评价的焦点应为研究药物在其他方面的潜在优势（如安全性更好，或更方便服用，服用时间更灵活等）。'可被翻译为：If an approach documenting assay sensitivity, without confirmative documentation of non-inferiority is chosen, and especially if specific claims in relation to marketed products are intended, the focus of the evaluations should lie on the potential advantages of the investigational compound in other domains (e.g. documenting better safety, ease of administration or administration schedule).\n'应尽可能根据对特定受体部位的作用来评估正在研究的药物类别所特有的潜在 AE 反应。'可被翻译为：Special efforts should be made to assess potential AE reactions that are characteristics of the class of drugs being investigated in view of actions on specific receptor sites.\n'单抗在家给药还是在诊所给药：如有发生，在诊所进行单抗治疗对于输注反应 或过敏性反应的迅速处理是有好处的，但是在家使用皮下给药单抗在病人护理 方面有优势。'可被翻译为：For administration of the mAb at home or in the clinic: Treatment with mAbs in the clinic may offer advantages for immediate mitigation of infusion reactions or anaphylaxis should they occur, but home use for subcutaneously administered mAbs may offer advantages for patient care.\n'应特别关注与在关键试验中计划给药的其他药物之间的安全性 和有效性相互作用。'可被翻译为：Particular attention should be focused on safety and efficacy interactions with other drugs planned to be administered during pivotal trials.\n\n根据上述已知信息，请将'如果选择这种方法，尤其是如果拟定与已上市药品相关的特殊主张， 那么评估的重点应放在该受试化合物是否在其他方面有潜在的优势（如 证实有更 好的安全性，便于给药或较简便的给药计划）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"If such an approach is chosen, especially if specific claims in relation to marketed products are intended, the focus of the evaluations should lie on the potential advantages of the investigational compound in other domains (e.g. documenting better safety, ease of administration or administration schedule)."
    },
    {
        "instruction":"已知信息：\n'已确定的风险 ICH指导原 则E2F 有充分证据显示与所关注的药品有关联的不良事 件。'可被翻译为：Identified risk ICH Guideline E2F An untoward occurrence for which there is adequate evidence of an association with the medicinal product of interest.\n'这份总结允许采用基于风险的方法来评价免疫原性，这意味着授予许可前的免疫原性研究和上市后风险管理计划的程度和类型可根据免疫原性风险及其潜在或实测后果的严重程度而调整。'可被翻译为：This summary allows a risk-based approach to  immunogenicity which means that the extent and type of pre-authorisation immunogenicity studies and post-marketing risk management program are tailored according to the risk of immunogenicity and the severity of its potential or observed consequences.\n'是否开展此类评价应取决于GT产品所需非临床BD分析的程度，采用基于风险的方法来确定。'可被翻译为：Decisions regarding the conduct of such assessments should be based on the extent of nonclinical BD analyses needed for the GT product, which is determined using a risk-based approach.\n'之后由一个多学科团队整合并权衡累积证据，基于现有数据可能的程度，得出关于药物与结局之间的关系的最终结论。'可被翻译为：The accumulated evidence is then integrated and weighed by a multidisciplinary team to reach an overall conclusion, to the extent possible based on the available data, regarding the relationship between the drug and the outcome.\n\n根据上述已知信息，请将'基于现有证据，对免疫原性风险进行充分评价，并且得出适当结论“产品是否构成此类潜在风险”。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The potential for immunogenicity should be fully evaluated based on the available evidence with appropriate conclusions drawn on whether or not a product may pose such a  (potential) risk."
    },
    {
        "instruction":"已知信息：\n'因此，在该人群中的特定研究被认为是不可行的，也是不要求的。'可被翻译为：Therefore specific studies in this population are not considered feasible and are not required.\n'虽然这些研究有时会被认为是使用“病人自 身作对照”，但实际上不存在内部对照。'可被翻译为：Although these studies are sometimes thought to use \"the patient as his own control\", they do not in fact have an internal control.\n'临床研究仅要求纳入正在接受 PPI 治疗且具有典型症状的患者， 因此认为纳 入对标准剂量或双倍剂量的 PPI 治疗无效或效果不佳的患者也同样是可以接受的。'可被翻译为：For the inclusion of patients with typical symptomatology while on PPI therapy into clinical trials, it is therefore considered likewise acceptable that patients are included on the basis of a non-response or insufficient response to PPIs and to standard dose or to double-dose PPI.\n'因此，通常在在诊断和疼痛强度方面具有同质性的试验人群（代表治疗预期适用的全部患者范围的一个子集）中研究有效性。'可被翻译为：Efficacy should in general therefore be studied in a trial population that is homogenous with respect to diagnosis and pain intensity, representing a sub-set of the full range of patients for whom the treatment is expected to be indicated.\n\n根据上述已知信息，请将'认为没有必要让所有纳入这些研究的患者服用相同的PPI，因为可以假定这个人群具有合理的同质性。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"It is not considered necessary that all patients take the same PPI for the inclusion into such trials, as reasonable homogeneity of such a population can be assumed."
    },
    {
        "instruction":"已知信息：\n'0-<12 岁儿童的临床试验应该从药动学研究开始，然后进行疗效和安全性研究，试验应包括 50 名儿童，至少 50EDs。'可被翻译为：The clinical study in children of 0-<12 years should be started  with PK followed by investigation of efficacy and safety for at least  50EDs each in 50 children.\n'0-<12 岁儿童临床试验须从药动学 研究开始，接着对至少 20 名儿童每人进行至少 50ED 的疗效和安全性研究。'可被翻译为：The clinical study in children of 0 - <12 years should be started with PK followed by investigation of efficacy and safety for at least 50 EDs each in 20 children.\n'从各年龄组选出10名患者，从药动学研究（增量回收率、体内半衰期、AUC和清除率）开始开展儿童临床试验。'可被翻译为：The clinical trial in children should begin with the investigation of pharmacokinetics (incremental recovery, in vivo half-life, AUC and clearance) in 10 patients of each age cohort.\n'在申请上市时，须递交 50 名儿童（0 至 12 岁）服药 50 天后的药动学参数（增量回收率、体内半衰期、药时曲线下面积和清除率）以及完整的疗效及安全性试验资料。'可被翻译为：Within the application for marketing authorisation, pharmacokinetic data (incremental recovery, in vivo  half-life, AUC and clearance) as well as the completed efficacy and safety trial in 50 children ( to 0 <12 y) followed for  EDs should be submitted.\n\n根据上述已知信息，请将'儿童临床试验应该从药动学研究（增量回收率、体内半衰期、药时曲线下面积和清除率）开始，每组选出 12 名患者进行研究。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The clinical trial in children should begin with the investigation of pharmacokinetics (incremental  recovery, in vivo half-life, AUC and clearance) in 12 patients of each age cohort."
    },
    {
        "instruction":"已知信息：\n'IRB还必须确定并用文件证明，符合21 CFR 50.24中所列 举的紧急临床研究豁免知情同意的相关规定。（21 CFR 50.24正文参见附录A）此 外，IRB必须确定，该项研究符合 21 CFR第50和56部分的相关要求。'可被翻译为：The IRB must also find and document that the requirements for exception from informed consent for emergency research detailed in 21 CFR 50.24 have been met. (See Appendix A for the text of 21 CFR 50.24.) In addition, the IRB must find that the study meets the relevant requirements of 21 CFR Parts 50 and 56.\n'必须采用知情同意豁免开展该项研究的依据；'可被翻译为：The rationale as to why the study must be conducted using an exception from informed consent;\n'涉及知情同意要求豁免的研究只有在申办方提交了IND或IDE9并事先收到FDA10和IRB书面批准后才可进行（即，IRB必须确定并用文件证明，符合这些法规中的特定要求11 )（21 CFR 50.24正文参见 附录A）'可被翻译为：Studies involving an exception from the informed consent requirements may proceed only after a sponsor has submitted an IND or IDE9 and received prior written authorization from FDA10 and IRB approval (i.e., the IRB must find and document that specific conditions in the regulations have been met11). (See Appendix A for the text of 21 CFR 50.24.)\n'45 根据21CFR50.24，关于涉及知情同意豁免的研究方案，临床研究 者或申办方应向IRB提供哪些信息？'可被翻译为：45. What information should the clinical investigator or sponsor provide to the IRB related to a research protocol involving an exception from informed consent under 21 CFR 50.24?\n\n根据上述已知信息，请将'7 IRB必须确定并用文件证明哪些信息，才可开展一项涉及豁免知情同意的研究？'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"7. What must the IRB find and document in order for a study involving an exception from informed consent to proceed?"
    },
    {
        "instruction":"已知信息：\n'在研究设计过 程中尽早与患者沟通有助于这种方法，并最终有助于确定关 键质量因素。'可被翻译为：Patient consultation early in the study design process can contribute to this approach and ultimately help to identify the critical to quality factors.\n'鼓励监管机构早期介入，以了解当地\/地区的要求和期 望，并有助于促进将质量设计融入研究中的能力。'可被翻译为：Early engagement with regulatory authorities to understand local\/regional requirements and expectations is encouraged and will facilitate the ability to design quality into the study.\n'FDA鼓励申办方尽早与临床研究者和IRB 合作，制订策略和公开披露信息样本。'可被翻译为：FDA encourages sponsors to work with clinical investigators and IRBs in developing model strategies and information for public disclosure as early as possible.\n'本指导原则一般适用于人用新化学实体和生物制品。某些情况下（例如当出现临床不良事件、新用药人群或新给药途径引起新的安全性担忧时），也适用于已上市药品。'可被翻译为：This guideline generally applies to new chemical entities and biotechnology-derived products for human use. This guideline can be applied to marketed pharmaceuticals when appropriate (e.g., when adverse clinical events, a new patient population, or a new route of administration raises concerns not previously addressed).\n\n根据上述已知信息，请将'鼓励尽早与监管机构沟通，尤其是当一项研究出现可能 影响质量的新关键要素（例如：确定患者人群、程序或终点） 时。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Early engagement with regulatory authorities is encouraged, particularly when a study has novel elements considered critical to quality (e.g., defining patient populations, procedures, or endpoints)."
    },
    {
        "instruction":"已知信息：\n'对于可显著影响主要结局的因素（例如CHADS2评分，研究中心等）可能需要分层随机。'可被翻译为：A stratified randomization may be needed to account for factors that may significantly influence the primary outcome (e.g. CHADS2 score, study centre, etc).\n'随机化应该相应地分层。'可被翻译为：Randomisation should be stratified accordingly.\n'强烈建议根据指标事件进行亚组分析（连同招募两种类型指标 VTE（DVT 和\/或PE）的临床试验中分层随机，见第6.1节）并且鼓励阐明与以下情相关的结局：'可被翻译为：Subgroup analyses are strongly encouraged according to index event (together with stratified randomization in trials recruiting both types of index VTE, DVT and\/or PE, see section 6.1) and are encouraged to illustrate outcome in relation to:\n'如果任何基线因素本身会显著影响预后，应事先考虑根据这些因素进行分层。'可被翻译为：If any baseline factors may in themselves significantly influence prognosis, prior stratification according to these factors should be considered.\n\n根据上述已知信息，请将'对于可显著影响主要结局的因素（如指数DVT或PE，研究中心等）可能需要采用分层随机。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Stratified randomisation may be needed to account for factors that may significantly influence the primary outcome (e.g. index DVT or PE, study centre, etc)."
    },
    {
        "instruction":"已知信息：\n'E.i反应\/事件（必要时重复）'可被翻译为：E.i REACTION(S)\/EVENT(S) (REPEAT AS NECESSARY)\n'○ E -反应\/事件；'可被翻译为：o E - Reaction(s)\/ Event(s);\n'E.i.1.2主要来源用于翻译报告的反应\/事件'可被翻译为：E.i.1.2 Reaction \/ Event as Reported by the Primary Source for Translation\n'E.i.2.1a用于反应\/事件的MedDRA版本'可被翻译为：E.i.2.1 Reaction \/ Event (MedDRA code)\n\n根据上述已知信息，请将'E -反应\/事件 1„n E.i -反应\/事件（必要时重复） E.i.1.1 -主要来源使用母语报告的反应\/事件 E.i.1.1b -主要来源语言报告的反应\/事件 E.i.1.2 -主要来源用于翻译报告的反应\/事件 E.i.2.1a -用于反应\/事件的MedDRA版本 E.i.2.1b ––MedDRA术语中的反应\/事件编码 E.I.3.1 -由报告者强调的术语 E.i.3.2 -事件层面的严重性标准 E.i.3.2a -导致死亡 E.i.3.2b -危及生命 E.i.3.2c -导致\/延长住院 E.i.3.2d –残疾\/功能丧失–残疾功能丧失 AESCONG -先天性异常或出生缺陷 E.i.3.2f -其他重要医学事件其他重要医学事件 E.i.4 -反应\/事件开始日期 E.i.5 -反应\/事件结束日期 E.i.6a -反应\/事件持续时间 E.i.6b -反应\/事件持续时间（持续时间单位） E.i.7 -末次观察时反应\/事件的结果 E.i.8 -医疗保健专业人士的医学确认 E.i.9 -发生反应\/事件的国家识别'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"E.i - Reaction(s)\/Event(s) (repeat as necessary) 1 ... n E - Reaction(s)\/Event(s) E.i.1.1a - Reaction \/ Event as Reported by the Primary Source in Native Language E.i.1.1b - Reaction \/ Event as Reported by the Primary Source Language E.i.1.2 - Reaction \/ Event as Reported by the Primary Source for Translation E.i.2.1a - MedDRA Version for Reaction \/ Event E.i.2.1b - Reaction \/ Event (MedDRA code) E.i.3.1 - Term Highlighted by the Reporter E.i.3.2 - Seriousness Criteria at Event Level E.i.3.2a - Results in Death E.i.3.2b - Life Threatening E.i.3.2c - Caused \/ Prolonged Hospitalisation E.i.3.2d - Disabling \/ Incapacitating E.i.3.2e - Congenital Anomaly \/ Birth Defect E.i.3.2f - Other Medically Important Condition E.i.4 - Date of Start of Reaction \/ Event E.i.5 - Date of End of Reaction \/ Event E.i.6a - Duration of Reaction \/ Event E.i.6b - Duration of Reaction \/ Event (duration unit) E.i.7 - Outcome of Reaction \/ Event at the Time of Last Observation E.i.8 - Medical Confirmation by Healthcare Professional E.i.9 - Identification of the Country Where the Reaction \/ Event Occurred"
    },
    {
        "instruction":"已知信息：\n'国家药监局关于发布天门冬氨酸氨基转移酶测定试剂等4项注册技术审查指导原则的通告'可被翻译为：NMPA Issued Four Guidelines for Technical Review of the Registration of Assay Reagents for Aspartate Aminotransferase and Others\n'为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局组织制定并于2020年3月5日发布了《胶体金免疫层析分析仪注册技术审查指导原则》《促卵泡生成素检测试剂注册技术审查指导原则》《肌酐检测试剂注册技术审查指导原则》《抗核抗体检测试剂注册技术审查指导原则》《抗甲状腺过氧化物酶抗体测定试剂注册技术审查指导原则》《糖化白蛋白测定试剂注册技术审查指导原则》和《总胆汁酸测定试剂注册技术审查指导原则》。'可被翻译为：To strengthen the supervision and guidance over the registration of medical device products and further improve the quality of registration review, NMPA has organized the formulation of and released on March 5, 2020 the Guidelines for Technical Review of the Registration of Colloidal Gold Immunochromatographic Analyzers, Guidelines for Technical Review of the Registration of Follicle stimulating Hormone Detection Reagents, Guidelines for Technical Review of the Registration of Creatinine Detection Reagents, Guidelines for Technical Review of the Registration of Antinuclear Antibody Detection Reagents, Guidelines for Technical Review of the Registration of Antithyroid Peroxidase Antibody Assay Reagents, Guidelines for Technical Review of the Registration of Glycated Albumin Assay Reagents, and the Guidelines for Technical Review of the Registration of Total Bile Acid Assay Reagents.\n'为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局于2020年3月10日组织制定并发布了《EB病毒核酸检测试剂注册技术审查指导原则》《乙型肝炎病毒e抗原、e抗体检测试剂注册技术审查指导原则》《地中海贫血相关基因检测试剂注册技术审查指导原则》《乙型肝炎病毒耐药相关的基因突变检测试剂注册技术审查指导原则》。'可被翻译为：To strengthen the supervision and guidance over the registration of medical device products and further improve the quality of registration review, NMPA has organized the formulation of and released on March 10, 2020 the Guidelines for Technical Review of the Registration of EB Virus Nucleic Acid Detection Reagents, Guidelines for Technical Review of the Registration of HBV e Antigen, e Antibody Detection Reagents, Guidelines for Technical Review of the Registration of Thalassemia-Related Gene Detection Reagents, and Guidelines for Technical Review of the Registration of HBV-Resistant Gene Mutation Detection Reagents.\n'为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局组织制定了《肺炎支原体IgM\/IgG抗体检测试剂注册技术审查指导原则》《隐球菌荚膜多糖抗原检测试剂注册技术审查指导原则》和《遗传性耳聋相关基因突变检测试剂注册技术审查指导原则》，于2021年1月18日予以发布。'可被翻译为：To strengthen the supervision and guidance over the registration of medical device products and further improve the quality of registration review, NMPA has organized the formulation of and released on January 18, 2021 the Guidelines for Technical Review of the Registration of Mycoplasma Pneumoniae IgM\/IgG Antibody Detection Reagents, Guidelines for Technical Review of the Registration of Cryptococcus Capsular Polysaccharide Antigen Detection Reagents, and Guidelines for Technical Review of the Registration of Hereditary Hearing Loss Gene Mutation Detection Reagents.\n\n根据上述已知信息，请将'为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局于2019年10月29日组织制定并发布了《天门冬氨酸氨基转移酶测定试剂注册技术审查指导原则》《总胆固醇测定试剂注册技术审查指导原则》《尿酸测定试剂注册技术审查指导原则》和《尿素测定试剂注册技术审查指导原则》。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"To strengthen the supervision and guidance over medical device product registration and further improve the quality of registration review, NMPA has organized the formulation of and released on October 29, 2019 the Guidelines for Technical Review of the Registration of Assay Reagents for Aspartate Aminotransferase, Guidelines for Technical Review of the Registration of Total Cholesterol Assay Reagents, Guidelines for the Technical Review of Registration of Uric Acid Determination Reagents, and Guidelines for Technical Review of the Registration of Urea Determination Reagents."
    },
    {
        "instruction":"已知信息：\n'父母要素 父母值 孩子要素 孩子值 C.1.5本报告最新资料的日期 2月2日 G.k.2药物识别 k=1 ‘戒烟 G.k.8 针对药物采取的措施 k=1 '停用药物 G.k.4.r 剂量及相关信 息 k=1, 1月1日: 0.5mg\/日, 口服 7 日 r=1 k=1, 1月8日: 1mg \/日, 口服7 日 r=2 k=1, 1月15-29日:1mg 每日两次, 口服 (已停用) r=3 G.k.9.'可被翻译为：Parent Element Parent Value Child Element Child Value C.1.5 Date of Most Recent Information for This Report February 2nd G.k.2 Drug Identification k=1 ‘QuitSmoking’ G.k.8 Action(s) Taken with Drug k=1 'drug withdrawn’ G.k.4.r Dosage and Relevant Information k=1, r=1 January 1st: 0.5mg daily, orally, x 7 days k=1, r=2 January 8th: 1mg daily, orally, x 7 days k=1, r=3 January 15th -29th:1mg twice daily, orally (stopped) G.k.9.\n'G.k.4.r.1a剂量（数）'可被翻译为：G.k.4.r.1a Dose (number)\n'Mk=药品最大日摄入量中k组分的量（g）'可被翻译为：Mk = mass of component k in the maximum daily intake of the drug product (g)\n'对于Cmax，蓄积因子采用3.2，该值按下列方程式估算而得：蓄积=1\/(1–e–k∙tau)，k=0.693\/t½， t½=14.924 小时，tau=8 小时（即，1\/(1–e–0.372)=1\/(1–0.690)=1\/0.31=3.2）。'可被翻译为：For Cmax, an accumulation factor of 3.2 was applied that was estimated from the equation: accumulation = 1\/(1 – e–k∙tau), where k = 0.693\/t½ with t½ = 14.924 hours and tau = 8 hours (i.e., 1\/(1 – e–0.372) = 1\/(1 – 0.690) = 1\/0.31 = 3.2).\n\n根据上述已知信息，请将'父母要素 父母值 孩子要素 孩子值 C.1.5本报告最新资料的日期 3月15日 G.k.2药物识别 k=1 ‘戒烟 G.k.8 针对药物采取的措施 k=1 '未知 G.k.4.r 剂量及相关信息 k=1, 1月1日: 0.5mg\/日, 连续口服 7 日 r=1 k=1, 1月8日: 1mg \/日, 连续口服7 日 r=2 k=1, 1月15-29日:1mg 每日两次, 口服 (已停用) r=3 k=1, 2月13日，未知，未知 r=4 G.k.9.'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Parent Element Parent Value Child Element Child Value C.1.5 Date of Most Recent Information for This Report March 15th G.k.2 Drug Identification k=1 ‘QuitSmoking’ G.k.8 Action(s) Taken with Drug k=1 ‘Unknown’ G.k.4.r Dosage and Relevant Information k=1, r=1 January 1st: 0.5mg daily, orally, x 7 days duration k=1, r=2 January 8th: 1mg daily, orally, x 7 days duration k=1, r=3 January 15th -29th: 1mg twice daily, orally (stopped) k=1, r=4 February 13th: unknown, unknown G.k.9."
    },
    {
        "instruction":"已知信息：\n'本部分不适用于根据本章第1部分的L部分要求建立或维护的记录。符合本章第1部分的L部分要求的同时也是其他适用的法规和条例所要求的记录，仍受本部分的约束。'可被翻译为：This part does not apply to records required to be established or maintained by subpart L of part 1 of this chapter. Records that satisfy the requirements of subpart L of part 1 of this chapter, but that also are required under other applicable statutory provisions or regulations, remain subject to this part.\n'本部分不适用于根据本章第1部分的O部分要求建立或维护的记录。符合本章第1部分的O部分要求的同时也是其他适用的法规和条例所要求的记录，仍受本部分的约束。'可被翻译为：This part does not apply to records required to be established or maintained by subpart O of part 1 of this chapter. Records that satisfy the requirements of subpart O of part 1 of this chapter, but that also are required under other applicable statutory provisions or regulations, remain subject to this part.\n'本部分不适用于根据本章第507部分要求建立或维护的记录。符合本章第507部分要求的同时也是其他适用的法规和条例所要求的记录，仍受本部分的约束。'可被翻译为：This part does not apply to records required to be established or maintained by part 507 of this chapter. Records that satisfy the requirements of part 507 of this chapter, but that also are required under other applicable statutory provisions or regulations, remain subject to this part.\n'本部分不适用于根据本章第112部分要求建立或维护的记录。符合本章第112部分要求的同时 也是其他适用的法规和条例所要求的记录，仍受本部分的约束。'可被翻译为：This part does not apply to records required to be established or maintained by part 112 of this chapter. Records that satisfy the requirements of part 112 of this chapter, but that also are required under other applicable statutory provisions or regulations, remain subject to this part.\n\n根据上述已知信息，请将'本部分不适用于根据本章第1部分的M部分要求建立或维护的记录。符合本章第1部分的M部分要求的同时也是其他适用的法规和条例所要求的记录，仍受本部分的约束。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"This part does not apply to records required to be established or maintained by subpart M of part 1 of this chapter. Records that satisfy the requirements of subpart M of part 1 of this chapter, but that also are required under other applicable statutory provisions or regulations, remain subject to this part."
    },
    {
        "instruction":"已知信息：\n'5.4.2 对体内微核试验阳性结果的追加'可被翻译为：5.4.2 Follow-up to a Positive In Vivo Micronucleus Assay\n'①一个明确的阳性结果，因此总体结果为阳性；'可被翻译为：(i) a clearly positive outcome, and thus an overall positive result;\n'在体内，吸入约25,000ppm乙基氯3天后，小鼠骨髓微核试验以及雌性小鼠肝脏非程序性DNA合成（UDS）试验（参考文献5）结果均为阴性。'可被翻译为：In vivo ethyl chloride was negative in a mouse bone marrow micronucleus test after inhalation at approximately 25,000 ppm for 3 days, and in an Unscheduled DNA Synthesis (UDS) assay in female mouse liver (Ref. 5).\n'环氧丙醇灌胃给予雄性和雌性P16Ink4a \/ p19Arf 单基因突变的小鼠，体内微核试验结果呈阳性。'可被翻译为：In vivo, glycidol was positive in a mouse micronucleus assay by oral gavage in male and female P16Ink4a\/p19Arf haploinsufficient mice.\n\n根据上述已知信息，请将'体内微核试验显示阳性结果（参考文献3）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In vivo, positive results were seen in the micronucleus assay (Ref. 3)."
    },
    {
        "instruction":"已知信息：\n'疼痛的治疗在临床实践中是一个挑战，因为并非所有患者对可用治疗反应充分，并且不良反应的负担可能很高。'可被翻译为：Treatment of pain is a challenge in clinical practice as not all patients respond sufficiently to available treatments and the burden of adverse reactions may be high.\n'因此，除非明确显示适应不良的特征，否则这些疼痛模型不被认为适合于支持慢性疼痛适应症。 然而，具有长期伤害性疼痛但没有突出的适应不良特征的患者形成适当的患者人群用于试验， 以表征主要用于治疗急性疼痛的药品的有效性维持。'可被翻译为：Thus, unless maladaptive characteristics are clearly shown, these pain models are not regarded as appropriate to support a chronic pain indication. Patients with long-standing nociceptive pain without prominent maladaptive features do however form an appropriate patient population for trials to characterise maintenance of efficacy for medicinal products intended primarily for the treatment of acute pain.\n'在临床实践中，难以表征个体患者中的这些不同的病理生理学方面。'可被翻译为：In clinical practice it is difficult to characterise these different pathophysiological aspects in individual patients.\n'目前，在慢性疼痛患者中伤害性和神经性组分的贡献在一般临床实践中不进行常规评价。'可被翻译为：At present the contribution of nociceptive and neuropathic components in patients with chronic pain is not routinely evaluated in general clinical practice.\n\n根据上述已知信息，请将'区分这些患者与适应不良的慢性疼痛患者（其中潜在的病理生理学是不同的）可能是 困难的，并且目前在一般的临床实践中是不常见的。 关于如何应对这些挑战的建议在以下章节中概述。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Distinguishing these patients from maladaptive chronic pain, in whom the underlying pathophysiology is different, can be difficult and is currently uncommon in general clinical practice. Recommendations on how to address these challenges are outlined in the following chapters."
    },
    {
        "instruction":"已知信息：\n'（五）研究者按照临床试验方案规定的试验流程和评估方法实施试验(如访视、给药、采血、安全性检查和疗效评估等)，采取措施保证关键步骤实施的准确性， 并保存相关记录， 如偏离试验方案应予以记录和解释， 合并用药或合并治疗与禁用药物的记录符合方案规定的要求。'可被翻译为：(5) The investigator implements the trial (such as visit, drug administration, blood drawing, safety examination and efficacy evaluation, etc.) in accordance with the trial procedures and evaluation methods specified in the clinical trial protocol, takes measures to ensure accuracy of the execution of key steps, and keeps the relevant records, for example, deviation from the trial protocol shall be recorded and explained, and records of concomitant medication or concomitant therapy and  prohibited drugs comply with the requirements of the protocol.\n'五、临床试验要求'可被翻译为：V. Requirements for clinical trials\n'第五十二条 申办者为保证临床试验的质量，可以组织独立于临床试验、并具有相应培训和经验的核查员对临床试验开展情况进行核查，评估临床试验是否符合试验方案的要求。'可被翻译为：Article 52 The sponsor may, in order to ensure the quality of the clinical trial, organize trained and experienced auditors independent of the clinical trial to verify the progress of the clinical trial and assess whether the clinical trial meets the requirements of the trial protocol.\n'第二十七条 企业应当按照培训管理制度制定年度培训计划并开展培训，使相关人员能正确理解并履行职责。培训工作应当做好记录并建立档案。'可被翻译为：Article 27 Enterprises shall, in accordance with the training management system, formulate annual training plans and carry out training so that relevant personnel can correctly understand and perform their duties. Training shall be well documented and related archives shall be established.\n\n根据上述已知信息，请将'（五）申办者和临床试验机构对试验培训的计划与培训记录要求；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(5) The requirements of the sponsor and clinical trial institutions for the trial training plan and training records;"
    },
    {
        "instruction":"已知信息：\n'在某些情况下，让一 组独立的评价人员根据通用标准以盲态的方式重新评价对 照组和试验组中的终点是十分有用的。'可被翻译为：In some cases, it may be useful to have an independent set of reviewers reassess endpoints in the control group and in the test group in a blinded manner according to common criteria.\n'评价应在研究结束时进行，但数据也可在中间时间点收集。'可被翻译为：Evaluations should be carried out at the end of the study, but data also can be collected at interim time points.\n'如第5章节所述，在试验的计划阶段，分析的主要特征 应在方案中确定。'可被翻译为：During the planning phase of a trial the principal features of the analysis should have been specified in the protocol as described in Section 5.\n'统 计分析计划应经审核或根据数据盲态审核（见第7.1章节定 义）结果更新后，在揭盲前最终确定。'可被翻译为：The plan should be reviewed and possibly updated as a result of the blind review of the data (see 7.1 for definition) and should be finalised before breaking the blind.\n\n根据上述已知信息，请将'当试验结束而且数据经整理可供初步检查 时，如第5章节提到的按计划进行盲态审核是有价值的。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"When the conduct of the trial is over and the data are assembled and available for preliminary inspection, it is valuable to carry out the blind review of the planned analysis also described in Section 5."
    },
    {
        "instruction":"已知信息：\n'生物类似药物对比的情况下，以复发相关的临床结果作为支持的话，可以接受基于MRI的变量作为主要研究终点；该临床结果无需进行正式的等效性检验，在效果上预 期和基于MRI的变量显示出相同的趋势。'可被翻译为：MRI-based variables are acceptable primary endpoints in the context of a biosimilar comparison if backed up by relapse-related clinical outcomes; no formal equivalence test is required for clinical outcomes, which would be expected to show the same trend in effect as the MRI-based variables.\n'应对生物类似物和参比制剂的 这些类别的MRI活性和临床复发情况进行比较。'可被翻译为：MRI activity and clinical relapses should be compared between these categories for both the biosimilar and reference product.\n'生物类似物开发方案的指导性原则是通过可能性最大的途径确立生物类似物和参比制剂的相似性，确保参比制剂已被证实的安全性和有效性同样适用于生物类似物。'可被翻译为：The guiding principle of a biosimilar development programme is to establish similarity between the biosimilar and the reference product by the best possible means, ensuring that the previously proven safety and efficacy of the reference medicinal product also applies to the biosimilar.\n'因此，为证明生物类似物 FSH 和参比制剂间的潜在差异，应考虑额外进行 可比性体内研究。'可被翻译为：Hence, to qualify any potential differences between the biosimilar FSH and the reference product, the need for additional comparative in vivo studies should be considered.\n\n根据上述已知信息，请将'用复发性多发性硬化症患者病变部位的核磁共振成像证明生物类似物和参比制剂间的临床相似性就足够了（见药效学）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For demonstrating clinical similarity of a biosimilar and reference product, magnetic resonance imaging of disease lesions in RMS may be sufficient (see Pharmacodynamics)."
    },
    {
        "instruction":"已知信息：\n'如果已证明了与症状有相关性，可通过测量症状 发生频率和严重程度的变化来量化疗效。'可被翻译为：Having proven a symptom association, the measuring change in frequency and severity of symptoms can be used to quantify a therapeutic effect.\n'为此，研究者需收集症状持续时间 的数据。'可被翻译为：For this purpose, the investigators have to collect data regarding symptoms duration.\n'典型的钳夹时间为速效胰岛素 8 到 10 小时，短效胰岛素 10 到 12 小时。'可被翻译为：Typical clamp durations are 8 to 10 hours for rapid-acting and 10 to 12 hours for short-acting insulins.\n'24 小时蛋白尿。'可被翻译为：24-hour proteinuria.\n\n根据上述已知信息，请将'在一项为时 8 到 24 小时的观察性研究中可以对典型症状进行量化。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Typical symptoms can be quantified during an 8-24 hour observational study."
    },
    {
        "instruction":"已知信息：\n'请参见行业指南I期研究药物，包括经充分鉴定的治疗性生物技术来源产品，研究新药申请（IND）的内容和格式，和 II 期和III 期研究的IND：化学、生产和控制信息。'可被翻译为：See the guidances for industry Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-derived Products and INDs for Phase 2 and Phase 3 Studies: Chemistry, Manufacturing, and Controls Information.\n'行业指导原则依法上市药品或生物制品治疗癌症研究的IND豁免\n行业指导原则：II 期和III 期研究的IND：化学、生产和控制信息'可被翻译为：Guidance for industry IND Exemptions for Studies of Lawfully Marketed Drug or Biological Products for the Treatment of Cancer\nGuidance for industry INDs for Phase 2 and Phase 3 Studies: Chemistry, Manufacturing, and\tControls Information\n'这种理论依据，尤其是对于I期试验，最好是通过体外和已有的动物数据来支持，如行业指导原则I期研究药物的研究新药申请（IND）的内容和格式，包括经充分鉴定的治疗性生物技术制品中所述。'可被翻译为：This rationale, particularly for phase 1 trials, is best supported by in vitro and available animal data, as described in the guidance for industry Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-Derived Products.\n'FDA审评员和申办方指导原则人类体细胞疗法研究新药申请（IND）的化学、生产和控制（CMC）信息的内容和审查\n植物药的行业指导原则'可被翻译为：Guidance for FDA reviewers and sponsors Content and Review of Chemistry, Manufacturing,\tand Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug\tApplications (INDs)\nGuidance for industry Botanical Drug Products\n\n根据上述已知信息，请将'行业指导原则I期研究药物的研究新药申请（IND）的内容和格式，包括经充分鉴定的治疗性生物技术制品'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Guidance for industry Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-Derived Products"
    },
    {
        "instruction":"已知信息：\n'一个化学反应中，产生的某一对映体多于其相应的对映体的程度。'可被翻译为：The degree to which a chemical reaction produces more enantiomers than its corresponding enantiomers.\n'药物的重量与等体积基质重量的比值。'可被翻译为：The ratio of the weight of the drug to the weight of the equal volume matrix.\n'又称\"［对映］异构体优劣比”。较高活性对映体（优对映体）与较低活性对映体（劣对映体）间生物活性强度的比值。'可被翻译为：Also known as \"the ratio of [enantiomer] to good\". The ratio of the strength of biological activity between the more active enantiomer (superior enantiomer) and the less active enantiomer (inferior enantiomer).\n'如果药物是消旋体或对映异构体的混合物，应对分析物（消旋体或对映异构体）的选择进行附加说明。'可被翻译为：If the drug substance is a racemate or some other mixture of enantiomers, additional justification should be made for the choice of the analyte [racemate or enantiomer(s)].\n\n根据上述已知信息，请将'含有对映体混合物的样品比旋度与纯单-异构体的比旋度的比值。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The ratio of the specific curl of a sample containing an enantiomer mixture to the specific curl of a pure mono-isomer."
    },
    {
        "instruction":"已知信息：\n'经与标准品\/对照品比对，符合质量和纯度要求的物质，供实验室日常分析使用。'可被翻译为：A substance of established quality and purity, as shown by comparison to a primary reference standard, used as a reference standard for routine laboratory analysis.\n'对照标准品：用于制备校正标样和质控样品的具有已知纯度和特性的物质。'可被翻译为：Reference Standard: A well-characterised substance of known purity and identity used to prepare calibration and quality control samples.\n'11.19 工作标准品\/对照品应当进行合理的制备、鉴别、检验、批准和 贮存。每批工作标准品\/对照品在首次使用前应与标准品\/对照品进行比对，以确定其适用性。应当按照书面文件对每批工作标准品\/对照 品定期进行确认。'可被翻译为：11.19 Secondary reference standards should be appropriately prepared, identified, tested, approved, and stored. The suitability of each batch of secondary reference standard should be determined prior to first use by comparing against a primary reference standard. Each batch of secondary reference standard should be periodically requalified in accordance with a written protocol.\n'采用准确、可靠的方法或直接与一级标准物质相比较的方法，测量标准物质的特性量值，测量准确度满足需要的标准物质。在实验室中通常是指与一级标准物质比对后作为对照使用的工作对照品（标准品）。'可被翻译为：The characteristic quantity value of the standard substance shall be measured by accurate and reliable method or by method directly compared with the first class standard substance, and the standard substance whose measurement accuracy meets the needs shall be measured. In the laboratory, it usually refers to the working reference material (standard material) used as a control after comparison with the primary reference material.\n\n根据上述已知信息，请将'通过与一级标准品的比对表明具有确定的质量和纯度的物质，作为日常实验室分析的标准品之用。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A substance of established quality and purity, as shown by comparison to a primary reference standard, used as a reference standard for routine laboratory analysis."
    },
    {
        "instruction":"已知信息：\n'因此，必须表示出使用DPI的患者人群在流量\/压力差范围中的流速依赖性特征。'可被翻译为：Therefore characterisation of flow rate dependency in the range of flows\/pressure drops in the patient populations in whom the DPI is to be used should be presented.\n'有明显的剂量 - 反应关系。'可被翻译为：A clear dose-response relationship is shown.\n'压力。'可被翻译为：Pressure.\n'该工具对于口头回应以及读写能力依赖性很强。'可被翻译为：The instrument relies heavily on verbal response and competence of reading and writing.\n\n根据上述已知信息，请将'与压力和非压力MDI相比，DPI的沉积特征一般具有很强的流量依赖性。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In comparison to pressurized and non-pressurized MDIs, the deposition characteristics of DPIs are more flow dependant."
    },
    {
        "instruction":"已知信息：\n'已确定口服、注射和吸入给药途径的PDE。'可被翻译为：PDEs were established for oral, parenteral and inhalation routes of administration.\n'综合所获得信息，确定了口服、注射和吸入 给药途径的PDE。'可被翻译为：The available information was reviewed to establish the oral, parenteral and inhalation PDEs.\n'因此，吸入途径的PDE值和口服PDE值一致。'可被翻译为：Therefore, the inhalation PDE is equal to the oral PDE.\n'因此，注射途径的PDE值和口服PDE值一致。'可被翻译为：Therefore, the parenteral PDE is equal to the oral PDE.\n\n根据上述已知信息，请将'因此，按注射PDE值设定吸入PDE值。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For this reason, the inhalation PDE is set at the parenteral PDE."
    },
    {
        "instruction":"已知信息：\n'我们认识到在安慰剂对照的治疗ABECB-COPD的新抗菌药的试验组中入选严重程度较高的ABECB-COPD患者不太合适。如果考虑对病情严重度较高的患 者进行研究，我们强烈建议与审核部门进行讨论。在任何拟定的试验中都必须建立适当的规定，进而保证人类受试者免于不合理的显著疾病或损伤风险（21 CRF 312.42）。'可被翻译为：We recognize that it is not appropriate for patients with ABECB-COPD of greater severity (e.g., patients who are mechanically ventilated) to be enrolled in placebo-controlled trials of a new antibacterial for ABECB-COPD. We strongly encourage discussion with the review division if study of patients with greater severity is being considered. It is essential that in any proposed trials, adequate provisions are in place so that human subjects are not exposed to an unreasonable and significant risk of illness or injury (21 CFR 312.42).\n'在这些情况下，不能通过相较某个已被批准用于所研究的感染类型的抗菌剂 的非劣效性研究来充分评价试验药物的临床利益。'可被翻译为：In these instances the clinical benefit of a test agent cannot be assessed with confidence in a non¬- inferiority study vs. an antibacterial agent that has been approved in the past for the type(s) of infection under consideration.\n'8 我们认识到治疗指导方针建议对患者进行分层，而其中ABECB-COPD更加严重的患者应接受抗菌药物治疗。尚未对ABECB-COPD更加严重的患者确定可靠且定义良好的治疗作用。'可被翻译为：8 We recognize that treatment guidelines suggest a stratification of patients in which those with more severe ABECB-COPD should receive treatment with an antibacterial drug. A reliable and well-defined magnitude of the treatment effect for patients with more severe ABECB-COPD has not been established.\n'·病情鉴定为重度（例如，需要住院）的ABECB-COPD患者'可被翻译为：·Patients with ABECB-COPD characterized as severe (e.g., requiring hospitalization).\n\n根据上述已知信息，请将'具有临床显著毒性的抗菌药可能不适合研究ABECB-COPD，除非治疗目标是针对ABECB-COPD人群中病情更加严重的患者。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Antimicrobials with clinically significant toxicity may not be appropriate for study of ABECB- COPD unless the treatment goal is directed at a more seriously ill patient portion of the ABECB- COPD population."
    },
    {
        "instruction":"已知信息：\n'钳夹研究需要考虑受试胰岛素制剂的已知作用时间和它的剂量依赖性。'可被翻译为：The duration of the clamp studies needs to take into account the known duration of action of the investigated insulin preparation and its dose-dependency.\n'应事先定义钳夹中血糖水平可接受的偏倚。'可被翻译为：Acceptable deviations of blood sugar levels from this value during the clamp should be pre-defined.\n'钳夹研究中常用的胰岛素剂量是速效\/短效胰岛素0.2-0.3U\/kg体重，中效胰岛素 0.3-04U\/kg 体重，长效胰岛素 0.4-0.6U\/kg。'可被翻译为：Frequently used insulin doses in clamp studies are 0.2 to 0.3 U\/kg bodyweight for rapid-\/short-acting insulins, 0.3 to 0.4 U\/ kg bodyweight for intermediate-acting insulins and 0.4 to 0.6 U\/kg for long- acting insulins.\n'在健康受试者进行的钳夹研究中，检测胰岛素浓度时应总是同时检测血清 C-肽，以估计内源性胰岛素受抑制的程度和一致性。'可被翻译为：In clamp studies employing healthy volunteers, serum C-peptide should always be measured in parallel to insulin concentrations throughout the experiment to estimate the extent and consistency of suppression of endogenous insulin.\n\n根据上述已知信息，请将'为了评估餐前胰岛素，在钳夹过程中胰岛素剂量应足够压制内源性胰岛素。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For evaluation of prandial insulins, the insulin bolus is expected to adequately suppress endogenous insulin for the duration of the clamp."
    },
    {
        "instruction":"已知信息：\n'但是，重要的是需要了解，在某些情况下，数据元素是否由于不适用、或者未知、或者受隐私法“保护”而为空元素。'可被翻译为：However, in certain cases it is important to understand if a data element is null because it is not applicable or because it is unknown or because it is ‘protected’ by privacy legislation.\n'它应 该与不存在的数据，或由于伴发事件而被认为没有意义的数据区 分开来。'可被翻译为：They should be distinguished from data that do not exist or data that are not considered meaningful because of an intercurrent event.\n'在 HL7 信息传输中，可以传输一个空元素，并对元素进行编码元素，以解释缺少数据的原因。'可被翻译为：In HL7 messaging it is possible to transmit an empty element and to code the element to explain the reason for the lack of data.\n'空白元素的原因称为空值的元素“flavor”。'可被翻译为：This reason for a blank element is referred to as the ‘flavor’ of the null value.\n\n根据上述已知信息，请将'在这些情况下，在数据元素的信息中纳入用于表示空值的规定元素，以说明不存在的数据及其原因。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In those cases, provisions for expressing a null value are included in the message for a data element to indicate the absence of data and reason."
    },
    {
        "instruction":"已知信息：\n'本附录不适用于粘膜给药（口腔、鼻腔、阴道）、局部眼科用药、直肠给药、表皮下和真皮下给药的药品。'可被翻译为：This Appendix does not apply to drug products intended for mucosal administration (oral, nasal, vaginal), topical ophthalmic, rectal, or subcutaneous and subdermal routes of administration.\n'本指导原则不适用于在临床研究阶段使用的药品。'可被翻译为：This guideline does not apply to drug products used during clinical research stages of development.\n'包装在看起来类似于眼用产品、耳用产品、鼻用产品或口服产品容器\/密 封件中的局部产品可导致局部产品通过眼、耳、鼻和口给药。'可被翻译为：Topical products packaged in containers with closures that look similar to eye, ear, nasal, or oral products have led to administration of the topical product in the eye, ear, nose, and mouth.\n'经鼻吸入的滥用通常涉及经鼻吸入研磨后的固体口服阿片类物质药物。'可被翻译为：Abuse by insufflation generally involves snorting of milled solid oral opioid drug products.\n\n根据上述已知信息，请将'本指南不适用于通过眼、耳、鼻、吸入、口服或注射途径的药品，亦不适用于经皮或局部给药系统（包括贴剂、局部贴剂或缓释膜剂）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"This guidance does not address drug products that are administered via ophthalmic, otic, nasal, inhalation, oral, or injection-based routes, or that are transdermal or topical delivery systems (including products known as patches, topical patches, or extended-release films)."
    },
    {
        "instruction":"已知信息：\n'对于其他类型的药物基因组学生物标志物，可采用不同方法进行HLA分型，从免疫分型到下一代基因测序。'可被翻译为：As with other types of pharmacogenomic biomarkers, different methods can be used for HLA typing, ranging from immunological serotyping to next generation sequencing.\n'例如，HLA基因分型可用于预防阿巴卡韦超敏综合征，这些包括随着继续给药会变得更为严重且可能危及生命的发热、皮疹、消化道和呼吸系统症状。'可被翻译为：For example HLA genotyping is used for the prevention of abacavir hypersensitivity syndrome, which comprises fever, rash, gastrointestinal tract and respiratory symptoms that become more severe with continued dosing, and can become life-threatening.\n'排除较高风险的患者：识别有较高风险发生严重的药物不良反应的患者，由此在后 续试验中或使用此类药物治疗中排除此类患者（例如HLA B* 5701和阿巴卡韦的使用，卡马 西平和HLA-B*1502）'可被翻译为：for excluding patients at increased risk: Identification of patients at increased risk of experiencing aserious adverse drug reactions for the purpose of excluding them from further clinical trials or treatment with that specific agent.(e.g., HLA B* 5701 and abacavir use or carbamazepine and HLA-B*1502)\n'需要注意的是，阿巴卡韦的药物基因组学相关性研究是在药物上市后阶段进行的，研究结果使得产品特征概要(SPC)进行了更新，同时也推荐使用（或再次使用） 阿巴卡韦之前进行HLA-B*5701等位基因筛查。'可被翻译为：Of note, the pharmacogenomic association studies for abacavir were conducted in the post authorisation period and resulted in an update of the summary of product characteristics (SPC), incorporating the recommendation for screening for the HLA-B*5701 allele prior to exposure (or re-exposure) to this agent.\n\n根据上述已知信息，请将'例子包括HLA等位基因和与阿巴卡韦、卡马西平和别嘌呤醇的特异性反应。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Studies demonstrating the predictive values of the genomic BM included both retrospective case- control studies and prospective clinical trials."
    },
    {
        "instruction":"已知信息：\n'下面所列举的特性能导致脂质体药品表现的改变，包括药物成分的泄漏。'可被翻译为：The properties listed in items below can lead to changes in the behavior of the liposome drug product, including leakage of the drug from the liposomes.\n'包入脂质体内的药物量与投料量的重量百分比。'可被翻译为：The percentage by weight of the amount of drug incorporated into the liposome and the amount of the feed.\n'脂质体药品的物理稳定性可受多个因素影响（如，脂质体的完整性，脂质囊泡的粒度分布，脂肪酸的不饱和度）。某些脂质体容易聚合（即较小的脂质体不可逆地聚集成较大的脂质体）、聚集（即两个或两个以上的脂质体可逆地非聚合性结团或淤积）和包载药物在存储中泄漏。'可被翻译为：The physical stability of liposome drug products can be affected by a number of factors (e.g., the liposome integrity, the size distribution of the lipid vesicles, unsaturation of the fatty acid groups). Some liposomes are susceptible to fusion (i.e., irreversible coalition of smaller liposomes to form larger liposomes), aggregation (i.e., reversible conglomeration or pooling of two or more liposomes without fusion), and leakage of the contained drug substance during storage.\n'例如，药物包封率（定义为包封在脂质体内部的药量与总药量的比值）和脂 质体载药率（定义为含药量与脂质量的百分比，也就是药物-脂质的比例）。'可被翻译为：For example, drug encapsulation efficiency (defined as percentage of drug contained inside liposomes compared with total amount of drug) and liposome drug loading (defined as the percentage of drug contained which is then compared with the amount of the lipid used, which is the drug-to-128 lipid ratio).\n\n根据上述已知信息，请将'聚集、聚合和泄漏都可能受脂质成 分或包载药物的影响。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Fusion, aggregation, or leakage can be affected by the lipid components in the liposome or by the contained drug substance."
    },
    {
        "instruction":"已知信息：\n'因此，存在一定的风险去检测这种无痛性肿瘤，发现临床重大的前列腺癌比治疗更具有挑战性。'可被翻译为：There is thus a risk related to the detection of indolent tumours and a challenge to identify clinical significant prostate cancer of importance to treat.\n'根据研究治疗的作用模式，可能需要特别注意对不同器官系统的长期影响。如果研究激素活性物质，应考虑前列腺癌的监测。'可被翻译为：Depending on the mode of action of the investigated treatment, special attention may have to be paid to long-term effects on different organ systems. Prostate cancer monitoring should be considered if hormonally active substances are investigated.\n'为了避免样本引起的偏倚，活性治疗组与安慰剂组之间的诊断程序相同至关重要。此外，需要较长的观察期，因为能检测出前列腺癌的诱导期和潜伏期都很长。即使治疗组之间的管理的微小差异也可能是重要的混杂因素。'可被翻译为：It is crucial to have identical diagnostic procedures between active and placebo groups in order to avoid sampling bias. Additionally, long observation periods are needed as both the induction period and the latency period to detect a prostate cancer are long. Even small differences in management between the treatment groups may harbour confounding factors of importance.\n'因此，可考虑使用更广泛的DLT观察期较长的DLT定义。'可被翻译为：Broader DLT definitions with longer DLT observation periods may therefore be relevant to consider.\n\n根据上述已知信息，请将'此外，需要较长的观察期，因为能检测出前列腺癌的诱导期和潜伏期都很长。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Additionally, long observation periods are needed as both the induction period and the latency period to detect a prostate cancer are long."
    },
    {
        "instruction":"已知信息：\n'（九）仿制或进口境内已上市药品\/制剂所用的原料药，原料药登记人登记后，可进行单独审评审批，通过审评审批的登记状态标识为“A”，未通过审评审批的标识为“I”。审评审批时限和要求按照现行《药品注册管理办法》等有关规定执行。'可被翻译为：(9) For APIs of generics or imported drug\/preparation domestically marketed, after the registration of the API registrants, they may be subject to separate review and approval, and the registration status of the passed review & approval shall be marked as A, otherwise: I. The time limit and requirements for review and approval shall comply with the Provisions for Drug Registration and other relevant regulations.\n'未通过关联审评审批的，化学原料药、辅料及直接接触药品的包装材料和容器产品的登记状态维持不变，相关药品制剂申请不予批准。'可被翻译为：Where chemical active drug ingredients, excipients and primary packaging materials and containers have failed a bundling review and approval, their registry status shall remain unchanged, and application of the corresponding drug product shall be disapproved.\n'（三）单独申报仿制境内已上市化学原料药的审评时限为二百日；'可被翻译为：(3) The review timeline for independent applications of generic products of domestically marketed chemical active drug ingredients is 200 days.\n'四、关于化学原料药一并审评审批'可被翻译为：IV. Associated review & approval for chemical APIs\n\n根据上述已知信息，请将'仿制境内已上市药品所用的化学原料药的，可以申请单独审评审批。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For the generic chemical active drug ingredients already used in marketed drug products within the territory of the People’s Republic of China, separated review and approval may be applied."
    },
    {
        "instruction":"已知信息：\n'用于确定分 析灵敏度（如使用不同的分界点）的方法应进行描述，但也应列出每个治疗组的在每个 时间点的效价分布。'可被翻译为：The approach used to determine assay sensitivity (e.g., by using different cut-off points) should be described but the distribution of titres should also be presented at each time point for each treatment arm.\n'这样的原因通常会提示适当的进一步分析和解释。'可被翻译为：Such an explanation will usually suggest appropriate further analysis and interpretation.\n'如果仅仅由于偶然而使治疗组间基线协变量有一定的不平衡，那么校正的治疗效果可能是这一观察到的不平衡的原因，而未校正的分析可能不能用于解释这种不平衡。'可被翻译为：When there is some imbalance between the treatment groups in a baseline covariate that is solely due to chance then adjusted treatment effects may account for this observed imbalance when unadjusted analyses may not.\n'应通过试验前的缜密考虑，确定这些协变量以及 预期对主要指标有重要影响的因素，并考虑在分析中如何处 理，以提高精度和补偿处理组之间的任何不平衡。'可被翻译为：Pre-trial deliberations should identify those covariates and factors expected to have an important influence on the primary variable(s), and should consider how to account for these in the analysis in order to improve precision and to compensate for any lack of balance between treatment groups.\n\n根据上述已知信息，请将'并说明“如何在分析中对其进行解释以提高精度、弥补组间不平衡的情况”。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"and to specify ‘how to account for them in the analysis in order to improve precision and to compensate for any lack of balance between groups’."
    },
    {
        "instruction":"已知信息：\n'应证明联合用药相对于单用 TKI 更优。'可被翻译为：Superiority should be demonstrated comparing the combination regimen with a single TKI.\n'对于针对急性期后和较长期阶段的干预（二级预防或斑块稳定），在同一临床试验中评估这两种情况可能是合理的。'可被翻译为：For interventions aimed at post-acute and longer term phases (secondary prevention or plaque stabilisation) it may be justified to address both conditions in the same clinical trial.\n'表A6. 用于幼龄动物试验的各种哺乳动物的主要优点和缺点 \n种属 \n优点 \n缺点'可被翻译为：Table A6. Principal Advantages and Disadvantages of Various Mammalian Species for Use in Juvenile Animal Studies \nSpecies \nAdvantages \nDisadvantages\n'表 1 用于发育与生殖毒性试验的不同种属的主要优点和缺点'可被翻译为：Table 1: Principle Advantages and Disadvantages of Various Species for Developmental and Reproductive Toxicity Testing\n\n根据上述已知信息，请将'同时开始使用两种药物的优点大于其缺点（不必要的治疗、安全问题）应该是合理的。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"It should be justified that the benefits of starting two drugs at the same time outweighs its disadvantages (unnecessary treatment, safety issues)."
    },
    {
        "instruction":"已知信息：\n'应考虑在不同种族人群中PK \/ PD相关临床变量和基因组学BM的潜在差异。'可被翻译为：The potential differences regarding the PK\/PD related clinical variables and genomic BMs in different ethnic populations should be considered.\n'还推荐通过群体PK分析评价内在因素的影响。'可被翻译为：It is recommended to also evaluate the influence of intrinsic factors through population PK analyses.\n'采用包括群体PK方法和\/或基于模型的方法（例如，暴露-反应 关系模型）的剂量选择策略，可有助于识别不同人群中药物反应的 重要影响因素，并为进一步的剂量-反应关系研究设定合适的剂量 范围提供帮助。'可被翻译为：A strategy for dose-selection involving population PK approaches and\/or model-based approaches (e.g., exposure-response models) may be useful to identify important factors affecting drug responses in different populations, and to set an appropriate dose range for further dose-response studies.\n'但是，如果预期PK和\/或PD 以及剂量-反应关系中不存在预期的重要区域差异（例如，药物反 应可能对内在和外在因素不敏感），则不必从所有计划纳入确证性 MRCT的区域获得受试者的PK-PD或剂量-反应关系数据（参见ICH E 5，附录D）。'可被翻译为：However, it may not be necessary to obtain PK-PD or dose-response data from subjects in all regions planned to be included in confirmatory MRCTs, if important regional differences in PK and\/or PD and dose-response are not anticipated (e.g., response to the drug is unlikely to be sensitive to intrinsic and extrinsic factors) (see ICH E5, appendix D).\n\n根据上述已知信息，请将'其中可包括在某一特定种族人群 或更广泛人群中的PK-PD或剂量-反应关系研究，这有助于进一步 评估内在和外在因素对剂量-反应关系的影响。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"These could include a PK-PD or dose-response study conducted in a particular ethnic population or studies conducted for a broader population, that would allow further evaluation of the impact of intrinsic and extrinsic factors on dose-response."
    },
    {
        "instruction":"已知信息：\n'在比较试验药物与活性对照药物时，为对照药和试验药 物选择一个适当的剂量和给药方案是重要的。'可被翻译为：In comparing the test drug with an active control, it is important to choose an appropriate dose and dose regimen of the control and test drugs.\n'相比之 下，活性对照试验或剂量比较试验检测的是相对于其他治疗 的效果。'可被翻译为：In contrast, an active control trial or a dose-comparison trial measures the effect relative to another treatment.\n'活性对照，目的在于表明实验药物比活性 对照优效（见2.4）'可被翻译为：• Active control seeking to show superiority of test drug to active control (see 2.4)\n'另一方 面，即使活性对照药物的剂量太低或者活性对照药的益处不 明确(但不能有害)，获得有利于试验药物结果的优效性研究 比较容易解读为有效性的证据。'可被翻译为：A superiority study favoring the test drug, on the other hand, is readily interpretable as evidence of efficacy, even if the dose of active control is too low or the active control is of uncertain benefit (but not if it could be harmful).\n\n根据上述已知信息，请将'然而，试验中试验药物所表 现的相对于对照药物的优效性，只有当活性对照药物在最佳 的给药剂量和给药方案下、用于合适的病人时才能判断为真 正的优效(见1.4.3)。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Such a result, however -- superiority in the trial of the test agent to the control -- is interpretable as true superiority of the test treatment to the control treatment only when the active control is used in appropriate patients at an appropriate dose and schedule (see section 1.4.3)."
    },
    {
        "instruction":"已知信息：\n'如果一个报告被提交给多个IND，则每个IND安全性报告都应说明报告提交的所有IND。'可被翻译为：If a report is submitted to multiple INDs, each IND safety report should identify all INDs to which the report is submitted.\n'所有设施的 信息可置于一份或多份文件中，同时可以置于一个或多个单位的章节中。'可被翻译为：All facility information could be in one document or multiple documents and within one or multiple Facility sections.\n'在获得所有必需的信息之后，IND 准备提交给 FDA。'可被翻译为：After all the needed information has been acquired, the IND is ready for submission to the FDA.\n'4. 其他IND提交 。当已有联合治疗IND和一种或多种单一药物IND时，申办方应考虑在计划 IND提交中的信息是否仅与一个IND或与多个IND相关。'可被翻译为：4. Other IND Submissions Where there is a combination IND and INDs for one or more individual drugs, sponsors should consider whether the information in a planned IND submission is relevant to only one IND or to multiple INDs.\n\n根据上述已知信息，请将'若信息与多个IND相关，可将信息全部提交给每个IND或可提交给一个IND而在其他IND中交叉参照。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Where information is relevant to more than one IND, the information can be submitted in its entirety to each IND or can be submitted to one IND and cross-referenced in the other INDs."
    },
    {
        "instruction":"已知信息：\n'荧光免疫分析'可被翻译为：fluorescence immunoassay\n'借助抗原、抗体在皮肤内或皮肤上的反应进行免疫学检测的方法。'可被翻译为：An immunological test based on the reaction of an antigen or antibody in or on the skin.\n'结合化学发光反应的高度灵敏度和免疫反应的高度专一性，用于测定超微量物质的一种检测技术。'可被翻译为：A detection technique that combines the high sensitivity of chemiluminescence reactions with the high specificity of immune reactions for the determination of ultramicroscopical substances.\n'某些情况下，这 种方法可能比其它免疫分析方法灵敏度低，需要很大的努力开发一种合适的检测。'可被翻译为：In some cases, this procedure may be less sensitive than other immunoassay methods and mayrequire significant development effort to produce a suitable assay.\n\n根据上述已知信息，请将'将免疫反应的特异性与荧光技术的灵敏度相结合的一种免疫分析方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"An immunoassay method that combines the specificity of an immune response with the sensitivity of a fluorescence technique."
    },
    {
        "instruction":"已知信息：\n'附录 I 至 III 为因 子 IX 产品的临床试验具体要求的“一览表”。'可被翻译为：Detailed “at a glance” requirements for clinical trials for factor IX products are found in Annexes I to III.\n'参见附录 I “临床试验概念综述”和附录 II“因子 VIII 制品临床试验：新制品”。'可被翻译为：EMA\/CHMP\/BPWP\/\/ rev  \/ Please refer to Annex I ‘Overview on clinical trial concept’ and Annex II ‘Clinical trials for factor VIII  products: new products’.  ...\n'请参考附录 I“临床试验概念综述”和附录 II“新因子IX制品的临床试验 ”。'可被翻译为：Please refer to Annex I ‘Overview on Clinical Trial Concept’ and Annex II ‘Clinical Trials for Factor IX Products “New Products”’ .\n'附录II因子VIII的临床试验：新药'可被翻译为：Annex II – Clinical trials with factor VIII products: new products\n\n根据上述已知信息，请将'因子VIII 制品临床试验的详细“一览”要求可参见附录 I 到 III。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Detailed “at a glance” requirements for clinical trials  for factor VIII products are found in Annexes I to III.  ."
    },
    {
        "instruction":"已知信息：\n'FDA和申办方之间的有效且及时的沟通可促进对相互目标的理解，对药物的开发过程至关重要。这一点的核心是能够在正式会议内外以口头和书面形式进行清楚地沟通。'可被翻译为：Effective and timely communication between FDA and sponsors promotes understanding of mutual goals and is invaluable to the drug development process. Central to this is the ability to communicate clearly, both orally and in writing, inside and outside the formal meeting format.\n'在药物开发的IND阶段，申办方和FDA每年都会进行成千上万次正式和非正式沟通，包括会议和电话会议。因为这些沟通往往是分享信息和提供关键建议（例如，试验设计、剂量选择、非临床研究的要求、生产和设备问题）的时机，因此进行有效且一致的相互交流以及清晰、简明且及时的沟通至关重要。'可被翻译为：Each year, sponsors and FDA engage in thousands of formal and informal communications, including meetings and teleconferences, during the IND phase of drug development. Because these communications are often opportunities to share information and provide critical advice  (e.g., trial design, dose selection, nonclinical study requirements, manufacturing and facility issues), it is important that interactions be conducted efficiently and consistently, with clear, concise, and timely communication.\n'参见行业指导原则FDA与申办方或申请者之间的正式会议以及FDA与仿制生物制品申办方或申请者之间的正式会议。'可被翻译为：See the guidances for industry Formal Meetings Between the FDA and Sponsors or Applicants and Formal Meetings Between the FDA and Biosimilar Biological Product Sponsors or Applicants.\n'22参见行业指导原则FDA与申办方或申请者之间的正式会议以及FDA与仿制生物制品申办方或申请者之间的正式会议。'可被翻译为：22 See the guidances for industry Formal Meetings Between the FDA and Sponsors or Applicants and Formal Meetings Between the FDA and Biosimilar Biological Product Sponsors or Applicants.\n\n根据上述已知信息，请将'涉及在药物开发期间在关键里程碑分享结果和信息的沟通或者终止开发计划所需进行的沟通最好在FDA与申办方之间的正式会议（例如，面对面会议、电话会议或仅书面答复（WRO））中进行。FDA通过正式会议流程向申办方发送反馈时间限详见处方药用户付费法案（PDUFA）和生物仿制药用户付费法案（BsUFA）协议以及FDA的正式会议指导原则。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Communications that involve sharing results and information at critical milestones during drug development or are necessary for a stalled development program to proceed are best addressed in formal meetings between FDA and sponsors (e.g., face-to-face meeting, teleconference, or written response only (WRO)). Timelines for FDA sending feedback to sponsors via the formal meeting process are described in Prescription Drug User Fee Act (PDUFA) and Biosimilar User Fee Act (BsUFA) agreements and in FDA’s formal meetings guidances."
    },
    {
        "instruction":"已知信息：\n'其他检测应该在中心实验室完成。'可被翻译为：Other assessments should be done in central laboratories.\n'建议在特定的中心实验室内开展监测。'可被翻译为：It is recommended that monitoring will take place in specialised central laboratories.\n'为减小实验结果的可变性，检测最好在中心实验室进行。'可被翻译为：Preferably, the testing should be conducted in a central laboratory to decrease variability in  test results.\n'一项临床试验中使用的所有当地实验室应进行实验室之间的对比 （轮流测试），以便得出标准化的结果并且使不同实验室甚至不同试验得出的这些结果相当。'可被翻译为：All local laboratories within a clinical trial should undergo inter-laboratorial comparisons (round-robin tests) in order to normalize results and thereby render them comparable between different laboratories and may be between different trials.\n\n根据上述已知信息，请将'中心实验室的结果应该由当地实验室的检测结果进行补 充，以填补缺失数据。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The central laboratory results should be supplemented by local laboratory results to fill in missing data."
    },
    {
        "instruction":"已知信息：\n'应采用定义良好的且可靠的PRO量表（如III.B.9疗效终点部分的讨论）评估基线症状。'可被翻译为：A well-defined and reliable PRO instrument, as discussed in section III.B.9., Efficacy Endpoints, should be used to assess symptoms at baseline.\n'将伴随用药的需求作为终点进行评估可能无法反映患者症状或体征的持久性；PRO量表可显示伴随药物使用之时持续的症状或体征，应采用该量表证实是否存在这类症状或体征。'可被翻译为：Assessment of the need for concomitant medications as an endpoint may not be reflective of the persistence of patient signs or symptoms; the presence of such signs or symptoms should be confirmed by a PRO instrument that shows continued signs or symptoms at the time of administration of the concomitant medication.\n'16如果要进行访谈，则应采用标准的访谈；另外，访谈者对根据患者访谈记录的症状不做任何解释。见行业指南患者报告的结局指标：为支持标签声明而在医学产品研发中的应用'可被翻译为：16 When interviews are used they should be standardized; in addition, symptoms recorded from the patient should be recorded without interpretation by the interviewer. See the guidance for industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims.\n'该试验主要强调的是抗菌药对结局（对患者具有临床重要性）的影响。应对 ABECB-COPD试验采用一项良好定义且可靠的评估患者症状的方法。因此，我们建议将有效且可靠的PRO量表用作主要结局指标。12  也应在基线使用相同的PRO量表定义入选标准；基于PRO量表评分的严重度水平应足以对有临床意义的反应（即，PRO量表上的变化）进行观测。对于有临床意义（并因此适合作出管理上的决定）的变化、改善或加重方向与幅度，应在量表研发期间进行测定，并在试验开始之前与FDA讨论。如果尚不能证实治疗的反应对患者具有临床意义，则参比剂给药方案之间统计学显著的差异可能不足以证明治疗益处，即患者的感 觉或功能如何。例如，用于诊断ABECB-COPD的症状或体征可能对临床医生非常重要，例如痰颜色，但可能对患者而言不是重要的结局，因此不适合作为测量治疗反应的疗效终点所用的评分部分。'可被翻译为：The primary emphasis of the trial should be the effect of the antimicrobial drug on outcomes that are clinically important to patients. A well-defined and reliable method of assessing patient symptoms should be used for ABECB-COPD trials. Accordingly, we recommend use of a valid and reliable PRO instrument as the primary outcome measure.12 The same PRO instrument also should be used at baseline to define enrollment criteria; the severity level based on the PRO instrument’s score should be sufficient to allow observation of a clinically meaningful response (i.e., change on the PRO instrument). The direction and magnitude of change, improvement or worsening, determined to be clinically meaningful (and therefore appropriate for regulatory decisions) should be determined during instrument development and should be discussed with the FDA before trial initiation. Statistically significant differences between comparator regimens may not be sufficient for demonstrating treatment benefit in terms of how a patient feels or functions if response to treatment has not been confirmed to be clinically meaningful to patients. For example, signs or symptoms used to diagnose ABECB-COPD that may be important to a clinician, such as the color of sputum, may not be an important outcome to patients and therefore would not be appropriate as part of the score used in the efficacy endpoint to determine response to treatment.\n\n根据上述已知信息，请将'12采用定义良好且可靠的PRO量表更能保证以始终一致的方式测量患者的症状。有关PRO指标研发的更多 信息，见行业指南患者报告的结局指标：为支持标签说明而在医学产品研发中的使用'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"12 The use of a well-defined and reliable PRO instrument can yield greater assurance that symptoms are being measured in a consistent manner across patients. For more information regarding the development of PRO measures, see the guidance for industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims."
    },
    {
        "instruction":"已知信息：\n'指南主要集中于旨在改变疾病进展的治疗。'可被翻译为：The guideline primarily focuses on treatments aimed to modify disease progression.\n'在所谓“基线对照研究”中，病人随着时间的状况变化与 基线情况比较。'可被翻译为：In so-called baseline-controlled studies, the patient's state over time is compared with their baseline state.\n'4.2. 预期改变疾病自然病程的治疗'可被翻译为：4.2. Treatments intended to modify the natural course of the disease\n'5.2. 预期改变疾病自然病程的治疗'可被翻译为：5.2. Treatments intended to modify the natural course of the disease\n\n根据上述已知信息，请将'这些过程的相对贡献在病程中不断改变。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The relative contribution of these processes changes during the course of the disease."
    },
    {
        "instruction":"已知信息：\n'高效微粒空气过滤器。'可被翻译为：High efficiency particulate air filter.\n'高效微粒空气过滤器'可被翻译为：high efficiency particulate air filter\n'1.有关洁净环境的设计、分类和测试的国际标准。\n2.国际标准组织(ISO)制定了一套洁净室的分类和测试标准。引用ISO 14644意味着最新版本及其所有独立部分。'可被翻译为：1.International standard relating to the design, classification and testing of clean environments.\n2.The International Standards Organization (ISO) has developed a set of standards for the classification and testing of cleanrooms. Where ISO 14644 is referenced it implies the latest revision and all its separate parts.\n'HEPA 过滤器：符合相关国际标准的高效空气过滤器。'可被翻译为：HEPA filter - High efficiency particulate air filter specified in accordance with a relevant international standard.\n\n根据上述已知信息，请将'1.高效微粒空气过滤器。\n2.按照相关国际标准指定的高效微粒空气过滤器。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.High-efficiency particulate air filter.\n2.A high-efficiency particulate air filter specified in accordance with a relevant international standard."
    },
    {
        "instruction":"已知信息：\n'出于实际原因并遵循基于风险的考虑， 可能没有必要或不可能对整个MODR进行验证。'可被翻译为：For practical reasons and following a risk-based approach, it may not be necessary or possible to validate the entirety of an MODR.\n'否则，可以应用简化或分期的研究设计。'可被翻译为：Otherwise, a reduced or staged study design may be applicable.\n'设计并进行研究（例如，机理和\/或动力学评价、多变量 试验设计、模拟、建模）来识别与确定物料属性和工艺参数 与原料药关键质量属性之间的关联和关系；'可被翻译为：Design and conduct studies (e.g., mechanistic and\/or kinetic evaluations, multivariate design of experiments, simulations, modelling) to identify and confirm the links and relationships of material attributes and process parameters to drug substance CQAs;\n'设计空间：输入变量（例如，物料属性）的多维度组合和相互作用以及被证明可保证药品质量的工艺参数。'可被翻译为：design space: The multidimensional combination and interaction of input variables (e.g. material attributes) and process parameters that have been demonstrated to provide assurance of quality.\n\n根据上述已知信息，请将'没有必要，申请者需要根据风险评估和所设计的操作灵 活性，确证选择哪些物料属性和工艺参数进行多变量试验。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"No, the applicant will need to justify the choice of material attributes and parameters for multivariate experimentation based on risk assessment and desired operational flexibility."
    },
    {
        "instruction":"已知信息：\n'如果药物研发者选择一种体外方法，则3T3 NRU-PT是目前应用最广泛的试验，而且在很多情况下用于 光毒性的初步检测。'可被翻译为：If the drug developer chooses an in vitro approach, the 3T3 NRU-PT is currently the most widely used assay and in many cases could be considered as an initial test for phototoxicity.\n'体外3T3中性红摄取光毒性试验。'可被翻译为：In vitro 3T3 Neutral Red Uptake Phototoxicity Test.\n'3T3 NRU-PT：体外3T3中性红摄取光毒性试验。'可被翻译为：3T3 NRU-PT: In vitro 3T3 Neutral Red Uptake Phototoxicity Test.\n'OECD TG：经济合作与发展组织，试验指导原则。'可被翻译为：OECD TG: Organisation for Economic Co-operation and Development, Test Guideline.\n\n根据上述已知信息，请将'应用最广泛的体外试验是3T3中性红摄取光毒性试验 （3T3 NRU-PT），参见经济合作与发展组织（OECD）指导原则（参考文献6），目前认为是可溶性化合物最合适的体外筛选方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The most widely used in vitro assay for phototoxicity is the 3T3 Neutral Red Uptake Phototoxicity Test (3T3 NRU-PT) for which an Organisation for Economic Co-operation and Development (OECD) guideline (Ref. 6) is available. This is currently considered the most appropriate in vitro screen for soluble compounds."
    },
    {
        "instruction":"已知信息：\n'对经完整验证的分析方法的修改可以通过部分验证进行评估。部分验证的内容应根据方法变更的范围和性质来确定，验证内容可从仅一项准确度和精密度验证到几乎完整验证（参见第6.1节）。'可被翻译为：Modifications to a fully validated analytical method may be evaluated by partial validation. Partial validation can range from as little as one accuracy an d precision determination to a nearly full validation (Refer to Section 6.1). The items in a partial validation should be determined according to the extent and nature of the changes made to the method.\n'部分验证：对选定验证参数进行评估的验证。用于在完整验证之后被变更的方法。'可被翻译为：Partial Validation: Validation based on evaluation of selected validation parameters. Applicable to methods that were changed after full validation.\n'至少2个质控样品浓度水平应在研究样品的浓度范围内。如果校准曲线范围被调整，则应重新验证生物分析方法（部分验证），以验证响应函数并确保准确度和精密度。'可被翻译为：At least 2 QC levels should fall within the range of concentrations measured in study samples. If the calibration curve range is changed, the bioanalytical method should be revalidated (partial validation) to verify the response function and to ensure accuracy and precision.\n'如果检测到的参数满足完整验证标准，则部分验证可以被接受。如果不满足这些标准，则需要额外的调查和验证。'可被翻译为：The parameters of the partial validations should meet the full validation criteria. If these criteria are not satisfied, additional investigation and validation is warranted.\n\n根据上述已知信息，请将'部分验证旨在评价对已经完整验证的生物分析方法的修改。部分验证的范围可由少至一个批内准确度和精密度的测定，到接近于完整验证。如果在一个场所建立了稳定性，则不必在另一个场所重复验证。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Partial validations evaluate modifications to already fully validated bioanalytical methods. Partial validation can range from as little as one within-run accuracy and precision determination, to a nearly full validation. If stability is established at one facility it does not necessarily need to be repeated at another facility."
    },
    {
        "instruction":"已知信息：\n'人用抗癌药品评价指南（CHMP\/ EWP\/ 205\/95）'可被翻译为：Guideline on the evaluation of anticancer medicinal products in man (CHMP\/EWP\/205\/95)\n'人类中的抗癌药品评价指导原则-EMA\/CHMP\/205\/95\/Rev.'可被翻译为：Guideline on the evaluation of anticancer medicinal products in man - EMA\/CHMP\/205\/95\/Rev.\n'抗癌药物的非临床评价EMEA\/CHMP\/ICH\/646107\/2008（ICH S9）EMA\/CHMP\/205\/95 Rev.5'可被翻译为：Nonclinical evaluation for anticancer pharmaceuticals EMEA\/CHMP\/ICH\/646107\/2008 (ICH S9)\n'人体抗癌药物评价指南 第34页 共39页 EMA\/CHMP\/205\/95 Rev.5 安全性数据库的大小应该是足以在研究的特定目标人群中进行获益风险评估。'可被翻译为：The size of the safety data base should be sufficient for benefit-risk assessment in the specific target population studied.\n\n根据上述已知信息，请将'人体抗癌药品的评估指南 - EMA \/CHMP \/205\/95 \/ 修订4'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Guideline on the evaluation of anticancer medicinal products in man - EMA\/CHMP\/205\/95\/Rev.4"
    },
    {
        "instruction":"已知信息：\n'这样的设计可证明每个药物对联合治疗活性的作用，而不使III期试验通常所需的大量患者暴 露于无充分活性的治疗药物。'可被翻译为：Such a design may demonstrate the contribution of each drug to the activity of the combination without exposing the large number of patients typically required for phase 3 trials to therapeutic products with inadequate activity.\n'当使用安慰剂对照试验来显示治疗的有效性时，它尽可能不受假设和外部(额外研究)信息的影响。'可被翻译为：When used to show effectiveness of a treatment, the placebo-controlled trial is as free of assumptions and reliance on external (extra-study) information as it is possible to be.\n'一般来说，随机对照平行组试验是疼痛试验中有效性的确证性证据最合适的设计。'可被翻译为：In general a randomised controlled parallel group trial is the most appropriate design for confirmatory evidence of efficacy in pain trials.\n'3.1.1 平行组设计'可被翻译为：3.1.1 Parallel Group Design\n\n根据上述已知信息，请将'平行组设计 在不可能进行疗效外推的情况下，平行组设计提供了最可靠的有效性和安全性证据。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Parallel group design In situations where extrapolation of efficacy is not possible, the parallel group design provides the most robust evidence for efficacy and safety and is the preferred design."
    },
    {
        "instruction":"已知信息：\n'iii. 该项研究完成后，必须向该研究的社区和其他研究者披露充分的信 息，包括该研究人群的人口统计学特征及其结果；'可被翻译为：(iii) Public disclosure of sufficient information following completion of the clinical investigation to apprise the community and researchers of the study, including the demographic characteristics of the research population, and its results;\n'开始这项研究之前，IRB会审评将要公开披露的信息，以确保这些信息将达 到更广泛的社区范围，并充分告知相关社区开展该项研究计划的执行及其风 险和预期益处。'可被翻译为：Prior to the initiation of an investigation, the IRB reviews the information that will be publicly disclosed to assure that the information will reach the broader communities involved and will adequately inform the affected communities of the plans to conduct the investigation and its risks and expected benefits.\n'临床研究完成后，IRB必须确认并且用文件证明，向社区和其他研究者披露 了充分信息，包括该研究人群的人口统计学特征和研究结果（21 CFR 50.24（a） （7）（iii））。'可被翻译为：Following completion of the clinical investigation, the IRB must find and document that sufficient information, including the demographic characteristics of the research population and the study results, will be disclosed to the community(ies) and to other researchers (21 CFR 50.24(a)(7)(iii)).\n'研究完成后，申办方准备信息，评估研究者和这项研究的社区，包括研究人 群的人口统计学特征和研究结果（21 CFR 50.24（a）（7）（iii））。'可被翻译为：Following completion of the study, the sponsor prepares information to apprise researchers and the community(ies) about the study, including demographic characteristics of the research population, and the study’s results (21 CFR 50.24(a)(7)(iii)).\n\n根据上述已知信息，请将'在研究完成后，IRB会审评将充足信息告知给社区和研究者的公开披露计划， 包括研究人群的人口统计学特征及其结果。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"After the study is completed, the IRB reviews the plans for disclosure of sufficient information to apprise the community and researchers of the study, including the demographic characteristics of the research population and its results."
    },
    {
        "instruction":"已知信息：\n'建议选择双盲、平行组、随机试验设计。'可被翻译为：Double blind, parallel group, randomised trial design is recommended.\n'B. 试验设计\n建议开展一项随机、双盲、安慰剂对照、平行组试验。'可被翻译为：B. Trial Design \nA randomized, double-blind, placebo-controlled, parallel-arm trial is recommended.\n'验证性试验： 设计认为最适用的验证试验设计为前瞻性、双盲、随机、对照、平行组临床试验。'可被翻译为：Confirmatory trials: Design The most appropriate design for confirmatory trials is considered to be a prospective, double-blind randomized, controlled, parallel group clinical trial.\n'建议采用安慰剂对照、随机、双盲、平行组设计。'可被翻译为：Placebo controlled, randomised, double blind and parallel group design is recommended.\n\n根据上述已知信息，请将'设计建议验证性试验采用双盲、随机、对照、平行的临床试验。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Design For confirmatory trials a prospective, double-blind randomised, controlled, parallel group clinical trial is recommended."
    },
    {
        "instruction":"已知信息：\n'第四十八条 应当根据药品品种、生产操作要求及外部环境状况等配置空调净化系统，使生产区有效通风，并有温度、湿度控制和空气净化过滤，保证药品的生产环境符合要求。'可被翻译为：Article 48 Production areas should be effectively ventilated, with air control facilities (including temperature, humidity and filtration) appropriate to the products handled, the operations undertaken within them and the external environment, to ensure that the production environment is in accordance with the requirements.\n'第四十六条 为降低污染和交叉污染的风险，厂房、生产设 施和设备应当根据所生产药品的特性、工艺流程及相应洁净度级 别要求合理设计、布局和使用，并符合下列要求：'可被翻译为：Article 46: In order to minimize the risks of contamination and cross-contamination, premises, facilities and equipment should be designed, laid out and used appropriately in accordance with the properties of the manufactured product and its process, as well as the corresponding cleanliness level, and the following requirements should be met:\n'第四十二条 厂房应当有适当的照明、温度、湿度和通风，确保生产和贮存的产品质量以及相关设备性能不会直接或间接地受到影响。'可被翻译为：Article 42 Lighting, temperature, humidity and ventilation should be appropriate and such that they do not adversely affect, directly or indirectly, either the product quality during their manufacture and storage, or the accurate functioning of equipment.\n'对温度、湿度等环境条件有特殊要求的，应当采取相应措施，保证医疗器械的安全、有效。'可被翻译为：If there are special requirements for temperature, humidity and other environmental conditions of the medical devices, the enterprise shall take corresponding measures to guarantee safety and effectiveness of the medical devices.\n\n根据上述已知信息，请将'第四十八条 应当根据药品品种、生产操作要求及外部环境 状况等配置空调净化系统，使生产区有效通风，并有温度、湿度 控制和空气净化过滤，保证药品的生产环境符合要求。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 48: Production areas should be effectively ventilated, with air control facilities (including temperature, humidity and filtration) appropriate to the products handled, the operations undertaken within them and the external environment, to ensure that the production environment is in accordance with the requirements."
    },
    {
        "instruction":"已知信息：\n'洁净室的消毒尤为重要。应根据书面程序彻底清洁洁净室并消毒。消毒前应清洁以去除表面污染物，确保消毒有效。清洁程序应有效去除消毒剂残留。应使用一种以上的消毒剂，确保这些消毒剂有不同作用机制，其联合使用能有效杀灭细菌和真菌。消毒应包括定期使用杀孢子剂。应定期进行监测，以评估消毒程序的有效性，并检测微生物菌群类型的变化（例如，对目前使用的消毒方式产生抗性的微生物）。'可被翻译为：The disinfection of cleanrooms is particularly important. They should be cleaned and disinfected thoroughly in accordance with a written programme. For disinfection to be effective, prior cleaning to remove surface contamination should be performed. Cleaning programmes should effectively remove disinfectant residues. More than one type of disinfecting agent should be employed to ensure that where they have different modes of action, their combined usage is effective against bacteria and fungi. Disinfection should include the periodic use of a sporicidal agent. Monitoring should be undertaken regularly in order to assess the effectiveness of the disinfection programme and to detect changes in types of microbial flora (e.g. organisms resistant to the disinfection regime currently in use).\n'洁净室内不应存在管道、风管等设施。如果此类设施不可避免，则安装时应确保不会产生凹槽、未密封的开口和难以清洁的表面。安装应便于管道外表面的清洁和消毒。'可被翻译为：Pipes, ducts and other utilities should not be present in cleanrooms. If unavoidable, then they should be installed so that they do not create recesses, unsealed openings and surfaces which are difficult to clean. Installation should allow cleaning and disinfection of outer surface of the pipes.\n'第七十一条 设备的设计、选型、安装、改造和维护必须符合预定用途，应当尽可能降低产生污染、交叉污染、混淆和差错的风险，便于操作、清洁、维护，以及必要时进行的消毒或灭菌。'可被翻译为：Article 71 The design, selection, installation, adaption and maintenance of equipment should be suitable for its intended use, minimize the risk of contamination, cross-contamination, mixups or errors, and facilitate operation, cleaning, maintenance, as well as disinfection or sterilization if necessary.\n'第七十一条 设备的设计、选型、安装、改造和维护必须符 合预定用途，应当尽可能降低产生污染、交叉污染、混淆和差错 的风险，便于操作、清洁、维护，以及必要时进行的消毒或灭菌。'可被翻译为：Article 71: The design, selection, installation, adaption and maintenance of equipment should be suitable for its intended use, minimize the risk of contamination, cross-contamination, mixups or errors, and facilitate operation, cleaning, maintenance, as well as disinfection or sterilization if necessary.\n\n根据上述已知信息，请将'设备及辅助装置和服务的设计和安装方式，应尽可能地使操作、维护和维修在洁净室外进行。如果必须在洁净室中进行维护，并且无法维持所要求的洁净和\/或无菌标准，则应当考虑预防措施，例如限制指定人员进入工作区，建立明确的工作方案和维护程序。还应考虑额外的清洁、消毒和环境监测。如果需要对设备进行灭菌，应尽可能在重新组装完成后灭菌。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"As far as practicable, equipment, fittings and services should be designed and installed so that operations, maintenance, and repairs can be performed outside the cleanroom. If maintenance has to be performed in the cleanroom, and the required standards of cleanliness and\/or asepsis cannot be maintained, then precautions such as restricting access to the work area to specified personnel, generation of clearly defined work protocols and maintenance procedures should be considered. Additional cleaning, disinfection and environmental monitoring should also be considered. If sterilisation of equipment is required, it should be carried out, wherever possible, after complete reassembly."
    },
    {
        "instruction":"已知信息：\n'（五）药品生产企业质量受权人签字并加盖企业公章的批生产及检定记录摘要；'可被翻译为：(V) Summary of batch production and testing records signed by the  Qualified Person of the drug manufacturer and affixed with the seal of the enterprise;\n'5.经批准的工艺规程和操作规程；'可被翻译为：5) Approved master manufacturing documents and operation procedures;\n'生物制品批生产及检验记录摘要，是指概述某一批生物制品全部生产工艺流程和质量控制关键环节检验结果的文件。该文件应当由企业质量管理部门和质量受权人审核确定。'可被翻译为：Summary of batch production and testing records of biological products refers to a document summarizing the testing results on all production processes and critical quality control links of a certain batch of biological products. Such document shall be reviewed and determined by the quality management department and the qualified person of the enterprise.\n'生物制品批生产及检定记录摘要，是指概述某一批生物制品全部生产工艺流程和质量控制关键环节检验结果的文件。该文件应当由企业质量管理部门和质量受权人审核确定。'可被翻译为：Summary of batch production and testing records of biological products refers to a document summarizing the testing results on all production processes and critical quality control links of a certain batch of biological products. Such document shall be reviewed and determined by the quality management department and Qualified Person of the enterprise.\n\n根据上述已知信息，请将'（五）质量受权人签字并加盖企业公章的批生产及检验记录摘要；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(V)  Summary of batch production and testing records signed by the qualified person and affixed with the seal of the enterprise;"
    },
    {
        "instruction":"已知信息：\n'经Q4B专家工作组（EWG）审核，ICH指导委员会建议，欧洲药典附录2.9.19（不溶性微粒检查）、日本药典附录6.07（注射剂不溶性微粒检查）和美国药典附录<788>（注射剂不溶 性微粒）中各自规定的分析方法在ICH区域中具有同等效力。'可被翻译为：The ICH Steering Committee, based on the evaluation by the Q4B Expert Working Group (EWG), recommends that the official pharmacopoeial texts, Ph.Eur. 2.9.19. Particulate Contamination: Sub-visible Particles, JP 6.07 Insoluble Particulate Matter Test for Injections, and USP <788> Particulate Matter in Injections can be used as interchangeable in the ICH regions subject to the following condition:\n'经Q4B专家工作组（EWG）审核，ICH指导委员会建议，欧洲药典附录2.9.7（未包衣片剂 的脆碎度检查）、日本药典一般信息26（片剂脆碎度检查）以及美国药典附录<1216>（片剂 脆碎度）中各自规定的分析方法，在ICH区域中具有同等效力。'可被翻译为：The ICH Steering Committee, based on the evaluation by the Q4B Expert Working Group (EWG), recommends that the analytical procedures described in the official pharmacopoeial texts, Ph.Eur. 2.9.7. Friability of Uncoated Tablets, JP General Information 26. Tablet Friability Test, and USP <1216> Tablet Friability, can be used as interchangeable in the ICH regions.\n'1.在世界卫生组织药品资格预审规划中认可的药典(即英国药典(BP)、欧洲药典(Ph.Eur.)、国际药典(Ph.Int.)、日本药典(JP)和美国药典(USP))。\n2.这些药典在世界卫生组织\/PQP(即国际药典(Ph. Int.)、欧洲药典(Ph. Eur.)、英国药典(BP)、日本药典(JP)和美国药典(USP)中得到认可。\n3.其标准被NMRA正式认可的药典。这些可能是国家、地区或国际药典，由NMRA自行决定。'可被翻译为：1.Those pharmacopoeias recognized in the WHO Prequalification of Medicines Programme (i.e. British Pharmacopoeia (BP), European Pharmacopoeia (Ph.Eur.), The International Pharmacopoeia (Ph.Int.), Japanese Pharmacopoeia (JP) and United States Pharmacopeia (USP).\n2.Those pharmacopoeias recognized in the WHO\/PQP (i.e. The International Pharmacopoeia (Ph. Int.), the European Pharmacopoeia (Ph. Eur.), the British Pharmacopoeia (BP), the Japanese Pharmacopoeia (JP) and the United States Pharmacopeia (USP)).\n3.Those pharmacopoeias whose standards are officially recognized by an NMRA. These may be national, regional or international pharmacopoeias, at the discretion of the NMRA.\n'从药典讨论组或一个或多个药典机构(美国药典、欧洲药典或日本药典)获 得的工作文件(包含推荐采纳的药典文本和任何其他用于 Q4B 评价的支持性文 件)的过程。'可被翻译为：The working documents received from the PDG or one or more pharmacopoeial sources (USP, Ph. Eur., or JP) that contain the proposed pharmacopoeial text and any other support documents provided for Q4B evaluation.\n\n根据上述已知信息，请将'这种情况是指，就药品的注册\/审批程序而言，在 ICH 区域内，来自日本药典、欧洲药典或美国药典的特定文本均可互相替代(在恰当引用的前提下)。对于任何可互相替代的方法，分析人员均可得出相同的可接受或不可接受的结论。 而无需考虑该文本是来自哪一个具体的 PDG 成员国药典。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Where such status is indicated, any of the official texts from JP, EP, or USP can be substituted one for the other (appropriately referenced) in the ICH regions for purposes of the pharmaceutical registration\/approval process. Using any of the interchangeable methods, an analyst will reach the same accept or reject decisions irrespective of which PDG pharmacopeia is used."
    },
    {
        "instruction":"已知信息：\n'以ACK.B开头的数据元素包含与接收到的批次中的每份ICSR消息相关的信息元素消息。B 节包含与批次内的每份ICSR相关的信息，包括该消息内检测到的任何错误消息。'可被翻译为：Data elements beginning with ACK.B contain information relating to each ICSR message within the received batch. This B section contains information related to each ICSR message within a batch, including any errors detected within the message.\n'以ACK.M开头的数据元素包含确认消息所需的技术信息元素消息。'可被翻译为：Data elements beginning with ACK.M contain technical information required for Acknowledgement message.\n'重要的是，要注意ICH ICSR确认函被结构化作为批量消息的答复，并且既适用于该批次也适用于该批次内的单个消息批量消息并且既适用于该批次也适用于该批次内的单个消息（报告）。'可被翻译为：It is important to note that the ICH ICSR Acknowledgement is structured as the response to a batch message, and that it contains information both for the batch and for individual messages (reports) within that batch.\n'一个批次可以包含一个或多个ICSR消息。每个ICSR消息仅包含一个ICSR。'可被翻译为：One Batch can contain one or more ICSR messages. Each ICSR message contains one ICSR.\n\n根据上述已知信息，请将'以 ACK.A 开头的数据元素包含与收到的批次相关的技术信息元素。本节提供了识别确认的批次信息，并提供收到和解析的摘要数据。尤其是，所提供的信息是针对整个批次而非该批次中的任何特定ICSR消息消息。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Data elements beginning with ACK.A contain technical information relating to batch received. This A section provides information to identify the batch being acknowledged as well as providing summary data on receipt and parsing. In particular, the information provided is for the entire batch rather than for any specific ICSR message in that batch."
    },
    {
        "instruction":"已知信息：\n'第三十二条 医疗器械经营企业、使用单位违反本办法第七条第一款规定的，责令停止销售、使用存在缺陷的医疗器械，并处5000元以上3万元以下罚款；造成严重后果的，由原发证部门吊销《医疗器械经营许可证》。'可被翻译为：Article 32 A medical device distributor or using unit that violates the Provisions of the Paragraph 1, Article 7 of these Provisions shall be ordered to stop the sale and use of defective medical devices, and a fine of not less than 5,000 Yuan but not more than 30,000 Yuan shall be imposed concurrently; for those who have caused serious consequences, the former license issuing department shall revoke their Medical Device Distribution License.\n'第三十一条 医疗器械生产企业有下列情形之一的，予以警告，责令限期改正；逾期未改正的，处3万元以下罚款：'可被翻译为：Article 31 In one of the following circumstances, the medical device manufacturer shall be warned and ordered to rectify the situation within a time limit; if it fails to rectify within the time limit, a fine of not more than 30,000 Yuan shall be imposed:\n'第三十七条 药品经营企业、使用单位拒绝配合药品生产企业或者药品监督管理部门开展有关药品安全隐患调查、拒绝协助药品生产企业召回药品的，予以警告，责令改正，可以并处2万元以下罚款。'可被翻译为：Article 37 Drug distributors and users who refuse to cooperate with drug manufacturers or drug regulatory departments in carrying out investigation on safety hazards of drugs and refuse to assist drug manufacturers in recalling drugs shall be warned, ordered to rectify within a time limit and fined (an amount) less than 20,000 Yuan.\n'第三十条 医疗器械生产企业有下列情形之一的，予以警告，责令限期改正，并处3万元以下罚款：'可被翻译为：Article 30 In one of the following circumstances, the medical device manufacturer shall be warned and ordered to rectify the situation within a time limit, and a fine of not more than 30,000 Yuan shall be imposed concurrently:\n\n根据上述已知信息，请将'第三十三条 医疗器械经营企业、使用单位拒绝配合有关医疗器械缺陷调查、拒绝协助医疗器械生产企业召回医疗器械的，予以警告，责令限期改正；逾期拒不改正的，处3万元以下罚款。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 33 A medical device distributor or using unit that refuses to cooperate in relevant medical device defect investigation or refuses to assist the medical device manufacturer in recalling the medical device shall be warned and ordered to rectify the situation within a time limit; if it fails to do so within the time limit, a fine of not more than 30,000 Yuan shall be imposed."
    },
    {
        "instruction":"已知信息：\n'容器\/密封系统存在对产品造成不良影响的可能性，应注意评价（见下）。'可被翻译为：The container\/closure has the potential to adversely affect the product and should be carefully evaluated (see below).\n'存在孔洞和泄漏的风险。'可被翻译为：The risk of holes and leakage.\n'当真空阶段是循环的一部分，或系统在灭菌后返回到低于灭菌柜环境的压力时，灭菌柜应定期（通常为每周）进行泄漏测试。'可被翻译为：Leak tests on the steriliser should be carried out periodically (normally weekly) when a vacuum phase is part of the cycle or the system is returned, post-sterilisation, to a pressure lower than the environment surrounding the steriliser.\n'用真空系统将容器或系统中的残余气体抽到海平面0.84巴的绝对真空水平。'可被翻译为：To remove residual gas from a container or system to a vacuum level of 0.84 bar absolute at sea level using a vacuum system.\n\n根据上述已知信息，请将'如果真空或压力系统的回流会对产品造成潜在风险，应采取措施阻止真空系统或压力系统关闭时产生的回流。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Where backflow from vacuum or pressure systems poses a potential risk to the product, there should be mechanism(s) to prevent backflow when the vacuum or pressure system is shut off."
    },
    {
        "instruction":"已知信息：\n'在准备导出ICH ICSR 消息时，应参考这些数据元素来验证数据录入的准确性和合规性 XML消息元素。'可被翻译为：These data elements should be consulted to verify the accuracy and compliance of data entry when preparing outbound ICH ICSR XML messages.\n'这一过程通常称为数据质量检查。'可被翻译为：This is commonly called data quality check.\n'3.6 (008) 2014年11月 使用HL7 nullFlavors需要实施非常具体的业务 规则来进行解析--不一定是ICSR文件验证的一 部分。'可被翻译为：3.6 (008) November 2014 Use of HL7 nullFlavors requires implementation of very specific business rules for parsing – not necessarily as part of ICSR file validation.\n'ACK.A.1 ICSR批号 用户指导原则 该数据元素标识正在确认的交易元素（批处理）。'可被翻译为：ACK.A.1 ICSR Batch Number User Guidance This data element identifies the transaction (that is the batch) that is being acknowledged.\n\n根据上述已知信息，请将'ICSR文件验证正在按照数据元素(数据 类型)检查适当的HL7 nullFlavors。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"ICSR file validation is checking appropriate HL7 nullFlavors by data element (datatype)."
    },
    {
        "instruction":"已知信息：\n'通常，纳入标准应该基于排便次数和一些附加的症状如自发性和完整性（CSBM），以及潜在的其他特征如标准稠度（BSFS 3-4） 等，比较在治疗结束时相比于基线的变化。'可被翻译为：Usually, a criterion based on bowel movement frequency – however, with additional features, such as spontaneity and completeness (CSBM), and potential additional other features such as normal consistency (BSFS 3-4) can be used, comparing the change from baseline to the end of treatment.\n'后来，总次数被限于所谓的“自发排便”（SBM）或“完全自发排便”（CSBM）。'可被翻译为：Later, the total frequency was restricted to so called “spontaneous bowel movements” (SBMs), or “complete spontaneous bowel movements” (CSBMs).\n'之前有关便秘的观点习惯上认为该疾病的主要特征是排便次数减少，据此用 来评估治疗此病的新型药物的试验把排便次数及其相比于基线的变化作为主要 有效性终点。 后来，把总的排便次数有限称为 “ 自主排便”（SBMs），或“完全 自主排便”（CSBMs）次数有限65,66。'可被翻译为：Traditionally, stemming from the previous view on constipation that a main feature of the disease is the reduced frequency of defecation, trials evaluating new substances for the disease have used the frequency of bowel movements and its change to baseline as the primary efficacy endpoint. Later, the total frequency was restricted to so called “spontaneous bowel movements” (SBMs), or “complete spontaneous bowel movements” (CSBMs)65,66.\n'排便疼痛或排便困难史'可被翻译为：History of painful or hard bowel movements\n\n根据上述已知信息，请将'与此同时，在这样的工具完善之前，使用基于 CSBM的主要终点将被认为是可以接受的，因为它包含自发（排便之前的24小时之内未服用任何“救援”药物（或任何其他的泻药，包括灌肠剂或栓剂））以及良好的排便。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In the meantime, until such an instrument is available, the use of a primary endpoint based on CSBMs will be considered to be acceptable because it incorporates spontaneity (without intake of any “rescue” medication (or any other laxative, including enema or suppository) within 24 hours before the bowel movement), as well as completeness, of the bowel movement."
    },
    {
        "instruction":"已知信息：\n'没有发现钴化物注射途径相关的数据。'可被翻译为：No relevant data on parenteral exposure to cobalt compounds were found.\n'金属钴虽在体外具有致突变性，但在体内却无致染色体畸变作用。'可被翻译为：Cobalt metal was positive for mutagenicity in vitro but negative for clastogenicity in vivo.\n'钴及其无机钴化合物的口服生物利用 度为18~97%[1]。'可被翻译为：The oral bioavailability of cobalt and inorganic cobalt compounds ranges from 18-97% (ATSDR, 2004).\n'没有数据表明无机汞对人体有致癌性。'可被翻译为：There is no data to indicate that inorganic mercury is carcinogenic in human.\n\n根据上述已知信息，请将'已经证实无机钴在人体内没有重要的生物功能。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"No essential biological function of inorganic cobalt in the human body has been identified."
    },
    {
        "instruction":"已知信息：\n'第四十四条 医疗器械注册人、备案人、受托生产企业的生产条件发生变化，不再符合医疗器械质量管理体系要求的，应当立即采取整改措施；可能影响医疗器械安全、有效的，应当立即停止生产活动，并向原生产许可或者生产备案部门报告。'可被翻译为：Article 44 Where changes occur in the manufacturing conditions of the registrant, filing entity, and contract manufacturer of medical devices, so that the conditions cease to meet the requirements of the quality management system for medical devices, measures for rectification shall be taken immediately; where the safety and effectiveness of the medical devices may possibly be affected, the enterprise shall immediately stop manufacturing and report the matter to the former department that issued the Manufacturing License or accepted for filing.\n'第七十六条  违反医疗器械生产质量管理规范，未建立质量管理体系并保持有效运行的，由药品监督管理部门依职责责令限期改正；影响医疗器械产品安全、有效的，依照医疗器械监督管理条例第八十六条的规定处罚。'可被翻译为：Article 76 For violation of the Good Manufacturing Practice for medical devices, failure in establishing a quality management system and maintaining its effective operation, the drug regulatory department shall order rectification within prescribed time limit according to its duties; if the safety and effectiveness of medical device products are affected, punishment shall be imposed in accordance with provisions in Article 86 of the Regulations on Supervision and Administration of Medical Devices.\n'第七十五条  未按照本办法规定办理第一类医疗器械生产备案变更的，依照医疗器械监督管理条例第八十四条的规定处理。'可被翻译为：Article 75 If failing to handle Class I medical device manufacturing or filing change as stipulated in these Provisions, it shall be handled in accordance with provisions in Article 84 of the Regulations on Supervision and Administration of Medical Devices.\n'第六十七条  违反医疗器械经营质量管理规范有关要求的，由药品监督管理部门责令限期改正；影响医疗器械产品安全、有效的，依照医疗器械监督管理条例第八十六条的规定处罚。'可被翻译为：Article 67 For violation of relevant requirements in the Good Supply Practice for medical devices, the drug regulatory departments shall order rectification within prescribed time limit; if safety and effectiveness of medical device products are influenced, punishment shall be imposed as stipulated in Article 86 of the Regulations on Supervision and Administration of Medical Devices.\n\n根据上述已知信息，请将'第七十七条  违反本办法第十五条第二款、第四十二条第三款的规定，生产条件变化，可能影响产品安全、有效，未按照规定报告即生产的，依照医疗器械监督管理条例第八十八条的规定处罚。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 77 For violation of provisions in Article 15(2) and Article 42(3) of these Provisions, where, the manufacturing conditions are changed, and the product safety and effectiveness might be affected, but the manufacturer performs manufacturing without making report as stipulated, it shall be punished in accordance with provisions in Article 88 of the Regulations on Supervision and Administration for Medical Devices."
    },
    {
        "instruction":"已知信息：\n'中国肿瘤免疫治疗会议已连续成功举办了5届，社会关注度和影响力不断扩大，会议为中外药品监管机构、学术界、企业界搭建了一个重要学术交流平台，促进了肿瘤免疫治疗领域的专业知识和经验交流，为推动我国药品监管领域的国际交流合作和肿瘤免疫治疗领域创新发展发挥了积极的作用。'可被翻译为：The China Cancer Immunotherapy Workshop has been successfully held for five consecutive years with rising social attention and influence. The Workshop has provided an important academic exchange platform for Chinese and foreign drug regulatory authorities, academia and industry, promoting the exchange of professional knowledge and experience in the field of cancer immunotherapy. It has played a positive role in promoting international exchanges and cooperation in the field of drug regulation and enhancing innovation and development in the field of cancer immunotherapy.\n'会议围绕肿瘤免疫治疗领域热点问题设置了免疫耐药和联合疗法、肿瘤免疫新型疗法、生物制药界视角-研发者说、检查点抑制剂的临床治疗进展、细胞疗法的临床进展、监管考量等7个专题。'可被翻译为：Focusing on the hot issues in the field of cancer immunotherapy, the Workshop setup 7 topics including Immune Resistance and Combination Therapy, Emerging New Immunotherapy, Perspective from Biopharma Industry, Clinical Update on Checkpoint Inhibitors, Clinical Update on Cellular Therapy and Regulatory Considerations.\n'2019年6月29日至6月30日，由中国食品药品国际交流中心(CCFDIE)主办，药品审评中心(CDE)、美国华裔血液及肿瘤专家学会(CAHON)和清华大学医学院协办的2019中国肿瘤免疫治疗会议在天津成功举办。'可被翻译为：2019 China Cancer Immunotherapy Workshop was successfully held on June 29-30, 2019 in Tianjin, China. The Workshop was organized by China Center for Food and Drug International Exchange(CCFDIE),in cooperation with the Center for Drug Evaluation(CDE) of National Medical Products Administration(NMPA), Chinese American Hematologist and Oncologist Network(CAHON) and School of Medicine Tsinghua University.\n'2019中国肿瘤免疫治疗会议成功举办'可被翻译为：2019 China Cancer Immunotherapy Workshop Successfully Held\n\n根据上述已知信息，请将'美国FDA、欧盟药品监管机构、国家药品监督管理局药品审评中心、美国华裔血液及肿瘤专家学会等50余位中外肿瘤免疫治疗学术界顶尖专家针对当前肿瘤免疫治疗的现状和热点进行演讲，并与参会代表进行互动交流。国内外学术机构代表、从事肿瘤免疫治疗临床研究的专家学者和生物制药企业代表参加了会议。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"More than 50 Chinese and foreign leading experts in the field of cancer immunotherapy, including US FDA, EMA, CDE, CAHON delivered speeches on the current status and hot topics of cancer immunotherapy and interactively communicated with the participants."
    },
    {
        "instruction":"已知信息：\n'给药途径；'可被翻译为：Route of administration;\n'● 给药途径、剂型和规格'可被翻译为：•Route of administration, dosage form, and strength\n'如果药物拟用于两种或两种以上临床给药途径，单一给药途径的JAS就足够，但应该在幼龄动物中为所有拟临床给药途径提供足够的暴露。'可被翻译为：If the pharmaceutical is intended for use by two or more clinical routes of administration, a JAS with a single route of administration is sufficient but should provide adequate exposure in juvenile animals for all intended clinical routes of administration.\n'药品含有相同的活性成分并且浓度、剂型及给药途径也相同。'可被翻译为：The drug contains the same active ingredient in the same concentration, dosage form, and route of administration.\n\n根据上述已知信息，请将'拟用于人的药物剂型和给药途径；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The formulation of the pharmaceutical and route(s) of administration intended for humans;"
    },
    {
        "instruction":"已知信息：\n'应考虑和测定此类基质成分对检测结果的影响。'可被翻译为：The influence of such matrix components on assay results should be considered and measured.\n'测定法特征的重要性和要求取决于测定法的使用。'可被翻译为：The importance and requirements of assay characteristics depends on the use of the assay.\n'这对检测法的影响有所不同，取决于检测法、检测 形式或类型以及抗体特征。'可被翻译为：This may affect assays differently, depending on the assay, assay format or type and the antibody characteristics.\n'应充分理解检测法的特异性以避免假阳性或假阴性结果，特别是数量有限的临床样本通常无法进行复检，例如鼻或皮肤拭子。'可被翻译为：The specificity of the assay should be well understood to avoid false-positive or false-negative results, particularly since retesting is not always feasible with clinical samples that are limited in quantity, such as nasal or skin swabs.\n\n根据上述已知信息，请将'应充分理解样本类型和组成对检测法性能的影响。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The effect of sample type and composition on assay performance should be well understood."
    },
    {
        "instruction":"已知信息：\n'原发性免疫性血小板减少症的主要治疗目标是保障血小板数量维持在足以防止严重出血的范围内，而不是将血小板数量纠正至正常水平。'可被翻译为：The major goal for treatment of ITP is to provide a platelet count that prevents major bleeding rather than correcting the platelet count to normal levels.\n'成人原发性免疫性血小板减少症在欧洲的年发病率为1.6－3.9例\/100000人， 发病率随年龄增高而增高。该病在中年女性（30－60岁）中的发病率高于同年 龄段男性。'可被翻译为：In Europe, adult ITP has an incidence of 1.6 to 3.9 cases per 100,000 per year with increasing incidence with older age and equal for the sexes except in the mid-adult years (30-60 years), when the disease is more prevalent in women.\n'本指南不包括拟用于病程少于12个月的原发性免疫性(特发性)血小板减少 症和继发性血小板减少症(免疫性或非免疫性)治疗的药品。'可被翻译为：This guideline does not cover primary immune (idiopathic) thrombocytopenia of less than 12 months duration or secondary thrombocytopenia (immune or non-immune) as the intended indications.\n'原发性免疫性血小板减少症的症状和体征均不典型。'可被翻译为：Signs and symptoms vary widely.\n\n根据上述已知信息，请将'高龄、生活方式、药物、遗传及获得性出血疾病等因素可增加出血风险。在制定原发性免疫性血小板减少症管理方案时，应充分考虑上述因素的影响。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Additional factors may increase the risk (e.g., advanced age, lifestyle factors, concomitant medications, congenital or acquired bleeding disorders) and should be evaluated before the appropriate management is determined."
    },
    {
        "instruction":"已知信息：\n'器官灌注'可被翻译为：organ perfusion\n'将注射液直接注射入动脉的给药方法。'可被翻译为：The method of administering an injection directly into the artery.\n'（2）暴露： a.测定血液或血浆中的药物相关物质。骨髓是血液灌注性良好的组织，血液或血浆中药物相关物质的水平通常与骨髓中观察到的水平相似。'可被翻译为：ii.Exposure: a. Measurement of drug related material either in blood or plasma.The bone marrow is a well perfused tissue and levels of drug related materials in blood or plasma are generally similar to those observed in bone marrow.\n'可采用以下方法测定药物在胃肠道中的渗透性：（1）人体体内肠道灌注研究；（2）使用合适的动物模型进行体内或原位肠道灌注研究；（3）离体人或动物肠道组织的体外渗透性研究；（4）单层人工培养上皮细胞的离体渗透性研究。'可被翻译为：The following methods can be used to determine the permeability of a drug substance from the GI tract: (1) in vivo intestinal perfusion studies in humans; (2) in vivo or in situ intestinal perfusion studies using suitable animal models; (3) in vitro permeation studies using excised human or animal intestinal tissues; or (4) in vitro permeation studies across a monolayer of cultured epithelial cells.\n\n根据上述已知信息，请将'将器官进行人工血液或营养液标准灌注的方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A method of standard infusion of an organ with artificial blood or nutrient solution."
    },
    {
        "instruction":"已知信息：\n'3.用于研究数据采集、传输、储存、处理、归档等的计算 机化系统(或者包含有计算机系统的设备和仪器)应经过验证，并保留相应的验证计划、记录和报告；系统更换硬件、软件或者系统升级、安装补丁后，应进行系统评估并保留有相关评估报告；评估结果需进行验证的，应保留相应的验证计划、记录和报告；'可被翻译为：3. Computerized systems (or equipment and instruments interface to a computer) applied to data acquisition, transmission, storage, processing, archiving, etc., should be validated properly, and the corresponding validation plans, records and reports should be maintained; when hardware or software replaced, upgraded or patched, the system should be evaluated and relevant evaluation reports should be kept; if an additional validation needed after evaluation, the relevant validation plans, records and reports should be kept;\n'5.43 计算机化系统应有足够的控制以防止未经许可的人员访问或更改数据。应有控制措施防止数据遗失（如系统关机导致数据未采集）。应当记录任何数据更改、原始值、更改人和更改时间。'可被翻译为：5.43 Computerized systems should have sufficient controls to prevent unauthorized access or changes to data. There should be controls to prevent omissions in data (e.g. system turned off and data not captured). There should be a record of any data change made, the previous entry, who made the change, and when the change was made.\n'5.对实施纠正和预防措施过程中所有发生的变更应当予以记录。'可被翻译为：5. To record all changes during CAPA implementation;\n'（五）对实施纠正和预防措施过程中所有发生的变更应当予 以记录；'可被翻译为：5. To record all changes during CAPA implementation;\n\n根据上述已知信息，请将'5.47 计算机化系统的变更应当根据变更规程执行，并经过正式批准、记录和测试，所有变更应当被记录，包括对系统的软硬件和其它任何关键部件的修改和升级。记录应证明系统处于验证状态。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"5.47 Changes to the computerized system should be made according to a change procedure and should be formally authorized, documented and tested. Records should be kept of all changes, including modifications and enhancements made to the hardware, software and any other critical component of the system. These records should demonstrate that the system is maintained in a validated state."
    },
    {
        "instruction":"已知信息：\n'在 FDA 收到 IND 之后，将会给申办方-研究者发一封 IND 确认信。'可被翻译为：After the FDA receives the IND, an IND Acknowledgement Letter will be sent to the sponsor- investigator.\n'III. 获取 IND 所需的信息和与 FDA 沟通（§§312.22，312.23）'可被翻译为：III. ACQUIRING INFORMATION NEEDED FOR THE IND AND COMMUNICATING WITH THE FDA (§§ 312.22, 312.23)\n'若信息与多个IND相关，可将信息全部提交给每个IND或可提交给一个IND而在其他IND中交叉参照。'可被翻译为：Where information is relevant to more than one IND, the information can be submitted in its entirety to each IND or can be submitted to one IND and cross-referenced in the other INDs.\n'如果一个报告被提交给多个IND，则每个IND安全性报告都应说明报告提交的所有IND。'可被翻译为：If a report is submitted to multiple INDs, each IND safety report should identify all INDs to which the report is submitted.\n\n根据上述已知信息，请将'在获得所有必需的信息之后，IND 准备提交给 FDA。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"After all the needed information has been acquired, the IND is ready for submission to the FDA."
    },
    {
        "instruction":"已知信息：\n'安全性角度的研究设计 从计划角度来看，考虑研究设计是如何影响获得的安全性信息是重要的。'可被翻译为：Study design from a safety perspective    From a planning perspective it is important to consider how the study design impacts on the safety information obtained.\n'G.3. 问：一项涵盖的临床研究的定义中包括“其中单一研究者对安全性的证明具 有重要贡献的任何研究 ”。'可被翻译为：G.3. Q: The definition of a covered clinical study includes “any study in which a single investigator makes a significant contribution to the demonstration of safety.”\n'G.1. 问：仅涵盖的临床研究， 具体而言， 那些被依赖于提供某种产品有效性的支 持或其中单一研究者对安全性的证明具有重要贡献的研究，才被要求进行财务 权益和安排的披露（21 CFR §§ 54.2（e ）和 54.3）。'可被翻译为：G.1.Q: Disclosure of financial interests and arrangements is required only for covered clinical studies, specifically, those studies relied upon to provide support for the effectiveness of a product or in which a single investigator makes a significant contribution to the demonstration of safety (21 CFR §§ 54.2(e) and 54.3).\n'如果每名研究者均对研究， 以及因此对于安全性的证明具有重要贡献，那么 这样的研究将被认为是涵盖的临床研究并需进行财务披露。'可被翻译为：If each investigator makes a significant contribution to the study and, therefore, to a demonstration of safety, such studies would be considered covered clinical studies and subject to financial disclosure.\n\n根据上述已知信息，请将'答：常开展的其中单一研究者对安全性的证明具有重要贡献的研究示例将是 被设计用以考察特定的安全性顾虑的研究。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A: Examples of commonly conducted studies in which a single investigator makes a significant contribution to the demonstration of safety would be studies that are designed to address a particular safety concern."
    },
    {
        "instruction":"已知信息：\n'当根据不良反应的可能性和严重性且用于禁忌的临床状态下的不良反应风险超过了对任何患者的任何可能益处时，通常可根据可预知的不良反应来禁用药物：'可被翻译为：Ordinarily, a drug should be contraindicated on the basis of an anticipated adverse reaction if the risk of the adverse reaction in the clinical situation to which the contraindication will apply, based on both likelihood and severity of the adverse reaction, outweighs any potential benefit to any patient:\n'• 以不良反应可能性和严重性为依据，用于禁忌的临床状态下的不良反应风险超过了对任何患者的任何可能益处。'可被翻译为：·The risk of the adverse reaction in the clinical situation to which the contraindication applies, based on both likelihood and severity of the adverse reaction, outweighs any potential benefit to any patient.\n'可预知的不良反应有别于“理论上的可能性”。可预知的不良反应可通过信息（例如，已知药理效应、类别效应、与已知引起不良反应的其他药物的化学关系、动物研究）予以支持并且可考虑列入禁忌部分。而完全以理论（理论上的可能性）为依据的不良反应没有数据支持并且不宜包括在禁忌部分。'可被翻译为：Anticipated adverse reactions are distinguishable from“theoretical possibilities\". Anticipated adverse reactions are supported by data (e.g., from known pharmacologic effects, class effect, chemical relationships to other drugs known to cause reactions, animal studies) and may be considered for the CONTRAINDICATIONS section. Adverse reactions based wholly on theory (theoretical possibilities) are not supported by data and would not be appropriate to include in the CONTRAINDICATIONS section.\n'只有使用风险明显超过任何可能治疗益处的临床情况下，才禁用药物。只有已知的危险，而不是理论上的可能，才能作为禁忌的根据。如果不是已知的药物禁忌，这部分必须说“不”。'可被翻译为：A drug should be contraindicated only in those clinical situations for which the risk from use clearly outweighs any possible therapeutic benefit. Only known hazards, and not theoretical possibilities, can be the basis for a contraindication. If there are no known contraindications for a drug, this section must state “None.”\n\n根据上述已知信息，请将'在特定临床状态下使用药物时，可预知发生的不良反应可作为禁忌的根据。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Adverse reactions that are anticipated to occur when a drug is used in a specific clinical situation can be the basis for a contraindication."
    },
    {
        "instruction":"已知信息：\n'FDA不鼓励排除患者，因为这会妨碍研究者提 高研究结果的概括性，影响统计学把握度，也阻碍了通过其它风险因素检查效应 调整。'可被翻译为：FDA discourages the exclusion of patients because it prevents investigators from enhancing the generalizability of the study results, compromises statistical power, and precludes the examination for effect modification by these other risk factors.\n'FDA不希望尽力联系受试者的法定授权代表或家属的工作一直持 续，直至耗尽可给予受试品前的整个治疗窗。'可被翻译为：No. FDA does not expect attempts to contact a legally authorized representative (LAR) or a family member to exhaust the entire therapeutic window before the test article may be administered.\n'这些担忧主要在于，在IRB审评不容易获得的条件下（例如：在没有 IRB的医疗保健条件下）对个体患者扩展使用权项目进行IRB审评。'可被翻译为：The concerns are primarily about IRB review of individual patient expanded access programs in settings in which IRB review is not readily accessible (e.g., healthcare settings that do not have IRBs).\n'Q10：个体患者使用权用药需要机构审查委员会（IRB）审评并批准吗？'可被翻译为：Q10: Is Institutional Review Board (IRB) review and approval required for individual patient access uses?\n\n根据上述已知信息，请将'FDA知道这种完全的IRB审评要求可能阻止个体患者对治疗用研究药物的 使用权。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"FDA is aware of concerns that this requirement for full IRB review may deter individual patient access to investigational drugs for treatment use."
    },
    {
        "instruction":"已知信息：\n'3.配备所需的资源，至少包括：'可被翻译为：3. All necessary resources are provided including:\n'3.适用的设备和维修保障；'可被翻译为：3) Suitable equipment and services;\n'● 允许最小化数据（重新）录入活动所需的资源。'可被翻译为：• allows minimising resources required for data (re-)entry activities.\n'（三）药品生产企业未配备专门质量受权人履行药品出厂放行责任；'可被翻译为：(3) the drug manufacturer has failed to appoint a dedicated Qualified Person to fulfill drug release responsibilities;\n\n根据上述已知信息，请将'（三）配备所需的资源，至少包括：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"3. All necessary resources are provided including:"
    },
    {
        "instruction":"已知信息：\n'通过控制策略和规定的桥接策略（见下文） 确保符合性能特征和标准，以评估变更的影 响'可被翻译为：Adherence to performance characteristics and criteria ensured by control strategy and defined bridging strategy (see below) to assess impact of changes\n'评价了分析方法性 能特征，变更后符 合标准 和 变更后结果仍然相 当或差异可接受， 并且对质量标准的 潜在影响进行了评 价'可被翻译为：Analytical procedure performance characteristics are evaluated and criteria are met after the change And Results are comparable after change or differences are acceptable and potential impact on specification evaluated\n'除非在桥接研究期间证明符合ATP中定义的性能特征和相关标准，申请人不得按照预先设定的报告类别实施新的分析方法。'可被翻译为：The applicant should not implement the new analytical procedure using the predefined reporting category unless adherence to the performance characteristics and associated criteria defined in the ATP are demonstrated during the bridging studies.\n'除非在桥接研究期间证明符合ATP中定义的性能特征和相关标 准，申请人不得按照预定义的报告类别实施新的分析方法。'可被翻译为：The applicant should not implement the new analytical procedure using the predefined reporting category unless adherence to the performance characteristics and associated criteria defined in the ATP is demonstrated during the bridging studies.\n\n根据上述已知信息，请将'QRM和遵守相关性能特征的有关标准和\/或后续执行桥接研究 如何确保变更后测量结果的质量，并有助于证明分析方法ECs 的相应报告类别和批准后变更管理的合理性。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"• How QRM and the adherence to associated criteria for relevant performance characteristics and\/or the subsequent execution of a bridging study can ensure the post-change quality of the measured result and help to justify the respective reporting categories for ECs and the post approval change management of analytical procedures."
    },
    {
        "instruction":"已知信息：\n'对于ICH ICSR消息，该模式定义了持有人\/申请人姓名（G.k.3.3）。'可被翻译为：For ICH ICSR messages, this schema defines the Name of Holder \/ Applicant (G.k.3.3).\n'对于ICH ICSR消息，此模式定义批次\/批号（G.k.4.r.7）。'可被翻译为：For ICH ICSR messages, this schema defines the Batch \/ Lot Number (G.k.4.r.7).\n'对于ICH ICSR消息，此模式定义根元素。'可被翻译为：For ICH ICSR messages, this schema defines root element.\n'G.k.3.1授权\/申请编号'可被翻译为：G.k.3.1 Authorisation \/ Application Number\n\n根据上述已知信息，请将'对于ICH ICSR消息，此模式定义授权\/申请编号（G.k.3.1）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For ICH ICSR messages, this schema defines Authorisation \/ Application Number (G.k.3.1)."
    },
    {
        "instruction":"已知信息：\n'PK（例如药物代谢酶的多态性，如CYP2D6或转运蛋白如SLCO1B1）和PD 的基因组BM检测的临床变量应包括药物浓度水平、缺乏疗效及特殊毒性。'可被翻译为：For the evaluation of genomic BM related to PK (e.g. polymorphisms in drug metabolising enzymes, such as CYP2D6, or transporters such as SLCO1B1) or PD, the clinical variables may include level of drug concentrations, in addition to lack of efficacy or particular toxicity.\n'在不同人种患者中PK\/PD 相关临床变量的基因组BM的潜在差异也应考虑在内。'可被翻译为：The potential differences regarding the PK\/PD related clinical variables and genomic BM in different ethnic populations should be considered as appropriate.\n'应考虑在不同种族人群中PK \/ PD相关临床变量和基因组学BM的潜在差异。'可被翻译为：The potential differences regarding the PK\/PD related clinical variables and genomic BMs in different ethnic populations should be considered.\n'在变异基因型患者中，对于替代给药、增加监测或避免特定药物，CYP2D6、的检测意义，以防止与药物或代谢物暴露增加相关的ADR（PK相关的基因组学BM）'可被翻译为：CYP2D6 testing implications for alternative dosing, increased surveillance or avoidance of particulardrugs in patients with a variant genotype in order to prevent ADRs related to increased drug ormetabolite exposure (PK related genomic BMs)\n\n根据上述已知信息，请将'对于与PK或PD相关的基因组学BM的评估，临床变量可以包括药物浓度水平、特定毒性或缺乏疗效。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For the evaluation of genomic BMs related to PK or PD, the clinical variables may include level of drug concentrations, particular toxicity or lack of efficacy."
    },
    {
        "instruction":"已知信息：\n'在开始临床研究之前，应提供支持联合用药合理性的数据。'可被翻译为：Data to support a rationale for the combination should be provided prior to starting the clinical study.\n'3.5 ICH S9的3.5节章节指出，计划联合使用的药物应分别进行良 的毒理学评价。怎样的非临床数据可被认为是“分别的良好的毒理学评价”以支持药物联合应用研究？ 如果需要，推荐何时需进行专门的毒理学研究？'可被翻译为：3.5 Section 3.5 of ICH S9 states that pharmaceuticals planned for use in combination should be well studied individually in toxicology evaluations. How are these nonclinical data considered “well studied individually in toxicology evaluations” to support a combination study? If needed, when would a dedicated toxicology study be recommended?\n'应对药物联合应用临床试验进行科学合理性的判断。如果可行，为支持药物联合应用的合理性，应提供在药理学研究（例如动物肿瘤模型，基于靶点生物学机理的体外或体内研究）中证明药物联合应用可提高抗肿瘤活性的数据。这些数据可以来自内部研究或科学文献。'可被翻译为：A scientific rationale should be provided to justify a combination clinical study. Data demonstrating increased anti-tumor activity by combined pharmaceuticals in pharmacology studies (e.g., animal tumor models, in vitro or in vivo studies based on mechanistic understanding of target biology) should be provided to support rationale for the combination, if feasible. This data could be from in-house studies or the scientific literature.\n'必要时证明药物联合应用的合理性'可被翻译为：if relevant, justify pharmaceutical combinations.\n\n根据上述已知信息，请将'3.6 ICH S9的3.5章节指出，支持药 物联合应用合理性的数据应在开始临床试验前完成。怎样的数据算是“支持药物联合应用合理性的数据” ?'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"3.6 Section 3.5 of ICH S9 states that data to support a rationale for the combination should be provided prior to starting the clinical study. What are “data to support a rationale for the combination study”?"
    },
    {
        "instruction":"已知信息：\n'剂量探索研究中的治疗持续时间将取决于试验药物的药效学性质和预期的起效时间，并且应该被证明是合理的。'可被翻译为：The treatment duration in dose-finding studies will depend on the pharmacodynamic properties and expected onset of action of the trial medication and should be justified.\n'试验持续时间应与治疗目的相关。'可被翻译为：Trial duration should be relevant to the treatment goal.\n'研究期限应该保证患者停药后能对患者进行足够的随访评估。其长短取决于 药物的预计的PK和PD性质。'可被翻译为：The duration of the studies should allow for sufficient follow-up assessments after discontinuation of medication and will depend on the predicted PK and PD characteristics of the individual drug.\n'因为试验类型取决于试验目标和所选择的活性对照，优效性试验和非劣效性 研究设计都是可以接受的。'可被翻译为：Because the type of trial depends on the objectives and chosen comparators the use of a superiority or non-inferiority design may both be acceptable.\n\n根据上述已知信息，请将'验证性临床研究的期限还取决于实验药物的性质和试验目标。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The duration of a confirmatory clinical study will also depend on the nature of the experimental drug and the objectives of the trial."
    },
    {
        "instruction":"已知信息：\n'提供的依据可能包括确认数据和批分析等信息。'可被翻译为：Justification may include information such as validation data and batch analyses.\n'这些因素可包括暴露 倍数、生物学合理性、剂量-反应关系证据、潜在可逆性、母体毒性混杂的可能性 以及种属间一致性证据。'可被翻译为：These can include exposure margins, biological plausibility, evidence of a dose-response relationship, potential for reversibility, the potential for confounding parental toxicity, and evidence for cross-species concordance.\n'作为药物警戒计划的一部分，通常要求对 这些AEs\/ADRs作更进一步评价（如，在正常使用条件下的频度， 严重程度，转归，高风险的人群，等等）。'可被翻译为：These AEs\/ADRs should usually call for further evaluation as part of the Pharmacovigilance Plan (e.g., frequency in normal conditions of use, severity, outcome, at-risk groups, etc.).\n'应确定严重程度、持续时间和可逆性。'可被翻译为：Severity, duration and reversibility should be determined.\n\n根据上述已知信息，请将'如果可能，这些信息应包括关于因果关系、严重程度、严重性、频度、可逆性和高风险人群的证据。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"This information should include evidence bearing on a causal relationship, severity, seriousness, frequency, reversibility and at-risk groups, if available."
    },
    {
        "instruction":"已知信息：\n'一般来说，MAH应在PBRER的适用参考产品信息的背景下进行利益-风险评估。'可被翻译为：In general, the MAH should perform the benefit-risk assessment within the context of the applicable Reference Product Information for the PBRER.\n'参考产品信息（CCDS）中包含的由 MAH 编写并要求在公司销售该药物的所有国家\/区域列出的所有相关的安全性信息，除非当地监管机构具体要求修改。它是 MAH用于 PBRER 的参考产品信息中包含的信息的一个子集。参考产品信息为公司核心数据表（CCDS）时，参考安全性信息为公司核心安全性信息（CCSI）。'可被翻译为：All relevant safety information contained in the reference product information (e.g., CCDS) prepared by the MAH and which the MAH requires to be listed in all countries where the company markets the drug, except when the local regulatory authority specifically requires a modification. It is a subset of information contained within the MAH’s reference product information for the PBRER. Where the reference product information is the Company Core Data Sheet (CCDS), the reference safety information is the Company Core Safety Information (CCSI).\n'为了 方便利益和利益-风险的评估，参考产品信息文件应列出ICH国家或区域的所有 已批准适应症。'可被翻译为：In order to facilitate the assessment of benefit and benefit-risk by indication in the evaluation sections of the PBRER, the reference product information document should list all approved indications in ICH countries or regions.\n'构成新信息的是可能会改变已批准适应症中产品的已知利益特征的有效性\/效用信 息。'可被翻译为：What constitutes new information is efficacy\/effectiveness information that might alter the known benefit profile of the product in the approved indication.\n\n根据上述已知信息，请将'销售许可证持有人（MAHs）通常具有以下一种参考信 息来源： 包括有助于利益-风险评估的所有参数（即利益，有效性\/疗效，适应症 和安全性信息）； 所有ICH区域都很常见；并且 所有情况（例如，仿制药，仅在一个国家许可的产品）的解决结果。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"It is generally impractical for Marketing Authorisation Holders (MAHs) to have one reference information source that: Encompasses all parameters that contribute towards the benefit-risk evaluation, (i.e., benefit, efficacy\/effectiveness, indication(s) and safety information); Is common to all ICH regions; and Addresses all circumstances, (e.g., generics, products licensed in one country only)."
    },
    {
        "instruction":"已知信息：\n'器官、液体或组织的采集'可被翻译为：Collection of organ, fluid, or tissue\n'样本采集的主要组织\/体液应包括以下组合：注射部位、 生殖腺、肾上腺、大脑、脊髓（颈椎、胸椎和腰椎）、肝脏、 肾脏、肺、心脏、脾脏和血液。'可被翻译为：The collected samples should include the following panel of tissues\/biofluids: injection site(s), gonads, adrenal gland, brain, spinal cord (cervical, thoracic, and lumbar), liver, kidney, lung, heart, spleen, and blood.\n'大体病理学 淋巴器官\/组织'可被翻译为：Gross pathology Lymphoid organs \/ tissues\n'器官重量、大体器官病理、临床生化和组织病理的改变可提示特定的内分泌作用。'可被翻译为：Changes in organ weight, gross organ pathology, clinical chemistry, and histopathology can all be indicative of particular endocrine effects.\n\n根据上述已知信息，请将'通常采集用于大体评估和组织病理学评估的器官包括内分泌敏感器官，例如 甲状腺、肾上腺、生殖器官和垂体。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Organs typically collected for gross and histopathological evaluation include endocrine-sensitive organs such as the thyroid gland, adrenal glands, reproductive organs, and pituitary gland."
    },
    {
        "instruction":"已知信息：\n'第七十条 伪造、变造、买卖、出租、出借医疗器械注册证的，按照《医疗器械监督管理条例》第六十四条第二款的规定予以处罚。'可被翻译为：Article 70 Where a medical device registration certificate is falsified, altered, bought or sold, leased or lent, punishments shall be made according to Paragraph 2, Article 64 of the Regulations on Supervision and Administration of Medical Devices.\n'第七十九条 提供虚假资料或者采取其他欺骗手段取得医疗器械注册证的，按照《医疗器械监督管理条例》第六十四条第一款的规定予以处罚。'可被翻译为：Article 79 Where a medical device registration certificate is obtained by providing spurious documents or by other deception means, punishments shall be imposed according to Paragraph 1, Article 64 of the Regulations on Supervision and Administration of Medical Devices.\n'第二十四条  任何单位或者个人不得伪造、变造、买卖、出租、出借医疗器械生产许可证。'可被翻译为：Article 24 No entity or individual is allowed to falsify, alter, trade in, rent or lend out the Medical Device Manufacturing License.\n'第二十八条  任何单位和个人不得伪造、变造、买卖、出租、出借医疗器械经营许可证。'可被翻译为：Article 28 No entity or individual is allowed to falsify, alter, trade in, rent or lend out the Medical Device Distribution License.\n\n根据上述已知信息，请将'第八十条 伪造、变造、买卖、出租、出借医疗器械注册证的，按照《医疗器械监督管理条例》第六十四条第二款的规定予以处罚。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 80 Where a medical device registration certificate is falsified, altered, bought or sold, leased or lent, punishments shall be made according to Paragraph 2, Article 64 of the Regulations on Supervision and Administration of Medical Devices."
    },
    {
        "instruction":"已知信息：\n'在操作性疼痛的评估中也可能需要测量焦虑。'可被翻译为：It may also be necessary to measure anxiety in the assessment of procedural pain.\n'情绪功能测量： 伴发焦虑和抑郁常见于慢性疼痛患者。'可被翻译为：Measurement of emotional functioning: Co-morbid anxiety and depression are common in chronic pain patients.\n'慢性疼痛疾病，如慢性下背痛（CLBP），通常与焦虑、抑郁、睡眠障碍、疲劳 相关，并且可能对身体和社会功能产生影响。'可被翻译为：Chronic pain disorders such as chronic low back pain (CLBP) are frequently associated with anxiety, depression, sleep disturbances, fatigue and may have an impact on physical and social functioning.\n'并存症状是常见的，如焦虑和抑郁、癫痫发作、注意力缺陷、攻击性行为和睡眠障碍。'可被翻译为：Co-morbid symptomsare frequent, such as anxiety and depression, seizures, attention deficits, aggressive behaviours andsleep disorders.\n\n根据上述已知信息，请将'情绪变化、焦虑和睡眠障碍可能会改变疼痛感觉，并可能会影响有效性评估。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Mood changes, anxiety and sleep disturbance may change pain perception and might affect efficacy assessments."
    },
    {
        "instruction":"已知信息：\n'利用天然或合成的高分子材料为膜壳，将固体或液体药物作为囊心物包裹而成的药库型微小胶囊。'可被翻译为：The use of natural or synthetic polymer material as the membrane shell, solid or liquid drugs as the core of the capsule wrapped into the drug store-like micro capsule.\n'微囊中被包裹的固态或液态物质。'可被翻译为：A solid or liquid substance encased in a microcapsule.\n'由天然或合成的高分子材料制成的、粒度在纳米数量级（0.1〜100nm）的固态胶体微粒。'可被翻译为：Solid colloidal particles with a particle size in the order of nanometers (0.1 to 100nm) made of natural or synthetic polymer materials.\n'利用天然或合成的高分子材料为载体材料，使药物溶解或\/和分散在高分子材料中，形成的骨架型微小球状实体。'可被翻译为：The use of natural or synthetic polymer materials as carrier materials, so that the drug dissolved or\/and dispersed in the polymer material, the formation of a skeleton type of tiny spherical entity.\n\n根据上述已知信息，请将'将固态或液态药物（囊心物）包裹在天然的或合成的高分子材料（囊材）中形成微囊的过程。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The process by which a solid or liquid drug (capsule substance) is encased in a natural or synthetic polymer material (capsule material) to form a microcapsule."
    },
    {
        "instruction":"已知信息：\n'又称\"测序仪”。自动测定多肽链中氨基酸序列的一种仪器。其工作原理是基于埃德曼降解法的重复应用。'可被翻译为：Also known as a \"sequencer\". An instrument that automatically determines the sequence of amino acids in a polypeptide chain. Its working principle is based on repeated application of the Edman degradation process.\n'氨基酸组成分析仪'可被翻译为：amino acid composition analyzer\n'测定蛋白质的多肽链的两端氨基酸排列顺序的分析法。'可被翻译为：An analytical process for determining the sequence of amino acids at the ends of a protein polypeptide chain.\n'在肽或蛋白质的序列中，氨基酸之间的氨基和竣基脱水成键，因此肽或蛋白质分子中的氨基酸已不是完整的氨基酸，被称为残基。'可被翻译为：In the sequence of peptide or protein, the amino group and the carboxyl group between amino acids are dehydrated to form a bond, so the amino acid in the peptide or protein molecule is not a complete amino acid and is called residue.\n\n根据上述已知信息，请将'自动测定氨基酸混合物、多肽或蛋白质样品中氨基酸组成的一种仪器。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"An instrument that automatically determines the amino acid composition of a sample of amino acid mixtures, peptides, or proteins."
    },
    {
        "instruction":"已知信息：\n'在产品的整个生命周期中，制药厂商都有机会去评估创新方法以改进产品质量（见ICH Q10）。'可被翻译为：Throughout the product lifecycle, companies have opportunities to evaluate innovative approaches to improve product quality (see ICH Q10).\n'这样，这个更系统化的研发策略可以促进药品在整个生命周期内的持续改进和创新（见ICH Q10）。'可被翻译为：As a result, this more systematic approach could facilitate continual improvement and innovation throughout the product lifecycle (See ICH Q10).\n'ICH将监管机构与制药行业连接在一起，以协调药物注册在科学和技术方面的问题。'可被翻译为：The ICH brings together regulatory authorities and the pharmaceutical industry to harmonise scientific and technical aspects of drug registration.\n'ICH的主要职责是便于制药行业与监管机构之间及内部交换药物警戒信息。'可被翻译为：The primary ICH application is for the exchange of pharmacovigilance information between and among the pharmaceutical industry and regulatory authorities.\n\n根据上述已知信息，请将'协调统一的生命周期管理的技术和法 规考虑将促进制药行业的创新及持续改进、加强质量保证和改善药 品供应，从而使患者、行业和监管机构从中受益。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A harmonised approach regarding technical and regulatory considerations for lifecycle management will benefit patients, industry, and regulatory authorities by promoting innovation and continual improvement in the pharmaceutical sector, strengthening quality assurance and improving supply of medicinal products."
    },
    {
        "instruction":"已知信息：\n'当监测和\/或 CCS 表明需要对微生物、微粒和内毒素\/热原进行控制时，原辅料、零部件和产品的质量标准应包括微生物、微粒和内毒素\/热原限度的要求。'可被翻译为：Specifications  for  raw  materials,  components  and  products  should  include  requirements  for  microbial, particulate and endotoxin\/pyrogen limits when the need for this has been indicated by monitoring and\/or by the CCS.\n'这些条件应采用适当的过程控制和合理的可接受限 度进行监测。'可被翻译为：These conditions should be monitored by appropriate in-process controls   with justified acceptance limits.\n'用来描述为确保原料药符合其标准而必须控制在预定标准范围内的工艺步骤、工艺条件、测试要求或其他有关参数或项目。'可被翻译为：Describes a process step, process condition, test requirement, or other relevant parameter or item that must be controlled within predetermined criteria to ensure that the API meets its specification.\n'与产品直接或间接接触的已灭菌设备、组件和辅助用品的拆包、装配和准备应作为无菌工艺过程，在 B 级环境下的 A 级区域内执行。无菌产品的灌装线组装和灌装应作为无菌工艺过程，在 B 级环境下的 A 级区域内执行。当使用隔离器时，背景应符合 4.20 节的规定'可被翻译为：The unwrapping, assembly and preparation of sterilised equipment, components and ancillary items with direct or indirect product contact should be treated as an aseptic process and performed in grade A with a grade B background. The filling line set-up and filling of the sterile product should be treated as an aseptic process and performed in grade A with a grade B background. Where an isolator is used, the background should be in accordance with paragraph 4.20\n\n根据上述已知信息，请将'温度和相对湿度等检测项目应控制在符合产品\/工艺\/人员要求的范围内，并应能够用于维护规定的洁净标准（例如 A 级或 B 级）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Other characteristics, such as temperature and relative humidity, should be controlled within ranges that align with product\/processing\/personnel requirements and support maintenance of defined cleanliness standards (e.g. grade A or B)."
    },
    {
        "instruction":"已知信息：\n'若已对活性代谢产物的药代动力学特征进行了研究，则应采用与活性药物相似的方法给出数据。如果原型药与代谢产物均具有活性，则还应给出各药理等值成分的暴露量总和。'可被翻译为：If the pharmacokinetics of active metabolites has been investigated, the data should be presented in a similar way as for an active drug. If both parent and metabolite are active, the sum of the exposure of pharmacological equivalents should be presented as well.\n'通常这 个倍数应按原形药水平来确定；但是，也应考虑确保人体主要代谢产物也具有充 足的暴露倍数（参见ICH M3和ICH M3 Q&A）。'可被翻译为：Usually this multiple should be determined based on parent drug levels; however, consideration should also be given to ensuring an adequate exposure margin to major human metabolites (see ICH M3 and ICH M3 Q&A).\n'如果拟进行剂量调整依据是Cmin而非AUC，则应考虑当药物的体内代谢产物改变时，Cmin 和 AUC 的关系可能会发生改变。'可被翻译为：If the proposed dose-adjustment is based on Cmin as a surrogate for AUC, it should be taken into account that the relation between Cmin and AUC may be altered, if the systemic metabolism of the drug is changed.\n'在前药的情况下，暴露倍数按 活性代谢产物计算更合适，尤其是如果实验种属体内活性代谢产物与前药的比率 比人体中的更低时。'可被翻译为：In the case of prodrugs, it can be more appropriate to establish the exposure multiple on the basis of the active metabolite, particularly if the test species has a lower ratio of active metabolite to prodrug, compared to humans.\n\n根据上述已知信息，请将'如果原型药具有药理活性且体内存在相关的活性代谢产物，则应在拟进行剂量调整时将此类代谢产物的暴露考虑在内。适当情况下可将该活性成分用于制定剂量调整方案（参见 6.1 节）。但是单一成分的暴露水平增加必须考虑在内。剂量调整后所有相关活性成分的暴露水平尽可能保持在可接受的范围内。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"If the parent drug is pharmacologically active and there are in vivo relevant active metabolites, the exposure of these metabolites should be taken into account when proposing dose adjustments. When relevant, the active moiety can be used to develop dose adjustment (see also section 6.1). However, increased exposure of the separate substances must also be considered. The exposure of all relevant active substances should, as far as possible, be within a well tolerated range after dose adjustment."
    },
    {
        "instruction":"已知信息：\n'联系信息在下文中给出。'可被翻译为：Contact information is provided below.\n'这些留言应包括可能能够暂时获得协助的其他工作人员的预期返回时间和联系信息，特别是对于时效性沟通（例如临床试验暂停通知）。'可被翻译为：The messages should include an expected return time and contact information for other staff that may be able to assist in the interim, particularly for time-sensitive communications (e.g., notification of clinical hold).\n'适当时，法规申报资料应包括更新的控制策略。'可被翻译为：If appropriate, the regulatory submission would include an updated control strategy.\n'当适当时，应测定系统药物水平'可被翻译为：Systemic drug levels should be measured, as appropriate\n\n根据上述已知信息，请将'在适当时，此联系信息应包括在外出留言中。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"This contact information should be included in out-of-office messages, whenever appropriate."
    },
    {
        "instruction":"已知信息：\n'带注释的QRD产品信息模板（‘QRD注释模板’）以及QRD模板所遵循的约定对格式和文本给出了指导，二者应结合核心SmPC和产品特性概要指南指导原则'可被翻译为：The QRD product information template with explanatory notes ( QRD annotated template’) and the convention to be followed for QRD templates provide general guidance on format and text and should be read in conjunction with the core SmPC and the Guideline on summary of product characteristics.\n'应遵循SmPC指南和QRD模板。带有注释的QRD产品信息模板（QRD注释模板）和QRD 模板应遵循的协定 提供了关于格式和文本的通用指南，并且应结合核心SmPC 和产品特性概要指导原则 解读。'可被翻译为：The QRD product information template with explanatory notes (‘QRD annotated template’) and the convention to be followed for QRD templates provide general guidance on format and text and should be read in conjunction with the core SmPC and the Guideline on summary of product characteristics.\n'带有注释的QRD产品信息模板（QRD注释模板1）和QRD模板2所遵循的协定会提供关于格式和文字的普通指导，二者应结合核心SmPC和产品特性概要3指导原则来阅读。'可被翻译为：The QRD product information template with explanatory notes (QRD annotated template1) and the convention to be followed for QRD templates2 provide general guidance on format and text and should be read in conjunction with the core SmPC and the Guideline on summary of product characteristics3 .\n'有注解的QRD产品信息模板（QRD注解模板）及其所遵循的协定提供了关于格式和文本的基本指导原则而且应结合核心SmPC及 产品特性总结指导原则'可被翻译为：The QRD product information template with explanatory notes (′QRD annotated template’) and the convention to be followed for QRD templates provide general guidance on format and text and should be read in conjunction with the core SmPC and the Guideline on summary of product characteristics.\n\n根据上述已知信息，请将'本核心SmPC应结合QRD产品模板和关于提供药物制剂提交资料一般原则 的产品特征概要指南3来理解，其中QRD产品模板含附注（‘QRD注释模板’）1和 QRD模板2应遵循的可提供关于SmPC、标签和包装说明书格式和文本一般指导原 则的约定。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"This core SmPC should be read in conjunction with the QRD product template with explanatory notes (′QRD annotated template’)1 and the convention to be followed for QRD templates2 which provide general guidance on format and text for SmPC, labelling and package leaflet, and with the Guideline on summary of product characteristics3 which provides general principles of presenting information on medicinal products."
    },
    {
        "instruction":"已知信息：\n'在有意向提交给药政管理当局临床数据时应当遵循本指导 原则。'可被翻译为：This guideline should be followed when generating clinical trial data that are intended to be submitted to regulatory authorities.\n'本指导原则涵盖生物学数据、临床试验和患者随 访。'可被翻译为：The guidance covers biological data, clinical trials and patient follow-up.\n'涉及药效学效应和适应症的固定剂量复方制剂的范例：'可被翻译为：Examples of Fixed Dose Combinations in relation to pharmacodynamics effects and indications:\n'. 治疗方案及治疗持续时间应按适应症进行列表， 除非所有适应症都采用相同 的治疗方案和持续时间。'可被翻译为：The dose regimen and the duration of treatment courses should be tabulated by indication unless there is only one regimen and duration applicable to all indications.\n\n根据上述已知信息，请将'这条指导原则涉及了支持适应症所需的药效学和临床数据、治疗尿失禁的剂量方案和持续时间。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"This guideline considers pharmacodynamic and clinical data required to support indications, dose regimens and durations of therapy for the treatment of urinary incontinence (UI)."
    },
    {
        "instruction":"已知信息：\n'6.持有人委托生产制剂的，应当与符合条件的药品生产企业签订委托协议和质量协议，委托协议和质量协议的内容应当符合有关法律法规规定。国家药监局发布药品委托生产质量协议指南后，委托双方应当按照要求对委托协议和质量协议进行完善和补充签订。'可被翻译为：6. If the holder entrusts the production of a preparation, it shall sign with a qualified pharmaceutical manufacturer an entrustment agreement and a quality assurance agreement, the contents of which shall comply with the relevant laws and regulations. After NMPA releases the guidelines for the quality agreement on drug consignment production, both parties to the consignment shall complete and sign the entrustment agreement and quality agreement as required.\n'（四）有保证药品质量的规章制度，并符合国务院药品监督管理部门依据本法制定的药品生产质量管理规范要求。'可被翻译为：(4) have rules and regulations in place to ensure the quality of drugs and comply with the requirements of the Good Manufacturing Practice for Pharmaceutical Products (GMP) formulated by the drug regulatory department under the State Council in accordance with this Law.\n'药品上市许可持有人委托符合条件的药品生产企业生产药品的，应当对受托方的质量保证能力和风险管理能力进行评估，根据国家药品监督管理局制定的药品委托生产质量协议指南要求，与其签订质量协议以及委托协议，监督受托方履行有关协议约定的义务。'可被翻译为：The drug MAH shall, if it entrusts a qualified drug manufacturer to manufacture drugs, assess the quality assurance capability and risk management capability of contracted accepting company, in accordance with the requirements in the guidelines for the quality agreement of contracted drug manufacturing formulated by the NMPA, sign a quality agreement and an entrustment agreement, and supervise its performance of obligations agreed in the agreements.\n'第三十二条  医疗器械注册人、备案人委托生产的，应当对受托方的质量保证能力和风险管理能力进行评估，按照国家药品监督管理局制定的委托生产质量协议指南要求，与其签订质量协议以及委托协议，监督受托方履行有关协议约定的义务。'可被翻译为：Article 32 If the registrant or filing entity of medical devices entrusts manufacturing to others, they shall evaluate the quality assurance capability and risk management capability of the entrusted party, sign Quality Agreement and Entrustment Agreement with the entrusted party in accordance with the requirements of Guidelines for Quality Agreement on Entrusted Manufacturing formulated by NMPA, and supervise the entrusted party in performing its obligations agreed in related agreements.\n\n根据上述已知信息，请将'（四）药品委托生产质量协议及委托协议；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(4) their quality agreements and entrustment agreements for entrusted drug manufacturing;"
    },
    {
        "instruction":"已知信息：\n'第二十八条 麻醉药品、精神药品、医疗用毒性药品、放射性药品、外用药品和非处方药品等国家规定有专用标识的，其说明书和标签必须印有规定的标识。'可被翻译为：Article 28 For narcotic drugs, psychotropic substances, medicinal toxic drugs, radioactive pharmaceuticals, drugs for topical use, non-prescription drugs and other drugs having special marks specified by the State, their special marks shall be printed in the drug insert sheets and labels.\n'第一百零八条 非处方药的注册申请，其药品说明书和包装标签应当符合非处方药的有关规定。'可被翻译为：Article 108 For the registration application of a non-prescription drug, the insert sheet and package label shall comply with the relevant regulations on non-prescription drugs.\n'第三十条 药品说明书和标签不符合本规定的，按照《中华人民共和国药品管理法》的相关规定进行处罚。'可被翻译为：Article 30 Where drug insert sheets and labels are not in compliance with the Provisions, a punishment shall be imposed in accordance with the relevant provisions of the Drug Administration Law of the People's Republic of China.\n'（五）按照变更技术要求，履行变更管理责任；'可被翻译为：(5) fulfill change management responsibilities according to technical requirements for changes;\n\n根据上述已知信息，请将'第十八条 药品说明书和标签的变更管理按照相关规定和技术要求进行。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 18 The change management of package inserts and labels shall be carried out in accordance with relevant regulations and technical requirements."
    },
    {
        "instruction":"已知信息：\n'此外，还应讨论如何评估本研究对有效治疗和无效治 疗的区分能力，例如，有可能找到一种治疗反应（根据既往 研究）来明确区分治疗人群和非治疗人群，这种治疗反应可 以是某些参数相对于基线的变化或其他特定转归，例如治愈 率或生存率。'可被翻译为：How to assess the ability of the present study to distinguish effective from ineffective therapy should also be discussed. For example, it may be possible to identify a treatment response (based on past studies) that would clearly distinguish between the treated population and an untreated group. Such a response could be the change of a measure from baseline or some other specified outcome like healing rate or survival rate.\n'研究的治 疗效应可能是与不接受药物治疗或与接受其他疗法治疗相比较的效应。'可被翻译为：The treatment effect of interest may be the effect relative to not receiving the drug or the effect relative to receiving other therapies.\n'特别是，非劣效的结果如果被解释为有效的证据，该试验必须能够区分有效与低效或无效治疗。'可被翻译为：Specifically, for a finding of non-inferiority to be interpreted as showing efficacy, the trial needs to have had the ability to distinguish effective from less effective or ineffective treatments.\n'如果通过显示等效性证明疗效（即新治疗相对于已确定 治疗不存在特定程度的劣效性），则应该说明与此类研究方 案设计相关的问题，尤其应提供该研究有能力区分有效和无 效治疗的依据。'可被翻译为：If efficacy was to be demonstrated by showing equivalence, i.e., the absence of a specified degree of inferiority of the new treatment compared to an established treatment, problems associated with such study designs should be addressed. Specifically there should be provided a basis for considering the study capable of distinguishing active from inactive therapy.\n\n根据上述已知信息，请将'如一项研究采用该治疗反应，则说明该研究可 以区分有效药物和无效药物。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Attainment of such a response would support the expectation that the study could have distinguished the active drug from an inactive drug."
    },
    {
        "instruction":"已知信息：\n'虽然 CBER 或 CDER 将最终确定会议的类型（即生物仿制启动咨询会议、 BPD 1 型、 2 型、 3 型或 4 型会议），申办方或申请人应提供其会议类型的评估结果，因为这涉及到产品的 研发。'可被翻译为：Although CBER or CDER will make the final determination as to the meeting type (i.e., Biosimilar Initial Advisory meeting, or BPD Type 1, 2, 3, or 4 meeting), the sponsor or applicant should provide its meeting type assessment as it relates to the product’s development.\n'5. BPD 4 型会议： BPD 4 型会议是讨论即将根据 PHS 法第 351(k)节提交的生物 类似药申请或补充材料的格式和内容的会议。'可被翻译为：5.BPD Type 4 meeting: A BPD Type 4 meeting is a meeting to discuss the format and content of a biosimilar biological product application or supplement to be submitted under section 351(k) of the PHS Act.\n'中心（即 CBER 或 CDER）可能 判定另一个会议类型更为恰当， 批准的会议类型 与所申请的有所不同（例如若申办方或申请人申请某产品的生物仿制启动咨询会 议， 但中心确定 BPD 3 型会议更为恰当，FDA 可能批准 BPD 3 型会议， 而非生 物仿制启动咨询会议）。'可被翻译为：The Center (i.e., CBER or CDER) may determine that a different meeting type is more  appropriate and it may grant a meeting of a different type than requested (e.g., if a sponsor or  applicant requests a Biosimilar Initial Advisory meeting for a product, but the Center determines  that a BPD Type 3 meeting is more appropriate, the FDA may grant a BPD Type 3 meeting  instead of a Biosimilar Initial Advisory meeting).\n'收到会议申请的 CBER 或 CDER 主管或指定人员将确定是否举行会议， 在收到 BPD1 型会议申请及会议资 料包后 14 个自然日内，在收到生物仿制启动咨询会议或 BPD 2 型、 3 型或 4 型 会议申请及会议资料包后 21个自然日内，回复申办方或申请人批准还是拒绝会议。'可被翻译为：The CBER or CDER division director or designee who receives a meeting request will determine whether to hold the  meeting and will respond to the sponsor or applicant by granting or denying the meeting within  14 calendar days of receipt of the request and meeting package for a BPD Type 1 meeting, andwithin 21 calendar days of receipt of the request and meeting package for a Biosimilar Initial 298 Advisory meeting or a BPD Type 2, 3, or 4 meeting.\n\n根据上述已知信息，请将'7. 所申请的会议类型（即生物仿制启动咨询会议、 BPD 1 型、 2 型、 3 型或 4 型会议）应包括申请该会议类型的理论依据。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"7.Meeting type being requested (i.e., Biosimilar Initial Advisory meeting, BPD Type 1, 2, 3, or 4 meeting). The rationale for requesting the meeting type should be included."
    },
    {
        "instruction":"已知信息：\n'静脉留置针输液'可被翻译为：infusion via in-dwelling venous catheter\n'将大量无菌溶液或药物直接滴入静脉的给药方法。可选用的静脉包括：四肢浅静脉、锁骨下静脉、小儿头皮静脉、股静脉等。'可被翻译为：A method of administration in which large quantities of sterile solution or drug are dripped directly into a vein. Alternative veins include: superficial veins in the extremities, subclavian veins, pediatric scalp veins, femoral veins, etc.\n'静脉给药困难'可被翻译为：IV route difficult\n'医疗机构为患者提供静脉用药集中调配专业技术服务的部门。静脉用药调配中心通过静脉用药处方医嘱审核干预、加药混合调配、参与静脉输液使用评估等药学服务，为临床提供优质可直接静脉输注的成品输液。'可被翻译为：The healthcare institution has a specialized department that provides centralized compounding services for intravenous medications. The Intravenous Medication Compounding Center, through services such as reviewing and intervening in intravenous medication prescriptions, compounding and mixing medications, and participating in assessments of intravenous infusion usage, delivers high-quality finished intravenous infusions ready for direct administration in clinical settings.\n\n根据上述已知信息，请将'在静脉输液中为保护患者静脉，避免反复穿刺的痛苦和随时保持畅通的静脉通道，便于急救和给药，所以对长期输液、年老、衰弱、血管穿刺困难的患者而设计的给药方法。常用静脉留置针保留于外周静脉或中央静脉。静脉留置针由针头部与肝素帽两部分组成。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In order to protect patients' veins in intravenous infusion, avoid the pain of repeated puncture and maintain a smooth venous channel at any time, so as to facilitate first aid and drug administration, the drug administration method is designed for patients with long-term infusion, old age, weakness and vascular puncture difficulties. The commonly used intravenous indentation needle is retained in the peripheral vein or central vein. The intravenous indwelling needle consists of two parts: the needle and the heparin cap."
    },
    {
        "instruction":"已知信息：\n'在计量学吸光光度法中，对多组分分析时采用的一种数据处理方法。'可被翻译为：In metrology absorptiometry, a data processing method used for multi-component analysis.\n'通过使用多于一个输入变量的多变量校正模型而确定结果的分析方法。（ICH Q2）'可被翻译为：An analytical procedure where a result is determined through a multivariate calibration model utilising more than one input variable. （ICH Q2）\n'20世纪中期发展起来的学科,线性规划模式中的所有方程式及函数都是线性的，是解决多变量最优决策的方法，是在各种相互关联的多变量约束条件下，解决或规划一个对象的线性目标函数最优的问题。在计量学吸光光度法中，是用于多组分分析的一种数据处理方法。'可被翻译为：A discipline developed in the middle of the 20th century, all equations and functions in the linear programming model are linear, and it is a method to solve the multi-variable optimal decision. It is a problem to solve or plan the linear objective function optimization of an object under various interrelated multi-variable constraints. In the metrology absorptiometry, it is a data processing method used for multi-component analysis.\n'在计量学吸光光度法分析检测多组分体系时，采用的一种化学计量学数据处理方法。'可被翻译为：A stoichiometric data processing method used in the analysis and detection of multi-component systems by metrological absorbance spectrophotometry.\n\n根据上述已知信息，请将'由瑞典经济计量学家沃尔德（H.Wold）于1966年首次提出的一种新型多元统计数据分析方法，是多因变量对多自变量的回归建模方法。在计量学吸光光度法中，是一种用于多组分分析的数据处理方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A new method of multivariate statistical data analysis, first proposed by the Swedish econometrician H. Wolde in 1966, is the regression modeling method of multivariate variables to multi-independent variables. In metrology absorptiometry, it is a data processing method for multi-component analysis."
    },
    {
        "instruction":"已知信息：\n'作为传统工艺验证的替代方法，持续的工艺确认（ICH Q8）可以用于最初的商业化生产的工艺验证方案中，同样也 可用于产品生命周期剩余阶段的生产工艺变更中，以进行持 续的改进。'可被翻译为：As an alternative to the traditional process validation, continuous process verification (ICH Q8) can be utilised in process validation protocols for the initial commercial production and also for manufacturing process changes for the continual improvement throughout the remainder of the product lifecycle.\n'持续工艺确认（Continuous Process Verification）：工艺验证的另一种方法，持续监控和评价生产工艺性能。'可被翻译为：Continuous Process Verification: An alternative approach to process validation in which manufacturing process performance is continuously monitored and evaluated.\n'ICH Q10所述的质量体系要素和管理职责意在鼓励在生命周期各阶段使用基于科学和基于风险的方法以促进药品在整个生命周期中持续改进。产品和工艺知识应从研发阶段开始进行管理，贯穿产品的整个商业化生命周期，直至产品退市。'可被翻译为：The quality system elements and management responsibilities described in ICH Q10 are intended to encourage the use of science-based and risk-based approaches at each lifecycle stage, thereby promoting continual improvement across the entire product lifecycle. Product and process knowledge should be managed from development through the commercial life of the product up to and including product discontinuation.\n'这样，这个更系统化的研发策略可以促进药品在整个生命周期内的持续改进和创新（见ICH Q10）。'可被翻译为：As a result, this more systematic approach could facilitate continual improvement and innovation throughout the product lifecycle (See ICH Q10).\n\n根据上述已知信息，请将'作为传统的工艺验证方法的一种替代选择，持续工艺确认（见 ICH Q8（R2）术语）可以被应用于最初的商业生产和此后在 产品整个生命周期中进行的持续改进的工艺验证方案中。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"As an alternative to the traditional process validation, continuous process verification [see definition in ICH Q8(R2) glossary] can be utilised in process validation protocols for the initial commercial production and for manufacturing process changes for the continual improvement throughout the remainder of the product lifecycle."
    },
    {
        "instruction":"已知信息：\n'第九十二条 国家食品药品监督管理局药品审评中心依据技术审评意见和样品检验结果等，形成综合意见，连同相关资料报送国家食品药品监督管理局，国家食品药品监督管理局依据综合意见，做出审批决定。符合规定的，发给《药物临床试验批件》；不符合规定的，发给《审批意见通知件》，并说明理由。'可被翻译为：Article 92 The Center for Drug Evaluation of the State Food and Drug Administration shall make a general opinion based on the technical review opinions and sample testing results, and report the general opinion together with relevant documents to the State Food and Drug Administration. The State Food and Drug Administration shall make a review and approval decision based on the general opinion. Where the regulations are conformed to, a Clinical Trial Approval shall be issued; where the regulations are not conformed to, a Disapproval Notice shall be issued with reasons.\n'第六十五条 国家食品药品监督管理局药品审评中心依据技术审评意见、样品生产现场检查报告和样品检验结果，形成综合意见，连同有关资料报送国家食品药品监督管理局。国家食品药品监督管理局依据综合意见，作出审批决定。符合规定的，发给新药证书，申请人已持有《药品生产许可证》并具备生产条件的，同时发给药品批准文号；不符合规定的，发给《审批意见通知件》，并说明理由。'可被翻译为：Article 65 The Center for Drug Evaluation of the State Food and Drug Administration shall make a general opinion based on the technical review opinions, production site inspection reports and sample testing results, and report the general opinion together with relevant documents to the State Food and Drug Administration. The State Food and Drug Administration shall make a review and approval decision based on the general opinion. Where the regulations are conformed to, a New Drug Certificate shall be issued; if the applicant already has a Drug Manufacturing Certificate and possesses the production conditions, a drug approval number shall be issued at the same time; where the regulations are not conformed to, a Disapproval Notice shall be issued with reasons.\n'国家食品药品监督管理局依据技术审评意见作出审批决定。符合规定的，发给《药物临床试验批件》；不符合规定的，发给《审批意见通知件》，并说明理由。'可被翻译为：The State Food and Drug Administration shall make review and approval decisions based on the technical review opinions. Where the regulations are conformed to, a Drug Clinical Trial Approval shall be issued; where the regulations are not conformed to, a Disapproval Notice shall be issued with reasons provided.\n'经审评符合规定的，国家食品药品监督管理局药品审评中心通知申请人申请生产现场检查，并告知国家食品药品监督管理局药品认证管理中心；经审评不符合规定的，国家食品药品监督管理局药品审评中心将审评意见和有关资料报送国家食品药品监督管理局，国家食品药品监督管理局依据技术审评意见，作出不予批准的决定，发给《审批意见通知件》，并说明理由。'可被翻译为：Where the regulations are conformed to as reviewed, the Center for Drug Evaluation of the State Food and Drug Administration shall notice the applicant to apply for production site inspection and inform the Center for Drug Certification of the State Food and Drug Administration. Where the regulations are not conformed to as reviewed, the Center for Drug Evaluation of the State Food and Drug Administration shall report the review opinions and relevant documents to the State Food and Drug Administration; the State Food and Drug Administration shall make a disapproval decision to the application based on the technical review opinions, and issue a Disapproval Notice with reasons.\n\n根据上述已知信息，请将'第八十一条 国家食品药品监督管理局药品审评中心依据技术审评意见、样品生产现场检查报告和样品检验结果，形成综合意见，连同相关资料报送国家食品药品监督管理局，国家食品药品监督管理局依据综合意见，做出审批决定。符合规定的，发给药品批准文号或者《药物临床试验批件》；不符合规定的，发给《审批意见通知件》，并说明理由。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 81 The Center for Drug Evaluation of the State Food and Drug Administration shall make a general opinion based on the technical review opinions, production site inspection reports and sample testing results, and report the general opinion together with relevant documents to the State Food and Drug Administration. The State Food and Drug Administration shall make a review and approval decision based on the general opinion. Where the regulations are conformed to, it shall issue a drug approval number or a Drug Clinical Trial Approval; where the regulations are not conformed to, it shall issue a Disapproval Notice with reasons."
    },
    {
        "instruction":"已知信息：\n'签署的电子记录应清楚表明与签名相关的信息，内容包括：'可被翻译为：Signed electronic records shall contain information associated with the signing that clearly indicates all of the following:\n'变更实施应当有相应的完整记录。'可被翻译为：The implementation of change should be fully recorded.\n'第一百六十一条 记录应当保持清洁，不得撕毁和任意涂改。记录填写的任何更改都应当签注姓名和日期，并使原有信息仍清晰可辨，必要时，应当说明更改的理由。记录如需重新誊写，则原有记录不得销毁，应当作为重新誊写记录的附件保存。'可被翻译为：Article 161 Records should be kept in a neat fashion without tearing up or uncontrolled alteration. Any alteration made to the entry on a document should be signed and dated; the alteration should permit the reading of the original information. Where appropriate, the reason for the alteration should be recorded. When transcription is needed, the original record should not be destroyed, and be kept as attachment of the transcribed record instead.\n'6.14 操作完成后，应当及时以不易擦除的方式在相应的空格内记录，并能识别填写人。记录填写的任何更改都应当签注姓名和日期，并使原有信息仍清晰可辨。'可被翻译为：6.14 When entries are made in records, these should be made indelibly in spaces provided for such entries, directly after performing the activities, and should identify the person making the entry. Corrections to entries should be dated and signed and leave the original entry still readable.\n\n根据上述已知信息，请将'记录填写的任何更改都应当签注姓名和日期，并使原有信息 仍清晰可辨，必要时，应当说明更改的理由。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Any alteration made to the entry on a document should be signed and dated; the alteration should permit the reading of the original information. Where appropriate, the reason for the alteration should be recorded."
    },
    {
        "instruction":"已知信息：\n'应建立妥善的救援措施。'可被翻译为：Appropriate rescue measures should be established.\n'应考虑以下指出的方面。'可被翻译为：The aspects indicated below should be considered.\n'健康和安全要求以尽可能减少操作员暴露（例如，药品粉尘对大气的污染）；'可被翻译为：health and safety requirements to minimize operator exposure (e.g. atmospheric containment of pharmaceutical dust);\n'在临床研究中使用EHR作为数据源需要一些额外的考量、计划和管理。'可被翻译为：Use of EHRs as a source of data in clinical investigations may require some additional considerations, planning, and management.\n\n根据上述已知信息，请将'应急计划考量（例如，如果气体或粉尘逸出、溅出、失火和消防用水用尽）'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"emergency planning considerations (e.g. in case of gas or dust release, spillage, f ire and firewater run-off)"
    },
    {
        "instruction":"已知信息：\n'在一些情况下，不能有助于更好的确定药物安全性特征的数据收集可能存在 不利影响。'可被翻译为：In some cases, collection of data that do not contribute to better characterizing the safety profile of a drug may have negative consequences.\n'因此，在临床试验期间获得的用户交互数据可能不足以评估药品是否可以安全和正确使用。'可被翻译为：Therefore, user interaction data obtained during clinical trials may be inadequate to assess whether a drug product can be used safely and correctly.\n'·当已有数据提示存在严重风险的可能性时，确认非预期的严重风险'可被翻译为：• To identify an unexpected serious risk when available data indicates the potential for a serious risk\n'·评价与药物使用有关的严重风险信号'可被翻译为：• To assess signals of serious risk related to the use of the drug\n\n根据上述已知信息，请将'·当数据不能提示与疫苗使用有关的严重风险或严重风险信号以及当现有数据不能表明严重风险的可能性时，针对疫苗实施的研究和临床试验，例如监测和观察药物流行病学研究，例如：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"• Studies and clinical trials conducted with vaccines, such as surveillance and observational pharmacoepidemiologic studies when data do not suggest a serious risk or signals of serious risk related to the use of the vaccine and when available data do not indicate the potential for serious risk, such as:"
    },
    {
        "instruction":"已知信息：\n'可以通过探索性分析来提高对于未纳入主要分析的协变量的理解，从而有助于申办方开发药物。'可被翻译为：Exploratory analyses may be carried out to improve the understanding of covariates not included in the primary analysis, and to help the sponsor with the ongoing development of the drug.\n'应根据指定的次要疗效变量，计划并进行额外的分析，如至事件发生的时间的分析。'可被翻译为：Additional analyses should be planned and performed according to the designated secondary efficacy variables, such as time to event analyses.\n'可能受治疗分配影响的协变量（例如在随机化后测定的协变量，如疗程、依从性水平或使用挽救用药）通常不应当包括在验证性试验的主要分析中。'可被翻译为：A covariate that may be affected by the allocated treatment (for example, a covariate measured after randomisation such as duration of treatment, level of compliance or use of rescue medication) should not be included in the primary analysis of a confirmatory trial.\n'此外，极多的层数会给分析带来问题（见第 6.2 节）。'可被翻译为：Furthermore, a huge number of strata might impose problems with the analysis (see 6.2).\n\n根据上述已知信息，请将'然而，这类协变量（如疗程）可能会包括在次要（探索性）分析中，并可能会给申办方在药物开发过程中带来帮助。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"However, such covariates (e.g. duration of treatment) might be included in secondary (exploratory) analyses and might offer the sponsor useful insights during the drug development process."
    },
    {
        "instruction":"已知信息：\n'在会议期间，申办方通常不应询问未包括在会议文件包或以前未提供给FDA或FDA在其初步意见中未要求的现有新数据或信息中的实质性问题。'可被翻译为：During the course of the meeting, sponsors should generally not ask substantive questions that were not included in the meeting package, or present new data or information that was not previously provided to FDA or requested by FDA in their preliminary comments.\n'- FDA项目经理应在会前发送对申办方所提问题的初步回复，以便将 与会时间用于需要进行更多讨论的未解决问题。在初步回复中，即 使有关这些议题的问题申办方没有明确提出，FDA也应为在审评会 议文件包期间发现的重要议题提供高级别建议。'可被翻译为：‒ FDA project managers should send preliminary responses to sponsor questions before the meeting so that the meeting time can be dedicated to unresolved issues for which more discussion is needed. In the preliminary responses, FDA should provide high-level recommendations for important issues identified during the review of the meeting package, even if questions concerning those issues were not explicitly posed by the sponsor.\n'FDA可能将这些初步回应传达给申办方或申请人。'可被翻译为：The FDA may communicate these  preliminary responses to the sponsor or applicant.\n'申办方或申请人与FDA的会前 沟通，可以作为讨论的基础， 也可以作为最终的会议回应。'可被翻译为：Communications before the meeting between sponsors or applicants and the FDA, including preliminary responses, can serve as a foundation for discussion or can be the final meeting responses.\n\n根据上述已知信息，请将'在申办方或申请人与 FDA一致认为初步回应构成了FDA的最终会议回应而不需要额外的讨论之前，不 应将初步回应视为最终回应。FDA传达初步回应的目的不是让他们提交新的会议 程序或新的问题。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A preliminary response should not be construed as final unless there is agreement between the sponsor or applicant and the FDA that  the response constitutes the FDA’s final response and additional discussion is not necessary. Preliminary responses communicated by the FDA are not intended to generate the submission of  a new meeting agenda and new questions."
    },
    {
        "instruction":"已知信息：\n'31见《联邦登记通知》，“通过加强输液药品的容器标签管理提高患者的安全性；公开会议，”2006年11月 28日（71 FR 68819）。'可被翻译为：31 See the Federal Register notice “Improving Patient Safety by Enhancing the Container Labeling for Parenteral Infusion Drug Products; Public Meeting,” November 28, 2006 (71 FR 68819).\n'D.大容量注射剂的标签'可被翻译为：D. Labels for Large Volume Parenterals\n'下列资料属标签混乱，而且不应包括在大容量注射剂容器标签上或出现在专业 说明书中：'可被翻译为：The following information is considered label clutter and should not be included on the large volume parenteral container label or presented, as appropriate, in the prescribing information:\n'美国注射剂协会'可被翻译为：Parenteral Drug Association (www.pda.org)\n\n根据上述已知信息，请将'这些问题在2007年由美国食品药品监督 局， 美国医疗安全协会和美国药典联合召开的公开会议上进行了讨论31  。基于公开 会议上提出的信息和建议，FDA 认为在大容量注射剂容器的标签，下列资料是必 要的：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"These concerns were addressed at a joint public meeting held by FDA, ISMP, and USP in 2007.31 Based on the information and recommendations presented at the public meeting, FDA considers the following information to be essential for the container label of large volume parenterals:"
    },
    {
        "instruction":"已知信息：\n'例 如，可以利用疾病登记进行一个流行病学研究，了解在特殊亚组， 如有并发疾病的患者中可能发生某种事件的频率。'可被翻译为：For example, an epidemiologic study can be conducted using a disease registry to understand the frequency at which the event of interest might occur in specific subgroups, such as patients with concomitant illnesses.\n'疾病登记，如血液异常、 严重的皮肤反应或先天性畸形，有助于收集与某一临床病症关 联的药物暴露情况以及其他可能相关的因素。'可被翻译为：Disease registries, such as registries for blood dyscrasias, severe cutaneous reactions, or congenital malformations can help collect data on drug exposure and other factors associated with a clinical condition.\n'在病例-对照研究中，先确定患病（或发生关注的事件）的患者作为病例组。'可被翻译为：In a case-control study, cases of disease (or events) are identified.\n'（一）生物制品批签发品种登记表；'可被翻译为：(I)  Registration form for biological products subject to lot release;\n\n根据上述已知信息，请将'疾病登记也可以 用作病例-对照研究的基础，比如将登记表中患有某种特定疾病 的一组患者作为病例组，登记表中（或登记表外）不患有该疾 病但具有可比性的一组个体作为对照组，比较两组暴露的差异。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A disease registry might also be used as a base for a case-control study comparing the drug exposure of cases identified from the registry and controls selected from either patients with another condition within the registry, or patients outside the registry."
    },
    {
        "instruction":"已知信息：\n'每2万盒（瓶），抽样一件，不足2万盒（瓶）的按2万盒（瓶）计。'可被翻译为：Take 1 product for sampling for every 20,000 boxes (vials), and the odd less than 20,000 boxes (vials) shall be counted as 20,000.\n'10件以内，抽样1件；11件－50件，每增加10件加抽1件，不足10件者以10件计；51件－100件，每增加20件加抽1件，不足20件者以20件计；101件以上，每增加50件加抽1件，不足50件者以50件计；1001件以上，每增加100件加抽1件，不足100件者以100件计；'可被翻译为：If the quantity is less than 10, take 1 product for sampling; if the quantity is 11 to 50, take additional 1 product for sampling for every additional 10, and the odd less than 10 shall be counted as 10; if the quantity is 51 to 100, take additional 1 product for sampling for every additional 20, and the odd less than 20 shall be counted as 20; if the quantity is more than 101, take additional 1 product for sampling for every additional 50, and the odd less than 50 shall be counted as 50; if the quantity is more than 1001, take additional 1 product for sampling for every additional 100, and the odd less than 100 shall be counted as 100;\n'100－1000毫升（含1000毫升）的注射液，每1万瓶抽样1件，不足1万瓶的按1万瓶计。1000毫升以上的注射液（含透析液），每5000瓶（袋）抽样1件，不足5000瓶（袋）的按5000瓶计。'可被翻译为：If the injection is 100 ml to 1000 ml (including), take 1 product for sampling for every 10,000 vials, and the odd less than 10,000 vials shall be counted as 10,000. If the injection (including dialysate) is more than 1000 ml, take 1 product for sampling for every 5,000 vials (bags), and the odd less than 5,000 vials (bags)shall be counted as 5,000.\n'4．1公斤以下的，每20公斤抽样1件，不足20公斤者以20公斤计（原装抽样）。'可被翻译为：4. If the products within one package are less than 1 kg, take 1 product for sampling for every 20 kg, and the odd less than 20 kg shall be counted as 20 kg (taking samples from original package).\n\n根据上述已知信息，请将'2万支（瓶）以下（含2万支），抽样1件；5万支（瓶）以下（含5万支），抽样2件；10万支（瓶）以下（含10万支），抽样3件；10万支（瓶）以上，每增加10万支（瓶）加抽1件，不足10万支（瓶）以10万支（瓶）计。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"If the quantity is below 20,000 vials (including), take 1 product for sampling; if the quantity is below 50,000 vials (including), take 2 products for sampling; if the quantity is below 100,000 vials (including), take 3 products for sampling; if the quantity is more than 100,000 vials, take additional 1 product for sampling for every additional 100,000 vials, and the odd less than 100,000 shall be counted as 100,000."
    },
    {
        "instruction":"已知信息：\n'如果试验的剂量、给药途径或患者人群方面存在重要差 异，应在表格中说明这些差异，亦可单独列表说明；'可被翻译为：When there are important differences among trials in dose, route of administration, or patient population, these differences can be noted in the tables, or separate tables can be considered;\n'分析应该显示临床治疗之间差异 的大小（点估计）、相关的置信区间以及假设检验的结果。'可被翻译为：The analysis should show the size (point estimate) of the difference between the treatments, the associated confidence interval, and where utilised, the results of hypothesis testing.\n'然而，PE患者和DVT患者之间存在一些重要的差异，表明在治疗PE过程中需要单独考虑某些方面。'可被翻译为：There are, however, some important differences between patients who present with PE and those who present with DVT that justify separate consideration of some aspects of the treatment of PE.\n'或 者，如果有用且可行，可以通过试验、适应症、给药途径或其它变量来展示 SAE的表格。'可被翻译为：Alternatively, when useful and feasible, tabulations of SAEs can be presented by trial, indication, route of administration, or other variables.\n\n根据上述已知信息，请将'剂量、给药途径或患者群的试验之间的重要差异可以在表格中注明， 如果适用，或者考虑单独的表格。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Important differences among trials in dose, routes of administration, or patient populations can be noted in the tables, if applicable, or separate tables can be considered."
    },
    {
        "instruction":"已知信息：\n'原料药中所需的立体化学构型在第一步反应化合物B的 合成中产生，反应中使用了一个外购的非手性前体A和一个 手性选择试剂。'可被翻译为：The desired stereochemical configuration in the drug substance results from the synthesis of compound B in Step 1 from a commercially available achiral precursor A and a stereo-selective reagent.\n'5. 起始原料和源物质的选择 5.1 总则 5.1.1 化学合成原料药的起始原料选择 在决定原料药生产工艺的起点时，应当考虑下列原则 （即，起始原料的选择）。'可被翻译为：Selection of Starting Materials and Source Materials 5.1 General Principles 5.1.1 Selection of Starting Materials for Synthetic Drug Substances The following general principles should be considered in determining where the drug substance manufacturing process begins (i.e., in selecting starting materials).\n'在这个案例中，步骤1对原料药的唯一 影响是其中的异构体杂质的量，这可以通过在化合物D中设 定一个对映异构体的合适限度的方法来控制。'可被翻译为：In this example, the only impact of Step 1 is on the amount of the enantiomeric impurity in the drug substance, and this could alternatively be controlled through an appropriate limit on the amount of the opposite enantiomer in compound D.\n'如果药物是消旋体或对映异构体的混合物，应对分析物（消旋体或对映异构体）的选择进行附加说明。'可被翻译为：If the drug substance is a racemate or some other mixture of enantiomers, additional justification should be made for the choice of the analyte [racemate or enantiomer(s)].\n\n根据上述已知信息，请将'此外，我们还知道在第一步 中最早形成的手性中心在所有后续步骤的生产条件下稳定 （例如：未发生过消旋化或不太可能发生消旋化），而且还有 合适的分析方法来测定化合物D中对映异构体的量。因此， 如果化合物D符合大部分5.1.1部分中所述的一般原则，那 么，根据生产过程的前期步骤往往较后期步骤对原料药的质 量影响更小这一原则，提议化合物D取代化合物A作为起 始原料应是合理的。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Furthermore, it is also known that the stereocentre first formed in Step 1 is stable to the manufacturing conditions in all of the steps that follow (i.e., no racemisation occurs or is ever likely to occur), and that a suitable analytical procedure exists for measuring the amount of the opposite enantiomer in compound D. Therefore, provided compound D is in accordance with most of the other general principles described in Section 5.1.1, it would be reasonable to propose D as the starting material instead of A in accordance with the principle that early steps in the manufacturing process tend to have a lower potential to impact drug substance quality than later steps."
    },
    {
        "instruction":"已知信息：\n'待测物：特定的被测化学组分，包括原形药物、生物分子或其衍生物，或在生物基质中的代谢物。'可被翻译为：Analyte: A specific chemical moiety being measured, including an intact drug, a biomolecule or its derivative or a metabolite in a biological matrix.\n'根据特定的原料药和制剂的特殊性质或用途而设定的检测。'可被翻译为：A test which is considered to be applicable to particular new drug substances or particular new drug products depending on their specific properties and\/or intended use.\n'在评价暴露量时，应通过科学判断确定AUC比较是基于原形 药物、原形药物和代谢物还是代谢物，并提供依据；'可被翻译为：In assessing exposure, scientific judgement is used to determine whether the AUC comparison is based on data for the parent, parent and metabolite(s), or metabolite(s). The justification for this decision is provided;\n'代谢物为原形的3倍'可被翻译为：• Metabolites are 3-fold parent\n\n根据上述已知信息，请将'特定的被测化学组分，包括原形药物、生物分子或其衍生物，或在生物基质中的代谢物。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A specific chemical moiety being measured, including an intact drug, a biomolecule or its derivative or a metabolite in a biological matrix."
    },
    {
        "instruction":"已知信息：\n'保证良好描述研究患者且治疗组在VTE复发风险方面相当同样重要。'可被翻译为：It is also important that studied patients are well characterised and that treatment groups are comparable regarding risk for recurrent VTE.\n'一些具有复发慢性风险因素的VTE患者可作为终身抗凝预防治疗的受试者。'可被翻译为：Some patients with VTE and chronic risk factors for recurrence may be candidates for life-long anticoagulant prophylaxis.\n'因为急性VTE患者在复发风险因素方面不同，建议根据在方案中预先规定的客观标准决定计划的治疗持续时间，客观标准与复方 VTE 的基线风险相关。'可被翻译为：As patients with acute VTE may be heterogeneous regarding risk factors for recurrence, it is recommended that the intended treatment duration should be decided according to objective criteria pre-specified in the protocol depending on the baseline risk for recurrent VTE.\n'在评估不同研究持续时间的试验中（例如：由于入选了不同复发风险的患者），应根据预期的治疗时间进行分层随机处理（例如：3、6或12 个月）。'可被翻译为：In trials assessing different durations of study treatments (e.g.: due to the inclusion of patients at different risk of recurrence), a stratified randomisation should be made depending on intended treatment duration (e.g.: 3, 6 or 12 months).\n\n根据上述已知信息，请将'此外，治疗的持续时间应根据研究患者人群的VTE复发风险进行调整。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In addition, the duration of therapy should be adapted to the risk for VTE recurrence in the patient population under study."
    },
    {
        "instruction":"已知信息：\n'治疗蛋白的原料药中含多种潜在杂质，这些杂质可充当免疫佐剂。'可被翻译为：There are a number of potential impurities in the drug substance of therapeutic proteins, which potentially can serve as adjuvants.\n'既存抗体也可见于未曾接受治疗的患者。'可被翻译为：Pre-existing antibodies may also be found in treatment-naïve patients.\n'免疫系统被激活的患者（例如患有慢性感染、过敏和自免疫疾病的患者） 更易于对治疗蛋白产生免疫应答。'可被翻译为：Patients with activated immune systems (for example those suffering from chronic infections, allergies and autoimmune diseases may be more prone to immune responses to therapeutic proteins.\n'4. 影响抗治疗蛋白的免疫应答形成的因素'可被翻译为：4. Factors that may influence the development of an immune response against a therapeutic protein\n\n根据上述已知信息，请将'经常会遇到抗多种蛋白治疗药的既存抗体（例如单克隆抗体、融合蛋白），尤其是在自免疫疾病的背景下。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Pre-existing antibodies against a variety of protein therapeutics (e.g. monoclonal antibodies, fusion proteins) are frequently encountered, especially in the context of autoimmune diseases."
    },
    {
        "instruction":"已知信息：\n'难溶性固体药物以微粒的形式分散于液体介质中形成的非均相液体制剂。'可被翻译为：Insoluble solid drug A heterogeneous liquid preparation formed in the form of particles dispersed in a liquid medium.\n'难溶性药物微粒分散在水中形成的非均相液体分散体系。'可被翻译为：A heterogeneous liquid dispersion system in which insoluble drug particles are dispersed in water.\n'将难溶性固体药物分散在适当介质中制备混悬剂的方法。'可被翻译为：Method for preparing a suspension by dispersing an insoluble solid drug in an appropriate medium.\n'固体或液体药物溶解在抛射剂中，形成均匀溶液，喷出后抛射剂挥发，药物以固体或液体微粒状态达到作用部位的制剂。'可被翻译为：The solid or liquid drug is dissolved in the ejector, forming a uniform solution, the ejector volatilizes after ejection, and the drug reaches the action site in a solid or liquid particle state.\n\n根据上述已知信息，请将'难溶性固体药物以微粒状态分散于分散介质中形成的非均匀的液体制剂。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Insoluble solid drug A non-uniform liquid preparation formed by dispersing in a dispersing medium in a granular state."
    },
    {
        "instruction":"已知信息：\n'无论研究的目的是否是正式对比几个不同的治疗持续时间，方案通常都应允 许试验治疗与参比治疗的治疗持续时间有一定的范围，只要在规定的时间窗内。'可被翻译为：Whether or not a study sets out to formally compare several durations of therapy the protocols should usually allow for some latitude regarding the duration of treatment with test and reference treatments within a defined window.\n'当然，这一研究中确立的有效 性仅仅是联合用药时产生的有效性，而且单独用药时的剂量 可能与联合用药时的有效剂量有所不同。'可被翻译为：Efficacy is, of course, established by such studies only for the combination treatment, and the dose in a monotherapy situation might be different from the dose found to be effective in combination.\n'可以考虑以下研究目标：− 提高存活率 − 延缓疾病进展 −改善ALS的症状，例如肌力及相关功能。'可被翻译为：The following study objectives could be considered: - Increased survival - Delay of disease progression - Improvement of symptoms of ALS, e.g. muscle strength and related function.\n'研究设计和对照组的选择目前尚无任何药物被批准用于肌肉力量的症状改善和随之发生的功能改善（包括与呼吸肌相关的改善）。'可被翻译为：Study design and choice of control groups At present no medicinal product is authorised for symptomatic improvement in muscle power and consequent functional improvement (including that related to respiratory muscles).\n\n根据上述已知信息，请将'研究持续时间 原则上，仅具有症状改善作用（如肌力和相关功能）的药物与具有潜在疾病修饰作 用的药物相比，研究持续时间可能要短一些。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Study duration Study duration for medicinal products with an effect only on symptomatic improvement (e.g. muscle strength and related function) may in principle be of shorter duration than for products with potential disease-modifying effects."
    },
    {
        "instruction":"已知信息：\n'2.涉及实验动物研究的，应具备符合研究要求的动物设 施，具有相应的实验动物使用许可证明；应完整保存研究期间动物设施环境控制数据及异常情况处理等记录；'可被翻译为：2. In case of laboratory animals used in a study, there should be proper animal facilities for carrying out the study with the corresponding approval documentation for the use of laboratory animals; records of environmental monitoring of animal facilities and handling of unexpected events in the course of the study should be retained completely;\n'（二）实验动物种、系、数量、年龄、性别、体重范围、等级等信息应与申报资料相符；'可被翻译为：(2) The information on laboratory animals such as species, quantity, age, gender, body weight range, grade and so forth should be consistent with that specified in the application dossiers;\n'（一）研究所需实验系统的来源应清晰合规，应完整保存 实验系统购入(转入)、质量鉴定等相关证明性文件；应完整保留适用性评估资料。'可被翻译为：(1) The source of the test system used in the study should be clear and compliant with the related regulation, and the relevant supporting documentation for acquisition and characterization of the test system should be kept completely; documentation for assessing suitability of the test system should be kept completely.\n'至少一种实验动物种属应显示出预期的 药效学（PD）效应。'可被翻译为：At least one of the test species should exhibit the desired pharmacodynamic response.\n\n根据上述已知信息，请将'（一）研究所需实验动物的来源应清晰合规。实验动物供 应商应具有相应的资质证明；应完整保留实验动物合格证及其他相关证明性文件；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(1) The source of laboratory animals used in the study should be clear and compliant with the related regulations. Suppliers should have corresponding qualification as required for manufacture or supply of laboratory animals; the guarantee certificate or other relevant documentation for the quality of laboratory animals should be maintained completely;"
    },
    {
        "instruction":"已知信息：\n'这些情况 下应该使用什么其他 方法评价QT\/QTc 和 潜在致心律失常作 用？ 当全面QT研究或浓度-QTc分析按照5.1描述满足相似的质量控制用于专门研究 不可行时，综合的非临床和临床QT\/QTc风险评估特别有价值。'可被翻译为：In such cases what other methods should be used for evaluation of An integrated nonclinical and clinical QT\/QTc risk assessment can be particularly valuable when a thorough QT study or concentration-QTc analysis meeting similar quality control as needed for a dedicated study as described in 5.1 is not feasible.\n'综合风险评估 编号 批准日期 问题 回答 1.1 将非临床信息用作延迟心室复极 化和尖端扭转型 室性心动过速综 合风险评估的一 部分，从而为临 床研究的设计及 其结果的解释提 供参考的总体策 略是什么？'可被翻译为：Integrated Risk Assessment # Date of Approval Questions Answers 1.1 What is the general strategy for use of nonclinical information as part of an integrated risk assessment for delayed ventricular repolarization and torsade de pointes that can inform the design of clinical investigations and interpretation of their results?\n'决策 基于非临床和临床QT\/QTc综合评估的结果，可以在上市申请时进行全面的证据 论证。'可被翻译为：Decision-Making A totality of evidence argument based on the results of an integrated nonclinical and clinical QT\/QTc assessment could be made at the time of marketing application.\n'此外，如果在ICH E14问答6.1所述的常规全面QT研究不可行的情况下，试验将用作 临床和非临床综合风险评估的一部分，则体内研究应具有足够的 灵敏度，以检测幅度类似于专门临床QT研究的QTc延长效应(见 ICH S7B Q&A 3.4)。'可被翻译为：In addition, if the assay is to be used as part of an integrated clinical and nonclinical risk assessment for situations where a conventional thorough QT study is not feasible as described in ICH E14 Q&A 6.1, the in vivo study should have sufficient sensitivity to detect a QTc prolongation effect of a magnitude similar to dedicated clinical QT studies (see ICH S7B Q&A 3.4).\n\n根据上述已知信息，请将'综合的非临床和临床QT\/QTc风险评估应包括：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The integrated nonclinical and clinical QT\/QTc risk assessment should include:"
    },
    {
        "instruction":"已知信息：\n'NOAEL: 未见不良反应剂量：在特定暴露条件下，通过实验或观察发现的不会导致目 标生物体的形态、功能、生长、发育、或寿命发生可被观察到不良反应的物质最 大量或浓度。'可被翻译为：NOAEL: No-Observed-Adverse-Effect Level: Greatest concentration or amount of a substance, found by experiment or observation, that causes no detectable adverse alteration of morphology, functional capacity, growth, development, or life span of the target organism under defined conditions of exposure.\n'暴露于某种物质的人体或动物其反应频率或严重性在生物学上无显著增加的最高物质剂量。'可被翻译为：The highest dose of substance at which there are no biologically significant increases in frequency or severity of any effects in the exposed humans or animals.\n'LOEL:最低可见反应剂量：在一项或一组研究中，在人或动物体上任何生物学效应 的频率或严重程度显著增加的最低暴露量。'可被翻译为：LOEL: Lowest-Observed-Effect Level: The lowest dose of substance in a study or group of studies that produces biologically significant increases in frequency or severity of any effects in the exposed humans or animals.\n'在一项或一组研究中，在人或动物体上任何生物学效应的频率或严重程度显著增加的最低暴露量。'可被翻译为：Lowest-Observed-Effect Level: The lowest dose of substance in a study or group of studies that produces biologically significant increases in frequency or severity of any effects in the exposed humans or animals.\n\n根据上述已知信息，请将'NOEL: 未见反应剂量：在人或动物体上未见任何生物学效应的频率或严重程度显著 增加的最高暴露量。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"NOEL: No-Observed-Effect Level: The highest dose of substance at which there are no biologically significant increases in frequency or severity of any effects in the exposed humans or animals."
    },
    {
        "instruction":"已知信息：\n'钒 V 2A 100 10 1'可被翻译为：V 2A 100 10 1\n'钒 V 2A 是 是 是 是'可被翻译为：V 2A yes yes yes yes\n'2A类元素包括：钴（Co）、 镍（Ni）和 钒（V）。'可被翻译为：The class 2A elements are: Co, Ni and V.\n'钒（V）'可被翻译为：Vanadium (V)\n\n根据上述已知信息，请将'钒 V 2A 10 1 0.1'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"V 2A 10 1 0.1"
    },
    {
        "instruction":"已知信息：\n'因果性评估不应该仅仅依赖于机制规则，例如“与对照药物组相比频率增加”，但 是必须包括一种医学\/药理学评估。'可被翻译为：The causality assessment should not rely solely on mechanical algorithms such as “increased frequency  compared with comparator arm” but must include a medical\/pharmacological assessment.\n'但是，基于这些试验不能将治疗因素的重要性与患者因素剥离开来。'可被翻译为：Based on these trials, however, the importance of the treatment factor cannot be fully disentangled from the patient factor.\n'不论设计是什么（例如是BA与A还是BA与CA）， 均不可能确定与单个药物的因果关系。'可被翻译为：Irrespective of design, e.g. BA vs. A or  BA vs. CA, it may not be possible to define causality in relation to the individual drugs.\n'可疑不良反应指不良事件由药品造成存在合理可能性的任何不良事件。对于 IND 安全报告的目的，“合理可能性” 指有证据表明药品和不良事件之间的因果关系。不良反应，即由药物造成的不良事件，可疑不良反应与之相比具有确定因果关系的可能性较小。'可被翻译为：Suspected adverse reaction means any adverse event for which there is a reasonable possibility that the drug caused the adverse event. For the purposes of IND safety reporting, ‘reasonable possibility’ means there is evidence to suggest a causal relationship between the drug and the adverse event. A suspected adverse reaction implies a lesser degree of certainty about causality than adverse reaction, which means any adverse event caused by a drug.\n\n根据上述已知信息，请将'试图确定与单个药物的因果关系不应该遮蔽主要 目的——即确定不良事件与研究的治疗方案相关的因果关系。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"These attempts  should not overshadow the main objective, i.e. to define causality of AEs in relation to the regimens  under study."
    },
    {
        "instruction":"已知信息：\n'研究监查的范围和性质根据具体的研究设计和目的以 及确保受试者安全的需要而进行调整。'可被翻译为：The extent and nature of study monitoring are tailored to the specific study design and objectives and the need to ensure participants’ safety.\n'安全性角度的研究设计 从计划角度来看，考虑研究设计是如何影响获得的安全性信息是重要的。'可被翻译为：Study design from a safety perspective    From a planning perspective it is important to consider how the study design impacts on the safety information obtained.\n'同样，可通过广泛的研 究设计和数据来源达到这些目的。'可被翻译为：Similarly, there is a wide range of study designs and data sources to address these objectives.\n'应严格设计研 究，以解决研究目的，并注重设计要素，例如：研究人群和 反应变量的选择以及使结果偏倚最小化的方法（第5节）。'可被翻译为：Studies should be rigorously designed to address the study objectives with careful attention to the design elements, such as the choice of study population and response variables and the use of methods to minimize biases in the findings (Section 5).\n\n根据上述已知信息，请将'研究目的影响研究设计和数据来源的选择，进而影响研 究支持监管决策和临床实践的力度。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Study objectives impact the choice of study design and data sources, which in turn impact the strength of a study to support regulatory decisions and clinical practice."
    },
    {
        "instruction":"已知信息：\n'B． 认知和功能复合评价的临床指标 AD疾病谱上最接近于发生明显痴呆的患者（也即，前兆AD或AD所致 MCI）的日常功能可能有为轻微但可见的损害。'可被翻译为：B. Clinical Measures That Combine Assessments of Cognition and Function Patients on the AD continuum closest to the onset of overt dementia (i.e., prodromal AD or MCI due to AD) are likely to have relatively mild but noticeable impairments in their daily  functioning.\n'6.1.关于虚弱和认知功能障碍的一般性考量'可被翻译为：6.1.General considerations on frailty and cognitive dysfunction\n'或者，可以在该人群中采用合并认知及其对日常功能影响评价的复合量表作为单一的主要终点。'可被翻译为：Alternatively, a composite scale with a combined assessment of cognition and its impact on daily functioning, could be used as single primary endpoint in this population.\n'IV.临床结局指标 \nA． 一般考虑 AD痴呆阶段的临床试验应采用复合主要结局指标的方法，需要证实药物对认知和功能或总体评估量表有效。'可被翻译为：IV.CLINICAL OUTCOME MEASURES  \nA. General Comments Clinical trials in the dementia stage of AD should use a co-primary outcome measure approach  in which a drug demonstrates efficacy on both a cognitive and a functional or global assessment scale.\n\n根据上述已知信息，请将'B． 认知和功能复合评价的临床指标'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"B. Clinical Measures That Combine Assessments of Cognition and Function"
    },
    {
        "instruction":"已知信息：\n'（四）申请人提交的申报资料不齐全、不符合法定形式，不一次告知申请人必须补正的全部内容的；'可被翻译为：(4) not informing the applicant at once of all the contents needed to be supplemented or corrected, where the drug application dossier submitted is incomplete or not conformed with the required format;\n'（四）批签发申请资料或者样品可能存在真实性问题的；'可被翻译为：(IV)  There may be authenticity issues of the application dossiers for lot release or the samples;\n'申请资料不齐全或者不符合规定形式的，批签发机构应当在5日内一次性书面告知批签发申请人需要补正的全部内容及资料补正时限。逾期不告知的，自收到申请资料和样品之日起即为受理。'可被翻译为：If the application dossiers are incomplete or nonconforming to the prescribed form, the lot release institution shall inform the lot release applicant of all contents to be supplemented and corrected and the time limit for supplementation in writing all at once within 5 days. Where the lot release institution fails to notify the applicant within the time limit, it shall be regarded as acceptance as of the date of receipt of application dossiers and samples.\n'（四）申请资料不齐全或者不符合法定形式的，应当当场或者在5个工作日内一次告知申请人需要补正的全部内容以及提交补正资料的时限。逾期不告知的，自收到申请资料之日起即为受理；'可被翻译为：(4) If the application documents are incomplete or do not conform to statutory form, the applicant shall be notified of all contents ought to be supplemented and corrected on site or within 5 working days one-off. If no notification is made within the prescribed time limit, the application shall be deemed to have been accepted upon receipt of the application documents;\n\n根据上述已知信息，请将'（四）批签发申请人提交的申请资料、样品不齐全、不符合法定形式，不一次告知批签发申请人必须补正的全部内容的；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(IV) Not informing the lot release applicant at once of all the content needed to be supplemented or corrected, where the application dossiers and samples submitted are incomplete or not conforming with the prescribed format;"
    },
    {
        "instruction":"已知信息：\n'FDA 一般期望申请人将能够提供这些信息。'可被翻译为：FDA generally expects that applicants will be able to provide this information.\n'应与FDA讨论这些评估的计划。'可被翻译为：Planning for these assessments should be discussed with the FDA.\n'符合法定标准的申请将获得批准。'可被翻译为：Applications that meet the statutory standards will result in approval.\n'电子递交加强了SPA递交内容的接收、处理和审核，特别是考虑到完成SPA所需的多学科意见。参见行业指南《采用eCTD规范以电子格式提供监管递交——某些人用药物申请和相关 提交》。'可被翻译为：Electronic submission enhances the receipt, processing, and review of an SPA submission, particularly in view of the multidisciplinary input required to complete the SPA. See the guidance for industry Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications.\n\n根据上述已知信息，请将'我们预计申请将提交且评估的使用费符合FDA的 使用费捆绑政策（参见行业指南，提交用于评估使用费的独立上市申请和临床数据）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"We anticipate that applications will be submitted and user fees assessed consistent with FDA’s user fee bundling policy (see Guidance for Industry, Submitting Separate Marketing Applications and Clinical Data for Purposes of Assessing User Fees)."
    },
    {
        "instruction":"已知信息：\n'业务规则 如果发送者已知姓名首字母缩写，但由于数据隐私要求而无法发送，则不应填写该数据元素元素，且不完整信息=MSK。'可被翻译为：Business Rule(s) If the initials are known to the sender but cannot be transmitted due to data privacy requirements, this data element should be left blank with nullFlavor = MSK.\n'如果已知发送者的姓名首字母缩写，但由于数据隐私要求而无法发送，则不应填写该数据元素，且不完整信息=MSK。'可被翻译为：If the elements that are being used to identify the reporter are known to the sender but cannot be transmitted due to data privacy requirements, then those data elements should be left blank with nullFlavor = MSK.\n'报告者（主要来源）的识别可能受到某些国家或地区保密性要求的限制。当符合保密要求时，应提供信息。'可被翻译为：The identification of the reporter (primary source) could be prohibited by certain national or regional confidentiality requirements. The information should be provided when it is in conformance with confidentiality requirements.\n'几个数据元素中的任意一个即可定义一个身份可识别的患者几个数据元素中的任意一个即可定义一个身份可识别的患者（例如姓名首字母缩写、年龄和性别）或一个身份可识别的报告者（例如姓名首字母缩写、地址和资格）。'可被翻译为：Any one of several data elements is sufficient to define an identifiable patient (e.g. initials, age, and sex) or an identifiable reporter (e.g. initials, address, and qualification).\n\n根据上述已知信息，请将'如果仅已知报告者的姓名，且保密性要求禁止传输报告者的全名或姓名首字母缩写，则数据元素元素 C.2.r.1.2，C.2.r.1.3 和（或）C.2.r. 1.4 可根据保密要求或报告者的要求，酌情掩盖和以不完整信息“填写”。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"If only the name of the reporter is known and confidentiality requirements prohibit transmission of the reporter’s full name or initials, the data elements C.2.r.1.2, C.2.r.1.3, and\/or C.2.r.1.4 can be masked and ‘populated’ with a nullFlavor as appropriate, in compliance with confidentiality requirements or reporter request."
    },
    {
        "instruction":"已知信息：\n'为了更全面地了解文本中的M4S参考文件，请参阅下文M4S指导原则的文件变更历史。'可被翻译为：For better comprehension of the M4S references within the text, please see below the document change history for M4S guideline.\n'为了更全面地了解文本的M4参考文件，请参阅下下文M4指导原则的文件变更历史。'可被翻译为：For better comprehension of the M4 references within the text, please see below the document change history for M4 guideline.\n'M4E问答 \n文件历史 \n首次编码 \n历史 \n日期 \n新编码 \n2005年11月 \nM4E问答 \n指导委员会批准。'可被翻译为：M4E Q&As \nDocument History \nFirst Codification \nHistory \nDate \nNew Codification \nNovember 2005 \nM4E Q&As \nApproval by the Steering Committee.\n'M4E文件历史 首次编码 历史 日期 新编码 2005年11月 M4E 指导委员会批准进入第二阶段，并发布公开征求意见。'可被翻译为：M4E Document History First Codification History Date New Codification November 2005 M4E Approval by the Steering Committee under Step 2 and release for public consultation.\n\n根据上述已知信息，请将'为了更全面地了解文本中M4E参考文件，请参阅下文M4E指导原则的文件变更历史。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For better comprehension of the M4E references within the text, please see below the document change history for M4E guideline."
    },
    {
        "instruction":"已知信息：\n'它是一种人体和动物必需的微量元素，在许多关键酶系中具有重要作用， 与正常的造血功能及细胞代谢密切相关。'可被翻译为：It is an essential trace element in both animals and humans. Copper plays a vital role in a number of critical enzyme systems and is closely linked with normal hematopoiesis and cellular metabolism.\n'活性物质'可被翻译为：active substance\n'一类维持生命活动所必需的体内不能合成或合成速度不能满足需要而必需从外界摄取的脂肪酸。'可被翻译为：A class of fatty acids essential for the maintenance of life that cannot be synthesized in the body or at an insufficient rate of synthesis and must be ingested from the outside world.\n'含有的必需氨基酸种类齐全、含量充足、比例适当因而能够维持生命和促进生长发育的一类蛋白质。'可被翻译为：A protein containing a complete range of essential amino acids in sufficient amounts and proportions to sustain life and promote growth and development.\n\n根据上述已知信息，请将'一类在体内含量极微的维持人体生命所必需的有机物质。是保持人体健康的重要活性物质。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Any of a class of organic substances found in very small amounts in the body that are essential for the maintenance of human life. It is an important active substance for maintaining human health."
    },
    {
        "instruction":"已知信息：\n'IND 必须包含足够的 CMC 信息，从而保证研究药物的正确鉴别、规格、质量和纯度。 应该提供的 CMC 信息数量因研究阶段、推荐的研究持续时间、剂型和其他可用信息 的数量而不同。不管在什么样的情况下，申办方-研究者必须在 IND 中包括下列信息：研究药物直接接触包装的说明书，该说明书必须包含声明“警告：新药-联邦（或者美国）法律限制研究使用”（§312.6（a））根据 21 CFR 25.40 所作的环境声明或者根据 21 CFR 25.31（e）中提供的规定 申请明确从环境声明中排除的声明（§312.23（a）（7）（iv）（e））'可被翻译为：An IND must include sufficient CMC information to ensure the proper identity, strength, quality, and purity of the investigational drug. The amount of CMC information that should be provided\twill vary with the phase of the investigation, the proposed duration of the investigation, the\tdosage form, and the amount of information otherwise available.  In all cases, the sponsor-investigator must include the following information in the IND: The label for the immediate packaging of the investigational drug, which must contain the statement “Caution: New Drug — Limited by Federal (or United States) law to investigational use” (§ 312.6(a)) An environmental assessment under 21 CFR 25.40 or a statement requesting a categorical exclusion from an environmental assessment under provisions provided for in 21 CFR 25.31(e) (§ 312.23(a)(7)(iv)(e))\n'IND 必须包括，作为豁免申请的一部分：\n充分解释为什么不需要或者为什么不能达到符合 21 CFR 312.23（a）（7）的全部要求 ；\n通过帮助保证研究药物具有正确的标识、规格、质量和纯度，让信息满足要求的目的；或者\n证明豁免的其他信息。\n与研究药物是否具有正确的标识、规格、质量和纯度有关的信息可能包括，例如，表明研究药物是否已经被具有和FDA类似的科学和监管标准的监管机构（例如，国际协调会议（ICH）国家）许可的信息。\n这部分信息应该尽可能地包括国外监管机构公开的批准信息概述和现行的产品说明书。'可被翻译为：The IND must include, as part of the waiver request:\nA sufficient explanation why compliance with the complete requirements of 21 CFR312.23(a)(7) is unnecessary or cannot be achieved;\nInformation that will satisfy the purpose of the requirement by helping to ensure that the investigational drug will have the proper identity, strength, quality, and purity; or\nOther information justifying a waiver.\nInformation that is relevant to whether the investigational drug will have the proper identity, strength, quality, and purity may include, for example, information indicating whether the investigational drug has been licensed by a regulatory authority that has similar scientific and regulatory standards as the FDA (e.g., International Conference on Harmonisation (ICH)\tcountries). \nThis should include, to the extent possible, summary approval information and\tcurrent product labeling made public by the foreign regulatory authority.\n'经合理论证，生产商包括分包装商和重新贴签方可以替换原始标签。'可被翻译为：With appropriate justification, manufacturers including repackagers and relabellers may replace the original label.\n'如果研究药物有既往的人用经验，要求申办方-研究者提供这部分信息的概述。'可被翻译为：If there has been previous human experience with the investigational drug, the sponsor- investigator is required to provide a summary of this information.\n\n根据上述已知信息，请将'除了豁免申请之外，申办方-研究者应该在 IND 包括尽可能多的 21 CFR312.23（a） （7）要求的可用 CMC 信息。这部分信息至少应该包括下列内容：\n研究药物生产商或者供应商的名称。\n研究药物的英文版说明书，包括包装说明书。\n用来将药品运送到美国临床研究中心的条件和容器的有关信息，和将被用来重新贴签研究用药品瓶子的重新贴签和重新包装的信息。\n这部分信息应该包括如何预防药品暴露于推荐储存条件以外的光照和温度条件的信息，还应该包括重新贴签操作可能会影响药品稳定性的风险评估。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In addition to the waiver request, the sponsor-investigator should include in the IND as much of\tthe CMC information required by 21 CFR 312.23(a)(7) as is available. This should include, at a\tminimum, the following:\nThe name of the manufacturer or supplier of the investigational drug.\nAn English version of the investigational drug’s labeling, including the package insert. \nInformation on the conditions and containers that will be used to transport the drug product to the U.S. clinical site(s) and information on the relabeling and repackaging operations that will be used to relabel the drug product vials for investigational use. \nThis should include information on how exposure of the drug product to light and temperature conditions outside of the recommended storage conditions will be prevented. A risk assessment on the affect the relabeling operations may have on drug product stability should also be included."
    },
    {
        "instruction":"已知信息：\n'联系信息可见于CDER监察员网页：http:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/OfficeofMedicalProductsandTobacco\/ CDER\/ContactCDER\/CDEROmbudsman\/default.htm。'可被翻译为：Contact information can be found on the CDER Ombudsman Web page at http:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/OfficeofMedicalProductsandTobacco\/CDER\/ContactCDER\/CDEROmbudsman\/default.htm.\n'联系信息可见于CBER监察员网页： http:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/OfficeofMedicalProductsandTobacco\/ CBER\/ucm122881.htm。'可被翻译为：Contact information can be found on the CBER Ombudsman Web page at http:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/OfficeofMedicalProductsandTobacco\/CBER\/ucm122881.htm.\n'CDER MAPP清单可见于 http:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/OfficeofMedicalProductsandTobacco\/ CDER\/Ma nualofPoliciesProcedures\/default.htm。'可被翻译为：A listing of CDER MAPPs can be found at http:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/OfficeofMedicalProductsandTobacco\/CDER\/Ma811 nualofPoliciesProcedures\/default.htm.\n'联系信息可见于罕见疾病计划网页： http:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/OfficeofMedicalProductsandTobacco\/ CDER\/ucm221248.htm。'可被翻译为：Contact information can be found on the Rare Diseases Program Web page at http:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/OfficeofMedicalProductsandTobacco\/CDER\/ucm221248.htm.\n\n根据上述已知信息，请将'CDER 监察专员联系信息：\nhttp:\/\/www.fda.gov\/aboutfda\/centersoffices\/officeofmedicalproductsandtobacco\/cder\/cont actcder \/cderombudsman\/default.htm'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"CDER Ombudsman contact information:\nhttp:\/\/www.fda.gov\/aboutfda\/centersoffices\/officeofmedicalproductsandtobacco\/cder\/contactcder 852 \/cderombudsman\/default.htm"
    },
    {
        "instruction":"已知信息：\n'IRB按照此规章审评研究，为了评价社区咨询和公开披露计划，其必须了解当地条件（21 CFR 50.24（a）（7））。'可被翻译为：The IRB that is responsible for finding and documenting that community consultation and public disclosure will take place (as required by 21 CFR 50.24(a)(7)) should be knowledgeable about local conditions in order to evaluate the community consultation and public disclosure plans.\n'例如，IRB必须审评社区咨询和公开披露的计划（21 CFR 50.24（a）（7）（i）， （ii），（iii））。'可被翻译为：For example, IRBs must review plans for community consultation and public disclosure (21 CFR 50.24(a)(7)(i), (ii), (iii)).\n'） 66 IRB在社区咨询过程中的作用是什么？ 批准研究前提是IRB必须能确定并用文件证明将进行社区咨询（根据情况包 括，由IRB进行的咨询；21 CFR 50.24（a）（7）（i））。'可被翻译为：66.What is the IRB’s role in the community consultation process? In order to approve the research, the IRB must find and document that community consultation will be provided (including, where appropriate, consultation carried out by the IRB; 21 CFR 50.24(a)(7)(i)).\n'采用顾问本身将不能充 分替代21 CFR 50.24（a）（7）（i）所要求的社区咨询； ◦ 要求申办方和研究者开展额外的或其他社区咨询活动；以及 ◦ 根据情况决定本身开展社区咨询活动（21 CFR 50.24（a）（7）（i））。'可被翻译为：Use of consultants would not by itself adequately substitute for the community consultation called for in 21 CFR 50.24(a)(7)(i); o Request that the sponsor and investigator conduct additional or other community consultation activities; and o Decide, where appropriate, to conduct community consultation activities itself (21 CFR 50.24(a)(7)(i)).\n\n根据上述已知信息，请将'按照21 CFR 50.24（a）（7）（i）的要求，为了确定并用文件证明已经进行了 社区咨询，IRB应当评估采用的方法，并决定来自社区的有意义反馈是否可信。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In order to find and document that community consultation has occurred, as required in 21 CFR 50.24(a)(7)(i), the IRB should determine whether meaningful feedback was secured from the community(ies)."
    },
    {
        "instruction":"已知信息：\n'就本文件而言，该术语的定义与国际原子能机构\/WHO《放射性药品良好生产规范》指南中的定义相同(3)，即在准备使用时含有一种或多种用于医疗目的的放射性核素(放射性同位素)的任何药品。'可被翻译为：For the purpose of this document, this term is defined in the same way as in the IAEA\/WHO guideline on good manufacturing practices for radiopharmaceutical products (3), as any pharmaceutical product that, when ready for use, contains one or more radionuclides (radioactive isotopes) included for medicinal purposes.\n'术语“药物批准”指获得该药物的上市许 可。'可被翻译为：The term “drug approval” refers to obtaining marketing authorisation for the drug.\n'5就本指南而言，术语“现有治疗”的定义与现有治疗行业指南中所述相同。'可被翻译为：5 For purposes of this guidance, the term “available therapy” is interpreted as it is described in the guidance for industry on Available Therapy.\n'本指导原则包括一系列术语及其定义。希望通过这些术语和定义，桥接通常存在于ICH成员监管机构各种 药典和文件间的差异。'可被翻译为：This guideline includes a collection of terms and their definitions, which are meant to bridge the differences that often exist between various compendia and documents of the ICH member regulatory authorities.\n\n根据上述已知信息，请将'就本文件而言，这些术语的定义与原子能机构\/WHO放射性药品良好生产规范指南(3)中的定义相同。它们是指按照上市许可持有人的指示执行的所有程序，这些程序涉及将经监管机构批准的放射性核素溶液添加到经批准的冷试剂盒中。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For the purpose of this document, these terms are defined in the same way as in the IAEA\/WHO guideline on good manufacturing practices for radiopharmaceutical products (3). They refer to all the procedures carried out as per instructions from marketing authorization holders that involve addition of radionuclide solution approved by regulatory authorities to an approved cold kit."
    },
    {
        "instruction":"已知信息：\n'FDA鼓励申请人和申办方，就可能引起顾虑的财务披露的特定情况，在产品开发过程中尽早联系本局获得咨询意见。'可被翻译为：FDA encourages applicants and sponsors to contact the agency for advice concerning specific circumstances regarding financial disclosures that may raise concerns as early in the product development process as possible.\n'鼓励考虑开发治疗CHC的抗病毒药物的申办方通过前-IND咨询程序与 FDA进行交流。'可被翻译为：Sponsors considering development of antiviral drugs for the treatment of CHC are encouraged to communicate with the FDA through the pre-IND consultation program.\n'FDA建议申办方在启动联合治疗方案的临床开发前咨询FDA关于共同开发的适宜性。'可被翻译为：FDA recommends that sponsors consult with FDA on the appropriateness of codevelopment before initiation of clinical development of a combination.\n'鼓励研究申办方在临床研究之前和期间就涉及临床研究者潜在偏倚的特殊 情形的管理咨询 FDA。'可被翻译为：Study sponsors are encouraged to consult with FDA prior to and during clinical studies about the management of specific situations involving potential bias on the part of a clinical investigator.\n\n根据上述已知信息，请将'还鼓励申办方在开发过程全程根据需要咨询FDA。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Sponsors also are encouraged to consult FDA as needed throughout the development process."
    },
    {
        "instruction":"已知信息：\n'应当评估商业化生产中所使用的体外细胞的寿命限度。'可被翻译为：The limit of in vitro cell age for commercial production should be assessed.\n'这种监测应在一支或多支冷冻保藏的细胞库细胞被解冻后、用来制备生产用细胞时进行，因为这时产品或生产过程的监测方式是相近的。或当一支或多支冷冻保藏的MCB被解冻并用于制备新的WCB时进行。'可被翻译为：The proposed monitoring can be performed at the time that one or more containers of the cryopreserved bank is thawed for production use, when the product or production consistency is monitored in a relevant way, or when one or more containers of the cryopreserved MCB is thawed for preparation of a new WCB (and the new WCB is properly qualified), as appropriate.\n'一般是在规定条件下从经选择的细胞克隆中制备的细胞单批合并物，等量分置于多个容器中并在特定条件下存放。 MCB是用作制备工作细胞库(WCB)的。检测一个新MCB(来自原细胞克隆、MCB或WCB)时，除非有正当理由，一般其检测方法应与检测该MCB的方法相同。'可被翻译为：An aliquot of a single pool of cells which generally has been prepared from the selected cell clone under defined conditions, dispensed into multiple containers and stored under defined conditions. The MCB is used to derive all working cell banks. The testing performed on a new MCB (from a previous initial cell clone, MCB or WCB) should be the same as for the MCB, unless justified.\n'MCB（主细胞库） 在指定条件下从选定的细胞克隆制备而得的单批细胞，它被分装到多个容器中，并在规定的条件下贮藏。'可被翻译为：Derivation and Characterisation of Cell Substrates MCB (Master Cell Bank) An aliquot of a single pool of cells which generally has been prepared from the selected cell clone under defined conditions, dispensed into multiple containers and stored under defined conditions.\n\n根据上述已知信息，请将'在生产中体外细胞的寿命应从解冻一个或多个容器MCB开始算起。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The starting point of reference for estimates of in vitro cell age during manufacturing should be the thawing of one or more containers of the MCB."
    },
    {
        "instruction":"已知信息：\n'标准外科技术不充分时<针对<成人> <{年龄组别}> > 的支持性疗法（参见 第5.1节）： - 用于改善止血 [产品特有信息，视是否已开展了具体临床研究而定：] <（列入通过可弯曲式内窥镜应用止血）> - 作为一种组织胶以促进粘合\/封闭，或作为缝合支持： <血管外科。>'可被翻译为：Supportive treatment <in <adults> <{age category}> > where standard surgical techniques are insufficient (see section 5.1): - for improvement of haemostasis [Product specific depending on whether specific clinical studies have been undertaken:] <(to include application through a flexible endoscope to stop bleeding)> - as a tissue glue to promote adhesion\/sealing, or as suture support: <In vascular surgery.>\n'这样的药物可能用于联合其他支持性治疗手段和\/或外科操作或作为单独的治疗。'可被翻译为：Such agents may be used in conjunction with other supportive measures and\/or surgical procedures or as sole treatments.\n'[含氨甲环酸产品的产品特有信息：]<神经外科手术和可能发生与脑脊髓液 或硬膜接触的外科手术（如：耳科、鼻科、眼科和脊椎手术）由于存在脑神经毒 性风险（例如水肿和发作），不应使用含氨甲环酸的产品。> 4.4 特殊警告和使用注意事项 仅用于损伤面上。'可被翻译为：[Product specific for products containing tranexamic acid:]<Products containing tranexamic acid should not be used in neurosurgery or surgical procedures where contact with cerebro-spinal fluid or dura mater can occur (e.g. otologic, rhinologic, ophthalmic and vertebral surgery) due to the risk of cerebral neurological toxicity (such as oedema and seizure).> 4.4 Special warnings and precautions for use For epilesional use only.\n'例如：] <在{说明类型}手术中，针对{x}例患者开展了旨在证明止血和缝合支持的临 床研究。>'可被翻译为：For example:] <Clinical studies demonstrating haemostasis and suture support were conducted in {x} patients in {specify type} surgery.>\n\n根据上述已知信息，请将'<在神经外科和可能接触脑脊髓液或硬膜的外科手术（如：耳科、鼻科、眼科和 脊椎手术）中用于组织粘合\/封闭和缝合支持。> <{其他适应症，请说明}>>'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"<For tissue adhesion\/sealing and suture support in neurosurgery and surgical procedures where contact with cerebro-spinal fluid or dura mater can occur, e.g. otologic, rhinologic, ophthalmic and vertebral surgery.> <{In other indications, specify}>>"
    },
    {
        "instruction":"已知信息：\n'尽管有很多未知的潜在问题却仅有少数可参考的资料，但是，仍应在将来根据药物的作 用机制在相应的药物-药物相互作用研究中进行探索，体外试验可能会有助于确定合适的受试物。'可被翻译为：Although the potential problem is largely unexplored and only a few data are available , this should in future be addressed in respective drug-drug interaction studies based on the mechanism of action of the compound, and potentially in in-vitro experiments which could help to determine adequate test substances.\n'只有在质量评估和\/或体外生物分析\/药理研究的结果对生物类似物和参比药品间的可比性仍存在一些不明确问题的时候，才考虑需要进行额外的研究。'可被翻译为：Only when the outcome of the quality evaluation and\/or the in vitro bioassays\/pharmacological studies leave uncertainties about the comparability of the biosimilar and reference medicinal product, the need for additional studies should be considered.\n'当确实存在担忧时，应进行附加的免疫毒性研究以验证化合物潜在的免疫毒性。这些研究也有助于确定受影响的细胞类型、 影响的可逆性和作用机制。此类信息也有助于进一步了解药物的潜在风险，也可能有助于临床试验中生物标志物的选择。'可被翻译为：If a cause for concern is identified, additional immunotoxicity studies should be performed to verify the immunotoxic potential of the compound. These studies can also help determine the cell type affected reversibility, and the mechanism of action. This type of information can also provide more insight into potential risk and possibly lead to biomarker selection for clinical studies.\n'表明存在不良内分泌作用的标准研究结果可能产生关于作用 机制和人类相关性的问题，可能通过机制研究来解决。'可被翻译为：Results of standard studies demonstrating evidence of adverse endocrine effects may trigger questions on mode of action and human relevance that could be addressed by mechanistic studies.\n\n根据上述已知信息，请将'虽然大多半潜在问题未被考察， 且仅有少量数据58,59 ，,但这应在未来基于 化合物作用机制的各项药物之间相互作用的研究中得以解决，体外研究可能有助于确定适当的受试药物。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Although the potential problem is largely unexplored and only a few data are available58,59, this should in future be addressed in respective drug-drug interaction studies based on the mechanism of action of the compound, and potentially on in-vitro experiments which could help to determine adequate test substances60."
    },
    {
        "instruction":"已知信息：\n'以实现疾病长期控制为目的的治疗 典型情况包括晚期乳腺癌、大肠癌、低分级淋巴瘤和慢性白血病的早期线治疗，有 已建立的参考疗法，而且下一线治疗方案可能是明显有效的。'可被翻译为：Treatment administered with the intent to achieve long-term disease control Typical conditions include early lines of therapy in advanced breast cancer, colorectal cancer, low- grade lymphomas and the chronic leukaemias for which established reference therapies are available and next-line treatment options are likely to be meaningfully efficacious.\n'治疗类型和治疗线'可被翻译为：Type and line of treatment\n'对于辅助疗法已确定的领域，如乳腺癌和大肠癌，并且如果获益-风险被视为有利于基于 DFS 和可用的安全和生存数据（包括在疾病复发后下一线疗法的 PFS）的试验方案， 可在药品上市后报告成熟生存数据。'可被翻译为：For established areas of adjuvant therapy, e.g. breast and colorectal cancer, and if benefit- risk is considered favourable for the experimental regimen based on DFS and available safety and survival data, including PFS on next-line therapy following recurrence of the disease, mature survival data may be reported post-licensing.\n'应注意的一点是，预期肿瘤的抗药性情况将受到疗法的影响。这对于下一线疗法的活性可能具有一定的关联性。如果维持疗法\/长期疗法与无治疗或安慰剂（如在固定周期数量 为标准数量的领域，如一线卵巢癌、NSCLC 以及某些血液学条件）相比，这就显得 尤为明显。因此，进展对维持疗法造成的后果至少代表着对维持方案的耐药性，并与进展疗法不同。在原则上，这适用于所有的参照，即关于下一线疗法的交叉耐药性程度在试验方案和对照方案之间可能不同。'可被翻译为：It should be noticed that it is expected that the tumour’s drug resistance profile is affected by therapy. This might be of relevance for the activity of next-line therapies. This is most obvious if maintenance\/prolonged therapy is compared with no treatment or placebo such as in areas where a fixed number of cycles is the standard, for example, first-line ovarian cancer, NSCLC and some haematological conditions. The consequences of progression on maintenance therapy, signifying resistance at least to the maintenance regimen, might thus differ from progression off therapy. In principle, this applies to all comparisons, i.e. the degree of cross resistance as regards next-line therapy might differ between experimental and control regimens.\n\n根据上述已知信息，请将'一般情况包括在晚期乳腺癌、大肠癌、低恶性度淋巴癌以及慢性白血病中的早期线疗法。可为这些疾病提供已确定的参照疗法，并且下一线治疗方案将可能实际产生疗效。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Typical conditions include early lines of therapy in advanced breast cancer, colorectal cancer, low- grade lymphomas and the chronic leukaemias for which established reference therapies are available and next-line treatment options are likely to be meaningfully efficacious."
    },
    {
        "instruction":"已知信息：\n'B. 研究设计：暴露的定义及确定'可被翻译为：B. Study Design: Exposure Definition and Ascertainment\n'B. 研究设计：暴露的定义及确定 1. 暴露的定义 研究者应定义出所关注的结局的暴露风险窗，详细描述在选择的数据来源中 对风险窗的测量。'可被翻译为：B. Study Design: Exposure Definition and Ascertainment 1. Exposure Definition The investigator should define the exposure risk window for the outcome of interest and describe in detail the measurement of the window in the selected data source(s).\n'2. 暴露的确定 – 研究设计 如上所述，研究设计应适用于所关注的研究疑问，并在研究方案中提出合理 依据；FDA不推荐任何特定的研究设计。'可被翻译为：2.Exposure Ascertainment — Study Design As previously mentioned, the study design should be tailored to the study question of interest and justified in the study protocol; FDA does not advocate the use of any specific study designs.\n'2. 研究设计的举例（不全面的）'可被翻译为：2. Examples of Study Designs (Not All-Inclusive)\n\n根据上述已知信息，请将'2. 暴露的确定 – 研究设计'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2. Exposure Ascertainment — Study Design"
    },
    {
        "instruction":"已知信息：\n'应在入选研究之前明确 EF。'可被翻译为：EF should be defined before inclusion in the study.\n'为了帮助选择合适的研究患者群和评估终点，建议在进行有预定目标的关键性研究之前 进行至少一项探索性研究。'可被翻译为：To assist in selecting appropriate patient populations for study and endpoints for evaluation it is suggested that at least one exploratory study is conducted before proceeding to pivotal studies with pre-defined objectives.\n'主要指标的选择应反映相关研 究领域公认的准则和标准。'可被翻译为：The selection of the primary variable should reflect the accepted norms and standards in the relevant field of research.\n'我们建议申办 方与FDA讨论关于在试验开始之前的活性药物对照选择和研究人群选择。'可被翻译为：We recommend sponsors discuss with the FDA regarding the choice of an active control and choice of study population before trial initiation.\n\n根据上述已知信息，请将'任何选择标准的匹 配或者由于人群差异所做的调整都应在选择对照和进行研 究之前说明。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Any matching on selection criteria or adjustments made to account for population differences should be specified prior to selection of the control and performance of the study."
    },
    {
        "instruction":"已知信息：\n'偏倚（统计的和操作的） 是指与临床试验的设计、实施、分析和结果评价有关的 任何因素导致的处理效应估计值偏离其真实值的系统趋势。'可被翻译为：Bias (Statistical & Operational) The systematic tendency of any factors associated with the design, conduct, analysis and evaluation of the results of a clinical trial to make the estimate of a treatment effect deviate from its true value.\n'这里 所说的偏倚(以及在E9使用的偏倚)，是指在临床试验的设 计、实施、分析和结果的解释方面出现的系统倾向，从而使 对治疗结果的估计偏离它的真实值。'可被翻译为：Bias here (and as used in ICH E9) means the systematic tendency of any aspects of the design, conduct, analysis, and interpretation of the results of clinical trials to make the estimate of a treatment effect deviate from its true value.\n'是指与临床试验的设计、实施、分析和结果评价有关的任何因素导致的处理效应估计值偏离其真实值的系统趋势。由实施偏离所引入的偏倚称为“操作”偏倚，而上述其他来源的偏倚称为“统计”偏倚。'可被翻译为：The systematic tendency of any factors associated with the design, conduct, analysis and evaluation of the results of a clinical trial to make the estimate of a treatment effect deviate from its true value. Bias introduced through deviations in conduct is referred to as 'operational' bias. The other sources of bias listed above are referred to as 'statistical'.\n'这些报 告中应包括方法和研究设计的说明，以及任何功能研究的实 施结果；'可被翻译为：These reports should include a description of the methods and study designs as well as the results of any functional studies performed;\n\n根据上述已知信息，请将'这里的术语“偏倚”是指与临床试验设计、实 施、分析和结果解释有关的任何因素所导致的处理效应（见 词汇表）的估计值与真实值偏离的系统性趋势。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"As used in this guidance, the term 'bias' describes the systematic tendency of any factors associated with the design, conduct, analysis and interpretation of the results of clinical trials to make the estimate of a treatment effect (see Glossary) deviate from its true value."
    },
    {
        "instruction":"已知信息：\n'表格应包括： 自发性ICSR中的严重和非严重的药物不良反应，包括医疗保健专业人 员、消费者、科学文献和监管机构的报告； 非干预性研究的严重不良反应；和 严重不良反应的征集报告*。'可被翻译为：The tabulation should include: Serious and non-serious adverse drug reactions from spontaneous ICSRs, including reports from healthcare professionals, consumers, scientific literature, and regulatory authorities; Serious adverse reactions from non-interventional studies; and Solicited reports* of serious adverse reactions.\n'2. 临床试验中的严重不良事件的累积总结表和上市后使用经验中的时间段 \/累积总结表'可被翻译为：2.Cumulative Summary Tabulation of Serious Adverse Events from Clinical Trials and Interval\/Cumulative Summary Tabulations from Marketed Experience;\n'当两个SAE具有同一个受试者编码以 及同一个MedDRA PT时，在表格的PT级别记录为一次事件。'可被翻译为：Where two SAEs for the same trial subject code to the same MedDRA PT, they have been counted as one event at the PT level in the tabulation.\n'• 提交报告用的是最新版的 MedDRA 及其结构。比如说，如果在报告用的版本中一个 PT 被从一个 HLT 移动到另一个 HLT，那么该 PT 输出显示的 HLT 与其最初编码时的 HLT 是不同的。'可被翻译为：• The most recent version of MedDRA would be used for reporting utilizing the structure of the most recent version. For example, if a PT moved from one HLT to another in the version used for reporting, it would be output to a different HLT than it was originally coded.\n\n根据上述已知信息，请将'表7 来自上市后使用经验的药物不良反应的数量 自发报告，包括监管机构和文献 非干预性上市后研究 以及来自其它征集来 源的报告* 严重 非严重 总自发报 告 严重 时间段 累积 时间段 累积 累积 时间段 累积 SOC1 MedDRA PT MedDRA PT MedDRA PT SOC2 MedDRA PT MedDRA PT MedDRA PT MedDRA PT *这并不包括干预性临床试验'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Periodic Benefit-Risk Evaluation Report (PBRER) 31 Table 7 – Numbers of Adverse Drug Reactions by Term from Post-Marketing Sources Spontaneous, including regulatory authority and literature Non-interventional post-marketing study and reports from other solicited sources* Serious Non-serious Total Spontaneous Serious Interval Cumulative Interval Cumulative Cumulative Interval Cumulative SOC 1 MedDRA PT MedDRA PT MedDRA PT SOC 2 MedDRA PT MedDRA PT MedDRA PT MedDRA PT *This does not include interventional clinical trials."
    },
    {
        "instruction":"已知信息：\n'直接从物料中采集的样品。'可被翻译为：Sample collected directly from the material.\n'直接分析测定用的样品溶液的通称。'可被翻译为：A general term for a sample solution used in direct analytical determination.\n'重量分析法的一种，用不相混溶的有机溶齐U，将待测组分从供试品中萃取，然后将溶剂蒸去，干燥至恒重，根据萃取物重量计算待测物的含量。'可被翻译为：A kind of gravimetric analysis, with immiscible organic solubilization U, the components to be tested from the test product extraction, and then the solvent steaming, drying to constant weight, according to the weight of the extract to calculate the content of the measured substance.\n'3. 剂型 [产品特有信息] <密封胶><密封胶用粉末和溶剂><密封胶用溶液><其他>。'可被翻译为：3.PHARMACEUTICAL FORM [Product specific] <Sealant><Powder and solvent for sealant><solution(s) for sealant><other>.\n\n根据上述已知信息，请将'用提取溶剂直接从固体粉末样品中萃取被测组分的方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The method of extracting the measured component directly from the solid powder sample with extraction solvent."
    },
    {
        "instruction":"已知信息：\n'代谢和其它药代动力学方面（如有需要）。'可被翻译为：Metabolism and other pharmacokinetic aspects, if needed.\n'用具有寻靶功能的分子修饰药物载体，定向。'可被翻译为：The drug carrier is modified with a molecule with target-seeking function, directed.\n'临床相关活性代谢物或主要活性代谢物是指估测会对总体靶向药效学活性产生显著作用的药理活性代谢物，显著的程度为代谢物暴露水平的改变可能影响整体疗效和安全性。'可被翻译为：Clinically relevant active metabolites, or major active metabolites, are defined as pharmacologically active metabolites estimated to contribute significantly to the total target pharmacodynamic activity, i.e. to an extent that alteration of the exposure to the metabolites might affect overall efficacy and safety.\n'在这种情况下，可以在II期B中考虑代谢物检测；'可被翻译为：In that case metabolite testing could be considered in Phase II B;\n\n根据上述已知信息，请将'ii）有特异性的、靶向、可定量测定的代谢物，'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"ii) having a specific, targeted, quantifiable metabolite"
    },
    {
        "instruction":"已知信息：\n'3.4 支持后续临床试验和上市的毒理学研究期限'可被翻译为：3.4 Duration of Toxicology Studies to Support Continued Clinical Development and Marketing\n'3.3 支持早期临床试验的毒理学研究期限和方案'可被翻译为：3.3 Duration and Schedule of Toxicology Studies to Support Initial Clinical Trials\n'但是，非啮齿类动物慢性毒性试验的期限仍存在不同的方 法。'可被翻译为：However, for chronic toxicity testing in non-rodents, there were different approaches to the duration of testing.\n'非啮齿类动物试验数据的全面回顾和分析，以及第一届ICH会议在啮齿类动物试验方面已达成的共识，也避免重复试验，并遵循新药慢性毒性试验的单一的开发计划，ICH三方监管机构可接受以下的慢性毒性试验的申报： 1） 啮齿类动物： 期限为6个月的试验； 2） 非啮齿类动物： 期限为9个月的试验。'可被翻译为：Arising from the extensive analysis and review of the above mentioned data in non- rodents and based upon the achievements of ICH1 for testing in rodents, and so as to avoid duplication and follow a single development plan for chronic toxicity testing of new medicinal products, the following studies are considered acceptable for submission in the 3 Regions: 1) Rodents: a study of 6 months duration; 2) Non-rodents: a study of nine months duration. 2\n\n根据上述已知信息，请将'4.ICH三方开发计划的慢性毒性试验期限的指导原则'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"4.GUIDANCE ON DURATION OF CHRONIC TOXICITY TESTING FOR TRIPARTITE DEVELOPMENT PLAN"
    },
    {
        "instruction":"已知信息：\n'否，在商业规模工艺验证研究中没有必要对设计空间的 外限进行验证。设计空间必须在开发研究的早期进行充分研 究（关于放大规模请参见章节2.1设计空间问题2；关于生 命周期法请参见章节1.1一般声明问题3）。'可被翻译为：No, there is no need to run the qualification batches at the outer limits of the design space during process validation studies at commercial scale. The design space must be sufficiently explored earlier during development studies (for scale up see also Chapter 2.1 Design Space Question 2; for life cycle approach see Chapter 1.1 for general clarification Question 3).\n'6 2009年4监管部门是否期望对现有产品进行设 计空间研究？'可被翻译为：6 April 2009 Is there a regulatory expectation to develop a design space for an existing product?\n'2010年11月'可被翻译为：November 2010\n'来自小规模研究的数据对全部验证工作的贡献大小将 取决于小规模研究的模型能否恰当地代表拟定的商业化规 模情况。'可被翻译为：The contribution of data from small-scale studies to the overall validation package will depend upon demonstration that the small-scale model is an appropriate representation of the proposed commercial-scale.\n\n根据上述已知信息，请将'9 2010年 11月 是否应在商业规 模工艺验证研究中对 设计空间的外限进行 评价？'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"9 Nov. 2010 Should the outer limits of the Design Space be evaluated during process validation studies at the commercial scale?"
    },
    {
        "instruction":"已知信息：\n'该标签说明应描述在临床试验入组的患者的疾病严重度。'可被翻译为：The labeling should describe the disease severity of patients enrolled in the clinical trials.\n'必须严格设定进行这 种研究条件，以便保证患者获益。'可被翻译为：The conditions for conducting such a study must be set rigorously so that the interest of the patient is guaranteed.\n'因此，可在 这些列表中分析和评估数据，确定每位患者和每例不良事件 的对应关系很重要。'可被翻译为：So that it is possible to analyse and evaluate the data in these tables, it is important to identify each patient having each adverse event.\n'需要注 意的是，这些数据在计划试验的阶段很重要，但在解读结果时并不是必须的，因为分析 灵敏度必须在试验中体现。'可被翻译为：Of note, these data are important at the planning stage of the trial but are not essential for the interpretation of the results as assay sensitivity has to be shown within the trial.\n\n根据上述已知信息，请将'需要限定入组试验的每例患者的ILAR类别，因为这对交叉试验比较很重要。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The ILAR category of each patient enrolled into trials needs to be defined as this is important for cross- trial comparisons."
    },
    {
        "instruction":"已知信息：\n'（二）标准品或对照品应当有适当的标识，内容至少包括名 称、批号、制备日期（如有）、有效期（如有）、首次开启日期、 含量或效价、贮存条件；'可被翻译为：2. The standard substances or reference substances should be properly labeled with at least the following information: name, batch number, data of preparation (if available), shelf life (if available), open date, purity or titration, and storage condition.\n'第一百四十一条 中国药品生物制品检定所负责对标定的标准物质从原材料选择、制备方法、标定方法、标定结果、定值准确性、量值溯源、稳定性及分装与包装条件等资料进行全面技术审核，并作出可否作为国家药品标准物质的结论。'可被翻译为：Article 141 The National Institute for the Control of Pharmaceutical and Biological Products shall be responsible for the overall technical evaluation of the characterized reference standards in respect of the data of source material selection, preparation methods, testing methods and results, accuracy of value assignment, traceability, stability, filling and packaging conditions, etc. and shall conclude whether or not the candidate materials can be used as national reference standards.\n'（二）体外诊断试剂强制性标准已经修订或者有新的国家标准品、参考品，该体外诊断试剂不能达到新要求的；'可被翻译为：(2) The mandatory standard(s) of in-vitro diagnostic reagents have been revised or national standard products and reference products have been established, and the in-vitro diagnostic reagent fails to meet the requirements of the new standards.\n'指国际或国家标准品。'可被翻译为：Refer to international or national standards.\n\n根据上述已知信息，请将'第二十五条 有国家标准品、参考品的产品应当使用国家标准品、参考品进行注册检验。中国食品药品检定研究院负责组织国家标准品、参考品的制备和标定工作。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 25 For the products with national standard products and reference products, it is required to use national standard products and reference materials for registration testing. National Institutes for Food and Drug Control is responsible for organizing the preparation and calibration of national standard products and reference materials."
    },
    {
        "instruction":"已知信息：\n'根据这一方法，将对患有前驱期\/AD 所致 MCI 以及轻度 AD 的患者一同进行研究。'可被翻译为：Following this approach, subjects with prodromal AD\/MCI due to AD and mild AD may be studied together.\n'已经认识到前驱期\/AD 所致 MCI 患者的临床特征可能有所重叠，在 AD 痴呆谱系的较轻端，尽管为了统一标准付诸努力，但尚未能明确界定可行的疾病阶段定义。'可被翻译为：It is recognized that the clinical characteristics of patients with prodromal\/MCI due to AD may overlap with those at the milder end of the AD dementia spectrum and that, despite all efforts for criteria harmonization, operationally defined stages of disease are not clearly demarcated.\n'前驱期AD\/AD 所致MCI 的有效性终点'可被翻译为：Efficacy endpoints in Prodromal AD\/MCI due to AD\n'重要的是，按照 NIA-AA 标准的 AD 所致 MCI 与IWG 发表的前驱期 AD 具有明显的差异，可能会导致不同的研究人群：'可被翻译为：It is important, that MCI due to AD according to the NIA-AA criteria and those for Prodromal AD as published by IWG show significant differences and may lead to different study populations:\n\n根据上述已知信息，请将'对于前驱期AD\/AD 所致MCI 诊断标准的任何建议仍保持开放的态度，将致力于建立进展为 AD 痴呆的速度已知的人群或统一的群组。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Any recommendation of diagnostic criteria particularly for prodromal AD\/ MCI due to AD is still kept open and all efforts should be focused in detecting a population or homogeneous groups of patients with a defined rate of progression to AD dementia."
    },
    {
        "instruction":"已知信息：\n'应强调新信息。'可被翻译为：New information should be highlighted.\n'评估的重点是在报告期内出现的新信息。'可被翻译为：The focus of the evaluation(s) is on new information which has emerged during the reporting interval of the PBRER.\n'【ICHQ7，第7.11、7.12和7.31章节】从不同方面对物料供应商评估作出了要求，包括贸易商，如适用。【ICHQ7，第7.12章节】要求物料应当按标准从经质量管理部门批准的供应商处采购【ICHQ7，第7.31章节】。'可被翻译为：Different phrases are used to describe the expectation for evaluation of suppliers of materials [ICH Q7, Sections 7.11, 7.12, 7.31], including traders, if any. [ICH Q7, Section 7.12] states that all materials are purchased against a specification and from suppliers approved by the quality unit [ICH Q7, Section 7.31].\n'适当的控制措施【ICHQ7，第4.42章节】包括但不限于以下：'可被翻译为：Appropriate containment measures and controls [ICH Q7, Section 4.42] include but are not limited to the following:\n\n根据上述已知信息，请将'新的标签应包括【ICHQ7，第9.42和9.43章节】中要求的信息。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The new label should contain information as per [ICH Q7, Sections 9.42, 9.43]."
    },
    {
        "instruction":"已知信息：\n'例如：母亲患有先兆子痫，婴儿未发生不良反应。应完成一份关于母亲的 ICSR （含先兆子痫的不良事件\/反应）。婴儿未被报告不良事件\/反应，因此无需提供一份链接的婴儿报告。'可被翻译为：Example: Mother suffers from pre-eclampsia and the child has no adverse reaction. Only one ICSR should be completed for the mother, with the adverse event\/reaction of pre-eclampsia. No events\/reactions are reported for the child, therefore a linked ICSR for the child is not applicable.\n'示例：胎儿窘迫的报告，母亲通过剖腹产分娩。仅需提供一份婴儿的仅需提供一份婴儿的 ICSR（包含胎儿窘迫的不良事件\/反应）。剖宫产不应视为母亲的不良事件\/ 反应。母亲的特征应在D节中记录，且剖腹产作为相关病史（D.10.7）。'可被翻译为：Example: A report of foetal distress, where the mother delivered via a Caesarean section. There will be one ICSR for the baby, with the adverse event\/reaction of foetal distress. The Caesarean section should not be considered an adverse event\/reaction for the mother. The mother’s characteristics, should be captured in Section D with the Caesarean section as relevant medical history (D.10.7).\n'情景3：胎儿或母乳喂养的婴儿通过母亲暴露于药物，并出现了不良事件\/反应 患者 (D) 婴儿\/胎儿 妊娠期在胎儿观察到 (D.2.2.1) 不适用 AE (E) 婴儿\/胎儿发生的AE 药物部分(G) 母亲服用了药物 给药途径 (G.k.4.r.10) 这通常是一种间接暴露，如通过乳汁 父\/母给药途径 (G.k.4.r.11) 母亲用药 对于一份父母-孩子\/胎儿 报告，关于父母的信息 (D.10) 根据用户指南母亲的信息见D部分 N, C to H'可被翻译为：Scenario 3: foetus or breast-feeding infant is exposed to drug(s) through the mother and experienced adverse events\/reactions Patient (D) Infant\/foetus Gestation Period When Reaction \/ Event Was Observed in the Foetus (D.2.2.1) Not applicable AE (E) AE experienced by Infant\/foetus Drug section (G) Product taken by mother Route of Administration (G.k.4.r.10) This is usually an indirect exposure, such as transmammary Parent Route of Administration (G.k.4.r.11) Route administered to mother For a Parent-child \/ Foetus Report, Information Concerning the Parent (D.10) Mother’s information according to the user guidance for section D\n'在父母-儿童\/胎儿报告的情况中，剂量部分适用于已知的父母所用剂量。例如，如果怀疑母亲服用的药物在哺乳婴儿中引起不良反应，则剂量信息（G.k.4.r.1 至 G.k.4.r.11.2）与母亲如何服用药物相关。如果母亲为疑似药物的来源，则剂量信息反映母亲如何服药或服药方式。如果父亲为疑似药物的来源，则提供有关药物的其他信息（G.k.10）。病例叙述（H.1）应描述整个病例，包括父亲的信息。'可被翻译为：In the case of a parent-child\/foetus report, the dosage section applies to the known parental dose. For example, if the mother took the drug(s) suspected of causing adverse reaction(s) in a nursing infant, then the dosage information (G.k.4.r.1 to G.k.4.r.11.2) relates to how the mother took the medication(s). If the mother is the source of the suspect drug(s) then the dosage information reflects how the mother ingested or was administered the drug(s). If a father is the source of the suspect drug(s) then the additional information on drug (G.k.10) is provided. The case narrative (H.1) should describe the entire case, including the father’s information.\n\n根据上述已知信息，请将'例如：母亲患有先兆子痫，分娩时婴儿的出生体重不足且患畸形足。应提交 2 个相关联的 ICSR：母亲的报告应包含先兆子痫的不良事件\/反应；婴儿的报告应包含低出生体重和畸形足的事件\/反应。先兆子痫术语仅适用于母亲的病例。应为 2份病例（即母亲和婴儿）完成数据元素C.1.10.r。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Example: Mother suffers from pre-eclampsia and, at parturition, the baby had a low birth weight and club foot. Two linked ICSRs should be submitted: The mother’s report should have the adverse event\/reaction of pre-eclampsia; the report for the baby should have event\/reaction terms for low birth weight and club foot. The term pre- eclampsia would only apply to the mother’s case. The data element C.1.10.r should be completed for both cases (e.g. the mother’s and baby’s)."
    },
    {
        "instruction":"已知信息：\n'描述应考虑来源、鉴 别、物理化学及功能特性研究以及成品中所有成分的预期功能。'可被翻译为：The description should take into account the origin, identification, physico- chemical and functional characterisation studies, and the expected function of all components in the  final product.\n'3.所用原辅料清单（包括生产过程中使用，但不在成品中出现的物料），阐明每一物料的指定名称、代码和用量；如原辅料的用量需要折算时，还应当说明计算方法。'可被翻译为：3) A list of all starting materials to be used, with the amount of each, described using the designated name and a reference that is unique to that material (mention should be made of any substance that may disappear in the course of processing); When conversion between measuring methods or units is needed, the calculation method should be specified.\n'速释制剂中的辅料用量应该与预期功能（例如润滑剂）相匹配以支持生物豁免申请。'可被翻译为：To support a biowaiver request, the quantity of excipients in the IR drug product should be consistent with the intended function (e.g., lubricant).\n'应针对3.2.P.1中辅料种类的选择、用量的确定以及影响制剂性能特性的辅料性质 进行论述。'可被翻译为：The choice of excipients listed in 3.2.P.1, their concentration, their characteristics that can influence the drug product performance should be discussed relative to their respective functions.\n\n根据上述已知信息，请将'应列表体现所用辅料及其用量和预期功能。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A list of excipients used, the amount used, and their intended functions should be provided."
    },
    {
        "instruction":"已知信息：\n'<复原后>{（发明的）名称}包含约{x}IU({y}IU\/{z}ml)人类凝血因子VIII<(rDNA), {INN}>。'可被翻译为：{(Invented) name} contains approximately {x} IU ({y}IU\/{z}ml) of human coagulation factor VIII <(rDNA), {INN}> <after reconstitution>.\n'人类凝血因子VIII和人类凝血因子VIII（rDNA）分别由欧洲药典专论（0275）和欧洲药典专 论（1643）定义。'可被翻译为：Human coagulation factor VIII is defined by the Ph. Eur. Monograph (0275) and human coagulation factor VIII (rDNA) by the Ph. Eur. Monograph (1643).\n'{（发明的）名称}的比活度为大约{x} IU\/mg 蛋白质。 <{INN}（人类凝血因子VIII (rDNA)）是一种含有{x}个氨基酸[包括任何药品特 有修饰]的蛋白质。'可被翻译为：The specific activity of {(Invented) name} is approximately {x} IU\/mg protein. <{INN} (human coagulation factor VIII (rDNA)) is a protein that has {x} amino acids [include any product specific modification].\n'<尚未有人类凝血因子VIII <(rDNA)>产品与其他药品相互作用的报道。'可被翻译为：<No interactions of human coagulation factor VIII <(rDNA)> products with other medicinal products have been reported.\n\n根据上述已知信息，请将'每个容器内名义上含{x}[根据标示含量] IU人类凝血因子VIII<(rDNA),{INN}>。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Each {container} contains nominally {x} [as per labelled content] IU human coagulation factor VIII <(rDNA), {INN}>."
    },
    {
        "instruction":"已知信息：\n'研究发现HLA-B*1502检测在特定亚洲人群中(例 如，汉族和泰国患者)非常重要，因为这类群体NPV较高，且携带上述等位基因的概率 较高。'可被翻译为：It is noted that the test for HLA-B*1502 is most useful in certain Asian populations (e.g. Han Chinese and Thai patients) due to high NPV as well as a relatively high frequency of this allele in these populations.\n'应当注意，HLA-B *1502的检测在某些亚洲人群（例如汉族和泰国）患者中是最有用的，这是由于高NPV以及这些人群中该等位基因的频率相对较高。'可被翻译为：It is noted that the test for HLA-B*1502 is most useful in certain Asian populations, e.g. Han Chinese and Thai patients, due to high NPV as well as a relatively high frequency of this allele in these populations.\n'另一方面，无HLA-B*5701等位基因的患者几乎不会发生这种不良反应，即96%或100%的高阴性预测值（NPV）。'可被翻译为：On the other side, almost no patients without the HLA-B*5701 allele will develop this adverse reaction, i.e. high negative predictive value (NPV) of 96% or 100%.\n'相比而言， 未携带HLA-B*5701等位基因的患者几乎无人发生此类不良反应（高负预测值（ NPV） 96% 或 100%）。'可被翻译为：On the other side, almost no patients who do not have the HLA-B*5701 allele will develop the adverse reaction (high negative predictive value, NPV, of 96% or 100%).\n\n根据上述已知信息，请将'在东南亚裔的特定种族组中（汉 族人、泰国人和马来人），HLA-B*15:02是一种重要的诱病等位基因，阴性预测 值为100%。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In certain ethnic groups of South East Asian origin (Han Chinese, Thai and Malays), HLA-B*15:02 is an important predisposing allele with a negative predictive value of 100%."
    },
    {
        "instruction":"已知信息：\n'有关将产品应用于膜上的具体给药技术，请参阅体外释放试验(IVRT)，实验设计，剂量'可被翻译为：For specific dosing techniques to apply the product to the membrane, refer to In Vitro Release Test (IVRT), Experimental Design, Dose.\n'有关将产品涂抹在皮肤上的具体剂量技术，请参阅体外渗透试验，实验设计，剂量。将泵设置为用于测试的流量，并将流出样管(应全部相同长度)与第一组小瓶或试管对齐。'可被翻译为：For specific dosing techniques to apply the product to the skin, refer to the In Vitro Permeation Test, Experimental Design, Dose. Set the pump to the flow rate to be used for testing and align the outflow sample tubes (which should all be the same length) with the first set of vials or test tubes.\n'有关给药前的药品稀释说明，请参见第 12 章。'可被翻译为：For instructions on dilution of the medicinal product before administration, see section 12.\n'^非标准的致癌性实验设计。只设一个剂量组，间歇给药，小样本量（参考文献 7）。'可被翻译为：˄Not a standard carcinogenicity design. Only one dose, intermittent dosing, and small sample size (Ref.7).\n\n根据上述已知信息，请将'将产品应用于膜的具体给药技术，请参见体外渗透试验，实验设计，剂量'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For specific dosing techniques to apply the product to the membrane, refer to In Vitro Permeation Test, Experimental Design, Dose."
    },
    {
        "instruction":"已知信息：\n'根据分子大小进行分离的一种液相色谱技术。'可被翻译为：A liquid chromatographic technique for separation based on molecular size.\n'分离和纯化'可被翻译为：Isolation and purification\n'色谱系统的系统适用性检查（例如，GC 或 HPLC）'可被翻译为：System suitability checks on chromatographic systems (e.g., GC or HPLC)\n'采用相对峰面积法定量的分离技术（例 如：产品相关的物质如电荷异构体）'可被翻译为：Separation techniques with relative area quantitation (e.g., product- related substances such as charge variants)\n\n根据上述已知信息，请将'杂质或含量测定的分离技术（例 如，HPLC、GC、CE）'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Separation techniques (e.g., HPLC, GC, CE) for impurities or assay"
    },
    {
        "instruction":"已知信息：\n'国际药物经济学与产出研究会'可被翻译为：ispor\n'国际药学联合会'可被翻译为：international pharmaceutical federation\n'药物经济学评价和研究的视角，主要包括社会角度、患者角度、医疗机构角度和保险方角度。不同的研究角度需要测量的成本和产出范围不同。'可被翻译为：The perspectives of pharmacoeconomic evaluation and research mainly include the social perspective, the patient perspective, the medical institution perspective and the insurance perspective. Different research perspectives need to measure different ranges of costs and outputs.\n'对特定健康水平或健康产出偏好的衡量。'可被翻译为：A measure of preference for a particular level of health or health output.\n\n根据上述已知信息，请将'致力于在药物经济学、健康产出评估和公共政策相关问题的研究的国际组织。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"An international organization dedicated to research on issues related to pharmacoeconomics, health outcomes evaluation, and public policy."
    },
    {
        "instruction":"已知信息：\n'除了比较试验中暴露-反应的估计之外，通常值得对汇总的数据进行暴露-反应分析。'可被翻译为：In addition to comparing estimates of exposure-response across trials, it is generally desirable to perform an exposure-response analysis on pooled data.\n'·多项研究中发生的不良事件通常相似'可被翻译为：·The occurrence of adverse events has been generally similar across multiple studies\n'在相似的暴露水平下可观察到对 骨骼和肾脏的影响，这些都是镉暴露的敏感标志[1]。'可被翻译为：Skeletal and renal effects are observed at similar exposure levels and are a sensitive marker of cadmium exposure (ATSDR, 2012).\n'16 当定稿时，本指南将代表FDA当前对这一主题的思考。'可被翻译为：16 When final, this guidance will represent the FDA’s current thinking on this topic.\n\n根据上述已知信息，请将'当以这一方法对FDA扩充数据库中的123个化合物 进行分析时，观察到一个类似的相对系统暴露量分布。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"When 123 compounds in the expanded FDA database were analysed by this approach, a similar distribution of relative systemic exposures was observed."
    },
    {
        "instruction":"已知信息：\n'http:\/\/www.fda.gov\/aboutfda\/centersoffices\/officeofmedicalproductsandtobacco\/cder\/ucm 184426.htm'可被翻译为：http:\/\/www.fda.gov\/aboutfda\/centersoffices\/officeofmedicalproductsandtobacco\/cder\/ucm184428596.htm 860\n'http:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/OfficeofMedicalProductsandTobacco\/CBE R\/default.htm'可被翻译为：http:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/OfficeofMedicalProductsandTobacco\/CBER\/def 867ault.htm\n'13 参见 http:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/OfficeofMedicalProductsandTobacco\/CDER\/ContactCDE R\/ucm444092.htm.'可被翻译为：13 See http:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/OfficeofMedicalProductsandTobacco\/CDER\/ContactCDER\/ucm444 092.htm.\n'联系信息可见于CDER监察员网页：http:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/OfficeofMedicalProductsandTobacco\/ CDER\/ContactCDER\/CDEROmbudsman\/default.htm。'可被翻译为：Contact information can be found on the CDER Ombudsman Web page at http:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/OfficeofMedicalProductsandTobacco\/CDER\/ContactCDER\/CDEROmbudsman\/default.htm.\n\n根据上述已知信息，请将'参见受管制物质工作人员网页： http:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/OfficeofMedicalProductsandTobacco\/ CDER\/ucm180753.htm。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"See the Controlled Substance Staff Web page at http:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/OfficeofMedicalProductsandTobacco\/CDER\/uc968 m180753.htm."
    },
    {
        "instruction":"已知信息：\n'估计目标的描述应该反映出与这 些伴发事件相关的临床问题，并且本增补介绍了反映不同临床问 题的策略。'可被翻译为：The description of an estimand should reflect the clinical question of interest in respect of these intercurrent events, and this addendum introduces strategies to reflect different questions of interest that might be posed.\n'构建相应临床问题的“估计目标”（见词汇表；A.3.）有助 于精确描述治疗效应，这就需要深思熟虑地定义“伴发事件” （见词汇表；A.3.1.），如终止分配的治疗，使用额外或其他治 疗，或终末事件（如死亡）等。'可被翻译为：Precision in describing a treatment effect of interest is facilitated by constructing the “estimand” (see Glossary; A.3.) corresponding to a clinical question of interest. Clarity requires a thoughtful envisioning of “intercurrent events” (see Glossary; A.3.1.) such as discontinuation of assigned treatment, use of an additional or alternative treatment and terminal events such as death.\n'临床问题中反映的伴发事件'可被翻译为：Intercurrent Events to be Reflected in the Clinical Question of Interest\n'前者代表一个伴 发事件，需通过在试验目的中对估计目标的精确说明加以解决；'可被翻译为：The former represents an intercurrent event, to be addressed in the precise specification of the trial objective through the estimand.\n\n根据上述已知信息，请将'估计目标的描述涉及特定属性的精确说明，这些属性不仅应 基于临床考虑而制定，还应基于所关注的临床问题中如何反映伴 发事件。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The description of an estimand involves precise specifications of certain attributes, which should be developed based not only on clinical considerations but also on how intercurrent events are reflected in the clinical question of interest."
    },
    {
        "instruction":"已知信息：\n'所有这些都有一定的适用性和局限性。根据疼痛持续时间疼痛可以描述为急性或慢性。'可被翻译为：All of them have certain applicabilities and limitations. According to its duration pain can be described as acute or chronic.\n'在适当情况下，应评价对观察到的疼痛测量的影响。'可被翻译为：The impact on the observed measures of pain should be evaluated where appropriate.\n'针对疼痛强度（SPID）或疼痛缓解（TOTPAR），替代方法基于时间-镇痛作用曲线下面积的分析。'可被翻译为：Alternative approaches are based on the analysis of the area under the time-analgesic effect curve for pain intensity (SPID) or pain relief (TOTPAR).\n'长期伤害性疼痛病症（例如髋关节和\/或膝关节和的骨关节炎）并不总是具有适应不良的特征。'可被翻译为：Long-standing nociceptive pain conditions such as osteoarthritis of the hip and\/or knee do not always feature maladaptive characteristics.\n\n根据上述已知信息，请将'评估必须适应疼痛的时间过程（例如间歇性或阵发性，随不同水平的强度或单次发作基本上是恒定的）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Assessments have to be adapted to the time course of pain (e.g. intermittent or paroxysmal, essentially constant with varying levels of intensity or single episode)."
    },
    {
        "instruction":"已知信息：\n'当采用免疫表型研究表征或鉴别特定白细胞群的改变时，应根据观察到的变化选择待评价免疫器官和\/或外周血。免疫表型研究易于结合常规重复给药毒性研究进行，在给药期和恢复期均可以检测免疫表型的变化。'可被翻译为：When immunophenotyping studies are used to characterize or identify alterations in specific leukocyte populations, the choice of the lymphoid organs and\/or peripheral blood to be evaluated should be based on changes observed. Immunophenotyping can be easily added to standard repeat dose toxicity studies and changes can be followed during the dosing phase and periods without drug exposure (reversal period).\n'2.3 免疫表型分析'可被翻译为：2.3 Immunophenotyping\n'流式细胞术用于特定细胞群计数时不属于功能性检测。然而，流式细胞术可用来测定淋巴细胞的抗原特异性免疫应答。外周血细胞流式分析数据能够与临床试验中外周血白细胞分析数据进行桥接。推荐采用淋巴细胞亚型的绝对数量和百分比对给药相关的变化进行评价。'可被翻译为：Flow cytometry, when employed to enumerate specific cell populations, is not a functional assay. However, flow cytometry can be used to measure antigen-specific immune responses of lymphocytes. Data obtained from peripheral blood can be useful as a bridge for clinical studies in which peripheral blood leukocytes are also evaluated. It is recommended that absolute numbers of lymphocyte subsets as well as percentages be used in evaluating treatment-related changes.\n'对于免疫调节类药物， 试验设计可能包括附加的终点指标（如流式细胞术的免疫表型分 析）。'可被翻译为：For immunomodulatory pharmaceuticals, additional endpoints (such as immunophenotyping by flow cytometry) might be included in the study design.\n\n根据上述已知信息，请将'免疫表型分析指采用抗体进行白细胞亚型的鉴定和\/或白细胞亚型的计数。免疫表型试验通常采用流式细胞术或免疫组织化学方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Immunophenotyping is the identification and\/or enumeration of leukocyte subsets using antibodies. Immunophenotyping is usually conducted by flow cytometric analysis or by immunohistochemistry."
    },
    {
        "instruction":"已知信息：\n'ICH Q10所述的质量体系要素和管理职责意在鼓励在生命周期各阶段使用基于科学和基于风险的方法以促进药品在整个生命周期中持续改进。产品和工艺知识应从研发阶段开始进行管理，贯穿产品的整个商业化生命周期，直至产品退市。'可被翻译为：The quality system elements and management responsibilities described in ICH Q10 are intended to encourage the use of science-based and risk-based approaches at each lifecycle stage, thereby promoting continual improvement across the entire product lifecycle. Product and process knowledge should be managed from development through the commercial life of the product up to and including product discontinuation.\n'ICH Q10所述的质量体系要素和管理职责意在鼓励在生命周期各阶段使用基于科学和基于风险的方法，从而促进整个产品生命周期中的持续改进。'可被翻译为：The quality system elements and management responsibilities described in ICH Q10 are intended to encourage the use of science-based and risk-based approaches at each lifecycle stage, thereby promoting continual improvement across the entire product lifecycle.\n'本指导原则中阐述的质量体系要素和管理职责旨在鼓励在（产品）生命周期的每个阶段使用基于科学和风险的方 法，从而促进整个产品生命周期的持续改进。'可被翻译为：The quality system elements and management responsibilities described in this guideline are intended to encourage the use of science and risk based approaches at each lifecycle stage, thereby promoting continual improvement across the entire product lifecycle.\n'ICHQ10中所述的质量体系和管理职责旨在鼓励在生命周期的每个阶段都使用基于科学和风险的方法，从而促使药品整个生命周期的持续改进。'可被翻译为：The quality systems and management responsibilities described in ICH Q10 are intended to encourage the use of science-based and risk-based approaches at each lifecycle stage, thereby promoting continual improvement across the entire product lifecycle.\n\n根据上述已知信息，请将'9. 生命周期管理 ICH Q10描述的质量体系要素和管理职责，意在鼓励在 生命周期的每一个阶段使用基于科学和基于风险的方法，以 促进整个产品生命周期的持续改进。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"9.Lifecycle Management The quality system elements and management responsibilities described in ICH Q10 are intended to encourage the use of science-based and risk-based approaches at each lifecycle stage, thereby promoting continual improvement across the entire product lifecycle."
    },
    {
        "instruction":"已知信息：\n'在所有情况下，必需要收集证据来支持从PK\/PD分析结果强烈预测用于预期用途的 疗效，PK\/PD分析结果来自于体外活性、非临床疗效证据及相关人体PK数据 等完整记录，这应该包括从患有一系列感染类型的全身疾病、申办方预期需要使用该新药的患者中获得的充分PK数据。'可被翻译为：In all cases it is essential to accumulate evidence to support a strong prediction of efficacy in the intended use(s) from PK\/PD analyses that are founded on a thorough documentation of in-vitro activity, non-clinical evidence of efficacy and relevant human PK data, which should include adequate PK data obtained from patients who are systemically ill with a range of types of infection in which the sponsor expects the new agent will need to be used.\n'对于大多数或所有临床数据来自于接受多个活性抗菌剂治疗的患者的临床开发项目，PK\/ PD分析对于支持所选择的剂量方案的可能疗效变得更加重要。'可被翻译为：For clinical development programmes in which most or all of the clinical data are obtained from patients receiving more than one potentially active antibacterial agent the role of the PK\/PD analyses becomes even more important to support the likely efficacy of the selected dose regimen.\n'因此，所有的患者将随机接受试验药物的多种剂量方案中的一种，从基于PK\/PD考虑 至少对某些可能的病原体可能有临床活性的最低剂量开始。'可被翻译为：Thus, all patients could be randomised to one of several dose regimens of the test agent starting from the minimum that might be clinically active at least against some potential pathogens based on PK\/PD considerations.\n'PK\/PD 关系的整体评估应足够全面， 以便有合理的信心评估该试验性抗菌剂 按充分的剂量方案使用时对于在体外试验中看起来敏感的相关病原体是否具有 有效的临床活性。'可被翻译为：The overall assessment of the PK\/PD relationship should be sufficiently comprehensive to assess with reasonable confidence whether or not the test antibacterial agent, when used at an adequate dose regimen, would have useful clinical activity against relevant pathogens that appear to be susceptible in vitro.\n\n根据上述已知信息，请将'这被认为是必需的，因为预期在这些情况下，PK\/PD分析将作为剂量方案和 针对靶病原体的临床活性的期望的合理依据之一。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"This is considered to be essential since it is expected that in these situations the PK\/PD analyses will form a major part of the justification for the dose regimen and the expectation of clinical activity against the target pathogens."
    },
    {
        "instruction":"已知信息：\n'按照银的口服生物利用度在1%至50%之间， 用口服途径PDE除以校正因子10（见第3.1章所述）来计算注射途径PDE。'可被翻译为：On the basis of an oral bioavailability between 1% and 50% for silver, the parenteral PDE was calculated by dividing the oral PDE by a modifying factor of 10 (as described in Section 3.1).\n'c：单次静脉推注给予500 mg\/m2的这个剂量被用于比较，尽管试验中也使用了更高的剂量（例如，~1500 mg\/m2\/天 CIV）。'可被翻译为：c: The dose of 500 mg\/m2 IV bolus was used for comparison although higher doses (e.g., ~1500 mg\/m2\/day CIV) are used.\n'甲氨蝶呤 CAS号：59-05-2 大鼠NOAEL 剂量 Cmax AUC 大鼠LOAEL 剂量 Cmax AUC 大鼠 发现 兔NOAEL 剂量 Cmax AUC 兔LOAEL 剂量 Cmax AUC 兔 发现 人剂量 Cmax AUC 暴露倍数 NOAEL\/人 LOAEL\/人 注释 未确定 NOAEL 0.1 mg\/kg IP GD9 [Jordan, Woo] Cmax=0.21 µg\/mLa AUC=0.067 µg∙h\/mLa 窝吸 收，畸 形 未确定 NOAEL 0.3 mg\/kg IV GD10 [Jordan] Cmax=1.58 µg\/mLb AUC=0.61 µg∙h\/mLb 脑积水、小 眼、唇腭 裂、小颌畸 形、尾骶尾 发育不良、 短肢畸形、 半肢、并 趾、缺趾； 胚胎致死 性，吸收胎 银屑病: 10-25 mg Q7D (5.9-14.7 mg\/m2) 口服或 IVc 急性淋巴细胞白血病 （ALL）：诱导–每天3.3 mg\/m2，维持–15 mg\/m2口 服，2次\/周 绒毛膜癌： 15–30 mg QD 口服×5 (8.8–17.6 mg\/m2) 淋巴瘤： 10–25 mg QD×4-8口服(5.9–14.7 mg\/m2)；0.625–2.5 mg\/kg (23 – 92.5 mg\/m2) 蕈样肉芽肿： 5–50 mg Q7D口服(2.9 – 29 mg\/m2) 类风湿性关节炎: 7.5 mg Q7D口服(4.4 mg\/m2) NOAEL: 大鼠 未确定 NOAEL 兔 未确定 NOAEL LOAEL: 大鼠 Cmax = 0.1 (0.21\/2.14) AUC=0.02 (0.067\/3.28) 兔 Cmax=0.7 (1.58\/2.14) AUC=0.2 (0.61\/3.28)'可被翻译为：METHOTREXATE CAS No.: 59-05-2 Rat NOAEL Dose Cmax AUC Rat LOAEL Dose Cmax AUC Rat Findings Rabbit NOAEL Dose Cmax AUC Rabbit LOAEL (Dose Cmax AUC Rabbit Findings Human Dosec Cmax AUC NOAEL Margins Notes NOAEL not identified 0.1 mg\/kg IP GD9 [Jordan, Woo] Cmax = 0.21 µg\/mLa AUC = 0.067 µg∙h\/mLa resorbed litters, malformations NOAEL not identified 0.3 mg\/kg IV GD10 [Jordan] Cmax = 1.58 µg\/mLb AUC = 0.61 µg∙h\/mLb hydrocephalus, microphthalmia, cleft lip and palate, micrognathia, dysplastic sacral and caudal vertebrate, phocomelia, hemimelia, syndactyly, and ectrodactyly; embryolethality, resorptions psoriasis: 10 – 25 mg Q7D (5.9 – 14.7 mg\/m2) oral or IVc ALL: induction – 3.3 mg\/m2 daily; maintenance – 15 mg\/m2 oral twice\/week choriocarcinoma: 15 – 30 mg oral QD 5 (8.8 – 17.6 mg\/m2) lymphoma: 10 – 25 mg QD 4-8 oral (5.9 – 14.7 mg\/m2); 0.625 – 2.5 mg\/kg (23 – 92.5 mg\/m2) mycosis fungoides: 5 – 50 mg Q7D oral (2.9 – 29 mg\/m2) RA: 7.5 mg Q7D oral (4.4 mg\/m2) Cmax = 2.14 µg\/mLd NOAEL: rat NOAEL not identified rabbit NOAEL not identified LOAEL: rat Cmax = 0.1 (0.21\/2.14) AUC = 0.02 (0.067\/3.28) rabbit Cmax = 0.7 (1.58\/2.14) AUC = 0.2 (0.61\/3.28)\n'大鼠剂量从 mg\/kg转换至mg\/m2的转换因子为6～7（6.5），人用剂量从mg\/kg 转换至mg\/m2的转换因子为40。'可被翻译为：The factor 6-7 (6.5) is used to convert rat doses from mg\/kg to mg\/m2 and the factor 40 is used to convert human doses from mg\/kg to mg\/m2.\n\n根据上述已知信息，请将'银屑病中的静脉给药剂量 25 mg（14.7 mg\/m2）被选择用 于PK倍数比较，因为这是非肿瘤适应症中的最高剂量，且也将能提供比口服给药（蕈样肉芽肿）50 mg（29 mg\/m2）更高的暴露，因为口服生物利用度 仅~40%。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"An intravenous dose of 25 mg (14.7 mg\/m2) in psoriasis was chosen for PK margin comparisons since this was the highest dose in a non-oncology indication and would also provide a higher exposure than a 50 mg (29 mg\/m2) oral dose (mycosis fungoides) since oral bioavailability is only ~40%."
    },
    {
        "instruction":"已知信息：\n'核心SmPC的历史年表：最初的核心SmPC（CPMP \/ BPWP \/ 859 \/ 95）于1997 年9月开始生效。第一版（CPMP\/BPWP\/859\/95 rev.1）于2000年12月生效。第二 版（CPMP\/BPWP\/859\/95 rev. 2）于2004年11月生效。EMA\/CHMP\/BPWP\/94038\/2007 rev 3于2011年5月生效。'可被翻译为：4. Timeline history of core SmPC: The original core SmPC (CPMP\/BPWP\/859\/95) came into operation in September 1997. First revision (CPMP\/BPWP\/859\/95 rev.1) came into operation in December 2000. Second revision (CPMP\/BPWP\/859\/95 rev. 2) came into operation in November 2004. EMA\/CHMP\/BPWP\/94038\/2007 rev 3 came into operation in May 2011.\n'SmPC 的历史年表：原核心 SPC（CPMP\/PhVWP\/BPWG\/2231\/99）于 2001 年 4 月生效。'可被翻译为：Timeline history of core SmPC: The original core SPC (CPMP\/PhVWP\/BPWG\/2231\/99) came into effect in April 2001.\n'核心 SmPC 的历史年表：'可被翻译为：Timeline history of core SmPC:\n'最初的核心SPC（CPMP\/BPWG\/282\/00）于2003 年1月开始生效。'可被翻译为：The original core SPC (CPMP\/BPWG\/282\/00) came into operation in January 2003.\n\n根据上述已知信息，请将'核心SmPC的大事年表历史：原核心SmPC（CPMP\/BPWP\/153\/00）于2005 年1月生效。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Timeline history of core SmPC: The original core SmPC (CPMP\/BPWP\/153\/00) came into operation in January 2005."
    },
    {
        "instruction":"已知信息：\n'在“生物等效性研究指导原则”和“缓控释制剂的药代动力学和临床评估”中给出了标准。'可被翻译为：Criteria are given in “Guideline on the Investigation of Bioequivalence” and the “Pharmacokinetic and clinical evaluation of modified-release dosage forms”.\n'对于探索剂量-效应或者浓度效应的研究，有关设计和分 析的进一步指导可参见ICH指南“支持药物注册的剂量-效应 信息”。'可被翻译为：Further guidance on the design and analysis of studies exploring dose-response or concentration response can be found in the ICH Guideline \"Dose-Response Information to Support Drug Registration\".\n'又称\"负载式经济评价”。在传统临床试验中同时附加药物经济学评价的研究设计。'可被翻译为：Also known as \"loaded economic evaluation\". A study design in which pharmacoeconomic evaluation is added to traditional clinical trials.\n'第6节讨论研究实施、确保研究受试 者安全和研究报告。'可被翻译为：Section 6 addresses study conduct, ensuring the safety of study participants, and study reporting.\n\n根据上述已知信息，请将'药物经济学的研究标准和研究报告格式，是研究设计和实施的指导。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Research standards and research reporting formats in pharmacoeconomics serve as guidelines for study design and implementation."
    },
    {
        "instruction":"已知信息：\n'第十一条 药品生产企业、药品批发企业销售药品时，应当开具标明供货单位名称、药品名称、生产厂商、批号、数量、价格等内容的销售凭证。'可被翻译为：Article 11 Where a drug manufacturer or wholesaler sells drugs, it shall provide sales document indicating supplier';s name, drug name, manufacturer, batch number, quantity, price, etc.\n'药品零售企业销售药品时，应当开具标明药品名称、生产厂商、数量、价格、批号等内容的销售凭证。'可被翻译为：Where a drug retailer sells drugs, it shall provide sales document indicating drug name, manufacturer, quantity, price, batch number, etc.\n'（三）做好拆零销售记录，内容包括拆零起始日期、药品的通用名称、规格、批号、生产厂商、有效期、销售数量、销售日期、分拆及复核人员等；'可被翻译为：(III) The records of dismantling sales shall be made, including the starting date of dismantling, adopted name, strength, lot number, manufacturer, and expiry date of drugs, sales quantity, sales date, dismantling and checking personnel, etc.;\n'第九十二条 企业应当做好药品销售记录。销售记录应当包括药品的通用名称、规格、剂型、批号、有效期、生产厂商、购货单位、销售数量、单价、金额、销售日期等内容。按照本规范第六十九条规定进行药品直调的，应当建立专门的销售记录。'可被翻译为：Article 92 Enterprises shall take records of drug sales. Sales records shall include the adopted name, strength, dosage form, lot number, expiry date, manufacturer, purchaser, sales quantity, unit price, amount and sales date of the drug. Special sales records shall be established for the direct transfer of drugs in accordance with Article 69 herein.\n\n根据上述已知信息，请将'第一百六十八条 企业销售药品应当开具销售凭证，内容包括药品名称、生产厂商、数量、价格、批号、规格等，并做好销售记录。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 168 Enterprises shall issue the proof of sales for drugs, including drug name, manufacturer, quantity, price, lot number and strength, and make the sales records."
    },
    {
        "instruction":"已知信息：\n'在计量学吸光光度法分析检测多组分体系时，采用的一种化学计量学数据处理方法。'可被翻译为：A stoichiometric data processing method used in the analysis and detection of multi-component systems by metrological absorbance spectrophotometry.\n'一种通过数学处理以消除分光光度法定量分析中干扰吸收的方法。使用与复合剂中多种组分不经分离的直接测定。'可被翻译为：The invention relates to a method of eliminating interference absorption in spectrophotometric quantitative analysis by mathematical treatment. Using direct determination without separation from multiple components of a compound.\n'由瑞典经济计量学家沃尔德（H.Wold）于1966年首次提出的一种新型多元统计数据分析方法，是多因变量对多自变量的回归建模方法。在计量学吸光光度法中，是一种用于多组分分析的数据处理方法。'可被翻译为：A new method of multivariate statistical data analysis, first proposed by the Swedish econometrician H. Wolde in 1966, is the regression modeling method of multivariate variables to multi-independent variables. In metrology absorptiometry, it is a data processing method for multi-component analysis.\n'20世纪中期发展起来的学科,线性规划模式中的所有方程式及函数都是线性的，是解决多变量最优决策的方法，是在各种相互关联的多变量约束条件下，解决或规划一个对象的线性目标函数最优的问题。在计量学吸光光度法中，是用于多组分分析的一种数据处理方法。'可被翻译为：A discipline developed in the middle of the 20th century, all equations and functions in the linear programming model are linear, and it is a method to solve the multi-variable optimal decision. It is a problem to solve or plan the linear objective function optimization of an object under various interrelated multi-variable constraints. In the metrology absorptiometry, it is a data processing method used for multi-component analysis.\n\n根据上述已知信息，请将'在计量学吸光光度法中，对多组分分析时采用的一种数据处理方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In metrology absorptiometry, a data processing method used for multi-component analysis."
    },
    {
        "instruction":"已知信息：\n'7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom 电话：+44(0)20 7418 8400 传真：+44(0)20 7418 8416 电子邮箱：info@ema.europa.eu 网址：www.ema.europa.eu 欧盟机构 ©2013年欧洲药物管理局版权所有。'可被翻译为：7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom An agency of the European Union Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8416 E-mail info@ema.europa.eu Website www.ema.europa.eu © European Medicines Agency, 2013.\n'EC 欧盟委员会（European Commission）'可被翻译为：EC European Commission\n'电子邮箱: admin@ich.org 网址：http:\/\/www.ich.org'可被翻译为：E-mail : admin@ich.org Web site : http:\/\/www.ich.org\n'2012 年 12 月 13 日 \nEMA\/CHMP\/205\/95\/第 4 版 \n肿瘤学工作组 \n人用抗肿瘤药评价指南 \n该指导原则替代指导原则\/NfG 参考内容。\n关键词 \n癌症、恶性肿瘤、生物标记物、靶向药物、药物基因组学 \n7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kindom \n电话：+44(0)20 7418 8400 传真：+44(0)20 7418 8416 \n电子邮箱：info@ema.europa.eu 网址：www.ema.europa.eu \t欧盟机构 \n©2013 年欧洲药物管理局版权所有。'可被翻译为：13 December 2012 \nEMA\/CHMP\/205\/95\/Rev.4 \nOncology Working Party \nGuideline on the evaluation of anticancer medicinal products in man \nThis guideline replaces guideline \/ NfG Reference. \nKeywords \nCancer, malignancy, biomarker, targeted drugs, pharmacogenomics \n7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom \nTelephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8416 \nE-mail info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union \n© European Medicines Agency, 2013.\n\n根据上述已知信息，请将'电子邮箱：info@ema.europa.eu 网址： www.ema.europa.eu 欧盟机构'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"E-mail info@ema.europa.eu Website www.ema.europa.eu"
    },
    {
        "instruction":"已知信息：\n'本次报告期间，未发现引用ZB3579的文献。'可被翻译为：There have been no literature articles citing ZB3579 during the period under review.\n'未使用ZB3579进行其他研究。'可被翻译为：No other studies have been conducted with ZB3579.\n'附录7 文献\/论文摘要 \n无本报告周期内与ZB3579相关的科学文献。'可被翻译为：APPENDIX 7 SCIENTIFIC ABSTRACTS \nNo presentations relevant to ZB3579 were made during the period under review.\n'观察性研究或流行病学研究；'可被翻译为：Observational or epidemiological studies;\n\n根据上述已知信息，请将'在本报告周期内，未启动、进行、完成或报告ZB3579的观察性 或流行病学研究。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"No observational or epidemiological studies of ZB3579 have been initiated, conducted, completed or reported during the period under review."
    },
    {
        "instruction":"已知信息：\n'第七十七条 设备所用的润滑剂、冷却剂等不得对药品或容 器造成污染，应当尽可能使用食用级或级别相当的润滑剂。'可被翻译为：Article 77: Lubricant and refrigerant etc. used in the equipment should not contaminate products or containers. Food grade or equivalent lubricant should be used whenever possible.\n'5.14 设备所需的润滑剂、加热或冷却介质等，不应当与中间产品或原料药直接接触，以免影响中间体或原料药的质量。当任何偏离上述要求的情况发生时，应当进行评估，确保不会对物料的预期用途造成不利影响。应当尽可能使用食用级润滑剂和润滑油。'可被翻译为：5.14 Any substances associated with the operation of equipment, such as lubricants, heating fluids or coolants, should not contact intermediates or APIs so as to alter their quality beyond the official or other established specifications. Any deviations from this should be evaluated to ensure that there are no detrimental effects upon the fitness for purpose of the material. Wherever possible, food grade lubricants and oils should be used.\n'润滑剂'可被翻译为：lubricant\n'润滑剂, 润滑'可被翻译为：lubricant, lubricate\n\n根据上述已知信息，请将'第七十七条 设备所用的润滑剂、冷却剂等不得对药品或容器造成污染，应当尽可能使用食用级或级别相当的润滑剂。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 77 Lubricant and refrigerant etc. used in the equipment should not contaminate products or containers. Food grade or equivalent lubricant should be used whenever possible."
    },
    {
        "instruction":"已知信息：\n'这一分类被肾脏病理学会工作组和国际肾病学会工作组（ISN\/RPS 标准，2003）的分类法替代，新的分类中狼疮性肾炎分为 6 个类型：'可被翻译为：This classification is superceded by the Renal Pathology Society Working Group and the International Society of Nephrology Working Group (ISN\/RPS Criteria from 2003) classification where six classes of lupus nephritis are described:\n'根据WHO的分类（1982年定义，1995年修订），狼疮性肾炎根据活检结果可以分为五类。'可被翻译为：According to the WHO classification (defined in 1982 and revised in 1995) lupus nephritis can be divided into five classes based on biopsy.\n'II 型为系膜增生性狼疮性肾炎，'可被翻译为：Class II mesangial proliferative lupus nephritis,\n'V 型为膜性狼疮性肾炎，'可被翻译为：Class V membranous lupus nephritis,\n\n根据上述已知信息，请将'如狼疮性肾炎的分类中的增生性肾小球肾炎（ISN\/RPS 2003 III 或 IV 类）或膜性肾病（ISN\/RPS 2003 V 类）；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"e.g. Classes of LN, such as proliferative glomerulonephritis (ISN\/RPS 2003 Class III or IV) or membranous nephritis (ISN\/RPS 2003 Class V);"
    },
    {
        "instruction":"已知信息：\n'如果在试验治疗结束后施加的预期治疗有可能混淆整体结局，那么在与 PFS、EFS 和生存趋势相关的诱导疗法结束后 CR 的大量增加应已足够。如果目标人群很小时， 这特别相关。'可被翻译为：A major increase in CR after induction therapy associated with trends in PFS or EFS, and survival, however, might be sufficient if scheduled treatments administered after the end of the experimental therapy are likely to confound overall outcome. This is of special relevance if the target population is small.\n'如果在诱导后实施巩固治疗和\/或维持治疗，在试验治疗结束后服用的疗法的混杂疗效 可能会使得终点比 PFS 或 EFS 更适合。这意味着当计划实施进一步的治疗时， 在试验疗法结束后的 CR（若已具体证实，则为 CR+PR）可作为可接受的主要终点。 在这种情况下，试验化合物对巩固治疗活性的潜在影响应适当进行处理，并且有关 CR 的结局应有 EFS 或 PFS 数据支持。'可被翻译为：In cases where induction is followed by consolidation and\/or maintenance therapy, confounding effects of therapies administered after the end of experimental therapy may make endpoints other than PFS or EFS more appropriate. This means that CR (and CR + PR, if specifically justified) after end of experimental therapy could be an acceptable primary endpoint when further therapy is scheduled. In these cases, the possible influence of the experimental compound on the activity of consolidation therapy should always be addressed and outcomes with respect to CR should be supported by EFS or PFS data.\n'如果诱导期后是进行巩固和\/或维持治疗，在实验性治疗结束后给予治疗的混杂效 应可能使PFS或EFS以外的终点是更合适的。'可被翻译为：In cases where induction is followed by consolidation and\/or maintenance therapy, confounding effects of therapies administered after the end of experimental therapy may make endpoints other than PFS or EFS more appropriate.\n'研究目的待定，如果在规定的治疗期后没有 观察到肿瘤缩小，退出治疗是可接受的。 当手术时的病理学CR作为次要终点被报告时，应将退出患者视为无缓解者。'可被翻译为：Pending on the objectives of the study it is accepted that treatment is withdrawn if tumour shrinkage is not observed after a defined treatment period. When pathological CR at time of surgery is reported as secondary endpoint, patients withdrawn should be considered as non-responders.\n\n根据上述已知信息，请将'这意味着当计划进行进一步的治疗时， 在实验性治疗结束后的CR（和CR+PR，如果是特别合理的）可能是可接受的主要终点。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"This means that CR (and CR + PR, if specifically justified) after end of experimental therapy could be an acceptable primary endpoint when further therapy is scheduled."
    },
    {
        "instruction":"已知信息：\n'总的来说，II期临床试验设计应为多种不 同DAA联用方案（所有尚在研究的药物或已批准的药物加尚在研究的药物）在 不同剂量和疗程下的随机比较。'可被翻译为：In general, phase 2 trial designs should be randomized comparisons of several different DAA combinations (all investigational or approved plus investigational) at various doses and treatment durations.\n'II期临床试验应表征 作为联合治疗方案部分的DAA的最佳剂量和疗程，同时考虑抗病毒活性和安全 性。'可被翻译为：Phase 2 trials should characterize the optimal dose and treatment duration of the DAA(s) as part of combination regimens with regard to both antiviral activity and safety.\n'c. DAA联合治疗方案II期临床试验'可被翻译为：c. Phase 2 trials with combination DAA regimens\n'II期临床试验的主要目的应是证明将要在III期临床试验中计划研究的含 DAA治疗方案的疗效（如SVR）。'可被翻译为：A primary objective of a phase 2 program should be demonstration of proof of concept of efficacy (i.e., SVR) for DAA-containing regimens that are planned for study in phase 3.\n\n根据上述已知信息，请将'推荐以下信息来支持多种DAA的II期临床试验：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The following information is recommended to support phase 2 trials of multiple DAAs:"
    },
    {
        "instruction":"已知信息：\n'该产品在这种环境下是否是非典型使用？'可被翻译为：Is this product atypical for use within this environment?\n'其他类似产品是否也在这种环境中使用（例如，相同或相似的药物类别、相 同或类似的包装设计）？'可被翻译为：Are other, similar products also used within this environment (e.g., same or similar drug class, same or similar packaging design)?\n'在缓释或迟释产品的开发期间，使缓释或迟释产品的规格不同于速释产品的 规格是有帮助的。'可被翻译为：During development of an extended or delayed release product, it is helpful to make the strengths of the extended or delayed release product different from those of immediate-release products.\n'·在缓释\/控释制剂的开发过程中，区分缓释\/控释制剂与速释制剂的规格，是非常有帮助的。如果描述不正确，例如修饰词的疏忽或后缀的不正确的使用，可能会导致速释制剂代替缓释\/控释制剂的分发和服用。上述错误是有可能发生的，是因为当所有产品特性重叠，或该规格的速释制剂 已上市。'可被翻译为：During development of an extended- or delayed-release product it is helpful to make the strengths of the extended- or delayed-release product distinct from the immediate-release products. Failures in prescribing, such as omission of modifiers or incorrect use of suffixes, can lead to dispensing and administration of the immediate-release product instead of the intended extended- or delayed-release product. This can occur because all product characteristics overlap, or the strength is achievable from the marketed immediate-release product strength.\n\n根据上述已知信息，请将'该产品是否是在这种环境中已经使用的产品的变体（例如，现有速释产品的 缓释剂型）？'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Is the product a variant of something already used in this environment (e.g., extended release dosage form of an existing immediate release product)?"
    },
    {
        "instruction":"已知信息：\n'数据的初次展示和分析可能表明其与人口统计学或其 他基线特征不存在显著关系。'可被翻译为：It may be apparent from initial display and inspection of the data that a significant relation to demographic or other baseline features is not present.\n'在研究产品与阳性对照之间无差异的无效假设下，如果 基于观察到无显著差异的检验结果，做出等效性或非劣效性的结论是不合适的。'可被翻译为：Concluding equivalence or non-inferiority based on observing a non-significant test result of the null hypothesis that there is no difference between the investigational product and the active comparator is inappropriate.\n'一种基于偏好的健康状态效用测量方法。测定为了获取一个给定的完全健康的生存年数，人们愿意放弃多少某种不健康状态的生存时间。'可被翻译为：A preference-based measure of health status utility. A measure of how many years of life in an unhealthy state a person would be willing to give up in order to obtain a given number of years of life in full health.\n'效用'可被翻译为：Utility\n\n根据上述已知信息，请将'用排序来反映偏好的一种效用表示方法，排列成序的效用间的差距大小没有意义。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A representation of utility in which preferences are reflected in a ranking, where the size of the difference between the ranked utilities is meaningless."
    },
    {
        "instruction":"已知信息：\n'测定临床相关的改变，使有效者分析成为可能。'可被翻译为：Clinically relevant changes should be determined, making a responder analysis possible.\n'研究方案应清楚地定义有效者，例被认为有临床意义的改善量。'可被翻译为：The protocol should define clearly a treatment responder, i.e. amount of improvement that is considered to be clinically relevant.\n'可以预期应当优先定义在临床上相关的药代动力学的变化，如可能，应该基于母体药物和\/或其代谢物的浓度-反应关系来证明。'可被翻译为：The change in pharmacokinetics that can be expected to be clinically relevant should preferably be prospectively defined and should, if possible, be justified on the basis of concentration-response relationship of the parent drug and\/or its metabolites.\n'必须完全证明其合理性。'可被翻译为：This has to be fully justified.\n\n根据上述已知信息，请将'研究方案应对QoL预先指定的方面（纬度）的临床相关变化进行定义并证明其合理性。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A clinically relevant change in pre-specified domains (dimensions) of QoL should be defined and justified in the study protocol."
    },
    {
        "instruction":"已知信息：\n'因此对用于患者及其看护者中的适当评价工具需要进一步研究并进行验证。'可被翻译为：Further studies are required to validate adequate instruments for assessment of these dimensions in patients and their caregivers.\n'因此，需要采用评估疾病结局的特定工具，这些工具需要一方面考虑到疾病进程和积极治疗，'可被翻译为：Therefore specific instruments to assess disease outcome are needed that would on the one hand take into consideration disease course and aggressive therapy\n'对于 期和晚期疾病阶段，需要采用单独的 ADL\/IADL 评价工具，对于 MCI，已经采用了一个ADSC-ADL 版本。'可被翻译为：Separate measurement tools of ADL\/IADL for early and advanced disease stages are needed, and a version of the ADSC-ADL has been already adapted for MCI.\n'更通用的健康相关生活质量（HRQOL）工具正在评估患者对疾病和治疗对日常生活、身体、心理和社会功能以及健康的影响的看法。'可被翻译为：More general Health-related quality of life (HRQOL) tools are assessing the patient’s perception of the impact of disease and treatment on daily life, physical, psychological and social functioning and well-being.\n\n根据上述已知信息，请将'由于很多工具正在进一步研究中，因此对方案中评价工具的选择及其工具对疾病 期或晚期的适用性，需要阐述其合理性。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"As many others are under further evaluation, the choice of the instrument for assessment and its applicability for early or advanced disease stages should be justified in the study protocol."
    },
    {
        "instruction":"已知信息：\n'4. 药品质量体系的持续改进'可被翻译为：4. CONTINUAL IMPROVEMENT OF THE PHARMACEUTICAL QUALITY SYSTEM\n'本节阐述了为管理和持续改进药品质量体系而应实施 的措施。'可被翻译为：This section describes activities that should be conducted to manage and continually improve the pharmaceutical quality system.\n'(e) 应在药品质量体系中明确管理职责，如第2节所述。'可被翻译为：(e) Management responsibilities, as described in Section 2, should be identified within the pharmaceutical quality system.\n'· 根据药品质量体系批准的程序和操作指令；'可被翻译为：· Approved procedures and instructions, in accordance with the Pharmaceutical Quality System;\n\n根据上述已知信息，请将'(e)对药品质量体系及相关程序的改进；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(e) Improvements to the pharmaceutical quality system and related processes;"
    },
    {
        "instruction":"已知信息：\n'FDA可以要求对用药指南进行开发或进行安全性相关的改变，并且可以要求这些事项尽快完成，无论用药指南是否是REMS的一部分。FDAAA增加了用药指南属于标签的一部分（21 CFR 201.57（c））并从属于FD&C 法案第505（o）（4）部分的安全性标签改变的条款。根据这些条款，FDA可以要求基于产品批准后FDA获知的新安全性信息对用药指南（或现有用药指南的安全性相关变化）进行开发。第505（o）（4）部分包括申请人提交的包含标签改变或该改变不需警示的原因说明的补充申请的严格的时间表，以及如果在法定的时间表内未能达成一致，将授权FDA责令这些标签改变。'可被翻译为：FDA can require the development of — or safety-related changes to — a Medication Guide and can require these to be completed quickly, whether or not a Medication Guide is part of a REMS. Medication Guides are part of labeling (21 CFR 201.57(c)) and are subject to the safety labeling change provisions of section 505(o)(4) of the FD&C Act, added by FDAAA. Under these provisions, FDA can require the development of a Medication Guide (or safety-related changes to an existing Medication Guide) based on new safety information of which FDA becomes aware after approval of the product. Section 505(o)(4) includes tight timeframes for applicant submission of a supplement containing the labeling changes or a statement detailing the reasons why such a change is not warranted, as well as authority for FDA to order the labeling changes if agreement is not reached within the statutorily specified timeframes.\n'4本指导原则中，术语“申办方”是指按照食品、药品和化妆品联邦法令或者公共卫生服务法案351节， 由FDA管理的一种新药、非专利药或生物制品的任何申办方、申请人或生产厂家。'可被翻译为：4 For purposes of this guidance, the term sponsor includes any sponsor of or applicant for an NDA, ANDA, or BLA under the Federal Food, Drug, and Cosmetic Act or section 351 of the Public Health Service Act.\n'依据505-1用药指南要求作为REMS的部分受限于评估和FD&C法案第505-1 （g） and （h）部分的修订条款。'可被翻译为：Medication Guides that are required as part of REMS under section 505-1 are subject to the assessment and modification provisions of section 505-1(g) and (h) of the FD&C Act.\n'见FD&C法案的505(o)(3)(A)、505(o)(3)(B) 和505(o)(3)(E)(ii)（21 U.S.C. 355(o)(3)(A), (B),和(E)(ii)）。'可被翻译为：See section 505(o)(3)(A), 505(o)(3)(B), and 505(o)(3)(E)(ii) of the FD&C Act (21 U.S.C. 355(o)(3)(A), (B), and (E)(ii)).\n\n根据上述已知信息，请将'9见用药指南法规指的是生产商。本指南讨论的是用药指南由FDAAA修订的FD&C法案的内容，我们使用的术语申请人包括FD&C法案505-1部分中的“已批准申请的持有人”和FD&C法 案（21 U.S.C. 355（o）（4））第505（o）（4）部分中的“责任人”。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"9 The Medication Guide regulations refer to manufacturers. For purposes of this guidance discussing Medication Guides in the context of the FD&C Act as amended by the FDAAA, we use the term applicant to include “holder of an approved covered application” in section 505-1 of the FD&C Act and “responsible person” in section 505(o)(4) of the FD&C Act (21 U.S.C. 355(o)(4))."
    },
    {
        "instruction":"已知信息：\n'以下所述的光源可用于光稳定性试验。'可被翻译为：The light sources described below may be used for photostability testing.\n'对其他光源\/光量系统，也可使用相同的方法，但各光量测定系统均应对所采用的光源进行校正。'可被翻译为：For other light sources\/actinometric systems, the same approach may be used, but each actinometric system should be calibrated for the light source used.\n'ID65相当于室内间接日光标准。'可被翻译为：ID65 is the equivalent indoor indirect daylight standard.\n'D65是国际认可的室外日光标准[ISO 10977(1993)]。'可被翻译为：D65 is the internationally recognized standard for outdoor daylight as defined in ISO 10977 (1993).\n\n根据上述已知信息，请将'采用任何输出相似于D65\/ID65发射标准的光源，如具 有可见-紫外输出的人造日光荧光灯、氙灯或金属卤化物灯。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Any light source that is designed to produce an output similar to the D65\/ID65 emission standard such as an artificial daylight fluorescent lamp combining visible and ultraviolet (UV) outputs, xenon, or metal halide lamp."
    },
    {
        "instruction":"已知信息：\n'致缺血作用'可被翻译为：Pro-ischaemic effects\n'铬（Cr）'可被翻译为：Chromium (Cr)\n'氟（18F）脱氧葡糖的细胞摄取通过组织特异性载体系统进行，其中部分载体是胰岛素依赖型，因此会受到摄入食物、营养状况和本身是否有糖尿病的影响。糖尿病患者的氟（18F）脱氧葡糖细胞摄取减少是由于组织分布的改变和葡萄糖代谢的改变而导致的。'可被翻译为：The cellular uptake of fludeoxyglucose (18F) is performed by tissue-specific carrier systems which are partly insulin-dependent and, thus, can be influenced by eating, nutritional condition and the existence of a diabetes mellitus. In patients with a diabetes mellitus a reduced uptake of fludeoxyglucose (18F) into the cells occurs due to a changed tissue distribution and glucose metabolism.\n'多发性硬化症（MS）是一种常见的神经系统疾病，全世界有超过一百万人受到该种疾病的困扰。'可被翻译为：Multiple Sclerosis is a common neurological disease affecting more than 1 million people worldwide.\n\n根据上述已知信息，请将'铬缺乏可导致葡萄糖和脂类代谢的改变，并与成年糖尿病、心血管疾病和神经系统疾病有关 [1,2]。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Chromium deficiency causes changes in the metabolism of glucose and lipids and may be associated with maturity-onset diabetes, cardiovascular diseases, and nervous system disorders (Anderson, 1993, 1995)."
    },
    {
        "instruction":"已知信息：\n'省、自治区、直辖市药品监督管理部门负责组织本行政区域生产或者进口的批签发产品的抽样工作，按照国家药品监督管理局药品抽样规定制定抽样管理程序，确定相对固定的抽样机构和人员并在批签发机构备案，定期对抽样机构和人员进行培训，对抽样工作进行督查指导。'可被翻译为：The drug regulatory departments of provinces, autonomous regions and municipalities directly under the Central Government shall be responsible for organizing the sampling of products subject to lot release for production or importation within their respective administrative regions, formulating sampling management procedures in accordance with the drug sampling regulations of the NMPA, determining relatively fixed sampling institutions and personnel to file at the lot release institutions, training the sampling institutions and personnel and conducting supervision and guidance for sampling work.\n'省、自治区、直辖市食品药品监督管理部门负责本行政区域批签发申请人的日常监管，协助批签发机构开展现场核实，组织批签发产品的现场抽样及批签发不合格产品的处置，对批签发过程中发现的违法违规行为进行调查处理。'可被翻译为：Food and drug regulatory departments of all provinces, autonomous regions and municipalities directly under the Central Government shall be responsible for routine regulation of the applicants for lot release within their respective administrative regions, assisting the lot release institutions in conducting on-site inspection, organizing on-site sampling of products subject to lot release, disposal of products failing to pass lot release as well as investigation and handling of violations in the lot release process.\n'第十四条 批签发申请人凭生物制品批签发申请表向省、自治区、直辖市食品药品监督管理部门或者其指定的抽样机构提出抽样申请，抽样人员在5日内组织现场抽样，并将所抽样品封存。批签发申请人将封存样品在规定条件下送至批签发机构办理批签发登记，同时提交批签发申请资料。'可被翻译为：Article 14 The lot release applicant shall propose a sampling application to the food and drug regulatory departments of the provinces, autonomous regions or municipalities directly under the Central Government or the sampling institutions designated thereby by virtue of the Application Form for Lot Release of Biological Products; sampling personnel shall organize on-site sampling within 5 days, and seal the samples. The lot release applicant shall be responsible for delivering the sealed samples under the stipulated conditions to the lot release institution to handle registration for lot release, and shall also submit lot release application dossiers.\n'第十四条    批签发申请人凭生物制品批签发申请表向省、自治区、直辖市药品监督管理部门或者其指定的抽样机构提出抽样申请，抽样人员在5日内组织现场抽样，并将所抽样品封存。批签发申请人将封存样品在规定条件下送至批签发机构办理批签发登记，同时提交批签发申请资料。'可被翻译为：Article 14 The lot release applicant shall propose a sampling application to the drug regulatory departments of provinces, autonomous regions or municipalities directly under the Central Government or the sampling institutions designated thereby by virtue of the Application Form for Lot Release of Biological Products; sampling personnel shall organize on-site sampling within 5 days, and seal the samples. The lot release applicant shall be responsible for delivering the sealed samples under the stipulated conditions to the lot release institution to handle registration for lot release, and shall submit lot release application dossiers at the same time.\n\n根据上述已知信息，请将'省、自治区、直辖市食品药品监督管理部门负责组织本行政区域生产或者进口的批签发产品的抽样工作，确定相对固定的抽样机构和人员并在批签发机构备案，定期对抽样机构和人员进行培训，对抽样工作进行督查指导。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Food and drug regulatory departments of all provinces, autonomous regions and municipalities directly under the Central Government shall be responsible for organizing the sampling of products subject to lot release for production or importation within their respective administrative regions, determining relatively fixed sampling institutions and personnel to file at the lot release institutions, training the sampling institutions and personnel and conducting supervision and guidance for sampling work."
    },
    {
        "instruction":"已知信息：\n'在验证研究之前，应拟定验证方案。'可被翻译为：Prior to the validation study, a validation protocol should be generated.\n'对 于既往未验证结局的研究，研究者应提供所使用的结局定义的适当依据。'可被翻译为：For studies lacking prior outcome validation, the investigator should provide appropriate justification of the outcome definition used.\n'拟纳入特定信息时则需要开展专项研究。'可被翻译为：Specific studies are needed when specific information is to be included.\n'尚未开展致突变性研究和长期致癌性研究。'可被翻译为：Mutagenicity studies and long-term carcinogenicity studies have not been carried out.\n\n根据上述已知信息，请将'当验证尚未完成时，应提供拟开展的研究综述。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Where validation is still to be completed, a summary of the studies intended to be conducted should be provided."
    },
    {
        "instruction":"已知信息：\n'探索性试验应根据预期分子学靶标的已知或假设的生物学功能，清晰地检验关于药物活性的假设。'可被翻译为：Exploratory trials should clearly test hypotheses of activity in accordance with known or presumed biological roles of their intended molecular targets.\n'探索性治疗研究 此类研究的目的是确定包括研究性新药的剂量-浓度-效应关系在内的适当的治疗范围，以及确定可能受益于该药品的患者。'可被翻译为：Exploratory therapeutic studies  The objectives of these studies will be to determine the appropriate therapeutic range including dose- concentration-response relationship of the new investigational agent and to identify patients who may benefit from the medicinal product.\n'其次，这种方法同样适合于对临床和分子学特征的分类有严格入选标准，以提高产生治疗反应和临床获益的可能性的验证性研究。'可被翻译为：Subsequently, the same applies to confirmatory trials which must restrict inclusion to categories of patients with clinical and molecular characteristics that increase the likeliness of response and hence clinical benefit.\n'由于这个目的，试验的受试者必须是已充分了解该病的相关生物标志物的患者。'可被翻译为：For this purpose, trial subjects must be constituted by patients with disease that is well characterized according to relevant biomarkers.\n\n根据上述已知信息，请将'探索性试验应根据预期分子学靶标的已知或假设的生物学功能，清晰地检验关于药物活性的假设。由于这个目的，试验的受试者必须是已充分了解该病的相关生物标志物的患者。其次，这种方法同样适合于对临床和分子学特征的分类有严格入选标准，以提高产生治疗反应和临床获益的可能性的验证性研究。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Exploratory trials should clearly test hypotheses of activity in accordance with known or presumed biological roles of their intended molecular targets. For this purpose, trial subjects must be constituted by patients with disease that is well characterized according to relevant biomarkers. Subsequently, the same applies to confirmatory trials which must restrict inclusion to categories of patients with clinical and molecular characteristics that increase the likeliness of response and hence clinical benefit."
    },
    {
        "instruction":"已知信息：\n'4-硝基氯苯—致癌性研究数据'可被翻译为：1-Chloro-4-nitrobenzene – Details of carcinogenicity studies\n'4-硝基氯苯在大鼠（参考文献13）、兔（参考文献14）和人（参考文献15）中被代谢还原成4-氯苯胺（对氯苯胺）。 已有研究表明对氯苯胺与4-硝基氯苯相似，可在大鼠和小鼠中诱发血管肉瘤和脾脏肿瘤（参考文献16）。对氯苯胺（参考文献16）和4-硝基氯苯（参考文献17）与苯胺相似，在肝脏和脾脏血管肿瘤形成的间接机制，是继发于红细胞氧化损伤和脾脏纤维化及增生。高铁血红蛋白症和相关毒性是4-硝基氯苯的显著毒性效应。剂量低于喂饲法（参考文献9, 10）的灌胃研究（参考文献11）发现高铁血红蛋白症和含铁血黄素沉着症，但未发现肿瘤，这一结果支持4-硝基氯苯诱发肿瘤的形成为非线性机制。'可被翻译为：1-Chloro-4-nitrobenzene is significantly metabolized by reduction to 4-chloroaniline (p- chloroaniline) in rats (Ref. 13), rabbits (Ref. 14) and humans (Ref. 15). p-Chloroaniline has been shown to produce hemangiosarcomas and spleen tumors in rats and mice, similar to 1- chloro-4-nitrobenzene (Ref. 16). Like aniline, an indirect mechanism for vascular tumorigenesis in liver and spleen was indicated, secondary to oxidative erythrocyte injury and splenic fibrosis and hyperplasia, both for 4-chloroaniline (Ref. 16) and 1-chloro-4- nitrobenzene (Ref. 17). Methemoglobinemia and associated toxicity is a notable effect of 1- chloro-4-nitrobenzene. A non-linear mechanism for tumor induction is supported by the fact that in the oral gavage study (Ref. 11), carried out at lower doses than the diet studies (Ref. 9, 10), methemoglobinemia and hemosiderin were seen but there was no increase in tumors.\n'4-硝基氯苯在以下情况下具有致突变性：'可被翻译为：Chloro-4-nitrobenzene was mutagenic in:\n'4-硝基氯苯在体内和体外试验中均显示出致突变性和遗传毒性。'可被翻译为：Chloro-4-nitrobenzene is mutagenic and genotoxic in vitro and in vivo.\n\n根据上述已知信息，请将'4-硝基氯苯（对硝基氯苯，CAS# 100-00-5）'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1-Chloro-4-Nitrobenzene (para-Chloronitrobenzene, CAS# 100-00-5)"
    },
    {
        "instruction":"已知信息：\n'与反应\/事件的结果相关的信息在E.i.7中-在最后一次观察时的反应\/事件的结果。'可被翻译为：The information related to the outcome of the reaction(s)\/event(s) is noted in E.i.7 - Outcome of Reaction \/ Event at the Time of Last Observation.\n'E.i.7末次观察时的反应\/事件的结果 用户指导原则 该数据元素获取报告时反应元素\/事件的末次结果。 在不可逆转的先天性异常的情况下，应使用未好转\/未缓解\/正在进行的选项。对于其他不可逆转疾病，应使用好转\/缓解且不伴后遗症。 当死亡可能与反应\/事件相关时，应使用致死性。考虑到在“反应\/事件导致的死亡”和“反应\/事件对死亡有显著影响”之间很难做出决定，这2个概念被分入单一类别。当死亡与反应\/事件无关时，根据报告者和发送者提供的信息，在此处不应该选择“致死性”但是，应在第D.9节报告死亡。'可被翻译为：E.i.7 Outcome of Reaction \/ Event at the Time of Last Observation User Guidance This data element captures the latest outcome of the reaction \/ event at the time of the report. In case of irreversible congenital anomalies, the choice not recovered\/not resolved\/ongoing should be used. For other irreversible medical conditions, recovered\/resolved with sequelae should be used. Fatal should be used when death is possibly related to the reaction\/event. Considering the difficulty of deciding between ‘reaction\/event caused death’ and ‘reaction\/event contributed significantly to death’, both concepts are grouped in a single category. Where the death is unrelated to the reaction\/event, according to both the reporter and the sender, ‘fatal’ should NOT be selected here; nevertheless, death should be reported under Section D.9.\n'如果再次用药后反应\/事件不再发生，G.k.9.i.4再次用药后反应\/事件是否再次发 生？应该为2（再次用药，反应没有发生）和E.i.7–在最后一次观察时的反应\/事 件的结果应该为1 =恢复\/解决。'可被翻译为：If the reaction(s)\/event(s) do not recur after reintroducing the drug, G.k.9.i.4 Did Reaction Recur on Re-administration? would be set to 2 (rechallenge was done, reaction did not recur) and E.i.7 – Outcome of Reaction \/ Event at the Time of Last Observation would be set to 1 = recovered\/resolved.\n'E -反应\/事件 1„n E.i -反应\/事件（必要时重复） E.i.1.1 -主要来源使用母语报告的反应\/事件 E.i.1.1b -主要来源语言报告的反应\/事件 E.i.1.2 -主要来源用于翻译报告的反应\/事件 E.i.2.1a -用于反应\/事件的MedDRA版本 E.i.2.1b ––MedDRA术语中的反应\/事件编码 E.I.3.1 -由报告者强调的术语 E.i.3.2 -事件层面的严重性标准 E.i.3.2a -导致死亡 E.i.3.2b -危及生命 E.i.3.2c -导致\/延长住院 E.i.3.2d –残疾\/功能丧失–残疾功能丧失 AESCONG -先天性异常或出生缺陷 E.i.3.2f -其他重要医学事件其他重要医学事件 E.i.4 -反应\/事件开始日期 E.i.5 -反应\/事件结束日期 E.i.6a -反应\/事件持续时间 E.i.6b -反应\/事件持续时间（持续时间单位） E.i.7 -末次观察时反应\/事件的结果 E.i.8 -医疗保健专业人士的医学确认 E.i.9 -发生反应\/事件的国家识别'可被翻译为：E.i - Reaction(s)\/Event(s) (repeat as necessary) 1 ... n E - Reaction(s)\/Event(s) E.i.1.1a - Reaction \/ Event as Reported by the Primary Source in Native Language E.i.1.1b - Reaction \/ Event as Reported by the Primary Source Language E.i.1.2 - Reaction \/ Event as Reported by the Primary Source for Translation E.i.2.1a - MedDRA Version for Reaction \/ Event E.i.2.1b - Reaction \/ Event (MedDRA code) E.i.3.1 - Term Highlighted by the Reporter E.i.3.2 - Seriousness Criteria at Event Level E.i.3.2a - Results in Death E.i.3.2b - Life Threatening E.i.3.2c - Caused \/ Prolonged Hospitalisation E.i.3.2d - Disabling \/ Incapacitating E.i.3.2e - Congenital Anomaly \/ Birth Defect E.i.3.2f - Other Medically Important Condition E.i.4 - Date of Start of Reaction \/ Event E.i.5 - Date of End of Reaction \/ Event E.i.6a - Duration of Reaction \/ Event E.i.6b - Duration of Reaction \/ Event (duration unit) E.i.7 - Outcome of Reaction \/ Event at the Time of Last Observation E.i.8 - Medical Confirmation by Healthcare Professional E.i.9 - Identification of the Country Where the Reaction \/ Event Occurred\n\n根据上述已知信息，请将'E.i.7末次观察时的反应\/事件的结果'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"E.i.7 Outcome of Reaction \/ Event at the Time of Last Observation"
    },
    {
        "instruction":"已知信息：\n'Fab相关功能（例如可溶性配体的中和、受体激活或阻断）'可被翻译为：Fab-associated functions (e.g. neutralization of a soluble ligand, receptor activation or blockade)\n'FC-相关联的功能（如抗体依赖性细胞介导的细胞毒性，ADCC;补体依赖性细胞毒性，疾病预防控制中心;补体活化）'可被翻译为：Fc-associated functions (e.g. antibody-dependent cell-mediated cytotoxicity, ADCC; complement-dependent cytotoxicity, CDC; complement activation)\n'作用方式：通过阻止TNF-α与TNF-α受体结合，中和可溶性 TNF-α的生物活性。'可被翻译为：• Mode of action: the neutralisation of the biological activity of soluble TNF-alpha by preventing TNF-alpha from binding to the TNF-alpha receptor;\n'药物的作用机制是通过阻止TNF-α与TNF-α受体结合而中和可溶性TNF-α的生物活性。'可被翻译为：The mode of action of the drug is the neutralisation of the biological activity of soluble TNF-alpha by preventing TNF-alpha from binding to the TNF-alpha receptor.\n\n根据上述已知信息，请将'与 Fab 相关的功能（如可溶性配体中和、受体活化或拮抗）'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"3. Fab-associated functions (e.g. neutralization of a soluble ligand, receptor activation or blockade)"
    },
    {
        "instruction":"已知信息：\n'可与相应的补体活性片段或调解蛋白结合，介导补体生物学效应的受体。包括CR1-CR5、C3aR、C2aR、C4aR等。'可被翻译为：A receptor that can bind to the corresponding complement active fragment or mediating protein and mediate the biological effects of complement. These include CR1-CR5, C3aR, C2aR, C4aR, etc.\n'例子包括HLA等位基因和与阿巴卡韦、卡马西平和别嘌呤醇的特异性反应。'可被翻译为：Studies demonstrating the predictive values of the genomic BM included both retrospective case- control studies and prospective clinical trials.\n'众所周知的干扰物质例如补体、甘露糖结合蛋白、Fc受体、可溶性靶分子、补体受体1和类风湿因子等，但是其它物质包括产品 本身也会造成问题。'可被翻译为：Well known examples of such interfering substances are complement components, mannose binding protein, Fc receptors, soluble target molecules, complement receptor 1 and rheumatoid factors, but other substances including the product itself can also cause problems.\n'药物作用的受体、靶分子和靶器官或靶系统。'可被翻译为：The receptor, target molecule, and target organ or system on which the drug acts.\n\n根据上述已知信息，请将'范例包括补体成分或补体受体、甘露糖结合蛋白、Fc 受体、可溶性靶分子和类风湿因子。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Examples include complement components or complement receptors, mannose binding protein, Fc receptors, soluble target molecules, and rheumatoid factors."
    },
    {
        "instruction":"已知信息：\n'鉴于B型血友病患者数量有限，上市前研究的数据被认为并不足以估算因子IX制品的所有治疗作用，特别是免疫原性。'可被翻译为：In view of the limited availability of patients suffering from haemophilia B, data from pre-licensing studies only are considered insufficient to estimate all aspects of therapy with factor IX products, especially with respect to immunogenicity.\n'因此，在获得批准时免疫原性数据的可用性有限。'可被翻译为：The availability of data on immunogenicity at time of approval might, therefore, be limited.\n'在甲型血友病患者的治疗中，形成因子VIII的中和抗体（抑制物）是已知的并 发症。'可被翻译为：The formation of neutralising antibodies (inhibitors) to factor VIII is a known complication in the management of individuals with haemophilia A.\n'甲型血友病患者可能产生因子VIII的中和抗体（抑制物）。如果抑制物产生， 机体会显示临床反应不足。'可被翻译为：Patients with haemophilia A may develop neutralising antibodies (inhibitors) to factor VIII. If such 18 inhibitors occur, the condition will manifest itself as an insufficient clinical response.\n\n根据上述已知信息，请将'由于甲型血友病患者数量有限，所以认为上市前研究的数据不足以评估因子 VIII 制品治疗情况的各个方面，特别是免疫原性。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In view of the limited availability of patients suffering from haemophilia A, data from pre-licensing  studies only are considered insufficient to estimate all aspects of therapy with factor VIII products,  especially with respect to immunogenicity."
    },
    {
        "instruction":"已知信息：\n'所有 意见均应标明《联邦公报》刊登的有效性通知中列出的文件编号。'可被翻译为：All comments should be identified with the docket number listed in the notice of availability that publishes in the Federal Register.\n'FDA认真审评并考虑了来自研讨会及指导原则草稿 记事表中的所有口头及书面的评论，创建了本指导原则。'可被翻译为：FDA carefully reviewed and considered all oral and written comments from the workshop and the draft guidance docket to create the current guidance.\n'人类细胞，组织和细胞组织产品的同源使用 \n行业和FDA工作人指南草案 \n这一指南文件仅用于评论目的 \n对于这一指南草案，可以在指南草案注册公告声明的可行性部分中的规定日期内提交电子或书面评论。'可被翻译为：Homologous Use of Human Cells, Tissues, and Cellular and Tissue-Based Products \nDraft Guidance for Industry and FDA Staff \nThis guidance document is for comment purposes only. \nSubmit one set of either electronic or written comments on this draft guidance by the date provided in the Federal Register notice announcing the availability of the draft guidance.\n'2015年4月1日，FDA在《联邦记事》中通知了“防止滥用的阿片类药物的评估及标 签”的最终指南的发布。'可被翻译为：On April 1, 2015, FDA published in the Federal Register a notice of availability for its final guidance, Abuse-Deterrent Opioids – Evaluation and Labeling.\n\n根据上述已知信息，请将'需确认所有带有记事表编号的评论都被列入到联邦登记出版的可行性声明部分中。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"You should identify all comments with the docket number listed in the notice of availability that publishes in the Federal Register."
    },
    {
        "instruction":"已知信息：\n'在整个过程中，应重点关 注对研究受试者的权利、安全和福祉的保护。'可被翻译为：Throughout this process there is critical attention to the protection of the rights, safety and wellbeing of study participants.\n'如果临床研究者具有应披露的财务权益或安排， FDA审核官员将仔细考虑申 办方采取的旨在减少偏倚19 的步骤； 这些在FDA3455中均有描述。'可被翻译为：When a clinical investigator has disclosable financial interests or arrangements, the FDA reviewer will carefully consider the steps taken by the sponsor to minimize bias19 as described in the attachment to the FORM FDA 3455.\n'鼓励研究申办方在临床研究之前和期间就涉及临床研究者潜在偏倚的特殊 情形的管理咨询 FDA。'可被翻译为：Study sponsors are encouraged to consult with FDA prior to and during clinical studies about the management of specific situations involving potential bias on the part of a clinical investigator.\n'对于所有数据来源，应执行可以确保保护受试者个人数 据的程序。'可被翻译为：For all data sources, procedures to ensure the protection of personal data of the individuals being studied should be implemented.\n\n根据上述已知信息，请将'在这些咨询期间，FDA工作人员应重点放在保护研 究受试者和减少所有潜在来源的偏倚方面。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"During these consultations, FDA staff should focus on the protection of research subjects and the minimization of bias from all potential sources."
    },
    {
        "instruction":"已知信息：\n'在不同天的另外一个分析批中，重新分析一部分已测样品，以确定原分析结果是否可以重现。'可被翻译为：Reanalysis of a portion of the incurred samples in a separate analytical run on a different day to determine whether the original analytical results are reproducible.\n'·在一项试验中，从不同实验室使用同一生物分析方法获得数据'可被翻译为：• Data are obtained within a study from different laboratories with the same bioanalytical method.\n'已测样品再分析（ISR）：在不同天的另外一个分析批中，重新分析一部分已测样品，以确定原分析结果是否可以重现。'可被翻译为：Incurred Sample Reanalysis (ISR): Reanalysis of a portion of the incurred samples in a separate analytical run on a different day to determine whether the original analytical results are reproducible.\n'（九）试验样品再分析(ISR) 的样品选取具有代表性， 数量符合要求。如果 ISR 符合接受标准， 但在多个样品的结果之间显示出较大或系统差异的情况(例如同一受试者的所有样品均失败、同一分析批的所有样品均失败)， 应该进行调查以明确原因。'可被翻译为：(9) The samples selected for incurred sample reanalysis (ISR) are representative, and the quantity meets the relevant requirement. If ISR meets the acceptance criteria, however, there is significant or systematic difference between results of multiple samples (for example, all samples of the same subject fail, all samples of the same analysis batch fail), investigation shall be conducted to determine the cause.\n\n根据上述已知信息，请将'通过使用同样的生物分析方法，在不同天单独的（即不同于原来的）分析批重新分析给定试验的部分样品，来开展ISR。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"ISR is conducted by repeating the analysis of a subset of samples from a given study in separate (i.e., different to the original) runs on different days using the same bioanalytical method."
    },
    {
        "instruction":"已知信息：\n'Hotchkiss CE, Bishop ME, Dertinger SD, Slikker W, Moore MM, MacGregor JT. Flow cytometric analysis of micronuclei in peripheral blood reticulocytes IV: an index of chromosomal damage in the rhesus monkey (macaca mulatta). Toxicol Sci 2008 ;102:352-8.'可被翻译为：Hotchkiss CE, Bishop ME, Dertinger SD, Slikker W, Moore MM, MacGregor JT. Flow cytometric analysis of micronuclei in peripheral blood reticulocytes IV: an index of chromosomal damage in the rhesus monkey (macaca mulatta). Toxicol Sci 2008 ;102:352 8.\n'16. Müller L, Mauthe RJ, Riley CM, Andino MM, De Antonis D, Beels C, DeGeorge J, De Knaep AGM, Ellison D, Fagerland JA, Frank R, Fritschel B, Galloway S, Harpur E, Humfrey CDN, Jacks ASJ, Jagota N, Mackinnon J, Mohan G, Ness DK, O’Donovan MR, Smith MD, Vudathala G, Yotti L. A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity. Regul Toxicol Pharmacol 2006;44:198- 211.'可被翻译为：16. Müller L, Mauthe RJ, Riley CM, Andino MM, De Antonis D, Beels C, DeGeorge J, De Knaep AGM, Ellison D, Fagerland JA, Frank R, Fritschel B, Galloway S, Harpur E, Humfrey CDN, Jacks ASJ, Jagota N, Mackinnon J, Mohan G, Ness DK, O’Donovan MR, Smith MD, Vudathala G, Yotti L. A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity. Regul Toxicol Pharmacol 2006;44:198-211.\n'IWG 标准(Dubois et al. 2007, 2010, 2014)和NIA-AA 标准(McKhann et al., 2011; Albert et al. 2011, Sperling et al 2011)都将 AD 连续过程划分为三个阶段(临床前AD,前驱期AD\/AD 所致MCI 和AD 痴呆)，在下文中进行详细描述（见定义）。'可被翻译为：The IWG criteria (Dubois et al. 2007, 2010, 2014) and the NIA-AA criteria (McKhann et al., 2011; Albert et al. 2011, Sperling et al 2011) similarly distinguish three stages in the AD continuum (preclinical AD, prodromal AD\/MCI due to AD, AD dementia) and are fully detailed below (see Definitions).\n'应当在含葡萄糖和 含半乳糖的培养基中评估线粒体毒性（即Crabtree效应；Marroquin, Hynes, et al. 2007）。'可被翻译为：Mitochondrial toxicity should be assessed in glucose-containing and in galactose-containing medium (i.e., Crabtree effect; Marroquin, Hynes, et al. 2007).\n\n根据上述已知信息，请将'Hayashi M, MacGregor JT, Gatehouse DG, Blakey DH, Dertinger SD, Abramsson-Zetterberg L et al. In vivo erythrocyte micronucleus assay. III. Validation and regulatory acceptance of automated scoring and the use of rat peripheral blood reticulocytes, with discussion of non-hematopoietic target cells and a single dose-level limit test. Mutat Res 2007;627:10-30.'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Hayashi M, MacGregor JT, Gatehouse DG, Blakey DH, Dertinger SD, Abramsson Zetterberg L et al. In vivo erythrocyte micronucleus assay. III. Validation and regulatory acceptance of automated scoring and the use of rat peripheral blood reticulocytes, with discussion of non-hematopoietic target cells and a single dose-level limit test. Mutat Res 2007;627:10-30."
    },
    {
        "instruction":"已知信息：\n'申办方-研究者应该提供所有适当的文件和\/或这部分信息的概述。'可被翻译为：The sponsor-investigator\tshould provide any appropriate documentation and\/or a summary of this information.\n'对于所有的载体来说， 需对其来源作适当的完整论述，并提供亲代病毒或细菌的历史及生物特性。'可被翻译为：For all vectors, full documentation of the origin where applicable, history and biological characteristics of the parental virus or bacterium should be provided.\n'应提供用于制备原代细胞基质的原材料及组成成分的资料，包括人和动物源性的所有试剂的特征、来源，以及对动物源性成分证明检测不出污染物和外源因子的检测方法和结果。'可被翻译为：Information on materials and components used for the preparation of primary cell substrates should be provided, including the identity and source of all reagents of human or animal origin. A description of testing performed on components of animal origin to certify the absence of detectable contaminants and adventitious agents should be included.\n'对某些胰岛素类似物，有特别的检定方法可以区分外源性和内源性胰岛素。'可被翻译为：For some insulin analogues, specific assays, capable of distinguishing between exogenous and endogenous insulin, exist.\n\n根据上述已知信息，请将'还应提供所有对基因操作和筛选的描述、细胞内源性和外源性因子的鉴别、特性和 检测结果等资料。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A description of any genetic manipulation or selection should be provided. All available information regarding the identification, characteristics, and results of testing of these cells for endogenous and adventitious agents should be provided."
    },
    {
        "instruction":"已知信息：\n'因此，不要求浓度-响应呈线性关系。'可被翻译为：Thus, linearity of the concentration-response relationship is not required.\n'在方案或统计分析 计划中预先设定的有关离群值的程序应当不倾向任何处理 组。'可被翻译为：Any outlier procedure set out in the protocol or the statistical analysis plan should be such as not to favour any treatment group a priori.\n'分层随机化常常用于在指定的协变量（一般为定性协变量或分类定量协变量）水平内减少治疗组间这种不平衡的概率。'可被翻译为：Stratified randomisation is often used to reduce the likelihood of such imbalances between treatment groups within the levels of specified covariates (generally qualitative covariates or categorised quantitative covariates).\n'在随机化阶段分层和分析时校正协变量可以看作对协变量作出解释的补充方法。'可被翻译为：Stratification at the stage of randomisation and adjustment for covariates in the analysis may be seen as complementary methods of accounting for covariates.\n\n根据上述已知信息，请将'这包括随机化中不用于分层的协变量。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"This includes the use of covariates not stratified for in the randomisation."
    },
    {
        "instruction":"已知信息：\n'安慰剂对照研究使用附加设计另一个可能的最佳标准，'可被翻译为：Placebo-controlled studies using add-on design to best standard of care are another possibility.\n'当研究设计需要安慰剂并且允许与其他有效治疗联合时，也可以使用添加安慰剂治疗。'可被翻译为：Add-on placebo therapy may also be used when study design requires placebo and allows for combination with other effective treatment.\n'在这种情况下，首选设计是有适当救援药物、采用附加设计的安慰剂对照试验（标准治疗+研究药物 vs. 标准治疗+安慰剂）。'可被翻译为：In this case a placebo-controlled trial with add-on design (standard therapy +study drug versus standard therapy +placebo) with adequate rescue medication would be the preferred design.\n'进行适当修改1的安慰剂对照（例如加载 研究 ）'可被翻译为：• Placebo control with appropriate design modifications1 (e.g., add-on study)\n\n根据上述已知信息，请将'如果新的治疗仅拟作为标准对症治疗（例如，AchEI）的辅助药物，简单的安慰剂对照加成交叉研究可作为适当的设计。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"If the new treatment is intended to be used exclusively as add-on to standard symptomatic treatment(e.g. AChEI) a simple two way placebo controlled add-on study is the appropriate design."
    },
    {
        "instruction":"已知信息：\n'变异等位基因CYP2C9*2和CYP2C9*3导致清除率降低和更有效的对映体S-华法林的血液水平更高，增加出血的风险。'可被翻译为：The variant alleles, CYP2C9*2 and CYP2C9*3, result in decreased clearance and higher blood levels of S-warfarin, the more potent enantiomer, increasing the risk of bleeding.\n'出于PBRER章节16.2的目的，信号与不良 作用有关。'可被翻译为：For the purpose of Section 16.2 of the PBRER, signals relate to adverse effects.\n'星号是相同等位基因上出现一个或多个功能上重要 的突变所独有的，每个被*标记的等位基因均基于其存在的具有功能学重要意义 的突变来描述其表型（参见人类细胞色素P450（CYP）等位基因命名网站2）。'可被翻译为：The star-number is unique for the presence of one or more functionally important mutations on the same allele and each *-marked allele has its phenotypic description based on the functionally important mutations present (see Human Cytochrome P450 (CYP) Allele Nomenclature website2).\n'又称\"沉默突变（silentmutation）\"。突变虽然替换了碱基，但氨基酸顺序未变，保持野生型的功能。'可被翻译为：Also called a \"silentmutation.\" The mutation replaces the bases, but the amino acid sequence remains the same, maintaining the function of the wild type.\n\n根据上述已知信息，请将'CYP星号（*）等位基因指定的命名系统考虑到引起功能不良后果的突变， 例如终止突变或氨基酸变化。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The nomenclature system for the CYP star (*)allele designation takes into account mutations causing 412 functional consequences such as stop mutations or amino acid changes."
    },
    {
        "instruction":"已知信息：\n'专属性\/选择性可通过证明被分析物的测定结果与另一个经充分表征的分析方法测定结果相当来确认，理想情况下该方法应为不同测定原理的方法。'可被翻译为：Specificity\/selectivity can be verified by demonstrating that the measured result of an analyte is comparable to the measured result of a second, well characterised analytical procedure that ideally applies a different measurement principle.\n'为了证明一个稳定性指示性检测方法的专属性\/选择性，应将含有相关降解产物的样品纳入研究。'可被翻译为：To demonstrate specificity\/selectivity of a stability-indicating test, samples containing relevant degradation products should be included in the study.\n'某一分析方法的定量限度是指在合适的准确性和精密度下，能够定量测定样品中被分析物的最低量。它是样品中含量下，能够定量测定样品中被分析物的最低量。它是样品中含量低的化合物定量测定的参数，特别适用于杂质和\/或降解产物的测定。'可被翻译为：The quantitation limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be quantitatively determined with suitable precision and accuracy. The quantitation limit is a parameter of quantitative assays for low levels of compounds in sample matrices, and is used particularly for the determination of impurities and\/or degradation products.\n'开发目的是获得适用于预期目的的分析方法：在可报告范围内，按照所需的专属性\/选择性、准确度、精密度，测量被分析物一项或多项属性。'可被翻译为：The goal of development is to obtain an analytical procedure fit for the intended purpose: to measure an attribute or attributes of the material with the needed specificity\/selectivity, accuracy, precision over the reportable range.\n\n根据上述已知信息，请将'应证明分析方法的专属性\/选择性，满足样品中被分析物含量或效价的准确度要求。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The specificity\/selectivity of an analytical procedure should be demonstrated to fulfil the accuracy requirements for the content or potency of an analyte in the sample."
    },
    {
        "instruction":"已知信息：\n'临床试验要求取决于作用机制和预期患者人群。'可被翻译为：The clinical trial requirements depend on the mechanism of action and the intended patient population.\n'根据试验的目的和试验用药物的预期获益风险特征， 应该先验性选择适当的患者人群。'可被翻译为：Depending on the purpose of the trial and the anticipated benefit-risk profile of the investigated agent, an appropriate patient population should be selected a priori.\n'由于药物的毒性在很大程度上受到给药方案的影响，应在毒理学试验中评价相类似的 临床给药方案。这点将在3.3和3.4章节进一步讨论。'可被翻译为：As the toxicity of the pharmaceutical can be greatly influenced by its schedule of administration, an approximation of its clinical schedule should be evaluated in toxicology studies. This is further discussed in Section 3.3 and 3.4.\n'A. 药物研发的一般注意事项 除非临床研发和早期药物研发之外，在以下章节论述了关于目标人群、疗效 和安全性的总体药物研发方法。'可被翻译为：A. General Drug Development Considerations  In addition to nonclinical development and early phase drug development, an overall drug development approach with respect to target population, efficacy, and safety is addressed in the following sections.\n\n根据上述已知信息，请将'在药物研发的早期阶段，临床试验受试者的选择在很大 程度上受到主观愿望的影响，即希望最大可能地观察到感兴 趣的特定临床疗效，因此，研究对象往往是药物最终适用的 患者总体中一个非常局限的亚组。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In the earlier phases of drug development the choice of subjects for a clinical trial may be heavily influenced by the wish to maximise the chance of observing specific clinical effects of interest, and hence they may come from a very narrow subgroup of the total patient population for which the drug may eventually be indicated."
    },
    {
        "instruction":"已知信息：\n'M7(R2) 在第二阶段中获得ICH大会成员批准，包括 将文件分拆为 M7(R2)指导原则及独立的 M7(R2)附录并且公开征求意见 2021年10 月6日'可被翻译为：M7(R2) Endorsement by the Members of the ICH Assembly under Step 2, including separation of the document into a M7(R2) Guideline and a standalone M7(R2) Addendum, and release for public consultation. 6 October 2021\n'M7（R1） 附录 在第二阶段中获得ICH大会成员批准，并且公开征求意见 2015年6月 11日'可被翻译为：M7(R1) Addendum Endorsement by the Members of the ICH Assembly under Step 2 and release for public consultation. 11 June 2015\n'M7 在第四阶段中获得执行委员会批准，并推荐ICH三方监管机构采纳。 2014年6月5 日'可被翻译为：M7 Approval by the Steering Committee under Step 4 and recommendation for adoption to the three ICH regulatory bodies. 5 June 2014\n'Q4B 附录9 第二阶段，获得指导委员会批准并公开征求意见。 2009年6月11日'可被翻译为：Q4B Annex 9 Approval by the Steering Committee under Step 2 and release for public consultation. 11 June 2009\n\n根据上述已知信息，请将'M7 在第二阶段中获得执行委员会批准，并且公开征求意见。 2013年2月6 日'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"M7 Approval by the Steering Committee under Step 2 and release for public consultation. 6 February 2013"
    },
    {
        "instruction":"已知信息：\n'在某些情况下，存在明显且经验证的代替证据，实验室检查可支持剂量选择；所用的分析方法应是经过验证的检测法，最好对所有参与的患者使用相同方法。'可被翻译为：In certain cases, where there is strong and confirmed evidenceof surrogacy, a laboratory test could support dose-selection; the assay used should be a validated test and should preferably be the same for all participating patients.\n'重复性的验证方法：'可被翻译为：Repeatability should be assessed using:\n'验证研究的实验设计应反映常规分析中生成一个可报告结果的重复测定次数。'可被翻译为：The experimental design of the validation study should reflect the number of replicates used in routine analysis to generate a reportable result.\n'重复性： 使用建立的分析方法参数在目标范围内进行，至少6次重复测定。'可被翻译为：Repeatability: Test at least 6 replicates using established analytical procedure parameters at target range\n\n根据上述已知信息，请将'如果证明合理，可以使用不同重复测定次数进行验证测试，也可根据验证期间生成的数据调整分析方法中的重复测定次数。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"If justified, it may be acceptable to perform some validation tests using a different number of replicates or to adjust the number of replicates in the analytical procedure based on data generated during validation."
    },
    {
        "instruction":"已知信息：\n'该类记录允许在研究中只纳入有可用数据的参保阶段，而无可用数据的退 保阶段可以适当地被排除。'可被翻译为：Such documentation allows only periods of enrollment during which data are available on the patients of interest to be included in the study, and periods of disenrollment when data are not available on patients can be appropriately excluded.\n'因此，在 ICSR 消息文件中的 “controlActProcess”中必须有一个且仅有一个“受试者”元素。'可被翻译为：Therefore, there must be one and only one ‘subject’ element within ‘controlActProcess’ in the ICSR message file.\n'为了数据可朔源性，数据元素19的起源（例如，EHR或者研究人员录入或修改临床研究数据）应以数据录入申办者电子系统20时的电子日期和时间戳进行确认。'可被翻译为：For the purposes of data traceability, the originator of the data elements19 (i.e., EHR or study personnel entering or modifying the clinical study data) should be identified along with an electronic date and time stamp at the time data enter the sponsor’s electronic system.\n'2.电子数据采集系统经过系统验证， 并保存验证记录。计算机化系统设置用户管理、角色管理和权限管理， 不同人员或角色具有唯一登录权限。具有稽查轨迹功能，能够显示修改数据与修改原因的记录。'可被翻译为：2. Electronic data collection system passes the system verification, and retains verification record. Set user management, role management and permission management for the computerized system, different personnel or roles have the unique logon rights. With audit track function, it can display the records of modification data and modification reason.\n\n根据上述已知信息，请将'这种情况下，申办者应该确保仅对于研究人员EHR研究组件，进行录入和修改数据的受限系统的登录具有适当的权限控制。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In such cases, the sponsor should ensure that the appropriate authority controls are in place to limit system access for entering and modifying data to the research component of the EHR to study personnel only."
    },
    {
        "instruction":"已知信息：\n'（三）对不需要进行验证的检验方法，企业应当对检验方法 进行确认，以确保检验数据准确、可靠；'可被翻译为：3. The manufacturer should verify those testing methods that do not need validation so as to ensure the accuracy and reliability of testing data.\n'必须对检测法进行验证以证明由样本中存在的试剂或物质引起的基质效应不会对所得结果产生不良影响。'可被翻译为：Assays must also be validated to show that matrix effects caused by reagents or substances present in samples do not adversely affect the results obtained.\n'4.检验方法应当经过验证或确认。'可被翻译为：4. Testing methods are validated or verified.\n'（四）检验方法应当经过验证或确认；'可被翻译为：4. Testing methods are validated or verified.\n\n根据上述已知信息，请将'3.对不需要进行验证的检验方法，企业应当对检验方法进行确认，以确保检验数据准确、可靠。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"3. The manufacturer should verify those testing methods that do not need validation so as to ensure the accuracy and reliability of testing data."
    },
    {
        "instruction":"已知信息：\n'应尽可能致力于临床试验中这种疾病的标准化。'可被翻译为：Standardisation of such conditions in a clinical trial should be aimed for as far as possible.\n'因此，背景治疗应该在标准化和稳定的前提下尽可能优化。'可被翻译为：Therefore, background therapy should be standardised and stable as far as possible without compromising optimisation.\n'9.4.7 既往和伴随治疗 应描述在进行试验研究之前和期间允许使用哪些药物 或操作，记录是否以及如何使用，以及与允许（或禁止）伴随治疗有关的任何其他具体规定和程序。'可被翻译为：9.4.7 Prior and Concomitant Therapy Which drugs or procedures were allowed before and during the study, whether and how their use was recorded, and any other specific rules and procedures related to permitted or forbidden concomitant therapy should be described.\n'•在每个研究周期之前和期间，要求受试者：（1）服药前1小时至服药后1小时内禁止饮水，其他时间自由饮水。（2）提供标准餐的时间不早于服药后4小时。（3）每个试验周期开始之前24小时至该试验周期最后一个采样完成之间禁止酒精摄入。'可被翻译为：·Before and during each study phase, we recommend that subjects: (1) be allowed water as desired, except for 1 hour before and after drug administration, (2) be provided standardized meals no less than 4 hours after drug administration, and (3) abstain from alcohol for 24 hours before each study period and until after the last sample from each period has been collected.\n\n根据上述已知信息，请将'在不可避免的情况下，伴随治疗应标准化，并在试验之前和试验期间保持稳定一个所定义的周期。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Where unavoidable, concomitant treatments should be standardised and should remain stable for a defined period before and during the trial."
    },
    {
        "instruction":"已知信息：\n'但是，在任何既往病例传输中使用的“全球唯一病例识别码病例识别码” （C.1.8.1）应始终保持不变（见C.1.8的用户指导原则）。'可被翻译为：However, the ‘Worldwide Unique Case Identification Number’ (C.1.8.1) used in any previous transmissions of the case should always remain the same (See the user guidance for C.1.8).\n'在一个病例周期中提交后续报告时，C.1.1应始终使用与被分配的初始ICSR 相同的标识符。'可被翻译为：Always use the same identifier for C.1.1 that was assigned to the initial ICSR when submitting follow-up reports for the lifecycle of a case.\n'基于区域性报告义务和药物警戒业务安排区域性，ICSR 可能会在不同的发送者和接收者之间重复传输多次。在此重新传输过程中，当该病例的新信息对重新发送者不可用时，在重新传输期间不应省略或改变从该病例上“接收到”的医疗信息。'可被翻译为：Based on regional reporting obligations and business arrangements in pharmacovigilance, an ICSR may be re-transmitted several times between different senders and receivers. During this re-transmission process, medical information ‘received’ on the case should not be omitted or changed during the retransmission when no new information on the case is available to the re- transmitting sender.\n'仅在发送者重新传输首次以ICH E2B（R2）格式接收的病例时，才允许*有“不完整信息”，C.1.7的相同数据元素可选择不填元素；在其他情况下，只能使用 “正确”或“错误”。'可被翻译为：*’nullFlavor’ is only allowed when sender is retransmitting a case that was first received ICH E2B (R2) format, where the equivalent data element for C.1.7 was optionally not populated; in other cases, only ‘false’ or ‘true’ should be used.\n\n根据上述已知信息，请将'当相同的发送者重新传输相同病例（例如：传输随访信息）时，C.1.1 通常保持不变。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"When the same sender retransmits the same case (e.g. to transmit follow- up information), C.1.1 usually remains constant."
    },
    {
        "instruction":"已知信息：\n'欧盟药品管理规则第2C卷给申请人的通知；产品特性概述指南（SmPC）2009年9月'可被翻译为：Rules governing medicinal products in the European Union Volume 2C Notice to applicants; A guideline on summary of product characteristics (SmPC) September 2009\n'欧盟药品管理法第2C卷通知申请人；产品特征概述的指导原则（SmPC）2009年9月'可被翻译为：The Rules Governing Medicinal Products in the European Union Volume 2C Notice to Applicants; A guideline on summary of product characteristics (SmPC) September 2009\n'SmPC中的信息应遵循申请人通告第2C卷中关于产品特性概述的指导。'可被翻译为：The information in the SmPC should follow the guidance on the Summary of Product Characteristics in the Notice to Applicant, Volume 2C.\n'9 在欧盟为产品特性概要（SmPC）；在日本为日本药品说明书；在美国为美国药品说明书。'可被翻译为：9 In the EU this would be the Summary of Product Characteristics (SmPC); in Japan this would be the Japanese Package Insert; and in the US this would be the US Package Insert.\n\n根据上述已知信息，请将'欧盟药品管理规定第 2C 卷申请人须知；产品特性概要指导原则(SmPC)，2009 年 9 月'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Rules governing medicinal products in the European Union Volume guideline on summary of product characteristics (SmPC) Septe 2C"
    },
    {
        "instruction":"已知信息：\n'S1B 指导委员会批准进入第四阶段，并推荐给 ICH三方监管机构采纳。 1997年7月16 日 S1B'可被翻译为：S1B Approval by the Steering Committee under Step 4 and recommendation for adoption to the three ICH regulatory bodies. 16 July 1997 S1B\n'S1A 指导委员会批准进入 第四阶段，并推荐给 ICH三方监管机构采 纳。 1995年11月29日 S1A'可被翻译为：S1A Approval by the Steering Committee under Step 4 and recommendation for adoption to the three ICH regulatory bodies. 29 November 1995 S1A\n'M4S 指导委员会批准进入第四阶段，并推荐给ICH三方监管机构采纳。 2000年11月8日 M4S'可被翻译为：M4S Approval by the Steering Committee under Step 4 and recommendation for adoption to the three ICH regulatory bodies. 8 November 2000 M4S\n'M4Q 指导委员会批准进入第四阶段， 并推荐给ICH三方监管机构采 纳。 2000年11月8日 M4Q'可被翻译为：M4Q Approval by the Steering Committee under Step 4 and recommendation for adoption to the three ICH regulatory bodies. 8 November 2000 M4Q\n\n根据上述已知信息，请将'S7A 指导委员会批准进入第四阶段，并推荐给ICH三方 的监管机构采纳。 2000年11月8日 S7A'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"S7A Approval by the Steering Committee under Step 4 and recommendation for adoption to the three ICH regulatory bodies. 8 November 2000 S7A"
    },
    {
        "instruction":"已知信息：\n'原址或者异地新建、改建、扩建车间或者生产线的，应当符合相关规定和技术要求，提交涉及变更内容的有关材料，并报经所在地省、自治区、直辖市药品监督管理部门进行药品生产质量管理规范符合性检查，检查结果应当通知企业。检查结果符合规定，产品符合放行要求的可以上市销售。有关变更情况，应当在药品生产许可证副本中载明。'可被翻译为：To build, rebuild or expand a workshop or manufacturing line at the original site or another site, relevant regulations and technical requirements shall be met, and relevant materials regarding the change shall be submitted to the local drug regulatory department of the province, autonomous region or municipality directly under the Central Government for GMP compliance inspection. The manufacturer shall be notified of the inspection results. Products on which the inspection results comply with relevant regulations, meeting release requirements, can be sold and marketed. Related changes shall be specified in the duplicate of the Drug Manufacturing Certificate.\n'第十二条 药品生产场地包括持有人自有的生产场地或其委托生产企业相应的生产场地。药品生产场地变更是指生产地址的改变或新增，或同一生产地址内的生产场地的新建、改建、扩建。生产场地信息应当在持有人《药品生产许可证》、药品批准证明文件中载明。'可被翻译为：Article 12 The drug manufacturing site includes the manufacturing site owned by the MAH or the corresponding manufacturing site of the contract manufacturer. The change of drug manufacturing site refers to the change or addition of manufacturing address, or the new construction, reconstruction and expansion of manufacturing site with the same production address. The manufacturing site information shall be specified in the Drug Manufacturing Certificate and drug approval document of the MAH.\n'第十五条  生产地址变更或者生产范围增加的，应当向原发证部门申请医疗器械生产许可变更，并提交本办法第十条规定中涉及变更内容的有关材料，原发证部门应当依照本办法第十三条的规定进行审核并开展现场核查。'可被翻译为：Article 15 In case of changes in manufacturing address or increase of manufacturing scope, the applicant shall apply to the former license issuing department for changes in Medical Device Manufacturing License, and submit relevant materials of the changes involved in Article 10 of these Provisions. The former license issuing department shall conduct review and carry out on-site inspection as stipulated in Article 13 of these Provisions.\n'同一个化妆品生产企业在同一个省、自治区、直辖市申请增加化妆品生产地址的，可以依照本办法的规定办理变更手续。'可被翻译为：Where the same cosmetics manufacturer applies for adding the manufacturing address of cosmetics in the same province, autonomous region or municipality directly under the central government, it may handle the procedures for change in accordance with provisions in these Provisions.\n\n根据上述已知信息，请将'变更生产地址或者生产范围，药品生产企业应当按照本办法第六条的规定及相关变更技术要求，提交涉及变更内容的有关材料，并报经所在地省、自治区、直辖市药品监督管理部门审查决定。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"To change the address of manufacturing site or the manufacturing scope, the drug manufacturer shall, in accordance with the provisions of Article 6 of these Provisions and relevant technical requirements, submit relevant materials related to the changes to the local drug regulatory department of the province, autonomous region or municipality directly under the Central Government for review and approval."
    },
    {
        "instruction":"已知信息：\n'如果不进行治疗，会导致关节破坏、畸形和功能障碍。'可被翻译为：If left untreated, it causes joint destruction, deformity and functional impairment.\n'此外， 重要的不良事件一般很明显， 因为它们导致停 止治疗，以及提交病例报告表。'可被翻译为：In addition, important adverse events will generally be apparent because they lead to cessation of therapy and submission of the case report form.\n'因使用药品引起以下损害情形之一的反应：导致死亡；危及生命；致癌、致畸、致出生缺陷；导致显著的或者永久的人体伤残或者器官功能的损伤；导致住院或者住院时间延长；导致其他重要医学事件，如不进行治疗可能出现上述所列情况的不良反应。'可被翻译为：Reactions resulting in one of the following harmful conditions due to the use of a drug: causing death; posing a life-threatening situation; causing cancer, teratogenicity, or congenital defects; leading to significant or permanent human injury or damage to organ function; resulting in hospitalization or prolonged hospital stay; causing other significant medical events, where failure to treat may lead to the aforementioned adverse reactions.\n'E.i.3.2f其他重要医学事件其他重要医学事件'可被翻译为：E.i.3.2f Other Medically Important Condition\n\n根据上述已知信息，请将'6.导致其他重要医学事件，如不进行治疗可能出现上述所列情况的。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"6. Other medically important events that without treatment could lead to the aforementioned outcomes."
    },
    {
        "instruction":"已知信息：\n'治疗方法的对比应包括考虑各中心疗效差异的分析。'可被翻译为：Treatment comparison should include analyses that allow for centre differences with respect to response.\n'分析应该显示临床治疗之间差异 的大小（点估计）、相关的置信区间以及假设检验的结果。'可被翻译为：The analysis should show the size (point estimate) of the difference between the treatments, the associated confidence interval, and where utilised, the results of hypothesis testing.\n'应在方案中给出计算样本量的方法，以及在计算中使用 的任何估计量（如方差、均值、反应率、事件率、待检测的 差异）。'可被翻译为：The method by which the sample size is calculated should be given in the protocol, together with the estimates of any quantities used in the calculations (such as variances, mean values, response rates, event rates, difference to be detected).\n'ACR 20\/50\/70 反应率'可被翻译为：ACR20, 50, 70 responder rates\n\n根据上述已知信息，请将'首选的主要分析应依赖于治疗反应率的差异。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The preferred main analysis should rely on the differences in the rate of responders."
    },
    {
        "instruction":"已知信息：\n'然而，评估时应将诸如剂量水平、给药方案、ROA和启动子变化等因素考虑在内。'可被翻译为：However, considerations such as the dose level(s), dosing regimen, ROA, and change in promotor will factor into this decision.\n'代谢和其它药代动力学方面（如有需要）。'可被翻译为：Metabolism and other pharmacokinetic aspects, if needed.\n'可对单个药物或联合治疗开展研究以评估内在（如肾损害和肝损害）和外在（如食物影响和药 物相互作用）因素对药代动力学、药效学和暴露-效应的影响。'可被翻译为：Studies to evaluate the effects of intrinsic (such as renal impairment and hepatic impairment) and extrinsic (such as food effect and drug interactions) factors on pharmacokinetics and pharmacodynamics, and exposure-response could be conducted either with the individual drugs or the combination.\n'该药物的药代动力学对内在和外在因素也不敏感。'可被翻译为：The pharmacokinetics of the drug are insensitive to intrinsic and extrinsic factors.\n\n根据上述已知信息，请将'如果其它因素对评估药代动力学有重要影响（例如可溶 性循环受体、肾或肝功能），那么还应明确这些因素的测定 时间和计划。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Where other factors are believed important in assessing pharmacokinetics (e.g., soluble circulating receptors, renal or hepatic function), the timing and plans to measure these factors should also be specified."
    },
    {
        "instruction":"已知信息：\n'对于每项变更，申请人将进行风险评估以确认对性能特征以及与ATP中CQA（生物活性）关联的潜在影响，将根据风险评估的结果确定所需的桥接研究的程度，用于证明符合性能指特征和相关标准。'可被翻译为：For every change, the applicant will perform a risk assessment to evaluate potential impact on the performance characteristics and the link to CQA (biological activity) as defined in the respective ATP. The outcome of the risk assessment informs the extent of the bridging studies used to demonstrate adherence to the performance characteristics and associated criteria.\n'该风险评估的结果可为支持变更所需研究（包括桥接策略，以证明经修订或新订方法适用于预期目的）的设计和程度提供参考。'可被翻译为：The outcome of this risk assessment informs the design and extent of the studies needed to support the change including a bridging strategy to demonstrate that the revised or new procedure remains fit for the intended purpose.\n'除非在桥接研究期间证明符合ATP中定义的性能特征和相关标准，申请人不得按照预先设定的报告类别实施新的分析方法。'可被翻译为：The applicant should not implement the new analytical procedure using the predefined reporting category unless adherence to the performance characteristics and associated criteria defined in the ATP are demonstrated during the bridging studies.\n'除非在桥接研究期间证明符合ATP中定义的性能特征和相关标 准，申请人不得按照预定义的报告类别实施新的分析方法。'可被翻译为：The applicant should not implement the new analytical procedure using the predefined reporting category unless adherence to the performance characteristics and associated criteria defined in the ATP is demonstrated during the bridging studies.\n\n根据上述已知信息，请将'作为风险评估的结果，将开展实验性桥接研究，以证明符合性 能特征和相关标准。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"As an outcome of the risk assessment, experimental bridging studies to demonstrate adherence to the performance characteristics and associated criteria will be performed."
    },
    {
        "instruction":"已知信息：\n'这类致突变致癌物常通过细菌 回复突变（致突变性）试验检测。'可被翻译为：This type of mutagenic carcinogen is usually detected in a bacterial reverse mutation (mutagenicity) assay.\n'发生回复突变的菌株。'可被翻译为：A strain that has reverted to a mutation.\n'细菌回复突变试验（Ames）：在代谢活化情况下，鼠伤寒沙门氏菌TA100和TA1535中表现出致突变性，在TA1537、 TA1538, TA98, and E.coli WP2uvrA菌株中未发现致突变性 （参考文献1- 4）。在4项研究的2项研究中，在未经代谢活化的TA1535菌株中也表现出弱致突变性（参考文献4）。'可被翻译为：Microbial reverse mutation assay (Ames) Salmonella typhimurium strains TA100 and TA1535 in the presence of S9 metabolic activation, and was negative in TA1537, TA1538, TA98, and E.coli WP2uvrA (Ref. 1, 2, 3, 4). It was also weakly positive without metabolic activation in TA1535 in 2 of 4 studies (Ref. 4).\n'5.2 体外试验结果评价 在评价阳性结果时，尤其是细菌回复突变试验，应考虑 受试物的纯度，以确定阳性结果是否是由于污染物所致。'可被翻译为：5.2 Evaluation of Results Obtained in In Vitro Tests In evaluating positive results, especially for the microbial mutagenicity test, the purity of the test compound should be considered, to determine whether the positive result could be attributable to a contaminant.\n\n根据上述已知信息，请将'（1）以一项细菌回复突变试验评价致突变性。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"i. Assessment of mutagenicity in a bacterial reverse gene mutation test."
    },
    {
        "instruction":"已知信息：\n'·每个用药错误和用药失败的发生概率的一个评估'可被翻译为：·An estimate of the probability of occurrence of each use error and failure\n'评估所识别的潜在用药错误和系统故障的潜在影响和后果的严重程度。'可被翻译为：Assessing potential effects and the severity of consequences of identified potential medication errors and system failures.\n'·潜在用药错误和系统失效的鉴定，可能发生在用药过程中每一个步骤。'可被翻译为：·Identification of the potential use errors and system failures that could occur at each step of the medication use process\n'NDO的潜在后果更严重，影响上尿路：膀胱输尿管反流，肾积水、肾盂肾炎复发和潜在肾损害。'可被翻译为：The potential consequences of NDO are more severe and affect the upper urinary tract: vesicoureteral reflux, hydronephrosis, recurrent pyelonephritis and potentially renal damage.\n\n根据上述已知信息，请将'·每个用药错误和用药失败的潜在影响和后果的严重程度的鉴定'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"·Identification of the potential effects and severity of consequences of each use error and failure"
    },
    {
        "instruction":"已知信息：\n'第十九条 进口临床急需药品、捐赠药品、新药研究和药品注册所需样品或者对照药品等，必须经国家食品药品监督管理局批准，并凭国家食品药品监督管理局核发的《进口药品批件》，按照本办法第十六条的规定，办理进口备案手续。'可被翻译为：Article 19 The importation of drugs in urgent clinical needs, drugs for donation purpose, samples or comparator products required for new drug research and drug registration and so on shall apply for approval from the State Food and Drug Administration, and shall go through the formalities of importation record filing in accordance with Article 16 of the Provisions by presenting the Import Drug Approval issued by the State Food and Drug Administration.\n'第二十条 口岸药品监督管理部门应当对备案资料的完整性、规范性进行形式审查，符合要求的，发给进口药品通关单，收回首次进口药材批件，同时向口岸药品检验机构发出进口药材口岸检验通知书，并附备案资料一份。'可被翻译为：Article 20 Drug regulatory departments of ports shall conduct a preliminary review on the completeness and normalization of filing materials. For those meeting the requirements, drug regulatory departments of ports shall issue the Drug Import Note, take back the approval document for first importation of crude drugs, and simultaneously issue the Notice for Port Testing for Importation of Crude Drugs to the drug control institutions of ports with a copy of filing materials attached.\n'第十条 下列情形的进口药品，必须经口岸药品检验所检验符合标准规定后，方可办理进口备案手续。检验不符合标准规定的，口岸药品监督管理局不予进口备案：'可被翻译为：Article 10 In any of the following cases, the importation record filing of drugs to be imported shall proceed only after they have been tested and confirmed by the drug control institute of port that they meet the prescribed standards. If they do not meet the prescribed standards based on testing, the drug regulatory department at ports of entry shall not approve the importation record filing.\n'第四条 本办法所称进口备案，是指进口单位向允许药品进口的口岸所在地药品监督管理部门（以下称口岸药品监督管理局）申请办理《进口药品通关单》的过程。麻醉药品、精神药品进口备案，是指进口单位向口岸药品监督管理局申请办理《进口药品口岸检验通知书》的过程。'可被翻译为：Article 4 Importation record filing in the Provisions refers to the process that drug importers apply for the Drug Import Note to the local drug regulatory department at ports of entry where drug importation is permitted (hereinafter referred to as the drug regulatory department at ports of entry). Importation record filing of narcotic drugs and psychotropic substances in the Provisions refers to the process that drug importers apply for the Notice of Port Testing for Import Drugs from the drug regulatory department at ports of entry.\n\n根据上述已知信息，请将'第四十条 进口暂未列入进口药品目录的原料药，应当遵照本办法的规定，到口岸药品监督管理局办理进口备案手续。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 40 To import drug substances which have been imported but have not yet been included in the list of imported drugs for the time being, the importer shall go through the formalities of importation record filing with the drug regulatory department at ports of entry in accordance with the regulations of the Provisions."
    },
    {
        "instruction":"已知信息：\n'应描述按计划进行的对研究结果的监查。'可被翻译为：Planned monitoring of the results of the study should be described.\n'5.试验方案、SOP  或其他试验操作文件的偏离应及时记录、评估并如实反映在总结报告中。'可被翻译为：5. Deviations from study protocol, SOPs or other operational instructions should be recorded, and evaluated in a timely manner, and reported truthfully in the final report.\n'可使用对症治疗作为抢救药物，但是应详细记录，并且应该在方案中说明对研究结果的可能影响以及相应的分析方法。'可被翻译为：Symptomatic treatment as rescue medication may be used, but should be documented carefully and the possible influence on the results and the way to analyse this should be indicated in the protocol.\n'参考21 CFR 320.38，320.63和FDA行业指南《生物利用度（BA）和生物等效性（BE）研究中试验样品的处理和保存》（2004年5月）和《21 CFR 320.38(c) BE样品留存的数量及生物利用度》（2020年8月），如适用，关于保留研究药物样品的考虑以及21 CFR 320.36关于保存BE检测记录的要求。在采用自研外用制剂和RS进行IVRT对比研究前，应从收到的药品中随机选择样品进行留样。应报告可能影响研究结果解释的试验观察，以及任何与方案发生的偏离。'可被翻译为：Refer to 21 CFR 320.38, 320.63 and the guidances for industry Handling and Retention of BA and BE Testing Samples (May 2004) and Compliance Policy for the Quantity of Bioavailability and Bioequivalence Samples Retained Under 21 CFR 320.38(c) (August 2020), as applicable, regarding considerations for retention of study drug samples and to 21 CFR 320.36 for requirements for maintenance of records of BE testing. Retention samples should be randomly selected from the drug supplies received before dispensing during the IVRT study in which the test topical product and RS are compared. Experimental observations that may have the potential to influence the interpretation of the study results, as well as any protocol deviations, should be reported.\n\n根据上述已知信息，请将'应对可能影响研究结果的研究程序进行适当控制。另外，应报告可能影响研究结果解释的试验观察，以及任何与方案或标准操作规程（SOP）发生的偏离。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Study procedures that have the potential to influence the results of the study should be appropriately controlled. Also, experimental observations that may have the potential to influence the interpretation of the study results, as well as any protocol or standard operating procedure (SOP) deviations, should be reported."
    },
    {
        "instruction":"已知信息：\n'E.避免使用外形相似的容器标签和纸盒标识'可被翻译为：E. Avoid Look-alike Container Labels and Carton Labeling\n'确保同一个生产线或跨生产线的产品的包装密闭容器看起来不相似。可通过大小、性状、颜色、触觉、或其它方式区分包装容器。将药品包装于相似外观的密闭容器中，会导致药品挑选错误，即分发和服用错误的药物或规格。导致药品挑选错误，即导致分发错误的药品或规格的例子，包括但不限于：'可被翻译为：·Ensure container closures do not look similar within a product line or across a different product line. Distinguish container closures by size, shape, color, tactile features, or some other means. Drug products packaged in container closures that have a similar appearance has led to product selection errors in which the wrong drug and wrong strength have been dispensed and administered. Examples that have contributed to product selection errors resulting in dispensing the wrong drug or wrong strength include but are not limited to:\n'事实上，当颜色编码被 应用在容器标签和纸盒标识上时，用户更难区分同一治疗类别的不同药物。因为这 些药物通常都存储在彼此附近，容器标签和纸盒标识的相似造成了错误规格，错误 剂量和错误药品的分发和配给。'可被翻译为：In fact, the color  coding has made it difficult for these users to differentiate between drugs within the same therapeutic class when the color code was used on the container label and carton labeling.  Because these products are typically stored near each other, the similar appearance of the  container labels and carton labeling has led to dispensing and administering the wrong strength,  wrong dose, and wrong product.\n'申办者应该创建一个能显著区别 于自己和其他厂商生产的药品的容器标签和纸盒标识，这样，药品的终端用户就可 以正确的识别，选择，分发和配给适当的药品，规格和剂量。 当容器标签或纸盒标识比较相似的药品并排或在附近存储时，药品混淆的可能 性就更大。'可被翻译为：Sponsors should create a container label and carton labeling design that is sufficiently distinct from that of their other products and the products of other manufacturers so that the end user is able to correctly identify, select, dispense, and administer the appropriate medication, strength, and dose. The potential for product confusion is especially problematic when products with similar looking  container labels or carton labeling are customarily stored side-by-side or near one another.\n\n根据上述已知信息，请将'E.避免使用外形相似的容器标签和纸盒标识 。 外观相似的容器标签和纸盒标识经常导致药品选择错误，从而又导致分发和配 给了错误的药品，错误的规格和\/或错误的剂量。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"E. Avoid Look-alike Container Labels and Carton Labeling  Look-alike container labels and carton labeling have frequently contributed to product selection  errors leading to the dispensing and administration of the wrong drug, wrong strength and\/or  wrong dose."
    },
    {
        "instruction":"已知信息：\n'通过两个编 码索引可以将数据或样本追溯到受试者本人。'可被翻译为：It is possible to trace the data or samples back to the individual by the use of both coding keys.\n'由 于样本及相关数据能通过两个编码索引间接追溯到受试者， 因此，可根据受试者的要求撤除样本或归还个人结果。'可被翻译为：As the samples and associated data can very indirectly be traced back to the subject via the use of both coding keys, it may be possible to undertake actions such as sample withdrawal, or the return of individual results in accordance with the subject’s request.\n'通过使用单一编码索引有可能将数 据或样本追溯到特定个体。'可被翻译为：It is possible to trace the data or samples back to a given individual with the use of a single coding key.\n'删除连接数据和样本与受试者识别信息间的编码索引，由于 能阻止通过使用编码索引对受试者进行再次识别，故可以为 编码数据和样本提供更多的保密性和个人隐私保护。'可被翻译为：The deletion of the coding key(s) linking the data and samples to a given subject’s identifiers provides additional confidentiality and privacy protection over coded data and samples, as it prevents subject re-identification through the use of the coding key(s).\n\n根据上述已知信息，请将'只有使用两种 编码索引，才能将数据或样本结果追溯到受试者的识别信息 上。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Access to both coding keys is needed to link any data or samples back to a subject identifier."
    },
    {
        "instruction":"已知信息：\n'为贯彻落实《国务院办公厅关于印发治理高值医用耗材改革方案的通知》（国办发〔2019〕37号），规范医疗器械唯一标识系统建设，加强医疗器械全生命周期管理，依据《医疗器械监督管理条例》，国家药监局制定并于2019年8月27日发布了《医疗器械唯一标识系统规则》，将于2019年10月1日起施行。'可被翻译为：Per the Notice of the General Office of the State Council on the Issuance of the Reform Plan for Governance over High value Medical Consumables (the State Council General Office [2019] No. 37), to standardize the construction of a unique identification system for medical devices ,and strengthen the life cycle management of medical devices, based on the Regulations for the Supervision and Administration of Medical Devices, NMPA has formulated and promulgated on August 27, 2019 the Rules for the Unique Identification System of Medical Devices, which will go into effect as from October 1, 2019.\n'医疗器械唯一标识系统规则'可被翻译为：Rules for Unique Device Identification System\n'第一条 为规范医疗器械分类，根据《医疗器械监督管理条例》，制定本规则。'可被翻译为：Article 1 The Rules is stipulated in accordance with the Regulations on Supervision and Administration of Medical Devices to standardize the classification of medical devices.\n'第一条 为加强医疗器械监督管理，保证医疗器械通用名称命名科学、规范，根据《医疗器械监督管理条例》，制定本规则。'可被翻译为：Article 1 The Rules is formulated in accordance with the Regulations on the Supervision and Administration of Medical Devices to enhance the supervision and administration of medical devices and ensure that the nomenclature of medical devices is scientific and normative.\n\n根据上述已知信息，请将'第一条 为规范医疗器械唯一标识系统建设，加强医疗器械全生命周期管理，根据《医疗器械监督管理条例》，制定本规则。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 1 The Rules are hereby formulated in accordance with the Regulations on Supervision and Administration of Medical Devices, so as to regulate the establishment of unique device identification system (UDI system) and strengthen the whole-life cycle management of medical devices."
    },
    {
        "instruction":"已知信息：\n'该类数据可以分开展 示，并作适当的说明。'可被翻译为：Such data can be presented separately with an explanation as appropriate.\n'不同剂量下暴露的患者数量应按年龄、 性别、种族亚组以及任何其他适宜亚组进行分类。'可被翻译为：The numbers of patients exposed to various doses should be broken down into age, sex, and racial subgroups, and any other pertinent subgroups.\n'表1根据已完成的研究的实际暴露数据和进行中的研究的入 组\/随机方案提供了临床研究中的总体受试者暴露量估计。'可被翻译为：Estimates of overall cumulative subject exposure are provided in Table 1, based upon actual exposure data from completed studies and the enrollment\/randomization schemes for ongoing studies.\n'应提供用于估计受试者\/患者暴露的方法的简要 描述及其限制。'可被翻译为：Brief descriptions of the method(s) used to estimate the subject\/patient exposure should be provided, as well as the limitations thereof.\n\n根据上述已知信息，请将'数据应根据以下分类展示： 1. 批准后（非临床试验）暴露： 应提供患者暴露的总体估计。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The data should be presented according to the following categories: 1. Post-approval (non-clinical trial) exposure: An overall estimation of patient exposure should be provided."
    },
    {
        "instruction":"已知信息：\n'随机撤药设计也可以将受试者分配到多个剂量水 平。'可被翻译为：Randomized withdrawal designs can also assign subjects to multiple dosage levels.\n'随机化的、固定剂量的剂量-效应试验中，受试者被随 机分配到几个固定剂量组中。'可被翻译为：In a randomized, fixed-dose, dose-response trial, subjects are randomized to one of several fixed-dose groups.\n'首选的方法是随机、对照、平行组、固定剂量设计，评价至少 3 个单独的剂量水平。'可被翻译为：The preferred approach is a randomised, controlled, parallel-group, fixed-dose design, evaluating at least 3 separate dose levels.\n'在剂量-效应研究中设立安慰剂组(零剂量组)有几个优 点。'可被翻译为：There are several advantages to inclusion of a placebo (zero-dose) group in a dose-response study.\n\n根据上述已知信息，请将'对于多数剂量-反应研究的一般规则为随 机分配至几个固定剂量组的平行组设计。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The parallel group design with randomization to several fixed dose groups is the general rule for the major dose-response studies."
    },
    {
        "instruction":"已知信息：\n'经国家药品监督管理局仿制药质量和疗效一致性评价专家委员会审核确定，现于6月22日发布仿制药参比制剂目录（第四十二批）。'可被翻译为：On June 22, the Catalogue of Reference Preparations of Generic Drugs (Forty-two Batch) was issued, upon review and determination by the NMPA Experts Committee of Quality and Efficacy Consistency Evaluation of Generic Drugs.\n'国家药监局关于发布仿制药参比制剂目录（第四十三批）的通告'可被翻译为：NMPA Announcement on Issuing the Catalogue of Reference Preparations of Generic Drugs (Forty-three Batch)\n'国家药监局关于发布仿制药参比制剂目录（第五十批）的通告'可被翻译为：NMPA Announcement on Issuing the Catalogue of Reference Preparations of Generic Drugs (Fiftieth Batch)\n'国家药监局关于发布仿制药参比制剂目录（第三十八批）的通告'可被翻译为：NMPA Announcement on Issuing the Catalogue of Reference Preparations of Generic Drugs  (Thirty-eighth Batch)\n\n根据上述已知信息，请将'国家药监局关于发布仿制药参比制剂目录（第四十二批）的通告'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"NMPA Announcement on Issuing the Catalogue of Reference Preparations of Generic Drugs (Forty-two Batch)"
    },
    {
        "instruction":"已知信息：\n'如果在其它动物研究中已经研究了建议的临床剂型和给药途径， 则不需要进行额外的局部耐受性研究。'可被翻译为：If the proposed clinical  formulation and route of administration have been examined in other animal studies, then separate local tolerance studies are not necessary.\n'如适用，静脉给药不必再进行额外的药理学研究。'可被翻译为：Additional pharmacology studies for intravenous use, if applicable, are not required.\n'1.6 高剂量选择的药效学终点'可被翻译为：1.6 Pharmacodynamic Endpoints in High Dose Selection\n'1.4 高剂量选择中动物和人AUC比较的标准 以下标准尤其适用于通过确定药代动力学暴露量进行高剂量 选择。'可被翻译为：1.4 Criteria for Comparisons of AUC in Animals and Man for use in High Dose Selection The following criteria are especially applicable for use in determining a pharmacokinetically-defined exposure for high dose selection.\n\n根据上述已知信息，请将'选择的高剂量应在给药动物中 产生足够的药效学反应，无需进一步提高剂量。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The high dose selected should produce a pharmacodynamic response in dosed animals of such magnitude as would preclude further dose escalation."
    },
    {
        "instruction":"已知信息：\n'答：是的， 文献报告可以被认为是一项涵盖的临床研究， 如果它被申请人或 FDA依赖于确定该产品是有效的（包括显示与一种有效的产品具有等效性） 或其中单一研究者对安全性的证明具有重要贡献18 。如果申请人以这种方式 依靠文献报告， 则需要进行临床研究者财务信息的披露。'可被翻译为：A: Yes, a literature report could be considered a covered clinical study if it is being relied upon by the applicant or FDA to establish that the product is effective (including showing equivalence to an effective product) or where a single investigator makes a significant contribution to the demonstration of safety.18 When an applicant relies on a literature report in this manner, clinical investigator financial disclosure is required.\n'G.7. 问：为支持一种药物制剂从处方药转换成非处方药（OTC）的要求而开展的 实际用途（actual use）和标签理解（labeling comprehension）研究符合涵盖的 临床研究定义吗？'可被翻译为：G.7.Q: Do actual use and labeling comprehension studies conducted to support a request to switch a drug product from prescription to over-the-counter (OTC) status fit the definition of covered clinical study?\n'E.8. 问：如果一较大型母公司的子公司在开展一项涵盖的临床研究， 仅报告临床 研究者在子公司中的财务权益和安排吗？'可被翻译为：E.8. Q: If a subsidiary of a larger parent company is conducting a covered clinical study, are the financial interests and arrangements of the clinical investigators with only the subsidiary reported?\n'E.9. 问：在确定涵盖研究的申办方时，哪些被认为是“重要支持 ”？'可被翻译为：E.9. Q: What is considered “material support” when identifying sponsors of the covered study?\n\n根据上述已知信息，请将'G.4. 问：文献报告可以被认为是涵盖的临床研究吗？'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"G.4. Q: Can a literature report be considered a covered clinical study?"
    },
    {
        "instruction":"已知信息：\n'第二十八条 药品生产企业应当按照本办法第二十条、第二十一条、第二十二条、第二十三条的规定向药品监督管理部门报告药品召回的相关情况，进行召回药品的后续处理。'可被翻译为：Article 28 The drug manufacturer shall report the relevant information of the recall to the drug regulatory department according to the provisions in Article 20, Article 21, Article 22 and Article 23 of these Provisions, and engage in subsequent handling of the recalled drug.\n'第二十六条 药品监督管理部门作出责令召回决定，应当将责令召回通知书送达药品生产企业，通知书包括以下内容：'可被翻译为：Article 26 After making the decision to order the recall, the drug regulatory department shall send the notice of ordered recall to the drug manufacturer. The notice includes the following items:\n'第二十六条 医疗器械生产企业收到责令召回通知书后，应当按照本办法第十五条、第十六条的规定通知医疗器械经营企业和使用单位或者告知使用者，制定、提交召回计划，并组织实施。'可被翻译为：Article 26 After receiving the ordered recall notice, the medical device manufacturer shall notify the medical device distributors and using units or inform the users in accordance with Article 15 and Article 16 of these Provisions, formulate and submit a recall plan, and organize its implementation.\n'第十六条 药品生产企业在作出药品召回决定后，应当制定召回计划并组织实施，一级召回在24小时内，二级召回在48小时内，三级召回在72小时内，通知到有关药品经营企业、使用单位停止销售和使用，同时向所在地省、自治区、直辖市药品监督管理部门报告。'可被翻译为：Article 16 After making the decision to recall the drug, the drug manufacturer shall make the recall plan and organize its implementation, notify the relevant drug distributors and users to stop selling and using the drug within 24 hours in the case of Class 1 recall, 48 hours in the case of Class 2 recall and 72 hours in the case of Class 3 recall, and at the same time report the case to the local drug regulatory department of the province, autonomous region or municipality directly under the Central Government.\n\n根据上述已知信息，请将'第二十七条 药品生产企业在收到责令召回通知书后，应当按照本办法第十六条、第十七条的规定通知药品经营企业和使用单位，制定、提交召回计划，并组织实施。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 27 After receiving the notice of ordered recall, the drug manufacturer shall notify the drug distributor and user according to the provisions in Article 16 and Article 17 of these Provisions, formulate and submit the recall plan and organize its implementation."
    },
    {
        "instruction":"已知信息：\n'然而，发送者不应推断日期，除 非有明确的临床依据，而这种依据应在病例描述中进行陈述。'可被翻译为：However, a sender should not infer dates unless there is a clear clinical rationale and this rationale should be stated in the case narrative.\n'如果发送者不知道具体信息，则开始 日期或结束日期或两者都留空白是可以接受的。'可被翻译为：A blank field for start date or end date or both is acceptable if the information is not known to the sender.\n'当信息未知或事件不严重时，应该填 “NI”。 （b）“留空白”，如果不严重，使用空白值“NI”。'可被翻译为：When the information is unknown or the event is not serious, “NI” should be populated. b) “Left blank” if not serious using the null flavor “NI”.\n'- 起始日期或发现事件的临床访视日期'可被翻译为：− Date of onset or date of clinic visit at which the event was discovered\n\n根据上述已知信息，请将'当确切的日期未知时，对于是否留 空白或一个给定事件推断日期应由发送者进行临床判断。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"When a precise date is not available, the decision of whether to leave blank or an inferred date for a given event should be left up to the sender’s clinical judgment."
    },
    {
        "instruction":"已知信息：\n'第四十二条 食品药品监督管理部门收到申请后对申报资料进行形式审查，并根据下列情况分别作出处理：'可被翻译为：Article 42 The food and drug regulatory department shall conduct formal review after accepting an application, and handle respectively according to the following circumstances:\n'第一百四十七条 药品监督管理部门收到申请后进行形式审查，并根据下列情况分别作出处理：'可被翻译为：Article 147 Drug regulatory departments shall conduct preliminary review on applications, and proceed according to the following circumstances respectively:\n'第八十五条 药品监督管理部门收到药品注册申请后进行形式审查，并根据下列情况分别作出是否受理的决定：'可被翻译为：Article 85 Upon receiving a drug registration application, the drug regulatory departments shall conduct preliminary review and make a decision of acceptance or rejection according to the following circumstances respectively:\n'第八条 省、自治区、直辖市药品监督管理部门收到申请后，应当根据下列情况分别作出处理：'可被翻译为：Article 8 After receiving the application, the drug regulatory department of the province, autonomous region or municipality directly under the Central Government shall handle it according to different cases:\n\n根据上述已知信息，请将'第三十二条 食品药品监督管理部门收到申请后对申报资料进行形式审查，并根据下列情况分别作出处理：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 32 The food and drug regulatory department shall conduct preliminary review after accepting an application, and handle respectively according to the following circumstances:"
    },
    {
        "instruction":"已知信息：\n'（四）因违法行为被药品监督管理部门责令停止销售、吊销药品批准证明文件或者吊销药品经营许可证的；'可被翻译为：(4) being ordered to stop selling, being revoked the drug approval documents or being revoked the drug distribution certificate by the drug regulatory department due to illegal acts;\n'（四）未按照规定进行药品不良反应监测的；'可被翻译为：(4) the adverse drug reaction monitoring is not conducted in accordance with regulations;\n'（七）其他未履行疫苗监督管理职责的行为，造成严重不良影响或者重大损失。'可被翻译为：(7) having any other dereliction of duty in vaccine administration, resulting in serious negative effects or heavy losses.\n'（一）履行职责不力，造成严重不良影响或者重大损失；'可被翻译为：(1) performing responsibility insufficiently, resulting in serious negative effects or heavy losses;\n\n根据上述已知信息，请将'（四）其他不履行药品监督管理职责，造成严重不良影响或者重大损失。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(4) failing to perform drug supervision and administration duties, resulting in serious adverse impact or serious losses."
    },
    {
        "instruction":"已知信息：\n'如 有正当理由，也可使用与感染性无关的定量分析。'可被翻译为：Quantitative assays not associated with infectivity may be used if justified.\n'对于暴露限度较大的情况，可能不需要进行附加研究。'可被翻译为：In situations where there is a large exposure margin, no additional studies may be necessary.\n'病毒清除方法评价研究：用“相关”和\/或特异“模型”病毒确定生产工艺去除和\/或灭活病毒效果的研究。'可被翻译为：Process Evaluation Studies of Viral Clearance Viral clearance studies in which “relevant” and\/or specific “model” viruses are used to determine the ability of the manufacturing process to remove and\/or inactivate these viruses.\n'对于此类平台分析方法的新应用，后续开发可进行简化，并且根据科学和风险评估的合理依据，可省略某些验证试 验。'可被翻译为：For a new application of such platform analytical procedures, the subsequent development can be abbreviated, and certain validation tests can be omitted based on a science- and risk-based justification.\n\n根据上述已知信息，请将'科学的根据、或参照指导原则不需要或明确排除此类研究，可以作为仅开展小规模的特定研究（例如，病毒的去除）的合理依据。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Scientific grounds, or reference to guidelines which do not require or specifically exclude such studies, can be an appropriate justification to conduct certain studies only at small- scale (e.g., viral removal)."
    },
    {
        "instruction":"已知信息：\n'评估终点的临床意义及其观察到的效应大小。'可被翻译为：An assessment of the clinical meaningfulness of endpoints and their observed effect sizes.\n'验证性试验中临床终点的定义应符合相关临床指导原则，以便于解释结果、允许跨临床研究进行比较、以及外推到临床实践。'可被翻译为：Definitions of clinical endpoints in confirmatory trials should be in line with the relevant clinical guidelines to facilitate interpretation of the results, to allow comparisons across clinical studies and to extrapolate to clinical practice.\n'在 III 期研究中，可以将这些终点作为次要终点进行评估以支持临床终点。'可被翻译为：In phase III studies, these endpoints can be investigated as secondary endpoints to support the clinical endpoints.\n'这种研究应具有充分的效能来证明主要疗效终点发生具有临床意义的变化。'可被翻译为：Such a study should be adequately powered to demonstrate a clinically meaningful change in the primary efficacy endpoint.\n\n根据上述已知信息，请将'相反，临床意义是旨在提供有效性证据以支持上市申请的一项研究的重要终点特征。将带有不同特征的多个终点纳入其中可提高研究结果的总体可判读性。例如，含有具有临床意义但是主观性较强的 主要疗效终点（即易于发生偏倚的终点）的III期临床试验可能从不易于发生偏倚的次要研究终点（例如实验室测定）中受益。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In contrast, clinical meaningfulness is an important endpoint characteristic in a study intended to provide evidence of effectiveness to support a marketing application. Including several endpoints with different characteristics may improve the overall interpretability of the study results. For example, a phase 3 clinical trial with a clinically meaningful but  subjective primary efficacy endpoint (i.e., one that may be prone to bias) may benefit from having secondary endpoints that are resistant to bias (such as laboratory measurements)."
    },
    {
        "instruction":"已知信息：\n'●当患者或患者的代理人要求获取用药指南。'可被翻译为：• When the patient or the patient’s agent requests a Medication Guide.\n'●用药指南要求每个授权的处方药品的配药员在药品分配时，必须直接向每个患者或每个患者的代理人提供，除非申请豁免。7'可被翻译为：• Each authorized dispenser of a prescription drug product for which a Medication Guide is required must provide the Medication Guide directly to each patient or each patient’s agent when the product is dispensed, unless an exemption applies.7\n'b．FDA不行使自由裁量权，必须向住院患者和门诊患者提供用药指南的各种情况'可被翻译为：b. Circumstances under which FDA will not exercise enforcement discretion and a Medication Guide must be provided to a patient in inpatient and outpatient settings\n'住院患者 必须提供用药指南 FDA行使自由裁量权；不需要提供用药指南 FDA行使自由裁量权； 不需要提供用药指南 FDA行使自由裁量权； 不需要提供用药指南 按照REMS规定必须提供用药指南'可被翻译为：Inpatient Must provide Medication Guide FDA intends to exercise enforcement discretion; Medication Guide need not be provided FDA intends to exercise enforcement discretion; Medication Guide need not be provided FDA intends to exercise enforcement discretion; Medication Guide need not be provided Must provide Medication Guide as specified in REMS\n\n根据上述已知信息，请将'在下列情况，必须向患者或患者的代理人提供用药指南（例如，FAD不行使自由裁量权）：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A Medication Guide must be provided to the patient or the patient’s agent (i.e., FDA does not intend to exercise enforcement discretion) in the following situations:"
    },
    {
        "instruction":"已知信息：\n'如果采用定量测定， 应根据LOD和定量限（LOQ），确定检测法的灵敏度。'可被翻译为：The sensitivity of the assay should be determined in terms LOD and the limit of quantitation (LOQ), if using a quantitative assay.\n'1.测定方法可以是定性的或是定量的。'可被翻译为：1. Assay methods may be either quantal or quantitative.\n'应对用于测定脱落的至少一种测定法进行定量。'可被翻译为：• At least one of the assays used to measure shedding should be quantitative.\n'有多种不同方法可用于评价感染性或生长，这些测定法均可得出定量读数（参考文献3）。'可被翻译为：• There are many different approaches to assess infectivity or growth with assays that have a quantitative read-out (Ref. 3).\n\n根据上述已知信息，请将'通常会采用显示定量读数的测定法，例如定量聚合酶链式反应（qPCR），因为易于开展测定\/实施标准化、工作通量较高、周转时间较快以及测定灵敏度极佳。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Often an assay with a quantitative readout, like quantitative polymerase chain reaction (qPCR), is used because of the ease of performing\/standardizing the assay, high throughput format, rapid turnaround time, and assay sensitivity."
    },
    {
        "instruction":"已知信息：\n'9.3.2 排除标准 应明确研究的排除标准，并说明理由（例如，安全性问 题，管理问题或不适于试验）。'可被翻译为：9.3.2 Exclusion Criteria The criteria for exclusion at entry into the study should be specified and the rationale (e.g., safety concerns, administrative reasons or lack of suitability for the trial) provided.\n'描述被排除在PP 人群之外的受试者及其排除原因的个例报告应包含在研究报告中。'可被翻译为：Individual case reports describing subjects who were excluded from the PP population, and the reasons for their exclusion, should be included in the study report.\n'治疗性研究的排除标准'可被翻译为：Exclusion criteria for the therapeutic studies\n'鉴于研究结果对于未来目标人群的可适性，强烈建议不要将排除标准定义得太窄，即多病患者（例如肾和\/或肝损害、心力衰竭），不应被自动排除在主要治疗性临床试验之外。'可被翻译为：For reasons of generalisability of the study results to the future target population it is strongly advised not to define the exclusion criteria too narrow, i.e. polymorbid patients (e.g. renal and\/or hepatic impairment, heart failure), should not automatically be excluded from the main therapeutic clinical trials.\n\n根据上述已知信息，请将'应在研究报告第13章或安全 性和疗效概述中讨论排除标准对研究普适性的影响。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The impact of exclusions on the generalisability of the study should be discussed in section 13 of the study report, or in an overview of safety and efficacy."
    },
    {
        "instruction":"已知信息：\n'认为很有必要更新涉及的指导原则，调整内容以适应当前的科学知识并与EMA 关于抗血栓药物临床研究相关的新的或修订的指南内容相一致。'可被翻译为：An update of the mentioned guideline is considered necessary to adapt its content to current scientific knowledge and to harmonise it with the content of new or revised EMA guidelines related to clinical investigation with antithrombotics.\n'当前，上述 CHMP 指导原则的更新被认为是必要的，以便根据文献审查和所获得的急性期及之后治疗药物的经验将这些新的发展考虑进去。'可被翻译为：Currently, an update of the above mentioned CHMP Guidelines is considered necessary to take these new developments into consideration based on literature review and experience gained with medicinal products intended for treatment during the acute phase and beyond.\n'本指导原则包括药物基因组学和遗传药理学中关键术 语，即基因组生物标志物、药物基因组学、遗传药理学、基 因组数据和样本编码分类的定义。'可被翻译为：This guideline contains definitions of key terms in the discipline of pharmacogenomics and pharmacogenetics, namely genomic biomarkers, pharmacogenomics, pharmacogenetics and genomic data and sample coding categories.\n'2.2 药物基因组学和遗传药理学'可被翻译为：2.2 Pharmacogenomics and Pharmacogenetics\n\n根据上述已知信息，请将'由于药物基因组学和遗传药理学 中不断出现新的科学知识，因此必要时，本指导原则将被审核并做补充完善。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"As new scientific knowledge in the discipline of pharmacogenomics and pharmacogenetics emerges, the current guideline will be reviewed and expanded if appropriate."
    },
    {
        "instruction":"已知信息：\n'分子的一种振动形式。分子中两个化学键端的原子同时做反向垂直于平面方向的运动。'可被翻译为：A form of vibration in a molecule. Atoms at two chemically bonded ends of a molecule move simultaneously in opposite directions perpendicular to the plane.\n'键角发生规律性变化的分子振动形式。'可被翻译为：The molecular vibration form of the bond Angle changes regularly.\n'分子的一种振动形式。原子沿垂直于它的键轴方向的运动。可能有键角的变化。弯曲振动又分为面内弯曲振动及面外弯曲振动两种。'可被翻译为：A vibrational form of a molecule. The movement of an atom in a direction perpendicular to its bond axis. There may be a change in bond Angle. The bending vibration is divided into two kinds: in-plane bending vibration and out-of-plane bending vibration.\n'分子的一种振动形式。是化学键沿着键轴方向做规律性的伸与缩的运动。即键长有变化，键角无变化。'可被翻译为：A vibrational form of a molecule. The regular extension and contraction of a bond along its axis. That is, the bond length changes, but the bond Angle does not change.\n\n根据上述已知信息，请将'分子的一种振动形式。振动过程中两键间键角无变化，但相对于分子的其余部分做面内摇摆。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A form of vibration of a molecule. The bond Angle between the two bonds does not change during vibration, but oscillates in-plane with respect to the rest of the molecule."
    },
    {
        "instruction":"已知信息：\n'用户指导原则 根据该数据元素获取发送者的给定名。'可被翻译为：User Guidance This data element captures the sender’s given name.\n'用户指导原则 根据该数据元素获取报告者的姓氏。元素'可被翻译为：User Guidance This data element captures the reporter's family name.\n'用户指导原则 根据该数据元素获取发送者的职称。'可被翻译为：User Guidance This data element captures the sender’s title.\n'用户指导原则 根据该数据元素获取发送者所在城市。'可被翻译为：User Guidance This data element captures the sender's city.\n\n根据上述已知信息，请将'用户指导原则 根据该数据元素获取发送者的姓氏。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"User Guidance This data element captures sender's family name."
    },
    {
        "instruction":"已知信息：\n'同时，对临床急需的短缺药品、防治重大传染病和罕见病等疾病的新药、儿童用药品优先审评审批；对治疗严重危及生命且尚无有效治疗手段的疾病以及公共卫生方面急需的药品，可以附带条件批准上市。'可被翻译为：Meanwhile, DAL will give priority to the review and approval of short supplied new drugs and pediatric drugs catering to urgent clinical needs, drugs for the prevention of major infectious diseases and rare diseases;as well as to conditioned marketing approval for drugs against diseases that are seriouslylife-threatening and have no proven effective treatment, and drugs urgently needed for public health.\n'（一）治疗严重危及生命且尚无有效治疗手段的疾病的药品，药物临床试验已有数据证实疗效并能预测其临床价值的；'可被翻译为：(1) Drugs used for treating serious life-threatening diseases for which no effective treatment is available, whose efficacy has been verified by data in drug clinical trials and whose clinical values can be predicted;\n'第九十六条 国家鼓励短缺药品的研制和生产，对临床急需的短缺药品、防治重大传染病和罕见病等疾病的新药予以优先审评审批。'可被翻译为：Article 96 The State encourages the research, development, and manufacture of drugs in shortage, and implements priority review and approval for drugs in shortage in urgent clinical needs or new drugs for prevention and treatment of serious infectious diseases and rare diseases.\n'对于创新药、改良型新药以及生物制品等，应当进行药品注册生产现场核查和上市前药品生产质量管理规范检查。'可被翻译为：Drug registration inspection of the manufacturing site and pre-marketing GMP inspection shall be carried out for innovative drugs, modified new drugs and biological products, etc.\n\n根据上述已知信息，请将'（一）临床急需的短缺药品、防治重大传染病和罕见病等疾病的创新药和改良型新药；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(1) Drugs with urgent clinical needs in shortage, innovative drugs and modified new drugs for the prevention and treatment of major infectious diseases or rare diseases;"
    },
    {
        "instruction":"已知信息：\n'例如，涉及对法规和法令的解释或现有FDA政策对新情况的应用的问题通常是复杂的（并不简单），因此需要额外的审评和回复时间。'可被翻译为：For example, questions that involve interpretation of regulations and statutes, or application of existing FDA policy to novel circumstances, are often complex (not simple) and therefore demand additional vetting and response time.\n'复杂的科学\/技术药物开发问题应通过提案或通过正式会议请求过程直 接反映给FDA项目经理，通常是审评部门RPM。'可被翻译为：• Complex scientific\/technical drug development questions should be directed to the FDA project manager, typically the review division RPM, via either a submission or through the formal meeting request process.\n'该确认回执可能包括：回复本身、估计的回复时间段、已经向具有未确定回复时间段的其他办公室\/中心咨询问题的通知、对经由正式会议请求提交的问题的建议、或者重新 寄给FDA的另一个专门功能领域（例如，导入\/导出）。'可被翻译为：The acknowledgment may include: the response itself, an estimated response time frame, notification that the question(s) have been consulted to other offices\/centers with an undetermined response time frame, a recommendation to submit the questions via a formal meeting request, or redirection to another specialized functional area in FDA (e.g., Import\/Export).\n'相反，应保留宝贵的会议时间，以便对会议文件包中确定的问题进行集中讨论，特别是在FDA将初步回复发送给申办方后仍未解决的问题或在FDA回复中提出的问题。'可被翻译为：Instead, valuable meeting time should be preserved for a focused discussion of issues identified in the meeting package, particularly those that are still unresolved after FDA’s preliminary responses have been sent to the sponsor or that have been raised in FDA’s responses.\n\n根据上述已知信息，请将'根据问题的性质和复杂性，FDA将对问题作出回复，或重新给申办方指定可接收回复的替代途径（例如，其他FDA 学科问题专家，正式会议请求过程）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Depending on the nature and complexity of the question(s), FDA will either respond to the question(s) or redirect the sponsor to an alternative pathway for receiving a response (e.g., other FDA subject matter expert, formal meeting request process)."
    },
    {
        "instruction":"已知信息：\n'药品生产'可被翻译为：pharmaceutical manufacturing\n'生产（例：制剂）'可被翻译为：Production (example: finished pharmaceutical product)\n'用于盛装和保护制剂的包装总和，包括内包装和次级包装，次级包装是为了给制剂提供进一步的保护。'可被翻译为：The sum of packaging components that together contain and protect the dosage form. This includes primary packaging components and secondary packaging components, if the latter are intended to provide additional protection to the drug product.\n'用于盛装和保护制剂的包装总和，包括内包装和次级包装，次级包装是为了给制剂提供进一步的保护。一个包装系统与一个包装容器系统相当。'可被翻译为：The sum of packaging components that together contain and protect the dosage form. This includes primary packaging components and secondary packaging components, if the latter are intended to provide additional protection to the drug product. A packaging system is equivalent to a container closure system.\n\n根据上述已知信息，请将'制剂生产产地（包括测试、初级和次级包装、药 械组合产品的器械组装）'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Drug Product Manufacturing sites (including those for testing, primary and secondary packaging, device assembly for drug product-device combination products"
    },
    {
        "instruction":"已知信息：\n'3.安全有效性数据不充分'可被翻译为：3. Insufficient data of safety and effectiveness\n'B. 支持儿科适应症安全性和有效性的证据不充足'可被翻译为：B. Insufficient Evidence to Support Safety and Effectiveness for a Pediatric Indication\n'1. 有效性的充足证据和支持安全性的充足证据'可被翻译为：1. Substantial Evidence of Effectiveness and Sufficient Evidence to Support Safety\n'A. 支持儿科适应症安全性和有效性的证据充足'可被翻译为：A. Sufficient Evidence to Support Safety and Effectiveness for a Pediatric Indication\n\n根据上述已知信息，请将'2. 支持安全性和有效性的证据不充足'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2. Insufficient Evidence to Support Safety and Effectiveness"
    },
    {
        "instruction":"已知信息：\n'尽管该章节的重点强调的是将自然史研究用作关键背景信息，但是在临床研发过程中此类研究仍然继续以评价新的测量手段和结局指标在未来治疗试验中的适用性。 可以前瞻性地或回顾性地采集自然史研究的数据，但是前瞻性的纵向自然史研究更有可能生成最有用的疾病信息。'可被翻译为：Although the emphasis in this section is on the use of natural history studies as critical background information, such studies may be continued during clinical development to assess the suitability of new measurement tools and outcome measures for use in future treatment trials. The data for natural history studies can be collected prospectively or retrospectively, but prospective longitudinal natural history studies are likely to generate the most useful information about a disease.\n'正如其它的TEAEs一样，纵向分析（包括剂量 调整的影响）和时间依赖性分析可能是有价值的。'可被翻译为：As with other TEAEs, longitudinal analysis, including impact of dose adjustments, and time-dependent analyses may be of value.\n'尽管有历史对照的研究已经应用在罕见病临床研发计划中，但是在许多情形下，历史对照不适用于充分的和良好对照的研究。'可被翻译为：While studies with historical controls have been used in clinical development programs of rare diseases, historical controls may be unsuitable for adequate and well-controlled studies in many circumstances.\n'历史对照数据和实验室经验有限'可被翻译为：Limited historical control data and laboratory experience\n\n根据上述已知信息，请将'纵向研究表征了个体的病程，并且能够更好地区分不同表型。 对于在临床试验中接受治疗的患者，将自然史数据用作历史对照通常是有意义的，但是使用历史对照所面临的挑战也已经为人们所熟知。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Longitudinal studies characterize the course of disease within individuals and better enable different phenotypes to be distinguished. The potential use of natural history data as a historical comparator for patients treated in a clinical trial is often of interest but the challenges associated with the use of historical controls are well recognized."
    },
    {
        "instruction":"已知信息：\n'用压力大于常压的饱和水蒸气加热杀灭微生物的方法。'可被翻译为：Method of killing microorganisms by heating saturated steam with pressure greater than normal pressure.\n'用火焰或干热空气进行灭菌的方法。'可被翻译为：Method of sterilization by flame or dry hot air.\n'应始终说明灭菌周期的方法（例如，饱和蒸汽周期、空气\/蒸汽过压周期、真空阶段）、压力、时间和温度以及生物负荷限度。'可被翻译为：Method (e.g. saturated steam cycle, 133 air\/steam-overpressure cycle, vacuum phase), pressure, time and temperature of the sterilisation cycle 134 and a bioburden limit should always be stated.\n'在线蒸汽灭菌'可被翻译为：Steam in place\n\n根据上述已知信息，请将'在饱和蒸汽、沸水或流通蒸汽中进行灭菌的方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Method of sterilization in saturated steam, boiling water, or circulating steam."
    },
    {
        "instruction":"已知信息：\n'统一的标准应该刺激供应商为标准本身开发互相通用的“现成”工具。'可被翻译为：A harmonised standard should stimulate vendors to develop ‘off-the-shelf’ tools that are interoperable due to the standard itself.\n'关系图、属性列表、数字代码和受限的ICH ICSR模式的开发，均为开发软件规范的过程的组成部分，用于促进ICSR的电子传输。'可被翻译为：The development of relational diagrams, attribute lists, numeric codes, and a constrained ICH ICSR schema are all parts of the process of developing the software specifications to facilitate electronic transmission of ICSRs.\n'欲了解更多关于 HL7 V3 的信息，请参见 Andrew Hinchley 的“了解版本 3：HL7 版本 3医疗互通性标准-规范版入门”。'可被翻译为：To learn more about HL7 V3, refer to ‘Understanding Version 3: A primer on the HL7 Version 3 Healthcare Interoperability Standard – Normative Edition,’ by Andrew Hinchley.\n'HL7 模型驱动的方法可用于制定基于共识的标准，用于医疗保健系统互通性和信息交换。 HL7 V3 信息是基于 XML 编码语法。'可被翻译为：The HL7 model-driven methodology is used to develop consensus-based standards for healthcare system interoperability and information exchange.HL7 V3 messages are based on an XML encoding syntax.\n\n根据上述已知信息，请将'元素 HL7 V3支持开发有助于系统间互通性的规范。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"HL7 V3 supports development of specifications that facilitate interoperability between systems."
    },
    {
        "instruction":"已知信息：\n'第二十七条  医疗器械注册人、备案人在其住所或者生产地址销售其注册、备案的医疗器械，无需办理医疗器械经营许可或者备案，但应当符合规定的经营条件；在其他场所贮存并销售医疗器械的，应当按照规定办理医疗器械经营许可或者备案。'可被翻译为：Article 27 If the registrant or filing entity of medical devices sells its registered and filed medical devices at its domicile or manufacturing address, it does not need to apply for Medical Device Distribution License or filing, but shall meet the prescribed distribution conditions; if it stores and sells the medical devices in other places, it shall apply for Medical Device Distribution License or filing as stipulated.\n'第三十六条  医疗器械注册人、备案人委托销售的，应当委托符合条件的医疗器械经营企业，并签订委托协议，明确双方的权利和义务。'可被翻译为：Article 36 If the registrant or filing entity of the medical devices entrusts the sale to other entities, they shall entrust the sale to medical device distributors conforming to conditions, and sign an entrustment agreement, specifying rights and obligations of both parties.\n'第五条 药品生产、经营企业对其药品购销行为负责，对其销售人员或设立的办事机构以本企业名义从事的药品购销行为承担法律责任。'可被翻译为：Article 5 Drug manufacturers or distributors shall be responsible for their drug purchases and sales, and liable for the purchases and sales activities of their sales staff or offices in the name of their enterprise.\n'第七条 药品生产、经营企业应当加强对药品销售人员的管理，并对其销售行为作出具体规定。'可被翻译为：Article 7 Drug manufacturers or distributors shall strengthen the management of the sales staff and set up specific rules for their sales behaviors.\n\n根据上述已知信息，请将'第三十七条  医疗器械注册人、备案人和经营企业应当加强对销售人员的培训和管理，对销售人员以本企业名义从事的医疗器械购销行为承担法律责任。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 37 The registrant, filing entity and distributor of the medical devices shall strengthen training and management of the sales personnel, and assume legal liabilities for purchase or sale of medical devices of the sales personnel in the name of the enterprise."
    },
    {
        "instruction":"已知信息：\n'经过所有生产阶段的产品，包括最终容器的包装和标签。药品成品可能含有一种或多种原料药。在某些情况下，它可能与医疗器械结合使用。'可被翻译为：A product that has undergone all stages of production, including packaging in its ﬁnal container and labelling. A finished pharmaceutical product may contain one or more APIs. In some cases, it may be in combination with a medical device.\n'药品生产过程中涉及的所有操作，包括加工、配制、配方、灌装、包装和标签。'可被翻译为：All operations involved in the production of a drug, including processing, compounding, formulating, filling, packaging, and labelling.\n'1.药物起始原料是一种活性药物成分(API)或赋形剂，预定或指定用于药品生产。\n2.在药品生产中使用的具有一定质量的物质，但不包括包装材料。这包括活性药物成分(api)和药用辅料。'可被翻译为：1.A pharmaceutical starting material is an active pharmaceutical ingredient (API) or an excipient intended or designated for use in the production of a pharmaceutical product.\n2.Any substance of a defined quality used in the production of a pharmaceutical product, but excluding packaging materials. This includes active pharmaceutical ingredients (APIs) and pharmaceutical excipients.\n'1.用于表示起始原料(活性药物成分和赋形剂)、试剂、溶剂、工艺助剂、中间体、包装材料和标签材料的总称。\n2.用于表示原材料(起始原料、试剂、溶剂)、工艺助剂、中间体、原料药以及包装和标签材料的通用术语。\n3.用于表示起始原料、工艺助剂、中间体、活性药物成分、包装和标签材料的术语。'可被翻译为：1.A general term used to denote starting materials (active pharmaceutical ingredients and excipients), reagents, solvents, process aids, intermediates, packaging materials and labelling materials.\n2.A general term used to denote raw materials (starting materials, reagents, solvents), process aids, intermediates, APIs and packaging and labelling materials.\n3.A term used to denote starting materials, process aids, intermediates, active pharmaceutical ingredients, packaging and labelling materials.\n\n根据上述已知信息，请将'所有与药学相关的产品，包括起始原料(活性药物成分和赋形剂)、成品剂型、生物制品和其他特定产品。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"All products related to pharmacy, including starting materials (active pharmaceutical ingredients and excipients), finished dosage forms, and biological and other specific products."
    },
    {
        "instruction":"已知信息：\n'14.10 不符合既定质量标准的中间体和原料药应进行标识并隔离。这些中间体或原料药可按以下要求进行返工或重新加工，不合格物料的最终处置应有记录。'可被翻译为：14.10 Intermediates and APIs failing to meet established specifications should be identified as such and quarantined. These intermediates or APIs can be reprocessed or reworked as described below. The final disposition of rejected materials should be recorded.\n'不合格、退货或召回的物料或产品应当隔离存放。'可被翻译为：Segregation should be provided for the storage of rejected, recalled or returned materials or products.\n'14.52 应当保存中间体或原料药退货记录。每次的退货记录应当包括： \n- 收货方的名称和地址； \n-退回中间体或原料药的批号、数量； \n-退货原因； \n- 退回中间体或原料药的使用或处置。'可被翻译为：14.52 Records of returned intermediates or APIs should be maintained. For each return, documentation should include: \n− Name and address of the consignee \n− Intermediate or API, batch number, and quantity returned \n− Reason for return \n− Use or disposal of the returned intermediate or API\n'14.51 退回的中间体或原料药在其退回之前、或者运输途中的贮存条件或其包装状况使其质量值得怀疑时，应当视情形对退回的中间体或原料药进行返工、重新加工或销毁。'可被翻译为：14.51 If the conditions under which returned intermediates or APIs have been stored or shipped before or during their return or the condition of their containers casts doubt on their quality, the returned intermediates or APIs should be reprocessed, reworked, or destroyed, as appropriate.\n\n根据上述已知信息，请将'14.50 应当对退回的中间体或原料药进行标识并隔离。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"14.50 Returned intermediates or APIs should be identified as such and quarantined."
    },
    {
        "instruction":"已知信息：\n'第一百零六条 信息中心负责建立药品品种档案，对药品实行编码管理，汇集药品注册申报、临床试验期间安全性相关报告、审评、核查、检验、审批以及药品上市后变更的审批、备案、报告等信息，并持续更新。药品品种档案和编码管理的相关制度，由信息中心制定公布。'可被翻译为：Article 106 The NMPAIC is responsible for establishing drug product master file, managing the drug coding system, collecting and continually updating information on drug registration applications, safety-related reports during clinical trials, review, inspection, testing, approval, as well as approval, filing and report for post-marketing changes, etc. Relevant regulations on drug product master file and code-based management shall be formulated and published by the NMPAIC.\n'对外信息办公室，药物信息部\n药物评估和研究中心\n食品药品监督管理局'可被翻译为：Office of Communications, Division of Drug Information\nCenter for Drug Evaluation and Research\nFood and Drug Administration\n'第十条 国家药品监督管理局加强信息化建设，为注册人、备案人提供便利化服务。'可被翻译为：Article 10 The NMPA shall strengthen informatization to provide convenient services for registrants and filing persons.\n'第七条 国家药品监督管理局加强信息化建设，为公众查询化妆品信息提供便利化服务。'可被翻译为：Article 7 The NMPA shall enhance informatization construction, to provide convenient services for the public in inquiring information on cosmetics.\n\n根据上述已知信息，请将'国家药品监督管理局信息中心负责药品追溯协同服务平台、药品安全信用档案建设和管理，对药品生产场地进行统一编码。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The Information Center of NMPA is responsible for the construction and management of the drug traceability coordination service platform and drug safety credit archives, and is in charge of the unified coding of drug manufacture sites."
    },
    {
        "instruction":"已知信息：\n'第二十条 关键人员应当为企业的全职人员，至少应当包括企业负责人、生产管理负责人、质量管理负责人和质量受权人。'可被翻译为：Article 20 Key posts should be occupied by full-time personnel, which should at least include the heads of the manufacturer, production management, quality management, and the Qualified Person.\n'第二十一条 企业负责人'可被翻译为：Article 21 The head of the manufacturer\n'质量管理负责人和生产管理负责人不得互相兼任。质量管理负责人和质量受权人可以兼任。应当制定操作规程确保质量受权人独立履行职责，不受企业负责人和其他人员的干扰。'可被翻译为：The heads of production and quality management must be independent from each other. The head of the quality management and the Qualified Person can be the same person. Procedures should be established to ensure the independence of the Qualified Person for fulfilling responsibilities, without interference from the head of the manufacturer or other personnel.\n'（七）生产管理负责人、质量管理负责人、质量受权人等关键人员变动情况的说明；'可被翻译为：(VII)  Description of the changes in the key personnel including the production management person, quality management person, and qualified person;\n\n根据上述已知信息，请将'第二十条 关键人员应当为企业的全职人员，至少应当包括 企业负责人、生产管理负责人、质量管理负责人和质量受权人。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 20: Key posts should be occupied by full-time personnel, which should at least include the heads of the manufacturer, production management, quality management, and the Qualified Person."
    },
    {
        "instruction":"已知信息：\n'建议由独立的裁定委员会进行盲态审查。'可被翻译为：A blinded review by an independent adjudicating committee is recommended.\n'如果不可行，则必需由行业专家组成的独立评估委员会对主要终点（有效性和安全性）进行盲态评估。'可被翻译为：If this is not feasible, blind evaluation of the main endpoints (efficacy and safety) by independent adjudication committees comprised of experts in the field is mandatory.\n'终点应由一个盲态委员会进行集中评判。'可被翻译为：Endpoints should be centrally adjudicated by a blinded committee.\n'应由独立且盲态的委员会判定所有次要疗效终点，以限制任何偏差的引入。'可被翻译为：All secondary efficacy endpoints should be adjudicated by an independent and blinded committee in order to limit the introduction of any bias.\n\n根据上述已知信息，请将'推荐由一个独立裁定委员会进行主要有效性和安全性结局的盲态评估（见第 4.3.4.4.节“主要终点的选择”）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"It is recommended that the assessment of the main efficacy and safety outcomes is performed blind by an independent adjudicating committee (see section 4.3.4.4. “Selection of the primary endpoints”)."
    },
    {
        "instruction":"已知信息：\n'22 2003 年 11 月 粒度文件：章节标题和编号、文档位置\/层级结构，文档分页 CTD规定了许多的章节标题和数字。 可以提供这些文档所有模块的关于文件位置标题和章节标题 的指导意见吗？ 还可以同时给出关于 CTD 和 eCTD 中多个文档可以位于层级结构中何处吗？作为这一定义的结果，可以指导如何分页文件，以及该模块目录应包括哪些内容？ 请参阅通用技术文档组织的附件：“颗粒度文件”。'可被翻译为：22 Nov. 2003 Granularity: section headings and numbers, documents location\/hierarchy, documents pagination The CTD specifies many section headings and numbers. Could guidance be provided for all modules on headings in relation to document location and the section headings within those documents? Could guidance also be provided on where in the CTD and eCTD multiple documents can be located in the hierarchy? As a consequence of this definition could guidance be given on how documents should be paginated and on what the module Table of Contents should therefore include? Please refer to the Annex of the Organisation of the Common Technical Document: \"Granularity Document\".\n'附件：粒度文件 CTD规定了很多章节的标题和编号。'可被翻译为：ANNEX : Granularity Document The CTD specifies many section headings and numbers.\n'是否可以为所有模块文件内与文件位置相关的标题及各章节的标题提供指导？\n是否也可以为CTD和eCTD文件中的哪些地方可以按层级排序提供指导？ \n根据该定义的结果，是否也能够为文件应如何编制页码提供指导，以及应纳入什么样的模块目录表？'可被翻译为：Could guidance be provided for all modules on headings in relation to document location and the section headings within those documents? \nCould guidance also be provided on where in the CTD and eCTD multiple documents can be located in the hierarchy? \nAs a consequence of this definition could guidance be given on how documents should be paginated and on what the module Table of Contents should therefore include?\n'3 \n2002年 9月 \n章节编号\/标题（模块5中） \n在CTD的模块5中，是否有必要在特定章节中注明每个 临床研究报告的章节编号，是否仅注明标题就已经足够： \n5.3.5 有效性报告...... \n5.3.5.1 研究报告...... \n5.3.5.1.1 安慰剂对照......'可被翻译为：3 \nSept 2002 \nSection Numbering\/Title (in Module 5) \nIn the module 5 of the CTD, is it necessary to have a section number for each clinical study report in a certain section, or is it enough just to mention the title: \n5.3.5 Reports of Efficacy... \n5.3.5.1 Study Reports.... \n5.3.5.1.1 Placebo Controlled....\n\n根据上述已知信息，请将'15 2003 年 7 月 CTD 中定义的术语“章节”是什么？ 模块 2 和 3 中的术语是否 有不同的用途？ ICH 的区域定义的章节是否是有差异的？ CTD 中的每个章节由一个数字和一个标题确定。请参阅“粒度文件附件”，查看每个章节中提供的说明文件。附件描述每个标题可能提供多个文件的情况。另外，当每个标题应提供一个或多个文件时参考章节指南。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"15 July 2003 Is the term, “section”, defined in the CTD? Is there a different use of the term in Module 2 and 3? Do the ICH regions define sections differently? Each section in the CTD is identified by a number and a heading Please refer to the Granularity Document Annex for a description documents to be provided in each section. The annex delineates when multiple documents per heading may be provided. Also, refer to regional guidance as to when one or multiple documents should be provided per heading."
    },
    {
        "instruction":"已知信息：\n'（一）应完整保存实验系统可追溯的接收、分组、给药、检测、处置等记录，并确保与申报资料一致。如：'可被翻译为：(1) Records of receipt, grouping designation, administration, testing and evaluation, and disposal of test system should be retained completely and traceably, and should be consistent with those in the application dossiers. For example:\n'（二）应完整保存可追溯的受试物和对照品的接收、配制、分析(如均一性、浓度、稳定性等)、使用、返还等记录，并与申报资料一致。如：'可被翻译为：(2) Records of receipt, formulating, analysis (such as homogeneity, concentration, stability, etc.), use and return of the test\/control articles should be retained completely and traceably and should be consistent with those in the application dossiers. For example:\n'（四）实验动物接收、检疫、使用、处理等应保存完整记录且数量吻合，并与申报资料相符；'可被翻译为：(4) Records of receipt, quarantine, use and disposal of laboratory animals should be retained completely, and the quantity shall be accountable and consistent with that specified in the application dossiers;\n'（三）应完整保存可追溯的生物样本(血液、尿液、组织 等)采集(时间等)、标识、处理、转运、交接、检测及保存等记录，并与申报资料一致。如：'可被翻译为：(3) Records of biological samples (such as blood, urine, tissue, etc.) on collection (such as collection time, etc.), labelling, processing, transfer, testing and storage should be retained in a complete and traceable manner and should be consistent with those in the application dossiers. For example:\n\n根据上述已知信息，请将'（二）实验系统的保存、取用、传代等应保存完整记录，且记录的时间、数量等信息应与申报资料相符。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(2) Records of storage, use, and passage, etc. of test system should be retained completely, and information such as time, quantity, and so forth in the records should be consistent with that specified in the application dossiers."
    },
    {
        "instruction":"已知信息：\n'在整个研 发过程中，新数据可能提示需要开展额外研究。'可被翻译为：Throughout development, new data may suggest the need for additional studies.\n'清除因子（由实验室或中试规模数据计算而来）数量级、杂质 引入点和对下游工艺清除点的理解，决定了是否需要中试\/商业批次数据。'可被翻译为：The need for data from pilot\/commercial batches is influenced by the magnitude of the purge factor calculated from laboratory or pilot scale data, point of entry of the impurity, and knowledge of downstream process purge points.\n'与采用方法3时一样，采用方法4时，如仅根据科学原理来进行论述是不够充分的，需提交分析数据来支持控制方法。提交的资料可包括：在下游化学反应中导致杂质结构改变的相关信息（去向）、中试批次的分析数据，某些情况下可提供实验室规模下加样研究结果。在这些情况下，证明该杂质的去向\/清除的论据的可靠性是至关重要的，它能够自始至终地保证最终原料药中杂质残留量超过可接受限度的可能性可以忽略。如果清除因子是根据研发数据得到的，须注意评估其规模依赖性或非依赖性。如果用于研发阶段的小规模模型被认为不能代表商业规模，则需要确认中试规模和\/或初始商业批次中所用的控制是适当的。根据由实验室或中试规模数据计算所得的清除因子大小、杂质引入步骤和对下游工艺清除工艺的理解，决定是否需要中试\/商业批次数据。'可被翻译为：For Option 4 approaches where justification based on scientific principles alone is not considered sufficient, as well as for Option 3 approaches, analytical data to support the control approach is expected. This could include as appropriate information on the structural changes to the impurity caused by downstream chemistry (“fate”), analytical data on pilot scale batches, and in some cases, laboratory scale studies with intentional addition of the impurity (“spiking studies”). In these cases, it is important to demonstrate that the fate\/purge argument for the impurity is robust and will consistently assure a negligible probability of an impurity residing in the final drug substance above the acceptable limit. Where the purge factor is based on developmental data, it is important to address the expected scale-dependence or independence. In the case that the small scale model used in the development stage is considered to not represent the commercial scale, confirmation of suitable control in pilot scale and\/or initial commercial batches is generally appropriate. The need for data from pilot\/commercial batches is influenced by the magnitude of the purge factor calculated from laboratory or pilot scale data, point of entry of the impurity, and knowledge of downstream process purge points.\n'初步表征包括剂量依赖性和时间依赖性的药代动力学特征。'可被翻译为：Initial characterisation of pharmacokinetics including dose and time-dependencies.\n\n根据上述已知信息，请将'如果清除因子是根据研发数据得到 的，一定要处理预期的规模依赖性或非依赖性。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Where the purge factor is based on developmental data, it is important to address the expected scale-dependence or independence."
    },
    {
        "instruction":"已知信息：\n'应使用上述WoE因素的综合分析来确定2年大鼠致癌性试验是否有助于人体致癌性风险评估。尽管所有因素都可能有助于综合分析，但每个因素的相对重要性将因所评估的化合物而异（图2）。'可被翻译为：An integrated analysis of the WoE factors described above should be used to determine whether or not a 2-year rat study would contribute to the human carcinogenic risk assessment. While all factors will contribute to the integrated analysis, the relative importance of each factor will vary depending on the compound being considered (Figure 2).\n'提供了一系列案例研究以说明WoE方法的应用。提供的这些案例仅用于说明目的，并非用作规范或表明支持WoE评估的数据充分程度。案例1和2是通过综合WoE关键因素得出2年大鼠试验不会为人体致癌性风险评估提供更多有价值的信息的结论。案例3描述了如何将WoE因素的数据进行整合，得出人体潜在致癌性尚不确定，2年大鼠致癌性试验将为人体致癌性风险评估提供更多有价值的信息的结论。案例4介绍了一个药物，尽管相同药理学类别中的其他化合物尚无可用数据，仍然得出了2年大鼠致癌性试验不会为人体致癌性风险评估贡献价值的结论。'可被翻译为：Case studies are provided to illustrate the application of the WoE approach. These cases are provided for illustrative purposes only and are not intended to be prescriptive nor to indicate the sufficiency of data to support a WoE assessment. Cases 1 and 2 are examples of pharmaceuticals for which the key WoE factors were integrated to conclude that a 2-year rat study would not add value to the assessment of human carcinogenic risk. Case 3 describes how data from the WoE factors were integrated to conclude that the carcinogenic potential for humans was uncertain, and a 2-year rat carcinogenicity study would add value to the assessment of human carcinogenic risk. Case 4 describes a pharmaceutical for which a 2-year rat carcinogenicity study was concluded to not contribute value to the assessment of human carcinogenic risk despite there being no data available for other compounds within the pharmacologic class.\n'2.2 综合WoE因素评估人体致癌性风险'可被翻译为：2.2 Integration of WoE Factors for Assessing Human Carcinogenic Risk\n'支持该风险评估的数据来源包括但不限于：'可被翻译为：The data that support this risk assessment can come from a number of sources that include, but are not limited to:\n\n根据上述已知信息，请将'WoE方法是基于对公开来源和相关药物开发研究中获得的与潜在致癌性相关的全部数据的综合评估。这些因素包括但不限于：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A WoE approach is based on a comprehensive assessment of the totality of data relevant to carcinogenic potential available from public sources and from relevant drug development studies. These factors include, but are not limited to:"
    },
    {
        "instruction":"已知信息：\n'（四）暂停、终止或者暂停后请求恢复临床试验；'可被翻译为：(4) Suspension, termination or request to recover the clinical trial suspended;\n'第三十一条 药物临床试验被责令暂停后，申办者拟继续开展药物临床试验的，应当在完成整改后提出恢复药物临床试验的补充申请，经审查同意后方可继续开展药物临床试验。药物临床试验暂停时间满三年且未申请并获准恢复药物临床试验的，该药物临床试验许可自行失效。'可被翻译为：Article 31 Where suspension of a drug clinical trial has been ordered and the sponsor plans to continue the drug clinical trial, a supplementary application for resuming the drug clinical trial shall be submitted after taking rectification actions, and the drug clinical trial may be continued after the application is reviewed and approved. Where a drug clinical trial has been suspended for three years and no application has been filed and approved for resumption of the drug clinical trial, the drug clinical trial permit shall cease to be valid automatically.\n'第二十七条 获准开展药物临床试验的药物拟增加适应症（或者功能主治）以及增加与其他药物联合用药的，申请人应当提出新的药物临床试验申请，经批准后方可开展新的药物临床试验。'可被翻译为：Article 27 For a drug approved for clinical trials, where an indication is to be added or the drug is to be used in combination with other drug(s), the applicant shall file a new drug clinical trial application to the CDE, and after approval shall the new drug clinical trial be conducted.\n'第三十二条 药物临床试验应当在批准后三年内实施。药物临床试验申请自获准之日起，三年内未有受试者签署知情同意书的，该药物临床试验许可自行失效。仍需实施药物临床试验的，应当重新申请。'可被翻译为：Article 32 A drug clinical trial shall be conducted within three years after approval. Where no subject has signed any informed consent form within three years since the date when the clinical trial application was approved, the drug clinical trial permit shall cease to be valid automatically. Where the sponsor plans to continue the drug clinical trial, a new drug clinical trial application shall be submitted.\n\n根据上述已知信息，请将'药物临床试验终止后，拟继续开展药物临床试验的，应当重新提出药物临床试验申请。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Where the sponsor plans to continue a drug clinical trial after it has been terminated, a new drug clinical trial application shall be submitted."
    },
    {
        "instruction":"已知信息：\n'骨吸收和形成的生化标志物应在骨质量研究中测量以提供关于骨转换的信息。'可被翻译为：Biochemical markers of bone resorption and formation should be measured in the bone quality studies to provide information on bone turnover.\n'应收集松质骨和皮质骨的pQCT数据。'可被翻译为：The pQCT data should be collected for both cancellous and cortical bone.\n'如果检测出软组织转移，需要根据RECIST标准评价治疗反应。但是，存在成骨细胞骨转移的前列腺癌不一定适合根据RECIST进行评估。因此，只要方案中预先定义了标准（例如PCWG2标准）来充分解决发作反应或者创伤的可能性，可以考虑将出现新的骨病灶作为疾病进展的一个标志。实际上，成功治疗的亚临床溶骨性骨病灶在恢复之前首先会出现成骨性反应。尤其是对于骨扫描，考虑到创伤和其它良性疾病（如骨质疏松性骨折）引起的骨吸收也是非常重要的。作为成骨细胞活性抑制剂的药物可能会干扰通过骨扫描评估疾病活动。'可被翻译为：The evaluation of response is performed according to RECIST criteria when soft-tissue metastases are detectable. However, prostate cancer is characterised by osteblastic bone metastases not always suitable to assessment according to RECIST. Therefore the occurrence of new bone lesions as a marker for progressive disease might be considered acceptable, provided that pre-specified criteria (an example being the PCWG2 criteria) adequately addressing the possibility of a flare reaction or trauma are defined in the protocol. Indeed, subclinical lytic bone lesion successfully treated may firstly responds with an osteoblastic reaction before restitution. Specifically for bone scan it is also of importance to consider uptake caused by trauma and other benign conditions such as osteoporotic fractures. Medicinal compounds acting as inhibitors of osteoblast activity may confound the assessment of disease activity by bone scans.\n'作为成骨细胞活性抑制剂的药物可能会干扰通过骨扫描评估疾病活动。'可被翻译为：Medicinal compounds acting as inhibitors of osteoblast activity may confound the assessment of disease activity by bone scans.\n\n根据上述已知信息，请将'尤其是对于骨扫描，考虑到创伤和其它良性疾病（如骨质疏松性骨折）引起的骨吸收也是非常重要的。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Specifically for bone scan it is also of importance to consider uptake caused by trauma and other benign conditions such as osteoporotic fractures."
    },
    {
        "instruction":"已知信息：\n'运用化学方法鉴别化合物。'可被翻译为：The identification of compounds by chemical methods.\n'特定的被测化学组分，包括原形药物、生物分子或其衍生物，或在生物基质中的代谢物。'可被翻译为：A specific chemical moiety being measured, including an intact drug, a biomolecule or its derivative or a metabolite in a biological matrix.\n'X 射线单晶衍射'可被翻译为：x-ray diffraction of single crystal\n'X 射线粉末衍射'可被翻译为：x-ray diffraction of powder\n\n根据上述已知信息，请将'对于化学全合成或半合成、微生物发酵以及从动、植物中提取的原料药，使用紫外可见吸收光谱、红外吸收光谱、核磁共振谱、质谱、比旋度、X射线单晶衍射或X射线粉末衍射、差示扫描量热法、热重等物理和化学方法，确证目标化合物结构的过程。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For chemical total synthesis or semi-synthesis, microbial fermentation and raw materials extracted from animals and plants, UV-visible absorption spectroscopy, infrared absorption spectroscopy, nuclear magnetic resonance spectroscopy, mass spectrometry, specific rotation, X-ray single crystal diffraction or X-ray powder diffraction, differential scanning calorimetry, thermogravimetric and other physical and chemical methods are used to confirm the process of the structure of the target compound."
    },
    {
        "instruction":"已知信息：\n'国际诞生日(IBD)'可被翻译为：international birth date (ibd)\n'4. 国际诞生日 # 批准日期 疑问 解答 4.1 2014年3月 当过渡到PBRER时，MAH如何处理 当前DLP与IBD的新定义不同步的药 品？ 指南中IBD的定义是指任何含有活性物质的任何产品在世界任何国家\/区域任何公司 的首次上市批准的日期。'可被翻译为：4.INTERNATIONAL BIRTH DATES # Date of Approval Questions Answers 4.1 March 2014 When transitioning to the PBRER, how should the MAH handle medicinal products whose current DLP is not synchronised to the new definition of the IBD? The definition of IBD in the Guideline refers to the date of the first marketing approval for any product containing the active substance granted to any company in any country in the world.\n'任何公司的任何含有活性物质的药品在世界上任何国家\/区域被首次批准上市销售的日期。'可被翻译为：The date of the first marketing authorisation for any product containing the active substance granted to any company in any country in the world.\n'2.8 定期和PBRER的数据锁定点 2.8.1 国际诞生日和数据锁定点 每种药品都应具有IBD：IBD是指任何公司的任何含有活性物质的药品在 世界上任何国家\/区域被首次批准上市销售的日期。'可被翻译为：2.8 Periodicity and PBRER Data Lock Point 2.8.1 International Birth Date and Data Lock Point Each medicinal product should have an IBD: the IBD is the date of the first marketing approval for any product containing the active substance granted to any company in any country in the world.\n\n根据上述已知信息，请将'国际诞生日(IBD) ICH指导原 则E2C 任何公司的任何含有活性物质的药品在世界上任何 国家\/区域被首次批准上市销售的日期。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"International Birth Date (IBD) ICH Guideline E2C The date of the first marketing authorisation for any product containing the active substance granted to any company in any country in the world. 9."
    },
    {
        "instruction":"已知信息：\n'如果阳性对照为历史数据，那时间-效应分析中应报告最小可 检测值，以提示递呈数据的变异度与历史数据一致。'可被翻译为：If historical positive controls are used, then the variance of the present data should be consistent with that seen historically, which can be demonstrated by reporting minimal detectable differences with by time analysis.\n'应当根据以往的证据（从之前的试验中得到的数据）和\/或临床背景，提供已知的或预期的与主要结果变量之间的相关性的依据。'可被翻译为：Known or expected associations with the primary outcome variable should be justified on the basis of previous evidence (e.g. data from previous trials) and\/or on clinical grounds.\n'历史对照\/参考数据可用 于帮助数据阐释。'可被翻译为：Historical control\/reference data can be used to assist data interpretation.\n'历史对照数据和实验室经验有限'可被翻译为：Limited historical control data and laboratory experience\n\n根据上述已知信息，请将'如果利用历史阳性对照 数据来证明试验灵敏度或根据历史对照数据计算统计学把握度，则当前数据的方 差应与历史数据保持一致。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"If historical positive control data are utilized to justify assay sensitivity or statistical power is calculated from historical control data, then the variance of the present data should be consistent with that seen historically."
    },
    {
        "instruction":"已知信息：\n'安全性评价应包括监测在重复输注新产品后的间隔内的短期和局部耐受性（血压、 心率、体温、监测其他不良事件、皮肤反应）。'可被翻译为：Safety evaluation should include monitoring of short term and local tolerance (blood pressure, heart rate, temperature, and monitoring of other adverse events, skin reactions) at repeated intervals following the infusion of the new product.\n'3.评价安全性所需的监测'可被翻译为：3. Need for Monitoring to Assess Safety\n'化合物重复给予后在相关光暴露组织的蓄积可能会增强光毒性反应，同样，化合物每次给予后重复光照射也会因累积损伤增强光毒性反应。'可被翻译为：Accumulation of compound in relevant light-exposed tissues after repeated administration might lead to an increased phototoxic response. Similarly, repeated irradiation after each dose might also lead to an increased phototoxic response due to the accumulation of damage.\n'IgG水平达到稳态后，需要按重复的时间间隔（约每周一次）给予一个维持剂量，使得累计月剂量达到约 0.4-0.8g\/kg。'可被翻译为：After steady state IgG levels have been attained, maintenance doses are administered at repeated intervals (approximately once per week) to reach a cumulative monthly dose of the order of 0.4-0.8 g\/kg.\n\n根据上述已知信息，请将'安全性评价应包括对重复给予新产品后在重复时间间隔的短期耐受性监测（血压、 心率、体温和其他相关参数的监测）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Safety evaluation should include monitoring of short term tolerance (blood pressure, heart rate, temperature, and monitoring of other relevant parameters) at repeated intervals following the administration of the new product."
    },
    {
        "instruction":"已知信息：\n'在体外通过稀释法或扩散法测定抗菌药物抑制或杀死细菌的能力。'可被翻译为：The ability of antibacterial agents to inhibit or kill bacteria is measured in vitro by dilution or diffusion.\n'利用药物在含有检定菌的琼脂平板上的扩散能力定量测定抗生素效价的方法。'可被翻译为：A method for quantifying the potency of an antibiotic using the ability of the drug to spread on an AGAR plate containing the tested bacteria.\n'抗生素效价测定是一个生物学方法，但抗生素的不同浓度要基于活菌才可以测定。对得 到的生物反应进行测量并基于中间标准【S3】和标准曲线【S1】、【S2】、【S3】和 【S5】进行评估。生物反应被称为秔生素活性或效价。抗生素效价取决于抑制微生物特 异性，采用优化条件下加入待测抗生素后，其对微生物生长的抑制性来表示。'可被翻译为：Antibiotic potency testing is a biological assay whereby varying concentrations of antibiotic are tested against a live microorganism. The resulting biological response is measured and evaluated against a median reference standard [S3] and standard curve [S1], [S2], [S4] and [S5]. The biological response is referred to as antibiotic activity or potency. Antibiotic potency is dependent upon antibiotic-microorganism specificity and is physically expressed by the inability of a microorganism to grow under optimal conditions in the presence of a specific test antibiotic.\n'将生长有待测菌株的琼脂块放置在含有检定菌的琼脂平板上测定其产生抗生素效价的方法。'可被翻译为：Method of determining the production of antibiotic titer by placing an AGAR block growing the strain to be tested on an AGAR plate containing the tested bacteria.\n\n根据上述已知信息，请将'将抗生素稀释成不同浓度抑制试验菌生长，测定其抗菌效果的方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The method of diluting antibiotics into different concentrations to inhibit the growth of test bacteria and determine its antibacterial effect."
    },
    {
        "instruction":"已知信息：\n'任何由两个或两个以上的氨基酸通过一个氨基酸的竣基与另一个氨基酸的氨基连接而成的自然界存在的或合成的化合物。一般将含50个氨基酸残基以下的这类化合物称为肽。'可被翻译为：Any naturally occurring or synthetic compound consisting of two or more amino acids joined by the carboxyl group of one amino acid to the amino group of another amino acid. Such compounds containing less than 50 amino acid residues are generally referred to as peptides.\n'由一个基因组，或一个细胞、组织表达的所有蛋白质。'可被翻译为：All the proteins expressed by a genome, or by a cell or tissue.\n'肽或蛋白质的具有游离的α-氨基末端。在表示氨基酸序列时，通常将氨基末端置于左侧。'可被翻译为：The free A-amino terminal of a peptide or protein. When representing an amino acid sequence, the amino terminal is usually placed on the left side.\n'肽或蛋白质的具有游离的α-羧基末端。在表示氨基酸序列时习惯上把竣基末端置于右侧。'可被翻译为：a peptide or protein having a free A-carboxyl terminal. It is customary to place the carboxyl terminal on the right side when representing an amino acid sequence.\n\n根据上述已知信息，请将'一种肽或蛋白质的组成，用构成它的氨基酸的相对量和种类来表示。通常以摩尔百分数表示。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The composition of a peptide or protein, expressed in terms of the relative amounts and types of amino acids of which it is composed. It is usually expressed in mole percent."
    },
    {
        "instruction":"已知信息：\n'确认工艺变化的潜在源头；'可被翻译为：Identify potential sources of process variability;\n'工艺知识和持续改进是变更的驱动因素。'可被翻译为：Process knowledge and continual improvement are drivers for change.\n'使用风险评估工具有助于识别可能影响测定和最终模型输出结果的变异度来源。'可被翻译为：Use of risk assessment tools can help to identify sources of variability with the potential to influence the measurements and resulting model outputs.\n'在整个产品生命周期内，它能促进工艺性能和产品质量的持续改进。'可被翻译为：It facilitates continual improvement of process performance and product quality throughout the product lifecycle.\n\n根据上述已知信息，请将'(d) 识别影响工艺性能和产品质量的变异的来源，以便进行潜在的持续改进活动来减少或控制变异；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(d) Identify sources of variation affecting process performance and product quality for potential continual improvement activities to reduce or control variation;"
    },
    {
        "instruction":"已知信息：\n'如果事件没有在研究者手册中列出，或没有被列为观察到特异性或严重性；或者，研究者手册不需要或不可用的情况下，与修订的当前申请中的一般研究计划或其它地方所描述的风险不一致，那么这个不良事件或可疑不良反应可以认为是“非预期的”。例如，根据这个定义，如果研究者手册只提到肝酶升高或肝炎，那么肝坏死就属于非预期的（更严重的后果）。同样，如果研究者手册只列出了脑血管意外，脑血栓栓塞和大脑血管炎就是非预期的（更高的特异性）。“非预期的”，如定义中所述的，也指在研究者手册提到的，与一类药品相关的或预期来自该药品的药理作用的，但是在研究中没有伴随该药品用药而发生的不良事件或可疑不良反应。'可被翻译为：An adverse event or suspected adverse reaction is considered “unexpected” if it is not listed in the investigator brochure or is not listed at the specificity or severity that has been observed; or, if an investigator brochure is not required or available, is not consistent with the risk information described in the general investigational plan or elsewhere in the current application, as amended. For example, under this definition, hepatic necrosis would be unexpected (by virtue of greater severity) if the investigator brochure referred only to elevated hepatic enzymes or hepatitis. Similarly, cerebral thromboembolism and cerebral vasculitis would be unexpected (by virtue of greater specificity) if the investigator brochure listed only cerebral vascular accidents. \"Unexpected,\" as used in this definition, also refers to adverse events or suspected adverse reactions that are mentioned in the investigator brochure as occurring with a class of drugs or as anticipated from the pharmacological properties of the drug, but are not specifically mentioned as occurring with the particular drug under investigation.\n'该定义完全依赖于研究中该药品的研究者手册（或者研究者手册不要求提供或不可获得的情况下，在一般研究计划中）所列的不良事件或可疑不良反应作为依据，以确定从临床试验或其它来源的报告中新获得的信息是否是属于非预期 。这意味着在研药品的研究者手册中没有列出的事件认为是“非预期的”而那些列出的认为是“预期的”。当收到新的不良事件信息，申办者有责任确定该事件用于IND安全性报告的递交是否是“非预期的”。在临床试验中，术语“预期的”使用有一些混乱，对于疾病治疗或研究人群，过去常被认为指“预测的”而不是“在研究者手册中列出的”。例如，一些不良事件可以预测会作为某疾病的结果而发生或者在老年人群中发生（例如，癌症试验中癌症相关死亡、中风或老年人群中急性心肌梗死）。然而，出于报告的目的，这些预测事件不是“预期的”因为他们没有在研究者手册中列出（例如，不会怀疑或肯定该受试药物导致了某些事件）。本文件 V.A.3 部分对监测和报告这类型预期事件有进一步的讨论。'可被翻译为：This definition relies entirely on the adverse events or suspected adverse reactions listed in the investigator brochure for the particular drug under investigation (or elsewhere in the general investigational plan if an investigator brochure is not required or available) as the basis for determining whether newly acquired information generated from clinical trials or reported from other sources is unexpected.6 This means that events not listed for the particular drug under investigation in the investigator brochure are considered “unexpected” and those listed are considered “expected.” When new adverse event information is received, it is the sponsor’s responsibility to determine whether the event is “unexpected” for IND safety reporting purposes. In the clinical trial setting, there has been some confusion with the term “expected” as it has been used to mean “anticipated” for the disease being treated or population being studied rather than “listed in the investigator brochure.” For example, some adverse events can be anticipated to occur as a result of a disease or in an older population (e.g., cancer-related deaths in a cancer trial, strokes or acute myocardial infarctions in an older population). However, for reporting purposes, these anticipated events are not “expected” because they are not listed in the investigator brochure (i.e., the test drug is not suspected or known to cause them). Monitoring and reporting these types of anticipated events are further discussed in section V.A.3 of this document.\n'●单一出现的罕见事件并已知与药物暴露密切相关（例如，血管性水肿、肝损伤、史蒂文斯-约翰逊综合征）'可被翻译为：·A single occurrence of an event that is uncommon and known to be strongly associated with drug exposure (e.g., angioedema, hepatic injury, Stevens-Johnson Syndrome)\n'关于临床风险信息，研究者手册应该特别和准确列出那些已经观察到的与研究用药物有关的不良事件，其与药物的因果关系是可疑的或确定的。此外，研究者手册应该列出常见的与一类药物有关的或根据药物药理学性质预测可发生的不良事件，警告研究者其发生的可能性，即使还未在药物研究中实际观察到。申办者应该对使用哪个术语准确反映特殊不良事件做出判断，包括综合征的名称（如适用）。研究者手册不应该列出不太可能由药物造成的不良事件，因为这样的列表可能稀释临床上有意义的风险信息的重要性。'可被翻译为：With respect to clinical risk information, the investigator brochure should specifically and accurately list those adverse events that have been observed with an investigational drug and for which a causal relationship with the drug is suspected or confirmed. In addition, the investigator brochure should list adverse events that commonly occur with the class of drugs or may be predicted to occur based on the pharmacological properties of the drug, even if not yet observed with the drug under investigation, to alert the investigator to the possibility of their occurrence. Sponsors should use judgment in determining which terms accurately reflect a particular adverse event, including syndrome names if applicable. The investigator brochure should not list adverse events that are unlikely to have been caused by the drug because such lists could dilute the importance of clinically meaningful risk information.\n\n根据上述已知信息，请将'研究者手册中列出的不良事件伴随同类药品用药出现的，或作为预期来自药品药理作用的，将认为是“非预期的”，直到在在研药品中观察到了这些不良事件为止。例如，尽管血管性水肿预计会发生在一些暴露于血管紧张素转化酶（ACE）抑制剂类的药品的患者中，而且作为伴随同类药品出现的血管性水肿将在研究者手册中进行描述，药物研究中观察到的一例血管性水肿应该认为是“非预期的”（用于报告的），直到其伴随研究用药物发生而将其列入研究者手册中为止。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Adverse events listed in the investigator brochure as occurring with members of the same class of drugs, or as anticipated from the pharmacological properties of the drug, would be considered unexpected until they have been observed with the drug under investigation. For example, although angioedema is anticipated to occur in some patients exposed to drugs in the angiotensin-converting enzyme (ACE) inhibitor class and angioedema would be described in the investigator brochure as a class effect, a case of angioedema observed with the drug under investigation should be considered unexpected for reporting purposes until it is included in the investigator brochure as occurring with the drug under investigation."
    },
    {
        "instruction":"已知信息：\n'检测中使用的试剂需要进行鉴定，必须符合验收质量标准，至少是最为重要的试剂必须符合标准。'可被翻译为：Reagents used in assays need to be qualified and acceptance specifications set, at least for those which are most important.\n'特殊情况下，在接收或使用前，还应当对试剂进 行鉴别或其他检验；'可被翻译为：In special cases, the laboratory reagents should be identified or tested upon reception or before use.\n'·病情鉴定为重度（例如，需要住院）的ABECB-COPD患者'可被翻译为：·Patients with ABECB-COPD characterized as severe (e.g., requiring hospitalization).\n'通过查找化合物库中光谱标准图谱确定化合物结构的一种检索方法。'可被翻译为：A search method for determining the structure of a compound by looking for a spectral standard pattern in a compound library.\n\n根据上述已知信息，请将'一种化合物必须符合特定标准，才能被鉴定为探针物质，例如'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"To qualify as a probe substance, a compound must fulfil certain criteria such as"
    },
    {
        "instruction":"已知信息：\n'仅用1支MCB或WCB来源的细胞进行测试就可以了。'可被翻译为：Testing cells derived from a single container is generally considered adequate.\n'但是，由于 其仅仅是示例，其中任何病毒的使用均无强制性规定，鼓励 生产商考虑其他病毒种类，特别是是对他们自身生产工艺更 适合的病毒。'可被翻译为：However, since these are merely examples, the use of any of the viruses in the table is not mandatory and manufacturers are invited to consider other viruses, especially those which may be more appropriate for their individual production processes.\n'通常对MCB作鉴别试验，而对每个WCB仅作有限的鉴别试验。'可被翻译为：Tests of identity are generally performed on the MCB. In addition, limited identity testing is generally performed on each WCB.\n'二级细胞库的概念，即主细胞库（MCB）传代产生工作细胞库(WCB)，通常被认为在连续生产产品时细胞基质供应的最实际方法。'可被翻译为：The concept of a two-tiered cell bank, in which the MCB which is used to generate Working Cell Banks (WCBs), is generally accepted as the most practical approach to providing a supply of cell substrate for continued manufacture of the product.\n\n根据上述已知信息，请将'如每年生产的产品仅需有限的几支细胞时，仅建有MCB而没有WCB的单级细胞库，原则上亦是允许的。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A single-tiered banking system consisting only of the MCB but no WCBs could be used in principle, for example, if relatively few containers were needed each year to produce the desired product."
    },
    {
        "instruction":"已知信息：\n'基因影响药物代谢动力学的可能性在I期研究中就应考虑在内。若体外研究数据不能排除已知的功能性多态酶的作用（即体外研究数据预测>50%的药物在体内通过单一的多态酶来清除），建议对首次人体试验人群中的相关基因进行基因分型，以避免发生基因相关性活性成分暴露量差异所带来的安全性问题。具有可能会导致活性成分暴露量显著升高的基因型受试者，若纳入首次人体试验，则建议使用低于广泛代谢者安全性剂量数倍的剂量。'可被翻译为：The possibility of genetic influence on the drug’s pharmacokinetics should be considered early in the Phase I program. When the in vitro data indicate that a relevant involvement of a known function polymorphic enzyme cannot be excluded (i.e., in vitro data predict >50% to be cleared by a single polymorphic enzyme in vivo), it is advised to genotype the first time substance exposure. Subjects with a genotype predicted to result in markedly increased exposure active substances should, preferably, only be allowed to enter in the first time in man study at dose several-fold lower than the doses expected to be safe in extensive metabolisers.\n'（i）药物代谢酶（细胞色素P450酶、（CYP）、II相酶），'可被翻译为：(i)drug-metabolising enzymes (cytochrome P450 enzymes, (CYPs), phase II enzymes),\n'人体药物代谢研究表明，ZB3579对细胞色素P450酶无作用，因 此ZB3579的临床药代动力学不太可能受到P450诱导剂或抑制剂的影响。'可被翻译为：Human drug metabolism studies indicate that ZB3579 has no effect on cytochrome P450 enzymes, such that the clinical pharmacokinetics of ZB3579 are unlikely to be affected by P450 inducers or inhibitors.\n'PM：弱代谢者'可被翻译为：PM: poor metaboliser\n\n根据上述已知信息，请将'有一定的新陈代谢能力的正常(野生型)情况，被称之为“广泛代谢者”(EM),而代谢的升高发生在“超速代谢者”(UM)中,通常是多个活动等位基因的结果; 低的新陈代谢发生在弱代谢者(PM)中，通常是基因突变或缺失所导致相应酶的活性降低或表达缺陷或功能丧失。30 - 50%的临床药物的代谢会受到功能多态酶的影响1,2，包括第一阶段细胞色素P450 酶(如CYP2C9、CYP2C19、CYP2D63酶)和第二阶段酶(如UDP-葡糖醛酸转移酶、N-乙酰化酶 2 和一些甲基转移酶)。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The normal (wild-type) situation with a certain metabolising capacity, is referred to as 'extensive metabolisers' (EM). Increased metabolism occurs in the 'ultrarapid metaboliser' (UM), and is usually the result of multiple active alleles; decreased metabolism occurs in the 'poor metaboliser' (PM), and is usually the result of mutations or gene deletions leading to reduced or abolished expression or function of the respective enzymes. 30-50% of all clinically used drugs are metabolized by functionally polymorphic enzymes 1,2, including Phase I cytochrome P450 enzymes (e.g., CYP2C9, CYP2C19 and CYP2D63), and phase II enzymes (e.g., UDP-glucuronosyltransferases, N-acetyltransferase-2 and some methyltransferases)."
    },
    {
        "instruction":"已知信息：\n'下述变更举例展示了产品和分析方法生命周期内可能发生的变更。'可被翻译为：The change described below is an example of one that could occur during the lifecycle of a product and analytical procedure.\n'对于两种新试验药物在不同情况中的联合应用，下列举例描述了可能的II期研究设计。'可被翻译为：The following scenarios illustrate possible phase 2 study designs for combinations of two new investigational drugs in different situations.\n'拟定变更的风险对于不同产 品应相似；根据此种方法应考量其他考虑，如： a. 一个或多个变更将在多个产品上实施（例如，使用相同包装系统的多个产品的胶塞变更）：相同的风险降低 策略应适用于所有受影响的产品； b.一个或多个变更将在多个产品和多个产地实施（例如，跨多个产地的分析方法变更、跨多个产品的产地变更）：相同的风险降低策略应适用于所有受影响的产品和\/或 产地（参见附件IE）。'可被翻译为：The risk of the proposed change(s) should be similar across products; additional considerations should be taken into account depending on the approach, for example: a. One or more changes to be implemented across multiple products (e.g., change in stopper across multiple products that use the same container closure system): the same risk mitigation strategy should be applicable across all impacted products; b. One or more changes to be implemented across multiple products and at multiple sites (e.g., change in analytical method across multiple sites, change in manufacturing site(s) across multiple products): the same risk mitigation strategy should be applicable across all impacted products and\/or sites (see Annex IE).\n'下面的第一个示例概述了单个产品的单个变更（单个产地变更）方案。'可被翻译为：The first example below outlines a protocol for a single change (a manufacturing site change) to a single product.\n\n根据上述已知信息，请将'第二个示例概述了可以为多个产品实施的多个变更（多个产地变更）方案。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The second example outlines a protocol for multiple changes (multiple manufacturing site changes) that could be implemented for multiple products."
    },
    {
        "instruction":"已知信息：\n'化学或生物材料可引发癌症发生的作用。'可被翻译为：The action of chemical or biological materials that can trigger the development of cancer.\n'通常在抗癌药物、抗癫痫药物以及抗心力衰竭药物的研 究中采用这类方法。'可被翻译为：It is common to study anticancer, antiepileptic, and heart failure drugs this way.\n'目前正在开发 一些化合物用于治疗阿片类药物引起的便秘38,39,40 ，所有这些药物是基于μ-阿片 受体外周拮抗剂。'可被翻译为：Several  compounds are currently under development for opioid-induced constipation 38, 39, 40, all of which  are based on peripheral antagonism to the µ-opioid receptor.\n'但是，由于活性差或有不利的安全性证据，仅有少数抗癌化合物完成了临床开发并获得了销售许可证。'可被翻译为：Only a minority, however, have completed the clinical development and obtained a marketing authorisation, due to poor activity or evidence of a detrimental safety profile.\n\n根据上述已知信息，请将'已经开发的和目前正在开发的抗癌化合物有很多。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A very large number of anti-cancer compounds have been and currently are under development."
    },
    {
        "instruction":"已知信息：\n'制造商的目标意图，例如，可以由标签声明，广告内容或者制造商或其代表口头的或书面的声明得到展示。'可被翻译为：A manufacturer’s objective intent may, for example, be shown by labeling claims, advertising matter, or oral or written statements by the manufacturer or its representatives.\n'制造商关于使用产品、工艺或服务的客观意图，反映在制造商提供的规格、说明书和信息中(18)。'可被翻译为：The objective intent of the manufacturer regarding the use of a product, process or service as reflected in the specifications, instructions and information provided by the manufacturer (18).\n'就制造商或其代表所知，HCT\/P可根据目的可不 做标签和广告，可能由其具体情况进行展示。'可被翻译为：It may be shown by the circumstances that the HCT\/P is, with the knowledge of the manufacturer or its representatives, offered for a purpose for which it is neither labeled nor advertised.\n'哮喘风险是由其严重程度决定的。'可被翻译为：The risk posed by asthma depends upon its severity.\n\n根据上述已知信息，请将'制造商的目的意图由制造商或其代表的表述决定，或可能由其相关文章分布情况 决定。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A manufacturer’s objective intent is determined by the expressions of the manufacturer or its representatives, or may be shown by the circumstances surrounding the distribution of the article."
    },
    {
        "instruction":"已知信息：\n'6.申报制剂中的原料药和辅料的标准和检验方法等资料。'可被翻译为：6.Specifications, test methods and other dossiers for APIs and excipients in the preparations applied.\n'应论述3.2.P.1中列出的辅料与原料药的相容性。此外，还应说明能影响制剂性能的原料药的关键理化性质（如，水分、溶解性、粒度分布、多晶型或固体形态等）。'可被翻译为：The compatibility of the drug substance with excipients listed in 3.2.P.1 should be discussed. Additionally, key physicochemical characteristics (e.g., water content, solubility, particle size distribution, polymorphic or solid state form) of the drug substance that can influence the performance of the drug product should be discussed.\n'应针对3.2.P.1中辅料种类的选择、用量的确定以及影响制剂性能特性的辅料性质 进行论述。'可被翻译为：The choice of excipients listed in 3.2.P.1, their concentration, their characteristics that can influence the drug product performance should be discussed relative to their respective functions.\n'制剂成品;它可能是冷冻干燥的，含有辅料，这些辅料应该被证明不会对稳定性产生不利影响。'可被翻译为：The finished formulated product; it may be freeze-dried and contain excipients, which should have been shown not to affect stability adversely.\n\n根据上述已知信息，请将'申报者应针对各种辅料的作用，详述其选择过程、配比以及可能影响制剂性能（如稳定性、生物利用度）或可生产性的特性。处方中应包括制剂生产中所用到的所有物质，不论其是否出现在成品中（如：工艺辅助剂）。必要时，应建立辅料之间的相容性（比如双重防腐系统中防腐剂的组合）。同时，应阐述辅料（如抗氧剂、渗透促进剂、崩解剂、控释剂）是否能实现预期的作用，是否能在预期的有效期内发挥作用。可能的情况下，可以利用有关辅料性能的资料，来论证辅料的选择和质量属性，并支持证明制剂质量标准的合理性 （3.2.P.5.6）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The excipients chosen, their concentration, and the characteristics that can influence the drug product performance (e.g., stability, bioavailability) or manufacturability should be discussed relative to the respective function of each excipient. This should include all substances used in the manufacture of the drug product, whether they appear in the finished product or not (e.g., processing aids). Compatibility of excipients with other excipients, where relevant (for example, combination of preservatives in a dual preservative system), should be established. The ability of excipients (e.g., antioxidants, penetration enhancers, disintegrants, release controlling agents) to provide their intended functionality, and to perform throughout the intended drug product shelf life, should also be demonstrated. The information on excipient performance can be used, as appropriate, to justify the choice and quality attributes of the excipient, and to support the justification of the drug product specification (3.2.P.5.6)."
    },
    {
        "instruction":"已知信息：\n'使用通用的（如 SF-36；SF-12）以及疾病特异性的工具（如 PAC-QOL） 评估生活质量'可被翻译为：Measurements of Quality of Life on generic (e.g. SF-36; SF-12) as well as disease specific instruments (e.g. PAC-QOL).\n'通用量表'可被翻译为：general instrument\n'生命质量（例如验证通用量表（SF-36），或疾病特定量表（AIMS）- 也可以考虑以下次要终点：'可被翻译为：Quality of Life (e.g. validated generic scales (SF-36), or disease specific scales (AIMS) The following secondary endpoints could also be considered:\n'包括最常使用的疲劳严重程度量表（FSS），它与包括8个量表的SF-36、FACIT疲劳量表或简易疲劳量表（BFI）有一定关联。'可被翻译为：including the fatigue severity scale (FSS) which is most commonly used and correlates moderately with the 8 scales of SF-36, the FACIT fatigue or the Brief Fatigue Inventory (BFI).\n\n根据上述已知信息，请将'通用量表（如SF-36、EQ5-D、健康效用指数[HUI]、疾病影 响程度测定量表[SIP]）（Bergner 1981）和特异性量表（如ALS评估问卷ALSAQ-40或ALSQ5）都是可用的，也可联合使用（如SIP\/ALS19）（McGuire 1997, Jenkinson 256 1999 and 2001, Bromberg 2001）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Both generic (e.g. SF-36, EQ5-D, the Health Utilities Index [HUI], Sickness Impact Profile [SIP]) (Bergner 1981) and specific scales, (e.g. ALS Assessment Questionnaires ALSAQ-40 or ALSQ5) are available which can be combined (e.g. SIP\/ALS19) (McGuire 1997; Jenkinson 1999 and 2001; Bromberg 2001)."
    },
    {
        "instruction":"已知信息：\n'因此， 应考虑与既存抗体间的潜在交叉反应性。'可被翻译为：Therefore, potential cross-reactivity with pre-existing antibodies should be considered.\n'既存抗体'可被翻译为：Pre-existing antibodies\n'可能影响治疗蛋白的免疫应答的患者相关因素包括遗传因素、患者年龄、疾病相关因素（包括其他治疗）以及因既往曾暴露于该产品或含结构相似性物质的产品而形成的既存抗体（蛋白治疗药-反应性抗体）；以及因工艺和产品相关杂质和辅料所致的患者致敏。'可被翻译为：Patient-related factors, which might influence the immune response to a therapeutic protein, include genetic factors, age of the patient, disease-related factors including other treatments, and pre-existing antibodies (protein therapeutic -reactive antibodies) due to previous exposure to the product or products containing substances with structural similarity; as well as sensitisation of patients due to process-and product-related impurities and excipients.\n'尽管对于既存抗体对生物制品安全性和\/或疗效的影响知之甚少，但是对于接受诸如抗凝血因子之类替代产品的患者，后果可能非常严重，如果既往抗体与新发现的蛋白产品发生交叉反应。'可被翻译为：While the impact of pre-existing antibodies on safety and\/or efficacy of biologics is poorly understood, consequences could be severe for e.g. patients receiving ‘replacement products’ like blood clotting factors, if the previous antibodies are cross-reacting with the newly introduced protein product.\n\n根据上述已知信息，请将'ii.交叉反应抗体，因既往曾接受相关物质治疗所致'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"ii. cross-reactive antibodies, e.g. due to previous therapy with related substances"
    },
    {
        "instruction":"已知信息：\n'国家药监局关于发布免于进行临床试验医疗器械目录（第二批修订）的通告'可被翻译为：NMPA Announcement on Issuing the Catalogue of Medical Devices Exempt from Clinical Trials (Revised Second Batch)\n'为贯彻实施《医疗器械监督管理条例》，国家药监局组织制定了《免于经营备案的第二类医疗器械产品目录》。于2021年6月28日予以公布。'可被翻译为：In order to implement the Regulations on the Supervision and Administration of Medical Devices, the NMPA organized to formulate the Catalogue of Distribution of Class II Medical Devices Exempted from Filing, which was issued on June 28，2021.\n'国家药监局已起草有关免于经营备案的第二类医疗器械产品目录，目前正在公开征求意见。产品目录发布后，按目录执行。'可被翻译为：NMPA has drafted a Catalogue of Class II Medical Devices Exempted from Distribution and Filing, for which public comments are currently solicited. After being issued, the Catalogue shall be executed.\n'第二十五条  对产品安全性、有效性不受流通过程影响的第二类医疗器械，可以免予经营备案。具体产品名录由国家药品监督管理局制定、调整并公布。'可被翻译为：Article 25 For those Class II medical devices of which product safety and effectiveness are not subject to influence of the circulation process, distribution filing may be exempted. The list of specific products shall be formulated, adjusted and announced by NMPA.\n\n根据上述已知信息，请将'国家药监局关于公布《免于经营备案的第二类医疗器械产品目录》的公告'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"NMPA Announcement on Issuing the Catalogue of Distribution of Class II Medical Devices Exempted from Filing"
    },
    {
        "instruction":"已知信息：\n'（五）受种者有疫苗说明书规定的接种禁忌，在接种前受种者或者其监护人未如实提供受种者的健康状况和接种禁忌等情况，接种后受种者原有疾病急性复发或者病情加重；'可被翻译为：(5) acute relapse of underlying diseases or worsening of disease conditions in vaccine recipients who have immunization contraindications prescribed on the vaccine package insert and who or whose guardian fails to provide truthful information about his\/her health condition and the contraindication for the vaccine prior to immunization;\n'既存抗体也可见于未曾接受治疗的患者。'可被翻译为：Pre-existing antibodies may also be found in treatment-naïve patients.\n'医疗卫生人员在实施接种前，应当按照预防接种工作规范的要求，检查受种者健康状况、核查接种禁忌，查对预防接种证，检查疫苗、注射器的外观、批号、有效期，核对受种者的姓名、年龄和疫苗的品名、规格、剂量、接种部位、接种途径，做到受种者、预防接种证和疫苗信息相一致，确认无误后方可实施接种。'可被翻译为：Before administering vaccines, medical and healthcare professionals shall, in accordance with the prescribed guidance for immunization, examine the vaccine recipient's health status, immunization contraindication, check the immunization certificate, examine the appearance, lot number and expiration date of the vaccine and syringe, and verify the recipient's name and age and the vaccine's name, specifications, dose, injection site and route of administration. Vaccine administration shall only take place after confirmation of information on the recipient, the immunization certificate and the vaccine to be administered.\n'第四十五条 医疗卫生人员实施接种，应当告知受种者或者其监护人所接种疫苗的品种、作用、禁忌、不良反应以及现场留观等注意事项，询问受种者的健康状况以及是否有接种禁忌等情况，并如实记录告知和询问情况。受种者或者其监护人应当如实提供受种者的健康状况和接种禁忌等情况。有接种禁忌不能接种的，医疗卫生人员应当向受种者或者其监护人提出医学建议，并如实记录提出医学建议情况。'可被翻译为：Article 45 Before administering vaccines, medical and healthcare professionals shall inform vaccine recipients or their guardian of the varieties, functions, contraindications, adverse reactions, stay for observation and other precautions of the vaccines to be administered, inquire the health condition of the vaccine recipients and whether they have any immunization contraindication, and truthfully record the informing and inquiry details. The vaccine recipients or their guardian shall truthfully provide information on the vaccine recipients' health condition and contraindication etc. Where a vaccine cannot be administered due to contraindications, the medical and healthcare professionals shall give medical advice to the vaccine recipients or their guardians and truthfully record such advice.\n\n根据上述已知信息，请将'（四）受种者在接种时正处于某种疾病的潜伏期或者前驱期，接种后偶合发病；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(4) coincidental events following immunization in recipients who were in the latent period or prodromal period of a certain disease at the time of immunization;"
    },
    {
        "instruction":"已知信息：\n'应评估取样装置，如移液器、注射器或自动化系统，以确保它们以足够的准确性和精密度抽取和替换受体溶液的样品量。'可被翻译为：Sampling devices, such as pipettes, syringes, or automated systems should be evaluated to ensure that they are withdrawing and replacing sample volumes of the receptor solution with sufficient accuracy and precision.\n'具有两个采样臂的池体通常通过替代进行采样。在样品时间点之前，停止所有搅拌。将替代受体溶液缓慢加入受体室以防止混合。受体溶液将样品从另一个采样臂中置换出来进行收集。样品收集好后，继续搅拌。通常，替代取样过程中需要一定的漂洗量，以确保当前样品不含有先前样品的残留物。这对自动化系统尤其重要'可被翻译为：Cells with two sampling arms are often sampled by displacement. Prior to the sample time point, all stirring is stopped. The replacement receptor solution is slowly added to the receptor compartment to prevent mixing. The receptor solution displaces the sample out the other sampling arm for collection. Once the sample is collected the stirring is resumed. Typically, a rinse volume is required in the process for displacement sampling to ensure that the current sample does not contain remnants of a previous sample. This is especially important for automated systems.\n'受体溶液既可以预热，也可以在扩散池体的受体室中平衡温度'可被翻译为：Receptor solution can either be preheated or allowed to equilibrate to temperature in the receptor compartments of the diffusion cells.\n'在IVRT开始运行之前，系统应在预定的实验条件下适当地平衡。在实验前或实验过程中，受体溶液(膜下)中不应出现气泡;如果合适，受体溶液可以脱气。系统温度(包括膜表面温度和循环水浴温度，如适用)应稳定且控制良好。IVRT膜在装配于扩散池之前可以用受体溶液预浸泡，或者在给药之前用扩散池内的受体溶液原位平衡(例如，在32°的膜温度下30分钟)，具体取决于方法。'可被翻译为：The system should be appropriately equilibrated under the predefined experimental conditions prior to the beginning of the IVRT run. No air bubbles should be present in the receptor solution (under the membrane) immediately prior to, or during the experiment; if appropriate, the receptor solution can be degassed. The system temperature (including the membrane surface temperature and the circulating water bath temperature, if applicable) should be stable and well controlled. IVRT membranes can be presoaked with receptor solution prior to assembling in the diffusion cell or equilibrated with the receptor solution in situ within the diffusion cell prior to dosing (e.g., for 30 min at a membrane temperature of 32°) depending upon the method.\n\n根据上述已知信息，请将'抽样取决于所使用的设备，在适当情况下应遵循制造商提供的说明。可以使用经过预热到与反应釜中受体温度一致的受体溶液，用于替代采样过程中去除的样品体积受体溶液，并且重要的是要确保在采样和在每个时间点重新填充受体溶液后膜下不存在气泡。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Sampling is dependent upon the equipment used and should follow instructions provided by the manufacturer, when appropriate. The receptor solution used to replace the volume removed during sampling may be pre-warmed to the temperature of the receptor solution in the receptor compartment, and it is important to ensure that air bubbles are not present beneath the membrane after sampling and refilling the receptor solution at each time point."
    },
    {
        "instruction":"已知信息：\n'** 可以用作DSUR的信息来源的PBRER章节。 *** 可以用作PBRER的数据来源的DSUR章节。'可被翻译为：** PBRER sections that could be used as an information source for the DSUR. *** DSUR sections that could be used as a data source for the PBRER.\n'指南的附录D列 出了可与其它法规文件共享的PBRER章节。'可被翻译为：Appendix D of the Guideline lists the PBRER sections that can be shared with other regulatory documents.\n'上一次更新：2014年3月31日 E2C（R2）疑问与解答  表1 PBRER与DSUR之间共享的内容 该表旨在补充附录D（可能与其它监管文件共享的PBRER章节列表），并列出了提出的共享章节。'可被翻译为：Last Update: 31 March 2014 E2C(R2)  Table 1 - Sharing Content between PBRER and DSUR This table is intended to supplement Appendix D (List of PBRER Sections that May be Shared with Other Regulatory Documents) and sets out the sections that were proposed to be common.\n'因此，本指导原则的制定，使得PBRER、 药物开发安全性更新报告（DSUR，ICH E2F）和风险管理计划（ICH E2E）的 安全性规范的相应章节内容可以相同（另见章节1.4，PBRER与其它ICH文件 的关系）。'可被翻译为：This Guideline has been developed, therefore, such that corresponding sections of the PBRER, Development Safety Update Report (DSUR, ICH E2F), and safety specification of a risk management plan (ICH E2E) can be identical in content. (See also Section 1.4, Relation of the PBRER to Other ICH Documents)\n\n根据上述已知信息，请将'此外，该表还标识了可被视为PBRER中相应章节的信息源的其它DSUR章节，反之亦然。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In addition, this table identifies additional DSUR sections that can be considered information sources for corresponding sections in the PBRER, or vice versa."
    },
    {
        "instruction":"已知信息：\n'该扩展的PACMP旨在支持生物技术产品原液生产场地转移的灵活性，即，将一个或多个产品从原场地转移到一个或多个新场地，包括CMO（该生产场地经检查后获得许可），进而减少相似内容的注册申报数量，并促进一致性。'可被翻译为：The primary objective of this expanded PACMP is to support the mobility across drug substance manufacturing sites, i.e., the transfer of one or multiple products from one donor site to one or more recipient site(s) including CMOs (sites already licensed with appropriate inspection record) thereby reducing the number of regulatory submissions of similar content and driving consistency.\n'对于小分子原料药的生产，新增产地应具有可接受的合规性状态；根据不同地区的情况，可能需要通过出具有效的GMP证书或其他适当的文件（例如质量授权人声明）证明其最近一次的GMP检查结果为可接受的。'可被翻译为：• Alternative manufacturing site to have acceptable compliance status for small molecule drug substance manufacturing; depending on the region, this may be indicated by the last GMP inspection with acceptable outcome, through a valid GMP certificate, or other appropriate documentation (e.g., Qualified Person declaration)\n'附件ID：PACMP示例1 小分子原料药新增产地 阶段1递交的提纲'可被翻译为：Annex ID: PACMP Example 1 Alternative manufacturing site for a small molecule drug substance Outline for Step 1 Submission\n'·固体口服制剂：'可被翻译为：Solid Oral Dosage Forms:\n\n根据上述已知信息，请将'该PACMP旨在允许为一个小分子固体口服制剂增加一个可选的原料药生产、检验和放行产地。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"This PACMP is intended to allow for the addition of an alternative manufacturing site for the manufacture, testing, and release of the drug substance for a small molecule solid oral drug product."
    },
    {
        "instruction":"已知信息：\n'使设计具备良好地接受新版本输入信息的能力。本概念适用于整个系统、数据通信、协议、文件格式和计算机编程语言。例如，如果按照旧标准设计的产品收、阅读、查看或播放新标准或格式（不包括新功能）下的信息，则认为该产品是具备“向上兼容性”的。'可被翻译为：The ability of the design to gracefully accept input intended for newer versions of itself. The concept can be applied to entire systems, data communications, protocols, file formats and computer programming languages. For example, if products designed for the older standard can receive, read, view or play the newer standard or format (excluding new functionality), then the product is said to be Forward Compatible.\n'向下兼容性'可被翻译为：backward (or downward) compatibility\n'该IG提供了必要的信息，以支持开发足够的信息工具（例如用于终端用户数据输入的表格及界面）以及设计样式表格、进行数据转换和编码格式良好的信息的技术要求。'可被翻译为：This IG provides the information necessary to support the development of adequate informatics tools (e.g. forms and interfaces for end user data entry) as well as technical requirements to design style sheets, conduct data transformations and code well-formed messages.\n'14 B. 安全源于设计： 防止用药错误的系统方法使最终用户倾向于用药错误的药品设计特征可能不总是通过产品标签或医疗保健提 供者或患者15教育克服。'可被翻译为：14 B. Safety by Design: A Systems Approach to Medication Error Prevention Drug product design features that predispose end users to medication errors may not always be overcome by product labeling or health care provider or patient15 education.\n\n根据上述已知信息，请将'使设计具备良好地接受旧版本输入信息的能力。本概念可用于整个系统、数据通信、协议、文件格式和计算机编程语言。例如，如果使用新标准设计的产品可以接收、阅读、查看或播放使用旧标准或格式设计的产品信息，那么就说该产品是向下兼容的。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The ability of the design to gracefully accept input created with older versions of itself. The concept can be applied to entire systems, data communications, protocols, file formats and computer programming languages. For example, if products designed for the new standard can receive, read, view or play older standards or formats, then the product is said to be Backward Compatible."
    },
    {
        "instruction":"已知信息：\n'定量下限（LLOQ）：使用预先定义其精密度和准确度的方法，使样品中的待测物可被定量测定的最低浓度。'可被翻译为：Lower Limit of Quantification (LLOQ): The lowest amount of an analyte in a sample that can be quantitatively determined using a method with predefined precision and accuracy.\n'某一分析方法的定量限度是指在合适的准确性和精密度下，能够定量测定样品中被分析物的最低量。它是样品中含量下，能够定量测定样品中被分析物的最低量。它是样品中含量低的化合物定量测定的参数，特别适用于杂质和\/或降解产物的测定。'可被翻译为：The quantitation limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be quantitatively determined with suitable precision and accuracy. The quantitation limit is a parameter of quantitative assays for low levels of compounds in sample matrices, and is used particularly for the determination of impurities and\/or degradation products.\n'一种独立分析方法的定量限是样品中某待测物能以适当的精密度和准确度被定量检出的最低量。定量限是一种针对样品中低含量物质定量分析的参数，特别用于杂质和\/或降解产物的测定。（ICH Q2）'可被翻译为：Limit of Quantitation: The quantitation limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be quantitatively determined with suitable precision and accuracy. The quantitation limit is a parameter of quantitative assays for low levels of compounds in sample matrices, and is used particularly for the determination of impurities and\/or degradation products. (ICH Q2)\n'定量限是指在有适当的准确度和精密度，能够定量测定样本中被分析物的最低量。'可被翻译为：The quantitation limit is the lowest amount of analyte in a sample which can be quantitatively determined with suitable precision and accuracy.\n\n根据上述已知信息，请将'LoQ： 定量限：一种分析方法的定量限是样品中某待测物能以适当的精密度和准确 度被定量检出的最低量。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"LoQ: Limit of Quantitation: The quantitation limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be quantitatively determined with suitable precision and accuracy."
    },
    {
        "instruction":"已知信息：\n'（二）接种疫苗未遵守预防接种工作规范、免疫程序、疫苗使用指导原则、接种方案；'可被翻译为：(2) conducting immunization activities that does not comply with the immunization work norms, immunization procedures, guidance for vaccines use and immunization plans;\n'（一）未按照规定供应、接收、采购疫苗；'可被翻译为：(1) failing to supply, receive, and purchase vaccines as required;\n'（三）未按照规定建立并保存疫苗接收、购进、储存、配送、供应、接种、处置记录；'可被翻译为：(3) failing to establish and maintain records of vaccine reception, purchase, storage, distribution, supply, inoculation, and disposal as required;\n'疾病预防控制机构、接种单位在接收或者购进疫苗时，应当索取前款规定的证明文件，并保存至疫苗有效期满后不少于五年备查。'可被翻译为：When accepting or purchasing vaccines, disease prevention and control institutions and immunization entities shall ask for the abovementioned supporting documents and keep such documents for no less than five years upon the expiration date of vaccines for reference.\n\n根据上述已知信息，请将'（二）接收或者购进疫苗时未按照规定索取并保存相关证明文件、温度监测记录；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(2) failing to obtain and keep relevant certification documents and temperature monitoring records when receiving or purchasing vaccines;"
    },
    {
        "instruction":"已知信息：\n'就诊断、起始治疗标准、合格性、缓解标准以及对照治疗而言，预期以科学证据和\/或公认的且不断更新的治疗指导原则为基础进行证明。虽然这在一般情况下都是对的，但还是预期通过判断性使用生物标记物开展探索研究，提供有关患者选择的指导内容，从而优化获益-风险，不论在计划的 III 期试验中患者选择是否需要确认。'可被翻译为：With respect to diagnosis, criteria for initiation of treatment, eligibility, response criteria and choice of reference therapy, a justification based on scientific evidence and\/or generally acknowledged and updated treatment guidelines are expected. While this is true in general, it is also expected that the exploratory studies through the judicious use of biomarkers provide guidance with respect to selection of patients in order to optimise benefit – risk, whether patient selection is in need for confirmation or not, in the planned phase III trials.\n'在个别情况下，由于有关生存的预后和若干下一线方案的可及性（包括在疾病进展时的试验疗法以及小目标群体），这可能无法实现。如果在研究中 PFS 被选为主要终点， 那么这需要进行彻底的证实。也需要在规划阶段开展认真讨论，以评估可能与疗法相关的死亡人数。即使可接受在 PFS 延长方面的重大获益，那么只要有可能所包含的患者 的数量应足以获得总生存期的预估值（预期出现有利方向趋势）。'可被翻译为：In individual cases this might be non-achievable due to expected good prognosis with respect to survival and availability of several active next-line regimens, including experimental therapies, at the time of disease progression and a small target population. If PFS is the selected primary endpoint for the study, this requires a thorough justification. A careful discussion at the planning stage is also needed for the assessment of possibly therapy-related fatalities. Even though only a major benefit in terms of PFS prolongation would be acceptable, whenever possible the number of patients included should be sufficient to obtain an estimate on overall survival where a trend in a favourable direction is expected.\n'原则上，PFS 是一个可接受的主要终点，但是需要生存期数据以便有合理的确定性来排除对生存期的不利作用。'可被翻译为：In principle, PFS is an acceptable primary endpoint, but survival data are needed in order to exclude with reasonable certainty detrimental effects on survival.\n'疾病进展的定义必须基于标准化的临床数据和生物学数据，需要进行集中的盲态审查来确认疾病进展。'可被翻译为：The definition of progression must be based on a combination of standardised clinical and biological data and centralised blinded review is needed in order to establish progression.\n\n根据上述已知信息，请将'验证性研究预期是随机、充分对照研究，采用已上市或基于证据的药物作为参比药物。原则上，PFS是一个可接受的主要终点，但是需要生存期数据以便有合理的确定性来排除对生存期的不利作用。但是，对于高风险的 MDS，生存期是患者获益的首选测量指标。在这种情况下，HSCT对于见效患者是个更现实的治疗选择，请参考“以治愈为目的的治疗”章节。疾病进展的定义必须基于标准化的临床数据和生物学数据，需要进行集中的盲态审查来确认疾病进展。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Confirmatory studies are expected to be randomised and well controlled using a licensed or evidence based medicinal product as reference. In principle, PFS is an acceptable primary endpoint, but survival data are needed in order to exclude with reasonable certainty detrimental effects on survival. In high risk MDS, however, survival is the preferred measure of patient benefit. In the case HSCT is a realistic treatment option in responding patients, please refer to the section “Treatment administered with curative intent”. The definition of progression must be based on a combination of standardised clinical and biological data and centralised blinded review is needed in order to establish progression."
    },
    {
        "instruction":"已知信息：\n'第一百一十三条 只有经质量管理部门批准放行并在有效 期或复验期内的原辅料方可使用。'可被翻译为：Article 113: Only starting materials which have been approved to release by the quality management department and which are within their shelf life or re-test date should be used.\n'在这段时间内，只要原料药保存于规定的条件下就被认为其质量符合标准要求，可用于生产相应的制剂。'可被翻译为：The period of time during which the drug substance is expected to remain within its specification and, therefore, can be used in the manufacture of a given drug product, provided that the drug substance has been stored under the defined conditions.\n'第一百一十四条 原辅料应当按照有效期或复验期贮存。'可被翻译为：Article 114: The storage of starting materials should be in accordance with the expiry or re-test date.\n'第一百一十四条 原辅料应当按照有效期或复验期贮存。贮存期内，如发现对质量有不良影响的特殊情况，应当进行复验。'可被翻译为：Article 114 The storage of starting materials should be in accordance with the expiry or re-test date. Re-test should be carried out for materials within the shelf life in case of encountering any abnormal situations that may adversely affect the quality of materials.\n\n根据上述已知信息，请将'第一百一十三条 只有经质量管理部门批准放行并在有效期或复验期内的原辅料方可使用。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 113 Only starting materials which have been approved to release by the quality management department and which are within their shelf life or re-test date should be used."
    },
    {
        "instruction":"已知信息：\n'可以考虑证明特异性的方法，例如抗体缺失、使用替代刺激（如果检测法对多种刺激产生应答）。'可被翻译为：Approaches for showing specificity such as antibody depletion, use of alternative stimuli (if assay responds to multiple stimuli) can be considered.\n'对于种族来源亦可用其他替代技术予以确认，如用染色体条带分析或种属特异性抗血清的方法。'可被翻译为：Other technologies may be substituted to confirm species of origin, including, for example, banding cytogenetics or use of species-specific antisera.\n'2. 基因组生物标志物可以具有一种或多种脱氧核糖核 酸（DNA）和\/或核糖核酸（RNA）特征。'可被翻译为：2. A genomic biomarker can consist of one or more deoxyribonucleic acid (DNA) and\/or ribonucleic acid (RNA) characteristics.\n'在该研究报告中，应根据所 测量的生物标志物的特征[例如：对于基因组生物标志物， SNP和（或）CNV]以及使用的方法（例如：对于基因组生 物标志物，采用微阵列和（或）聚合酶链式反应方法）确定 数据的适当格式。'可被翻译为：Within the study reports, the appropriate format of the data will depend on the characteristics of the biomarker measured (e.g., for genomic biomarkers, SNPs and \/ or CNV) and the methodology used (e.g., for genomic biomarkers, microarray and \/ or Polymerase Chain Reaction).\n\n根据上述已知信息，请将'替代方法可显示其独特的标志物。例如，通过使用染色体细胞遗传学来检测独特的标记染色体，或用DNA分析来检测基因组多态性(例如，限制性片段长度多态性，串联重复数目的变化，或基因组双核 苷酸重复数目)。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"An alternative strategy would be to demonstrate the presence of unique markers, for example, by using banding cytogenetics to detect a unique marker chromosome, or DNA analysis to detect a genomic polymorphism pattern (for example, restriction fragment length polymorphism, variable number of tandem repeats, or genomic dinucleotide repeats)."
    },
    {
        "instruction":"已知信息：\n'因此，有必要使用批量平衡法进行另一研究（对于2 种污泥，OPPTS 835.1110或OECD 106，和\/或使用3个土壤类型，OECD 106）。'可被翻译为：Thus, it is necessary to perform an- other study using a batch equilibrium method (OPPTS 835.1110 or OECD 106 for 2 sludges and\/or OECD 106 with 3 soil types).\n'如果有两个2类或3类杂质， 应制定各自限度。'可被翻译为：When there are two Class 2 or Class 3 impurities, individual limits apply.\n'当吸附常数被用于II期A级（OPPTS 835.1110或OECD 106）确定是否触发土壤（或地下水）的II期B级评估时（参见Q.10iv），首选使用污泥测定吸附常数。'可被翻译为：The adsorption constant is preferably determined using sludge when it is used in Phase II Tier A (OPPTS 835.1110 or OECD 106) to determine whether a Phase II Tier B assessment for soil (or groundwater) is triggered (see Q. 10iv).\n'iii）应该使用污泥还是土壤来确定吸附？'可被翻译为：iii) Should sludge or soil be used to determine sorption?\n\n根据上述已知信息，请将'根据OECD 106，优先考虑使用2种类型的污泥和3种土壤类型的研究。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A study using 2 types of sludge and 3 soil types according to OECD 106 is preferred."
    },
    {
        "instruction":"已知信息：\n'疫苗接种方案应使在整个胚胎、胎仔和出生后早期阶段尽可能提高母体抗体 滴度和\/或免疫应答。'可被翻译为：The vaccination regimen should maximize maternal antibody titers and\/or immune response throughout the embryonic, fetal, and early postnatal periods.\n'研究妊娠期女性可能使用的药物具有重要意义。'可被翻译为：Investigation of drugs that may be used in pregnancy is important.\n'当缺乏合适的动物模型（包括NHP）时，兔、大鼠或小鼠的EFD试验仍然 可以提供妊娠期间使用疫苗组分\/制剂的潜在胚胎\/胎仔毒性和产品安全性的重要 信息。'可被翻译为：When there is a lack of an appropriate animal model (including NHP), an EFD toxicity study in rabbits, rats, or mice can still provide important information regarding potential embryo-fetal toxicity of the vaccine components\/formulation and safety of the product during pregnancy.\n'当以基于暴露的终点作为选择EFD试验剂量的基础时，TK数据应来源于遵循GLP试验中的妊娠动物。'可被翻译为：When exposure-based endpoints are used as the basis for selection of the dose levels for EFD studies, TK data from pregnant animals in a GLP-compliant study is expected.\n\n根据上述已知信息，请将'当正在开发的疫苗拟用于妊娠期间时，应基于其拟定用途（例如，在妊娠 期间保护母亲或在出生后早期保护儿童）提供该特异性试验设计的合理性。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"When developing vaccines to be given during pregnancy, a justification should be provided for the specific study design, based upon its intended use (e.g., protecting the mother during pregnancy or protecting the child early postnatally)."
    },
    {
        "instruction":"已知信息：\n'给药到钳夹结束时间 t 的葡萄糖输注速率曲线下面积；'可被翻译为：Area under the glucose infusion rate curve from administration to end of clamp at time t;\n'2.血药浓度-时间曲线下面积'可被翻译为：2.Area under the concentration versus time curve\n'血浆浓度-时间曲线面积'可被翻译为：area under the plasma concentration-time curve\n'药物制剂被机体吸收的速率和吸收程度的种量度。为非静脉注射给药后的浓度-时间曲线下面积与静脉给药后的浓度-时间曲线下面积的比值。'可被翻译为：A measure of the rate and degree of absorption of a drug preparation by the body. It is the ratio of the area under the concentration-time curve after non-intravenous administration to the area under the concentration-time curve after intravenous administration.\n\n根据上述已知信息，请将'给药到钳夹结束时间 t 的血浆浓度曲线下面积；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Area under the plasma concentration curve from administration to end of clamp at time t;"
    },
    {
        "instruction":"已知信息：\n'锂的治疗窗窄，在治疗剂量下即可产生毒性。'可被翻译为：The therapeutic margin is narrow and Li toxicity can occur at therapeutic exposures.\n'根据处方记载，血清中锂的治疗浓度范围是0.6~1 mmol\/L[1]。'可被翻译为：The therapeutic range for lithium has been established at 0.6-1 mmol\/L in serum, depending upon the formulation administered (Grandjean and Aubry, 2009).\n'锂盐治疗需要在医师的密切监控下进行，包括锂浓度的监测。'可被翻译为：Treatment with lithium salts requires frequent controls by the treating physician, including measurement of lithium concentrations.\n'锂可用于人类疾病治疗，大量人体数据表明，锂盐可治疗躁狂症、双相障碍和反复发作的单相抑郁。'可被翻译为：Lithium is used as a human therapeutic, and extensive human data exists in the administration of lithium salts in the treatment of mania, bipolar disorder, and recurrent unipolar depression.\n\n根据上述已知信息，请将'锂盐治疗可能会引起尿频、甲状腺功能减退、 甲状旁腺机能亢进及体重增加的风险[2]。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Lithium treatment in humans is mainly associated with an increased risk of reduced urinary concentrating ability, hypothyroidism, hyperparathyroidism, and weight gain (McKnight et al, 2012)."
    },
    {
        "instruction":"已知信息：\n'12.42 第12.12节中所述的所有原料药工艺一般都应进行前验证。原料药工艺的前验证应当在用其生产的制剂产品上市销售前完成。'可被翻译为：12.42 Prospective validation should normally be performed for all API processes as defined in 12.12. Prospective validation performed on an API process should be completed before the commercial distribution of the final drug product manufactured from that API.\n'临床试验应该在申请上市许可之前进行。'可被翻译为：Clinical trials should be conducted before marketing authorisation.\n'良好的行业实践是原料药的记录在其制剂产品市场销售期间予以保留。'可被翻译为：It is good industry practice to consider retaining records for the period of time the drug product(s) in which the API was used may be available on the market.\n'节 490.100 需要上市批准的制剂和原料药的工艺验证要求(CPG 7132c.08) (3\/2004)'可被翻译为：Sec. 490.100 Process Validation Requirements for Drug Products and Active Pharmaceutical Ingredients Subject to Pre-Market Approval (CPG 7132c.08) (3\/2004)\n\n根据上述已知信息，请将'原料药的生产工艺验证应在其制剂产品上市销售前进行。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The drug substance manufacturing process should be validated before commercial distribution of resulting drug product."
    },
    {
        "instruction":"已知信息：\n'给药方案不同于核心药品特征摘要中规定的标准给药剂量时，应提供临床数据支持。'可被翻译为：Dosage regimens different from the standard dosages stated in the core SmPC should be supported by clinical data.\n'有时还需 要采集至少部分年龄组的治疗反应数据，以验证推荐剂量是否合理。'可被翻译为：It may sometimes be necessary that data on therapeutic response should also be collected in at least some age groups in order to validate the dose recommendations.\n'这条指导原则涉及了支持适应症所需的药效学和临床数据、治疗尿失禁的剂量方案和持续时间。'可被翻译为：This guideline considers pharmacodynamic and clinical data required to support indications, dose regimens and durations of therapy for the treatment of urinary incontinence (UI).\n'当考虑改变临床方案时，应评估已有临床数据支持方案变更的合理性。'可被翻译为：When considering a change in the clinical schedule, an evaluation of the existing clinical data should be conducted to justify such change.\n\n根据上述已知信息，请将'如果要求其他剂量方案，应该得到临床数据的支持。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"If other dosage regimens are requested, they should be supported by clinical data."
    },
    {
        "instruction":"已知信息：\n'对于可能支持监管决策的次要试验目 的（例如，与次要变量相关），相应的估计目标也应当明确定义 和说明，并且每个估计目标都有相应的主估计方法和合适的敏感性分析。'可被翻译为：Estimands for secondary trial objectives (e.g. related to secondary variables) that are likely to support regulatory decisions should also be defined and specified explicitly, each with a corresponding main estimator and a suitable sensitivity analysis.\n'A.5.3. 补充分析 试验结果的解释应侧重于对应每个估计目标的主估计方法， 并通过敏感性分析验证相应估计值的稳健性。'可被翻译为：A.5.3.Supplementary Analysis Interpretation of trial results should focus on the main estimator for each agreed estimand providing that the corresponding estimate is verified to be robust through the sensitivity analysis.\n'图1：协调估计的目标、估计的方法和敏感性分析，使其与给定试验目的对应 该框架有助于制定适当的试验计划，以明确区分估计的目标 （试验目的，估计目标）、估计的方法（估计方法）、数值结果 （“估计值”，见词汇表）和敏感性分析。'可被翻译为：Figure 1: Aligning target of estimation, method of estimation, and sensitivity analysis, for a given trial objective This framework enables proper trial planning that clearly distinguishes between the target of estimation (trial objective, estimand), the method of estimation (estimator), the numerical result (“estimate”, see Glossary), and a sensitivity analysis. This will assist sponsors in planning trials, regulators in their reviews, and will enhance the interactions between these parties when discussing the suitability of clinical trial designs, and the interpretation of clinical trial results.\n'估计目标和敏感性分析的记录'可被翻译为：DOCUMENTING ESTIMANDS AND SENSITIVITY ANALYSIS\n\n根据上述已知信息，请将'A.6. 估计目标和敏感性分析的记录 试验方案应当定义并明确说明与主要试验目的相对应的主要 估计目标。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A.6.DOCUMENTING ESTIMANDS AND SENSITIVITY ANALYSIS A trial protocol should define and specify explicitly a primary estimand that corresponds to the primary trial objective."
    },
    {
        "instruction":"已知信息：\n'将 RODAC 碟用于取样的琼脂表面轻轻但牢固地接触被取样的表面，垂直均匀按压，取下，小心地重新盖上盖子。避免碟表面与取样面摩擦，因为可能会使琼脂裂开。'可被翻译为：Gently but firmly touch the RODAC agar surface against the area being sampled, exert moderate, even, vertical pressure and then carefully replace lid. Avoid using rubbing motions of the plate at the sample site as this may break the agar.\n'4.立即将 Hycheck 条和 RODAC 碟在 30-35ºC 充分培养 2 天，然后在 20 ºC -25 ºC 培养5 天。如果容器可能导致生长缓慢，则可能需要更长时间。每天检查培养碟中菌群污染物情况，以减少较小菌落过分生长难以看清。'可被翻译为：4. Hycheck slides and RODAC plates should promptly be incubated at 30-35ºC for 2 days and then 20 ºC -25 ºC for 5 days. Longer incubation times may be required when contaminants are suspected to be slow growing. Check plates daily for colony formation to minimize obscuring visualization of smaller colonies by over growth.\n'根据微生物学家的判断，可能需要使用 RODAC 碟对不规则表面取样。在此情形下，适合使用无色琼脂 RODAC 碟如 TSA，应避免使用有颜色的琼脂如 D\/E 琼脂。'可被翻译为：At the microbiologist’s discretion, it may be determined that a RODAC plate should be used to sample the irregular surface. In this situation, a RODAC plate comprised of colorless agar such as tryptic soy agar would be appropriate. A colored agar such as D\/E agar should be avoided.\n'检查分离时所用的原始碟，查看是否可能在使用前就被污染（即，在琼脂表面未接种位置生长，表面下生长）'可被翻译为：Check the original plates used for isolation for possible pre-existing contamination (i.e. growth in non-streaked locations on the agar surface, subsurface growth)\n\n根据上述已知信息，请将'小心取下 RODAC 碟的盖子或松开 Hycheck 滑管的盖子。小心不要接触琼脂培养基表面。注：检查琼脂是否被污染或脱水'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Carefully remove the lid of RODAC plate or loosen the cap on the Hycheck slide tube. Take care not to touch the agar surface.Note: Examine agar for contamination and or dehydration"
    },
    {
        "instruction":"已知信息：\n'对产品和工艺的理解可以确定待检测的质量属性。'可被翻译为：Product and process understanding informs the quality attributes to be tested.\n'应证明分析方法的专属性\/选择性，满足样品中被分析物含量或效价的准确度要求。'可被翻译为：The specificity\/selectivity of an analytical procedure should be demonstrated to fulfil the accuracy requirements for the content or potency of an analyte in the sample.\n'专属性\/选择性（SPECIFICITY\/SELECTIVITY） 在用指定分析方法测定某一分析物时，专属性和选择性均用于 描述其他物质的干扰程度。'可被翻译为：SPECIFICITY\/SELECTIVITY Specificity and selectivity are both terms to describe the extent to which other substances interfere with the determination of an analyte according to a given analytical procedure.\n'无干扰：阳性模板、RT-qPCR无逆转录对照，无模板对照。'可被翻译为：Absence of interference: Positive template, no-reverse transcription control for RT-qPCR and no template control.\n\n根据上述已知信息，请将'如果被分析物是工艺相关杂质，还必须对照产 品确认专属性（无干扰）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In cases where the analyte is a process-related impurity, specificity (non-interference) must also be confirmed against the product."
    },
    {
        "instruction":"已知信息：\n'这对于小型临床试验而言尤其重要。'可被翻译为：This can be particularly important for small clinical trials.\n'如果进行这些研究，应认 真考虑能选择进入进一步评估的明确剂量方案所需的样本量。'可被翻译为：If such studies are performed they should be based on a careful consideration of the sample size needed to provide a clear answer regarding the regimen to be selected for further evaluation.\n'如果存在活性代谢物，则总活性部分（临床相关活性实体的总和，考虑到每个活性实体的效能和非结合暴露水平）的增加应当指导给药意见。'可被翻译为：If there are active metabolites, the increase in total active moiety (sum of clinically relevant active entities, taking into account the potency and unbound exposure to each active entity) should guide the dosing recommendation.\n'组规模小，因此统计效能较低、组间变异性大'可被翻译为：Small group size, hence low statistical power and wide variability across groups\n\n根据上述已知信息，请将'结合须仔细挑选后确立，以增加小试验的效能和采集一些相关的临床参数。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"They have to be chosen carefully to serve a specific purpose of increasing the power of small studies and capture a number of relevant clinical parameters."
    },
    {
        "instruction":"已知信息：\n'临床或症状评分'可被翻译为：Clinical or symptom scores\n'临床可判读性。'可被翻译为：Clinical interpretability.\n'症状量表  应该使用经过验证的覆盖患者完整年龄范围的量表对症状进行评估。'可被翻译为：Symptomatic scales Symptoms should be assessed with scales validated for the full age range of patients to be studied.\n'数值综合变量在一个量表上对不同临床症状或体征进行评分，通过得出一个数值评分来反映控制。'可被翻译为：Numerical composite variables score several clinical symptoms or signs on a scale and give a numerical score to represent control.\n\n根据上述已知信息，请将'症状评分：症状的评估是一个可接受的临床变量，尽管尚无经过验证的量表。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Symptom scores: Assessment of symptoms is an acceptable clinical variable although there are no validated scales."
    },
    {
        "instruction":"已知信息：\n'因此，MAH不应包括仅确认产品已知的新有效性\/效用信息。'可被翻译为：As such, the MAH should not include new efficacy\/effectiveness information that only confirms what was already known for the product.\n'在会议期间，申办方通常不应询问未包括在会议文件包或以前未提供给FDA或FDA在其初步意见中未要求的现有新数据或信息中的实质性问题。'可被翻译为：During the course of the meeting, sponsors should generally not ask substantive questions that were not included in the meeting package, or present new data or information that was not previously provided to FDA or requested by FDA in their preliminary comments.\n'PACMP或批准后CMC承诺（如适用）'可被翻译为：PACMP or Post-approval CMC Commitment (if applicable)\n'批准后CMC承诺：MAH和监管机构在批准时达成一致的将在 商业阶段实施的特定CMC开发活动（如特定的工艺监测、额外测试）应列于PLCM文件中。'可被翻译为：Post-approval CMC commitments: specified CMC development activities, agreed between the MAH and regulatory authority at the time of approval (e.g., specific process monitoring, additional testing) that will be performed during the commercial phase should be listed in the PLCM document.\n\n根据上述已知信息，请将'EC不应与MAH在MAA中向监管机构提供数据或信息而作出 的CMC承诺（如稳定性、批准后CMC承诺和其他承诺）相混淆。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"ECs should not be confused with CMC regulatory commitments (e.g., stability, post- approval CMC commitment and other commitments) made by a MAH to provide data or information to the regulatory agency in a MAA."
    },
    {
        "instruction":"已知信息：\n'5.在易产生交叉污染的生产区内，操作人员应当穿戴该区域专用的防护服。'可被翻译为：5. Keeping dedicated protective clothing inside areas where products with special risk of cross-contamination are processed;\n'第一百九十七条 生产过程中应当尽可能采取措施，防止污染和交叉污染，如：'可被翻译为：Article 197 Measures should be taken to avoid, as far as possible, contamination and cross-contamination during production, for example:\n'4.16 实验区域\/操作通常应当与生产区域分开。当生产操作不影响检验结果的准确性，且检验操作对生产过程、中间体或者原料药也无不利影响时，有些实验区域，尤其是中间控制实验室可设在生产区内。'可被翻译为：4.16 Laboratory areas\/operations should normally be separated from production areas. Some laboratory areas, in particular those used for in-process controls, can be located in production areas, provided the operations of the production process do not adversely affect the accuracy of the laboratory measurements, and the laboratory and its operations do not adversely affect the production process or intermediate or API.\n'4.42 应当建立并执行适宜的措施，防止由于人员、物料等在各专用区域间流动而造成的交叉污染。'可被翻译为：4.42 Appropriate measures should be established and implemented to prevent cross- contamination from personnel, materials, etc. moving from one dedicated area to another.\n\n根据上述已知信息，请将'（五）在易产生交叉污染的生产区内，操作人员应当穿戴该 区域专用的防护服；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"5. Keeping dedicated protective clothing inside areas where products with special risk of cross-contamination are processed;"
    },
    {
        "instruction":"已知信息：\n'当量表被用作主要指标时，阐明内容效度（见词汇表）、 评价者内和评价者间信度（见词汇表）及检测疾病严重程度 变化的反应度等尤其重要。'可被翻译为：When a rating scale is used as a primary variable, it is especially important to address such factors as content validity (see Glossary), inter- and intra-rater reliability (see Glossary) and responsiveness for detecting changes in the severity of disease.\n'如果全局实用性指标被用作主要指标，则将特定 的有效性和安全性结局分别作为附加的主要指标考虑是非 常重要的。'可被翻译为：If global usefulness is specified as primary, it is important to consider specific efficacy and safety outcomes separately as additional primary variables.\n'特别是基于主观 标准（例如，采用类风湿关节炎症状量表）选择受试者时，各区域 应采用相同方法（例如，已验证的症状量表和\/或评分量表的相应 译本）。'可被翻译为：In particular, when subject selection is based on subjective criteria (e.g., use of symptom scales in rheumatoid arthritis), the same methods (e.g., validated symptom scales and\/or scores in the appropriate language) should be used uniformly across regions.\n'全局评价指标 是指将客观指标和研究者对受试者的状态或状态变化 的总体印象综合起来所设定的一个单一指标，通常是一个有 序分类量表。'可被翻译为：Global Assessment Variable A single variable, usually a scale of ordered categorical ratings, which integrates objective variables and the investigator's overall impression about the state or change in state of a subject.\n\n根据上述已知信息，请将'使用全局评价指标作 为主要或次要指标时，应该在方案中对量表的以下方面进行 详细说明： \n1）量表与试验主要目的的相关性； \n2）量表的效度和信度基础； \n3）如何根据所收集的数据将个体受试者归类于量表中的特定类别； \n4）如何将有缺失数据的受试者归类于量表中的特定类 别，或用其他方法评价。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"When a global assessment variable is used as a primary or secondary variable, fuller details of the scale should be included in the protocol with respect to: \n1) the relevance of the scale to the primary objective of the trial; \n2) the basis for the validity and reliability of the scale; \n3) how to utilise the data collected on an individual subject to assign him\/her to a unique category of the scale; \n4) how to assign subjects with missing data to a unique category of the scale, or otherwise evaluate them."
    },
    {
        "instruction":"已知信息：\n'12 参见行业指南人用处方药物和生物制品的标签的临床研究部分- 内容和格式。'可被翻译为：12 See the guidance for industry Clinical Studies Section of Labeling for Human Prescription Drug and Biological Products — Content and Format.\n'18 参见行业指南《提供人用药品和生物制品有效性的临床证据》。'可被翻译为：18 See the guidance for industry Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products.\n'行业指南草案药物和生物制品的适应性临床试验设计 \n行业指南草案支持人用药物和生物制品批准的临床试验的富集策略 \n行业指南草案非劣效性临床试验 \n行业指南人用处方药物和生物制品的标签的临床研究部分- 内容和格式 行业指南申请的临床和统计学部分的格式和内容的指南 行业指南有效性和安全的综合总结：通用技术文件内的位置 \n15 行业指南可以在FDA药品指南网页 http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htm上找到。'可被翻译为：Draft guidance for industry Adaptive Design Clinical Trials for Drugs and Biologics \nDraft guidance for industry Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products \nDraft guidance for industry Non-Inferiority Clinical Trials \nGuidance for industry Clinical Studies Section of Labeling for Human Prescription Drug and Biological Products — Content and Format Guidance for industry Guideline on Format and Content of Clinical and Statistical Sections of an Application Guidance for industry Integrated Summaries of Effectiveness and Safety: Location Within the Common Technical Document \n15 Guidances for industry can be found on the FDA Drugs guidance Web page at http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htm.\n'请参见行业指南人用药品和生物制品申请的环境评估。'可被翻译为：See the guidance for industry Environmental Assessment of Human Drug and Biologics Applications.\n\n根据上述已知信息，请将'14参见行业指南人用处方药物和生物制品的标签的临床研究部分- 内容和格式。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"14 See the guidance for industry Clinical Studies Section of Labeling for Human Prescription Drug and Biological Products — Content and Format."
    },
    {
        "instruction":"已知信息：\n'如果申办者也同时在对固定复方制剂的各个成分进行临 床试验，应为每个成分分别递交DSUR。'可被翻译为：If the sponsor is also conducting clinical trials with individual component(s) of the fixed combination product, separate DSUR(s) should be submitted for each component.\n'几种活性物质组合在一个单独的药物制剂中就称为“固定复方”药品。'可被翻译为：The combination of active substances within a single pharmaceutical form of administration is a ‘fixed combination’ medicinal product.\n'本指南涵盖了包含两种及两种以上活性物质且具有一种剂型的固定复方制剂（又称固定剂量复方制剂，FDC）。'可被翻译为：This guideline covers fixed combination (also referred to as fixed dose combinations, FDCs) medicinal products containing two or more active substances within a single pharmaceutical form.\n'固定剂量复方制剂'可被翻译为：Fixed Dose Combinations\n\n根据上述已知信息，请将'通常，固定组成复方制剂（例如，复方中至少含有两种固定 剂量活性成分，并以单一剂型给药）的临床试验仅需递交一份 DSUR。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In general, a single DSUR should be prepared for clinical trials involving a fixed combination product (i.e., a product consisting of at least two active ingredients in a fixed dose that is administered in a single dosage form)."
    },
    {
        "instruction":"已知信息：\n'工艺知识和持续改进是变更的驱动因素。'可被翻译为：Process knowledge and continual improvement are drivers for change.\n'通常工艺知识、分析方法知识和持续改进都是变 更的推动因素。'可被翻译为：Typically, process knowledge, analytical procedure knowledge and continual improvement are drivers for change.\n'在整个产品生命周期内，它能促进工艺性能和产品质量的持续改进。'可被翻译为：It facilitates continual improvement of process performance and product quality throughout the product lifecycle.\n'•工艺性能和产品质量监测系统；'可被翻译为：• Process performance and product quality monitoring system;\n\n根据上述已知信息，请将'创新、持续改进、工艺性能和产品质量监测结果以及CAPA会导致变更。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Innovation, continual improvement, the outputs of process performance and product quality monitoring and CAPA drive change."
    },
    {
        "instruction":"已知信息：\n'也就是说，在体 内试验结果为阴性（无MEFL）的情况下，替代试验应该在某些外推剂量水平上 预测为阴性结果。'可被翻译为：That is, the alternative assay should predict a negative result at some extrapolated level under the conditions for which the in vivo study yielded a negative result (no MEFL).\n'② 当使用pEFD试验时，需要两种种属的正式体内EFD试验的阴性结果，以确 定替代试验结果为假阳性。'可被翻译为：2) While pEFD studies can be used, negative results from definitive in vivo EFD studies in two species are warranted to establish that alternative assay results represent a false positive.\n'若该替代试验不能预测MEFL阳性时，则应在两种种属的正式体内EFD试验中 进行确认。'可被翻译为：If the alternative assay does not predict MEFL, this should be confirmed in definitive in vivo EFD studies in two species.\n'但是，若结果为可疑或被认为是假阳性，应进行一种或两种种属的正式体内 EFD试验以帮助人类风险评估。'可被翻译为：However, if the results are equivocal or thought to represent a false positive, definitive in vivo studies in one or two species should be conducted to assist human risk assessment.\n\n根据上述已知信息，请将'如果第一种种属的替代试验预测为阴性结果（即无MEFL），则应进行第二 种种属的正式体内EFD试验以确认该评估结果。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"If the alternative assay for the first species predicts a negative outcome (i.e., no MEFL), a definitive in vivo EFD study in the second species should be conducted to confirm the assessment."
    },
    {
        "instruction":"已知信息：\n'人体饮食摄入钴的平均值约为11 μg \/天[1]。'可被翻译为：The average person receives about 11 µg Co\/day in the diet (ATSDR, 2004).\n'钴是维生素B12的组成部分，是合成血红蛋白的多种酶的辅酶且具有预防恶性贫血的作用，因此，钴是人体必需的元素。'可被翻译为：Cobalt is essential in the human body because it is an integral component of Vitamin B12 and functions as a co-enzyme for several enzymes critical in the synthesis of hemoglobin and the prevention of pernicious anemia.\n'PDE=0.1 µg\/kg\/天 50 kg=5.0 µg\/天'可被翻译为：PDE = 0.1 µg\/kg\/d x 50 kg = 5.0 µg\/day\n'总和 2.5g -- -- - - - - - 1.2µg 0.8µg 0.7µg 0.7µg 4µg 9.5µg 12.5µg'可被翻译为：TOTAL 2.5 g - - - - - - - 1.2 µg 0.8 µg 0.7 µg 0.7 µg 4 µg 9.5 µg 12.5 µg\n\n根据上述已知信息，请将'推荐的维生素B12摄入量为0.7~2.4 μg\/天[2]，相当于0.03~0.1 μg的钴。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The Recommended Dietary Allowance of Vitamin B12 ranges from 0.7 to 2.4 µg\/day (NAS, 2010), which corresponds to 0.03 to 0.1 µg of cobalt."
    },
    {
        "instruction":"已知信息：\n'有时从校正的分析和未校正的分析中可以获得不同的结果。'可被翻译为：sometimes, different results may be obtained from adjusted and unadjusted analyses.\n'当分析方法不专属时，可证明其选择性。'可被翻译为：Selectivity could be demonstrated when the analytical procedure is not specific.\n'一个例子是CYP2D6超快代谢者（UM）中的可待因 代谢的情况，其将形成更活跃的代谢物，例如吗啡和吗啡-6-葡萄糖醛酸苷。'可被翻译为：One example is the case of codeine metabolism in CYP2D6 ultra-rapid metabolisers (UM), who will form more active metabolites such as morphine and morphine-6-glucuronide.\n'另外，不检测MCB，而对WCB进行全面检测来作为替 代手段也是可以的。'可被翻译为：An alternative approach in which full tests are carried out on the WCB rather than on the MCB would also be acceptable.\n\n根据上述已知信息，请将'然而，CYP2D6也是一个很好的例子来说明不彻底的分析手段会导致错误地指定UM。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"However, CYP2D6 is also a good example where non thorough analytics could lead to erroneous UM designation."
    },
    {
        "instruction":"已知信息：\n'境外生产药品发生上述变更的，应当在变更实施前报药品审评中心备案。'可被翻译为：Where a drug manufactured overseas undergoes the aforementioned changes, they shall be reported to the CDE for filing prior to implementation.\n'第十五条 境外持有人变更药品生产场地且变更后生产场地仍在境外的，应按照相关技术指导原则进行研究、评估和必要的验证，向药审中心提出补充申请或备案。'可被翻译为：Article 15 Where the overseas MAH changes the drug manufacturing site and the new manufacturing site is still overseas, it shall conduct study, evaluation and necessary verification in accordance with relevant technical guidelines and submit supplementary application or filing to CDE.\n'第九条 境外持有人之间变更的，由变更后持有人向药审中心提出补充申请。'可被翻译为：Article 9 For the change between overseas MAHs, the new MAH shall submit a supplementary application to CDE.\n'国家药监局药审中心关于发布《境外已上市境内未上市药品临床技术要求》'可被翻译为：Center for Drug Evaluation, NMPA issued the Clinical Technical Requirements for Drugs Marketed Overseas but Not Marketed in China\n\n根据上述已知信息，请将'境外生产药品上述信息的变更向药审中心提出备案。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The change of the above information for drugs manufactured overseas shall be filed to the CDE."
    },
    {
        "instruction":"已知信息：\n'它还描述了替代性试验的资格验证，以及可能的应用场景，并提供了延 迟发育毒性试验的选择。'可被翻译为：It also describes qualification of alternative assays, potential scenarios of use, and provides options for deferral of developmental toxicity studies.\n'在有限的情况下，由单独的经资格验证合格的替代试验（见术语表），或连 同一个或多个体内试验所产生的数据，可用于支持危害鉴定和风险评估。'可被翻译为：Data generated from qualified alternative assays (see glossary) conducted alone or in conjunction with one or more in vivo studies can be utilized to support hazard identification and risk assessment under limited circumstances.\n'表 1 替代试验资格验证用阳性对照参考化合物示例'可被翻译为：Table 1: Reference Compound Positive Control Examples for Qualifying Alternative Assays\n'试验资格验证时每个训练集（用于探索潜在预测关系的数据）和测 试集（用于评估预测关系强度和效用的数据）的化合物清单，以及选择这 些化合物的依据。'可被翻译为：The list of compounds in each of the training sets (data used to discover potentially predictive relationships) and test sets (data used to assess the strength and utility of a predictive relationship) for qualification of the assay and the basis for selection of these compounds.\n\n根据上述已知信息，请将'此清单中的化合物以及其它化合物，可用于支持一个或一组替代试验的资格 验证。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The compounds in this list as well as others can be used to support qualification of an alternative assay or battery of assays."
    },
    {
        "instruction":"已知信息：\n'如上所述，对 QT 延长的时间进程 的检查是重要的。'可被翻译为：As mentioned above, inspection of the time course of QT prolongation is important.\n'这种相关性应纳入考虑范畴。'可被翻译为：This relationship should be taken into consideration.\n'3. 如果有意从多项研究中汇集ECG间期数据，则检查异质性很重要。'可被翻译为：3.If there is an intention to pool ECG interval data from multiple studies, it is important to test for heterogeneity.\n'非啮齿类动物种属在QT-RR关系中表现出种属特定的个体差异。'可被翻译为：Non-rodent species show species-specific and individual differences in their QT-RR relationships. 3.4 How should the sensitivity of the assay be evaluated?\n\n根据上述已知信息，请将'QT-RR间期之间的关系也很重要。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"QT-RR interval relationship is also important."
    },
    {
        "instruction":"已知信息：\n'细节程度取决于药物所处的研发 阶段。'可被翻译为：The appropriate level of detail is likely to be dependent on the stage of drug development.\n'在临床研究结束后计划市售药品的产品特征变化可能引发担忧“临床研究的有效性和安全性结果不适用于新生产的药物”。'可被翻译为：Product characteristic changes in the planned commercial drug after the end of clinical studies might raise concern that the effectiveness and safety findings of the clinical studies do not apply to the newly manufactured drug.\n'很有必要在药品的物理设计完成之前评价相似药品的问题为什么以及怎么发生的。若能早期阶段识别到，可消除设计中容易出错的特性，以便相同类型的错误不会在研发过程中出现。一旦产品设计达到研发的最后阶段，是很难改变产品特征如形状、规格和剂型，因为这种变更会要求收集额外的临床试验或CMC数据，来支持即使很小的修订。'可被翻译为：Evaluation of why and how problems have occurred with similar products can be helpful and should be conducted before finalizing the physical design features of a drug product. When identified early, error prone features can be eliminated from the design so that the same type of error does not occur with the product under development. Once a drug product reaches the final stages of development it may be difficult to change product features such as shape, strength, and dosing because such changes may require the collection of additional clinical or CMC data to support even minor modifications.\n'该产品是否具有可能使这些产品之间的差异难以区分的特征，从而允许可能的用药错误未被检测到（例如，颜色、形状、尺寸、味 道、气味等）。'可被翻译为：Do the products have characteristics that might make the variation between these products difficult to distinguish, allowing possible medication errors to go undetected (e.g., color, shape, size, taste, smell, etc.)?\n\n根据上述已知信息，请将'一旦药品到达 开发的最终阶段，可能难以改变产品特征，例如形状、尺寸、规格和剂量，因为这 样的变化可能需要收集额外的临床或化学、生产和控制数据以支持甚至小修改。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Once a drug product reaches the final stages of development, it may be difficult to change product features such as shape, size, strength, and dosing because such changes may require the collection of additional clinical or chemistry, manufacturing, and controls data to support even minor modifications."
    },
    {
        "instruction":"已知信息：\n'但是，应该支持通过多种试验药物的拓展性应用的治疗使用，通过：'可被翻译为：However, treatment use through expanded access of multiple investigational drugs should be supported by:\n'对上市药物已批准适应症进行的临床试验（即，治疗应 用试验IV期）；'可被翻译为：Clinical trials conducted using marketed drugs in approved indications (i.e., therapeutic use trials (Phase IV));\n'例如，可以采用非劣效性试验，以一个已经获批的血小板生成素受体激动剂药物作为活性对照，对一个将用于长期治疗的受试血小板 生成素受体激动剂药物进行试验研究。'可被翻译为：For example, an experimental TPO-R agonist drug intended for chronic use may be studied against an approved TPO-R agonist using a non-inferiority design.\n'对于处于加速期但是之前在慢性期接受过治疗的患者，可能需要开展对比其它TKI的试验。对于在加速期得出诊断且之前慢性期没有接受过治疗的患者，需要开展对比一线TKI的试验。总体来说，因为加速期的治疗方法需根据之前的治疗类型而定，所以对照药也需要根据患者的用药史决定。'可被翻译为：For those patients that are on accelerated phase (AP) but had prior treatment for chronic phase a trial versus another TKI may be conducted if possible. In the case presentation at diagnosis is accelerated phase without prior chronic phase a trial versus a first line TKI will be expected. In general, as treatment on AP depends on type of prior therapy the comparator used will be defined by prior patient treatment history.\n\n根据上述已知信息，请将'目前已经有几种药物被批准用于治疗慢性期的 CML，对比试验应采用已获批的药物作为对照药。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"As there are currently several medicinal products approved for the treatment of CML in CP a comparative trial should be undertaken against a licensed reference product."
    },
    {
        "instruction":"已知信息：\n'没有已知危险因素下，患者遭受严重不良反应或缺乏有效性'可被翻译为：patients suffering from serious adverse reactions or lack of efficacy without known risk factors\n'4.临床数据显示无效或存在安全性问题'可被翻译为：4. The clinical data show ineffectiveness, or there are safety problems\n'不适用（N\/A） 不适用 此节没有起草Q&A'可被翻译为：N\/A N\/A No Q&A drafted on this section\n'不适用'可被翻译为：Not applicable\n\n根据上述已知信息，请将'已确认的风险 \n临床前数据 \n临床数据 \n措施 \n无已确认的风险 \n不适用 \n不适用 \n不适用'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Identified Risks \nPreclinical data \nClinical data \nActions \nNone identified \nNot applicable \nNot applicable \nNot applicable"
    },
    {
        "instruction":"已知信息：\n'还应记录并发症及合并治疗。'可被翻译为：Co-morbidities and concomitant therapies should be documented.\n'除了标准的不良事件监测（根据GCP标准），还须监测患者增加的残余尿量及尿路感染， 因为用于尿失禁的药物可能影响膀胱排空。'可被翻译为：In addition to standard adverse event monitoring (according to GCP standards), it is important to monitor patients for increased residual urine and urinary tract infections, as drugs intended for use in urinary incontinence may affect bladder emptying.\n'症状：有或没有急迫性尿失禁的尿急，通常伴有尿频和夜尿。'可被翻译为：Symptom: Urgency with or without urge incontinence, usually combined with frequency and nocturia.\n'另外伴随或不伴随尿失禁的尿路功能紊乱相关的症状或综合征定义如下：'可被翻译为：Other pertinent symptoms and syndromes suggestive of lower urinary tract dysfunction which may or may not be accompanied by urinary leakage are defined as follows:\n\n根据上述已知信息，请将'也须记录和研究并发症或症状恶化或新发尿失禁症状。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Complications or worsening of the symptoms or de novo appearance of new urinary symptoms must also be recorded and investigated."
    },
    {
        "instruction":"已知信息：\n'规定范围内，所需准确度 和精密度特征得到证明。'可被翻译为：Stated range for which the required accuracy and precision characteristics are demonstrated\n'能达到一定精密度、准确度和线性，测试方法适用的高低限浓度或量的区间。'可被翻译为：The range of high-low limit concentrations or amounts for which the test method is applicable, with precision, accuracy, and linearity.\n'QL：准确度和精密度符合要求情况下的最低加标水平。'可被翻译为：QL: The lowest spiking level with acceptable accuracy and precision\n'分析方法的可报告范围包括从最低至最高可报告结果的所有值，这些值具有适当水平的精密度和准确度。'可被翻译为：The reportable range of an analytical procedure includes all values from the lowest to the highest reportable result for which there is a suitable level of precision and accuracy.\n\n根据上述已知信息，请将'准确度、精密度和响应符合要求情况下，范围从QL（包括QL）延伸到最高加标水平'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The range extends from and is inclusive of the QL to the highest spiking level with acceptable accuracy, precision and response"
    },
    {
        "instruction":"已知信息：\n'编码于DNA或RNA（一些病毒）核昔酸序列中的可遗传的生物信息。'可被翻译为：The heritable biological information encoded in the nucleotide sequence of DNA or RNA (some viruses).\n'遗传信息'可被翻译为：genetic information\n'自起始密码子到终止密码子之间的核昔酸三联体序列。一般情况下，可读框即指某个基因的编码序列。'可被翻译为：A nucleotide triad sequence from start codon to stop codon. In general, the readable frame is the code sequence of a gene.\n'mRNA（或DNA）上的三联体核昔酸残基序歹鼠该序列编码着一个指定的氨基酸，tRNA的反密码子与mRNA的密码子互补。密码子具有连续性、简并性、方向性和通用性的特点。'可被翻译为：The sequence encodes a specific amino acid, and the anticodon of the tRNA is complementary to the codon of the mRNA. The codon is characterized by continuity, degeneracy, directivity, and versatility.\n\n根据上述已知信息，请将'核昔酸序列所携带的遗传信息。编码20种氨基酸和多肽链起始及终止的一套64个三联体密码子。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The genetic information carried by the nucleotide sequence. A set of 64 triplet codons that encode the start and end of 20 amino acid and polypeptide chains."
    },
    {
        "instruction":"已知信息：\n'三室模型'可被翻译为：three-compartment model\n'图3中的虚线箭头说明了根据模型重新评估的可能输出重新进入生命周期流程的情形。'可被翻译为：The dashed arrows in Figure. 3 illustrate reintroduction into the lifecycle flow based on the potential outcomes of the model reassessment.\n'又称“药-时曲线”。给药后药物浓度随时间迁移发生变化,以药物浓度(或对数浓度)为纵坐标,以时间为横坐标绘出的曲线图。'可被翻译为：Also known as the \"drug-time curve\". The change of drug concentration with time migration after administration, with drug concentration (or logarithmic concentration) as the vertical coordinate and time as the horizontal coordinate plot.\n'AUC0-tau –稳态时单次给药间隔的浓度时间曲线下面积。'可被翻译为：AUC0-tau - Area under the concentration time curve for one dosing interval at steady-state.\n\n根据上述已知信息，请将'药物缓慢进入骨和脂肪时，或与某组织结合得非常牢固时，这时的浓度-时间曲线呈三相指数衰减，即为三室模型。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"When the drug enters bone and fat slowly, or binds to a tissue very firmly, the concentration-time curve decreases exponentially in three phases, that is, the three-compartment model."
    },
    {
        "instruction":"已知信息：\n'有临床资料证明静脉注射免疫球蛋白和血栓栓塞事件如心肌梗死、脑血管意外 （包括中风）、肺栓塞及深静脉血栓形成有关，其中深静脉血栓形成被认为与高危患 者接受高剂量免疫球蛋白输入使得血液粘度相对增加有关。'可被翻译为：There is clinical evidence of an association between IVIg administration and thromboembolic events such as myocardial infarction, cerebral vascular accident (including stroke), pulmonary embolism and deep vein thromboses which is assumed to be related to a relative increase in blood viscosity through the high influx of immunoglobulin in at-risk patients.\n'会明显影响血液凝结或者免疫反应的伴随疾病或伴随用药（须包括任何关于这 个问题的信息）'可被翻译为：Co-morbidity or co-medication which would significantly impact blood coagulation or immunoreaction (any information concerning this issue should be included)\n'非常罕见的不良反应：血栓栓塞反应如心肌梗死、中风、肺栓塞、深静脉血栓 形成。'可被翻译为：Very rarely: Thromboembolic reactions such as myocardial infarction, stroke, pulmonary embolism, deep vein thromboses.\n'静脉血栓栓塞症临床表现为深静脉血栓（DVT）和肺栓塞（PE）。'可被翻译为：VTE clinically manifests as deep vein thrombosis (DVT) and pulmonary embolism (PE).\n\n根据上述已知信息，请将'已知使用免疫球蛋白会造成动脉和静脉血栓栓塞事件，包括心肌梗塞、中风、深静脉血栓和肺栓塞。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Arterial and venous thromboembolic events including myocardial infarction, stroke, deep venous thrombosis and pulmonary embolism have been associated with the use of immunoglobulins."
    },
    {
        "instruction":"已知信息：\n'在这里，将上一次治疗前的TTP与实验性治疗的TTP\/PFS进行比较。'可被翻译为：Here TTP on last prior therapy is compared with TTP\/PFS on the experimental therapy.\n'在先前治疗的患者中，患者自身比较 TTP\/PFS 可以提供活性证据。将在最后先前治疗的 TTP 与试验治疗的 TTP\/PFS 进行比较。但是，需注意的一点是，无法证实在整个期间 至少保持相似增长率的潜在假设。对于探索性目的而言，这并不是主要的问题。建议招募对先前治疗存在继发性耐药或原发性耐药的受试者。这至少可以保证在某种程度上研究人群具有相关性。也应注意到先前治疗中早期失败（原发性耐药）的患者可能由于随着肿瘤生长率的波动和影像技术的可变性而出现 TTP 相反的情况。'可被翻译为：In previously treated patients, a within patient comparison of TTP\/PFS might provide evidence of activity. Here TTP on last prior therapy is compared with TTP\/PFS on the experimental therapy. It should be noted, however, that the underlying assumption of at least similar growth rate over time cannot always be substantiated. For exploratory purposes this constitutes no major concern. It is advisable to recruit patients with secondary as well as primary resistance on prior therapy. This ensures at least to some extent, that the study population is relevant. It should also be noted that patients with early failure (primary resistance) on prior therapy may show some inversions in terms of TTP just due to fluctuations in tumour growth rate and variability related to imaging techniques.\n'还应当注意的是，既往治疗时 出现早期衰竭的患者（原发性耐药）的TTP可能会由于肿瘤生长率的波动和成像技 术相关的变异性而出现一些逆转。 对于某些适应症，在未接受过治疗的患者进行自身比较可能也是合理的，即随访不 接受治疗的患者至出现疾病进展，然后在疾病进展时进行实验性治疗。'可被翻译为：It should also be noted that patients with early failure (primary resistance) on prior therapy may show some inversions in terms of TTP just due to fluctuations in tumour growth rate and variability related to imaging techniques. For certain indications, a within patient comparison may be justified also in treatment naïve patients, i.e. patients are followed without therapy until progression followed by experimental therapy until progression.\n'一项随机、剂量比较临床试验，例如将可能具有药理活性的最低剂量和较高剂量进 行比较，如果显示出TTP\/PFS有差异，则显然提供了有活性的证据，但这不是绝对 的。'可被翻译为：A randomised, dose comparative trial, e.g. comparing the lowest dose likely to be pharmacologically active with higher dose(s), if showing a difference in TTP\/PFS, will obviously provide evidence of activity, but not in absolute terms.\n\n根据上述已知信息，请将'在接受既往治疗的患者中，患者自身的TTP\/PFS比较可提供药物活性的证据。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In previously treated patients, a within patient comparison of TTP\/PFS might provide evidence of activity."
    },
    {
        "instruction":"已知信息：\n'术语复发性MS包括1）RRMS患者，2）SPMS和合并复发患者，以及3）只有一次脱髓鞘性临床 事件并且在随后的核磁共振扫描中显示时间和空间上有病变扩散的患者。'可被翻译为：The term relapsing MS includes 1) patients with RRMS, 2) patients with SPMS and superimposed relapses and 3) patients with a clinically isolated demyelination event and evidence of dissemination of lesions in time and space on the MRI.\n'患者样本均匀，患者确诊为复发缓解型多发性硬化症（RRMS），其复发频率有足 够的疾病活性和\/或满足预期MRI迅速发生变化的MRI标准。'可被翻译为：This would be a homogeneous sample of patients with a confirmed diagnosis of relapsing-remitting MS (RRMS) and sufficient disease activity based on relapse frequency and\/or MRI criteria to anticipate rapid changes in MRI.\n'短暂性脑缺血发作（TIA）：脑、脊髓或视网膜缺血引起的局灶性神经功能障碍 短暂发作，神经影像学未显示急性脑梗死。'可被翻译为：Transient ischaemic attack (TIA): transient episode of focal neurological dysfunction caused by brain, spinal cord, or retinal ischemia, without acute infarction on neuroimaging.\n'在十年时间内， 超过 50% 的复发缓解型 MS 患者的病情最终会发展到有复发或无复发合并症状的持续性恶化状态；这种形式的疾病被称为继发进展型多发性硬化症（SPMS）。'可被翻译为：Within ten years more than 50% of patients who suffer from arelapsing-remitting form eventually develop sustained disability with or without superimposed relapses; this form is called the secondary progressive multiple sclerosis (SPMS).\n\n根据上述已知信息，请将'有大约 85%的患者所患的是复发缓解型 MS（RRMS），其特点是不可预测的神经功能障碍急 性发作，也称为临床发作或复发，随后是不稳定的恢复期和临床稳定期。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Approximately 85 % of all MS patients present relapsing-remitting (RR) MS, which is characterised by unpredictable acute episodes of neurological dysfunction named relapses, followed by variable recovery and periods of clinical stability."
    },
    {
        "instruction":"已知信息：\n'申请人提出要求时， 申办方应检查其记录中的这些信息； 并且在符合任何隐私法规定 的前提下（注意，其他国家的法律可能与美国法律不同），申办方应向申请 人提供应披露信息。'可被翻译为：On request from an applicant, sponsors should check their records for such information and, subject to any privacy laws (noting that other countries’ laws may differ from United States law), the sponsor should then provide disclosable information to the applicant.\n'签署的电子记录应清楚表明与签名相关的信息，内容包括：'可被翻译为：Signed electronic records shall contain information associated with the signing that clearly indicates all of the following:\n'使用电子签名前或期间应向主管部门证明1997年8月20日或之后再系统中使用的电子签名与传统手写签名具有同等的法律效力。'可被翻译为：Persons using electronic signatures shall, prior to or at the time of such use, certify to the agency that the electronic signatures in their system, used on or after August 20, 1997, are intended to be the legally binding equivalent of traditional handwritten signatures.\n'每个电子签名应对应唯一的个体，且不应被他人重新使用或重新分配给他人。'可被翻译为：Each electronic signature shall be unique to one individual and shall not be reused by, or reassigned to, anyone else.\n\n根据上述已知信息，请将'建立、分配、证明或批准个体的电子签名或电子签名的任何要素前，应核实个人身份。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Before an organization establishes, assigns, certifies, or otherwise sanctions an individual's electronic signature, or any element of such electronic signature, the organization shall verify the identity of the individual."
    },
    {
        "instruction":"已知信息：\n'按照需要，这些风险可能要通过上市后监测和监控做进一步证实。'可被翻译为：These risks may have to be further substantiated by post-marketing surveillance and monitoring as required.\n'按照在风险管理计划（RMP）中确定的潜在风险，对上市后安全性和有效性进行监测。'可被翻译为：Post marketing safety and efficacy measures should be addressed according to potential risk identified in the Risk Management Plan (RMP).\n'因此，在获得上市许可后通常需要开展进一步的系统性免疫原性试验，并且纳入风险管理计划中。'可被翻译为：Thus, further systematic immunogenicity testing is often necessary after marketing authorization, and may be included in the risk management plan.\n'第七十七条 药品上市许可持有人应当制定药品上市后风险管理计划，主动开展药品上市后研究，对药品的安全性、有效性和质量可控性进行进一步确证，加强对已上市药品的持续管理。'可被翻译为：Article 77 MAHs shall formulate a drug post-marketing risk management plan and take the initiative to conduct drug post-marketing studies to further confirm the safety, efficacy, and quality management of drugs, and strengthen continuous management of marketed drugs.\n\n根据上述已知信息，请将'上市后风险管理可能是这些量表进一步的潜在应用领域。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Post-authorisation risk management could be a further potential area of application of such scales."
    },
    {
        "instruction":"已知信息：\n'一旦完成数据验证，应按照预先拟定的计 划进行分析，越依从于这些计划，结果的可信度越高。'可被翻译为：Once data validation is complete, the analysis should proceed according to the pre-defined plans; the more these plans are adhered to, the greater the credibility of the results.\n'在结局验证程序中收集的 信息应被纳入到分析计划和方案中，如果适当，应作为最终方案修订案提交。'可被翻译为：Information gathered in the outcome validation process should be incorporated into the analysis plan and protocol and, if appropriate, be submitted as a final protocol amendment.\n'如果基于FAS分析和PPS分析的结果一 致，则可增强试验结果的可信度。'可被翻译为：Consistent results from analyses based on the FAS and the PPS is indicated as increasing confidence in the trial results.\n'当全分析集和符合 方案集得出实质上相同的结论时，会增加试验结果的可信度， 但应注意，对于排除了大比例受试者的符合方案分析会给试 验的整体正确性带来一些疑虑。'可被翻译为：When the full analysis set and the per protocol set lead to essentially the same conclusions, confidence in the trial results is increased, bearing in mind, however, that the need to exclude a substantial proportion of subjects from the per protocol analysis throws some doubt on the overall validity of the trial.\n\n根据上述已知信息，请将'对方案中步骤的遵循程度和主要分析预先计划的程 度，都将决定试验最终结果和结论的可信度。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The extent to which the procedures in the protocol are followed and the primary analysis is planned a priori will contribute to the degree of confidence in the final results and conclusions of the trial."
    },
    {
        "instruction":"已知信息：\n'8 2002 年9月 通用术语表 通用术语表有没有在CTD中使用推荐术语的通用术语表？ 目前没有提供术语表的计划。'可被翻译为：8 Sept. 2002 General Glossary of Terms Will there be a general glossary of recommended terminology for use in the CTD? No glossary of terms is planned at this time.\n'16 2003 年 7 月 在日本、欧盟和美国强制性提交 CTD 的最后期限（在美国强 烈推荐）也涉及 eCTD？ ICH 是否考虑计划组织一个研讨会来帮助 CTD 和 eCTD 提交 工作？ 尽管监管机构接受 eCTD 的提交，但截止日期并不涉及 eCTD。有关 eCTD 提交的具体指导，请参阅区域的指导。 目前，ICH 并不打算举办 CTD 研讨会。 然而，ICH6 会议，将于 2003 年 11 月在日本大版举行，着重于 CTD 和 eCTD。'可被翻译为：16 July 2003 Does the deadline for mandatory submission of the CTD in Japan, the EU and the US (highly recommended in the US) also refer to the eCTD? Has ICH considered planning a seminar to help with CTD and eCTD submissions? The deadline does not refer to the eCTD although the regulatory authorities are accepting eCTD submissions. Please refer to regional guidance for specific guidance on eCTD submissions. Currently the ICH is not planning to conduct a CTD seminar. However, the ICH6 Conference, November 2003 in Osaka Japan, will focus on the CTD and eCTD.\n'21 2003 年 11 月 草药产品CTD 将出版 CTD 的草药产品版本，以及药物 CTD 将有多少变 化？ ICH 没有发布任何特定版本草药产品 CTD 的计划。'可被翻译为：21 Nov. 2003 Herbal CTD Will a Herbal Products version of the CTD be published and how much will it vary from the pharmaceutical CTD. ICH does not plan to issue any specific version of the CTD for Herbal Products.\n'18 2003 年 11 月 有没有定义CTD 中应该包含哪些附件？ 不建议在 CTD 中包含其他附件。'可被翻译为：18 July 2003 Is there a definition of which attachments should be included in the CTD? It is not suggested that additional attachments be included in the CTD.\n\n根据上述已知信息，请将'19 2003 年 11 月 CTD培训 ICH 是否有推荐的有关 CTD 实施的综合培训课程？ 没有，没有关于 CTD 实施培训的通用 ICH 建议。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"19 Nov. 2003 CTD training Does ICH recommend any particular comprehensive training course on the implementation of the CTD? No, there are no general ICH recommendations for training on CTD implementation."
    },
    {
        "instruction":"已知信息：\n'本药品详细信息可以在欧洲药品管理局的网站http:\/\/www.ema.europa.eu获得。'可被翻译为：Detailed information on this medicinal product is available on the website of the European Medicines Agency http:\/\/www.ema.europa.eu\n'<本药品详细信息可在欧洲药品局的网站http:\/\/www.ema.europa.eu.获得。>'可被翻译为：<Detailed information on this medicinal product is available on the website of the European Medicines 460 Agency http:\/\/www.ema.europa.eu.>\n'<有关本品的详细信息，请见欧洲药品管理局的网站 http:\/\/www.ema.europa.eu.'可被翻译为：<Detailed information on this medicinal product is available on the website of the European Medicines Agency http:\/\/www.ema.europa.eu.>\n'有关 ISO\/HL7 27953-2 的详细信息，请登录 ISO网站http:\/\/www.iso.org\/iso\/home\/store.htm 查询。'可被翻译为：Detailed information about ISO\/HL7 27953-2 can be obtained from ISO web site: http:\/\/www.iso.org\/iso\/home\/store.htm.\n\n根据上述已知信息，请将'该药的详细信息可见于欧洲药品管理局网站：http:\/\/www.ema.europa.eu。<还有关于罕见疾病和治疗的其他网站链接。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Detailed information on this medicine is available on the European Medicines Agency web site: http:\/\/www.ema.europa.eu <There are also links to other websites about rare diseases and treatments."
    },
    {
        "instruction":"已知信息：\n'（一）申请人提出药物临床试验、药品上市注册及化学原料药申请时，应按照国家药品监管部门公布的相关技术指导原则的有关要求开展研究，并按照现行版《M4：人用药物注册申请通用技术文档（CTD）》（以下简称CTD）格式编号及项目顺序整理并提交申报资料。不适用的项目可合理缺项，但应标明不适用并说明理由。'可被翻译为：(1) While applying for drug clinical trials, drug marketing registration and chemical APIs, the applicants shall carry out the study in accordance with the requirements of relevant technical guidances promulgated by NMPA, collate and submit the application dossier as per the format number and item order of the current version of M4: Common Technical Document for the Registration Application of Pharmaceuticals for Human Use (hereinafter referred to as CTD). If some items are not applicable, they can be missing, but \"not applicable\" shall be indicated and the reasons shall be specified.(Non-applicable items can be left default but \"not applicable\" shall be indicated and reasons shall be specified.)\n'第三十三条 申办者应当在开展药物临床试验前在药物临床试验登记与信息公示平台登记药物临床试验方案等信息。药物临床试验期间，申办者应当持续更新登记信息，并在药物临床试验结束后登记药物临床试验结果等信息。登记信息在平台进行公示，申办者对药物临床试验登记信息的真实性负责。'可被翻译为：Article 33 The sponsor shall, before carrying out the drug clinical trial, submit the drug clinical trial protocol and other information on the drug clinical trial registry and information disclosure platform. During the drug clinical trial, the sponsor shall continually update the registered information and, after the drug clinical trial ends, submit results of the drug clinical trial and other related information. Information posted on the platform shall be disclosed to the public. The sponsor is responsible for the authenticity of registered information about the drug clinical trial.\n'第十条 申请人在申请药品上市注册前，应当完成药学、药理毒理学和药物临床试验等相关研究工作。药物非临床安全性评价研究应当在经过药物非临床研究质量管理规范认证的机构开展，并遵守药物非临床研究质量管理规范。药物临床试验应当经批准，其中生物等效性试验应当备案；药物临床试验应当在符合相关规定的药物临床试验机构开展，并遵守药物临床试验质量管理规范。'可被翻译为：Article 10 Before applying for marketing registration of a drug, the applicant shall complete related research including Chemical, Manufacturing and Control (CMC), pharmacological and toxicological studies and drug clinical trials. Non-clinical safety evaluation studies shall be carried out in institutions meeting Good Laboratory Practice (GLP) requirements and be in compliance with the GLP. Drug clinical trials shall be approved, and bioequivalence studies shall be filed for record. Drug clinical trials shall be carried out in clinical trial institutions that comply with relevant regulations and adhere to the Good Clinical Practice (GCP).\n'● 指导原则根据ICH\/CTD格式提交上市申请：一般注意事项'可被翻译为：• Guidance Submitting Marketing Applications According to the ICH\/CTD Format: General Considerations\n\n根据上述已知信息，请将'（二）申请人在完成临床试验提出药品上市注册申请时，应在CTD基础上提交电子临床试验数据库。数据库格式以及相关文件等具体要求见临床试验数据递交相关指导原则。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(2) While applying for drug marketing registration upon completion of the clinical trial, the applicant shall submit the electronic clinical trial database on the basis of CTD. For specific requirements such as database format and related documents, please refer to the relevant guidelines for clinical trial data submission."
    },
    {
        "instruction":"已知信息：\n'针对患者的病情和个体化情况所选择或调整的治疗药物、剂量、用法、给药频次及给药疗程。'可被翻译为：The selection or adjustment of therapeutic drugs, dosage, usage, frequency of administration and course of administration according to the patient's condition and individual situation.\n'将医嘱每日药物剂量一次服下的给药方法。以期达到最佳治疗效果。'可被翻译为：A method of administration in which a prescribed daily dose is taken once. To achieve the best results.\n'通过测定患者体内的药物暴露、药理标志物或药效指标，利用定量药理模型，以药物治疗窗为基准，制订适合患者的个体化给药方案。其核心是个体化药物治疗。'可被翻译为：By measuring drug exposure, pharmacological markers, or therapeutic indicators within a patient's body and utilizing quantitative pharmacological models, personalized dosing regimens are developed based on the drug therapeutic window. The core focus is on individualized drug therapy.\n'在医疗过程中，根据疗效和病情，按照一定规律增加或减少药物剂量使达到有效和安全的医疗行为。'可被翻译为：In the course of medical treatment, according to the efficacy and condition, according to a certain law to increase or reduce the drug dose to achieve effective and safe medical behavior.\n\n根据上述已知信息，请将'根据患者的具体病情和个体差异选择治疗药物，制订给药方案，进行安全有效的治疗。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"According to the patient's specific condition and individual differences to select therapeutic drugs, formulate drug delivery plan, safe and effective treatment."
    },
    {
        "instruction":"已知信息：\n'在实验动物中观察到的毒性效应。'可被翻译为：Toxic effects observed in laboratory animals.\n'发育毒性'可被翻译为：developmental toxicity\n'吸入途径的最大相关毒性可能是致癌。'可被翻译为：The possible carcinogenic effects were considered the endpoint of greatest toxicological relevance for this route of exposure.\n'长期吸入高剂量的锑可导 致人和动物呼吸系统的不良反应，包括致癌性。'可被翻译为：Inhalation of high levels of antimony over a long period can cause adverse respiratory effects in both humans and animals, including carcinogenicity.\n\n根据上述已知信息，请将'脱发是人和动物的主要毒性反应，吸入途径的吸收和毒性很高[6]。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The major toxicity identified in humans and animals is alopecia, and absorption and toxicity is considered high by the inhalation route (IPCS, 1996)."
    },
    {
        "instruction":"已知信息：\n'意图纳入能反映疾病流行病学特征的患者人群（主要是指患病率）。因此，以后所有研发项目应纳入相关比例的老年受试者。试验样本量和纳入的高龄患者比例都应该足够大，这样才能合理的总结出新药在疗效和安全性上的相同和不同。'可被翻译为：The intent to include a population reflecting the epidemiology of the disease (in terms of prevalence), and thus including a relevant proportion of elderly subjects should be part of all future development plans. Studies, and the proportion of elderly people included, should be big enough to allow a reasonable conclusion on similarity or differences in the efficacy and safety of a new compound.\n'探索性研究旨在考察药物在特定患者群体中的安全性 和有效性。'可被翻译为：Exploratory studies are designed to investigate safety and efficacy in a selected population of patients for whom the drug is intended.\n'对于这 些研究，可以接受所研究的患者范围比在关键有效性试验中预期的患者范围更窄，并且排除存在显著并存病或伴随药物的患者，以便最大化试验检测治疗组之间差异的能力。'可被翻译为：For these studies it is acceptable to study a narrower range of patients than would be expected in the pivotal efficacy trials, and to exclude patients with significant co-morbidities or concomitant medications, in order to maximise the ability of the trial to detect differences between treatment groups.\n'研究计划应包括足够数量的老年患者，特别是高龄老年人（>75岁），因为他们代表急性和慢性疼痛中的大目标人群。对于已知的药物类别，总体数据库中的全部老年人群的亚组分析通常是足够的。'可被翻译为：The investigational program should include a sufficient number of elderly patients, particularly the very elderly (>75 years old) as they represent a large target population in both acute and chronic pain. For known drug classes, subgroup analyses of the whole elderly population in the overall database are in general sufficient.\n\n根据上述已知信息，请将'有效性研究中包括的人群与上市时预期接受药物的总患者人群（例如，在老年人常见疾病的药物的研究中排除75岁以上的患者）之间的潜在差异。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Potential differences between the population(s) included in effectiveness studies and the overall patient population expected to receive the drug when it is marketed (e.g., exclusion of patients over 75 years old in studies of a drug for a disease common in the elderly)."
    },
    {
        "instruction":"已知信息：\n'根据以及考虑到预期用途，开发、优化和选择测定法。'可被翻译为：Assays need to be developed, optimized and selected according to and taking account of their intended use.\n'选择适当的技术及相关仪器或适宜设备；'可被翻译为：• Selecting an appropriate technology and related instruments or suitable apparatus;\n'3．体内QT研究的最佳实践考虑 编号 批准日期 问题 回答 3.1 （标准）体内QT 研究的种属选择 和总体设计的最 佳实践考虑是什 么？ 应选择最合适的种属并说明理由（ICH S7B第3.1.3节）。'可被翻译为：3Best Practice Considerations for the In vivo QT Studies # Date of Approval Questions Answers 3.1 What are best practice considerations for species selection and general design of the (standard) in vivo QT study? The most appropriate species should be selected and justified (ICH S7B, Section 3.1.3).\n'研究者应选择最适于解决特定研究假设的数据来源。'可被翻译为：Investigators should select data sources that are most appropriate to address the specific study hypotheses.\n\n根据上述已知信息，请将'对最 佳做法、最先进技术以及监管预期的了解，有助于为特定目标选择 最合适的技术。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Knowledge of best practices, state-of-the-art technologies and regulatory expectations contribute to the selection of the most suitable technology for a given purpose."
    },
    {
        "instruction":"已知信息：\n'用于不良事件报告的国际医学用语词典（MedDRA）术语在全球范围内由生物制药行业和监管机构使用，以促进报告和数据分析的一致性。'可被翻译为：Medical Dictionary for Regulatory Activities (MedDRA) terminology for adverse event reporting used globally by the biopharmaceutical industry and regulators to promote consistent reporting and data analysis.\n'MedDRA®-国际医学用语词典-是用于分类与使用生物药物和其他医疗产品（如医疗器械和疫苗）相关的不良事件信息的医学术语。将这些数据编码为一套标准的 MedDRA 术语，使卫生监管机构和生物制药行业能够更容易地交换和分析与医疗产品安全使用相关的数据11。'可被翻译为：MedDRA® - the Medical Dictionary for Regulatory Activities - is a medical terminology used to classify adverse event information associated with the use of biopharmaceuticals and other medical products (e.g. medical devices and vaccines). Coding these data to a standard set of MedDRA terms allows health authorities and the biopharmaceutical industry to more readily exchange and analyze data related to the safe use of medical products11.\n'3.2.1.2 MedDRA -国际医学用语词典'可被翻译为：3.2.1.2 MedDRA - the Medical Dictionary for Regulatory Activities\n'国际公认的药物遗传学\/药物基因组学术语应用于数据挖掘或数据呈现，包括包括国际医学用语词典（MedDRA）中的那些术语。'可被翻译为：Internationally recognised pharmacogenetic\/pharmacogenomic terms should be used for data mining or data presentation including those that are included in the medical dictionary for regulatory activities (MedDRA).\n\n根据上述已知信息，请将'国际医学用语词典 用于不良事件报告的国际医学用语词典（MedDRA）术语在全球范围 内由生物制药行业和监管机构使用，以促进报告和数据分析的一致性。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Medical Dictionary for Regulatory Activities Medical Dictionary for Regulatory Activities (MedDRA) terminology for adverse event reporting used globally by the biopharmaceutical industry and regulators to promote consistent reporting and data analysis."
    },
    {
        "instruction":"已知信息：\n'试验应持续足够长的时间以确认 是否有持续的反应， 和覆盖后面可能发生的患者脱落。'可被翻译为：The trials should be long enough to determine if any response will be sustained, and to cover a potential late drop-out.\n'对光稳定的药物，则在合理的光暴露后即可以终止研究。'可被翻译为：For photostable materials, studies may be terminated after an appropriate exposure level has been used.\n'ICH三方协调的新原料药和制剂的稳定性试验指导原则 （以下称总指导原则）指出光照试验是强力试验的组成部分。'可被翻译为：The ICH Harmonized Tripartite Guideline covering the Stability Testing of New Drug Substances and Products (hereafter referred to as the Parent Guideline) notes that light testing should be an integral part of stress testing.\n'如果制剂需在内包装或在上市包装条件下进行试验，样品应相对于光源水平或横向放置，以保证样品获得最均匀的光照。'可被翻译为：If testing of the drug product in the immediate container or as marketed is needed, the samples should be placed horizontally or transversely with respect to the light source, whichever provides for the most uniform exposure of the samples.\n\n根据上述已知信息，请将'试验应一直做到其结果显示该制剂可以充分抵御光照为止。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Testing should progress until the results demonstrate that the drug product is adequately protected from exposure to light."
    },
    {
        "instruction":"已知信息：\n'在出血的情况中：由医师和患者详细记录，判断严重程度和治疗结果（消耗量）'可被翻译为：In case of bleeding: documentation of particulars; judgement of severity and treatment outcome by clinician and patient (consumption)\n'应根据公认的分类法对出血进行分类。'可被翻译为：Bleedings should be categorised according to an acknowledged classification.\n'在无菌产品的生产中，洁净室\/区分为四个等级。'可被翻译为：For the manufacture of sterile products, there are four grades of cleanroom\/zone.\n'总体评价是指由具有痴呆患者管理经验的临床医师对患者状况作出的总体主观独立等级评定。'可被翻译为：Global assessment refers to an overall subjective independent rating of the patient’s condition by a clinician experienced in the management of patients with dementia.\n\n根据上述已知信息，请将'由医师将使用制品进行大出血住院治疗的患者的反应分为“无效”、“一般”、“良好”和“显著”四个等级。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Response should be assessed as “none”, “moderate”,  “good” or “excellent” by the physician for those patients who were treated in hospital with the product  for major bleeds."
    },
    {
        "instruction":"已知信息：\n'第一百一十条 变更研制新药、生产药品和进口药品已获批准证明文件及其附件中载明事项的，应当提出补充申请。'可被翻译为：Article 110 For the variation of the items specified in the approval document and its attachment for approved new drug development, drug production and import drug, supplementary applications shall be made.\n'第八章 补充申请的申报与审批'可被翻译为：Chapter VIII  Submission, Review and Approval of Supplementary Application\n'第十一条 药品注册申请包括新药申请、仿制药申请、进口药品申请及其补充申请和再注册申请。'可被翻译为：Article 11 Drug registration applications include applications for new drugs, generic drugs, import drugs and their supplementary applications as well as re-registration applications.\n'仿制药申请，是指生产国家食品药品监督管理局已批准上市的已有国家标准的药品的注册申请；但是生物制品按照新药申请的程序申报。'可被翻译为：Application for generic drugs refers to registration application for producing the drugs having existing national drug standard which is approved to be marketed by the State Food and Drug Administration, whereas the application for biological products shall be submitted as the process of new drug application.\n\n根据上述已知信息，请将'补充申请，是指新药申请、仿制药申请或者进口药品申请经批准后，改变、增加或者取消原批准事项或者内容的注册申请。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Supplementary application refers to application for variation, addition, or cancellation of the items or contents approved in the original application for new drug, generic drug or import drug."
    },
    {
        "instruction":"已知信息：\n'治疗全身性或局部性风湿病的药物。抗风湿药有备体激素类、非淄体消炎药类和免疫抑制药三大类。淄体激素类药物如氢化可的松、泼尼松龙、去炎松和地塞米松等糖皮质激素类；非淄体类药物包括解热镇痛药如阿司匹林等：免疫抑制药物如青霉胺、来氟米特等。'可被翻译为：Drugs used to treat systemic or local rheumatism. Antirheumatic drugs include donor hormones, non-Zietic anti-inflammatory drugs and immunosuppressive drugs. Glucocorticoid drugs such as hydrocortisone, prednisolone, desimonone and dexamethasone; Non-zietian drugs include antipyretic and analgesic drugs such as aspirin, immunosuppressive drugs such as penicillamine, leflunomide and so on.\n'除非甾体类抗炎药以外的药物治疗主要是控制体征和症状、疾病活动度、病情进展。'可被翻译为：Pharmacological therapies other than NSAIDs for RA are intended to treat signs and symptoms, disease activity and structural progression of disease.\n'DMARD改善病情抗风湿药物'可被翻译为：DMARD Disease-modifying antirheumatic drug\n'认为非甾体类抗炎药（NSAID）是大多数新诊断的JIA病例的一线治疗方案，其次是关节内糖皮质激素和改善病情的抗风湿药物（DMARD）。'可被翻译为：Nonsteroidal anti-inflammatory drugs (NSAIDs) are considered a first–line treatment option in most cases of newly diagnosed JIA, followed by intra-articular glucocorticosteroids and disease modifying antirheumatic drugs (DMARDs).\n\n根据上述已知信息，请将'可用药物一般包括合成改善病情抗风湿药物、生物型改善病情抗风湿药物和糖皮质激素。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Available agents include synthetic disease- modifying anti-rheumatic drugs (DMARDs), biological DMARDs and glucocorticoids."
    },
    {
        "instruction":"已知信息：\n'确认：证明设施、系统或设备经过恰当安装和\/或正确运行并得到预期结果，有能力达到既定标准的文件化证明'可被翻译为：qualification：Documented evidence that premises, systems or equipment are able to achieve the predetermined specifications when properly installed, and\/or work correctly and lead to the expected results.\n'性能确认（PQ）：证明设备或系统性能在正常操作环境下（即生产环境下）持续重复满足既定标准和参数的文件化工作。'可被翻译为：performance qualification (PQ): Documented verification that the equipment or system performs consistently and reproducibly within defined specifications and parameters in its normal operating environment (i.e. in the production environment).\n'1.这个条件涉及到在正常的生产过程中，在设备运行的情况下，在正常的工作人员在场的情况下进行房间分类试验。\n2.系统或子系统在所有预期工作范围内按预期运行的文件验证。\n3.这是证明设备在其正常工作范围内按照其设计规范运行，并在所有预期工作范围内按预期运行的文件证据。\n4.运行确认是证明设备在其正常运行范围内按照其设计规范运行，并在所有预期运行范围内按预期运行的书面证据。'可被翻译为：1.This condition relates to carrying out room classification tests with the normal production process with equipment in operation, and the normal staff present in the room.\n2.Documented verification that the system or subsystem performs as intended over all anticipated operating ranges.\n3.This is the documentary evidence to verify that the equipment operates in accordance with its design specifications within its normal operating range and performs as intended throughout all anticipated operating ranges.\n4.Operational qualification is the documentary evidence to verify that the equipment operates in accordance with its design specifications in its normal operating range and performs as intended throughout all anticipated operating ranges.\n'3.运行确认应当证明厂房、设施、设备的运行符合设计标准；'可被翻译为：3. Operational qualification is to verify that the premises, facilities and equipment operate in accordance with their design specifications;\n\n根据上述已知信息，请将'运行确认（OQ）：证明系统或子系统按既定预期运行范围运行的文件化工作。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"operational qualification (OQ): Documented verification that the system or subsystem performs as intended over all anticipated operating ranges."
    },
    {
        "instruction":"已知信息：\n'避免药品的开发成像糖果一样（如，棒棒糖）。'可被翻译为：Avoid development of products that resemble candy (e.g., lollipop).\n'E.避免使用外形相似的容器标签和纸盒标识'可被翻译为：E. Avoid Look-alike Container Labels and Carton Labeling\n'下面的内容提供了一些实例，是关于不良的产品设计和不良的直接接触产品的包装设计引起的问题和错误。如果在完成产品设计之前产品的修订采用前瞻性的风险评估进行评价，这些错误是可以避免的。申办方应考虑这些经验教训来使有关产品设计的风险最小化。'可被翻译为：The following sections provide examples of known problems and errors due to poor design of the drug product and container closure systems. These errors could have been avoided if product modifications had been evaluated using proactive risk assessments before finalizing the design. Sponsors should consider the lessons learned from these experiences to help minimize risks associated with their designs.\n'此外，独立于临床和生产约束（例如上市考虑）的影响也可 能影响产品设计。'可被翻译为：Additionally, influences independent of clinical and manufacturing constraints, such as marketing considerations, may also affect product design.\n\n根据上述已知信息，请将'避免类似于糖果（例如，棒棒糖）的产品设计。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Avoid product designs that resemble candy (e.g., a lollipop)."
    },
    {
        "instruction":"已知信息：\n'当连续6个月符合非活动性疾病状态的定义时，患者被认为通过药物治疗达到临床缓解。'可被翻译为：When the definition of inactive disease status is met for 6 continuous months, the patient is considered to be in clinical remission on medication.\n'无疾病活动性，如无MRI活动、复发和进展。'可被翻译为：Absence of disease activity, e.g. absence of MRI-activity, relapses and progression.\n'这些终点包括基于JADAS的最小疾病活动度和非活动性疾病，以及基于ACR的非活动性疾病\/临床缓解（治疗和\/或不治疗）。'可被翻译为：These endpoints include minimal disease activity and inactive disease based on the JADAS, and inactive disease \/ clinical remission (on and\/or off treatment) based on the ACR.\n'在用于治疗急性VTE药物的临床研究中，初步评价的研究期限至少为三个月到 12 个月。'可被翻译为：In studies evaluating medicinal products intended for the acute treatment of VTE, the study period for primary evaluation should be at least three months up to 12 months.\n\n根据上述已知信息，请将'当在没有任何药物的情况下长达12个月符合非活动性疾病状态时，将患者分类为无药物治疗即达到临床缓解状态。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"When the inactive disease status is met for 12 months in the absence of any medication, the patient is classified as being in a state of clinical remission off medication."
    },
    {
        "instruction":"已知信息：\n'评价剂量降低对减轻药物不良反应的影响是重要的。'可被翻译为：Evaluation of the effect of dose reduction on the precipitating adverse drug reaction(s) is of importance.\n'可通过减少剂量、延长剂量间隔或两者组合来实现。'可被翻译为：This may be achieved by a reduced dose, prolonged dose interval or a combination of both.\n'接受药物或安慰剂的受试者中约50%精子浓度有所降低 \n接受药物或安慰剂的受试者中约5%精子浓度降低50%或以上'可被翻译为：Approximately 50 percent of subjects receiving either drug or placebo had a decrease in sperm concentration\nApproximately 5 percent of subjects receiving either drug or placebo had a 50 percent or greater decrease in sperm concentration 0-50\n'对于提交脂质体药品的ANDA，请参考所有具体脂质体品种的仿制药品人体药代动力学和其它生物等效性研究的FDA指南，这些指南文件还讨论其它的特征研究和证明与RLD药学等效的必要资料（如药品的组成，活性成分载药量）。因为药物从脂质体中释放到组织药物摄取相互间的复杂性，简单地测量血浆中总药物浓度可能不能有效地反应靶器官（即作用部位）的生物利用度。'可被翻译为：For ANDA submissions for liposome drug products, please refer to applicable product-specific FDA guidance documents that outline recommendations regarding human pharmacokinetic and other bioequivalence studies for generic liposome drug products. These guidance documents also discuss additional characterization studies and information (e.g., drug product composition and active ingredient loading) necessary to demonstrate pharmaceutical equivalence to the RLD. Because of the complexity of the interaction between drug release from liposome drug product and tissue uptake of the drug substance, a simple measurement of total drug substance concentration in plasma may not be reflective of bioavailability of the drug at the intended target organ (i.e., site of action).\n\n根据上述已知信息，请将'拮抗剂的药物可以有效地降低作用部位活性药物浓度的情况。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Antagonist drugs can effectively reduce the concentration of the active drug at the site of action."
    },
    {
        "instruction":"已知信息：\n'情况D：当检测出已知的人致病原（如表3脚注1所指12的）时，除特殊情况外，该产品是不能被接受的。'可被翻译为：Case D: Where a known human pathogen, such as those indicated by footnote 1 in Table 3, is identified, the product may be acceptable only under exceptional circumstances.\n'如果不能使用已鉴定的病毒，应使用相关模型 病毒或特异模型病毒来评估其工艺清除效果是否可被接受。'可被翻译为：If it is not possible to use the identified virus, “relevant” or specific “model” viruses should be used to demonstrate acceptable clearance.\n'情况A：细胞或未加工品中未发现有病毒、病毒样颗粒或逆转录病毒样颗粒时，应使用上述非特异模型病毒进行病 毒消除和病毒灭活研究。'可被翻译为：Case A: Where no virus, virus-like particle or retrovirus-like particle has been demonstrated in the cells or the unprocessed bulk, virus removal and inactivation studies should be performed with non-specific “model” viruses as previously stated.\n'病毒去除：用物理方法将病毒颗粒从产品中分离。'可被翻译为：Virus Removal Physical separation of virus particles from the intended product.\n\n根据上述已知信息，请将'情况E：在细胞或未加工品中检测到用现有方法无法分类的病毒时，由于这种病毒有可能是致病性的，因此该产品一般不予接受。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Case E: When a virus, which cannot be classified by currently available methodologies, is detected in the cells or unprocessed bulk, the product is usually considered unacceptable since the virus may prove to be pathogenic."
    },
    {
        "instruction":"已知信息：\n'药物中存在的杂质或污染物可能导致安全性担忧。最好依靠纯化工艺去除杂质和污染物，而不是为了限度确定建立一套临床前试验计划。在任何情况下，都应该充分明确产品的特征，以便对临床前安全性试验进行合理设计。'可被翻译为：Safety concerns may arise from the presence of impurities or contaminants. It is preferable to rely on purification processes to remove impurities and contaminants rather than to establish a preclinical testing program for their qualification. In all cases, the product should be sufficiently characterised to allow an appropriate design of preclinical safety studies.\n'一般来说，应做安全性研究专门关注免疫原性。'可被翻译为：Generally, safety studies should be performed with specific focus on immunogenicity.\n'生物技术衍生药品的临床前安全性评价之 ICH S6（R1）协调三方指导原则'可被翻译为：ICH S6 (R1) Harmonised Tripartite Guideline on Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals\n'参见ICH行业指导原则M3（R2）适用于药品人体临床试验和上市批准的非临床安全性研究和S6（R1） 生物技术衍生药品的临床前安全性评价。'可被翻译为：See the ICH guidances for industry M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals and S6(R1) Preclinical Safety Evaluation of Biotechnology- Derived Pharmaceuticals.\n\n根据上述已知信息，请将'由于免疫原性问题是由杂质或污染物的存在引起的，所以首选依赖纯化工艺来除去杂质和污染物，而非建立临床前试验计划来进行鉴别（请参考 ICH S6（R1）生物技术衍生药品的临床前安全性评价协调三方指导原则）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Since immunogenicity concerns may arise from the presence of impurities or contaminants, it is preferable to rely on purification processes to remove impurities and contaminants rather than to establish a preclinical testing program for their qualification (refer to ICH S6 (R1) Harmonised Tripartite Guideline on Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals)."
    },
    {
        "instruction":"已知信息：\n'大鼠肝脏非程序性DNA合成（UDS）试验 \n• 尤其是细菌突变试验仅在S9代谢活 化条件下结果为阳性时 • 针对下列肝脏代谢物：已知在试验所用的种属中产生能够诱导大的加合物'可被翻译为：Rat liver Unscheduled DNA Synthesis (UDS) test \n• In particular for bacterial mutagenicity positive with S9 only • Responsible liver metabolite known o to be generated in test species used o to induce bulky adducts\n'对于直接作用的致突变物（不加S9细菌突变为阳性） 和已知的致突变化合物* 大鼠肝非程序性 DNA 合成（UDS） 试验'可被翻译为：For directly acting mutagens (bacterial mutagenicity positive without S9) and compounds known to be clastogenic* Rat liver Unscheduled DNA Synthesis (UDS) test\n'已知相关的肝代谢物会 o 在试验所用物种中产生 o 诱导大的加合物 彗星试验'可被翻译为：Responsible liver metabolite known o to be generated in test species used o to induce bulky adducts Comet assay\n'微核试验（血或骨髓） \n• 检测直接诱变剂（细菌突变试验在非 S9代谢活化条件下结果为阳性时） 和已知染色体断裂剂*'可被翻译为：Micronucleus test (blood or bone marrow) \n• For directly acting mutagens (bacterial mutagenicity positive without S9) and compounds known to be clastogenic*\n\n根据上述已知信息，请将'大鼠肝脏非程序性DNA合成（UDS）试验 \n• 尤其是细菌突变试验仅在S9代谢活化条件下结果为阳性时 \n• 已知可产生下列变化的肝脏代谢物\no在试验所用物种中产生 \no诱导大的加合物'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Rat liver Unscheduled DNA Synthesis (UDS) test \n·In particular for bacterial mutagenicity positive with S9 only \n·Responsible liver metabolite known\n o to be generated in test species used\n o to induce bulky adducts"
    },
    {
        "instruction":"已知信息：\n'对于已批准的适应症，在实际使用条件下的有效性\/疗效的新信 息（如果有）也应在本章节中描述。'可被翻译为：For approved indications, new information on efficacy\/effectiveness under conditions of actual use should also be described in this section, if available.\n'此外，MAH应在章节17.2中列出在报告期内批准的新适应症的简明信息。'可被翻译为：In addition, the MAH should include in Section 17.2 concise information on new indications approved during the reporting interval.\n'关于有效性\/疗效的新确定信息'可被翻译为：Newly Identified information on Efficacy\/Effectiveness\n'3.17.3 利益的表征 PBRER章节17.3提供了在报告期内获得的关于已批准适应症的基线利益 信息（见章节3.17.1）和任何相关新的利益信息（见章节3.17.2）的整合。'可被翻译为：3.17.3 Characterisation of Benefits Section 17.3 of the PBRER provides an integration of the baseline benefit information (see Section 3.17.1) and any relevant new benefit information (see Section 3.17.2) that became available during the reporting interval for approved indications.\n\n根据上述已知信息，请将'3.17.2 关于有效性\/疗效的新确定信息 在本章节中，应介绍在报告期内可能已获得的关于已批准适应症的有效性\/ 疗效的新信息。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"3.17.2 Newly Identified information on Efficacy\/Effectiveness New information on efficacy\/effectiveness in approved indications that may have become available during the reporting interval should be presented in this section."
    },
    {
        "instruction":"已知信息：\n'然 而，当在申办方和FDA项目经理之间的电话会谈期间讨论复杂的、监管的或技 术问题时，应采用书面沟通（例如电子邮件、申办方提案、FDA信函）随访呼 叫者，以记录讨论和\/或对在会谈期间请求的信息的回复。'可被翻译为：However, when complex, regulatory, or technical issues are discussed during the course of a telephone conversation between the sponsor and the FDA project manager, the caller should follow-up with a written communication (e.g., email, sponsor submission, FDA correspondence) to document the discussion and\/or respond to information requested during the conversation.\n'涉及在药物开发期间在关键里程碑分享结果和信息的沟通或者终止开发计划所需进行的沟通最好在FDA与申办方之间的正式会议（例如，面对面会议、电话会议或仅书面答复（WRO））中进行。FDA通过正式会议流程向申办方发送反馈时间限详见处方药用户付费法案（PDUFA）和生物仿制药用户付费法案（BsUFA）协议以及FDA的正式会议指导原则。'可被翻译为：Communications that involve sharing results and information at critical milestones during drug development or are necessary for a stalled development program to proceed are best addressed in formal meetings between FDA and sponsors (e.g., face-to-face meeting, teleconference, or written response only (WRO)). Timelines for FDA sending feedback to sponsors via the formal meeting process are described in Prescription Drug User Fee Act (PDUFA) and Biosimilar User Fee Act (BsUFA) agreements and in FDA’s formal meetings guidances.\n'根据问题的性质和复杂性，FDA将对问题作出回复，或重新给申办方指定可接收回复的替代途径（例如，其他FDA 学科问题专家，正式会议请求过程）。'可被翻译为：Depending on the nature and complexity of the question(s), FDA will either respond to the question(s) or redirect the sponsor to an alternative pathway for receiving a response (e.g., other FDA subject matter expert, formal meeting request process).\n'当此类沟通具有时效性或为沟通行动（例如临床试验暂停）时，项目经理应当通过安全电子邮件向申办方发送书面FDA信函的副本。'可被翻译为：Project managers should send a courtesy copy of written FDA correspondence to sponsors via secure email when such communications are time-sensitive or communicate actions (e.g., clinical hold).\n\n根据上述已知信息，请将'根据会谈期间所提出的问题的性质，可让申办方进行正式会议过程，以便与附加审评人员和管理人员更充分地讨论问题。FDA项目经理和申办方应提供相互的姓名和电话号码，用于沟通时效性问 题（例如临床试验暂停通知）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Depending on the nature of the questions presented during the conversation, the sponsor may be referred to the formal meeting process for a fuller discussion of the issue(s) with additional review staff and management. Both FDA project managers and sponsors should provide mutual names and telephone numbers for communicating time-sensitive issues (e.g., notification of clinical hold)."
    },
    {
        "instruction":"已知信息：\n'18.11 “生物技术工艺”（生物技术）指使用细胞或组织生产原料药，这些细胞或组织可通过DNA重组技术、杂交瘤技术或其它技术得到。生物技术工艺生产的原料药通常由蛋白质、多肽等高分子物质组成，本章提出了相应的具体要求。某些低分子原料药，如抗生素、氨基酸、维生素和碳水化合物也可使用DNA重组技术生产，其控制要求与传统发酵工艺生产的原料药相似。'可被翻译为：18.11 The term “biotechnological process” (biotech) refers to the use of cells or organisms that have been generated or modified by recombinant DNA, hybridoma or other technology to produce APIs. The APIs produced by biotechnological processes normally consist of high molecular weight substances, such as proteins and polypeptides, for which specific guidance is given in this Section. Certain APIs of low molecular weight, such as antibiotics, amino acids, vitamins, and carbohydrates, can also be produced by recombinant DNA technology.The level of control for these types of APIs is similar to that employed for classical fermentation.\n'本指南适用于通过化学合成、提取、细胞培养\/发酵生产，或从天然资源中获取的原料药，也包括采用上述多种方法组合生产的原料药。第18章规定了采用细胞培养\/发酵工艺生产原料药的特定要求。'可被翻译为：This Guide covers APIs that are manufactured by chemical synthesis, extraction, cell culture\/fermentation, by recovery from natural sources, or by any combination of these processes. Specific guidance for APIs manufactured by cell culture\/fermentation is described in Section 18.\n'虽然整个ICHQ7指南并不适用于传统发酵工艺引入细胞之前的步骤，如【ICH Q7，第1.3章节】表1所示，但应对细胞库建立适当的GMP控制。'可被翻译为：Although the entire ICH Q7 Guideline does not apply prior to the introduction of cells into the classical fermentation process, as shown in Table 1 of [ICH Q7, Section 1.3], an appropriate level of GMP controls suitable for cell banks should be established.\n'这些蛋白质和多肽主要是由重组或非重组表达系统产生的。'可被翻译为：These proteins and polypeptides are mainly produced by recombinant or non-recombinant expression systems.\n\n根据上述已知信息，请将'18.10 本章专门对采用天然或重组组织进行细胞培养或发酵生产的原料药或中间体提出了未在之前章节充分阐明的特殊控制要求。本章并非独立存在章节。总体上，本指南其它章节中的GMP原则通常也适用于本章节。需要说明是，生产小分子化合物的“传统”发酵工艺与 采用重组与非重组组织生产蛋白质和\/或多肽的发酵工艺本质相同，只是控制程度有所不同。生产蛋白质和多肽的生物技术工艺的控制要求通常要严于传统发酵工艺，本章对此作出了规定\/阐述。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"18.10 Section 18 is intended to address specific controls for APIs or intermediates manufactured by cell culture or fermentation using natural or recombinant organisms and that have not been covered adequately in the previous sections. It is not intended to be a stand-alone Section. In general, the GMP principles in the other sections of this document apply. Note that the principles of fermentation for “classical” processes for production of small molecules and for processes using recombinant and non-recombinant organisms for production of proteins and\/or polypeptides are the same, although the degree of control will differ. Where practical, this section will address these differences. In general, the degree of control for biotechnological processes used to produce proteins and polypeptides is greater than that for classical fermentation processes."
    },
    {
        "instruction":"已知信息：\n'非活性成分 氯化钠(4.5 mg\/mL)，柠檬酸（7.2mg\/mL），溶于注射用水(WFI)'可被翻译为：Inactive ingredients Sodium chloride (4.5 mg\/mL), Citrate (7.2 mg\/mL) in water for injection (WFI)\n'9mg\/mL'可被翻译为：9 mg\/mL\n'辅料清单 [产品特定的] 氯化钠 9 mg\/mL 注射用水'可被翻译为：List of excipients [Product specific] Sodium chloride 9 mg\/mL Water for injections.\n'每mL氟（18F）脱氧葡糖中含有 9 mg氯化钠。'可被翻译为：Each mL of fludeoxyglucose (18F) contains 9 mg of sodium chloride.\n\n根据上述已知信息，请将'可用 9 mg\/mL 注射用氯化钠溶液稀释药品。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The medicinal product may be diluted with sodium chloride 9 mg\/mL solution for injection."
    },
    {
        "instruction":"已知信息：\n'i. 如适用，应提供合成工艺和纯化过程的完整描述'可被翻译为：i. A complete description of the synthetic process and purification procedures, as applicable\n'18.41 收获和纯化的操作规程中，应当详细规定去除或灭活生产用微生物、细胞碎片和培养基组分（同时尽可能确保减少降解、污染和对质量的影响）的操作，确保中间体或原料药具有持续稳定的质量。'可被翻译为：18.41 Harvest and purification procedures that remove or inactivate the producing organism, cellular debris and media components (while minimizing degradation, contamination, and loss of quality) should be adequate to ensure that the intermediate or API is recovered with consistent quality.\n'去除或灭活致热物质(如内毒素)至规定最小量的过程。'可被翻译为：A process designed to remove or inactivate pyrogenic material (such as endotoxin) to a specified minimum quantity.\n'当判断病毒灭活\/去除过程的效果时，应综合考虑以下各种因素：'可被翻译为：A combination of factors must be considered when judging the data supporting the effectiveness of virus inactivation\/removal procedures. These include:\n\n根据上述已知信息，请将'iv. 提取和纯化过程的描述，如适用。应描述相关过程，适用时确保避开、去除、和\/或动物蛋白、病毒及任何其它感染剂。在生产过程中，应通过确定恰当的控制方法，解决避免、和\/或去除热源物质和细菌内毒素的问题。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"iv. A description of extraction and purification procedures, as applicableYou should describe procedures to ensure the avoidance, removal, and\/or inactivation of animal proteins and viruses and any other infectious agents, where applicable. You should address the avoidance and\/or removal of pyrogenic material and bacterial endotoxins by establishing appropriate controls during the manufacturing process."
    },
    {
        "instruction":"已知信息：\n'这些临床进展也要求对这些治疗的评估建议进行修订。'可被翻译为：These advancements require modified recommendations for the assessment of these therapies.\n'以下建议的试验设计可以进行调整，尤其是参数、时间点和评估方面，且仍需满足试验目的。'可被翻译为：The suggested study designs below can be modified, particularly with respect to parameters, timings, and assessments and still meet the study objectives.\n'IPSS基于诊断时的骨髓原始细胞百分比、细胞遗传学以及外周血细胞数量和减少程度，可以用来评判四个风险组：低、中度-1、中度-2和高风险组。最近，新发现的临床和实验室变量被认为有可能增加IPSS中的预后信息（红细胞输血依赖性、高水平LDH）。因此当这些变量被充分验证后，建议申办方紧密跟进用于临床试验设计的预后评分的改进。'可被翻译为：IPSS is based on the percentage of bone marrow blasts, cytogenetics and number and degree of peripheral cytopenias at diagnosis, enabling identification of four risks groups: low, intermediate-1, intermediate-2, and high risk. Recently, new clinical and laboratory variables were identified tha might add prognostic information to the IPSS (red blood cell transfusion dependency, high levels of LDH). Sponsors are therefore advised to follow closely the expected refinement of prognostic scores to be used in the design of clinical trials when sufficiently validated.\n'在这种情况下，建议采用已充分建立的预后评分系统（如IPSS）对患者进行分层。'可被翻译为：Stratification using a well established prognostic score such as IPSS is recommended in such cases.\n\n根据上述已知信息，请将'因此当这些变量被充分验证后，建议申办方紧密跟进用于临床试验设计的预后评分的改进。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Sponsors are therefore advised to follow closely the expected refinement of prognostic scores to be used in the design of clinical trials when sufficiently validated."
    },
    {
        "instruction":"已知信息：\n'·有其他可能干扰试验药物疗效解释的伴随疾病（例如，肺癌，充血性心力衰竭，支气管扩张，气胸）的患者'可被翻译为：·Patients with any concomitant illness that may confound the interpretation of the effect of trial drugs (e.g., pulmonary malignancy, congestive heart failure, bronchiectasis, pneumothorax).\n'此外，研究治疗的药效学影响可能影响这些合并症。'可被翻译为：Furthermore, pharmacodynamic effects of the investigational treatment may influence these comorbidities.\n'血脂水平可能受其他临床病症的影响，如糖尿病、甲状腺疾病或肾病综合征；在这种情况下，一旦控制或治疗了基础疾病 应重新评估血脂水平。'可被翻译为：Blood lipid levels may be affected by other clinical conditions such as diabetes mellitus, thyroid disorders or nephrotic syndrome; in such cases, the lipid levels should be reassessed once the underlying disease has been controlled or treated.\n'应尽可能确认和控制对照组和活性药物治疗组的伴随药物（包括抢救药物）差异所产生的可能偏倚。 视情况而定，应对研究药物对与神经性疼痛相关的特定疾病（例如，糖尿病和血糖控制）产生 的任何潜在不利影响进行积极研究。'可被翻译为：Possible bias introduced by differences in concomitant medications (including rescue medication) should be recognised and controlled as far as possible in control and active groups. Any potential detrimental effects of the investigational drug on specific diseases associated with neuropathic pain (e.g., diabetes and glycemic control) should be actively investigated as appropriate.\n\n根据上述已知信息，请将'a) 用于治疗给定疾病的药物可能影响其他并行疾病（即，降压药beta阻滞剂可 能损害糖尿病或哮喘的控制）；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"a) a drug used to treat a given disease may have an impact on other concurrent disease(s) (i.e. beta blockers used for hypertension may impair control of diabetes or asthma);"
    },
    {
        "instruction":"已知信息：\n'最理想的是试验能得到明确的阳性或阴性结果。'可被翻译为：Ideally it should be possible to declare test results clearly negative or clearly positive.\n'1. 应根据ICH公布的M7指导原则进行Ames测试，但是，在 M7公布前所做的Ames测试不需要重复。'可被翻译为：1. Ames tests should be conducted according to M7 upon ICH publication. However, Ames tests conducted prior to publication of M7 need not be repeated.\n'3.3.2 试验设计\/试验方案 对于体外中期相细胞染色体损伤的细胞遗传学评价，试验方案应包括在有和无代谢活化两种条件、设有合适的阳性和阴性对照情况下进行试验。'可被翻译为：3.3.2 Study Design\/Test Protocols For the cytogenetic evaluation of chromosomal damage in metaphase cells in vitro, the test protocol should include the conduct of tests with and without metabolic activation, with appropriate positive and negative controls.\n'对于MLA，试验方案应包括在有和无代谢活化两种条件、设有合适的阳性和阴性对照情 况下进行试验，受试物应给药处理3~4小时。'可被翻译为：For MLA, the test protocol should include the conduct of tests with and without metabolic activation, with appropriate positive and negative controls, where the treatment with the test article is for 3 to 4 hours.\n\n根据上述已知信息，请将'与OECD和IWGT报告建议的一个不同点是：基于药物检测的经验，当Ames试验结果是明确的阳性或阴性，且是在完全适当的方案下进行（包括在有和无代谢活化条件下使用所有菌株，能满足高浓度选择标准的合适的浓度范围，有合适的阳性和阴性对照）时，一个单独的Ames试验被认为 是足够的。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"One difference from the OECD and IWGT recommendations is that, based on experience with testing pharmaceuticals, a single bacterial mutation (Ames) test is considered sufficient when it is clearly negative or positive, and carried out with a fully adequate protocol including all strains with and without metabolic activation, a suitable dose range that fulfills criteria for top dose selection, and appropriate positive and negative controls."
    },
    {
        "instruction":"已知信息：\n'·在限定患者亚群（例如，轻度疾病患者）中的应用，药物风险绝不允许药物在 更大的亚群中使用7'可被翻译为：·Use in a defined subset of patients (e.g., people with mild disease) where the risks of the drug are such that the drug should never be used in that subset of the larger population7\n'如果数据支持药物在儿科人群中用于某一特定适应症，当合适时，儿科用药信息必须放在如下所述的说明书相关位置上（21 CFR 201.57（c）（9）（iv）（B）、 （C）和（D））。以下项目列表中包含的信息适用于21 CFR 201.57（c）中所描述的完整处方信息。在人用处方药和生物制品的处方信息中，处方信息要点部分的特殊人群用药儿科用药中，应包含药物在儿科人群中应答或使用的任何有临床意义的差异的简明摘要。'可被翻译为：When data support the use of a drug in a pediatric population for a particular indication, pediatric use information must be placed in relevant sections of labeling, as applicable, as described below (21 CFR 201.57(c)(9)(iv)(B), (C), and (D)). The information contained in the following bulleted list is intended for the full prescribing information as described in 21 CFR 201.57(c). In the prescribing information for human prescription drugs and biological products, the Highlights of Prescribing Information, USE IN SPECIFIC POPULATIONS, Pediatric Use, should contain a concise summary of any clinically significant differences in response or use of a drug in a pediatric population.\n'只有当存在已证实的药物所致超敏反应的病例或者根据类似药物信息（例如，同一药理类别或相似化学结构或在一个类别内交叉过敏是公认的现象）可预知这种反应时，才把超敏反应患者的禁忌包括在说明书中。当存在这种反应风险的患者使用药物的风险超过可能的益处时（即，临床上不宜再激发对该药或类似药物有超敏反应史的患者），应包括对这类患者使用的禁忌。在描述禁忌的同时，说明书应简要说明观察到的（或预知的）反应的类型和性质，并酌情与说明书其他部分的更详细讨论相互参照。'可被翻译为：A contraindication in patients with hypersensitivity reactions should be included in labeling only when there are demonstrated cases of hypersensitivity with the product or such reactions may be anticipated based on data from similar drugs (e.g., those in the same pharmacological class or with similar chemical structures, or when cross-sensitivity within a class is a recognized phenomenon). When the risk of using the drug in a patient at risk for such a reaction outweighs the potential benefits (i.e., it would be clinically inappropriate to rechallenge a patient with a history of a hypersensitivity reaction to the drug or a similar drug), a contraindication to use in such patients should be included. Along with the contraindication statement, the labeling should briefly describe the type and nature of the observed (or anticipated) reaction(s), and cross-reference to a more detailed discussion elsewhere in the labeling, as appropriate.\n'当根据不良反应的可能性和严重性且用于禁忌的临床状态下的不良反应风险超过了对任何患者的任何可能益处时，通常可根据可预知的不良反应来禁用药物：'可被翻译为：Ordinarily, a drug should be contraindicated on the basis of an anticipated adverse reaction if the risk of the adverse reaction in the clinical situation to which the contraindication will apply, based on both likelihood and severity of the adverse reaction, outweighs any potential benefit to any patient:\n\n根据上述已知信息，请将'7适应症和用法部分必须包含当考虑药物安全性时的药物应用信息，即某些患者（例如，有严重疾病的患者）或某些状态下（例如，其他药物耐药的患者）应保留药物的应用（§ 201.57(c)(2)(i)(B) 和(E)）。在罕见的情况下，当某种药物的风险明显大于任何可能的治疗益处时，并且该药应该从未用在某个选定患者亚集中，在禁忌部分也应描述此患者亚集的用药禁忌。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"7The INDICATIONS AND US AGE section must contain information about use of the drug when safety  considerations are such that the drug should be reserved for certain patients (e.g, patients with severe disease) or situations (e.g., patients refractory to other drugs) (§201.57(c)(2)(i)(B) and (E)).In rare cases, when the risks of the drug clearly outweigh any possible therapeutic benefit and the drug should never be used in a selected patient subset, a contraindication for use of the drug in that subset should also be described in the CONTRAINDICATIONS section."
    },
    {
        "instruction":"已知信息：\n'药物谷浓度应维持在5g\/L水平以上。'可被翻译为：The trough levels should be maintained above 5g\/l.\n'给药方案应使IgG达到至少5-6g\/l的谷浓度（在下一次输液前测量），并且最终达到该年龄下血清IgG的参考范围内。'可被翻译为：The dose regimen should achieve a trough level of IgG (measured before the next infusion) of at least 5 to 6 g\/l and aim to be within the reference interval of serum IgG for age.\n'原发性免疫缺陷综合征的替代治疗 剂量方案应使IgG谷浓度水平（在下一次注射前测量）至少达到5到6g\/L。开 始治疗后的三到六个月要求能达到平衡状态。'可被翻译为：Replacement therapy in primary immunodeficiency syndromes The dose regimen should achieve a trough level of IgG (measured before the next infusion) of at least 5 to 6 g\/l. Three to six months are required after the initiation of therapy for equilibration to occur.\n'为了减少感染的发生率，可 能需要增加剂量以及提高谷浓度水平。'可被翻译为：To reduce the rate of infection, it may be necessary to increase the dosage and aim for higher trough levels.\n\n根据上述已知信息，请将'要求谷浓度水平达到5-6g\/L的给药剂量为0.2-0.8g\/kg\/月。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The dose required to achieve a trough level of 5-6 g\/l is of the order of 0.2-0.8 g\/kg\/month."
    },
    {
        "instruction":"已知信息：\n'50只\/组雄性F344大鼠 （SPF） 2年（喂饲） 50只 3个：40；200； 1000 ppm（1.9： 9.8； 53.8mg\/kg\/天） 嗜铬细胞瘤\/雌 性 53.8mg\/kg\/天 116.9**'可被翻译为：50\/group female F344 rats (SPF) 2 years (Diet) 50 3: 40; 200; 1000 ppm. (1.9; 9.8;53.8 mg\/kg\/d) Pheochromo- cytoma\/Female 53.8 mg\/kg\/d 116.9**\n'参考文献5* 50只\/性别\/组 F344\/N大鼠 2年 5天\/周 灌胃 50只 2个： 26.5； 53.8mg\/kg\/d 乳腺\/ 雌性 4.15'可被翻译为：Ref. 5* 50\/sex\/ group F344\/N rats 2 years 5 days\/wk Oral gavage 50 2: 26.5; 53.8 mg\/kg\/d Mammary gland\/Female 4.15\n'50只\/组雄性 Crj:BDF1 （SPF） 2年 （喂饲） 50只 3个：125；500； 2000 ppm （15.3：60.1； 240.1mg\/kg\/ 天） NA'可被翻译为：50\/group male Crj:BDF1 (SPF) 2 years (Diet) 50 3: 125;500; 2000 ppm. (15.3; 60.1;240 .1 mg\/kg\/d) NA\n'50只\/组雌性 Crj:BDF1 （SPF） 2年（喂饲） 50只 3个：125；500； 2000 ppm （17.6：72.6； 275.2mg\/kg\/ 天） 肝血管内皮瘤 275.2mg\/kg\/天 1919.9'可被翻译为：50\/group female Crj:BDF1 (SPF) 2 years (Diet) 50 3: 125;500; 2000 ppm. (17.6; 72.6; 275.2 mg\/kg\/d) Hepatic hemangiosarcomas 275.2 mg\/kg\/d 1919.9\n\n根据上述已知信息，请将'50只\/组雄性F344大鼠（SPF） 2年（喂饲） 50只 3个：40；200；1000 ppm（1.5：7.7；41.2mg\/kg\/天） 脾脏、血管肉瘤mg\/kg\/天 173.5'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"+ 50\/group male F344 rats (SPF) 2 years (Diet) 50 3: 40; 200; 1000 ppm. (1.5; 7.7; 41.2 mg\/kg\/d) Spleen hemangiosarcomas 7.7 mg\/kg\/d 173.5"
    },
    {
        "instruction":"已知信息：\n'相反，不能仅仅根据交互作用的显著性检验而认为存在某种交互作用。'可被翻译为：Conversely, an interaction cannot be considered as relevant on the sole basis of a significant test for interaction.\n'因为不能确保研究的检测灵敏度，如果 试验药物未能显示优效，那么缺少恰当的对照治疗还会让该 研究作为一个非劣效研究不可用。'可被翻译为：Lack of appropriate use of the control treatment would also make the study unusable as a non-inferiority study, if superiority of the test drug is not shown, because assay sensitivity of the study would not be ensured (see section 1.5.2).\n'根据统计学显著性检验对交互作用项的评价价值不大。'可被翻译为：Assessment of interaction terms based on statistical significance tests is therefore of little value.\n'交互作用（定性和定量）'可被翻译为：interaction (qualitative & quantitative)\n\n根据上述已知信息，请将'交互作用的检验常常缺乏统计学把握度，一个交互作用无统计学证据并不能证明不存在有临床意义的交互作用。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Tests for interactions often lack statistical power and the absence of statistical evidence of an interaction is not evidence that there is no clinically relevant interaction."
    },
    {
        "instruction":"已知信息：\n'当规格重叠或市售速释产品规格可实现延释产 品规格时，可以增加用药错误的风险。 片剂刻痕 确保片剂刻痕与推荐剂量一致。'可被翻译为：The risk for medication error can be increased when strengths overlap or the strength of the extended release product is achievable from the marketed immediate- release product strength. • Tablet Scoring Ensure that tablet scoring is consistent with the recommended dosing.\n'FDA建议研发缓释固体口服制剂的申请人进行体外研究，评价药物在体内酒精环境中出现药物突释的可能性。应考察药物在不同浓度的酒精溶媒中的释放情况。某些特定情况下可能需要进行体内药物与酒同服时的生物等效性研究。可参考相关行业指导原则《个别药物生物等效性要求》以及任何可用的相关的特殊药 物的指导原则以获取更多信息25'可被翻译为：FDA recommends applicants developing certain extended release solid oral dosage forms to conduct in vitro studies to determine the potential for dose dumping in alcohol in vivo. In vitro assessments of the drug release from the drug product using media with various alcohol concentrations may be recommended. An in vivo BE study of the drug product when administered with alcohol may be suggested in some cases. For information on specific products, we recommend that applicants consult the guidance for industry Individual Product Bioequivalence Recommendations and any available relevant product-specific guidance.25\n'与递送系统（例如透皮、鼻内、经颊）有关的潜在安全性问题应根据相关指南进行评价和报告。'可被翻译为：Potential safety issues relating to the delivery system (e.g. transdermal, intranasal, buccal) should be evaluated and reported in accordance with the relevant guidelines.\n'本指南提供了为支持简化新药申请(ANDA) 而提交的评价透皮递送系统 (TDS)和外用贴剂黏附性能的研究的设计和执行建议。'可被翻译为：This guidance provides recommendations for the design and conduct of studies evaluating the adhesive performance of a Transdermal Delivery System (TDS) or a topical patch submitted in support of an Abbreviated New Drug Application (ANDA).\n\n根据上述已知信息，请将'如果强效阿片类药物产品配制为口服延释产品，则仔细评价剂量倾斜的可能性（例如与酒精相关）是特别重要的。应当用透皮递送系统（例如暴露于热）研究类似的效应'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"If strong opioid products are formulated as oral prolonged release products, careful evaluation of the potential for dose-dumping (e.g. in connection with alcohol) is of particular importance. Similar effects should be investigated with transdermal delivery systems (e.g. exposure to heat)."
    },
    {
        "instruction":"已知信息：\n'2在本指南中，药物包括《联邦食品、药品、化妆品法案》第505部分监管的药物以及《公众健康服务法案》第351部分监管的生物制品。'可被翻译为：2 For the purposes of this guidance, drug includes drugs regulated under section 505 of the Federal Food, Drug, and Cosmetic Act and biological products regulated under section 351 of the Public Health Service Act.\n'2本指南适用于药物，包括生物制品。就本指南的目的而言，药品或药物将被用来指代人用处方药和生物制品，并且按药物的规定来对生物制品进行监管。'可被翻译为：2 This guidance applies to drugs, including biological drug products. For the purposes of this guidance, drug product or drug will be used to refer to human prescription drug and biological products that are regulated as drugs.\n'6第 312 款适用于，除了某些例外，服从于联邦食品、药品和化妆品法（21 U.S.C355） 第 505 款或者公共保健服务法（58stat. 632，经修订（42 U.S.C 201 以及下面的 内容））许可规定药物和生物制品的所有临床研究。'可被翻译为：Part 312 applies, with certain exceptions, to all clinical investigations of drugs and biological products that are subject to section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) or to the licensing provisions of the Public Health Service Act (58 Stat. 632, as amended (42 U.S.C. 201 et seq.)).\n'该指南提供了关于联邦食品、药品和化妆品法案（法案） （21 U.S.C. 355(o)）新的第505(o)部分的实施信息，添加了食品药品监督管理局2007 修订案 （FDAAA）的第901部分。第505(o)(3)部分授权FDA对于该法案第505部分批准 的处方药物和按照美国卫生及公共服务部第351部分（PHS法案）（42 U.S.C. 262）3批准的生物制品要求一定的上市后研究和临床试验2 该指南提供了法案 第 505(o)(3)部分实施上市后研究和临床试验有关要求的信息。该指南也描述了上市后 研究和临床试验的类型：'可被翻译为：This guidance provides information on the implementation of new section 505(o) of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. 355(o)), added by section 901 of the Food and Drug Administration Amendments Act of 2007 (FDAAA). Section 505(o)(3) authorizes FDA to require certain postmarketing studies and clinical trials2 for prescription drugs approved under section 505 of the Act and biological products approved under section 351 of the Public Health Service Act (the PHS Act) (42 U.S.C. 262).3 This guidance provides information about the requirements for postmarketing studies and clinical trials under section 505(o)(3) of the Act. The guidance also describes the types of postmarketing studies and clinical trials that:\n\n根据上述已知信息，请将'2出于本指导原则的目的，药物以及药品和生物制品指的是包括按照联邦食品、药品和化妆品法案第505节（21 U.S.C. 355）批准的药品以及按照公共保健服务法（PHSA）（42 U.S.C. 262）许可的属于药物的生物制品。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2 For the purposes of this guidance, references to drugs and drug and biological products include drugs approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) and biological products licensed under section 351 of the Public Health Service Act (PHSA) (42 U.S.C. 262) that are drugs."
    },
    {
        "instruction":"已知信息：\n'给药方案和动物种属、品系的选择应尽可能根据已有的药代动力学和毒代动力学信息确定。实际上，大多数研究采用大鼠和小鼠进行。'可被翻译为：The treatment regimen, species and strain selection should, as far as is feasible, be determined with regard to the available pharmacokinetic and toxicokinetic information. In practice, the vast majority of these studies is conducted in the rat and mouse.\n'应选择合适的剂量和动物种属来解决导致考虑进行重复给药组织分布研究的问题。'可被翻译为：Dose level(s) and species should be chosen to address the problem that led to the consideration of the repeated dose tissue distribution study.\n'对于人体药代动力学研究，研究方案设计和使用方法信息应和药代动力学 数据同时提交。'可被翻译为：For human PK studies, information on study design and methods used along with the PK data.\n'药代动力学 应进行常规药代动力学研究（参见关于人体药代动力学研究的指南的说明）。'可被翻译为：Pharmacokinetics  The usual pharmacokinetic studies should be performed (see note for guidance on pharmacokinetic studies in man).\n\n根据上述已知信息，请将'给药方案（注释11）和种属的选择应尽可能与药效学和药代动力学原则相符。但在既无动物也无人体药代动力学数据可借鉴的研究初期，此要求或许难以达到。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The treatment regimen (Note 11) and species should be selected whenever possible with regard to pharmacodynamic and pharmacokinetic principles. This may not be achievable for the very first studies, at a time when neither animal nor human pharmacokinetic data are normally available."
    },
    {
        "instruction":"已知信息：\n'以特定受体为靶位筛选具有拮抗剂作用的。'可被翻译为：Screening for antagonists targeting specific receptors.\n'受体拮抗剂'可被翻译为：receptor antagonist\n'• 药物浓度高达10 µM时，未见脱靶相互作用的证据，包括与雌激素、雄激素、糖皮质激素受体的相互作用。'可被翻译为：• No evidence of off-target interactions at drug concentrations up to 10 µM, including no interaction with estrogen, androgen, glucocorticoid receptors.\n'计算被设计的药物分子与受体结合的空间和电性的互补性，修饰并优化药物分子的取代基和分子构象，优化受体与配体间相互作用的过程。'可被翻译为：Calculate the spatial and electrical complementarity of the binding of the designed drug molecule with the receptor, modify and optimize the substitution group and molecular conformation of the drug molecule, and optimize the interaction process between the receptor and ligand.\n\n根据上述已知信息，请将'• 拮抗剂与一种脱靶受体有结合相互作用，其Ki值比 临床最大剂量下的Cmax 高8倍。脱靶受体的已知药 理作用与肿瘤发生无关。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"• Antagonist binding interaction identified for one off-target receptor with Ki 8-fold higher than Cmax at maximum clinical dose. Known pharmacology of off-target receptor not associated with tumorigenesis."
    },
    {
        "instruction":"已知信息：\n'2.电子数据采集系统经过系统验证， 并保存验证记录。计算机化系统设置用户管理、角色管理和权限管理， 不同人员或角色具有唯一登录权限。具有稽查轨迹功能，能够显示修改数据与修改原因的记录。'可被翻译为：2. Electronic data collection system passes the system verification, and retains verification record. Set user management, role management and permission management for the computerized system, different personnel or roles have the unique logon rights. With audit track function, it can display the records of modification data and modification reason.\n'3.用于研究数据采集、传输、储存、处理、归档等的计算 机化系统(或者包含有计算机系统的设备和仪器)应经过验证，并保留相应的验证计划、记录和报告；系统更换硬件、软件或者系统升级、安装补丁后，应进行系统评估并保留有相关评估报告；评估结果需进行验证的，应保留相应的验证计划、记录和报告；'可被翻译为：3. Computerized systems (or equipment and instruments interface to a computer) applied to data acquisition, transmission, storage, processing, archiving, etc., should be validated properly, and the corresponding validation plans, records and reports should be maintained; when hardware or software replaced, upgraded or patched, the system should be evaluated and relevant evaluation reports should be kept; if an additional validation needed after evaluation, the relevant validation plans, records and reports should be kept;\n'4.具有稽查轨迹功能的计算机化系统应开启稽查轨迹功能，所产生的电子数据应保留有完整的稽查轨迹和电子签名，保证电子数据真实、可溯源；计算机化系统操作权限设置合理。'可被翻译为：4. The electronic audit trail feature (when present) should be turned on; the electronic data generated should be with the complete audit trail and electronic signature to ensure its authenticity and traceability; access to the computerized system should be properly authorized and controlled.\n'动态格式，如电子记录，允许用户和记录内容之间的交互关系。例如，数据库格式的电子记录允许用户对数据进行跟踪、趋势和查询;以电子记录形式维护的色谱记录允许用户或审稿人(具有适当的访问权限)重新处理数据并扩展基线，以便更清楚地查看集成情况。'可被翻译为：Dynamic formats, such as electronic records, allow an interactive relationship between the user and the record content. For example, electronic records in database formats allow the user to track, trend and query data; chromatography records maintained as electronic records allow the user or reviewer (with appropriate access permissions) to reprocess the data and expand the baseline to view the integration more clearly.\n\n根据上述已知信息，请将'（二）采用电子记录的计算机化系统经过系统验证， 并保存验证记录。计算机化系统设置用户管理、角色管理和权限管理，不同人员或角色具有唯一登录权限。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(2) Electronic data collection system passes the system verification, and retains verification record. Set user management, role management and permission management for the computerized system, different personnel or roles have the unique logon rights."
    },
    {
        "instruction":"已知信息：\n'良好的贸易和分销惯例(GTDP)'可被翻译为：good trade and distribution practices (gtdp)\n'(良好的贸易和分销规范)是质量保证的一部分，通过对贸易和分销过程中发生的众多活动进行充分控制，确保药品质量得到保持。'可被翻译为：(Good trade and distribution practices are) that part of quality assurance that ensures that the quality of pharmaceutical products is maintained by means of adequate control throughout the numerous activities which occur during the trade and the distribution process.\n'分析方法应根据现行WHO技术报告系列中发布的指南进行验证。'可被翻译为：Analytical procedures should be validated according to the guidelines as published in current WHO Technical Report Series (7).\n'技术报告系列'可被翻译为：TRS Technical Report Series\n\n根据上述已知信息，请将'良好的贸易和分销做法(附件2，WHO技术报告系列，第917号)。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Good Trade and Distribution Practices (Annex 2, WHO Technical Report Series, No. 917)."
    },
    {
        "instruction":"已知信息：\n'第一百四十八条 确认或验证应当按照预先确定和批准的方案实施，并有记录。确认或验证工作完成后，应当写出报告，并经审核、批准。确认或验证的结果和结论（包括评价和建议）应当有记录并存档。'可被翻译为：Article 148 Qualification or validation should be implemented in accordance with a predefined and approved protocol, and be recorded. Upon completion of qualification or validation, a report should be prepared, reviewed and approved. The qualification or validation result and conclusion (including comments and suggestions) should be recorded and archived.\n'提交适当的批准后监管申报，描述及证明已批准ECs的拟定修订。'可被翻译为：Submission of an appropriate post-approval regulatory submission describing and justifying the proposed revision to the approved ECs.\n'第一百四十七条 应当根据确认或验证的对象制定确认或 验证方案，并经审核、批准。'可被翻译为：Article 147: The qualification or validation protocol should be prepared based on its object. The protocol should be reviewed and approved.\n'第一百四十七条 应当根据确认或验证的对象制定确认或验证方案，并经审核、批准。确认或验证方案应当明确职责。'可被翻译为：Article 147 The qualification or validation protocol should be prepared based on its object. The protocol should be reviewed and approved. Responsibilities should be specified in the protocol.\n\n根据上述已知信息，请将'确认或验证工作完成后，应当写出报告， 并经审核、批准。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Upon completion of qualification or validation, a report should be prepared, reviewed and approved."
    },
    {
        "instruction":"已知信息：\n'可以包括支持或否定已确认的安全性 问题的信息，以及新的安全性信号的证据。'可被翻译为：It could include information that supports or refutes previously identified safety issues, as well as evidence of new safety signals.\n'它 可以包括支持或驳斥先前确定的安全性问题的信息，以及新的安全性信号的证 据。'可被翻译为：It could include information that supports or refutes previously identified safety concerns, as well as evidence of new safety signals.\n'5它 可以包括支持或驳回先前确定的安全性问题的信息，以及新的安全信号的证 据。'可被翻译为：5 It could include information that supports or refutes previously identified safety concerns, as well as evidence of new safety signals.\n'确认试验必须提供有效性和安全性证据。'可被翻译为：Confirmatory trials are necessary to provide evidence of efficacy and safety.\n\n根据上述已知信息，请将'12可以包括支持或否定已确认的安全性 问题的信息，以及新的安全性信号*的证据。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"12 It could include information that supports or refutes previously identified safety issues, as well as evidence of new safety signals.*"
    },
    {
        "instruction":"已知信息：\n'22见指导原则草案，应用人为因素和使用工程学以便优化医疗器械设计，一经定稿，即代表FDA对于本课 题的当前想法。'可被翻译为：22 See draft guidance, Applying Human Factors and Usability Engineering to Optimize Medical Device Design. When final, this guidance will represent FDA’s current thinking on this topic.\n'14见FDA指导原则：源于设计，医疗器械中人为因素的介绍，1996年12月；为行业和FDA上市前和设计 控制审评人员制定的指导原则：医疗器械使用-安全：把人为因素工程学整合到风险管理中，2000年7月18日；为行业和食品药品监督管理局工作人员制定的指导原则草稿-应用人为因素和使用工程学以便优化医疗器械设计，2011年6月22日；FDA医疗器械指导原则网址： http:\/\/www.fda.gov\/MedicalDevices\/DeviceRegulationandGuidance\/GuidanceDocuments\/default.htm（一经定稿，本指导原则将代表FDA关于这一主题的最新见解）'可被翻译为：14 See FDA guidances: Do it by Design, An Introduction to Human Factors in Medical Devices, December 1996; guidance for industry and FDA Premarket and Design Control Reviewers: Medical Device Use-Safety: Incorporating Human Factors Engineering into Risk Management, July 18, 2000; and draft guidance for industry and Food and Drug Administration staff - Applying Human Factors and Usability Engineering to Optimize Medical Device Design, June 22, 2011; available on FDA Medical Devices guidance Web page at http:\/\/www.fda.gov\/MedicalDevices\/DeviceRegulationandGuidance\/GuidanceDocuments\/default.htm (when final, this guidance will represent FDA’s current thinking on this topic).\n'19FDA指导原则草案，片剂刻痕：用于评价的术语、标签和数据，2011年8月。一经定稿，本指导原则将 代表FDA关于这一主题的最新见解。'可被翻译为：19 FDA draft guidance for industry, Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation, August 2011. When final, this guidance will represent FDA’s current thinking on this topic.\n'39本指导原则一经定稿即代表FDA关于这一主题的最新见解。'可被翻译为：39 When final, this guidance will represent the FDA’s current thinking on this topic.\n\n根据上述已知信息，请将'18FDA指导原则草案，应用人为因素和使用工程学以便优化医疗器械设计，2011年6月22日。一经定稿，本指导原则将代表FDA关于这一主题的最新见解。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"18 FDA draft guidance, Applying Human Factors and Usability Engineering to Optimize Medical Device Design, June 22, 2011. When final, this guidance will represent FDA’s current thinking on this topic."
    },
    {
        "instruction":"已知信息：\n'第十七条 核查中心根据工作需要建立专家咨询制度，在注册核查过程中就重大疑难问题听取专家意见。'可被翻译为：Article 17 CFDI shall establish an expert consultation system if needs and seek for expert opinions on major and difficult issues during the registration inspection process.\n'第二十八条 在注册核查工作中，核查组有权对申请人和被核查单位、人员、设施设备、管理要求等进行核查，进入研制、生产及其他核查相关场地，调阅相关资料，询问相关人员。'可被翻译为：Article 28 During the registration inspection work, the inspection team has the right to inspect the applicant and the inspected institution, personnel, facilities and equipment, management requirements, etc., enter the development, manufacture, and other inspection related sites, read relevant dossiers, and inquire the relevant personnel.\n'对于各类现场核查分别涉及多个核查对象和场地的，核查中心应当综合对所涉及所有核查对象和场地的现场核查情况，作出最终核查审核结论。'可被翻译为：For various types of on-site inspections that involve multiple inspection objects and sites, CFDI shall make a final inspection conclusion on the on-site inspection of all the inspection objects and sites involved.\n'第三十四条 核查组应当对现场核查情况进行讨论汇总，提出现场核查综合评定意见，并依据核查结果判定原则，作出现场核查结论，撰写形成现场核查报告和现场核查问题表。'可被翻译为：Article 34 The inspection team shall discuss and summarize the on-site inspection, put forward comprehensive evaluation opinions on on-site inspection, and make on-site inspection conclusions based on the principle of inspection results, form on-site inspection reports and on-site inspection question sheets.\n\n根据上述已知信息，请将'第三十八条 对于复杂或者有争议的问题，核查中心可召开注册核查专家会审会，听取核查、审评、检验等方面的专家意见。核查中心应当综合专家意见作出核查审核结论。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 38 For complex or controversial issues, CFDI may hold a review meeting of registration inspection experts to listen to expert opinions on inspection, evaluation, and test. CFDI shall inspect and review conclusion based on the opinions of experts."
    },
    {
        "instruction":"已知信息：\n'20本指南最终定案后，将代表 FDA 当前对这个主题的见解。'可被翻译为：20 When final, this guidance will represent the FDA’s current thinking on this topic.\n'监管机构对制造商和\/或授权代表实施的所有控制措施，在提供单个医疗器械的阶段，并作为其在管辖范围内分销和\/或使用的条件。'可被翻译为：All controls applied by the regulatory authority to the manufacturer and\/or authorized representative at the stage of, and as a condition of, making available an individual medical device with a view to its distribution and\/or use within the jurisdiction.\n'第六十七条  省、自治区、直辖市药品监督管理部门应当建立并及时更新辖区内第二类、第三类医疗器械注册人、受托生产企业信用档案，设区的市级负责药品监督管理的部门应当依法按照职责建立并及时更新辖区内第一类医疗器械备案人、受托生产企业信用档案。'可被翻译为：Article 67 The drug regulatory department of the province, autonomous region, or municipality directly under the central government shall establish and timely update the credit files of the registrant or the contract manufacturer of Class II and Class III medical devices within the jurisdiction area, the department in charge of drug supervision and administration at the level of a city divided into districts shall establish and promptly update the credit files of Class I medical device filing entity or the contract manufacturer within the jurisdiction area according to its duties.\n'第六十五条  药品监督管理部门应当定期组织开展风险会商，对辖区内医疗器械质量安全风险进行分析和评价，及时采取相应的风险控制措施。'可被翻译为：Article 65 The drug regulatory department shall regularly organize risk conference or consultation, to make analysis and evaluation of the quality and safety risks of the medical devices within the jurisdiction area, and take corresponding risk control measures in a timely manner.\n\n根据上述已知信息，请将'缔约方向管辖区内的监管机构提交信息的过程，涉及在该管辖区内已供应或将供应给市场的医疗器械的识别(20)。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The process whereby a party submits information to the regulatory authority in a jurisdiction, regarding the identification of a medical device(s) that is or will be supplied to the market in that jurisdiction (20)."
    },
    {
        "instruction":"已知信息：\n'为支持在晚期肿 瘤患者中进行临床试验时，不要求进行单独的安全药理学研究。'可被翻译为：Conducting stand-alone safety pharmacology studies to support studies in patients with advanced cancer is not called for.\n'拟用于治疗晚期肿瘤患者的药物上市，致癌性试验通常不是必要的。'可被翻译为：Carcinogenicity studies are not warranted to support marketing for therapeutics intended to treat patients with advanced cancer.\n'对于拟用于治疗晚期肿瘤患者的药物，遗传毒性研究不是支持其进行临床试验所必需的。'可被翻译为：Genotoxicity studies are not considered essential to support clinical trials for therapeutics intended to treat patients with advanced cancer.\n'对于拟用于晚期肿瘤患者长期用药的生物制品，毒性试验期限的原则见ICH S9。'可被翻译为：For chronic use of biopharmaceutical products developed for patients with advanced cancer, the principles for duration of toxicology studies are outlined in ICH S9 Guideline.\n\n根据上述已知信息，请将'通常，拟用于晚期肿瘤患者联合用药的安全性毒理学研究是没有必要的。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In general, toxicology studies investigating the safety of combinations of pharmaceuticals intended to treat patients with advanced cancer are not warranted."
    },
    {
        "instruction":"已知信息：\n'化学转化步骤'可被翻译为：chemical transformation step\n'对于化学实体药物，指从其前体分子片段合成原料药化学结构的反应步骤。典型的有 C-X 或 C-C 键的形成或断裂。'可被翻译为：For Chemical Entities, a step involved in the synthesis of the chemical structure of the drug substance from precursor molecular fragments. Typically it involves C-X or C-C bond formation or breaking.\n'Q11实施工作组原料药开发和生产（化学实体和生物技术\/生物实体药物）'可被翻译为：ICH Q11 Guideline: DEVELOPMENT AND MANUFACTURE OF DRUG SUBSTANCES (CHEMICAL ENTITIES AND BIOTECHNOLOGICAL\/BIOLOGICAL ENTITIES)\n'内含在生产工艺设计中的控制（例如，精制步骤的顺序 [生物技术\/生物原料药]，或试剂的加入顺序[化学实体药物]）；'可被翻译为：Controls implicit in the design of the manufacturing process (e.g., sequence of purification steps [biotechnological\/biological drug substances], or order of addition of reagents [chemical entities]);\n\n根据上述已知信息，请将'11. 术语 化学转化步骤（Chemical Transformation Step）：对于 化学实体药物，指从其前体分子片段合成原料药化学结构的 反应步骤。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"11. Glossary Chemical Transformation Step: For Chemical Entities, a step involved in the synthesis of the chemical structure of the drug substance from precursor molecular fragments."
    },
    {
        "instruction":"已知信息：\n'消息标准'可被翻译为：message standard\n'考虑到世界范围内信息交流的潜在参与者人数众多，应该提供一种标准格式，该标准格式可以使用标准化信息传输来帮助数据库至数据库的直接传输。'可被翻译为：Considering the large number of potential participants in a world-wide exchange of information, there should be a standard format that is capable of accommodating direct database-to-database transmission using standardised message transfers.\n'以ACK.B开头的数据元素包含与接收到的批次中的每份ICSR消息相关的信息元素消息。B 节包含与批次内的每份ICSR相关的信息，包括该消息内检测到的任何错误消息。'可被翻译为：Data elements beginning with ACK.B contain information relating to each ICSR message within the received batch. This B section contains information related to each ICSR message within a batch, including any errors detected within the message.\n'在消息中构建XML编码的编码值列表。这些值不携带消息发送的源数据，即不表示包含在消息内容中的数据，而旨在标识 XML 文件的组件，以供接收传输消息的 IT 系统进行解析。通常，它们不是由最终用户输入的（例如，借助用于编码元素的下拉选择列表等），而是被实施应用的IT系统构建的用于导出和传输的XML消息。'可被翻译为：A list of coded values that are used to structure the xml coding within a message. These values do not carry source data that is being transmitted by the message, i.e. they do not represent data contained in the content of a message, but instead are used to identify components of an xml file for parsing by an IT system receiving transmitted message. Usually they are not entered by an end user (for instance through a drop-down pick list such as used for coded elements), but are instead used by an implementing IT system to construct an xml message for export and transmission.\n\n根据上述已知信息，请将'一种指定的打包多方认同的信息的方式。消息传递标准通过内容需求（关键数据和包含关键数据的结构）和事务性要求（时间选择和指定内容）的组合来定义特定消息。消息传递标准还定义了编码信息的方式，以允许此类信息在不同系统之间进行交换。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A defined manner of packaging information for a message that has been agreed upon by multiple parties. Messaging standards define specific messages by a combination of content requirements (key data and structures for containing it) and transactional requirements (timing and specified content at stages). Messaging standards also define the means for coding such information in a manner that allows the exchange of this information between different systems."
    },
    {
        "instruction":"已知信息：\n'50只B6C3F1 小鼠（雄性） 2年灌胃 50只 3个：1.79；7.14； 14.3mg\/kg\/d 前胃 5.92+'可被翻译为：50 B6C3F1 Mice (M) 2 years Gavage 50 3: 1.79;7.14; 14.3 mg\/kg\/d Forestomach 5.92+\n'参考文献5 50只\/性别\/组 B6C3F1小鼠 2年 5天\/周 灌胃 50只 2个： 17.7； 35.4mg\/kg\/d 哈氏腺\/ 雌性 32.9'可被翻译为：Ref. 5 50\/sex\/ group B6C3F1 mice 2 years 5 days\/wk Oral gavage 50 2: 17.7; 35.4 mg\/kg\/d Harderian gland \/Female 32.9\n'参考文献6盐酸对氯苯 胺 50只\/组 雌性 B6C3F1 小鼠 103周 5次\/周 灌胃 50只 3个： 3；10；30mg\/kg （2.1；7.1；21.4 mg\/kg\/d） 阴性 NA'可被翻译为：Ref. 6 p- chloroaniline HCl 50\/group female B6C3F1 mice 103 weeks 5 times\/ wk Gavage 50 3: 3; 10; 30 mg\/kg (2.1; 7.1; 21.4 mg\/kg\/d) Negative NA\n'参考文献5* 50只\/性别\/组 F344\/N大鼠 2年 5天\/周 灌胃 50只 2个： 26.5； 53.8mg\/kg\/d 乳腺\/ 雌性 4.15'可被翻译为：Ref. 5* 50\/sex\/ group F344\/N rats 2 years 5 days\/wk Oral gavage 50 2: 26.5; 53.8 mg\/kg\/d Mammary gland\/Female 4.15\n\n根据上述已知信息，请将'50只B6C3F1小鼠（雌性） 2年灌胃 50只 3个：1.79；7.14；14.3mg\/kg\/d 前胃 6.77+'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"50 B6C3F1 Mice (F) 2 years Gavage 50 3: 1.79;7.14; 14.3 mg\/kg\/d Forestomach 6.77+"
    },
    {
        "instruction":"已知信息：\n'在设计研究时，应优先确定对研究至关重要的质量因素，研究程序应与研究 中固有的风险及所收集信息的重要性相匹配。'可被翻译为：The quality factors should be prioritised to identify those that are critical to the study, at the time of the study design, and study procedures should be proportionate to the risks inherent in the study and the importance of the information collected.\n'在临床试验 中，当考虑使用期中分析时，申办方应该参照ICH E9。'可被翻译为：The SAP should include provisions that ensure the interim analysis does not compromise trial integrity. Sponsors should refer to ICH E9 when considering the use of interim analyses in clinical trials.\n'临床试验的统计学原则（CPMP\/ICH\/363\/96（ICH E9））'可被翻译为：Statistical Principles for Clinical Trials (CPMP\/ICH\/363\/96 (ICH E9))\n'如第3节所述，在研究规划时，应通过前瞻性、跨职能 部门的讨论和决策来支持识别关键质量因素。'可被翻译为：The identification of critical to quality factors should be supported by proactive, cross- functional discussions and decision making at the time of study planning, as described in Section 3.\n\n根据上述已知信息，请将'在对关键质量因素和风险管理进行前瞻性规划和持续 审查期间，需要特别关注具有适应性特征和\/或中期决策点 的研究（ICH E9临床试验的统计学原则）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Studies with adaptive features and\/or interim decision points need specific attention during proactive planning and ongoing review of critical to quality factors, and risk management (ICH E9 Statistical Principles for Clinical Trials)."
    },
    {
        "instruction":"已知信息：\n'但同时给的基础胰岛素注射会改变 NPH 葡萄糖的葡萄糖动力学，对长效胰岛素制剂的改变甚至更大，造成高估受试胰岛素的效果。'可被翻译为：but the co-administration of basal insulin infusion has been shown to alter the late glucodynamic profile of NPH insulin and possibly and even more relevantly of long-acting insulin preparations, overestimating the effect of the study insulins.\n'高胰岛素血水平多在胰岛素剂量-效应曲线的陡部，因此在检测两种胰岛素时间-作用情况差异时高度敏感。'可被翻译为：The resulting levels of hyperinsulinaemia are expected to lie on the steep part of the dose-response curve of insulin and can thus be expected to be highly sensitive to detect potential differences in the time-action profiles of two insulins.\n'钳夹研究需要考虑受试胰岛素制剂的已知作用时间和它的剂量依赖性。'可被翻译为：The duration of the clamp studies needs to take into account the known duration of action of the investigated insulin preparation and its dose-dependency.\n'两次研究期之间的洗脱期应考虑受试胰岛素制剂的作用时间以避免交叉效应。'可被翻译为：The wash-out phase between study periods should take into account the duration of action of the investigated insulin preparation to avoid carry-over effects.\n\n根据上述已知信息，请将'导致胰岛素敏感性的迅速和明显的恶化，因此影响受试胰岛素制剂的时间-作用情况评估。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"lead to a rapid and pronounced worsening of insulin sensitivity, thus influencing the estimated time-action profile of the investigated insulin preparation."
    },
    {
        "instruction":"已知信息：\n'应合并具有相同对照组 （安慰剂或特定阳性对照）的研究的结果，并分别展示每个 提供充足数据的对照组的结果。'可被翻译为：The results from trials which use a common comparator (placebo or specific active comparator) should be combined and presented separately for each comparator providing sufficient data.\n'数据来源可以在患者水平进行合并，或者由于隐私或其它局限性，可以在总结统计水平进行合并。'可被翻译为：The data sources can be pooled on a patient level, or because of privacy or other limitations, the data sources can be pooled at a summary statistical level.\n'这些数据可能来自于一项用于治疗靶生物体引起的充分证实的感染的研究，该研究可以针对性地或广泛地研究这些病原体。'可被翻译为：These data could come from a study in which data on well-documented infections due to the target organisms are treated, which may be confined to or enriched for these pathogens.\n'我们反对将多项试验的脱落数据合并，因为同一种产品针对不同适应症进行研究，针对某种给定适应症的脱落研究所得结果不能泛化为其他适应 症。'可被翻译为：We recommend against pooling shedding data from multiple trials in which the same product is studied for different indications because results from a shedding study in a given indication may not be generalizable to other indications.\n\n根据上述已知信息，请将'来自于针对某特定病原体、用于某个适应症的多项研究的疗效数据可以合并，只要 这些研究的设计相同或非常相似。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Data on efficacy against a specific pathogen obtained from more than one study in a single indication may be pooled if these are of the same or very similar design."
    },
    {
        "instruction":"已知信息：\n'虽然很难确定提前退出试验的影响，有时甚至难以确 定产生偏差的方向，但应尽可能全面地探讨可能的影响。'可被翻译为：Although the effects of early dropouts, and sometimes even the direction of bias, can be difficult to determine, possible effects should be explored as fully as possible.\n'当最佳方法存在不确定性时，建议使用科学建议或确认程序。'可被翻译为：Use of scientific advice or qualification procedures are recommended when uncertainty exist on the best approach.\n'方案还应该说明旨在减少研究实施 中任何预期的且可能影响数据分析的不规则问题的程序，这 些不规则问题包括各种类型的方案违背、退出和数据缺失。'可被翻译为：The protocol should also specify procedures aimed at minimising any anticipated irregularities in study conduct that might impair a satisfactory analysis, including various types of protocol violations, withdrawals and missing values.\n'如果在试验方案中未预先规定应对离群值的程序，则需要在 对实际值做一次分析的同时，至少进行一次排除或减少离群 值效应的分析，并讨论它们的结果之间的差异。'可被翻译为：If no procedure for dealing with outliers was foreseen in the trial protocol, one analysis with the actual values and at least one other analysis eliminating or reducing the outlier effect should be performed and differences between their results discussed.\n\n根据上述已知信息，请将'由于一些问题的不可预测性，有时把不规则问题应对方 法的详细考虑推迟到试验结束对数据进行盲态审核时可能 更可取，如果这样做则需要在方案中加以说明。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Because of the unpredictability of some problems, it may sometimes be preferable to defer detailed consideration of the manner of dealing with irregularities until the blind review of the data at the end of the trial, and, if so, this should be stated in the protocol."
    },
    {
        "instruction":"已知信息：\n'Cmax=2.6 µg\/mLa AUC=3.89 µg·h\/mLa 15 mg\/kg 单次IP给药 GD9 [Wilson] Cmax=3.87 µg\/mLa AUC=5.83 µg·h\/mLa Wilson: 15 mg\/kg: 畸形，胚胎- 胎仔致死性 Kuwagata: ≥17 mg\/kg: 小\/无眼，颅 面缺损，脑积 水，脑膨出 未确定 NOAEL [DeSesso] 40 mg\/kg SC GD12 [DeSesso] Cmax=111 µg\/mLb AUC=11 µg·h\/mLb 85%的 成熟胎 仔肢体 异常 各类给药方案中 500 mg\/m2 (400- 600 mg\/m2)，包 括连续46小时静 脉输注给药 （CIV）至3000 mg\/m2 c Cmax=29 µg\/mLd AUC=11.5 µg·h\/mLd NOAEL: 大鼠 Cmax=0.09 (2.6\/29) AUC=0.3 (3.89\/11.5) 兔 未确定NOAEL LOAEL: 大鼠 Cmax=0.1 (3.87\/29) AUC=0.5 (5.83\/11.5) 兔 Cmax=3.8 (111\/29) AUC=1.0 (11\/11.5)'可被翻译为：Cmax = 2.6 µg\/mLa AUC = 3.89 µg·h\/mLa 15 mg\/kg single dose IP GD9 [Wilson] Cmax = 3.87 µg\/mLa AUC = 5.83 µg·h\/mLa Wilson: 15 mg\/kg: malformations, embryofetal lethality Kuwagata: ≥17 mg\/kg: micro- \/anophthalmos, craniofacial defect, hydrocephaly, brain hernia NOAEL not identified [DeSesso] 40 mg\/kg SC GD12 [DeSesso] Cmax = 111 µg\/mLb AUC = 11 µg·h\/mLb limb anomalies 85% of term fetuses 500 mg\/m2 (400 – 600 mg\/m2) in a variety of dosing regimens, including doses up to 3000 mg\/m2 CIV for 46 hoursc Cmax = 29 µg\/mLd AUC = 11.5 µg·h\/mLd NOAEL: rat Cmax = 0.09 (2.6\/29) AUC = 0.3 (3.89\/11.5) rabbit no NOAEL identified LOAEL: rat Cmax = 0.1 (3.87\/29) AUC = 0.5 (5.83\/11.5) rabbit Cmax = 3.8 (111\/29) AUC = 1.0 (11\/11.5)\n'6 μg\/mLa 225 mg\/kg 经口 GD6-15 （美国 FDA， 1989） Cmax = 128 μg\/mLa AUC = 1010 μg•h\/mLb 225 mg\/kg： 在存在母体 毒性（死 亡、临床症 状）情况下 着床前和着 床后丢失 NOAEL （MEFL） 135 mg\/kg 经口 GD6-18 （美国FDA， 1989） Cmax = 137 μg\/mLc AUC = 642 μg•h\/mLc 更低剂量时的暴 露 15 mg\/kg 经口 未确定 未观察 到 MEFL MRHD 10 mg 单次给药后暴露 量： Cmax = 0.33 μg\/mLd AUC(0-24h): 3.0 μg•hr\/mLd'可被翻译为：h\/mLb 25 mg\/kg oral GD6-15 (FDA, United States 1989) Cmax = 12 µg\/mLa 225 mg\/kg oral GD6-15 (FDA, United States 1989) Cmax = 128 µg\/mLa AUC = 1010 µg•h\/mLb 225 mg\/kg: pre- and post- implantation loss in presence of maternal toxicity (death, clinical signs) NOAEL (MEFL) 135 mg\/kg oral GD6-18 (FDA, United States 1989) Cmax = 137 µg\/mLc AUC = 642 µg•h\/mLc Exposure data at lower doses 15 mg\/kg oral GD6-18 (FDA, United States 1989) Cmax = 15 µg\/mLc AUC = 71 µg•h\/mLc 45 mg\/kg oral GD6-18 (FDA, United States 1989) Not established No MEFL observed 10 mg MRHD Exposure values after single dose: Cmax = 0.33 µg\/mLd AUC(0-24h): 3.0 µg•hr\/mLd\n'沙利度胺 CAS号：50-35-1 大鼠NOAEL 剂量 Cmax AUC 大鼠LOAEL 剂量 Cmax AUC 大鼠 发现a 兔NOAEL 剂量 Cmax AUC 兔LOAEL 剂量 Cmax AUC 兔 发现 人剂量 Cmax AUC 暴露倍数 NOAEL\/人 LOAEL\/人 注 释 10 mg\/kgb [Janer] Cmax=0.97µg\/ mLc AUC(0-24h) =10.75 µg·h\/mLc 50 mg\/kgb [Newman, Schardein] Cmax=4.87µg\/ mLc AUC(0-24h) =53.75 µg·h\/mLc 着床点 减少 20 mg\/kg 经口 GD7-19 [Christian] 在GD19时 Cmax=0.82 µg\/mLd AUC(0- 24h)=4.18 µg·h\/mLd 60 mg\/kg 经口 GD7-19 [Christian] 在GD19时 Cmax=2.16 µg\/mLe AUC(0- 24h)=14.4 µg.h\/mLe'可被翻译为：Thalidomide CAS No.: 50-35-1 Rat NOAEL Dose Cmax AUC Rat LOAEL Dose Cmax AUC Rat Findingsa Rabbit NOAEL Dose Cmax AUC Rabbit LOAEL Dose Cmax AUC Rabbit Findings Human Dose Cmax AUC Margins NOAEL\/Human LOAEL\/Human Notes 10 mg\/kgb [Janer] Cmax = 0.97µg\/mLc AUC(0-24h) = 10.75 µg·h\/mLc 50 mg\/kgb [Newman, Schardein] Cmax = 4.87µg\/mLc AUC(0-24h) = 53.75 µg·h\/mLc decreased implanta- tion sites 20 mg\/kg oral GD7-19 [Christian] at GD19 Cmax = 0.82 µg\/mLd AUC(0-24h) = 4.18 µg·h\/mLd 60 mg\/kg oral GD7-19 [Christian] at GD19 Cmax = 2.16 µg\/mLe AUC(0-24h) = 14.4 µg.h\/mLe\n'顺铂 CAS号：15663-27-1 大鼠NOAEL 剂量 Cmax AUC 大鼠LOAEL 剂量 Cmax AUC 大鼠 发现 兔NOAEL 剂量 Cmax AUC 兔LOAEL 剂量 Cmax AUC 兔 发现 注释 Wistar大鼠于GD6、 8、11或14腹腔注射0.3 mg\/kg （Keller） Cmax=0.32 μg\/mLa AUC=0.25 μg∙h\/mLa Wistar大鼠在GD8 或11腹腔注射1 mg\/kg （Keller） Cmax=1.08 µg\/mLa AUC=0.85 µg∙h\/mLa 胎仔死亡率上 升，每个母体活 胎数减少 未确定NOAEL 未确定LOAEL'可被翻译为：CISPLATIN CAS No.: 15663-27-1 Rat NOAEL Dose Cmax AUC Rat LOAEL Dose Cmax AUC Rat Findings Rabbit NOAEL Dose Cmax AUC Rabbit LOAEL Dose Cmax AUC Rabbit Findings Notes 0.3 mg\/kg IP on GD6,8,11, or 14 in Wistar rats (Keller) Cmax = 0.32 μg\/mLa AUC = 0.25 μg∙h\/mLa 1 mg\/kg IP on GD8 or 11 in Wistar rats (Keller) Cmax = 1.08 µg\/mLa AUC = 0.85 µg∙h\/mLa increased fetal mortality, decreased live fetuses per dam NOAEL not identified LOAEL not identified\n\n根据上述已知信息，请将'吸收胎 肢体旋转或弯 曲(60 mg\/kg剂量下 4\/38胎仔，180 mg\/kg 剂量下15\/25 胎仔) 脑积水 (n=2\/38) 在180 mg\/kg剂 量下：着床后丢失 增加，包括死胎， 以及大量外观和内 脏畸形 50 mg 口服f Cmax=0.62 µg\/mLg AUC(0-inf)=4.9 µg·h\/mLg NOAEL: 大鼠 Cmax = 1.6 (0.97\/0.62) AUC = 2.2 (10.75\/4.9) 兔 Cmax = 1.3 (0.82\/0.62) AUC = 0.9 (4.18\/4.9) LOAEL: 大鼠 Cmax = 7.9 (4.87\/0.62) AUC = 11.0 (53.75\/4.9) 兔 Cmax = 3.5 (2.16\/0.62) AUC = 2.9 (14.4\/4.9)'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"resorptions rotated or flexed limbs (4\/38 fetuses at 60 mg\/kg and 15\/25 fetuses at 180 mg\/kg) hydrocephaly (n=2\/38) increased postimplantation loss, including dead fetuses, and numerous external and visceral malformations at 180 mg\/kg 50 mg oralf Cmax = 0.62 µg\/mLg AUC(0-inf) = 4.9 µg·h\/mLg NOAEL: rat Cmax = 1.6 (0.97\/0.62) AUC = 2.2 (10.75\/4.9) rabbit Cmax = 1.3 (0.82\/0.62) AUC = 0.9 (4.18\/4.9) LOAEL: rat Cmax = 7.9 (4.87\/0.62) AUC = 11.0 (53.75\/4.9) rabbit Cmax = 3.5 (2.16\/0.62) AUC = 2.9 (14.4\/4.9)"
    },
    {
        "instruction":"已知信息：\n'经审评，符合附条件批准要求的，在药品注册证书中载明附条件批准药品注册证书的有效期、上市后需要继续完成的研究工作及完成时限等相关事项。'可被翻译为：Where requirements for conditional approval are met upon review, the Drug Approval License shall specify the validity period of the conditional Drug Approval License, the post-approval studies to be completed, the timeline for completing post-approval studies and other relevant details.\n'第八十一条 药品上市后提出的补充申请，需要核查、检验的，参照本办法有关药品注册核查、检验程序进行。'可被翻译为：Article 81 For where inspection and testing are needed with post-marketing supplementary applications, they shall be performed as per the procedures for drug registration inspection and testing in these Provisions.\n'第六十六条 对附条件批准的药品，持有人应当在药品上市后采取相应的风险管理措施，并在规定期限内按照要求完成药物临床试验等相关研究，以补充申请方式申报。'可被翻译为：Article 66 For a conditionally approved drug, the MAH shall take appropriate risk management measures after the drug is marketed and complete relevant studies including drug clinical trials as requested and submit supplementary applications within the specified timeline.\n'第二十四条 申请人拟开展生物等效性试验的，应当按照要求在药品审评中心网站完成生物等效性试验备案后，按照备案的方案开展相关研究工作。'可被翻译为：Article 24 To carry out a bioequivalence trial, the applicant shall file the bioequivalence trial at the CDE website as required before carrying out relevant studies as per the filed protocol.\n\n根据上述已知信息，请将'药品注册证书及附件要求持有人在药品上市后开展相关研究工作的，持有人应当在规定时限内完成并按照要求提出补充申请、备案或者报告。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Where the Drug Approval License and its attachments require the MAH to carry out relevant post-marketing studies, the MAH shall complete the studies within the specified timeline and submit a supplementary application, filing or report as required."
    },
    {
        "instruction":"已知信息：\n'进口药品的再注册申请由申请人向国家食品药品监督管理局提出。'可被翻译为：Where applying for an import drug re-registration, the applicant shall submit the application to the State Food and Drug Administration.\n'第八十二条 持有人应当在药品注册证书有效期届满前六个月申请再注册。境内生产药品再注册申请由持有人向其所在地省、自治区、直辖市药品监督管理部门提出，境外生产药品再注册申请由持有人向药品审评中心提出。'可被翻译为：Article 82 MAHs shall apply for registration renewal at least 6 months prior to expiration of the Drug Approval License. The application for registration renewal of a drug manufactured within the territory of the People's Republic of China shall be submitted by the MAH to the drug regulatory departments of the provinces, autonomous regions or municipalities directly under the Central Government where it is located; the application for registration renewal of a drug manufactured overseas shall be submitted by the MAH to the CDE.\n'第八十三条 药品再注册申请受理后，省、自治区、直辖市药品监督管理部门或者药品审评中心对持有人开展药品上市后评价和不良反应监测情况，按照药品批准证明文件和药品监督管理部门要求开展相关工作情况，以及药品批准证明文件载明信息变化情况等进行审查，符合规定的，予以再注册，发给药品再注册批准通知书。不符合规定的，不予再注册，并报请国家药品监督管理局注销药品注册证书。'可被翻译为：Article 83 After a drug registration renewal application is accepted, the drug regulatory departments of the provinces, autonomous regions or municipalities directly under the Central Government or the CDE shall review the MAH’s activities on post-marketing evaluation and adverse reaction monitoring, relevant work carried out as required in the drug approval documents and by the drug regulatory departments as well as changes to information listed on the drug approval documents. Where requirements are met, registration shall be renewed and a Drug Registration Renewal Approval Notice shall be issued. Where requirements are not met, registration shall not be renewed, and a request for cancellation of the Drug Approval License shall be reported to the NMPA.\n'第一百一十九条 补充申请获得批准后，换发药品批准证明文件的，原药品批准证明文件由国家食品药品监督管理局予以注销；增发药品批准证明文件的，原批准证明文件继续有效。'可被翻译为：Article 119 After the supplementary application is approved, if a drug approval document is to be renewed, the original one shall be cancelled by the State Food and Drug Administration; if an additional drug approval certificate is to be issued, the original one shall remain valid.\n\n根据上述已知信息，请将'再注册申请，是指药品批准证明文件有效期满后申请人拟继续生产或者进口该药品的注册申请。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Re-registration application refers to application for continued production or importation of a drug after the expiration of the valid term of the drug approval document."
    },
    {
        "instruction":"已知信息：\n'上市审批时，应提供至少三批试生产规模或生产规模的纯化后 产品的检定数据。'可被翻译为：For marketing authorisation, data from at least 3 lots of purified bulk at pilot-plant scale or commercial scale should be provided.\n'在进行上市注册申请时，至少应上报三批试生产或规模化生产的未加工品的研究资料。'可被翻译为：Data from at least 3 lots of unprocessed bulk at pilot- plant scale or commercial scale should be submitted as part of the marketing application\/registration package.\n'在向管理机构申报全套资料时，如果稳定性研究数据来源于比上市规模小的中试规模发酵及纯化工艺所生产的原液时，则申请人应承诺在获得批准后，对最初三批规模化生产的原液进行长期稳定性试验。'可被翻译为：Data from pilot-plant scale batches of drug substance produced at a reduced scale of fermentation and purification may be provided at the time the dossier is submitted to the regulatory agencies with a commitment to place the first 3 manufacturing scale batches into the long-term stability program after approval.\n'8. 应对可能存在的病毒使用具有高特异性和高敏感性的方法进行检测，并确证纯化后产品中无可检测的病毒。当进行上市申请时，应至少提供三批次中试生产或商业化生产规模的原液纯化制造数据。对于像CHO这类内源性颗粒已充分鉴定且已经证明能够被有效清除的细 胞系，通常不需要再对纯化后产品进行非感染性颗粒的检测。'可被翻译为：8. The absence of detectable virus should be confirmed for purified bulk by means of suitable methods having high specificity and sensitivity for the detection of the virus in question. For the purpose of marketing authorisation, data from at least 3 lots of purified bulk manufactured at pilot-plant scale or commercial scale should be provided. However, for cell lines such as CHO cells for which the endogenous particles have been extensively characterised and adequate clearance has been demonstrated, it is not usually necessary to assay for the presence of the non-infectious particles in purified bulk.\n\n根据上述已知信息，请将'申请上市时，应提供至少三批试生 产规模或生产规模纯化后产品的检定数据。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For the purpose of marketing authorisation, data from at least 3 lots of purified bulk manufactured at pilot-plant scale or commercial scale should be provided."
    },
    {
        "instruction":"已知信息：\n'第二十五条 技术审评机构收到省、自治区、直辖市药品监督管理部门或者化妆品新原料注册人、备案人的反馈或者报告后，应当结合不良反应监测机构的化妆品年度不良反应统计分析结果进行评估，认为通过调整化妆品新原料技术要求能够消除安全风险的，可以提出调整意见并报告国家药品监督管理局；认为存在安全性问题的，应当报请国家药品监督管理局撤销注册或者取消备案。国家药品监督管理局应当及时作出决定。'可被翻译为：Article 25 The technical assessment agency shall, after receiving the feedback or report from the drug regulatory department of the province, autonomous region, or municipality, or the registrant and filing person of new cosmetic ingredients, assess the situation in accordance with the annual statistical analysis results of cosmetic adverse reactions from the adverse reaction monitoring agency. When believing that the safety risks can be eliminated by adjusting technical requirements of the new cosmetic ingredients, the technical assessment agency may propose opinions of adjustment and report to the NMPA; when believing that there are safety issues, the technical assessment agency shall report to the NMPA and request to revoke the registration or nullify the filing. The NMPA shall make decisions in a timely manner.\n'第五十八条 承担备案管理工作的药品监督管理部门发现已备案化妆品、化妆品新原料的备案资料不符合要求的，应当责令限期改正，其中，与化妆品、化妆品新原料安全性有关的备案资料不符合要求的，可以同时责令暂停销售、使用。'可被翻译为：Article 58 If the filing drug regulatory department finds that the dossiers of filed cosmetics or new cosmetic ingredients do not meet the requirements, the filing management department shall order that correction be made within a specified timeline; where the data filed that relate to the safety of cosmetics and new cosmetic ingredients do not meet the requirements, the filing management department may at the same time order suspension of their sales and use.\n'第七条 化妆品、化妆品新原料注册人、备案人依法履行产品注册、备案义务，对化妆品、化妆品新原料的质量安全负责。'可被翻译为：Article 7 The registrant and filing person of cosmetics and new cosmetic ingredients shall perform product registration and filing obligations in accordance with law and shall be responsible for the quality and safety of cosmetics and new cosmetic ingredients.\n'第二十条 安全监测的期限内，化妆品新原料注册人、备案人可以使用该化妆品新原料生产化妆品。'可被翻译为：Article 20 During the safety monitoring period, registrants and filing persons of new cosmetic ingredients may use the new cosmetic ingredient to produce cosmetics.\n\n根据上述已知信息，请将'第五十条 根据科学研究的发展，对化妆品、化妆品原料的安全性认识发生改变的，或者有证据表明化妆品、化妆品原料可能存在缺陷的，承担注册、备案管理工作的药品监督管理部门可以责令化妆品、化妆品新原料注册人、备案人开展安全再评估，或者直接组织相关原料企业和化妆品企业开展安全再评估。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 50 Where progress in scientific research changes the understanding of the safety of cosmetics and cosmetic ingredients, or there is evidence to show that certain cosmetics and cosmetic ingredients may be defective, the drug regulatory departments undertaking registration and filing may order the registrants and filing persons of cosmetics and new cosmetic ingredients to carry out safety re-evaluation or may directly organize relevant ingredients and cosmetics enterprises to conduct a safety re-evaluation."
    },
    {
        "instruction":"已知信息：\n'药物对体重、神经肌肉功能和\/或情绪的影响也可能影响交配和生育能力。'可被翻译为：Drugs affecting body weight, neuromuscular function, and\/or mood can also appear to affect mating and fertility.\n'对于大多数药物而言，申办方会常规开展一系列实验，从而确定该药物是否 损伤生育力或影响胚胎\/胎仔和初生期发育。某些发育阶段（例如，妊娠期、初生期和围青春期）对内分泌作用尤为敏感。'可被翻译为：For most drugs, sponsors routinely conduct a battery of tests designed to determine if a drug potentially impairs fertility or affects embryo\/fetal and neonatal development. Some developmental stages (e.g., gestational, neonatal, peripubertal) are particularly sensitive to endocrine effects.\n'例如，如果在标准研究中发现内分泌组织的改变，可探索P450同工酶抑制或诱导的情况，因为药物可能是通过此类抑制或诱导这一机制改变动物激素水平。'可被翻译为：For example, if changes in endocrine tissues are noted in a standard study, the role of inhibition or induction of P450 isozymes might be appropriate to explore, because such inhibition or induction can be a mechanism by which drugs alter hormone levels in animals.\n'如果在处理开始时动物未成熟，但在研究结束时应可达到成熟，那么应确定药物是否可对睾丸发育和精子生成造成短暂或永久影响。'可被翻译为：If animals were immature at the beginning of treatment but should have attained maturity by the end of the study, then it is important to determine if the drug can have temporary or permanent effects on testicular development and spermatogenesis.\n\n根据上述已知信息，请将'例如，药物诱导的内分泌功能改变可影响睾丸重量、配子的成熟和释放、精子数目和\/或生育能力。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For example, drug-induced alterations in endocrine function can affect testicular weight, gamete maturation and release, sperm count, and\/or fertility."
    },
    {
        "instruction":"已知信息：\n'4.4 日本厚生劳动省（MHLW）的考虑 当符合本附录规定的条件时，本附录第2.1节中各药典的文件具有同等效力。'可被翻译为：4.4 MHLW consideration: The pharmacopoeial texts referenced in Section 2.1 of this annex can be used as interchangeable in accordance with the conditions set out in this annex.\n'当符合本附录规定的条件时，本附录第2.1节中各药典的文件具有同等效力。'可被翻译为：The pharmacopoeial texts referenced in Section 2.1 of this annex can be used as interchangeable in accordance with the conditions set out in this annex.\n'当本附录在 日本实施时，MHLW将在通告中规定具体的实施要求。 4.5 加拿大卫生部的考虑 在加拿大，当符合本附录规定的条件时，本附录第2.1节所述的相关药典具有同等效力。'可被翻译为：Details of implementation requirements will be provided in the notification by MHLW when this annex is implemented. 4.5 Health Canada Consideration In Canada, any of the pharmacopoeial texts cited in section 2.1 of this annex and used in accordance with the conditions set out in this annex can be considered interchangeable.\n'当本附录在日本实施时，MHLW将在通告中规定具体的实施要求。'可被翻译为：Details of implementation requirements will be provided in the notification by MHLW when this annex is implemented.\n\n根据上述已知信息，请将'当符合本附录规定的条件时，本附录第2.1节中各药典的文件具有同等效力。当本附录在日本实施时，MHLW将在通告中规定具体的实施要求。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The pharmacopoeial texts referenced in Section 2.1 of this annex can be used as interchangeable in accordance with the conditions set out in this annex. Details of implementation requirements will be provided in the notification by MHLW when this annex is implemented."
    },
    {
        "instruction":"已知信息：\n'现有数据不允许从某种程度的 pCR 作用精确地预测出 EFS\/DFS\/OS 的作用幅度。'可被翻译为：Currently available data do not allow a precise prediction of the magnitude of the EFS\/DFS\/OS effect from a certain pCR effect.\n'在这些情况下，认知获益的临 床结局难以在临床试验的合理持续时间内得到证实。'可被翻译为：In these cases, it would be difficult to establish a clinical consequence of  any cognitive benefit during the course of a trial of reasonable duration.\n'如果存在药理学活性对受精\/着床方面潜在影响的特别担忧，并且NHP是唯一的相关种属时，这些问题应该通过试验来解决。当对这些担忧特别关注时，同源产品或者转基因模型可能是评估对受精或者着床潜在影响的唯一可行的方 法。但不建议仅为在啮齿类动物中进行交配试验，而生产同源产品或者建立转基因模型。在缺乏非临床信息的情况下，应通过临床试验管理过程、知情同意、以及适当的产品说明书来降低患者的风险。'可被翻译为：If there is a specific concern from the pharmacological activity about potential effects on conception\/implantation and the NHP is the only relevant species, the concern should be addressed experimentally. A homologous product or transgenic model could be the only practical means to assess potential effects on conception or implantation when those are of specific concern. However, it is not recommended to produce a homologous product or transgenic model solely to conduct mating studies in rodents. In absence of nonclinical information, the risk to patients should be mitigated through clinical trial management procedures, informed consent and appropriate product labeling.\n'在临床上可能会进行长期治疗，要求通过长期数据来评价疗效的维持、反弹效应、停药现象以及安全性。'可被翻译为：Treatment may be prolonged in clinical practice and longer term data are required to address maintenance of efficacy, rebound effect, discontinuation phenomena and safety.\n\n根据上述已知信息，请将'对发育中的CNS的 潜在影响的担忧无法通过临床上的监测和管理来解决。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The concern for a potential effect on the developing CNS cannot be addressed clinically by monitoring and management."
    },
    {
        "instruction":"已知信息：\n'第一百二十八条 成品放行前应当待验贮存。'可被翻译为：Article 128: Finished products should be held in quarantine until release.\n'第一百一十八条 中间产品和待包装产品应当在适当的条件下贮存。'可被翻译为：Article 118 Intermediate and bulk products should be kept under appropriate conditions.\n'第一百二十九条 成品的贮存条件应当符合药品注册批准的要求。'可被翻译为：Article 129 Finished products should be stored under conditions in accordance with the approved specifications of drug registration.\n'第一百二十九条 成品的贮存条件应当符合药品注册批准 的要求。'可被翻译为：Article 129: Finished products should be stored under conditions in accordance with the approved specifications of drug registration.\n\n根据上述已知信息，请将'第一百二十八条 成品放行前应当待验贮存。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 128 Finished products should be held in quarantine until release."
    },
    {
        "instruction":"已知信息：\n'16.1 研究信息 16.1.1 方案和方案修订案 16.1.2 病例报告表样本（仅提供唯一页面） 16.1.3 IEC或IRB列表（如果监管机构要求，加上委员会主 席姓名）-代表性患者书面信息和同意书样本 16.1.4 研究者及其他重要研究参与者的列表和描述，包括个 人简历（1页）或同等的临床研究相关培训和经验汇总 16.1.5 主要或协调研究者或申办方负责医学专员的签名，根 据监管机构的要求而定 16.1.6 如使用1批以上药物，接受特定批次试验药品\/研究性 产品的患者列表'可被翻译为：16.1 STUDY INFORMATION 16.1.1 Protocol and protocol amendments 16.1.2 Sample case report form (unique pages only) 16.1.3 List of IECs or IRBs (plus the name of the committee Chair if required by the regulatory authority) - Representative written information for patient and sample consent forms 16.1.4 List and description of investigators and other important participants in the study, including brief (1 page) CVs or equivalent summaries of training and experience relevant to the performance of the clinical study 16.1.5 Signatures of principal or coordinating investigator(s) or sponsor’s responsible medical officer, depending on the regulatory authority's requirement 16.1.6 Listing of patients receiving test drug(s)\/investigational product(s) from specific batches, where more than one batch was used\n'也可参见 IRB、临床研究者和申办方指导原则草案知情同意信息表。'可被翻译为：See also the draft guidance for IRBs, clinical investigators, and sponsors Informed Consent Information Sheet.\n'并应在附录16.1.3中列出所 有IEC或IRB的列表，如果监管机构要求，应提供委员会 主席的姓名。 5.2 研究的伦理行为 应确认该项研究是按照符合赫尔辛基宣言的伦理原则 进行的。 5.3 患者知情与同意 应当描述如何以及何时获得与患者入选有关的知情同 意书（例如分配时，筛选前）。'可被翻译为：A list of all IECs or IRBs consulted should be given in appendix 16.1.3 and, if required by the regulatory authority, the name of the committee Chair should be provided. 5.2 ETHICAL CONDUCT OF THE STUDY It should be confirmed that the study was conducted in accordance with the ethical principles that have their origins in the Declaration of Helsinki. 5.3 PATIENT INFORMATION AND CONSENT How and when informed consent was obtained in relation to patient enrolment, (e.g., at allocation, pre-screening) should be described.\n'附录16.1.3应提供患者的代表性书面告知信（如有） 和患者同意书样本。'可被翻译为：Representative written information for the patient (if any) and a sample patient consent form should be provided in appendix 16.1.3.\n\n根据上述已知信息，请将'IEC或IRB列表（如果监管机构要求，加上委员会主席姓名）- 代表性患者书面信息和同意书样本'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"List of IECs or IRBs (plus the name of the committee Chair if required by the regulatory authority) - Representative written information for patient and sample consent forms"
    },
    {
        "instruction":"已知信息：\n'第二十四条  任何单位或者个人不得伪造、变造、买卖、出租、出借医疗器械生产许可证。'可被翻译为：Article 24 No entity or individual is allowed to falsify, alter, trade in, rent or lend out the Medical Device Manufacturing License.\n'第四十五条  从事医疗器械经营活动的，不得经营未依法注册或者备案，无合格证明文件以及过期、失效、淘汰的医疗器械。'可被翻译为：Article 45 An enterprise to be engaged in distribution activities of medical devices shall not engage in distributing medical devices that have not been registered or filed, without qualification certification documents or that have been expired, invalid or obsolete.\n'第二十二条 任何单位或者个人不得伪造、变造、出租、出借、买卖药品生产许可证。'可被翻译为：Article 22 No entity or individual shall forge, alter, rent, lend, or buy and sell the Drug Manufacturing Certificate.\n'第七十条 伪造、变造、买卖、出租、出借医疗器械注册证的，按照《医疗器械监督管理条例》第六十四条第二款的规定予以处罚。'可被翻译为：Article 70 Where a medical device registration certificate is falsified, altered, bought or sold, leased or lent, punishments shall be made according to Paragraph 2, Article 64 of the Regulations on Supervision and Administration of Medical Devices.\n\n根据上述已知信息，请将'第二十八条  任何单位和个人不得伪造、变造、买卖、出租、出借医疗器械经营许可证。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 28 No entity or individual is allowed to falsify, alter, trade in, rent or lend out the Medical Device Distribution License."
    },
    {
        "instruction":"已知信息：\n'而比较长效胰岛素更宜用 I 型糖尿病患者。'可被翻译为：while patients with T1DM may be preferable for comparison of long-acting insulins.\n'长效胰岛素制剂用来产生一个与生理性胰岛素基本分泌尽可能一致的时间-浓度关系。'可被翻译为：Long-acting insulin preparations are intended to produce a time-concentration profile which, as far as possible, approximates physiological basal insulin secretion.\n'健康受试者或者I型糖尿病患者的钳夹试验都适于比较短效或中效胰岛素，'可被翻译为：Clamp studies including either healthy subjects or patients with T1DM are considered appropriate for comparison of insulins with a short or intermediate duration of action,\n'安全性研究应包括合理数量的I型糖尿病患者。'可被翻译为：Safety studies should include a reasonable number of patients with type 1 diabetes.\n\n根据上述已知信息，请将'因此，一般认为长效胰岛素的时间-作用数据更适于通过I型糖尿病患者来测定。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Therefore, patients with type 1 diabetes are generally considered more suitable to determine the time-action profile of long-acting insulins."
    },
    {
        "instruction":"已知信息：\n'测试抗生素\/未知样品（【U3】）的计算效价必须为中值标准品（【S3】）的 80-125%'可被翻译为：The calculated potency of the test antibiotic\/unknown sample ([U3]) must be 80% to 125% of the median reference standard ([S3]);\n'抗生素国际标准品'可被翻译为：international standard for antibiotics\n'内部质量控制来源于每个测试平板和试管。由于抗生素在每个标签上都标明不同剂量， 检测抗生素\/未知样品被稀释为已知样品浓度（【U3】）。未知样品【U3】与中间对照 （【S3】）的浓度相同。中值标准品（【S3】）浓度处于5点标准浓度曲线（【S1】， 【S2】，【S4】和【S5】）中间（即，中点）。5点标准的作用是建立检测范围，它们采用可追溯的在效期内的USP标准品（RS）制备。'可被翻译为：An internal quality control is built into each plate and tube tested. Since antibiotics have different listed dosages per label, the test antibiotic\/unknown sample is diluted to a known sample concentration ([U3]). The unknown sample [U3] has an equivalent concentration of the median reference standard ([S3]). The median reference standard ([S3]) is the median concentration (i.e. mid-point) of the five-point standard curve ([S1], [S2], [S4] and [S5]). The five- point standard functions as the testable detection range and is prepared from a traceable and within expiry USP Reference Standard (RS).\n'一式三份抗生素\/未知样品【U3】试管中含有生长肉汤、接种物和受检抗生素\/未知样品【U3】。一式三份标准曲线（【S1】-【S5】）管含有生长肉汤、接种物和各代表性标准曲线浓度【S1】、【S2】、【S3】、【S4】和【S5】。QC 管含有另一份中值标准品【S3】，该管是用于进行初始吸光度检查，作为检测中所用稀释倍数和接种物的质量检\n查。参见图 6 浊度法一次独立检测，及标准曲线和知样品一式三份样品管设置示例。'可被翻译为：Test antibiotic\/unknown [U3] tubes will contain the growth broth, inoculum and the test \nantibiotic\/unknown [U3] in triplicate. The standard curve ([S1]-[S5]) tubes will contain the growth broth, inoculum and each of the respective standard curve concentrations [S1], [S2], [S3], [S4], and [S5] in triplicate. The QC tubes will contain additional median reference standard [S3], will be used to perform preliminary absorbance checks and serve as a quality check for diluents and inoculum used in test. See Diagram 6 for an example of one independent test run for the Tube Method and placement of the standard curve and unknown sample into triplicate tubes.\n\n根据上述已知信息，请将'抗生素标准品（【S1】-【S5】）和未知样品（【U3】）制备'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Antibiotic Reference Standards ([S1] – [S5]) and Unknown Sample (U3]) Preparation"
    },
    {
        "instruction":"已知信息：\n'一种药物的制剂形式，如片剂、胶囊剂、溶液剂、乳膏剂，它们以前未在地区或成员国注册过。通常是一种药物成份与辅料的组合，但不一定都是。'可被翻译为：A pharmaceutical product type, for example, tablet, capsule, solution, cream, etc., which has not previously been registered in a region or Member State, and which contains a drug ingredient generally, but not necessarily, in association with excipients.\n'任何作为活性成分且用于医药产品生产的物质或混合物质。该类物质旨在预防、诊断、处置、缓解或治疗疾病中发挥药理作用或其它直接效用，或者影响人体的结构和机能。'可被翻译为：Any substance or mixture of substances intended to be used in the manufacture of a drug (medicinal) product and that, when used in the production of a drug, becomes an active ingredient of the drug product. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure and function of the body.\n'1.FPP的形式，如片剂、胶囊、酏剂或栓剂。\n2.药品成品的形态，如片剂、胶囊、酏剂、注射剂、栓剂。\n3.完整的药物制剂形式，如片剂、胶囊、酏剂、栓剂。\n4.制剂的形式，如片剂、胶囊、酏剂或栓剂。\n5.制成品的形式，如片剂、胶囊、酏剂或栓剂。'可被翻译为：1.The form of the FPP, e.g. tablet, capsule, elixir or suppository.\n2.The form of the completed pharmaceutical product, e.g. tablet, capsule, elixir, injection, suppository.\n3.The form of the completed pharmaceutical preparation, e.g. tablet, capsule, elixir, suppository.\n4.The form of the completed pharmaceutical product, e.g. tablet, capsule, elixir or suppository.\n5.The form of the finished pharmaceutical product, e.g. tablet, capsule, elixir or suppository.\n'药物及辅料以适当形式填装于空心胶囊中制成的固体制剂。'可被翻译为：A solid preparation made of drugs and excipients filled in hollow capsules in an appropriate form.\n\n根据上述已知信息，请将'通常含有一种药物活性成分及各种辅料（但不一定必须有辅料）制成的药物制剂形式（如片剂、胶囊、溶液剂、乳膏剂）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A pharmaceutical product type (e.g., tablet, capsule, solution, cream) that contains a drug substance generally, but not necessarily, in association with excipients."
    },
    {
        "instruction":"已知信息：\n'新辅助疗法的目的可能包括提高整体结局（OS、DFS\/PFS）并确保手术和器官保存 （如更为保守的手术）。'可被翻译为：The objectives of neoadjuvant therapy may include improved overall outcome (OS, DFS\/PFS), enabling surgery and organ preservation (e.g. more conservative surgery).\n'新辅助和辅助治疗'可被翻译为：Neoadjuvant and Adjuvant therapy\n'（新）辅助治疗'可被翻译为：(Neo)adjuvant therapy\n'1.5 ICH S9是否涵盖辅助治疗或新辅助治疗的临床试验？'可被翻译为：1.5 Are clinical trials in the adjuvant or neo-adjuvant setting covered under ICH S9?\n\n根据上述已知信息，请将'（新）辅助治疗 辅助治疗的最终目的是提高治愈率。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(Neo)adjuvant therapy In the adjuvant setting, the ultimate aim is to increase cure rate."
    },
    {
        "instruction":"已知信息：\n'任何对现有指导原则的偏离均须加以说明。'可被翻译为：Any deviation from existing guidelines needs to be justified.\n'然而，缺乏常用术语的统一定义会造成管理文件 和指导原则之间术语使用的冲突或管理机构、伦理委员会和 申办公司间对其解释的不一致。'可被翻译为：However, the lack of consistently applied definitions to commonly used terminology raises the potential for either conflicting use of terms in regulatory documentation and guidelines, or, inconsistent interpretation by regulatory authorities, ethics committees and sponsor companies.\n'一、申请人需在现行技术要求基础上，尽早按照ICH指导原则的要求开展研究。本公告发布之日起6个月后开始的相关研究（以试验记录时间点为准），适用上述ICH指导原则。'可被翻译为：I. Applicants are required to carry out the study in accordance with the ICH Guidelines as early as possible based on current technical requirements. For relevant studies that start 6 months after the issuance date of this Announcement(based on the time point of the trial record), the above ICH Guidelines shall apply.\n'应提供指导原则《电离辐射在药品生产中的使用》所要求的数据，必要时按ISO 11137和Ph. Eur. 5.1.1中给出的数据要求补充。'可被翻译为：Data as requested in Note for Guidance “The use of Ionization Radiation in the Manufacture for Medicinal Products” should be provided, supplemented as necessary by data requirements given in ISO 195 11137 and Ph. Eur. chapter 5.1.1.\n\n根据上述已知信息，请将'ISO 11137中的任何要求与EMA发布的任何指导原则中载明的要求冲突的， 适用指导原则的要求。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Where any requirements in ISO 11137 are in contradiction to requirements stated in any Note for Guidance issued by the EMA, the requirements of the Note for guidance apply."
    },
    {
        "instruction":"已知信息：\n'这条指导原则涉及了支持适应症所需的药效学和临床数据、治疗尿失禁的剂量方案和持续时间。'可被翻译为：This guideline considers pharmacodynamic and clinical data required to support indications, dose regimens and durations of therapy for the treatment of urinary incontinence (UI).\n'开发新的药物治疗尿失禁的目标应该是使患者的症状获得改善或治疗，因此患者对治疗效果的感知应作为 III 期临床试验的主要终点。'可被翻译为：The aim for developing new drugs for urinary incontinence should be to obtain improvement or cure of symptoms for the patient, hence patient perception of treatment effect should be included in the primary endpoint in phase III trials.\n'该指导原则替代指导原则\/CPMP\/EWP\/18\/01。'可被翻译为：This guideline replaces guideline CPMP\/EWP\/18\/01\n'执行摘要 本文件是2003年5月生效的指导原则注释（CPMP\/EWP\/2922\/01）的修订版。'可被翻译为：Executive summary This document is a revision of the Note for Guidance (CPMP\/EWP\/2922\/01) which came into effect in May 2003.\n\n根据上述已知信息，请将'执行摘要 \n随着治疗尿失禁药物临床试验指导原则\/CPMP\/EWP\/18\/01的采纳， 指导方针的一些内容将因批准要求和上市批准重要变更要求得到进一步的解释而改善。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Executive summary \nFollowing adoption of the Note for Guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence (CPMP\/EWP\/18\/01) it became apparent that some areas of the guideline would benefit from further explanation of the requirements for approval and for significant variations to the marketing authorisation."
    },
    {
        "instruction":"已知信息：\n'根据是否有可用的授权对照药，在SOC基础上的安慰剂对照研究或与已批准标准治疗的比较将是必要的。'可被翻译为：Depending on the availability of authorised comparators, placebo-controlled studies on top of SOC or a comparison with approved standard of care are needed.\n'在所考察的病症没有普遍认可和接受的治疗 时，应将标准治疗作为参比治疗。'可被翻译为：In case of no generally approved and accepted therapy for the condition studied, standard of care should be the comparator.\n'最终用户可以 包括参与药品的常规采购、储存、储存和管理的任何人，例如患者或患者的护理人 员、处方医生、护士、药剂师或药学技术人员等。'可被翻译为：End users could include anyone involved in routine procurement, stocking, storage, and administration of the drug product, such as the patient or patient’s caregiver, the prescribing physician, nurse, pharmacist, or pharmacy technician, among others.\n'涉及到的最终用户包括，但不限于：患者，患者的护理员，处方医生、护士、药剂师、药房技术员，和其他参与药品日常采购、存储和 管理的人员 （如，药物技术人员）。'可被翻译为：References to end user(s) include, but are not limited to, the patient, patient’s caregiver, the prescribing  physician, nurse, pharmacist, pharmacy technician, and other individuals who are involved in  routine procurement, stocking, storage, and administration of medications (e.g., medication  technicians).\n\n根据上述已知信息，请将'建议参与登记（包括标准护理），这允许对比。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"It  is recommended to participate in registries which include standard care as well, which may allow comparisons."
    },
    {
        "instruction":"已知信息：\n'主要终点的选择不应导致没有足够的数据来评估对生存期的作用。'可被翻译为：The choice of primary endpoint should not lead to insufficient data for assessing the effect on survival.\n'基于随机后测量的事件不应将患者从该人群中排除（例如，失访）。'可被翻译为：Patients should not be excluded from this population based upon events that are measured after randomization (e.g., loss to follow-up).\n'一般情况下，对于终末事件类型的伴发事件，不能采用疗法 策略，原因是该类伴发事件后变量的值不再存在。'可被翻译为：In general, the treatment policy strategy cannot be implemented for intercurrent events that are terminal events, since values for the variable after the intercurrent event do not exist.\n'诸如终止治疗、转组治疗或使用额外药物等事件可能导致 变量的后续观测值即使可以收集到数据也与估计目标不相关或难 以解释。而对于死亡的受试者，死亡后的观测值是不存在的。'可被翻译为：Events such as discontinuation of treatment, switching between treatments, or use of an additional medication may render the later measurements of the variable irrelevant or difficult to interpret even when they can be collected. Measurements after a subject dies do not exist.\n\n根据上述已知信息，请将'对于死亡等终末事件，变量不能在伴发事件后进行观测， 但这些数据通常都不应被视为缺失。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For terminal events such as death, the variable cannot be measured after the intercurrent event, but neither should these data generally be regarded as missing."
    },
    {
        "instruction":"已知信息：\n'给药期间每日对妊娠动物称体重可提供有用的信息。对某些化合物，在非妊娠期(交配前、交配期、哺乳期)则最好每周称体重 2 次以上。'可被翻译为：Daily weighing of pregnant females during treatment can provide useful information. Weighing an animal more frequently than twice weekly during periods other than pregnancy (premating, mating, lactation) may also be advisable for some compounds.\n'研究妊娠期女性可能使用的药物具有重要意义。'可被翻译为：Investigation of drugs that may be used in pregnancy is important.\n'EFD试验的目的是妊娠雌性动物于器官发生期（C段）给药后，检测对妊娠 雌性动物和胚胎和胎仔发育的不良影响。'可被翻译为：The aim of the EFD studies is to detect adverse effects on the pregnant female and development of the embryo and fetus following treatment (Stage C) of the pregnant female during organogenesis.\n'对于NHP，雌性 动物应从确认妊娠（约GD20）到至少妊娠50天（主要器官发生结束）给药。'可被翻译为：For NHP, females are dosed from confirmation of pregnancy (approximately GD 20) to at least Day 50 (end of major organogenesis)\n\n根据上述已知信息，请将'e：给药期间对妊娠雌性动物每天称重可以提供有用的信息。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"e: Daily weighing of pregnant females during treatment can provide useful information."
    },
    {
        "instruction":"已知信息：\n'起始原料作为重要的结构片段并入原料药的结构中。'可被翻译为：A starting material is incorporated as a significant structural fragment into the structure of the drug substance.\n'“重要结构片断的选择原则经常被误解为所选起始原料应该与原 料药具有相似的结构。但是，正如ICH Q11所声明的，该原则旨在帮助将试剂、催化剂、溶剂以及其他原料与起始原料区分开来。'可被翻译为：The selection principle about “significant structural fragment” has frequently been misinterpreted as meaning that the proposed starting material should be structurally similar to the drug substance. However, as stated in ICH Q11, this general principle is intended to help distinguish starting materials from reagents, catalysts, solvents, or other raw materials.\n'1.用于表示起始原料(活性药物成分和赋形剂)、试剂、溶剂、工艺助剂、中间体、包装材料和标签材料的总称。\n2.用于表示原材料(起始原料、试剂、溶剂)、工艺助剂、中间体、原料药以及包装和标签材料的通用术语。\n3.用于表示起始原料、工艺助剂、中间体、活性药物成分、包装和标签材料的术语。'可被翻译为：1.A general term used to denote starting materials (active pharmaceutical ingredients and excipients), reagents, solvents, process aids, intermediates, packaging materials and labelling materials.\n2.A general term used to denote raw materials (starting materials, reagents, solvents), process aids, intermediates, APIs and packaging and labelling materials.\n3.A term used to denote starting materials, process aids, intermediates, active pharmaceutical ingredients, packaging and labelling materials.\n'应提交所选起始原料制备信息（例如，起始原料生产工艺的流程图，标明所有使用的试剂、催化剂和溶剂），以帮助对起始原料的控制进行论证。应包括所拟起始原料中实际和潜在杂质信息。'可被翻译为：Information on how the proposed starting material is made (e.g., a flow chart of the starting material manufacturing process, showing all reagents, catalysts and solvents used) should be provided to help justify the controls applied to the starting material. Information about the actual and potential impurities in the proposed starting material should be provided.\n\n根据上述已知信息，请将'此处所说的“重要结构片段”用于区分起始原料与试剂、溶剂及其他原材料。用来制备盐、酯或其他简单衍生物的常用化学 物质应该被视为试剂。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"“Significant structural fragment” in this context is intended to distinguish starting materials from reagents, solvents, or other raw materials. Commonly available chemicals used to create salts, esters or other simple derivatives should be considered reagents."
    },
    {
        "instruction":"已知信息：\n'在使用 X 之前请通知您的核医学医生：'可被翻译为：Talk to your nuclear medicine doctor before being administered X:\n'如果您有任何问题，请咨询监管此过程的核医学医生。'可被翻译为：- If you have any further questions, ask your nuclear medicine doctor who will supervise the procedure.\n'如果您可能怀孕、如果您没来月经、或者如果您正在母乳喂养，在使用X前，必须告知您的核医学医生。一旦有疑问，一定要咨询您的核医学医生，这一点十分重要。'可被翻译为：You must inform the nuclear medicine doctor before the administration of X if there is a possibility you might be pregnant, if you have missed your period or if you are breast-feeding.\n'在出现以下情况时，请通知您的核医学医生：'可被翻译为：Inform your nuclear medicine doctor in the following cases;\n\n根据上述已知信息，请将'如果您对使用 X 有任何进一步的问题，请咨询监管此过程的核医学医生。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"If you have any further question on the use of X, please ask your nuclear medicine doctor who supervises the procedure."
    },
    {
        "instruction":"已知信息：\n'适用时，进一步确定最佳的给药途径'可被翻译为：When applicable, further characterise the optimum route of administration Selection and number of patients\n'可增强对治疗蛋白的免疫应答的因素包括剂量、给药方案和给药途径。'可被翻译为：Factors which may increase the immune response to a therapeutic protein include dosage, dosing schedule and route of administration.\n'应特别注意停药部分的持续时间，特别是对于具有长半衰期或长期生物效应的药物。'可被翻译为：Particular attention should be devoted to the duration of the withdrawal part especially for drugs with long half-life or prolonged biologic effect.\n'对于生物制品，如果适当，应进行抗药抗体（ADA）采样并评价（参见ICH S6）。'可被翻译为：For biopharmaceuticals, samples for anti-drug antibodies should be collected, and evaluated if appropriate (see ICH S6).\n\n根据上述已知信息，请将'4 对于具有广泛的药理作用、长半衰期或过敏反应潜力的分子，本表中的给 药方案应进行适当调整。此外，应考虑免疫原性的潜在作用（见ICH S6）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"4 The treatment schedules described in this table should be modified as appropriate for molecules with extended pharmacodynamic effects, long half-lives or potential for anaphylactic reactions. In addition, the potential effects of immunogenicity should be considered (see ICH S6)."
    },
    {
        "instruction":"已知信息：\n'（二）以非药品冒充药品或者以他种药品冒充此种药品；'可被翻译为：(2) a non-drug substance is substituted for a drug or one drug is substituted for another;\n'（一）未取得药品批准证明文件生产、进口药品；'可被翻译为：(1) manufacture of import drugs without drug approval documents;\n'第一百一十二条 国务院对麻醉药品、精神药品、医疗用毒性药品、放射性药品、药品类易制毒化学品等有其他特殊管理规定的，依照其规定。'可被翻译为：Article 112 Where the State Council has other special administrative provisions on narcotic drugs, psychiatric drugs, toxic drugs for medical use, radioactive drugs, and pharmaceutical precursor chemicals., such provisions shall be followed.\n'第一百二十条 麻醉药品、精神药品、医疗用毒性药品、放射性药品、药品类易制毒化学品等有其他特殊管理规定药品的注册申请，除按照本办法的规定办理外，还应当符合国家的其他有关规定。'可被翻译为：Article 120 Registration applications of narcotics, psychotropics, toxic substances for medical use, radiopharmaceuticals, pharmaceutical precursor chemicals and other drugs subject to special administration shall be handled not only in compliance with these Provisions but also with other relevant State regulations.\n\n根据上述已知信息，请将'（一）以麻醉药品、精神药品、医疗用毒性药品、放射性药品、药品类易制毒化学品冒充其他药品，或者以其他药品冒充上述药品；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(1) substitute narcotics, psychotropic substances, toxic drugs for medical use, radioactive drugs or pharmaceutical precursor chemicals for other drugs, or vice versa;"
    },
    {
        "instruction":"已知信息：\n'已知发生群体畸形'可被翻译为：Malformation clusters are known to occur\n'如果单个动物模型可能无法解决所有方面的问题， 研究中需要使用各种不同的动物模 型。'可被翻译为：In case a single animal model might not suffice to address all these aspects, various different animal models should be employed in these studies.\n'小型猪'可被翻译为：Mini-pig\n'犬：季节性繁殖，多近亲繁殖，历史背景资料不足。'可被翻译为：Dogs: seasonal breeders, inbreeding factors, insufficient historical background data.\n\n根据上述已知信息，请将'家养猪和\/或小型猪：群体畸形的背景情况多变，所需的受试物量大，需要较大饲养空间，历史背景资料不足。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Domestic and\/or mini pigs: malformation clusters with variable background rate, large amounts of compound required, large housing necessary, insufficient historical background data."
    },
    {
        "instruction":"已知信息：\n'为确保您拥有最新版本的指导原则，请查见FDA指导原则网页：www.fda.gov\/RegulatoryInformation\/Guidances\/default.htm'可被翻译为：To make sure you have the most recent version of a guidance, check the FDA guidance Web page at www.fda.gov\/RegulatoryInformation\/Guidances\/default.htm.\n'http：\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htm'可被翻译为：http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htm\n'22 见http:\/\/www.fda.gov\/RegulatoryInformation\/Guidances\/ucm129901.htm.'可被翻译为：22 See http:\/\/www.fda.gov\/RegulatoryInformation\/Guidances\/ucm129901.htm.\n'http:\/\/www.fda.gov\/MedicalDevices\/default.htm \n一般信息'可被翻译为：http:\/\/www.fda.gov\/MedicalDevices\/default.htm\nGeneral Information\n\n根据上述已知信息，请将'请参阅 http:\/\/www.fda.gov\/RegulatoryInformation\/RulesRegulations\/default.htm。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"See http:\/\/www.fda.gov\/RegulatoryInformation\/RulesRegulations\/default.htm."
    },
    {
        "instruction":"已知信息：\n'定量风险评估中使用的数值因子，用于表示或允许在特定实验室物种或暴露人群中观察到的暴露浓度及其相关健康结果的外推、不确定性或可变性，这些暴露浓度将与相同的给药剂量相关(例如，从动物到人类患者以及从短期暴露到慢性暴露)。在处理临床数据时也可以使用调整因子，例如，当研究人群不能代表一般人群时。'可被翻译为：Numerical factor used in a quantitative risk assessment to represent or allow for the extrapolation, uncertainty, or variability of an observed exposure concentration and its associated health outcome in a particular laboratory species or exposed population to an exposure concentration for the target population (for example, from animals to human patients and short-term exposure to chronic exposure) that would be associated with the same delivered dose. Adjustment factors can also be used when dealing with clinical data, e.g.  when a study population is not representative of the general population.\n'调整因子： 毒理学家通过专业评判确定的一个因子，用于生物测定数据与人体安全性数 据的关联。（ICH Q3C）（见相关术语：安全因子）'可被翻译为：Modifying Factor: An individual factor determined by professional judgment of a toxicologist and applied to bioassay data to relate that data to human safety. (ICH Q3C) (See related term Safety Factor)\n'标志着开始进行低剂量外推以得出HBEL的剂量反应点。这个点可以是未观察到不良效应水平(NOAEL)或未观察到效应水平(NOEL)，最低观察到不良效应水平(LOAEL)或观察到的效应的基准剂量水平(BMDL)[未观察到不良反应的最高剂量(NOEL\/NOAEL)，或者，如果无法获得，则首次观察到显著不良反应的剂量(LOEL\/LOAEL)]。'可被翻译为：The dose-response point that marks the beginning of a low-dose extrapolation to derive an HBEL. This point can be a No Observed Adverse Effect Level (NOAEL) or No Observed Effect Level (NOEL), Lowest Observed Adverse Effect Level (LOAEL) or Lowest Observed Effect Level (LOEL), or Benchmark Dose Level (BMDL) for an observed effect [the highest dose at which no unwanted\/adverse effect is observed (NOEL\/NOAEL), or, if unavailable, the dose at which a significant adverse effect is first observed (LOEL\/LOAEL)].\n'通常期望为DART确定一个未见不良影响剂量（NOAEL）。'可被翻译为：It is generally desirable to establish a no observed adverse effect level (NOAEL) for DART.\n\n根据上述已知信息，请将'安全因子： 风险评估专家针对NOAEL或其他参照点，例如基准剂量或基准剂量置信下 限，应用的一种复合（简化）因子，用以推算一个被认为安全或未见风险的参照 剂量；例如一个可接受的日摄入量或日耐受量（参照剂量通过NOAEL或其他参 照点除以安全因子计算得出）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Safety Factor: A composite (reductive) factor applied by the risk assessment experts to the NOAEL or other reference point, such as the benchmark dose or benchmark dose lower confidence limit, to derive a reference dose that is considered safe or without appreciable risk, such as an acceptable daily intake or tolerable daily intake (the NOAEL or other reference point is divided by the safety factor to calculate the reference dose)."
    },
    {
        "instruction":"已知信息：\n'国家鼓励、引导药品零售连锁经营。从事药品零售连锁经营活动的企业总部，应当建立统一的质量管理制度，对所属零售企业的经营活动履行管理责任。'可被翻译为：The State encourages and guides the operation of retail drug chains. The headquarters of a retail drug chain shall establish a unified quality management system and perform management responsibilities for the business activities of the chain retailers.\n'第一百八十条 本规范为药品经营质量管理的基本要求。对企业信息化管理、药品储运温湿度自动监测、药品验收管理、药品冷链物流管理、零售连锁管理等具体要求，由国家食品药品监督管理总局以附录方式另行制定。'可被翻译为：Article 180 The GSP provides basic requirements for quality management of drug distribution. Specific requirements for enterprise informatization management, automatic monitoring of temperature and humidity for drug storage and transportation, drug acceptance inspection management, drug cold chain logistics management, and retail chain management shall be separately formulated by the National Medical Products Administration (NMPA) in the form of appendixes.\n'第一百五十二条 企业采购药品，应当符合本规范第二章第八节的相关规定。'可被翻译为：Article 152 Purchase of drugs by enterprises shall comply with the relevant provisions of Section 8 of Chapter II herein.\n'第一百六十四条 企业设置库房的，库房的药品储存与养护管理应当符合本规范第二章第十节的相关规定。'可被翻译为：Article 164 Where an enterprise establishes a warehouse, the drug storage and maintenance management in the warehouse shall comply with Section 10 of Chapter II herein.\n\n根据上述已知信息，请将'第一百七十九条 药品零售连锁企业总部的管理应当符合本规范药品批发企业相关规定，门店的管理应当符合本规范药品零售企业相关规定。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 179 The management of the headquarters of drug retail chain enterprise shall comply with the relevant provisions of the GSP for drug wholesale enterprises, and the management of its stores shall comply with the relevant provisions of the GSP for drug retail enterprises."
    },
    {
        "instruction":"已知信息：\n'• 所有提交报告都使用同一 MedDRA 版本。'可被翻译为：• All reports would be generated with the same version of MedDRA.\n'本节中讨论的所有终点被认为同等适用于试验设计。'可被翻译为：All endpoints discussed in this section are considered equally appropriate in terms of study design.\n'2) 所有的报告应使用 MedDRA 的最新版本。编码用的 MedDRA 版本号码应在所有的报告中显示清楚。'可被翻译为：2) All reporting should be done using the most recently released version of MedDRA. The version number of the MedDRA release used to code the report data should be included in all reports.\n'在临床试验中，用进行 MedDRA 编码时，据了解，许多机构可能不希望每次 MedDRA 版本更新时都重新编码数据。如此以来，一个项目或一个临床试验可能会 “固定” 使用一个 MedDRA 的版本（即在整个项目或临床试验使用相同版本的 MedDRA），然后在项目或临床试验的关键节点时选择是否需要重新编码数据。'可被翻译为：For coding with MedDRA in clinical trials, it is understood that many organizations may not want to re-code data as frequently as MedDRA updates are available. As such, it is assumed that a project or a trial will “freeze” (i.e., utilize the same version of MedDRA for the entirety of the project or trial) on a version of MedDRA and then optionally re- code at a later milestone in the project\/trial.\n\n根据上述已知信息，请将'• 一个项目下所有的临床试验使用同一 MedDRA 版本编码。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"• All trials within the project would be coded with the same version of MedDRA."
    },
    {
        "instruction":"已知信息：\n'ICH E10 \n现行第四阶段版本 \n2000年7月20日 \n该指导原则由相应的ICH专家工作组制定，按照ICH 进程，已通过药品监管机构讨论。'可被翻译为：ICH HARMONISED TRIPARTITE GUIDELINE CHOICE OF CONTROL GROUP AND RELATED ISSUES IN CLINICAL TRIALS E10 \nCurrent Step 4 version \ndated 20 July 2000 \nThis Guideline has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH Process.\n'ICH E15 \n现行第四阶段版本 \n2007年11月1日 \n该指导原则由相应的ICH专家工作组制定，按照ICH进 程，已通过药品监管机构讨论。'可被翻译为：ICH HARMONISED TRIPARTITE GUIDELINE DEFINITIONS FOR GENOMIC BIOMARKERS, PHARMACOGENOMICS, PHARMACOGENETICS, GENOMIC DATA AND SAMPLE CODING CATEGORIES E15 \nCurrent Step 4 version \ndated 1 November 2007 \nThis Guideline has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH Process.\n'ICH E2F ICH进程第四阶段推荐采纳 2010年8月17日 该指导原则由相应的ICH专家工作组制定，按照ICH 进程，已通过药品监管机构讨论。'可被翻译为：INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE DEVELOPMENT SAFETY UPDATE REPORT E2F Current Step 4 version dated 17 August 2010 This Guideline has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH Process.\n'ICH E9 \n现行第四阶段版本 \n1998年2月5日 \n该指导原则由相应的ICH专家工作组制定，按照ICH进程，已通过药品监管机构讨论。'可被翻译为：ICH HARMONISED TRIPARTITE GUIDELINE STATISTICAL PRINCIPLES FOR CLINICAL TRIALS E9 \nCurrent Step 4 version \ndated 5 February 1998 \nThis Guideline has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH Process.\n\n根据上述已知信息，请将'ICH E16 \n现行第四阶段版本 \n2010年8月20日 \n该指导原则由相应的ICH专家工作组制定，按照ICH进 程，已通过药品监管机构讨论。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"ICH HARMONISED TRIPARTITE GUIDELINE BIOMARKERS RELATED TO DRUG OR BIOTECHNOLOGY PRODUCT DEVELOPMENT: CONTEXT, STRUCTURE AND FORMAT OF QUALIFICATION SUBMISSIONS E16 \nCurrent Step 4 version \ndated 20 August 2010 \nThis Guideline has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH Process."
    },
    {
        "instruction":"已知信息：\n'（五）对有证据证明可能危害人体健康的药品及其有关材料，依法采取查封、扣押措施；'可被翻译为：(5) seal up and detain the drugs and related materials as proved by evidence that may cause potential harm to human health according to law;\n'（五）生产、销售国务院药品监督管理部门禁止使用的药品；'可被翻译为：(5) manufacture or sale of drugs prohibited by the drug regulatory department of the State Council;\n'（三）生产、销售的生物制品属于假药、劣药；'可被翻译为：(3) manufacture and sale of counterfeit or inferior biological products;\n'（四）生产、销售假药、劣药，造成人身伤害后果；'可被翻译为：(4) manufacture and sale of counterfeit or inferior drugs which cause personal injuries;\n\n根据上述已知信息，请将'（五）生产、销售假药、劣药，经处理后再犯；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(5) repeated violations of manufacture and sale of counterfeit or inferior drugs; or"
    },
    {
        "instruction":"已知信息：\n'估计目标的描述涉及特定属性的精确说明，这些属性不仅应 基于临床考虑而制定，还应基于所关注的临床问题中如何反映伴 发事件。'可被翻译为：The description of an estimand involves precise specifications of certain attributes, which should be developed based not only on clinical considerations but also on how intercurrent events are reflected in the clinical question of interest.\n'构建相应临床问题的“估计目标”（见词汇表；A.3.）有助 于精确描述治疗效应，这就需要深思熟虑地定义“伴发事件” （见词汇表；A.3.1.），如终止分配的治疗，使用额外或其他治 疗，或终末事件（如死亡）等。'可被翻译为：Precision in describing a treatment effect of interest is facilitated by constructing the “estimand” (see Glossary; A.3.) corresponding to a clinical question of interest. Clarity requires a thoughtful envisioning of “intercurrent events” (see Glossary; A.3.1.) such as discontinuation of assigned treatment, use of an additional or alternative treatment and terminal events such as death.\n'对于在设计阶段未预见但在试验实施过程中发现的伴 发事件，不仅要讨论分析方法的选择，还要讨论它们对估计目标 的影响，即对所估计的治疗效应描述的影响，和对试验结果解释 的影响。'可被翻译为：Addressing intercurrent events that were not foreseen at the design stage, and are identified during the conduct of the trial, should discuss not only the choices made for the analysis, but the effect on the estimand, i.e. on the description of the treatment effect that is being estimated, and the interpretation of the trial results.\n'退出试验的受试者在退出前可能已经发生了伴发 事件。'可被翻译为：Subjects who withdraw from the trial may have experienced an intercurrent event before withdrawal.\n\n根据上述已知信息，请将'前者代表一个伴 发事件，需通过在试验目的中对估计目标的精确说明加以解决；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The former represents an intercurrent event, to be addressed in the precise specification of the trial objective through the estimand."
    },
    {
        "instruction":"已知信息：\n'联系相应FDA项目经理的上一级主管，适用于帮助获得项目经理的回复'可被翻译为：• Contact the appropriate FDA project manager’s next level supervisor for assistance in eliciting a response from the project manager\n'联系CDER的ECT或CBER的监察专员，适用于帮助获得项目经理的回复'可被翻译为：• Contact CDER’s ECT or CBER’s Ombudsman for assistance in eliciting a response from 441 the project manager\n'联系相应的FDA项目经理，通常是审评部门RPM，适用于FDA回复时间已过的预期时间（例如，在MAPP中描述的时间限）的状态更新；或者联系相应的FDA项目经理，通常是审评部门RPM，适用于估计回复时间已过（例如，之前估计的与申办方沟通的FDA回复日期）的状态更新'可被翻译为：• Contact the appropriate FDA project manager, typically the review division RPM, for a status update after the expected amount of time (e.g., the timelines described in a MAPP) for FDA response has passed; Contact the appropriate FDA project manager, typically the review division RPM, for a status update after the estimated response time has passed (i.e., the estimated FDA-response date communicated to the sponsor previously)\n'FDA项目经理还应包括其部门在CDER中的CPMS或CBER中的替代项目管理人员的联系信息。'可被翻译为：FDA project managers should also include contact information for their division’s CPMS in CDER or the alternative project management staff in CBER.\n\n根据上述已知信息，请将'联系相应部门或办公室管理人员，适用于帮助获得项目经理的回复'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"• Contact the appropriate division or office management officials for assistance in eliciting 438 a response from the project manager"
    },
    {
        "instruction":"已知信息：\n'第一百八十八条 不得在同一生产操作间同时进行不同品种和规格药品的生产操作，除非没有发生混淆或交叉污染的可能。'可被翻译为：Article 188 Operations on different products should not be carried out simultaneously in the same room unless there is no risk of mixups or cross-contamination.\n'第九十八条 禁止生产（包括配制，下同）、销售、使用假药、劣药。'可被翻译为：Article 98 The manufacture (including preparation, same hereinafter), sale, or use of counterfeit or inferior drugs is prohibited.\n'同一药品：指同一生产企业生产的同一药品名称、同一剂型、同一规格的药品。'可被翻译为：The same drug refers to drugs of the same name, dosage form and strength manufactured by the same drug manufacturer.\n'第一百六十八条 每种药品的每个生产批量均应当有经企业批准的工艺规程，不同药品规格的每种包装形式均应当有各自 的包装操作要求。'可被翻译为：Article 168: A master manufacturing document approved by the manufacturer should exist for each batch size of every drug. A packaging instruction should exist for every package type of different drug strengths and dosage forms.\n\n根据上述已知信息，请将'第一百八十八条 不得在同一生产操作间同时进行不同品 种和规格药品的生产操作，除非没有发生混淆或交叉污染的可能。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 188: Operations on different products should not be carried out simultaneously in the same room unless there is no risk of mixups or cross-contamination."
    },
    {
        "instruction":"已知信息：\n'放射化学纯度'可被翻译为：radiochemical purity\n'放射性物质制剂的比放射性是有关元素或化合物每单位质量的放射性。'可被翻译为：The specific radioactivity of a preparation of a radioactive material is the radioactivity per unit mass of the element or of the compound concerned.\n'在注射之前，必须立即用放射性测量仪来测量氟（18F）脱氧葡糖的放射性。'可被翻译为：The activity of fludeoxyglucose (18F) has to be measured with activimeter immediately prior to injection.\n'蛋白质经单向电泳分离后被转移到硝酸纤维素膜上，然后用放射性或酶标记的特异抗体来检测相应抗原的存在。'可被翻译为：Proteins are separated by unidirectional electrophoresis and transferred to a nitrocellulosic membrane, where the presence of the corresponding antigen is detected with a specific radioactive or enzyme-labeled antibody.\n\n根据上述已知信息，请将'将样品分成等量的两部分，分别加入不同量的相同化学形式的非放射性化合物，然后用反稀释测量各部分的比放射性，由此测知放射性化合物含量的方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A method of determining the content of radioactive compounds by dividing a sample into two equal parts, adding different amounts of the same chemical form of a non-radioactive compound, and then measuring the specific activity of each part by antidilution."
    },
    {
        "instruction":"已知信息：\n'药物相互作用；'可被翻译为：• Drug interactions;\n'药物相互作用'可被翻译为：drug interaction\n'还讨论了 与单药治疗时活性最小但是在联合应用时有协同作用的药物的联合应用，以及与传统细 胞毒性药物的联合应用。'可被翻译为：Combinations of drugs with minimal activity as monotherapy, but synergistic effects when combined, as well as combinations of conventional cytotoxics, are also discussed.\n'还有其他一些可能的情况：联合治疗中的一种或多种药物可能仅限于联合应用，或可能适用于联合应用及单药治疗，和\/或与除了共同开发的药物以外的其他药物联合应用。'可被翻译为：There are a range of other potential scenarios in which one or more of the drugs in a combination may be limited to combination use only, or may be indicated for combination use, monotherapy, and\/or in combination with drugs other than those with which the drug was codeveloped.\n\n根据上述已知信息，请将'作用性质相同药物的联合应用，产生的相加或协同效应。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The additive or synergistic effect produced by the combination of drugs with identical properties of action."
    },
    {
        "instruction":"已知信息：\n'审核和复核结果应当反馈持有人。对持有人的评价结果存在异议的，可以要求持有人重新开展评价。'可被翻译为：Review and re-check results shall be fed back to MAHs. In case of any objection to the evaluation results of MAHs, MAHs may be required to carry out re-evaluation again.\n'变更后的注册人应当符合本办法关于注册人的规定，并对已经上市的产品承担质量安全责任。'可被翻译为：The altered registrant shall comply with requirements of a registrant in these Provisions and shall be responsible for the quality and safety of the products already on the market.\n'第五十八条  持有人主动开展医疗器械再评价的，应当制定再评价工作方案。通过再评价确定需要采取控制措施的，应当在再评价结论形成后15日内，提交再评价报告。其中，国家药品监督管理局批准注册或者备案的医疗器械，持有人应当向国家监测机构提交；其他医疗器械的持有人应当向所在地省级监测机构提交。'可被翻译为：Article 58 In case of voluntarily carrying out medical device re-evaluation, MAHs shall develop re-evaluation plan. Where control measures are required through re-evaluation, MAHs shall submit the re-evaluation report within 15 days upon the formation of re-evaluation conclusion. For medical devices approved by the NMPA to be registered or filed shall submit the report to national monitoring agencies; MAHs of other medical devices shall submit the report to the provincial monitoring agencies where MAHs locate.\n'第三十条  持有人所在地省级监测机构应当在收到持有人评价结果10日内完成对评价结果的审核，必要时可以委托或者会同不良事件发生地省级监测机构对导致或者可能导致严重伤害或者死亡的不良事件开展现场调查。其中，对于国家药品监督管理局批准注册的医疗器械，国家监测机构还应当对省级监测机构作出的评价审核结果进行复核，必要时可以组织对导致死亡的不良事件开展调查。'可被翻译为：Article 30 Local provincial monitoring agencies where MAHs locate shall complete the review of evaluation results within 10 days upon the receipt of evaluation results from MAHs, and if necessary, may carry out on-site investigation on the adverse events that cause or possibly cause severe injuries or death by entrusting or cooperating with the provincial monitoring agencies where adverse events occur. For the medical devices approved by the NMPA to be registered, national monitoring agencies shall also re-check the evaluation review results by provincial monitoring agencies, and if necessary, may organize investigation on the adverse events causing death.\n\n根据上述已知信息，请将'持有人应当对发现的不良事件进行评价，根据评价结果完善产品质量，并向监测机构报告评价结果和完善质量的措施；需要原注册机关审批的，应当按规定提交申请。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"MAHs shall evaluate the identified adverse events, improve the product quality based on evaluation results and report the evaluation results and measures for quality assurance to monitoring agencies; where review and approval by the original registration authority is required, application shall be submitted in accordance with the regulations."
    },
    {
        "instruction":"已知信息：\n'关于生产重组DNA修饰细胞系的更多资料，可参阅其他有关(如地区或国际性)指导原则。'可被翻译为：For further information on generation of rDNA-modified cell substrates, consult other relevant (e.g., regional or international) guidelines.\n'可从EMA网站的指导原 则部分找到相关信息（在生物制品-原料药-血浆源药品下）。'可被翻译为：Information can be found in the guidelines on the EMA website (under Biologicals - Drug Substance - Plasma-derived Medicinal Products).\n'本指导原则并未涉及非临床开发、治疗 幼年型特发性关节炎的药物的开发，以及生物类似物的开发。'可被翻译为：This guidance does not address nonclinical development, development of drug  products for juvenile idiopathic arthritis, or development of biosimilar products.\n'为了促进生物标志物在全球药物或生物技术产品开发 中的应用，建议同时向有关监管机构提交资格认定申请。'可被翻译为：To facilitate the integration of biomarkers in global drug or biotechnology product development it is recommended that qualification submissions be submitted simultaneously to pertinent regulatory authorities.\n\n根据上述已知信息，请将'如需更多指导原则规定以外的详细信息，开发生物类似物的公司可以和EEA的监管机构联络，进一步获取有关开发的建议。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Companies developing biosimilars are invited to contact Regulatory Authorities in the EEA to obtain further advice on their development, whenever there is a need for more detailed information than provided in the guidelines already available."
    },
    {
        "instruction":"已知信息：\n'但是，应该证明这是合理的， 因为不同恶性肿瘤的靶点表达和抑制的重要性可能会有所不同。'可被翻译为：This, however, should be justified as the importance of target expression and inhibition thereof might differ between malignancies.\n'尽管如此，尽可能确定证实的疗效局有临床相关性仍是重要的。'可被翻译为：Nevertheless it remains important to establish that the demonstrated effects of treatment are clinically relevant.\n'例如，在探讨以一种特异性的、假定对疾病关键的明确分 子结构为靶点的化合物的活性研究中，可能会招入组织学诊断不同但表达该靶点的患者。'可被翻译为：For example, in studies investigating the activity of a compound targeting a specific, molecularly well-defined structure assumed to be pivotal for the condition(s), it might be possible to enrol patients with formally different histological diagnosis, but expressing this target.\n'药物靶点的一般生物学信息，或靶点在生殖或发育中的已知作用。'可被翻译为：Aspects of the general biology of the pharmaceutical target, or known roles of the target in reproduction or development.\n\n根据上述已知信息，请将'但是，必须证明靶点在不同组织学诊断中的关键作用。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The pivotal role of the target in different histological diagnoses, however, must be demonstrated."
    },
    {
        "instruction":"已知信息：\n'就旨在确定治疗应持续多长时间的研究 来说，这样的纳入标准则提供了研究人群以及要做的比较。'可被翻译为：In the case of studies intended to determine how long a therapy should be continued, such entry criteria provide the study population and comparison of interest.\n'研究持续时间试验持续时间取决于预期进展率，而后者又转而取决于所纳入的人群。'可被翻译为：Study duration Trial duration depends on the expected rate of progression which in turn depends on the population included.\n'对于残疾的明显声称，将需要大规模长期平行组试验，以确 立对疾病进展的临床相关性治有效性应。'可被翻译为：For a distinct claim on disability large-scale long-term parallel group trials will be required to establishclinically relevant treatment effects on disease progression.\n'应包括阳性研究和未能显示有效性的研究。'可被翻译为：Both positive studies and studies that failed to show effectiveness should be included.\n\n根据上述已知信息，请将'研究持续时间将取决于所研究的人群，并应足以显示对残疾的可靠和相关治有效性应。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Study duration will depend on the population studied, and should be sufficient to show a reliable and relevant effect on disability."
    },
    {
        "instruction":"已知信息：\n'全因子设计研究可能会减少疗效不足或无效患者研究中某些步骤的需要；'可被翻译为：A full factorial design study may reduce the need for certain steps in the inadequate or non responder studies;\n'在这种情况下，应设计临床研究以降低因治疗组间不平衡的治疗方式而可能产生的偏差。'可被翻译为：In such cases, the clinical studies should be designed to decrease any potential bias due to unbalanced therapeutic modalities between treatment groups.\n'导入期可能需要缩短'可被翻译为：The run-in period may need to be shortened\n'可能需要缩短导入期'可被翻译为：- The run-in period may need to be shortened\n\n根据上述已知信息，请将'如果要进行疗效研究，随机治疗阶段可能需要缩短。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In case an efficacy study has to be conducted, the randomised treatment period may need to be shortened."
    },
    {
        "instruction":"已知信息：\n'在生产过程中，为达到期望的效果，工艺参数可能会被调整。'可被翻译为：During manufacture, the process parameters may be adjusted to deliver the expected outcome.\n'在研发过程中，生产工艺可以改变。'可被翻译为：The manufacturing process can change during the course of development.\n'对于 AD 痴呆阶段BPSD 的症状治 疗，建议持续时间为 8 ~ 12 周，但研究持续时间应根据症状及其波动进行调整。'可被翻译为：For symptomatic treatment of BPSD in dementia stages of AD a duration of 8 to 12 weeks is recommended, however study duration depends on the symptoms and their fluctuation and should be justified.\n'由生物源生产或从生物源中提取的物质，对其进行物化生物学试验、生产过程及其控制相结合，以表征和确定其质量。'可被翻译为：A substance that is produced by or extracted from a biological source and for which a combination of physicochemical-biological testing and the production process and its control is needed for its characterization and the determination of its quality.\n\n根据上述已知信息，请将'制造商应根据其特定产品及其生产过程调整本文推荐的方案。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The manufacturers should adjust the recommendations presented here to their specific product and its production process."
    },
    {
        "instruction":"已知信息：\n'IPCS： 国际化学品安全计划'可被翻译为：IPCS: International Programme for Chemical Safety.\n'国际化学品安全规划署（International Programme on Chemical Safety）'可被翻译为：Intraperitoneal\n'CICAD 简明国际化学品评估文件（Concise International Chemical Assessment Document）'可被翻译为：CICAD Concise International Chemical Assessment Document\n'举例来说，甲醛口服不产生致癌性，因此监管限度是基于非癌症终点的。加拿大卫生部（Health Canada）（参考文献8），世界卫生组织国际化学品安全规划小组（WHO IPCS）（参考文献9）以及美国环境保护署（EPA）（参考文献10）推荐口服限度为0.2mg\/kg\/天，或50kg的成年人10mg\/天。'可被翻译为：For example, formaldehyde is not a carcinogen orally, so that regulatory limits have been based on non-cancer endpoints. Health Canada (Ref. 8), WHO IPCS (Ref. 9) and US Environmental Protection Agency (EPA) (Ref. 10) recommend an oral limit of 0.2 mg\/kg\/day, or 10 mg\/day for a 50 kg person.\n\n根据上述已知信息，请将'IPCS 国际化学品安全规划小组（International Programme on Chemical Safety）'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"IPCS International Programme on Chemical Safety"
    },
    {
        "instruction":"已知信息：\n'国家药监局关于发布《化妆品分类规则和分类目录》的公告'可被翻译为：NMPA Announcement on Issuing the Classification Rules and Classification Catalogue of Cosmetics\n'第四十一条 已经注册的特殊化妆品的注册事项发生变化的，国家药品监督管理局根据变化事项对产品安全、功效的影响程度实施分类管理：'可被翻译为：Article 41 If the registration items of the registered special cosmetics are changed, the NMPA shall implement classified management according to the degree of influence of the changed items on product safety and efficacy:\n'为贯彻落实《化妆品监督管理条例》，规范和指导化妆品功效宣称评价工作，国家药监局组织起草了《化妆品功效宣称评价规范》，于2021年4月8日予以公布，自2021年5月1日起施行。'可被翻译为：In order to fully implement the Regulations on the Supervision and Administration of Cosmetics and standardize and guide the evaluation of efficacy claims of cosmetics, the NMPA has organized to formulate the Standard for the Evaluation of Efficacy Claims Cosmetics, which was issued on April 8 and shall take effect as of May 1, 2021.\n'为贯彻落实《化妆品监督管理条例》，规范和指导化妆品安全评估工作，国家药监局组织起草了《化妆品安全评估技术导则（2021年版）》，于4月8日发布，自2021年5月1日起施行。'可被翻译为：In order to fully implement the Regulations on the Supervision and Administration of Cosmetics and standardize and guide the safety evaluation of cosmetics, the NMPA has organized to formulate the Technical Guidance for the Safety Evaluation of Cosmetics (2021 Edition), which was issued on April 8 and shall take effect as of May 1,2021.\n\n根据上述已知信息，请将'为贯彻落实《化妆品监督管理条例》，规范和指导化妆品分类工作，国家药监局制定了《化妆品分类规则和分类目录》，于2021年4月8日予以公布，自2021年5月1日起施行。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In order to fully implement the Regulations on the Supervision and Administration of Cosmetics and standardize and guide the classification of cosmetics, the NMPA has formulated the Classification Rules and Classification Catalogue of Cosmetics, which was issued on April 8 and shall take effect as of May 1, 2021."
    },
    {
        "instruction":"已知信息：\n'• 在个例报告过程中应用半年度版本控制的建议'可被翻译为：• Single Case Reporting Using Semi-annual Version Control\n'注3：可以选择将一个或多个控制策 略的总结文件放在此处。'可被翻译为：Note 3: One or more control strategy summary documents may optionally be placed here.\n'本节的目的是提供关于MSSO对 MedDRA 版本更新的建议，及其在自发个例报告和上市 前个例报告中的实施。'可被翻译为：The purpose of this section is to provide the MSSO’s recommendations regarding the issue of MedDRA versions and their implementation for spontaneous single case reports and pre-market single case reports.\n'MSSO 向 MedDRA 用户在报告自发个例报告和上市前个例报告时提出以下建议：'可被翻译为：The MedDRA MSSO makes the following recommendations to the users of MedDRA in the reporting of spontaneous single case reports and pre-market single case reports:\n\n根据上述已知信息，请将'3. 在个例报告中应用半年度版本控制的建议'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"3. SINGLE CASE REPORTING USING SEMI-ANNUAL VERSION CONTROL"
    },
    {
        "instruction":"已知信息：\n'在传统的生产工艺开发及控制策略中，通常为了确保生产的一致性，基于试验数据所设定的参数及操作范围通常都很窄。'可被翻译为：In a traditional approach to developing a manufacturing process and control strategy, set points and operating ranges are typically set narrowly based on the observed data to ensure consistency of manufacture.\n'当研发工作相对有限时，可能会导致确保方法性能的狭窄操作窗口。'可被翻译为：When more limited development studies have been conducted this may result in a narrow operating window to ensure method performance.\n'6.相关生产操作或活动、工艺参数及控制范围，以及所用主要生产设备的编号。'可被翻译为：6. Any relevant processing operation or event, process parameters and control limits, and the reference number of major equipment used;\n'（六）相关生产操作或活动、工艺参数及控制范围，以及所 用主要生产设备的编号；'可被翻译为：6. Any relevant processing operation or event, process parameters and control limits, and the reference number of major equipment used;\n\n根据上述已知信息，请将'对于工艺参数范围较窄并固定设备的生产操作，仅用现 有的生产数据可能无法论证工艺参数操作范围的放大或了 解多参数之间的相互作用，可能需要进行其他研究来开发设 计空间。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For manufacturing operations run under narrow operational ranges in fixed equipment, an expanded region of operation and an understanding of multi-parameter interactions may not be achievable from existing manufacturing data alone and additional studies may be needed to develop a design space."
    },
    {
        "instruction":"已知信息：\n'药典的组成部分之一，是与药品标准相关的章节或参考资料。包括制剂通则、通用检测方法和指导原则等。'可被翻译为：One of the components of the pharmacopoeia is the section or reference material related to the drug standard. It includes general rules for preparations, general testing methods, and guidelines.\n'3.2.P.4.1 质量标准 辅料质量标准 质量标准中的每个质量属性 检验方法 可接受标准 或者，如适用， 参考药典各论'可被翻译为：3.2.P.4.1 Specifications Excipient Specification For each Quality Attribute on the specification Test Method Acceptance Criteria Or, if applicable, Reference to pharmacopoeial monograph\n'有关资料在各附录中加以说明，所用定义参见所附 专用词汇表。'可被翻译为：Related information is described in the appendices and selected definitions are provided in the glossary.\n'药品注册标准收载检验项目少于药典规定或质量指标低于药典要求的，应执行药典规定。'可被翻译为：Where the test items recorded in drug registration standards are fewer than those specified in the pharmacopoeia, or the quality indicators are lower than the pharmacopoeia requirements, the pharmacopoeia provisions shall prevail.\n\n根据上述已知信息，请将'药典的组成部分之一，解释和使用药典正确进行质量检定的基本指导原则。把与正文、附录及质量检定有关的共性问题加以规定,避免在全书中重复说明。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"One of the components of the pharmacopoeia that explains and uses the pharmacopoeia's basic guidelines for proper quality verification. Specify common issues related to the main body, appendices, and quality verification to avoid repetition throughout the book."
    },
    {
        "instruction":"已知信息：\n'超过允许偏差24小时的偏离，应在研究报告中说明并评估其影响。'可被翻译为：Excursions that exceed the defined tolerances for more than 24 hours should be described in the study report and their effect assessed.\n'5.试验方案、SOP  或其他试验操作文件的偏离应及时记录、评估并如实反映在总结报告中。'可被翻译为：5. Deviations from study protocol, SOPs or other operational instructions should be recorded, and evaluated in a timely manner, and reported truthfully in the final report.\n'（五）影响受试者权益、安全和健康或者临床试验科学性的临床试验方案偏离，包括请求偏离和报告偏离。'可被翻译为：(5) Deviation from the clinical trial protocol that has an impact on the subjects' rights and interests, safety and health or clinical trial scientificity, including the request deviation and report deviation.\n'第六十六条 研究者应当严格遵循临床试验方案，未经申办者和伦理委员会的同意，或者未按照规定经国家食品药品监督管理总局批准，不得偏离方案或者实质性改变方案。但在受试者面临直接危险等需要立即消除的紧急情况下，也可以事后以书面形式报告。'可被翻译为：Article 66 The investigator shall strictly follow the clinical trial protocol and shall not deviate from the protocol or make a substantive change of plan without the consent of the sponsor and the ethics committee or the approval of China Food and Drug Administration in accordance with the regulations. However, when immediate treatment is needed in the face of emergencies such as direct danger to the subjects, the written report can be provided afterwards.\n\n根据上述已知信息，请将'为保护受试者权益、安全和健康，在紧急情况下发生的偏离无法及时报告的，应当在事后以书面形式尽快按照相关规定报告。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In order to protect the subjects' rights and interests, safety and health, the deviation in emergency that cannot be reported in time shall be reported in writing in accordance with the relevant regulations as soon as possible afterwards."
    },
    {
        "instruction":"已知信息：\n'开始这项研究之前，IRB会审评将要公开披露的信息，以确保这些信息将达 到更广泛的社区范围，并充分告知相关社区开展该项研究计划的执行及其风 险和预期益处。'可被翻译为：Prior to the initiation of an investigation, the IRB reviews the information that will be publicly disclosed to assure that the information will reach the broader communities involved and will adequately inform the affected communities of the plans to conduct the investigation and its risks and expected benefits.\n'这些额外的责任包括咨询将要从事研究和选取受试者的社区代表，在开始该 项研究和完成后公开披露信息，研究者承诺尽力联系受试者的法定授权代表或家 属，以确定家属有反对该受试者参与研究的机会，并且由一个独立的数据监测委 员会监督研究。（21 CFR 50.24正文参见附录A）'可被翻译为：These additional responsibilities include consultation with representatives of the community(ies) in which the research will take place and from which the subjects will be drawn, public disclosure of information before the start of the study and following its completion, a commitment by the investigator to try to locate the subject’s legally authorized representative or contact a family member to determine whether the family member objects to the subject's participation, and study oversight by an independent data monitoring committee. (See Appendix A for the text of 21 CFR 50.24.)\n'◦ 对受试者权利和福利额外保护的计划，至少包括开始该项研究之前社区 咨询和公开披露的计划。 研究者和申办方（或IRB，如果IRB自己决定自身开展社区咨询活动）开展 社区咨询活动。'可被翻译为：o plans for additional protections of the rights and welfare of subjects, including, at least, plans for community consultation and public disclosure prior to the start of the study. The investigator and sponsor (or the IRB, when the IRB has decided at its discretion to carry out community consultation activities itself) conduct the community consultation activities.\n'例如，涉及一种与安慰剂比较的新型治疗的研究可能需要对于将要开展该项研究的 社区和从中招募受试者的社区进行广泛的咨询。'可被翻译为：For example, a study involving a novel treatment that is being compared with placebo may require extensive consultation with the community in which the research will be conducted and with the community from which subjects will be drawn.\n\n根据上述已知信息，请将'例如，这些法规要求，在研究开始前，需要咨询将要从事研究和选取受试者的社区代表；在研究开始和直至完成必须公开披露信息，告知该社区和该项研究的研究者。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For example, the regulations require consultation with representatives of and public disclosure to the communities in which the clinical investigation will be conducted and from which the subjects will be drawn, prior to initiation of the clinical investigation. They also require public disclosure of sufficient information following completion of the clinical investigation to apprise the community and researchers of the study."
    },
    {
        "instruction":"已知信息：\n'在有双键或环状结构的分子中，由于分子中与双键或环相连接的原子或基团的自由旋转受阻碍，存在不同的空间排列而产生的立体异构现象。'可被翻译为：Stereoisomerism in a molecule with a double bond or ring structure, due to the obstruction of the free rotation of the atoms or groups connected to the double bond or ring in the molecule, there are different spatial arrangements resulting in a stereoisomerism.\n'几何异构'可被翻译为：geometrical isomerism\n'含有两个或两个以上多价原子的有机化合物，由于单键自由旋转导致分子中其他原子或基团在空间排列不同，分子的这种立体形象称为构象。'可被翻译为：Organic compounds containing two or more polyvalent atoms, because the free rotation of single bonds causes other atoms or groups in the molecule to be arranged differently in space, this stereoscopic image of the molecule is called conformation.\n'分子能够通过单键自由旋转改变其构象的性质。'可被翻译为：Molecules are able to freely rotate through single bonds to change the properties of their conformation.\n\n根据上述已知信息，请将'当分子中存在双键或由于空间位阻使单键不能自由旋转时，相邻两个原子上的取代基的相对距离和空间排列情况可出现两种几何异构体，相同的取代基处于双键或固定单键同一侧的构象。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"When a double bond is present in the molecule or when the single bond cannot rotate freely due to steric hindrance, the relative distance and spatial arrangement of the substituents on two adjacent atoms may result in two geometric isomers, the same substituent on the same side of the double bond or fixed single bond."
    },
    {
        "instruction":"已知信息：\n'2.根据中国药品出口工作实践和世卫组织相关的最新指南，《药品出口销售证明》新模板（见附件）将投入使用。自2022年12月1日起，各省级药品监管部门应当按照更新后的模板签发《药品出口销售证明》。'可被翻译为：2. A new template for the Certificate of a Pharmaceutical Product (see annex) will be put into use in line with China's pharmaceutical export practices and the latest World Health Organization guidelines. From Dec 1, 2022, all provincial-level drug regulatory authorities shall issue the Certificate of a Pharmaceutical Product in accordance with the new template.\n'国家药监局关于启用《出口欧盟原料药证明文件》和《药品出口销售证明》电子证明的公告'可被翻译为：NMPA Announcement on putting into use the electronic certificates of Documentation for Export of APIs to EU and Certificate of a Pharmaceutical Product\n'该系统于2019年12月31日启用，操作说明详见附件。如药品出口销售证明、出口欧盟原料药证明文件申请是在所在地省级药品监督管理部门自建系统填报的，可继续按原方式办理。'可被翻译为：The system was launched on December 31, 2019, and the operation instructions are detailed in the attachment. If the application for drug export sales certificate and export EU API certificate is filled in the self-built system of the local provincial drug supervision and administration department, it can continue to be handled in the original way.\n'1.自2022年12月1日起，对签发的《出口欧盟原料药证明文件》和《药品出口销售证明》启用电子证明。电子证明与纸质证明具有同等效力。'可被翻译为：1. From Dec 1, 2022, the electronic certificates of the Documentation for Export of APIs to EU and Certificate of a Pharmaceutical Product will be put into use. The electronic certificate and the paper version are equally authentic.\n\n根据上述已知信息，请将'附件：《药品出口销售证明》模板（2022年版）'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Annex: The template for Certificate of a Pharmaceutical Product (2022 Edition)"
    },
    {
        "instruction":"已知信息：\n'为了证明一个稳定性指示性检测方法的专属性\/选择性，应将含有相关降解产物的样品纳入研究。'可被翻译为：To demonstrate specificity\/selectivity of a stability-indicating test, samples containing relevant degradation products should be included in the study.\n'必要时，通过适当的强制降解样品 证明其稳定性指示特性'可被翻译为：Demonstration of stability- indicating properties through appropriate forced degradation samples, if necessary\n'为确立标签上建议（或批准）的复检期和货架期、在推荐的贮藏条件下进行的稳定性研究。'可被翻译为：Stability studies under the recommended storage condition for the re-test period or shelf life proposed (or approved) for labeling.\n'在强力条件下检查降解产物，有助于了解降解途经和开发并验 证所使用的分析方法的有效性。'可被翻译为：Examining degradation products under stress conditions is useful in establishing degradation pathways and developing and validating suitable analytical procedures.\n\n根据上述已知信息，请将'原液或制剂暴露于极端条件下的稳定性研究可能有助于揭示产品的降解形式，如有降解，则应在建议的贮藏条件下监测这些变化。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Studies of the exposure of the drug substance or drug product to extreme conditions may help to reveal patterns of degradation; if so, such changes should be monitored under proposed storage conditions."
    },
    {
        "instruction":"已知信息：\n'符合规定条件的，依法作出准予许可的书面决定，并于10个工作日内发给《医疗器械生产许可证》；不符合规定条件的，作出不予许可的书面决定，并说明理由，同时告知申请人享有依法申请行政复议或者提起行政诉讼的权利。'可被翻译为：If the applicant meets the specified conditions, its application shall be approved according to law, and the Medical Device Manufacturing License shall be issued within 10 working days; if it does not meet the specified conditions, its application shall not be approved and the reasons shall be given in writing. In the meantime, the applicant shall be notified that it is entitled to apply for administrative reconsideration or administrative litigation according to law.\n'经审查符合规定条件的，准予延续，延续后的医疗器械经营许可证编号不变。不符合规定条件的，责令限期整改；整改后仍不符合规定条件的，不予延续，并书面说明理由。逾期未作出决定的，视为准予延续。'可被翻译为：If specified conditions are met upon review, renewal shall be granted, and the number of the renewed Medical Device Distribution License shall remain the same. If specified conditions are not met, rectification within a prescribed time limit shall be ordered; if specified conditions are still not met upon rectification, renewal shall not be granted, and the reasons shall be given in writing. If no decision is made within prescribed time limit, it shall be deemed that renewal is granted.\n'经审查符合规定的，予以批准，并自书面批准决定作出之日起十日内颁发药品生产许可证；不符合规定的，作出不予批准的书面决定，并说明理由。'可被翻译为：The application shall be approved if it meets the requirements after review, and the Drug Manufacturing Certificate shall be issued within 10 days since the date of written approval. A written decision to disapprove the application along with an explanation shall be given if it does not meet the requirements.\n'第十三条 省、自治区、直辖市药品监督管理部门应当根据申请资料审核和现场核查等情况，对符合规定条件的，作出准予许可的决定，并自作出决定之日起5个工作日内向申请人颁发化妆品生产许可证；对不符合规定条件的，及时作出不予许可的书面决定并说明理由，同时告知申请人依法享有申请行政复议或者提起行政诉讼的权利。'可被翻译为：Article 13 The drug regulatory department of the province, autonomous region or municipality directly under the central government shall, according to review of the application documents and on-site inspection, grant approval for application if the specified requirements are met, and issue cosmetic manufacturing license to the applicant within 5 working days upon making the decision; if the specified requirements are not met, it shall not grant approval and shall give the reasons in writing in a timely manner, and in the meantime inform the applicant of being entitled to apply for administrative reconsideration or file an administrative litigation according to law.\n\n根据上述已知信息，请将'符合规定条件的，作出准予许可的书面决定，并于10个工作日内发给医疗器械经营许可证；不符合规定条件的，作出不予许可的书面决定，并说明理由。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"If specified conditions are met, a written decision on granting license shall be made, and the Medical Device Distribution License shall be issued within 10 working days; if specified conditions are not met, a written decision on not granting license shall be made, and the reasons shall be given."
    },
    {
        "instruction":"已知信息：\n'基于强化研究的参数的方法： EC：'可被翻译为：Enhanced Parameter-Based Approach: • EC:\n'可认为基于性能的方法是基于强化研究的参数的方法开发的。'可被翻译为：It is assumed that a performance-based approach is developed on the basis of an enhanced approach.\n'基于强化研究的参数的方法'可被翻译为：Enhanced Parameter-Based Approach\n'o 考虑到尚未研究温度和输入Y的影响，并且文献表明此类 参数对CQA具有潜在影响，因此将此类参数的变更视为 高风险。'可被翻译为：o Considering that the impact of temperature and Input Y was not studied, and that literature suggests potential impact of these parameters on CQA, changes to these parameters are considered high risk.\n\n根据上述已知信息，请将'基于强化研究的参数的方法： EC： 已经确定了CQA，对选定的CQA的DoE研究表明：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Enhanced Parameter-Based Approach: • EC: CQAs have been identified and DoE studies for selected CQAs show that:"
    },
    {
        "instruction":"已知信息：\n'为进一步指导和规范真实世界证据用于支持药物研发和审评的有关工作，保障药物研发工作质量和效率，国家药品监督管理局组织制定了《真实世界证据支持药物研发与审评的指导原则（试行）》，并于2020年1月7日发布。'可被翻译为：To further guide and standardize the use of real-world evidence in drug R&D and review, and ensure the quality and efficiency of drug R&D, NMPA has organized the formulation of the Guidelines for Real-World Evidence to Support Drug Development and Review (Interim), which has been released on January 7, 2020.\n'国家药监局药审中心关于发布《用于产生真实世界证据的真实世界数据指导原则（试行）》的通告'可被翻译为：NMPA CDE Announcement on Issuing the Guidance for Real-World Data Used to Generate Real-World Evidences (Interim)\n'国家药监局发布关于支持《真实世界证据支持药物研发与审评的指导原则（试行）》的公告'可被翻译为：NMPA Issued the Announcement on the Guidelines for Real-World Evidence to Support Drug Development and Review (Interim)\n'考虑到我国儿童药物研发及药品注册中的实际需要，帮助企业更好地理解《真实世界证据支持药物研发与审评的指导原则（试行）》在儿童药物研发中的应用，在国家药品监督管理局的部署下，药审中心组织制定了《真实世界研究支持儿童药物研发与审评的技术指导原则（试行）》。自发布之日起施行。'可被翻译为：Considering the actual needs in research &development and registration of pediatric drugs, to help enterprises better understand the application of the Guidance for Real World Evidences Supporting Research &Development and Evaluation of Drugs(Interim) in research & development of pediatric drugs, upon the approval by the NMPA, CDE issued the Technical Guidance for Real-World Study Supporting Research& Development and Evaluation of Pediatric Drugs (Interim) , which shall come into force as of the date of issuance.\n\n根据上述已知信息，请将'为进一步指导和规范申办者利用真实世界数据生成真实世界证据支持药物研发，药审中心组织制定了《用于产生真实世界证据的真实世界数据指导原则（试行）》，经国家药品监督管理局审查同意，于4月13日发布实施。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In order to further guide and regulate sponsors to use real-world data to generate real-world evidences to support drug R&D, the CDE has organized to formulate the Guidance for Real-World Data Used to Generate Real-World Evidences (Interim),which was issued for implementation on April 13 upon review and approval by NMPA."
    },
    {
        "instruction":"已知信息：\n'需要分析和生物活性相关的转基因表达水平、载 体\/传递系统行动的预期机制相关的所有因素，包括维持靶细胞中的治疗序列。'可被翻译为：The level of transgene expression, associated biological activity, and all factors associated with the proposed mechanism of action of the vector\/delivery system including maintenance of the therapeutic sequence in the target cell should be analysed.\n'根据生物等效性研究指导原则（CPMP\/EWP\/QWP\/1401\/98 Rev.1\/Corr），应该验证FDC中所有活性物质的生物等效性。'可被翻译为：Bioequivalence should be demonstrated for all active substances in the FDC according to the principles of the Guideline on the investigation of bioequivalence (CPMP\/EWP\/QWP\/1401\/98 Rev. 1\/Corr).\n'与其它任何药品联合用药的作用需逐一进行研究， 因为它可能会影响载体的感染效 力、治疗基因的表达、表达蛋白质的生物活性以及载体的组织分布。'可被翻译为：As for any other medicinal products, the effects of co-medications should be investigated on a case by case basis since it can affect infection efficacy of the vector, therapeutic gene expression, biological activity of the expressed proteins and tissue distribution of the vector.\n'成功的基因治疗所面临的障碍可能有： 载体被靶细 胞吸收、转运及脱壳、载体或序列稳定性、转基因持续转录\/表达、对载体的预存免疫 或诱导免疫以及转基因表达的蛋白。'可被翻译为：Barriers to a successful gene therapy include: vector uptake by the target cells, transport and uncoating, vector or sequence persistence, sustained transcription\/expression of the transgene, pre-existing or induced immunity to vectors and the protein expressed by the transgene.\n\n根据上述已知信息，请将'应确认所有转基因 和其它任何表达序列的体内生物活性。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The in vitro biological activity of all transgene(s) and any other expressed sequences  should be determined."
    },
    {
        "instruction":"已知信息：\n'此外，临床试验应证明FDC的安全性有所提高，即利用明确定义的安全性事件作为协同主要终点。'可被翻译为：In addition, the clinical trial should demonstrate improved safety of the FDC, utilising explicitly defined safety events as co-primary endpoint(s).\n'支持FDC适用于初始治疗的临床疗效\/安全性研究将取决于FDC的基本原理。'可被翻译为：The clinical efficacy\/safety studies to support an FDC application for initial treatment will depend on the rationale of the FDC.\n'在这种情况下，应开展随机对照试验来表明：'可被翻译为：In such case, an RCT should demonstrate:\n'在疗效不足或无效患者研究中，需要开展可证明FDC相对于单个（或多个）活性成分的优效性的随机对照试验（RCT），用以证明FDC比相应的单药成份更有效。'可被翻译为：A randomised controlled trial (RCT) to prove superiority in inadequate\/non-responders to single (or multiple) active components of the FDC is required to demonstrate that the FDC has greater efficacy in comparison with the respective mono-components.\n\n根据上述已知信息，请将'如果基本原理是首次使用FDC可以提高安全性，应开展随机对照试验来证明：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"If the rationale is that the initial use of an FDC results in improved safety, an RCT should be performed to demonstrate"
    },
    {
        "instruction":"已知信息：\n'器官功能受损\/不成熟和年龄'可被翻译为：Impaired or immature organ function and age\n'器官功能受损的患者'可被翻译为：Patients with impaired organ function\n'药物间相互作用、器官功能受损\/不成熟以及年龄相关的遗传药理学考虑事项'可被翻译为：Special pharmacogenetics considerations with respect to drug-drug interactions, impaired\/immature organ functions and age\n'器官功能受损的患者 请见第4节——药代动力学。'可被翻译为：Patients with impaired organ function   Please refer to Section 4, Pharmacokinetics.\n\n根据上述已知信息，请将'4.2.2. 受损或不成熟的器官功能和年龄'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"4.2.2. Impaired or immature organ function and age"
    },
    {
        "instruction":"已知信息：\n'（1）比较个别研究以更好地理解整体结果（见第III.C.1节，个别研究的结果 的比较）；和'可被翻译为：(1) comparing the individual studies to better understand the overall results (see section III.C.1., Comparison of Results of Individual Studies); and\n'研究持续时间也可 能受到其他种属特异性因素的影响。'可被翻译为：Study duration also can be affected by other species-specific considerations.\n'然而，一些设计和实施外部对照 试验的具体方法也可能使试验更具说服力并减少偏倚。'可被翻译为：Nonetheless, some approaches to design and conduct of externally controlled trials could lead them to be more persuasive and potentially less biased.\n'本指导原则中使用的术语-试验药物仅表示正在研究或开发的研究产品。注意：这个术语比包括参比药和安慰剂的“试验用药品”更具针对性。'可被翻译为：The term investigational drug is used in this Guideline to indicate only the experimental product under study or development. Note: This term is more specific than “investigational medicinal product,” which includes comparators and placebos.\n\n根据上述已知信息，请将'考虑一些研究比其他研究更具说服力的原因。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The reasons for considering some studies more persuasive than others."
    },
    {
        "instruction":"已知信息：\n'第二十二条 对贮藏有特殊要求的药品，应当在标签的醒目位置注明。'可被翻译为：Article 22 For drugs with special requirements on storage, its requirements shall be marked in the notable place of the label.\n'9.42 中间体或原料药容器上的标签应当注明与质量有关的关键信息，如产品名称、代码、批号及贮存条件。'可被翻译为：9.42 Labels used on containers of intermediates or APIs should indicate the name or identifying code, the batch number of the product, and storage conditions, when such information is critical to assure the quality of intermediate or API.\n'9.43 中间体或原料药一旦脱离生产商物料管理系统的控制，其标签上还应当注明生产商名称、地址、数量、特殊运输条件和特殊法定要求。有有效期\/复验期的中间体或原料药，应当在标签和检验报告中 注明有效期\/复验期。'可被翻译为：9.43 If the intermediate or API is intended to be transferred outside the control of the manufacturer’s material management system, the name and address of the manufacturer, quantity of contents, and special transport conditions and any special legal requirements should also be included on the label. For intermediates or APIs with an expiry date, the expiry date should be indicated on the label and Certificate of Analysis. For intermediates or APIs with a retest date, the retest date should be indicated on the label and\/or Certificate of Analysis.\n'10.23 生产企业应当确保原料药或中间体的运输方了解运输和贮存条件要求，并遵照执行。'可被翻译为：10.23 The manufacturer should ensure that the contract acceptor (contractor) for transportation of the API or intermediate knows and follows the appropriate transport and storage conditions.\n\n根据上述已知信息，请将'10.22 有特殊运输或贮存条件要求的原料药或中间体应当在其标签中注明。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"10.22 Special transport or storage conditions for an API or intermediate should be stated on the label."
    },
    {
        "instruction":"已知信息：\n'有时数据表明降解和变异非常小，则从数据上就可以明显看出所申请的复检期是合理的，这时通常不必进行正式的统计分析，只要提供省略的理由即可。'可被翻译为：The data may show so little degradation and so little variability that it is apparent from looking at the data that the requested re-test period will be granted. Under these circumstances, it is normally unnecessary to go through the formal statistical analysis; providing a justification for the omission should be sufficient.\n'如果有充分的理由，描述性统计可能就足够了，可能 不需要正式的非劣效性证明。'可被翻译为：Descriptive statistics may suffice and no formal non-inferiority exercise may be needed, if adequately justified.\n'如果有相关理由和 验证数据，原料药步骤中的杂质及工艺相关的杂质检测可以省略。'可被翻译为：Tests for impurities and process-related impurities from the DS steps could be omitted based on relevant justification and validation data.\n'附件：7个药物临床试验数据自查核查注册申请清单（省略）'可被翻译为：Annex: List of Registration Applications for 7 Drugs with Self-Examination &Verification of Clinical Trial Data (Omitted)\n\n根据上述已知信息，请将'有时数据表明降解和变异非常小，以至于从数据上就可以明显看出所申请的货架期是合理的，这时通常不必进行正式的统计分析，只要提供省略的理由即可。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Where the data show so little degradation and so little variability that it is apparent from looking at the data that the requested shelf life will be granted, it is normally unnecessary to go through the formal statistical analysis; providing a justification for the omission should be sufficient."
    },
    {
        "instruction":"已知信息：\n'通常，如果揭盲后不良事件作为单一事件满足报告标准，且该受试者接受了安慰剂，因为药物造成该不良事件不具有合理可能性，所以该事件不能在 IND 安全性报告中进行报告。如果揭盲后这个受试者是接受药物治疗的（受试药物或阳性对照药），则必须在 IND 安全性报告中进行报告（21 CFR 312.32（c）（1）（i）（A））。对于不进行报告的不良事件，如果确定它们是可疑不良反应，需要对药品治疗组和安慰剂组中该事件的发生率进行分析和报告，但汇总分析表明这些事件在药物治疗组发生的频率高于安慰剂组的情况下除外。'可被翻译为：In general, if the blind is broken and a subject with an adverse event that would meet the criteria for reporting as a single event was receiving placebo, the event should not be reported in an IND safety report because there is not a reasonable possibility that the drug caused the adverse event. If the blind is broken and this subject was receiving drug treatment (test drug or active comparator), it must be reported in an IND safety report (21 CFR 312.32(c)(1)(i)(A)). For those adverse events that would not be reported unless an aggregate analysis indicated that they are occurring more frequently in the drug treatment group than in the placebo group, a determination that the adverse event is a suspected adverse reaction would require analysis and reporting of the event rates in both the drug-treatment and placebo groups.\n'按照V.A.3.a部分的描述，通常情况下，没有必要在IND安全报告中报告揭盲的研究终点。许多情况下，独立的DMC可以监控严重事件的研究终点（见FDA的指导原则文件“临床试验数据监测委员会的建立和运作”）。 如果申办者担心不良事件的揭盲会影响研究的完整性，申办者可以提前提出一个替代的报告格式或报告频率保持盲态，但必须得到负责IND审查的FDA审查部门主任的同意（21CFR 312.32（c）（3））（见VI.A部分）。'可被翻译为：As described in section V.A.3.a, there should generally be no need to report unblinded study endpoints in an IND safety report. In many cases, an independent DMC would monitor the serious events that are study endpoints (see FDA’s guidance document on Establishment and Operation of Clinical Trial Data Monitoring Committees).10 If a sponsor has concerns that unblinding of adverse events will compromise the integrity of the study, the sponsor can propose in advance an alternative reporting format or frequency to maintain the blind that must be agreed to by the director of the review division in FDA with responsibility for review of the IND (21 CFR 312.32(c)(3)) (see section VI.A).\n'（四）盲法试验(如涉及) 按照试验方案的要求设盲、保持盲态和实施揭盲； 意外破盲或因 SAE(严重不良事件) 等需紧急揭盲时， 研究者应按照紧急揭盲规程操作并书面说明原因。'可被翻译为：(4) Blind trials (if any) are set up, kept blind and unblinded according to the requirements of the trial protocol; accidental unblinding or emergency unblinding due to SAE (serious adverse events) should be unblinded according to the emergency unblinding procedure and explained in writing by the investigator.\n'为了评估按叙述性格式整理的汇总数据，FDA 和参与研究的研究者需要获得总结于报告中的个体病例的信息。因此，在提交叙述性格式 IND 安全性报告的同时，也应该提交经过分析的个体病例（例如，针对每个病例的完整的 FDA 表格 3500A）。如果一些个体病例先前按照 IND 安全性报告进行提交，则应该重新提交并需标明为副本。提交前，每个个体病例报告一般应该进行揭盲。如果申办者担心揭盲会破坏研究的完整性，申办者应该提前与审查部门进行讨论（见VI.C）。'可被翻译为：To evaluate the aggregated data in narrative format, FDA and participating investigators need the information on the individual cases that are summarized in the report. Therefore, at the same time that the narrative format IND safety report is submitted, the individual cases that were analyzed should also be submitted (e.g., a completed FDA Form 3500A for each case). If some individual cases were previously submitted as IND safety reports, they should be resubmitted and clearly identified as duplicates. Before submission, each individual case report should generally be unblinded. If a sponsor has concerns that unblinding will compromise the integrity of the study, the sponsor should discuss this in advance with the review division (see section VI.C).\n\n根据上述已知信息，请将'提交给 FDA 和所有参与研究者的 IND 安全性报告通常应该进行破盲。接受治疗的知识对于解释相关事件是必须的，对于受试者的医疗管理也是很重要的，也可以提供对正在进行的试验产生影响的药品关键安全性信息（例如，监控、知情同意）。机构不相信揭盲单一或小数量的严重和非预期不良事件病例会破坏研究的完整性，部分原因是这种揭盲应该是很少发生的。例如，由于依据§ 312.32（c）（5）的要求特别描述了研究终点的不同的报告要求，在一项评估死亡、心肌梗死和中风作为终点的试验中，肝损伤的病例在揭盲后，不会对整体研究的完整性有影响。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The blind should ordinarily be broken for IND safety reports submitted to FDA and all participating investigators. Knowledge of the treatment received is necessary for interpreting the event, may be essential for the medical management of the subject, and may provide critical safety information about a drug that could have implications for the ongoing conduct of the trial (e.g., monitoring, informed consent). The Agency does not believe that unblinding single or small numbers of serious and unexpected adverse event cases will compromise the integrity of the study, in part because such unblinding should be infrequent. For example, because the requirement under § 312.32(c)(5) specifically describes different reporting requirements for study endpoints, in a trial evaluating death, myocardial infarctions, and strokes as endpoints, a case of liver injury, if unblinded, would have no effect on overall study integrity."
    },
    {
        "instruction":"已知信息：\n'· 将每个标准化的整窝分配至单个剂量组'可被翻译为：• assign each standardised whole litter to a single dose group\n'应选择合适的剂量和动物种属来解决导致考虑进行重复给药组织分布研究的问题。'可被翻译为：Dose level(s) and species should be chosen to address the problem that led to the consideration of the repeated dose tissue distribution study.\n'这可以通过如何构建和标准化试验窝，并结合如何将试验窝分配至不同剂量组，以及 如何将个体幼仔分配至终点指标亚组来实现。'可被翻译为：This can be achieved by how the study litters are constructed and standardised in combination with how the study litters are assigned to dose groups and how the individual pups are assigned to endpoint subsets.\n'在确定性试验中，当将个体动物分配至终点指标组时，为了避免母体护理偏差，建议不要将同性别的同窝幼仔分配至同一终点指标组（参见附录C）。'可被翻译为：When assigning individual animals to endpoints in definitive studies, it is recommended that litter mates of the same sex not be assigned to the same endpoint to avoid maternal care biases (see Appendix C).\n\n根据上述已知信息，请将'对于将试验动物分配至剂量组，首选将每一标准化窝分配至一个剂量组，以尽可能减少交叉污染的风险和避免给药组和对照组子代竞争哺乳位置和时间。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For assigning study animals to dose groups, it is preferred that each standardised litter be assigned to a single dose group to minimise the risk for cross-contamination and to avoid treated and control offspring competing for suckling position and time."
    },
    {
        "instruction":"已知信息：\n'治疗可能为单独治疗（包括不同剂量或方案）、联合治疗或不 治疗，并且可能包括指定的背景治疗。'可被翻译为：These might be individual treatments (including different doses or regimens), combinations of treatments, or no treatments, and can include specification of background treatments.\n'如果认为一个组成成分是单药治疗的可接受治疗方案，那么与联合治疗比较单药治 疗方案的随机II期研究就是有用的。'可被翻译为：If one of the components is regarded as an acceptable treatment regimen in monotherapy, a randomised phase II study comparing the monotherapy regimen with the combination is informative.\n'适当时，亦可采用有相同四个治疗组的自适应试验设计9，最初使用上述治疗组，若已明确证实单药活性远低于联合治疗，可提前终止单药组。'可被翻译为：An adaptive trial design9 with the same four treatment arms might also be used where appropriate, initially using the treatment arms described above and terminating the single- drug arms early if it becomes clear that the single agents have much less activity than the combination.\n'根据II期结 果，在III期中一个或者两个单药治疗组就不是必需的。 如果联合应用伙伴（B）的单药治疗组是III期（A+B、B和参考）的一部分，那么 II期（A+B、A和参考治疗）就不需要包括同样的单药治疗。'可被翻译为：Depending on the phase II results one or both monotherapy arms may be dispensable in phase III. In case the monotherapy arm of one combination partner (B) is part of phase III (A+B vs. B vs. reference) the same monotherapy may not need to be included in phase II (A+B vs. A vs. reference treatment).\n\n根据上述已知信息，请将'因此，除联合治疗组外纳入单药治疗组可能有助于解决这一问题。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Therefore, the inclusion ofmonotherapy arms in addition to the combination arms may be helpful to address this."
    },
    {
        "instruction":"已知信息：\n'如果非临床研究未显示出低风险（或未开展），则在没有阳性对照的情况下较 难得出缺乏效应的结论；然而，如果估计ΔQTc最大效应的双侧90%置信区间的上限 小于10ms，则该治疗不太可能具有高达20ms的实际平均效应。'可被翻译为：If nonclinical studies do not show low risk (or are not performed), there is reluctance to conclude a lack of an effect in an absence of a positive control; however, if the upper bound of the two-sided 90% confidence interval around the estimated maximal effect on ΔQTc is less than 10 ms, the treatment is unlikely to have an actual mean effect as large as 20 ms.\n'当使用浓度-反应分析作为决定 药物风险分类决策的主要依据时，通过暴露-反应分析估计药物治疗的 QTc 效应，在最高临床相关暴露时，双侧 90%置信区间的上限应为<10ms，则可 得出药物开发的后期阶段不需要扩展的 ECG 安全性评价的结论。（见 ICH E14，第 2.2.4 节和问答#7）。'可被翻译为：When using a concentration-response analysis as the primary basis for decisions to classify the risk of a drug, the upper bound of the two-sided 90% confidence interval for the QTc effect of a drug treatment as estimated by exposure-response analysis should be <10 ms at the highest clinically relevant exposure to conclude that an expanded ECG safety evaluation during later stages of drug development is not needed. (See ICH E14, Section 2.2.4 and Q&A #7).\n'2. 替代性QT临床研究设计，结合了ECG评估和尽可能多的常规“全面QT\/QTc”设 计特征（参见ICH E14第2.2节和问答5.1）。'可被翻译为：2.Alternative QT clinical study designs incorporating ECG assessments with as many of the usual “thorough QT\/QTc” design features as possible (see ICH E14 Section 2.2 and Q&A 5.1).\n'在无法评估高临床暴露QT\/QTc效应的情况下，在暴露于高临床暴露时进行非临 床体内研究尤为重要（参见 ICH E14问答5.1对于高临床暴露的定义）。'可被翻译为：In situations where it is not possible to evaluate the QT\/QTc effects at high clinical exposure, it is particularly important that the nonclinical in vivo studies are conducted at exposures covering the high clinical exposure (see ICH E14 Q&A 5.1 for definition of high clinical exposure).\n\n根据上述已知信息，请将'2. 在替代性QT临床评估中采集到的高质量ECG数据（参见ICH E14和E14问答 #1）未显示QT延长，在此问答中通常定义为，通过浓度-反应分析或交叉检验 计算，对ΔQTc估计最大效应的双侧90%置信区间上限小于10ms。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The high-quality ECG data (see ICH E14 and E14 Q&A #1) collected in the alternative QT clinical assessment do not suggest QT prolongation, generally defined under this Q&A as an upper bound of the two-sided 90% confidence interval around the estimated maximal effect on ΔQTc less than 10 ms, as computed by the concentration-response analysis or the intersection-union test."
    },
    {
        "instruction":"已知信息：\n'第六条 医疗器械通用名称由一个核心词和一般不超过三个特征词组成。'可被翻译为：Article 6 The generic name of a medical device is composed of a core word and generally no more than three feature words.\n'第五条 具有相同或者相似的预期目的、共同技术的同品种医疗器械应当使用相同的通用名称。'可被翻译为：Article 5 The same generic name shall apply to medical devices in the same category with the same or similar intended use and common technologies.\n'第七十四条 医疗器械注册或者备案单元原则上以产品的技术原理、结构组成、性能指标和适用范围为划分依据。'可被翻译为：Article 74 Medical device registration or filing units shall in principle be classified according to the technical mechanism, structural composition, performance indicators and scope of application of the product.\n'化学组成类似的不同物质形成结构相同或很相近似的晶体的现象。'可被翻译为：The phenomenon in which different substances of similar chemical composition form crystals of the same or very similar structure.\n\n根据上述已知信息，请将'核心词是对具有相同或者相似的技术原理、结构组成或者预期目的的医疗器械的概括表述。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The core word is a generalized expression for medical devices with the same or similar technical principles, structure or intended use."
    },
    {
        "instruction":"已知信息：\n'界值往往是根据既往在与计划的新试验相 似的条件下、经过恰当设计的安慰剂对照试验的经验来确定 的，但也可以通过剂量反应或活性对照的有效研究获得。'可被翻译为：The margin generally is identified based on past experience in placebo- controlled trials of adequate design under conditions similar to those planned for the new trial, but could also be supported by dose response or active control superiority studies.\n'值得注意的是，有效性灵敏度历史证据的确定只适用于 一种特别设计的试验。'可被翻译为：As noted, a determination regarding historical evidence of sensitivity to drug effects applies only to trials of a specific design.\n'如果试验治疗与对照治疗之间差值的置信区间排除了大于等于界值的劣效等级，就可以宣布试验治疗非劣效于对照治疗；假如置信区间包含了界值范围，则不能得到试验治 疗非劣于对照治疗的结论。'可被翻译为：If the confidence interval for the difference between the test and control treatments excludes a degree of inferiority of the test treatment as large as, or larger than, the margin, the test treatment can be declared non- inferior; if the confidence interval includes a difference as large as the margin, the test treatment cannot be declared non-inferior.\n'在试验开始以 前，要选定一个等效或非劣效的界值，有时称为“δ”。'可被翻译为：Prior to the trial, an equivalence or non-inferiority margin, sometimes called delta, is selected.\n\n根据上述已知信息，请将'界值的选定只有根据以往的经验这一事实，说明非劣效 性试验与历史性对照(外部对照)试验有一个共同的要素。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The fact that the choice of the margin to be excluded is based on historical evidence gives the non-inferiority trial an element in common with a historically controlled (externally controlled) trial."
    },
    {
        "instruction":"已知信息：\n'A）从交配前至受孕（成年雄性和雌性生殖功能、配子的发育和成熟、交配行为、受精）。'可被翻译为：A) Premating to conception (adult male and female reproductive functions, development and maturation of gametes, mating behavior, fertilization).\n'C）从着床至硬腭闭合（成年雌性生殖功能、胚胎发育、主要器官形成）。'可被翻译为：C) Implantation to closure of the hard palate (adult female reproductive functions, embryonic development, major organ formation).\n'联合进行所选的多项生殖毒性研究时，应注意在动物成年期和从受孕到幼仔性成熟的发育各阶段给药。为测定出给药所致的速发和迟发效应，其观察应持续一个完整的生命周期，即从某一代的受孕到其下一代受孕间的时间周期。为方便测试，可将生命周期的这一完整过程分成以下几个阶段：\nA. 从交配前到受孕（成年雄性和雌性生殖功能、配子的发育和成熟、交配行为、受精）。\nB. 从受孕到着床（成年雌性生殖功能、着床前发育、着床）。\nC. 从着床到硬腭闭合（成年雌性生殖功能、胚胎发育、主要器官形成）。\nD. 从硬腭闭合到妊娠终止（成年雌性生殖功能、胎仔发育和生长、器官发育和生长）。\nE. 从出生到离乳（成年雌性生殖功能、幼仔对宫外生活的适应性、离乳前发育和生长）。\nF. 从离乳到性成熟（离乳后发育和生长、独立生活的适应能力、达到性成熟的情况）。'可被翻译为：The combination of studies selected should allow exposure of mature adults and all stages of development from conception to sexual maturity. To allow detection of immediate and latent effects of exposure, observations should be continued through one complete life cycle, i.e. from conception in one generation through conception in the following generation. For convenience of testing this integrated sequence can be subdivided into the following stages. \nA. Premating to conception (adult male and female reproductive functions, development and maturation of gametes, mating behavior, fertilisation). \nB. Conception to implantation (adult female reproductive functions, preimplantation development, implantation). \nC. Implantation to closure of the hard palate (adult female reproductive functions, embryonic development, major organ formation). \nD. Closure of the hard palate to the end of pregnancy (adult female reproductive functions, fetal development and growth, organ development and growth). \nE. Birth to weaning (adult female reproductive functions, neonate adaptation to extrauterine life, preweaning development and growth). \nF. Weaning to sexual maturity (postweaning development and growth, adaptation to independent life, attainment of full sexual function).\n'雌性动物给药应持续至至少着床。'可被翻译为：Treatment of females should continue through at least implantation.\n\n根据上述已知信息，请将'B）从受孕至着床（成年雌性生殖功能、着床前发育、着床）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"B) Conception to implantation (adult female reproductive functions, preimplantation development, implantation)."
    },
    {
        "instruction":"已知信息：\n'多个产品相关因素将影响抗治疗蛋白的免疫应答的形成（见第 4 章节）。'可被翻译为：Several product-related factors will influence the development of an immune response against a therapeutic protein (see chapter 4).\n'然而，抗治疗产品的免疫应答是多种因素综合作用的结果，因此伴随免疫调节药物的潜在影响之相关结论不是直接明了的。'可被翻译为：However, an immune response against a therapeutic product is a result of many factors and thus, conclusions on potential impact of the concomitant immuno-modulating medication are not straightforward.\n'会影响免疫应答可能性的产品相关因素 包括生产工艺、制剂和稳定性特征。'可被翻译为：Product-related factors that influence the likelihood of an immune response include the manufacturing process, formulation, and stability characteristics.\n'可能影响治疗蛋白的免疫应答的患者相关因素包括遗传因素、患者年龄、疾病相关因素（包括其他治疗）以及因既往曾暴露于该产品或含结构相似性物质的产品而形成的既存抗体（蛋白治疗药-反应性抗体）；以及因工艺和产品相关杂质和辅料所致的患者致敏。'可被翻译为：Patient-related factors, which might influence the immune response to a therapeutic protein, include genetic factors, age of the patient, disease-related factors including other treatments, and pre-existing antibodies (protein therapeutic -reactive antibodies) due to previous exposure to the product or products containing substances with structural similarity; as well as sensitisation of patients due to process-and product-related impurities and excipients.\n\n根据上述已知信息，请将'这些产品可能诱导不良免疫应答，并且受到多种因素的影响，包括患者和疾病相关因素以及产品 相关因素。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"These products may induce unwanted immune responses, which can be influenced by various factors, including patient- and disease-related factors as well as product-related factors."
    },
    {
        "instruction":"已知信息：\n'MRCT可在多个 区域同步递交上市许可申请，支持监管决策，使新药能够 及早在世界各地上市。'可被翻译为：MRCTs may enable simultaneous submission of marketing authorisation applica- tions and support regulatory decision-making in multiple regions, allowing earlier access to new drugs worldwide.\n'本指导原则主要针对MRCT，其数据用于提交 至多个监管机构的药物批准（包括批准增加适应症、新剂型以及新 给药方案）或满足上市后要求的研究。'可被翻译为：The primary focus of this guideline is on MRCTs designed to provide data that will be submitted to multiple regu- latory authorities for drug approval (including approval of additional indications, new formulations and new dosing regimens) and for studies conducted to satisfy post-market- ing requirements.\n'如果MRCT是作为桥接策略（基于ICH E5指导原则）的数据来源， 则MRCT可提供比单区域试验更可靠的证据用于研究结果的外推。'可被翻译为：If MRCTs are the source of data in the bridging strategy based on the ICH E5 guideline, MRCTs could provide more robust evidence than single regional trials for extrapolation of study results.\n'由于药物研发计划日益全球化，在ICH指导原则的协调 下，多区域数据的可用性最大限度地减少了在不同区域进行 个别研究的需要。'可被翻译为：The availability of multi-regional data as a result of the increased globalisation of drug development programmes, facilitated by the harmonisation of ICH Guidelines, minimises the need to conduct individual studies in different regions.\n\n根据上述已知信息，请将'随着药物研发日益全球化，不同区域和国家监管机构能够接 受多区域临床试验（Multi-Regional Clinical Trials, MRCT） 数据作为支持药物（医药产品）批准上市的主要证据来源已经变得 很重要。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"With the increasing globalisation of drug development, it has become important that data from multi-regional clinical trials (MRCTs) can be accepted by regulatory authorities across regions and countries as the primary source of evidence, to support marketing ap- proval of drugs (medicinal products)."
    },
    {
        "instruction":"已知信息：\n'12. 安全性评价 可在三个方面考虑安全性相关数据的分析。'可被翻译为：12.SAFETY EVALUATION Analysis of safety-related data can be considered at three levels.\n'PD 参数应作为III期试验的一部分进行研究。'可被翻译为：PD parameters should be investigated as part of the phase III trial.\n'对于致癌性元素用1:100000风险水平的单位风险系数确定PDE；这些在附录3的各 论中均有描述。'可被翻译为：For carcinogenic elements unit risk factors were used to set the PDE using a 1:100000 risk level; these are described in the individual monographs in Appendix 3.\n'附录1详细讨论了每个元素杂质的PDE的确定方法。'可被翻译为：The method used for establishing the PDE for each elemental impurity is discussed in detail in Appendix1.\n\n根据上述已知信息，请将'附录3包含了确定各元素PDE的关键研究的安全性评估总结。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A summary safety assessment identifying the critical study for setting a PDE for each element is included in Appendix 3."
    },
    {
        "instruction":"已知信息：\n'事实上，当颜色编码被 应用在容器标签和纸盒标识上时，用户更难区分同一治疗类别的不同药物。因为这 些药物通常都存储在彼此附近，容器标签和纸盒标识的相似造成了错误规格，错误 剂量和错误药品的分发和配给。'可被翻译为：In fact, the color  coding has made it difficult for these users to differentiate between drugs within the same therapeutic class when the color code was used on the container label and carton labeling.  Because these products are typically stored near each other, the similar appearance of the  container labels and carton labeling has led to dispensing and administering the wrong strength,  wrong dose, and wrong product.\n'颜色编码的某些应用是恰当的，比如对特定药品规格进行颜色编码，如含华法林，甲状腺素，和共轭雌激素产品。'可被翻译为：Certain applications of color coding are appropriate. Examples include the color coding of  certain drug product strengths such as warfarin, levothyroxine, and conjugated estrogen-  containing products.\n'在大多数情况下，FDA一 般不建议使用颜色编码。'可被翻译为：FDA generally  recommends avoiding color coding in most instances.\n'b. 颜色编码 颜色编码是一种使用颜色来指定特定含义的技术。'可被翻译为：b. Color Coding  Color coding is a technique that uses color to designate a specific meaning.\n\n根据上述已知信息，请将'颜色编码是留到特殊情况下才使用的，并且只有经过对所有终端用户进行对原形的人为因素测试和反馈，且结果被FDA收集到 和评价后才可使用。药品标签上颜色编码的使用已被限制，并且是有风险的。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Color coding is reserved for special circumstances and only after human factors testing and feedback on the prototype from all end  users is received and evaluated by FDA prior to use. The use of color coding on drug labels has been limited and not without risk."
    },
    {
        "instruction":"已知信息：\n'在SmPC 中表明缺乏数据。'可被翻译为：Lack of data is reflected in the SmPC.\n'WoE分析表明附加的非临床试验将不会提供有用的信息。'可被翻译为：The WoE analysis indicates that additional nonclinical investigations will not contribute useful information.\n'·没有在任何儿科人群中开展研究以及不可能从成人有效性数据外推至儿科人群'可被翻译为：• No studies are available in any pediatric population and extrapolation of adult effectiveness data to the pediatric population is not possible\n'另一个必须意识到问题是，在剂量-效应研究中，各剂 量组之间没有差异是常见的；如果没有安慰剂组为有效性提 供清楚证明，这种研究就是没有任何结果的试验。'可被翻译为：It should also be appreciated that it is not uncommon to show no difference between doses in a dose-response study; if there is no placebo group this is usually an uninformative outcome.\n\n根据上述已知信息，请将'这可能反映没有任何数据，或者没有质量可接受的研究。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"This may reflect the absence of any data or the absence of studies of acceptable quality."
    },
    {
        "instruction":"已知信息：\n'如果回应是致电形式，那么CDER或CBER应在口头通知的14个日历日内以书面形式予以确认。'可被翻译为：If the response is by telephone, CDER or CBER should follow up with a written confirmation within 14 calendar days of the verbal notification.\n'决策官员应在这个30天的窗口内以书面或致电形式向申办方作出回应（即，30-天回应）。'可被翻译为：The deciding official should respond to the sponsor within the 30-day window in writing or by telephone (i.e., 30-day response).\n'决策官员应在收到申办方申请信息的30个日历日内就该项上诉给出临时回应或作出决定。如果决策官员决定需与申办方举行会议才可发布回应，则应在收到该 FDRR的30个日历日内发出这一会议要求。'可被翻译为：The deciding official should provide an interim response or a decision on the appeal within 30 calendar days from receipt of the information to the sponsor’s application. In instances when the deciding official decides a meeting with the sponsor is needed before a response can be issued, a meeting request should be sent within 30 calendar days from receipt of the FDRR.\n'在该讨论会举行之后，决策官员应在该讨论日期的30个日历日内就该项上诉给出临时回应或作出决定。如果决策官员决定征求某个咨询委员会的意见，CDER或CBER应在收到该FDRR的30个日历日内通知申办方这一要求。'可被翻译为：After this discussion takes place, the deciding official should provide an interim response or a decision on the appeal within 30 calendar days from the date of the discussion. In instances when the deciding official decides to seek input from an advisory committee, CDER or CBER should inform the sponsor of this request within 30 calendar days from receipt of the FDRR.\n\n根据上述已知信息，请将'如果回应是致电形式，那么该决策官员应在口头回应的14个日历日内以书面形式予以确认。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"If the response is by telephone, the deciding official should follow up with a written confirmation within 14 calendar days of the verbal response."
    },
    {
        "instruction":"已知信息：\n'血液毒理学'可被翻译为：hematotoxicology\n'研究药物对生物体产生的毒性作用的学科。主要包括新药临床前毒理学研究或临床前安全性评价和临床毒理学研究。'可被翻译为：The study of the toxic effects of drugs on living organisms. It mainly includes preclinical toxicology studies or preclinical safety evaluation and clinical toxicology studies of new drugs.\n'生殖医学与毒理学结合而形成的一门重要交叉学科。主要研究环境因素对生殖系统损害作用的原因、机制和后果。'可被翻译为：Reproductive medicine and toxicology combine to form an important interdisciplinary subject. It mainly studies the causes, mechanisms and consequences of environmental factors damaging the reproductive system.\n'研究不同人群或个体对某些药物代谢、药物效应的差异，以及引起这些差异的酶的作用机制及其遗传机制形成的药学科学中的一门分支学科，也是人类遗传学和生物化学遗传学的交叉学科。'可被翻译为：A branch of pharmaceutical science that studies the differences in the metabolism and effects of certain drugs among different populations or individuals, as well as the mechanisms of action of enzymes causing these differences and their genetic mechanisms. It is also an interdisciplinary subject of human genetics and biochemical genetics.\n\n根据上述已知信息，请将'研究药物、非治疗性化学物和其他环境因素对血液和造血组织产生毒害效应的一门交叉学科。是综合了传统血液学和毒理学的基本理论而形成的。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"An interdisciplinary study of the toxic effects of drugs, nontherapeutic chemicals, and other environmental factors on blood and hematopoietic tissue. It is a synthesis of the basic theories of traditional hematology and toxicology."
    },
    {
        "instruction":"已知信息：\n'鼓励M7公布后立即实施；但是，由于本指导原则的复杂性，因此预计M7在ICH公布18个月后予以执行。'可被翻译为：Implementation of M7 is encouraged after publication; however, because of the complexity of the guideline, application of M7 is not expected prior to 18 months after ICH publication.\n'各地区的实施时间可以不同。'可被翻译为：Timing might differ for each region.\n'3. 鉴于商业生产工艺的发展面临类似的挑战，上述M7 所列的内容不适用于新上市申请（不包括IIb和III期临床试验），预计直到ICH发布后36个月才会执行。'可被翻译为：3. Given the similar challenges for development of a commercial manufacturing process, application of the aspects of M7 listed above to new marketing applications that do not include Phase 2b\/3 clinical trials would not be expected until 36 months after ICH publication of M7.\n'1. 应根据ICH公布的M7指导原则进行Ames测试，但是，在 M7公布前所做的Ames测试不需要重复。'可被翻译为：1. Ames tests should be conducted according to M7 upon ICH publication. However, Ames tests conducted prior to publication of M7 need not be repeated.\n\n根据上述已知信息，请将'指南实施： 鼓励M7 公布后即行实施；但是，由于本指南的复杂性，因此预计M7在 ICH 公布18个月后予以执行。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk 26 Implementation of Guideline: Implementation of M7 is encouraged after publication; however, because of the complexity of the guideline, application of M7 is not expected prior to 18 months after ICH publication."
    },
    {
        "instruction":"已知信息：\n'PUP 的临床试验要求基于因子 IX 产品的类型（比如：为延长半衰期而进行修饰的新蛋白）进行。'可被翻译为：Clinical trials in PUPs are required depending on the type of factor IX product (e.g. novel modified proteins to extend half-life).\n'应在产品特性总结（SmPC）中明确说明尚未评估对死亡率和发病率有益作用，直至临床试验数据可用。'可被翻译为：Until clinical trial data are available, it should be specifically mentioned in the Summary of product characteristics (SmPC) that beneficial effects on mortality and morbidity have not been evaluated.\n'[产品特性—更详细内容见临床指导原则]'可被翻译为：[Product specific – see clinical guideline for further details]\n'对于需要进行 PUP 研究的新 产品，在得到 20 名 PUP 的疗效和安全性数据前，应通过 4.2 给药剂量和方法（见核心SmPC）中的声明来说明。'可被翻译为：For novel products requiring a PUP study, the lack of data in PUPs should be indicated through a statement in 4.2 Posology and method of administration (see core SmPC), until data from 20 PUPs investigated for efficacy and safety are available.\n\n根据上述已知信息，请将'[要求进行PUP研究但仍未获得结果的产品的产品特性-更详细内容见临床指导 原则：]'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"[Product specific for products where a study in PUPs is required but results are not yet available – see clinical guideline for further details:]"
    },
    {
        "instruction":"已知信息：\n'必须证明联合疗法相对于单独MTX的优效性，并且需要 具有临床意义。'可被翻译为：Superiority of the combination to MTX alone has to be shown and needs to be clinically meaningful.\n'必要时证明药物联合应用的合理性'可被翻译为：if relevant, justify pharmaceutical combinations.\n'如果在基线时可以识别出TKI治疗失败的风险更高的患者，】能会进行在一种对CML患者有活性的非TKI的基础上附加其它药物的研究。应证明联合用药相对于单用TKI 更优。在探索两种TKI联用的研究中，应该充分阐明联用时毒性增加的可能性。'可被翻译为：If patients with increased risk of efficacy failure to TKIs are identifiable at baseline, it is foreseen that add-on studies with a non-TKI that is active in patients with CML may be undertaken. Superiority should be demonstrated comparing the combination regimen with a single TKI. In studies exploring the combination of two TKI the potential of additive toxicity should be fully addressed.\n'相对于单用活性物质而言，应通过增强或增加疗效或者通过改善FDC的安全性来提高联用活性物质的获益\/风险。'可被翻译为：The combined use of the active substances should improve the benefit\/risk by either increasing or adding therapeutic efficacy, or by improving safety with the FDC in comparison to the use of the single active substance.\n\n根据上述已知信息，请将'应证明联合用药相对于单用 TKI 更优。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Superiority should be demonstrated comparing the combination regimen with a single TKI."
    },
    {
        "instruction":"已知信息：\n'OID  2.16.840.1.113883.3.989.2.1.1.3'可被翻译为：OID 2.16.840.1.113883.3.989.2.1.1.3\n'OID   \n2.16.840.1.113883.3.989.2.1.1.1'可被翻译为：OID \n2.16.840.1.113883.3.989.2.1.1.1\n'OID 库 OID 注册表'可被翻译为：oid repository oid registry\n'OID（对象标识符）'可被翻译为：oid (object identifier)\n\n根据上述已知信息，请将'OID  2.16.840.1.113883.3.989.2.1.1.9'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"OID 2.16.840.1.113883.3.989.2.1.1.9"
    },
    {
        "instruction":"已知信息：\n'8.所有因质量原因造成的退货、投诉、召回及调查；'可被翻译为：8. All quality-related returns, complaints, recalls and the investigations;\n'（八）所有因质量原因造成的退货、投诉、召回及调查；'可被翻译为：8. All quality-related returns, complaints, recalls and the investigations;\n'2.50 应当对原料药定期进行质量回顾，以确认工艺稳定可靠。通常，应当每年进行一次回顾并形成文件，至少应当包括： \n- 回顾关键中间控制点及原料药关键检验结果； \n- 回顾所有不符合质量标准的批次； \n- 回顾所有重大偏差或不符合情形及其相关调查； \n- 回顾所有生产工艺或检验方法等的变更； \n- 回顾稳定性考察的结果；\n- 回顾所有质量相关的退货、投诉和召回； \n- 回顾纠正措施的充分性。'可被翻译为：2.50 Regular quality reviews of APIs should be conducted with the objective of verifying the consistency of the process. Such reviews should normally be conducted and documented annually and should include at least: \n− A review of critical in-process control and critical API test results; \n− A review of all batches that failed to meet established specification(s);\n− A review of all critical deviations or non-conformances and related investigations; \n− A review of any changes carried out to the processes or analytical methods; \n− A review of results of the stability monitoring program; \n− A review of all quality-related returns, complaints and recalls; and \n− A review of adequacy of corrective actions.\n'15.10 应当按照书面规程对所有与质量相关的口头或书面投诉进行记录和调查。'可被翻译为：15.10 All quality related complaints, whether received orally or in writing, should be recorded and investigated according to a written procedure.\n\n根据上述已知信息，请将'（七）对所有与质量相关的退货、投诉和召回以及当时进行的调查进行回顾；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(viii) A review of all quality-related returns, complaints and recalls and the investigations performed at the time;"
    },
    {
        "instruction":"已知信息：\n'（一）使用禁止用于化妆品生产的原料、应当注册但未经注册的新原料生产儿童化妆品，或者在儿童化妆品中非法添加可能危害人体健康的物质；'可被翻译为：(1) producing raw materials banned from use in manufacturing of cosmetics, or new raw materials should be registered but not registered to manufacture cosmetics for children, or add substances that may cause potential harm to human health to the cosmetics for children illegally;\n'第三十六条 供儿童使用的化妆品应当符合法律、法规、强制性国家标准、技术规范以及化妆品生产质量管理规范等关于儿童化妆品质量安全的要求，并按照国家药品监督管理局的规定在产品标签上进行标注。'可被翻译为：Article 36 Cosmetics for children shall comply with requirements for quality and safety of cosmetics for children in laws, regulations, mandatory national standards, technical specifications, and Good Manufacturing Practice for Cosmetics, etc., and shall be indicated on the product label as specified by the NMPA.\n'第三十八条 化妆品注册人、备案人、受托生产企业应当采取措施避免产品性状、外观形态等与食品、药品等产品相混淆，防止误食、误用。'可被翻译为：Article 38 The registrant, the filing entity and the contract manufacturer of cosmetics shall take measures to avoid the product character and appearance, etc. from being confused with food, drug and other products, so as to prevent being eaten or used by mistake.\n'（四）化妆品生产许可依法被撤回、撤销或者化妆品生产许可证依法被吊销的；'可被翻译为：(4) Cosmetics Manufacturing License is withdrawn or canceled according to law, or the license for production of cosmetics is revoked according to law;\n\n根据上述已知信息，请将'生产、销售用于未成年人的玩具、用具等，应当依法标明注意事项，并采取措施防止产品被误用为儿童化妆品。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In the manufacturing and sale of toys and utensils, etc. for juveniles, the precautions shall be indicated according to law, and measures shall be taken to prevent the products from being used as cosmetics for children by mistake."
    },
    {
        "instruction":"已知信息：\n'A. 动物致癌性方案'可被翻译为：A. Animal Carcinogenicity Protocols\n'申办方在制定背景文件时应参考行业指南《动物（效应）法规下的药品开发》。'可被翻译为：Sponsors should consult the guidance for industry Product Development Under the Animal Rule when developing background documents.\n'申办方应确 保递交的支持提议方案的数据是最新的、完整的和准确的，因为基础数据、假设 和信息的任何更改都可能影响方案的评估以及由此产生的建议和\/或SPA同意。 对于动物致癌性方案，审核人员将向执行致癌性评估委员会（ECAC）提出 评估。'可被翻译为：Sponsors should ensure that the data submitted in support of the proposed protocol are current, complete, and accurate, because any change in the underlying data, assumptions, and information could affect the assessment of the protocol and the resulting recommendations and\/or SPA agreement. For animal carcinogenicity protocols, review staff will present their assessment to the Executive Carcinogenicity Assessment Committee (ECAC).\n'申办方应该包括与方案分开的背景信息，详细描述所有相关数据（包括临 床数据）、假设和有助于FDA评价方案和回应申办方问题的信息。'可被翻译为：The sponsor should include background information, separate from the protocol, that describes in detail all relevant data (including clinical data), assumptions, and information that can assist FDA in evaluating the protocol and responding to the sponsor’s questions.\n\n根据上述已知信息，请将'A. 动物致癌性方案 除了完整的方案外，申办方还应包括行业指南《致癌性研究方案递交》中详 述的背景信息。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A. Animal Carcinogenicity Protocols The sponsor should include the background information detailed in the guidance for industry Carcinogenicity Study Protocol Submissions in addition to the complete protocol."
    },
    {
        "instruction":"已知信息：\n'第四十条 开展体外诊断试剂临床试验，应当向申请人所在地省、自治区、直辖市食品药品监督管理部门备案。接受备案的食品药品监督管理部门应当将备案情况通报临床试验机构所在地的同级食品药品监督管理部门和卫生计生主管部门。'可被翻译为：Article 40 The clinical trial of in-vitro diagnostic reagents shall be filed with the food and drug regulatory department of the provinces, autonomous regions and municipalities directly under the central government where the applicant is located. The food and drug regulatory department accepting the filling shall report to the food and drug regulatory department and the competent health and family planning department at the same level where the clinical trial institution is located.\n'第十三条 申请人或者备案人申请注册或者办理备案，应当遵循体外诊断试剂安全有效的各项要求，保证研制过程规范，所有数据真实、完整和可溯源。'可被翻译为：Article 13 When applying for registration or filing, the applicant or filing entity shall complete the research and development of in-vitro diagnostic reagents in accordance with the essential requirements for safety and effectiveness of in-vitro diagnostic reagents and make sure the research and development process is true and standardized and all the data is authentic, complete and traceable.\n'第五十八条 办理医疗器械备案，备案人应当按照《医疗器械监督管理条例》第九条的规定提交备案资料。'可被翻译为：Article 58 For a medical device filing, the filing entity shall submit the filing documents in accordance with Article 9 of the Regulations on Supervision and Administration of Medical Devices.\n'办理第一类体外诊断试剂备案的，备案人可以提交产品自检报告。'可被翻译为：For the filing of class I in-vitro diagnostic reagent, the filing entity may submit the product self-testing report.\n\n根据上述已知信息，请将'第六十八条 办理体外诊断试剂备案，备案人应当按照《医疗器械监督管理条例》第九条的规定提交备案资料。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 68 For an in-vitro diagnostic reagent filing, the filing entity shall submit the filing materials in accordance with Article 9 of the Regulations on Supervision and Administration of Medical Devices."
    },
    {
        "instruction":"已知信息：\n'ACS 是动脉粥样硬化的一种危及生命的表现。'可被翻译为：ACS represents a life-threatening manifestation of atherosclerosis.\n'并存病 并存病在 ASD 中非常普遍。'可被翻译为：Comorbidities Comorbid medical conditions are highly prevalent in ASD.\n'主要考虑因素是发病率 和死亡率，这是疾病的潜在后果。'可被翻译为：The primary consideration relates to the degree of morbidity and mortality that is a potential consequence of the disease.\n'●可能是潜在疾病体现的严重不良体验（例如，死亡率或主要发病率）'可被翻译为：·Serious adverse experiences (e.g., mortality or major morbidity) that were likely to have been manifestations of the underlying disease\n\n根据上述已知信息，请将'其中，冠状动脉疾病（CAD）是最为常见的，导致了高死亡率和发病率。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Among these, coronary artery disease(CAD) is the most prevalent manifestation and is associated with high mortality and morbidity."
    },
    {
        "instruction":"已知信息：\n'建议的非劣效性边界应该基于极有可能足以区别试验药物相较不接受抗菌剂的治疗作用并反映出相较一种适当的活性参比治疗方案具有临床可接受的差异来选择。'可被翻译为：The suggested non-inferiority margins have been selected on the basis that they are very likely to be sufficient to differentiate the treatment effect of the test agent from no antibacterial therapy and reflect a clinically acceptable difference to an appropriate active comparative regimen.\n'此外，应通过临床判断来评估所观察到 的试验性抗菌剂与安慰剂之间的治愈率差异是否具有临床意义。'可被翻译为：In addition, clinical judgement should be applied to assess whether the observed difference in cure rates between the test antibacterial agent and placebo is clinically relevant.\n'尤为重要的是， 非劣效性研究应尽可能避免入组那些在 一定的时间内无需抗菌治疗即能痊愈的感染患者， 否则会降低检测到试验治疗方 案与参比治疗方案之间的疗效差异的几率。'可被翻译为：It is particularly important that non-inferiority studies should try to avoid enrolment of patients with infections that are likely to resolve without antibacterial therapy within a reasonable timeframe since this reduces the chance of detecting differences in efficacy between the test and active comparative regimens.\n'在与一种活性参比治疗进行对比的、被认可的非劣效性研究中：'可被翻译为：In a valid non-inferiority study against an active comparative treatment:\n\n根据上述已知信息，请将'非劣效性边界的最终选择应考虑到在临 床上如何判断在每种类型的感染中， 试验治疗与参比治疗之间的差异幅度达到多 大可被视为有临床重要性。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The final choice of the non-inferiority margin should take into account clinical judgement regarding how large a difference between the test and reference treatments could be considered clinically important in each type of infection."
    },
    {
        "instruction":"已知信息：\n'（1）体内不存在的条件（pH值、渗透压、沉淀物）。'可被翻译为：i. The conditions do not occur in vivo (pH; osmolality; precipitates).\n'iii. 脂质体中的非脂质成分'可被翻译为：iii. Nonlipid components of the liposome\n'为进一步加强重组胶原蛋白类医疗产品监督管理，推动产业高质量发展，国家药监局组织制定了《重组胶原蛋白类医疗产品分类界定原则》，于2021年4月13日予公布。'可被翻译为：In order to strengthen the supervision and administration of recombinant collagen products and promote the high-quality development of the industry, NMPA has organized to formulate the Principles for the Classification Defining of Recombinant Collagen Products, which was issued on April 13,2021.\n'国家药监局关于发布重组胶原蛋白类医疗产品分类界定原则的通告'可被翻译为：NMPA Announcement on Issuing the Principles for the Classification Defining of Recombinant Collagen Products\n\n根据上述已知信息，请将'（3）人体分泌物或提取物，比如乳汁，胶原蛋白和细胞因子等，但不包括精 液；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(3) Secreted or extracted human products, such as milk, collagen, and cell factors, except that semen is considered an HCT\/P;"
    },
    {
        "instruction":"已知信息：\n'虽然很难确定提前退出试验的影响，有时甚至难以确 定产生偏差的方向，但应尽可能全面地探讨可能的影响。'可被翻译为：Although the effects of early dropouts, and sometimes even the direction of bias, can be difficult to determine, possible effects should be explored as fully as possible.\n'但是，研究者对症状进行的评估作为次要终点可能是有用的。'可被翻译为：However, symptom assessment done by the investigator may be useful as a secondary endpoint.\n'活性对照试验有 助于受试者的招募和IRB\/IEC对试验的批准，而且有可能进 行较大样本的研究；并能减少由于缺乏有效性而退出试验的 受试者数量。'可被翻译为：Recruitment and IRB\/IEC approval may be facilitated, and it may be possible to study larger samples. There may be fewer withdrawals due to lack of effectiveness.\n'“客观”(复合)主要终点的的选择可能因不同研究而不同， 将取决于研究的目的和入选标准。'可被翻译为：The choice of “objective” (co)- primary endpoints may vary between studies and will depend on the aim of the study and the inclusion criteria.\n\n根据上述已知信息，请将'但应注意到，有时因缺乏有效性而退出 试验可以作为研究的终点。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"With care, however, withdrawal for lack of effectiveness can sometimes be used as a study endpoint."
    },
    {
        "instruction":"已知信息：\n'应按照相应的国家\/地区的要求，在标签上说明贮藏条件。'可被翻译为：A storage statement should be established for the labeling in accordance with relevant national\/regional requirements.\n'10.22 有特殊运输或贮存条件要求的原料药或中间体应当在其标签中注明。'可被翻译为：10.22 Special transport or storage conditions for an API or intermediate should be stated on the label.\n'光敏性原料药和制剂的正式标签要求是根据国家\/地区的要求制定的。'可被翻译为：The formal labeling requirements for photolabile drug substances and drug products are established by national\/regional requirements.\n'在药品标签中说明的其它结果'可被翻译为：Other labelling consequences\n\n根据上述已知信息，请将'2.2.10 说明\/标签 应按照相应的国家\/地区的要求，在标签上说明贮藏条件。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2.2.10.Statements\/Labeling A storage statement should be established for the labeling in accordance with relevant national\/regional requirements."
    },
    {
        "instruction":"已知信息：\n'在与ICH协作下，ISO制定了一套标准，以加强药品信息交换。'可被翻译为：In collaboration with ICH, ISO developed a set of standards to enhance exchange of information for medicinal products.\n'在本IG描述的信息标准之前，由ICH M2 EWG开发了ICH电子信息传输标准，用于监管信息电子传输标准（ESTRI）。'可被翻译为：Prior to the message standard described in this IG, ICH electronic messaging standards were developed by the ICH M2 EWG for Electronic Standards for the Transmission of Regulatory Information(ESTRI).\n'2006年，ICH决定为制定E2B的第3个修订版（由SDO参与开发）寻求更新。该IG描述了通过此新程序制定的E2B（R3）信息传输实施的标准。'可被翻译为：In 2006, the ICH decided to pursue an alternative model for the development of the third revision of E2B that engaged SDOs. This IG describes the messaging standard for the implementation of the E2B(R3) message developed through this new process.\n'对于 ICH，与 SDO 合作利用电子标准开发的资源、避免重叠、产生相反效果或反作用标准，对于实现和维护其自身的统一目标至关重要。'可被翻译为：For the ICH, working with SDOs to leverage resources for electronic standards development and avoid overlapping, counter-productive, or counter-acting standards is critical to achieving and maintaining its own harmonisation goals.\n\n根据上述已知信息，请将'本IG中描述的标准发展代表了ICH流程的变化，因为通过与外部标准开发机构（SDO）合作开发了信息传输标准。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Development of the standard described in this IG represents a change of the ICH process, as the messaging standard was developed through a partnership with external Standards Development Organisations (SDOs)."
    },
    {
        "instruction":"已知信息：\n'某些方面的疗效评价可能需要长期对照的临床试验数据。'可被翻译为：Assessment of efficacy in some domains may require long-term controlled clinical trial data.\n'试验持续时间应与治疗目的相关。'可被翻译为：Trial duration should be relevant to the treatment goal.\n'具体来讲，对于II期临床试验结束会议，应提交来自关键支撑性II期 临床试验的所有入组受试者的SVR4数据和来自II期临床试验所有可用SVR12（或 更长）数据，以支持进入III期临床试验。'可被翻译为：Specifically, for an end-of-phase 2 meeting, SVR4 data from all enrolled patients in key supporting phase 2 trials, and all available SVR12 (or longer) data from phase 2 trials should be submitted to support progression to phase 3.\n'I期临床试验和II期临床试验过程中观察到药代动力学异常值。'可被翻译为：When pharmacokinetic outliers are observed in the course of Phase I to IV studies.\n\n根据上述已知信息，请将'应对入组I期和II期临床试验的受试者进行耐药性相关取 代的潜在持续性表征，从而到完成III期临床试验时获得初步的长期随访数据。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The potential persistence of resistance-associated substitutions should be characterized for patients enrolled in phase 1 and phase 2 clinical trials so that preliminary long term follow-up data are obtained by the time of completion of phase 3 trials."
    },
    {
        "instruction":"已知信息：\n'雄性：合笼前≥2周至至少确认交配成功'可被翻译为：M: ≥ 2 weeks prior to cohabitation through at least confirmation of mating\n'让雌性与雄性合笼2周以上，可使 这些雌性重新开始动情周期并妊娠。'可被翻译为：Leaving the female with the male for longer than 2 weeks can allow these females to restart estrous cycles and become pregnant.\n'雌性：合笼前≥2周至着床（GD6）'可被翻译为：F: ≥ 2 weeks prior to cohabitation through implantation (GD6)\n'交配期b ≥2周'可被翻译为：Mating period b ≥ 2 weeks\n\n根据上述已知信息，请将'每天，从合笼前2周开始，直到确认交配'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Daily, commencing 2 weeks before cohabitation and until confirmation of mating"
    },
    {
        "instruction":"已知信息：\n'如果T的细颗粒（<500μm）的质量百分比≥10％，则应推进到层次2的检测。'可被翻译为：If the % mass of fine particles (<500 µm) of T ≥10%, testing should proceed to Tier 2.\n'如果T的细颗粒（<500μm）的 质量百分比<10％，则认为T不适合鼻吸入。'可被翻译为：If the % mass of fine particles (<500 µm) of T <10%, then T is deemed unsuitable for insufflation.\n'如果R的细颗粒（<500μm）的质量百分比<10％，则认为R不适合鼻 吸入。'可被翻译为：If the % mass of fine particles (<500 µm) of R <10%, then R is deemed unsuitable for insufflation.\n'如果R产品通过PK研究或人类滥用可能性研究已被证明采取了防止经鼻途径的滥用 的措施，并且T产品可以研磨成细颗粒并且细颗粒（< 500μm）的质量百分比≥10%，则检测应推进到层次2。'可被翻译为：Testing should proceed to Tier 2 if R product has been demonstrated to have abuse deterrence for the nasal route of abuse by PK or human abuse potential studies of the R product and T product can be milled into fine particles with % mass of fine particles (<500 µm) ≥10%.\n\n根据上述已知信息，请将'T的细颗粒（＜500 m）的 质量百分比＜10%？'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Is % mass of fine particles of T (< 500 µm) < 10%?"
    },
    {
        "instruction":"已知信息：\n'公共当局为确保产品符合立法规定的要求并且不危害健康、安全或公共利益保护的任何其他方面而开展的活动和采取的措施(基于2008年7月9日欧盟理事会指令EC No 756\/2008，关于与产品营销有关的认证和市场监督要求和废止法规(EEC) No 339\/93)(21)。'可被翻译为：The activities carried out and measures taken by public authorities to ensure that products comply with the requirements set out in legislation and do not endanger health, safety or any other aspect of public interest protection (based on EU Council Directive EC No 756\/2008 of 9 July 2008 concerning the requirements for accreditation and market surveillance relating to  the marketing of products and repealing Regulation (EEC) No 339\/93) (21).\n'监管机构在制造商的医疗器械投放市场或投入使用后对制造商和\/或授权代表实施的所有控制措施。'可被翻译为：All controls applied by the regulatory authority to the manufacturer and\/or authorized representative after a manufacturer’s medical device has been placed on the market or put into service.\n'1.在避孕套包装上，印有证明该产品符合欧盟委员会关于医疗器械的93\/42\/EEC指令基本要求的标志(4)。\n2.在医疗产品包装上，有证明产品符合欧洲医疗器械指令93\/42\/EEC基本要求的标志。'可被翻译为：1.On condom packaging, a mark certifying that the product conforms to the essential requirements of the European Commission Directive 93\/42\/EEC on medical devices (4).\n2.On medical product packaging, a mark certifying that the product conforms to the essential requirements of European Medical Device Directive 93\/42\/EEC.\n'1.由于药品的缺陷或严重的投诉而从分销链中撤回或移除药品的过程。召回可能由制造商\/进口商\/分销商或负责机构发起。\n2.任何旨在实现已提供给最终用户的产品的回收的措施(基于欧盟理事会指令EC No 756\/2008，关于与产品营销相关的认证和市场监督要求和废止法规(EEC) No 339\/93)(21)。'可被翻译为：1.A process for withdrawing or removing a pharmaceutical material from the distribution chain because of defects in the materials or complaints of a serious nature. The recall might be initiated by the manufacturer\/importer\/distributor or a responsible agency.\n2.Any measure aimed at achieving the return of a product that has already been made available to the end-user (based on EU Council Directive EC No 756\/2008 of 9 JULY 2008 concerning the requirements for accreditation and market surveillance relating to the marketing of products and repealing Regulation (EEC) No 339\/93) (21).\n\n根据上述已知信息，请将'监管机构为确保投放市场的医疗器械符合法规且不危害健康、安全或公共卫生的任何其他方面而开展的活动和采取的措施(基于欧盟理事会1993年6月14日关于医疗器械的第93\/42\/EEC号指令)(23)。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The activities carried out and measures taken by a regulatory authority to ensure that medical devices placed on the market comply with regulations and do not endanger health, safety or any other aspect of public health (based on EU Council Directive 93\/42\/EEC of 14 JUNE 1993 concerning medical devices) (23)."
    },
    {
        "instruction":"已知信息：\n'响应函数：充分描述仪器响应（例如，峰面积或高比或信号）与校正标样中待测物浓度（量）之间关系的数学表达式。响应函数是在给定浓度范围内定义的。另见校正曲线。'可被翻译为：Response Function: A mathematical expression which adequately describes the relationship between instrument response (e.g., peak area or height ratio or signal) and the concentration (amount) of analyte in the calibration standards. Response function is defined within a given range. See also Calibration Curve.\n'仪器响应（例如峰面积、峰高或信号）与给定范围内校正标样中的待测物浓度（含量）的关系。也称为“标准曲线”。'可被翻译为：The relationship between the instrument response (e.g., peak area, height or signal) and the concentration (amount) of analyte in the calibration standards within a given range. Also referred to as Standard Curve.\n'标准曲线：仪器响应（例如峰面积、峰高或信号）与给定范围内校正标样中待测物浓度（量）之间的关系。也称为校准曲线。'可被翻译为：Standard Curve: The relationship between the instrument response (e.g., peak area, height or signal) and the concentration (amount) of analyte in the calibration standards within a given range. Also referred to as calibration Curve.\n'校准曲线：仪器响应（例如峰面积、峰高或信号）与给定范围内校正标样中的待测物浓度（含量）的关系。也称为“标准曲线”。'可被翻译为：Calibration Curve: The relationship between the instrument response (e.g., peak area, height or signal) and the concentration (amount) of analyte in the calibration standards within a given range. Also referred to as Standard Curve.\n\n根据上述已知信息，请将'充分描述仪器响应（例如，峰面积或高比或信号）与校正标样中待测物浓度（量）之间关系的数学表达式。响应函数是在给定浓度范围内定义的。另见校正曲线。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A mathematical expression which adequately describes the relationship between instrument response (e.g., peak area or height ratio or signal) and the concentration (amount) of analyte in the calibration standards. Response function is defined within a given range. See also Calibration Curve."
    },
    {
        "instruction":"已知信息：\n'当药物对常规实验种属的靶点没有足够的活性时，可采用替代分子评估潜在 的生殖和发育毒性。'可被翻译为：When the pharmaceutical does not have adequate activity against the target in the routine test species, surrogate molecules can be used to assess potential adverse effects on reproduction and development.\n'如果受试者能够决定已采集的数据是否被包括或被排除，那么偏倚的可能性很大，尤其是如果临床研究未设盲。'可被翻译为：If a subject were to be able to dictate whether already collected data are included or excluded, the potential for bias would be immense, particularly if the clinical investigation were not blinded.\n'遵循分层测试策略可能是恰当的，例如，如果预期对雌激素或雄激素受体有作用，可以进行体内筛选试验（OECD 229或OECD 230）（注意，这些试验 仅适用于检测抗-雄激素效应）。'可被翻译为：It could be appropriate to follow a tiered testing strategy, e.g., an in vivo screening test (OECD 229 or OECD 230) can be performed if effects on the estrogen or androgen receptor are expected (note that these tests are only suitable to detect anti-androgenic effects).\n'这些试验还评估了黑头呆鱼或青鳉中的第二性 征（OECD 229和230）或性腺组织病理学（OECD 229）。'可被翻译为：These tests also evaluate secondary sexual characteristics in fathead minnow or medaka (OECD 229 and 230) or gonad histopathology (OECD 229).\n\n根据上述已知信息，请将'如果从例如哺乳动物毒性研究已知雌激素或雄激素受体为靶子，筛选检测 （OECD 229或230）可能变得多余。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In case it is already known from e.g. mammalian toxicity studies that estrogenic or androgenic recep- tors are targeted, the screening assay (OECD 229 or 230) may become redundant."
    },
    {
        "instruction":"已知信息：\n'另外，FDAAA要求申请人报告每一项研究和临床试验“否则由申请人承担安全问题调查”（见第505(o)(3)(E)(ii)部分）。依据21 CFR 314.81(B)(2)(viii)，针对报告中这些研究和临床试验的信息已经有所要求。'可被翻译为：In addition, FDAAA requires that applicants report on each study and clinical trial “otherwise undertaken by the applicant to investigate a safety issue” (see section 505(o)(3)(E)(ii)). Reports on these studies and clinical trials would previously have been required under 21 CFR 314.81(b)(2)(viii).\n'申请人一般可以报告由申请人实施的PMRs、PMCs和研究或临床试验，用于调查我们的法规已有要求的周期报告（例如每年一次）中的安全性问题。根据具体情况，一项PMR在特定阶段，可以对“定期报告”增加一个附加职责。另外，尽管大多数PMRs和PMCs是在药物的IND下进行，但年度报告是按照NDA\/BLA要求进行的。当多个相关申请存在时（例如相同申请人同一药物的几个处方），将会 考虑统一报告，与过去做法一致。提出相同报告的一个申请人应该与审评部门讨论建议。按照NDA\/BLA提交的REMS评估需要单独时间表。由于按照PMR报告要求，REMS评估可以参考年度报告，但年度报告不能代替REMS评估。'可被翻译为：Applicants may generally report on PMRs, PMCs, and studies or clinical trials undertaken by the applicant to investigate a safety issue in periodic reports (e.g., annually) that are already required by our regulations. On a case-by-case basis, a PMR may impose an additional obligation to “periodically report” at specified milestones. In addition, although most PMRs and PMCs will be conducted under the IND for a drug, annual reports are required under the NDA\/BLA. When multiple related applications exist (e.g., several formulations of the same drug with the same applicant), unified reporting, consistent with past practice, may be considered. An applicant who proposes unified reporting should discuss the proposal with the review division. REMS assessments, submitted under the NDA\/BLA, are required under separate schedules. While the REMS assessments may reference the annual report for the required PMR reporting, the annual report does not replace the REMS assessment.\n'法规要求申请方就所要求的上市后研究和临床试验向FDA提供一定信息（第505(o)(3)(E)(ii)部分）。根据第505(o)(3)(E)(ii)部分，这些信息必须包括：'可被翻译为：The applicant is required to provide certain information to FDA with regard to required postmarketing studies and clinical trials (section 505(o)(3)(E)(ii)). Under section 505(o)(3)(E)(ii), this information must include:\n'● 对于依据第505(o)(3)章所要求的每一项研究，都要定期报告研究状况，包括完成这些研究过程中是否遇到任何困难。'可被翻译为：• For each study required under section 505(o)(3), periodic reports on the status of the study, including whether any difficulties in completing the study have been encountered\n\n根据上述已知信息，请将'对于按FDAAA要求进行的每个PMR，申请人必须定期报告研究或临床试验 的状况（见第505(o)(3)(E)(ii) 部分）。对于临床试验，该报告必须包括招募是否已 经开始、参与者登记数量、预期完成日期、完成临床试验是否遇到任何困难和依据 PHS法案第402(j)部分要求的注册信息（见505(o)(3)(E)(ii)）。我们承认某些临床试验要求报告的信息还与观察性药物流行病学研究相关，FDA将对该要求进行解释包括适用于所有在人体中进行的研究或临床试验信息。临床试验的注册信息应包括根据FDAAA标题VIII注册PMR的文件20。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For each PMR required under FDAAA, the applicant must periodically report on the status of the study or clinical trial (see section 505(o)(3)(E)(ii)). For clinical trials, the report must also include whether enrollment has begun, the number of participants enrolled, the expected completion date, whether any difficulties completing the clinical trials have been encountered, and registration information as required under section 402(j) of the PHS Act (see section 505(o)(3)(E)(ii)). We recognize that some of the information required for clinical trial reporting is also relevant to observational pharmacoepidemiologic studies, and FDA will interpret the requirement to include this information as applicable to all studies or clinical trials performed in humans. Registration information for clinical trials should include documentation that the PMR is registered in accordance with Title VIII of FDAAA.20"
    },
    {
        "instruction":"已知信息：\n'对一个不太成熟的数据集进行中期分析的解释是有问题的。'可被翻译为：The interpretation of interim analyses conducted on a less mature data set is problematic.\n'在没有考虑和说明每 个数据呈现或统计分析所对应的估计目标的情况下，不同来源数 据之间的简单比较，或者来自多个试验的数据整合可能会产生误 导。'可被翻译为：A naïve comparison between data sources, or integration of data from multiple trials without consideration and specification of the estimand that is addressed in each data presentation or statistical analysis, could be misleading.\n'在某些情况下，一项小规模的、随机、参考对 照研究参考是最好的选择；在其它情况下，患者自身的TTP\/PFS分析（或联合应用） 可能是一个更好的选择。'可被翻译为：In some cases a small, randomised, reference controlled study is the best option, in other cases a within-patient TTP\/PFS analysis (or the combination) might be a better alternative.\n'但是在原则上，进展时间(TTP)和无进展生存期(PFS)是潜在肿瘤增长率和抗肿瘤化合物 活性的一项函数。同样地，如果已记录的恶化疾病为一项纳入标准，那么很难在大多数患者中定义潜在增长率，历史数据也将更难解释。因此，在无随机性参照的情况下解释 TTP\/PFS 数据是有问题的。特别是在乳腺癌中，临床获益率(CBR)，即 CR、PR 以及连续 6 个月无恶化，是抗肿瘤活性中已确定的指标，并可用于研究比较，即使 与TTP\/PFS 一样遇到相同的原则问题。'可被翻译为：For exploratory purposes, studies without a randomised reference are therefore considered interpretable and guidance provided in the section about cytotoxic compounds is relevant. Irrespective of this, inclusion of a randomised reference arm is encouraged and might be of special interest in order to explore whether, e.g. a selected biomarker is prognostic and\/or predictive (see 7.1.2). Time to progression (TTP) and progression-free survival (PFS), however, are in principle a function of underlying tumour growth rate and the activity of the anti-tumour compound. Also, if documented progressive disease is an inclusion criterion, underlying growth rate is hard to define in most patients and historical data will be even harder to interpret. Therefore, the interpretation of TTP\/PFS data without a randomised reference is problematic. In particular in breast cancer, clinical benefit response rate (CBR), i.e. CR, PR and absence of progression at 6 months, is a well established measure of anti- tumour activity and might be used for between study comparisons, even though subject to the same principle problem as TTP\/PFS.\n\n根据上述已知信息，请将'因此，对没有随机参考的TTP\/PFS数据进行解释是有问题的。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Therefore, the interpretation of TTP\/PFS data without a randomised reference is problematic."
    },
    {
        "instruction":"已知信息：\n'虽然这些研究有时会被认为是使用“病人自 身作对照”，但实际上不存在内部对照。'可被翻译为：Although these studies are sometimes thought to use \"the patient as his own control\", they do not in fact have an internal control.\n'这些考 虑是否在实践上(而不是在理论上)限制了研究结果的通用性 还没有被确定。'可被翻译为：Whether these concerns actually (as opposed to theoretically) limit generalizability has not been established.\n'自我报告工具通常优先于观察者评定工具，并且应该基于个人使用自我报告工具的能力来应用。'可被翻译为：Self-report tools are generally preferred to observer-rated tools and should be applied based on individual’s ability to use self-report tools.\n'因此在确保所用方法有理论依据并且是合理的情况下，评价工具的选择应不断发展完善。 痴呆患者进行自我观察、报告症状和行为的能力很差，因此自我报告测试不如相关观察者的测试敏感，尤其是对中度到重度疾病阶段。'可被翻译为：Hence the choice of assessment tools should remain open, provided that the rationale for their use is presented and justified. b) demented patients are poor observers and reporters of their own symptoms and self-report scales of behaviour tend therefore to be less sensitive to treatment effects than observer-related instruments, particularly in moderate to severe disease stages.\n\n根据上述已知信息，请将'此外，在验证研究中，往往未对评价形式（知情人报告，自我报告，基于表现，临床医生评价）进行比较。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In addition, assessment modalities  (informant-report, self-report, performance-based, clinician rated) are often not compared in validation studies."
    },
    {
        "instruction":"已知信息：\n'应提供3.2.S.7.3的稳定性结果汇总表，必要时提供相应的图示。'可被翻译为：A tabulated summary of the stability results from 3.2.S.7.3, with graphical representation where appropriate, should be provided.\n'应提供3.2.P.8.2所述的批准后的稳定性研究方案。'可被翻译为：The post-approval stability protocol, as described in 3.2.P.8.2, should be provided.\n'应提供3.2.S.4.4中的批分析汇总表，必要时提供相应的图示。'可被翻译为：A tabulated summary of the batch analyses from 3.2.S.4.4, with graphical representation where appropriate, should be provided.\n'应提供3.2.P.5.4中的批分析汇总表，必要时提供相应的图示。'可被翻译为：A tabulated summary of the batch analyses provided under 3.2.P.5.4, with graphical representation where appropriate should be included.\n\n根据上述已知信息，请将'应提供3.2.P.8.3的稳定性结果汇总表，必要时提供相应的图示。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A tabulated summary of the stability results from 3.2.P.8.3, with graphical representation where appropriate, should be included."
    },
    {
        "instruction":"已知信息：\n'11.4.7 疗效结论 应简明扼要的描述疗效相关的重要结论，考虑主要和次 要终点、预先规定和可替代的统计学方法以及探索性分析的 结果。'可被翻译为：11.4.7 Efficacy Conclusions The important conclusions concerning efficacy should be concisely described, considering primary and secondary end points, pre-specified and alternative statistical approaches and results of exploratory analyses.\n'讨论和总体结论'可被翻译为：DISCUSSION AND OVERALL CONCLUSIONS\n'14. 参考但不纳入文本的表格、图示和图表 应使用图示直观的总结重要结果或阐明使用表格不太 容易理解的结果。'可被翻译为：14.TABLES, FIGURES AND GRAPHS REFERRED TO BUT NOT INCLUDED IN THE TEXT Figures should be used to visually summarise the important results, or to clarify results that are not easily understood from tables.\n'参考但不纳入文本的表格、图示和图表'可被翻译为：TABLES, FIGURES AND GRAPHS REFERRED TO BUT NOT INCLUDED IN THE TEXT\n\n根据上述已知信息，请将'13. 讨论和总体结论 应简要汇总并讨论研究的疗效和安全性结果以及风险 和获益关系，如需要可参考上述表格、图示和章节。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"13.DISCUSSION AND OVERALL CONCLUSIONS The efficacy and safety results of the study and the relationship of risks and benefit should be briefly summarised and discussed, referring to the tables, figures, and sections above as needed."
    },
    {
        "instruction":"已知信息：\n'这种情况下，可以纳入该文件的专有目录， 以便识别该文件内所含小节的排列和标题。'可被翻译为：In this case, a specific Table of Contents for that document can be included to identify the chronology and titles of the subsections contained therein.\n'如果在一个章节内有数份文件，通过对文件标题进行有提示性的命名可进行一 定程度的区分。'可被翻译为：If there are several documents within a section, some differentiation can be achieved by informative naming of the documents’ titles.\n'15 2003 年 7 月 CTD 中定义的术语“章节”是什么？ 模块 2 和 3 中的术语是否 有不同的用途？ ICH 的区域定义的章节是否是有差异的？ CTD 中的每个章节由一个数字和一个标题确定。请参阅“粒度文件附件”，查看每个章节中提供的说明文件。附件描述每个标题可能提供多个文件的情况。另外，当每个标题应提供一个或多个文件时参考章节指南。'可被翻译为：15 July 2003 Is the term, “section”, defined in the CTD? Is there a different use of the term in Module 2 and 3? Do the ICH regions define sections differently? Each section in the CTD is identified by a number and a heading Please refer to the Granularity Document Annex for a description documents to be provided in each section. The annex delineates when multiple documents per heading may be provided. Also, refer to regional guidance as to when one or multiple documents should be provided per heading.\n'如果想要在只含有一个文件的章节中附录更多信息，则该 信息只能加入该文件内部。'可被翻译为：If there is a desire to append or attach additional information to a section that is comprised of only one document, this information should be incorporated within that document.\n\n根据上述已知信息，请将'站在申请人的角度考虑，含有多个文件的特殊章节也可建立一个目录，以 便确定文件的次序和主题。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"At the applicant’s discretion, a Table of Contents can also be included for a particular section that contains multiple documents, in order to identify the chronology and the document subject matter."
    },
    {
        "instruction":"已知信息：\n'与药物制剂相关的原料药质量属性'可被翻译为：Drug Substance Quality Link to Drug Product\n'确认对原料药的关键质量属性产生影响的物料属性及工艺参数的简述；'可被翻译为：Brief description of the material attributes and process parameters identified as impacting drug substance CQAs;\n'案例1：物料属性和工艺参数与原料药关键质量属性的关联-化学实体药物'可被翻译为：Example 1: Linking Material Attributes and Process Parameters to Drug Substance CQAs - Chemical Entity\n'3.1.5 物料属性和工艺参数与原料药关键质量属性的关联 生产工艺的开发程序应当确认哪些物料的属性（例如原 材料、起始原料、试剂、溶剂、工艺助剂、中间体的属性） 和工艺参数应该被控制。'可被翻译为：3.1.5 Linking Material Attributes and Process Parameters to Drug Substance CQAs The manufacturing process development program should identify which material attributes (e.g., of raw materials, starting materials, reagents, solvents, process aids, intermediates) and process parameters should be controlled.\n\n根据上述已知信息，请将'物料属性和工艺参数与原料药关键质量属性的关联'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Linking Material Attributes and Process Parameters to Drug Substance CQAs ."
    },
    {
        "instruction":"已知信息：\n'如果药物的最佳有效剂量未知，那么更 为谨慎的做法是选择一个剂量范围，而不是选择一个可能被 证明是次优或有不可接受毒性的单一剂量。'可被翻译为：If the optimally effective dose is not known, it may be more prudent to study a range of doses than to choose a single dose that may prove to be suboptimal or to have unacceptable adverse effects.\n'较低剂量的选 择应考虑暴露量、药理学和毒性，以便在合适时可建立结果的剂量-反应关系。'可被翻译为：The selection of lower dose levels should take into account exposure, pharmacology, and toxicity, such that the dose-response of findings can be established when appropriate.\n'r-hFSH的剂量应当合理，考虑量效曲线中线性部分的一个剂量适用于检测生物类似物 和参比药品的药代动力学特征的潜在差异。'可被翻译为：The dose of r-hFSH should be justified, taking into account that a dose in the linear part of the dose response curve is suitable to detect potential differences in the pharmacokinetic profiles of the biosimilar and the reference medicinal product.\n'部分情况下，累积剂量可能比较适宜。'可被翻译为：In some cases, cumulative dose might be pertinent.\n\n根据上述已知信息，请将'选择的剂量应该在剂量-浓度曲线的线形部分，如果参比制剂可用的信息过少，测试不止一种剂量较为适宜。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The selected dose should be in the linear part of the dose-concentration curve; if available information on the reference product is too scarce, more than one dose should preferably be tested."
    },
    {
        "instruction":"已知信息：\n'在疾病导致的损害情况的长期随访中，可以采用SLICC\/ACR损害指数进行评估。'可被翻译为：In long term follow up the accrual of damage caused by the disease could be evaluated using SLICC\/ACR damage index.\n'实验室指标显示肾脏疾病活动或慢性损害：'可被翻译为：Laboratory indices, showing either activity of the renal disease or chronic damage:\n'如果一种新的研究药物会发生SLICC\/ACR损害指数中未列出的毒性，则可能无法使用该损害指数来测量。'可被翻译为：Using a SLICC\/ACR damage index may be problematic when a new study drug is associated with toxicities not listed in the Damage Index used to.\n'步速可被视为是一个简单、可用的生存力综合指数，因为它它综合了已知和未被识别的多器官系统的损害，其中许多这些损害影响生存。'可被翻译为：Gait speed could be considered a simple and accessible summary indicator of vitality because it integrates both known and unrecognised impairment of multiple organ systems, many of which affect survival.\n\n根据上述已知信息，请将'通过SLICC\/ACR损害指数测量的累积多系统慢性器官损害适用于入组患者是发病时间较短且无既存损害的研究，'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Accumulated multi-system chronic organ damage as measured by the SLICC\/ACR damage index is suitable to use in studies enrolling patients particularly those with short duration of disease and without pre-existing damage,"
    },
    {
        "instruction":"已知信息：\n'B. 心血管结局声明补遗的格式'可被翻译为：B. Format of Cardiovascular Outcome Claim Supplements\n'C. 宣传材料中的心血管结局声明的适用性'可被翻译为：C. Applicability of Cardiovascular Outcome Claims in Promotional Materials\n'我们预期极少有心血管结局声明补遗需要支付使用者费用，因为它们不需要临床数据获得批准。6'可被翻译为：We anticipate that few cardiovascular outcome claim supplements will require the payment of user fees because they will not need clinical data for approval.6\n'1. 声明该提交资料是心血管结局声明的补遗的一份声明，并参考本指南及编号FDA-2008-D-0150的相关文档。'可被翻译为：1. A statement that the submission is a cardiovascular outcome claim supplement, with reference to this guidance and related Docket No. FDA-2008-D-0150\n\n根据上述已知信息，请将'A. 心血管结局声明补遗的使用者费用的适用性'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A. Applicability of User Fees to Cardiovascular Outcome Claim Supplements"
    },
    {
        "instruction":"已知信息：\n'<200 或 250g\/l 人血白蛋白的胶体渗透压大约相当于血浆的 4 倍。因此，当给予 高浓度的白蛋白时，须小心确保患者有足够的水分。应仔细监测患者以防循环超负荷和过度水化。>'可被翻译为：<The colloid-osmotic effect of human albumin 200 or 250 g\/l is approximately four times that of blood plasma. Therefore, when concentrated albumin is administered, care must be taken to assure adequate hydration of the patient. Patients should be monitored carefully to guard against circulatory overload and hyperhydration.>\n'人血白蛋白在数量上占血浆总蛋白的一半以上，占肝蛋白质合成的 10%左右。物理-化学数据：<人血白蛋白{40 到 50g\/l}对于正常血浆有轻微的低渗作用。>'可被翻译为：Human albumin accounts quantitatively for more than half of the total protein in the plasma and represents about 10 % of the protein synthesis activity of the liver.\n'{（发明的）产品名称<规格 g\/l>}是一种包含{X}g\/l<{X\/10}%>总蛋白的溶液，其中至少 95%是人血白蛋白。'可被翻译为：{(Invented) name of product <strength in g\/l>} is a solution containing {X}g\/l <{X\/10} %> of total protein of which at least 95% is human albumin.\n'第 1 修订版（2005 年 10 月生效）对人血白蛋白溶液核心 SPC 的第 1 和第 2 部分 进行了修订，使用 g\/l 代替%表示规格。'可被翻译为：Revision 1 (came into effect October 2005) amended sections 1 and 2 of the Core SPC for human albumin solution to express the strength in g\/l instead of %.\n\n根据上述已知信息，请将'与 40-50g\/l 的人血白蛋白溶液相比，200-250g\/l 人血白蛋白溶液的电解质含量较低。 当给予白蛋白时，需要监测患者的电解质状况（见第 4.2 部分）并采取适当措施来恢复 和维持电解质平衡。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"200-250g\/l Human albumin solutions are relatively low in electrolytes compared to the 40-50 g\/l human albumin solutions. When albumin is given, the electrolyte status of the patient should be monitored (see section 4.2) and appropriate steps taken to restore or maintain the electrolyte balance."
    },
    {
        "instruction":"已知信息：\n'温度变化（如，相对32℃±1℃的-1℃和+1℃）'可被翻译为：Temperature variations (e.g., - 1°C and +1°C relative to 32°C ± 1°C)\n'温度。'可被翻译为：Temperature.\n'3.在非水溶液中进行有机酸或有机碱的滴定。当中和反应达到等当点后，利用稍过量的酸碱标准溶液作为催化剂使事先加入的一种叫做单体的烯泾发生离子聚合作用，同时放出热量，使被测定溶液的温度骤然升高，从而指示终点。'可被翻译为：3. Titration of organic acids or bases in non-aqueous solutions. After the neutral reaction reaches the equivalent point, a slightly excessive acid and base standard solution is used as a catalyst to cause ionic polymerization of a kind of olefins called monomers that are added in advance, and heat is released at the same time, so that the temperature of the measured solution rises abruptly, indicating the end point.\n'（一）降低或阻碍某一化学反应的物质。（2）降低或抑制另一种物质（如酶）活性的物质。'可被翻译为：(1) A substance that reduces or hinders a chemical reaction. (2) A substance that reduces or inhibits the activity of another substance, such as an enzyme.\n\n根据上述已知信息，请将'单位质量的某种物质，温度降低1k或升高1℃所吸收或放出的热量。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The amount of heat absorbed or emitted per unit mass of a substance by lowering its temperature by 1k or increasing it by 1 ° C."
    },
    {
        "instruction":"已知信息：\n'与无菌产品相关的一些具体质量控制要求的指导。'可被翻译为：Guidance on some of the specific Quality Control requirements relating to sterile products.\n'6.无菌测试区设计、操作规程、监测、无菌技术、更衣程序、适当的样品容器消毒、表面监测、HEPA 过滤器证书等'可被翻译为：6. Sterility testing area design, operational procedures, monitoring, aseptic technique, gowning procedures, proper sample container disinfection, surface\/air monitoring, HEPA filter certification, etc.\n'参数放行是实时放行检测的一种。'可被翻译为：Parametric release is one type of RTR testing.\n'湿热灭菌的终端灭菌药品的参数放行'可被翻译为：Parametric Release of Pharmaceuticals Terminally Sterilized by Moist Heat\n\n根据上述已知信息，请将'提出无菌的参数放行的，应考虑《实时放行检验指导原则 （EMA\/CHMP\/QWP\/811210\/2009-Rev1，前《参数放行指导原则》）（仅人用 药品）、《参数放行指导原则》 (EMEA\/CVMP\/QWP\/339588\/2005)（仅兽用药 品）以及Ph. Eur.第5.1.1节内容。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"When parametric release of sterility is proposed, the Guideline on real time release testing (formerly  Guideline on parametric release), EMA\/CHMP\/QWP\/811210\/2009-Rev1 (human products only), the  Guideline on Parametric release, EMEA\/CVMP\/QWP\/339588\/2005 (veterinary products only) and the   text of Ph. Eur. Chapter 5.1.1 should be taken into account."
    },
    {
        "instruction":"已知信息：\n'之后研究者应描述简要的研究目的以及研究设计所 基于的可行假设。'可被翻译为：Investigators should then describe the concise study objectives and feasible hypotheses upon which the study design has been based.\n'对于研究设计考虑，如入选和排除标准、适当的终点和预期的研究持续时间，应参考相关的治疗指导原则。'可被翻译为：For study design considerations, such as inclusion and exclusion criteria, appropriate endpoints and expected study duration, the relevant therapeutic guidelines should be consulted.\n'将被描述并纳入到任何法规提交资料中的在数据来源、研究设计和分析计划等特定方面的选择的最佳规范在本指导原则的章节IV、V和VI中详细讨论。'可被翻译为：Specific aspects of best practices for the selection of the data sources, study design, and analysis plan to be described and included in any regulatory submission are discussed in detail in sections IV, V, and VI of this guidance.\n'研究者应该在研究方案和最终报告中 讨论选择某种特殊的研究设计的依据。'可被翻译为：Investigators should discuss their rationale for selecting a particular study design in the study protocol and final report.\n\n根据上述已知信息，请将'研究者应预先定义与研究的设计、分析、执行和报告有关的方面，将其整理形成研究方案和最终报告，附上与研究的这些方面有关的科学研究选择的科学依据；关于这些方面的更多信息在本指导原则的章节IV、V和VI中提供。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Investigators should predefine aspects of the study related to the design, analysis, conduct, and reporting of the study and articulate them in the study protocol and final reports, along with a science-based rationale for the scientific study choices pertaining to these aspects of the study; more information regarding these aspects is provided in sections IV, V, and VI of this guidance."
    },
    {
        "instruction":"已知信息：\n'在患者进入研究时应检查是否出现了血清自身抗体，即抗双链 DNA 抗体。'可被翻译为：Testing for the presence of serologic autoantibodies, i.e. anti-dsDNA, should be done at study entry.\n'应仔细研究新型构造（例如杂交分子融合以形成 具有生理学功能的分子）与相关内源性（或自体）蛋白质发生 ADA 交叉反应的可能性。'可被翻译为：Novel constructs, like hybrid molecules fused to physiological functional molecules, should be carefully investigated for ADAs cross-reacting with relevant endogenous (or self) proteins.\n'代表着内源性蛋白对应物的治疗蛋白的免疫应答会导致出现针对内源性蛋白的交叉反应性，如果在内源性蛋白不断合成的情况下。'可被翻译为：An immune response to a therapeutic protein representing a counterpart to an endogenous protein may result in cross-reactivity, directed to the endogenous protein in cases where endogenous protein is still produced.\n'自免疫：与内源性蛋白质的交叉反应性'可被翻译为：Autoimmunity: Cross-reactivity to an endogenous counterpart\n\n根据上述已知信息，请将'如果疑似出现自体免疫，应研究ADA与相关内源性蛋白的交叉反应性。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Cross- reactivity of the ADAs with relevant endogenous proteins should be investigated if emerging autoimmunity is suspected."
    },
    {
        "instruction":"已知信息：\n'ICH Q2（R2）对分析方法的各种验证试验的选择和评价提供指导和建议。'可被翻译为：ICH Q2(R2) provides guidance on selection and evaluation of the various validation tests for analytical procedures.\n'应根据ICHQ2对RTRT分析方法进行验证，并证明工艺测定对目标质量属 性具有适当的专属性。'可被翻译为：An RTRT analytical procedure should be validated as recommended in ICH Q2 and it should be demonstrated that the process measurements have appropriate specificity for the targeted quality attribute.\n'ICH Q2 分析方法验证'可被翻译为：ICH Q2 Validation of Analytical Procedures\n'本指导原则是对ICH Q2“分析方法验证”的补充。'可被翻译为：This guideline complements ICH Q2 Validation of Analytical Procedures.\n\n根据上述已知信息，请将'分析方法验证中考虑的性能特征描述详见ICH Q2。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Details of the performance characteristics considered for analytical procedure validation are described in ICH Q2."
    },
    {
        "instruction":"已知信息：\n'第三十四条 申请人在完成支持药品上市注册的药学、药理毒理学和药物临床试验等研究，确定质量标准，完成商业规模生产工艺验证，并做好接受药品注册核查检验的准备后，提出药品上市许可申请，按照申报资料要求提交相关研究资料。经对申报资料进行形式审查，符合要求的，予以受理。'可被翻译为：Article 34 After having completed studies to support the drug marketing registration including CMC, pharmacological and toxicological studies and drug clinical trials, established the specifications and completed commercial-scale manufacturing process validation and preparation for drug registration inspection and testing, the applicant shall file a drug marketing authorization application and submit related study data as per application dossier requirements. The application shall be accepted when the application dossiers comply with requirements and pass the preliminary review.\n'第六十九条 申请人在提出药品上市许可申请前，应当与药品审评中心沟通交流，经沟通交流确认后，在提出药品上市许可申请的同时，向药品审评中心提出优先审评审批申请。符合条件的，药品审评中心按照程序公示后纳入优先审评审批程序。'可被翻译为：Article 69 The applicant shall communicate with the CDE for confirmation prior to filing the drug marketing authorization application and then, when filing the drug marketing authorization application, submit a priority review and approval application to the CDE at the same time. Applications that meet the requirements shall be included into the priority review and approval procedure by the CDE after going through the prescribed public disclosure process.\n'经审评，符合附条件批准要求的，在药品注册证书中载明附条件批准药品注册证书的有效期、上市后需要继续完成的研究工作及完成时限等相关事项。'可被翻译为：Where requirements for conditional approval are met upon review, the Drug Approval License shall specify the validity period of the conditional Drug Approval License, the post-approval studies to be completed, the timeline for completing post-approval studies and other relevant details.\n'第六十五条 审评过程中，发现纳入附条件批准程序的药品注册申请不能满足附条件批准条件的，药品审评中心应当终止该品种附条件批准程序，并告知申请人按照正常程序研究申报。'可被翻译为：Article 65 During review, where it is found that a drug registration application included into the conditional approval procedure does not meet the requirements for conditional approval, the CDE shall terminate the conditional approval procedure and inform the applicant to apply as per the normal review procedure.\n\n根据上述已知信息，请将'第六十四条 申请附条件批准的，申请人应当就附条件批准上市的条件和上市后继续完成的研究工作等与药品审评中心沟通交流，经沟通交流确认后提出药品上市许可申请。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 64 Where conditional approval is applied for, the applicant shall communicate with the CDE about the conditions for conditional marketing approval and the studies to be completed after marketing. Upon confirmation through consultation and communication, a drug marketing authorization application may be filed."
    },
    {
        "instruction":"已知信息：\n'近来针对存在一系列哮喘和COPD共有特征的患者人群提出了哮喘COPD重叠综合征这一术语。'可被翻译为：The term Asthma COPD Overlap Syndrome has recently been proposed for a patient population with a similar number of features of both asthma and COPD.\n'慢性阻塞性肺病（COPD）和哮喘有不同的病因，但可能共存于同一患者。'可被翻译为：Chronic obstructive pulmonary disease (COPD) and asthma have different aetiologies but may coexist in the same patient.\n'以COPD为主的患者应从哮喘研究中排除。'可被翻译为：Patients with predominantly COPD should be excluded from studies in asthma.\n'关于COPD的定义及其在临床试验入组中与哮喘的区别，请参见CHMP‘慢性阻塞性肺病（COPD）治疗药物临床研究指导原则’（EMA\/CHMP\/483572\/2012）。'可被翻译为：For the definition of COPD and its separation from asthma for patient recruitment into clinical trials, see also the CHMP Guideline on Clinical Investigation of Medicinal Products in the Treatment of Chronic Obstructive Pulmonary Disease (COPD) EMA\/CHMP\/483572\/2012.\n\n根据上述已知信息，请将'最近对哮喘与COPD综合征（ACOS）的重叠给予了关注。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Recently attention is given to the overlap of asthma and COPD syndrome (ACOS)."
    },
    {
        "instruction":"已知信息：\n'• 住院治疗或延长现有住院治疗时间'可被翻译为：• Inpatient hospitalization or prolongation of existing hospitalization\n'症状评分、住院或ICU病房住院时间长短、血液动力学测量和左心室功能超声心动图测量结果作为次要或辅助终点。'可被翻译为：Symptom scores, duration of hospitalisation or ICU stay, hemodynamic measurements and echocardiographic measures of LV function could serve as secondary or supportive endpoints.\n'因心力衰竭住院（HFH）的患者是指因失代偿急性发作而住院的经标准治疗后病情稳定且但是未接受胃肠外治疗但是仍在住院的患者；可将此类患者纳入研究，以评估住院期间、出院时或出院之后 30 天内开始的长期治疗的效果。'可被翻译为：Patients hospitalised because of an acute episode of de-compensation who are stabilized by standard therapy and are not receiving parenteral treatments but remain hospitalised are defined as patients hospitalised for heart failure (HFH); these patients can be included in studies to assess the effect of chronic therapies that are started during the hospitalisation, at discharge or during the 30 days after hospital discharge.\n'5.导致住院或者住院时间延长；'可被翻译为：5. Requiring inpatient hospitalization or resulting in prolongation of existing hospitalization;\n\n根据上述已知信息，请将'ICU病房住院时间或普通病房住院时间的长短都能指示至病情稳定（如转为二级护理或出院）的时间，'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Duration of stay in intensive care unit (ICU) or duration of hospitalisation both indicate time to stabilisation (for step down care or discharge as appropriate)"
    },
    {
        "instruction":"已知信息：\n'在识别每 项单独研究的关键质量因素时，可能需要考虑其他方面。'可被翻译为：Other aspects may need to be considered to identify the critical to quality factors for each individual study.\n'拟纳入特定信息时则需要开展专项研究。'可被翻译为：Specific studies are needed when specific information is to be included.\n'申请人应根据药品的预期患者人群和拟定治疗适应症，考虑开展药物相互作用和\/或特殊用药人群的研究。 如果申请人具有设计和开展这些研究方面的疑问，可咨询CDER审评小组 获取建议。'可被翻译为：Depending on the target patient population and the proposed therapeutic indication for the drug, you should consider conducting drug interactions and\/or studies in specific populations. You should consult the appropriate CDER review division regarding the conduct and design of these studies if you have questions.\n'BD非临床研究可以独立进行，也可以结合非临床药理学和毒理学研究开展。'可被翻译为：Nonclinical studies for BD assessment can be conducted as stand-alone BD studies or in conjunction with nonclinical pharmacology and toxicology studies.\n\n根据上述已知信息，请将'3.要求申请人开展额外的独立研究，核实疑问研究的结果；以及'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"3.Requesting that the applicant conduct additional independent studies to confirm the results of the questioned study; and"
    },
    {
        "instruction":"已知信息：\n'镇静催眠药'可被翻译为：sedative-hypnotics\n'中枢兴奋药'可被翻译为：central nervous system stimulants\n'能够消除焦虑不安和紧张状态而又不明显影响意识的药物。按其化学结构可分为：①苯二氮革类：如地西泮、硝西泮；②氨基酸酯类，如甲丙氨酯；③二苯甲烷类，如羟嗪。'可被翻译为：Drugs that eliminate anxiety, restlessness and tension without significantly affecting consciousness. According to its chemical structure can be divided into: ① benzodiazepine leather: such as diazepam, nitrazepam; ② Amino acid esters, such as methalanine; ③ diphenylmethane, such as hydroxyzine.\n'所有能改变血糖水平的药物会影响检查的灵敏度（如皮质类固醇、丙戊酸钠、卡马西平、苯妥英、苯巴比妥和儿茶酚胺）。'可被翻译为：All medicinal products that modify blood glucose levels can affect the sensitivity of the examination (e.g. corticosteroids, valproate, carbamazepine, phenytoin, phenobarbital and catecholamines).\n\n根据上述已知信息，请将'对中枢神经系统能产生不同程度的抑制作用，引起镇静和催眠的药物。常用的药物有：巴比妥类（如苯巴比妥）、苯二氮卓类（如地西泮）和其他类（如甲丙氨酯）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Drugs that can produce varying degrees of inhibition on the central nervous system, causing sedation and hypnosis. Commonly used drugs are: barbiturates (e.g. Phenobarbital), benzodiazepines (e.g. Diazepam), and others (e.g. Methalamine)."
    },
    {
        "instruction":"已知信息：\n'本指导原则为2000年秋天颁布的《基于生物药剂学分类的速释口服固体制剂的体内生物利用度和生物等效性研究的豁免》的更新版本，并阐述了在何种情况下速释口服制剂可按照BCS分类方法申请生物豁免的情况。'可被翻译为：This guidance updates the guidance for industry on Waiver of In Vivo Bioavailability and Bioequivalence Studies forImmediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, published in August 2000, and explains when biowaivers can be requested for IR solid oral dosage forms based on an approach termed the Biopharmaceutics Classification System (BCS).\n'a.若所有活性组分均属于BCS第一类：如果速释的复方制剂中所有的药物均 属于BCS第一类，各组分间无PK相互作用，且辅料满足章节V.A.（i）中的要 求，则可提出基于BCS分类的生物豁免申请。如果有PK相互作用，辅料应满 足章节V.A.（ii）中的要求。否则需进行体内生物等效性研究。'可被翻译为：Combinationsapplicable for IR fixed dose combination products if all the drugs in the combination belong to BCS class 1; provided there is no PK interaction between the components, and the excipients fulfill the considerations outlined in section V.A. (i). If there is a PK interaction, the excipients should fulfill the considerations outlined in section V.A. (ii). Otherwise, in vivo bioequivalence testing is required.\n'申请生物豁免的制剂，其药物活性成分需为高溶解性（BCS第一类和BCS第三类）和高渗透性（BCS第一类），且制剂需快速溶出（BCS第一类）或者极快速溶出（BCS第三类）。'可被翻译为：The drug product for which a biowaiver is being requested should include a drug substance that is highly soluble (BCS class 1 and BCS class 3) and highly permeable (BCS class 1), and the drug product should be rapidly dissolving (BCS class 1) or very rapidly dissolving (BCS class 3).\n'若要提交生物豁免申请，速释制剂必须是快速溶出（BCS第一类）或者极快速溶出（BCS第三类）。'可被翻译为：For submission of a biowaiver request, an IR product should be rapidly dissolving (BCS class 1) or very rapidly dissolving (BCS class 3).\n\n根据上述已知信息，请将'IV.基于BCS分类的的生物豁免 \n本指导原则适用于基于BCS分类的BA\/BE豁免（生物豁免），适用于BCS 第一类和第三类速释固体口服制剂。 \n对于BCS第一类制剂，需证明下列几点： \n• 药物活性成分具有高溶解性 \n• 药物活性成分具有高渗透性 \n• 试验和参比制剂可快速溶出，且\n• 制剂不包含任何可影响药物吸收速度和程度的辅料（参见章节V.A.） \n对于BCS第三类制剂，需证明下列几点： \n• 药物活性成分具有高溶解性 \n• 试验制剂和参比制剂均可快速溶出（参见章节II.C.），且 \n• 与参比制剂相比，试验制剂应含有相同的组分，且各组分含量应相似， 如，符合规模扩大或上市后变更（SUPAC）速释制剂的第一类和第二类变更的要求。（参见章节V.A.）'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"IV. \tBIOWAIVERS BASED ON BCS \nThis guidance is applicable for BA\/BE waivers (biowaivers) based on BCS, for BCS class 1 and class 3 immediate-release solid oral dosage forms. \nFor BCS class 1 drug products, the following should be demonstrated: \n• the drug substance is highly soluble \n• the drug substance is highly permeable \n• the drug product (test and reference) is rapidly dissolving, and \nthe product does not contain any excipients that will affect the rate or extent of absorption of the drug (see section V.A.)\nFor BCS class 3 drug products, the following should be demonstrated:\nthe drug substance is highly soluble \nthe drug product (test and reference) is very rapidly dissolving (see section II.C.), and \nthe test product formulation is qualitatively the same and quantitatively very similar, e.g., falls within scale-up and post-approval changes (SUPAC) IR level 1 and 2 changes, in composition to the reference (see section V.A.)"
    },
    {
        "instruction":"已知信息：\n'信息中所使用的外部代码集和OID包括：'可被翻译为：The external code sets and OIDs used in the message include:\n'还有一些是为 ICH 创建的特定代码列表。'可被翻译为：Still others are specific code lists created for the ICH.\n'下表列出了从第5.5节论述中得到的元素杂质的数据的示例。'可被翻译为：The following table shows example data on elemental impurities that may be derived from the sources described in Section 5.5:\n'下表列出了评估的识别阶段的结果总结。'可被翻译为：The table below shows a summary of the findings of the identification stage of the assessment.\n\n根据上述已知信息，请将'下表列出了使用这些外部代码集的ICSR元素：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The following table lists the ICSR elements using these external code sets:"
    },
    {
        "instruction":"已知信息：\n'数据的初次展示和分析可能表明其与人口统计学或其 他基线特征不存在显著关系。'可被翻译为：It may be apparent from initial display and inspection of the data that a significant relation to demographic or other baseline features is not present.\n'除描述性统计量之外，预计不进行详细的统计分析。'可被翻译为：Other than descriptive statistics, detailed statistical analysis is not expected.\n'按照常规方式根据上市批准条件进行处方的研究。患者不依据既定的试验方案分配治疗方案，而是依照现行的临床实践进行，同 时，研究中的药品的处方与患者是否入选试验无关。对这类患者 不进行额外诊断或监测，仅用流行病学方法对收集的数据进行分析。'可被翻译为：A study where the medicinal product(s) is (are) prescribed in the usual manner in accordance with the terms of the marketing authorisation. The assignment of the patient to a particular therapeutic strategy is not decided in advance by a trial protocol but falls within current practice and the prescription of the medicine is clearly separated from the decision to include the patient in the study. No additional diagnostic or monitoring procedures are applied to the patients and epidemiological methods are used for the analysis of collected data.\n'B. 根据需要，在目标患者人群中向未经治疗个体传播的临床监测数据和分 析（更多信息，参见本指导原则的第XI.B.章节）。'可被翻译为：B. As needed, data and analysis of clinical monitoring for transmission to untreated individuals in the target patient population (refer to section XI.B. of this guidance for additional information).\n\n根据上述已知信息，请将'对这类患者 不进行额外诊断或监测，仅用流行病学方法对收集的数据进行分 析。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"No additional diagnostic or monitoring procedures are applied to the patients and epidemiological methods are used for the analysis of collected data."
    },
    {
        "instruction":"已知信息：\n'如ICH S6指导原则所述，如果因为生物制品与所有种属 的直系同源靶点均没有相互作用而不能确定相关种属时，则可以考虑使用同源分子或者转基因模型。'可被翻译为：As described in ICH S6 Guideline, when no relevant species can be identified because the biopharmaceutical does not interact with the orthologous target in any species, use of homologous molecules or transgenic models can be considered.\n'如果不存在相关试验种属，应考虑使用替代模型， 例如使用作用于直系同源靶标的类似药物（替代品），或使用表达人类靶标的动物的转基因模 型。'可被翻译为：In cases where no relevant test species exists, consideration should be given to the use of alternative models, such as the use of an analogous drug (surrogate) against the orthologous target, or the use of a transgenic model in which the animal is made to express the human target.\n'如果没有相关种属、转基因动物 或替代分子，进行体内生殖毒性试验没有意义。'可被翻译为：If there are no relevant species, genetically modified animals or surrogates available, in vivo reproductive toxicity testing is not meaningful.\n'如果没有测试临床候选物的相关动物种属，假设对模型具有充分的背景知识（如历史背景数据），可以考虑使用表达人体靶点的转基因小鼠，或者使用表达人体靶点同源基因种属中的同源蛋白（参见第I部分，注释1）。对于以外源性物质（如细菌和病毒）为靶点的产品，一般不需要进行生殖毒性试验（参见第2.1部分）。'可被翻译为：When no relevant animal species exists for testing the clinical candidate, the use of transgenic mice expressing the human target or homologous protein in a species expressing an ortholog of the human target can be considered, assuming that sufficient background knowledge exists for the model (e.g., historical background data) (see Part I, Note 1). For products that are directed at a foreign target such as bacteria and viruses, in general no reproductive toxicity studies would be expected (see Section 2.1).\n\n根据上述已知信息，请将'如ICH S6所述，当生物制品由于不与任何生殖毒性试验相关种属的同源靶 点相互作用而确定无相关种属时，可以考虑使用替代分子或转基因模型。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"When no relevant species can be identified because the biopharmaceutical does not interact with the orthologous target in any species relevant to reproductive toxicity testing, use of surrogate molecules or transgenic models can be considered, as described in ICH S6."
    },
    {
        "instruction":"已知信息：\n'往复隔膜泵'可被翻译为：reciprocating diaphragm pump\n'依靠泵缸与啮合齿轮间所形成的工作容积变化和移动来输送液体或使之增压的回转泵。'可被翻译为：A rotary pump that depends on the working volume change and movement formed between the pump cylinder and the meshing gear to transport the liquid or pressurize it.\n'当两种反应物互不相溶（液-液两相体系或固-液两相体系）难于反应时，加入催化剂能把种实际参加反应的实体（如负离子）从一相转移到另一相中，实现两种反应物在均相中发生反应，使反应加速或者较易进行的方法。'可被翻译为：When the two reactants are insoluble to each other (liquid-liquid two-phase system or solid-liquid two-phase system), it is difficult to react, adding a catalyst can transfer the entity (such as negative ions) that actually participates in the reaction from one phase to another phase, and realize the reaction of the two reactants in the homogeneous phase, so that the reaction can be accelerated or easier to carry out.\n'用于填充液相色谱柱的粒状固定相。'可被翻译为：A granular stationary phase used to fill liquid chromatographic columns.\n\n根据上述已知信息，请将'简称\"隔膜泵\"。一种特殊往复泵。专用于输送高磨蚀固-液两相介质的新一代往复泵。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Referred to as \"diaphragm pump\". A special reciprocating pump. A new generation reciprocating pump specially used for conveying high abrasive solid-liquid two-phase medium."
    },
    {
        "instruction":"已知信息：\n'对于一些可能要求证明优于安慰剂或某种活性参比治疗方案的适应症，关于探索适当的患者群及终点提出了一些建议，但目前缺乏数据来支持关于研究设计的明确建议。'可被翻译为：In indications for which a demonstration of superiority over placebo or an active comparative regimen could be required some suggestions are made for exploring appropriate patient populations and endpoints in the light of the current lack of data to support definitive recommendations for study design.\n'如果特定目标人群没有确定的治疗方法， 可采用可证明优效性的安慰剂对照研究。'可被翻译为：If there is no established therapy for the specific target population, a placebo-controlled study aiming to demonstrate superiority, might be acceptable.\n'基于主要微生物学终点的疗效证明以及反映出所观察到的对携带菌的作用的适应症只有在当前临床意见（例如，已发表的文献和\/或专业团体提出的基于证据的建议） 认为已充分确立在所研究的特定情况下携带菌的消除具有临床获益并且被广泛推荐时才能接受。'可被翻译为：A demonstration of efficacy based on a primary microbiological endpoint and an indication that reflects the observed effect on carriage would only be acceptable if current clinical opinion (e.g. supported by published literature and\/or evidence-based recommendations of professional bodies) considers that eradication of carriage in the specific circumstance studied is well established to be clinically beneficial and is widely recommended.\n'3.5.3 携带菌的消除'可被翻译为：3.5.3. Eradication of carriage\n\n根据上述已知信息，请将'如果没有足够的数据来支持两者的联系，与对携带菌的治疗作用相关的临床获益应该通过安慰剂对照研究的主要临床终点来证明。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In the absence of adequate data to support such a link, the clinical benefit associated with the effect of treatment on carriage should be demonstrated in a placebo-controlled study with a primary clinical endpoint."
    },
    {
        "instruction":"已知信息：\n'一旦皮肤的水合作用和温度达到平衡(例如，30分钟后)，应测量皮肤表面温度。在施用剂型之前，皮肤表面温度应在目标温度(32°)的±1°内。受体溶液的温度，或循环水浴的温度，或干热系统的设定点，或系统的任何其他组成部分的温度不应假定与皮肤表面温度相同。相反，应直接测量皮肤表面温度(使用红外温度计或热电偶)，并根据需要调整FDC系统的温度调节机制，使皮肤表面温度达到32°的目标温度。'可被翻译为：Once the hydration and temperature of the skin has equilibrated (e.g., after 30 min) the skin surface temperature should be measured. The skin surface temperature should be within ±1° of the target temperature (32°) prior to applying the dosage form. The temperature of the receptor solution, or the circulating water bath, or the set point of a dry heat system, or any other component of the system should not be assumed to be the same as the skin surface temperature. Instead, the skin surface temperature should be directly measured (with an infrared thermometer or a thermocouple), and the thermoregulatory mechanism of the FDC system should be adjusted as needed to produce the target temperature of 32° at the skin surface.\n'皮肤表面温度应使用红外温度计测量。加热块的温度必须设置高于所需的膜温度(例如，对于32°的皮肤表面温度设为33°)。'可被翻译为：Skin surface temperature should be measured using an IR thermometer. The temperature of the heating block must be set higher than the desired membrane temperature (e.g., 33° for a 32° skin surface temperature).\n'在IVPT开始运行之前，系统应在预先确定的实验条件下进行适当的平衡。在实验之前和实验过程中，受体溶液(膜下)中不应出现气泡;如果合适，受体溶液可以脱气。系统温度(包括膜表面温度和循环水浴温度，如适用)应稳定且控制良好。冷冻的生物膜应在室温下解冻，然后组装在扩散池上。一旦安装，皮肤切片应该被允许平衡到生理上相关的水合作用和温度状态(例如，在32°的膜表面温度下30分钟)。'可被翻译为：The system should be appropriately equilibrated under the predefined experimental conditions prior to the beginning of the IVPT run. No air bubbles should be present in the receptor solution (under the membrane) immediately prior and during the experiment; if appropriate, the receptor solution can be degassed. The system temperature (including the membrane surface temperature and the circulating water bath temperature, if applicable) should be stable and well controlled. Frozen biological membranes should be thawed at ambient temperature prior to assembling on the diffusion cells. Once mounted, the skin sections should be allowed to equilibrate to a physiologically relevant state of hydration and temperature (e.g., for 30 min at a membrane surface temperature of 32°).\n'在IVRT开始运行之前，系统应在预定的实验条件下适当地平衡。在实验前或实验过程中，受体溶液(膜下)中不应出现气泡;如果合适，受体溶液可以脱气。系统温度(包括膜表面温度和循环水浴温度，如适用)应稳定且控制良好。IVRT膜在装配于扩散池之前可以用受体溶液预浸泡，或者在给药之前用扩散池内的受体溶液原位平衡(例如，在32°的膜温度下30分钟)，具体取决于方法。'可被翻译为：The system should be appropriately equilibrated under the predefined experimental conditions prior to the beginning of the IVRT run. No air bubbles should be present in the receptor solution (under the membrane) immediately prior to, or during the experiment; if appropriate, the receptor solution can be degassed. The system temperature (including the membrane surface temperature and the circulating water bath temperature, if applicable) should be stable and well controlled. IVRT membranes can be presoaked with receptor solution prior to assembling in the diffusion cell or equilibrated with the receptor solution in situ within the diffusion cell prior to dosing (e.g., for 30 min at a membrane temperature of 32°) depending upon the method.\n\n根据上述已知信息，请将'一旦皮肤的水合作用和温度达到平衡(即30分钟后)，应测量皮肤表面温度。在施用剂型之前，皮肤表面温度应在目标温度(32°)的±1°内。受体溶液的温度，或循环水浴的温度，或干热系统的设定点，或系统的任何其他组成部分的温度不应假定与皮肤表面温度相同。而是直接测量皮肤表面温度(使用红外温度计或热电偶)，并根据需要调节VDC系统的热调节机制，使皮肤表面温度达到32°的目标温度。搅拌器可以在平衡期间运行，以加速温度稳定。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Once the hydration and temperature of the skin has equilibrated (i.e., after 30 min) the skin surface temperature should be measured. The skin surface temperature should be within ±1° of the target temperature (32°) prior to applying the dosage form. The temperature of the receptor solution, or the circulating water bath, or the set point of a dry heat system, or any other component of the system should not be assumed to be the same as the skin surface temperature. Instead, the skin surface temperature should be directly measured (with an infrared thermometer or a thermocouple), and the thermoregulatory mechanism of the VDC system should be adjusted as needed to produce the target temperature of 32° at the skin surface. The stirrers can be run during the duration of the equilibration to speed up temperature stabilization."
    },
    {
        "instruction":"已知信息：\n'本节的目的不是对试验药的获益－风险进行全 面评估。'可被翻译为：This section is not intended to be a full benefit-risk assessment of the investigational drug.\n'相反，涉及大量研究者的大型、开放性、安全性研究和治疗方案一般不被认 为是涵盖的临床研究。'可被翻译为：By contrast, large open safety studies and treatment protocols that have large numbers of investigators would generally not be considered covered clinical studies.\n'扩展治疗用研究药品的使用权——Qs & As'可被翻译为：Expanded Access to Investigational Drugs For Treatment Use — Qs & As\n'一般问题 Q16：一般情况下，FDA如何确定授权一种药物的扩展使用权不会干扰临床试 验或药物开发？ A16：按照21 CFR 312.305(a)(3)，对于任何类别扩展使用权的授权，FDA 必须确定要求用药的使用权不会干扰可能支持扩展使用权用药的上市批件的临 床研究的开始、实施或完成，而且不会在其他方面损害扩展使用权用药的潜在开 发。'可被翻译为：General Questions Q16. In general, how does FDA determine that authorizing expanded access to a drug will not interfere with clinical trials or drug development? A16. Under 21 CFR 312.305(a)(3), to authorize any category of expanded access, FDA must determine that access to the drug for the requested use will not interfere with the initiation, conduct, or completion of clinical investigations that could support marketing approval of the expanded access use, or otherwise compromise the potential development of the drug for the expanded access use.\n\n根据上述已知信息，请将'扩展使用权与涵盖在IND研究中常规使用研究药物之间的差别在于，扩展使用权用药不以 获得药物安全性或有效性信息为主要目的。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The distinction between expanded access and the use of an investigational drug in the usual studies covered under an IND is that expanded access uses are not primarily intended to obtain information about the safety or effectiveness of a drug."
    },
    {
        "instruction":"已知信息：\n'二氢吡啶类钙通道阻滞剂 氨氯地平，非洛地平，依拉地平，尼卡地 平，硝苯地平，尼索地平'可被翻译为：dihydropyridine calcium channel blockers amlodipine, felodipine, isradipine, nicardipine, nifedipine, nisoldipine\n'动脉扩张剂 肼苯哒嗪，米诺地尔'可被翻译为：arteriolar vasodilators hydralazine, minoxidil\n'纠正各种心律失常症状的药物。分类有：①I相治疗药，如普鲁卡因胺、利多卡因、苯妥英钠和普罗帕酮；②Ⅱ相治疗药，如普蔡洛尔；③Ⅲ相延长动作电位时程药，如胺碘酮；④Ⅳ相钙通道阻滞剂，如维拉帕米、地尔硫卓。'可被翻译为：Medications to correct various arrhythmia symptoms. The categories are: ① Phase I treatment agents, such as procainamine, lidocaine, phenytoin sodium, and propafenone; ② Phase II therapeutics, such as przeolol; ③ Phase III drugs that prolong action potential duration, such as amiodarone; ④ Phase IV calcium channel blockers, such as verapamil and diltiazem.\n'β-肾上肾素受体阻滞剂 醋丁洛尔，阿替洛尔，倍他洛尔，比索洛 尔，卡维地洛，卡替洛尔，艾司洛尔，拉 贝洛尔，美托洛尔，纳多洛尔，喷布特罗， 心得乐，心得安，噻吗心安'可被翻译为：beta-adrenergic blockers acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, carteolol, esmolol, labetolol, metoprolol, nadolol, penbuterol, pindolol, propranolol, timolol\n\n根据上述已知信息，请将'非二氢吡啶类钙通道阻滞剂 地尔硫卓，维拉帕米'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"non-dihydropyridine calcium channel blockers diltiazem, verapamil"
    },
    {
        "instruction":"已知信息：\n'○ C.1 –个例安全性报告的识别–个；'可被翻译为：o C.1 - Identification of the Case Safety Report;\n'使用以下符号表示C.1.1： 使用以下符号表示C.1.8： 尽管属性 可以在信息中重复，但是对于特定安全性报告但是对于特定安全性报告，必须有一个 属性的单个实例，其根值为 “2.16.840.1.113883.3.989.2.1.3.2”。'可被翻译为：The following notation will be used to represent C.1.1: <id extension=\"country code-company name-report no\" root=\" 2.16.840.1.113883.3.989.2.1.3.1 \"\/> The following notation will be used to represent C.1.8: <id extension=\"country code-company name-report no\" root=\" 2.16.840.1.113883.3.989.2.1.3.2\"\/> Although the attribute <id> can repeat in the message, but there must be a single instance of the <id> attribute with the root value of ‘2.16.840.1.113883.3.989.2.1.3.2 ‘ for a particular case safety report.\n'图中的每个框代表 E2B（R3）数据元素结构的相关章节，该框中的所有数据元素均列在属性列表元素元素（第 3.4 节）中。'可被翻译为：Each box in the diagram represents a related section of the E2B(R3) data element structure, and all the data elements in that block are listed in the attribute list (Section 3.4).\n'3.4 ICH E2B（R3）数据元素元素'可被翻译为：3.4 ICH E2B(R3)DATA ELEMENTS\n\n根据上述已知信息，请将'例如，病例安全性识别报告图中的框 C.1 表示 E2B（R3）数据元素对应的ICH E2B（R3）数据元素列表的C.1全章和表中所列出的元素C.1模块。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For example, box C.1 in the diagram Identification of the Case Safety Report represents the complete C.1 section of the E2B(R3) data elements and the C.1 block of elements listed in the ICH E2B(R3) data element list."
    },
    {
        "instruction":"已知信息：\n'第二十一条 药品生产、经营企业和医疗机构发现或者获知新的、严重的药品不良反应应当在15日内报告，其中死亡病例须立即报告；其他药品不良反应应当在30日内报告。有随访信息的，应当及时报告。'可被翻译为：Article 21 Drug manufacturers, distributors and medical institutions shall report any new and serious ADRs no later than 15 days from discovering or becoming aware of the information, death case shall be reported immediately, and other ADRs shall be reported no later than 30 days. Follow-up information (if any) shall be reported in a timely manner.\n'第三十四条 国家药品不良反应监测中心应当对收到的药品不良反应报告进行分析、评价，每半年向国家食品药品监督管理局和卫生部报告，发现提示药品可能存在安全隐患的信息应当及时报告。'可被翻译为：Article 34 The National Center for ADR Monitoring shall analyze and evaluate ADR reports received and report to the SFDA and the Ministry of Health semiannually; once information indicating potential drug safety risks is identified, reports shall be submitted in a timely manner.\n'第二十八条  设区的市级监测机构应当自收到医疗器械不良事件报告之日起10日内，对报告的真实性、完整性和准确性进行审核，并实时反馈相关持有人。'可被翻译为：Article 28 The monitoring agencies at the level of the municipality consisting of districts shall review the truthfulness, completeness and accuracy of the received medical device adverse event reports within 10 days upon the receipt date, and feed back to relevant MAHs promptly.\n'设区的市级、县级药品不良反应监测机构应当对死亡病例进行调查，详细了解死亡病例的基本信息、药品使用情况、不良反应发生及诊治情况等，自收到报告之日起15个工作日内完成调查报告，报同级药品监督管理部门和卫生行政部门，以及上一级药品不良反应监测机构。'可被翻译为：ADR monitoring institutions of municipalities with districts and counties shall investigate death cases to have a detailed understanding of the basic information about the case, information of drug use, and occurrence, diagnosis and treatment of the adverse reactions, etc. The investigation report shall be completed within 15 days after receiving the case report and submitted to the drug regulatory department and health administrative department at the same level and the ADR monitoring institution at a higher level.\n\n根据上述已知信息，请将'第二十四条 设区的市级、县级药品不良反应监测机构应当对收到的药品不良反应报告的真实性、完整性和准确性进行审核。严重药品不良反应报告的审核和评价应当自收到报告之日起3个工作日内完成，其他报告的审核和评价应当在15个工作日内完成。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 24 ADR monitoring institutions of municipalities with districts and counties shall review the authenticity, completeness and accuracy of ADR reports received. The review and evaluation of serious ADR reports shall be completed within 3 working days after receiving the reports; the review and evaluation of other reports shall be completed within 15 working days."
    },
    {
        "instruction":"已知信息：\n'对于 F.r.3.3“检测结果检测”，存在一个例外。ICH 对此领域不提供限制性 UCUM代码，允许使用各种单位。UCUM代码可以从原始UCUM列表中选择，并在表8中列出OID。'可被翻译为：There is an exception for F.r.3.3 ‘Test Result’. ICH does not provide constrained UCUM codes for this field to allow variety of units. UCUM codes can be selected from the original UCUM list and OID is listed in the table 8.\n'还有一些是为 ICH 创建的特定代码列表。'可被翻译为：Still others are specific code lists created for the ICH.\n'这包括“官方指定的”国家代码加上在“特别保 留”类别中的“欧盟”。'可被翻译为：This includes “Officially assigned” country codes plus “EU” in the “Exceptionally reserved” category.\n'ICH 数据类型 “AN” 接受 UTF8中列出的 所有字符吗？'可被翻译为：Does ICH data type “AN” accept all characters listed in UTF8?\n\n根据上述已知信息，请将'ICH只接受“官方指定的代码” 吗？ 注：“欧盟”分类为“特别保留”。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Does ICH accept “Officially assigned codes” only?"
    },
    {
        "instruction":"已知信息：\n'故意和欺诈性地在标识和\/或来源方面贴错标签的药品。品牌产品和非专利产品都可能被假冒，假冒产品可能包括成分正确、成分错误、没有有效成分、有效成分数量不足或包装虚假的产品。'可被翻译为：A pharmaceutical product that is deliberately and fraudulently mislabelled with respect to identity and\/or source. Both branded and generic products can be counterfeited, and counterfeit products may include products with the correct ingredients, with the wrong ingredients, without active ingredients, with insufficient quantity of active ingredients or with fake packaging.\n'А假药是指在身份和\/或来源方面故意和欺骗性地贴错标签的药品。假冒既可以适用于品牌产品，也可以适用于仿制产品和假冒产品，可能包括成分正确或成分错误、没有有效成分、有效成分不足或包装虚假的产品。'可被翻译为：А counterfeit medicine is one which is deliberately and fraudulently mislabelled with respect to identity and\/or source. Counterfeiting can apply to both branded and generic products and counterfeit products and may include products with the correct ingredients or with the wrong ingredients, without active ingredients, with insufficient active ingredients or with fake packaging.\n'1.成分是在草药材料或草药制剂中发现的化学定义的物质或物质群。\n2.在草药材料或草药制剂中发现的化学上定义的物质或一组\/组物质。'可被翻译为：1.Constituents are chemically defined substances or group(s) of substances found in a herbal material or herbal preparations.\n2.Chemically defined substances or group\/group(s) of substances found in a herbal material or herbal preparation.\n'有毒成分是化学定义的物质或物质群，其毒性占主导地位，尽管它们可能有助于草药材料或草药制剂的治疗活性。'可被翻译为：Toxic constituents are substances or group(s) of substances that are chemically defined and their toxic property is predominant, although they may contribute to the therapeutic activities of the herbal material or herbal preparation.\n\n根据上述已知信息，请将'掺假剂是草药材料，是故意或无意(通过交叉污染或污染)添加到草药材料、草药制剂或草药成品中的草药成分或其他物质。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Adulterant is herbal material, a herbal constituent or other substance that is either deliberately or non-intentionally (through cross-contamination or contamination) added to a herbal material, herbal preparation, or finished herbal product."
    },
    {
        "instruction":"已知信息：\n'第五十六条 国家药品监督管理局和省、自治区、直辖市药品监督管理部门组织监督检查时，应当制定检查方案，明确检查标准，如实记录现场检查情况，需要抽样检验或者研究的，按照有关规定执行。检查结论应当清晰明确，检查发现的问题应当以书面形式告知被检查单位。需要整改的，应当提出整改内容及整改期限，必要时对整改后情况实施检查。'可被翻译为：Article 56 When organizing supervision and inspections, the NMPA and the drug regulatory authority of the province, autonomous region or municipality directly under the Central Government shall make inspection plans to clarify the inspection standards, record the on-site inspections truthfully, conduct the inspections in accordance with relevant rules when sample testing or study is required. The conclusion of the inspection shall be clear and unambiguous, and the problems found during the inspection shall be notified to the inspected company in written format. If corrective actions are required, the content and the deadline of corrective actions shall be proposed, and the situation after the remediation shall be inspected if necessary.\n'第四十八条  设区的市级、县级负责药品监督管理的部门应当制定年度检查计划，明确监管重点、检查频次和覆盖范围并组织实施。'可被翻译为：Article 48 The department in charge of drug supervision and administration at the level of a city divided into districts or at county level shall make annual inspection plan, specifying the key points of supervision and administration, inspection frequency and coverage scope, and organize the implementation.\n'第四十九条  省、自治区、直辖市药品监督管理部门应当制定年度医疗器械生产监督检查计划，确定医疗器械监督管理的重点，明确检查频次和覆盖范围，综合运用监督检查、重点检查、跟踪检查、有因检查和专项检查等多种形式强化监督管理。'可被翻译为：Article 49 The drug regulatory department of the province, autonomous region, or municipality directly under the central government shall formulate annual supervision and inspection plan for manufacturing of medical devices, determine the key points of supervision and administration of medical devices, specify the inspection frequency and coverage, and make comprehensive use of multiple means such as supervision and inspection, key inspection, follow-up inspection, for-cause inspection and special inspection, etc. to strengthen supervision and administration.\n'第六十四条  省、自治区、直辖市药品监督管理部门应当制定本行政区域的医疗器械不良事件监测监督检查计划，确定检查重点，并监督实施。'可被翻译为：Article 64 The drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government shall formulate supervision and inspection plan on medical device adverse event within the administrative region, and explicitly define inspection work focus and supervise the implementation.\n\n根据上述已知信息，请将'第五十四条 省、自治区、直辖市药品监督管理部门应当坚持风险管理、全程管控原则，根据风险研判情况，制定年度检查计划并开展监督检查。年度检查计划至少包括检查范围、内容、方式、重点、要求、时限、承担检查的机构等。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 54 The drug regulatory department of the province, autonomous region or municipality directly under the Central Government shall stick to the principles of risk management and whole-process management and control, and in accordance with the risk analysis and assessment, establish annual inspection plan and carry out the inspection. The annual inspection plan shall at least include: the inspection scope, content, methods, priorities, requirements, timelines, and inspection agency."
    },
    {
        "instruction":"已知信息：\n'应从微生物角度证明拟定的例行程序是合理的。'可被翻译为：The proposed routines should be justified from a  microbiological perspective.\n'在微生物学和临床的开发项目中，申办方应该收集足够的数据来阐明试验性抗菌剂对近期临床分离株的体外抗菌活性（例如， 提交注册申请前大约5年内的数据） 。'可被翻译为：During the microbiological and clinical development programmes the sponsor should collect sufficient data to characterise the in-vitro antibacterial activity of the test antibacterial agent against recent clinical isolates (e.g. obtained within approximately 5 years prior to filing an application dossier).\n'本附录重申：疗效主要评估一般应在治愈访视的检查中进行，每个治疗组均在相同的随机后时间窗内进行并且需在方案定义治疗的最后一次可能剂量之后过了最低规定天数的时间点。'可被翻译为：This addendum reiterates that the primary assessment of efficacy should usually occur at a test of cure visit that takes place within the same post-randomisation window in each treatment group and is timed to occur when a minimum numbers of days have elapsed from the last possible dose of protocol- defined treatment.\n'研究者应证明暴露风险窗所选择的单位是合理的（如人员-时间，患者，处方）。'可被翻译为：Investigators should justify the units selected for the exposure risk window (e.g., person-time, patients, and prescriptions).\n\n根据上述已知信息，请将'细菌感染的微生物学证明应根据在研究治疗首次剂量之后严格观察的时间 窗之前或时间窗内获取的样本。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Microbiological documentation of bacterial infections should be sought from specimens obtained before or within a strictly-observed window after the first dose of study therapy is given."
    },
    {
        "instruction":"已知信息：\n'企业按照本规范第六十九条规定直调药品的，直调药品出库时，由供货单位开具两份随货同行单（票），分别发往直调企业和购货单位。随货同行单（票）的内容应当符合本规范第七十三条第二款的要求，还应当标明直调企业名称。'可被翻译为：Where an enterprise directly transfers drugs in accordance with Article 69 herein, the supplier shall issue two copies of the same accompanying sheet (bill) at the time of ex-warehousing of the directly transferred drugs which shall be respectively sent to the directly transferring enterprise and the purchaser. The contents of the accompanying sheet (bill) shall comply with the requirements of Paragraph 2 of Article 73 herein and also indicate the name of the directly transferring enterprise.\n'第九十八条 药品出库时，应当附加盖企业药品出库专用章原印章的随货同行单（票）。'可被翻译为：Article 98 At the time of ex-warehousing of drugs, the accompanying sheet (bill) stamped with the original special seal for drug ex-warehousing of enterprises shall be attached.\n'第一百五十三条 药品到货时，收货人员应当按采购记录，对照供货单位的随货同行单（票）核实药品实物，做到票、账、货相符。'可被翻译为：Article 153 Upon arrival of drugs, the receiving personnel shall, in accordance with the purchase records, check the material objects according to the accompanying sheet (bill) provided by suppliers and ensure that the bills, account and goods are consistent.\n'第九十五条 药品出库复核应当建立记录，包括购货单位、药品的通用名称、剂型、规格、数量、批号、有效期、生产厂商、出库日期、质量状况和复核人员等内容。'可被翻译为：Article 95 Records shall be established for ex-warehousing check of drugs, including the purchaser, adopted name, dosage form, strength, quantity, lot number, expiry date, and manufacturer of drugs, ex-warehousing date, quality status and checker, etc.\n\n根据上述已知信息，请将'随货同行单（票）应当包括供货单位、生产厂商、药品的通用名称、剂型、规格、批号、数量、收货单位、收货地址、发货日期等内容，并加盖供货单位药品出库专用章原印章。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The accompanying sheet (bill) shall include the supplier, the manufacturer, the adopted name, dosage form, strength, lot number and quantity of drugs, the consignee, receiving address, shipping date and other contents, and stamped with the original special seal for drug ex-warehousing of the supplier."
    },
    {
        "instruction":"已知信息：\n'无论MAH使用的参考产品信息如何，PBRER章节17.1总结的重要基线有 效性和疗效信息将构成利益评估的基础（或“参考”）。'可被翻译为：The important baseline efficacy and effectiveness information summarised in Section 17.1 of the PBRER will form the basis (or “reference”) for the benefit evaluation, irrespective of the reference product information used by the MAH.\n'如果来自临床试验的新临床重要有效性\/效用信息已被包括在PBRER的前几章中， 例如在章节7、9.1或13中，MAH应包括相关章节的交叉索引，因为它不一定是在 其它章节中提供的重复信息。'可被翻译为：If new clinically important efficacy\/effectiveness information from clinical trials has been included in previous sections of the PBRER, for example, in Sections 7, 9.1, or 13, the MAH should include cross-references to the relevant section(s), because it is not necessary to duplicate information presented elsewhere in the document.\n'15.3 2014年3月 章节17.2（新确定的关于有效性\/效用的信息）应包括哪些新信息？'可被翻译为：15.3 March 2014 What new information should be included in Section 17.2 (newly identified information on efficacy\/effectiveness) of the PBRER?\n'MAH应提供关于批准适应症的相关并且支持PBRER章节17.3所述的利益表征的任 何有效性\/效用信息。'可被翻译为：The MAH should present any efficacy\/effectiveness information on approved indications that is relevant and supports the characterisation of benefit presented in Section 17.3 of the PBRER.\n\n根据上述已知信息，请将'15.2 2014年3月 PBRER章节17.1（重要的基线有效性 \/效用信息）应提供哪些有效性\/效用信 息？ 除了指南章节3.17.1所提供的指导外，在提交PBRER章节17.1提出有效性\/效用信 息时，MAH不妨考虑以下几点。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"15.2 March 2014 What efficacy\/effectiveness information should be presented in Section 17.1 (Important Baseline Efficacy\/Effectiveness Information) of the PBRER? In addition to the guidance provided in Section 3.17.1 of the Guideline, the MAH may wish to consider the following points when presenting efficacy\/effectiveness information in Section 17.1 of the PBRER."
    },
    {
        "instruction":"已知信息：\n'额外信息请参见第 E.4 节。'可被翻译为：See Question E.4 for additional information.\n'额外信息参见第 IV.E 节，申办方。'可被翻译为：See Section IV.E, Sponsor, for additional information.\n'4见http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm065015.htm 和 http:\/\/www.fda.gov\/ForIndustry\/DataStandards\/StructuredProductLabeling\/ucm241316.htm.'可被翻译为：4 See http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm065015.htm and http:\/\/www.fda.gov\/ForIndustry\/DataStandards\/StructuredProductLabeling\/ucm241316.htm.\n'4 取自 http:\/\/www.fda.gov\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/Cellularand GeneTherapy\/ucm401869.htm。'可被翻译为：4 Available at http:\/\/www.fda.gov\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/CellularandG eneTherapy\/ucm401869.htm.\n\n根据上述已知信息，请将'4“Co-existence of Traditional EDI with XML-EDI”、Skip Stein、Management Systems Consulting, Inc.， http:\/\/www.msc-inc.net\/'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"4‘Co-existence of Traditional EDI with XML-EDI’, Skip Stein, Management Systems Consulting, Inc., http:\/\/www.msc-inc.net\/"
    },
    {
        "instruction":"已知信息：\n'然而，在使用控制药物治疗的患者中，可能很难达到该值。'可被翻译为：However, in patients on controller therapy this figure may be difficult to attain.\n'现有数据不允许从某种程度的 pCR 作用精确地预测出 EFS\/DFS\/OS 的作用幅度。'可被翻译为：Currently available data do not allow a precise prediction of the magnitude of the EFS\/DFS\/OS effect from a certain pCR effect.\n'临床研究的目的应该是提供尽可能多的关于 FDC 对于存在预期会受到抑制的 β- 内酰胺酶的表达的生物体的效果数据。'可被翻译为：The clinical studies should aim to provide as much data as possible on efficacy of the FDC against organisms that express the beta-lactamases that are expected to be inhibited.\n'应该有对于一系列 β- 内酰胺酶的酶动力学 的详细数据。'可被翻译为：There should be detailed data on enzyme kinetics against a range of beta-lactamases.\n\n根据上述已知信息，请将'但是，可能无法提供预期会受到抑制的所有酶的临床疗效数据， 对于 单个酶的数据可能也很有限。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"However, it may not be possible to provide clinical efficacy data for all the enzymes that are predicted to be inhibited and the data for individual enzymes may be very limited."
    },
    {
        "instruction":"已知信息：\n'如果产品及其组件暴露于环境下，且产品不会进行后续过滤（通过除菌级过滤器）或最终灭菌时，无菌产品（如软膏剂、霜剂、混悬剂和乳剂）的制备和灌装应在 B 级环境下的 A 级内进行。如果采用隔离器或RABS，其环境应符合 4.20 节的规定。'可被翻译为：Preparation and filling of sterile products such as ointments, creams, suspensions and emulsions should be performed in grade A with a grade B background when the product and components are exposed to the environment and the product is not subsequently filtered (via a sterilising grade filter) or terminally sterilised. Where an isolator or RABS is used, the background should be in accordance with paragraph 4.20.\n'无菌连接应在 B 级环境下的 A 级区域内进行，除非随后经在线灭菌或使用内部无菌连接装置，从而最大程度地降低来自周围环境的潜在污染。内部无菌连接装置的设计应降低污染风险。'可被翻译为：Aseptic connections should be performed in grade A with a grade B background unless subsequently sterilised in place or conducted with intrinsic sterile connection devices that minimize any potential contamination from the immediate environment. Intrinsic sterile connection devices should be designed to mitigate risk of contamination\n'应在开放式隔离器的接口处进行气流流型研究，以证明没有空气进入。'可被翻译为：Airflow pattern studies should be performed at the interfaces of open isolators to demonstrate the absence of air ingress.\n'与产品直接或间接接触的已灭菌设备、组件和辅助用品的拆包、装配和准备应作为无菌工艺过程，在 B 级环境下的 A 级区域内执行。无菌产品的灌装线组装和灌装应作为无菌工艺过程，在 B 级环境下的 A 级区域内执行。当使用隔离器时，背景应符合 4.20 节的规定'可被翻译为：The unwrapping, assembly and preparation of sterilised equipment, components and ancillary items with direct or indirect product contact should be treated as an aseptic process and performed in grade A with a grade B background. The filling line set-up and filling of the sterile product should be treated as an aseptic process and performed in grade A with a grade B background. Where an isolator is used, the background should be in accordance with paragraph 4.20\n\n根据上述已知信息，请将'用于无菌工艺的RABS的环境应至少为 B级，并且应进行气流流型研究以证明在干预过程中没有空气进入，包括开门（如适用）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The background environment for RABS used for aseptic processing should correspond to a minimum of grade B and airflow pattern studies should be performed to demonstrate the absence of air ingress during interventions, including door openings if applicable."
    },
    {
        "instruction":"已知信息：\n'目前的指南不要求检测代谢物。'可被翻译为：The current guidance does not require testing of metabolites.\n'无需对T和R产品进行进一步的对比检测。'可被翻译为：No further comparative testing of T and R products is needed.\n'II期和III期研究'可被翻译为：Phase II and III studies\n'遗憾的是， AD 的药物研发领域遭遇了重重挫折，在一些情况下，探索性试验未能为III期研究提供 “假说验证”的信息。'可被翻译为：Unfortunately the field of AD drug development has witnessed many failures and it is noted that in some cases, exploratory trials did not provide ‘proof of concept’ to inform Phase 3.\n\n根据上述已知信息，请将'无须在 III 期药物研发中例行进行测压研究。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A routine performance of manometry studies in phase III of the drug development will not be required."
    },
    {
        "instruction":"已知信息：\n'此处未列出的其他例子应与FDA进行讨论。'可被翻译为：Other examples not listed here should be discussed with FDA.\n'可能不要求申办方-研究者提交依法上市药品研究的IND， 例如，如果符合IND豁免的标准 。'可被翻译为：A sponsor-investigator may not be required to submit an IND for, for example, a study of a lawfully marketed drug if the criteria for an IND exemption are met.\n'更多信息，见FDA的行业指南 临床研究中的电子源数据。'可被翻译为：For more information, see FDA’s guidance for industry Electronic Source Data in Clinical Investigations.\n'21更多信息，见FDA的行业指南“临床研究中使用的计算机化系统”。'可被翻译为：21 For more information, see FDA’s guidance for industry Computerized Systems Used in Clinical Investigations.\n\n根据上述已知信息，请将'更多信息，见 FDA的行业指南和FDA工作人员FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND; Frequently Asked Questions。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For more information, see FDA’s guidance for industry and FDA staff FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND; Frequently Asked Questions."
    },
    {
        "instruction":"已知信息：\n'b：每窝每性别应至少保留1只动物，以进行行为和其它功能检测，并评估 生殖功能。'可被翻译为：b: At least one animal per sex per litter should be retained to conduct behavioral and other functional tests, and to assess reproductive function.\n'这些窝数是指可用于评估的窝数量。'可被翻译为：These numbers refer to litters available for evaluation.\n'PND21时，至少每窝1只雄性和1只雌性，使可达到16 只动物\/组\/性别'可被翻译为：PND 21, at least 1 male and 1 female\/litter where possible to achieve 16 animals per group\/sex\n'在进行多个试验的情况下，除了用于预测模型的综合评估之外，还 应单独对每个试验的性能进行单独描述。'可被翻译为：• In cases when more than one assay is conducted, a separate description of the performance of each assay, in addition to the integrated assessment used for the predictive model.\n\n根据上述已知信息，请将'某些情况下，每窝可保留更多的动物用于单独的功能性评估。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"There can be circumstances where more animals per litter can be retained for independent functional assessments."
    },
    {
        "instruction":"已知信息：\n'药物基因组学：与药物反应相关的DNA和RNA特征的差异的研究（ICH15）。'可被翻译为：Pharmacogenomics: the study of variations of DNA and RNA characteristics as related to drug response (ICH15).\n'研究 DNA序列中与药物反应相关的变异，这是药物基因组学的一个分支（ICH15）；研究 DNA 序列中与药物分布（药代动力学）或药物作用（药效学）有关的且可影响临床应答的个体间变异（CIOMS VII（2005））'可被翻译为：the study of variations in DNA sequence as related to drug response, asubset of pharmacogenomics (ICH15); the study of interindividualvariations in DNA sequence related to drug disposition(pharmacokinetics)or drug action (pharmacodynamics) that caninfluence clinical response(CIOMS VI(2005))\n'CIOMs VII（2005）：药物基因组学被更广泛地定义为应用基因组学技术来阐明疾病易感性、药物发现、药理学功能、药物处置和治疗反应。'可被翻译为：CIOMs VII (2005): Pharmacogenomics is defined more broadly as the application of genomic technologies to elucidate disease susceptibility, drug discovery, pharmacological function, drug disposition and therapeutic response.\n'产生应答的指标的一种可测定的DNA和\/或RNA特征 （ICH15）'可被翻译为：a measurable DNA and\/or RNA characteristic that is an indicator of normal biologic processes, pathogenic processes, and\/or response to therapeutic or other interventions (ICH5)\n\n根据上述已知信息，请将'研究与药物反 应有关 的 DNA 或 RNA特征变异（ICH15）；应用基因组技术来阐明疾病易感性、药物发现、药理学功能、药物分布和治疗应答（CIOMS VII（2005））'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"the study of variations of DNA and RNA characteristics as related todrug response (ICH15); the application of genomic technologies toelucidate disease susceptibility, drug discovery, pharmacologicalfunction, drug disposition and therapeutic response (CIOMS VII (2005))"
    },
    {
        "instruction":"已知信息：\n'此外，在试验的导入期应能证明对至少其中一种泻药应答不佳。'可被翻译为：Additionally, the inadequate response to at least one of the agents should be documented during the run-in period of the trials.\n'研究设计应提出可能破坏结果可靠性的潜在偏倚来源。'可被翻译为：The study design should address potential sources of bias that can undermine the reliability of results.\n'E. 上市后安全性监测考虑 上市后安全性监测应考虑到与单个新试验药物上市的风险相比，两种或两种 以上联合应用的新试验药物最初上市可能会出现的额外上市后风险。'可被翻译为：E. Postmarketing Safety Monitoring Considerations Postmarketing safety monitoring should consider additional postmarketing risks that may be presented by initial marketing of two or more new investigational drugs for use in combination as compared to the risks associated with marketing a single new investigational drug.\n'合适的试验药物应至少证明对大肠杆菌有体外活性。'可被翻译为：Suitable test agents should at least demonstrate in-vitro activity against E. coli.\n\n根据上述已知信息，请将'在研究设计时，应考虑到在肠道内预期达到的浓度下出现对试验药物不太可能敏感的大肠杆菌和其它菌种的生物体的风险，这一风险可能会影响研究中心的地理位置。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The risk of encountering organisms of this and other species that are unlikely to be susceptible to the test agent at concentrations expected within the gut should be taken into account in the study design and may influence the geographical location of study sites."
    },
    {
        "instruction":"已知信息：\n'出血可以是缺血性卒中的后果。'可被翻译为：Haemorrhage may be a consequence of ischaemic stroke.\n'应将伴有出血性转化 的缺血性卒中视为“主要缺血性”。'可被翻译为：An ischaemic stroke with haemorrhagic conversion should be considered as “primary ischaemic”.\n'因此建议采用由“所有卒中（即缺血性、未定义和出血性卒中） 和其他非中枢神经系统栓塞事件”组成的次要终点临床相关净临床获益。'可被翻译为：A clinically relevant net clinical benefit secondary endpoint consisting of “all strokes (i.e. ischaemic, undefined and haemorrhagic stroke) and other non-central nervous system embolic events” is therefore recommended.\n'例如，对于急性心肌梗死的病人，溶栓药可 以降低死亡率，但会增加出血性卒中的危险。'可被翻译为：For example, thrombolytics in patients with acute myocardial infarction can reduce mortality but increase hemorrhagic stroke risk.\n\n根据上述已知信息，请将'在这种情况下，卒中是伴随出血性转换的缺 血性卒中，而不是出血性卒中。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In this situation, the stroke is an ischaemic stroke with haemorrhagic transformation and not a haemorrhagic stroke."
    },
    {
        "instruction":"已知信息：\n'潜在风险的示例包括： 在临床研究中尚未观察或解决的非临床安全性 问题； 在临床试验或流行病学研究中观察到的不良事 件与对照组（安慰剂或活性物质或未暴露组） 相比，在所关注的参数方面的差异程度引起怀 疑，但不足以提示因果关系； 已知与相同类别的其它产品相关的或可基于药 品的性质预期会发生的事件。'可被翻译为：Examples of potential risks include: non-clinical safety concerns that have not been observed or resolved in clinical studies; adverse events observed in clinical trials or epidemiological studies for which the magnitude of the difference, compared with the comparator group (placebo or active substance, or unexposed group), on the parameter of interest raises a suspicion of, but is not large enough to suggest, a causal relationship; an event which is known to be associated with other products of the same class or which could be expected to occur based on the properties of the medicinal product.\n'有充分证据显示与所关注的药品有关联的不良事件。已确定风险的示例包括：·非临床研究中充分显示并经临床资料确认的不良反应；·在设计良好的临床试验或流行病学研究中观察到的不良反应，与比较组（安慰剂或活性物质）相比在某个关注参数上的差异程度表明有因果关系；·由许多证据充分的自发性报告中提出的不良反应，其中时序关系和生物学合理性强烈地支持因果关系，如过敏反应或应用部位反应。'可被翻译为：An untoward occurrence for which there is adequate evidence of an association with the medicinal product of interest.Examples of identified risks include:·an adverse reaction adequately demonstrated in non_x0002_clinical studies and confirmed by clinical data;·an adverse reaction observed in well designed clinical trials or epidemiological studies for which the magnitude of the difference compared with the comparator group (placebo or active substance) on a parameter of interest suggests a causal relationship; ·an adverse reaction suggested by a number of well documented spontaneous reports where causality is strongly supported by temporal relationship and biological plausibility, such as anaphylactic reactions or application site reactions.\n'临床试验或流行病学研究中观察到的不良事件，且与对照组 （安慰剂或活性成分或非暴露组）相比，检测参数的差异程度可 以怀疑，但不足以提示存在因果关系；'可被翻译为：Adverse events observed in clinical trials or epidemiological studies for which the magnitude of the difference, compared with the comparator group (placebo or active substance, or unexposed group), on the parameter of interest raises a suspicion of, but is not large enough to suggest, a causal relationship;\n'13. 潜在风险 ICH指导原 则E2F 有一定的依据怀疑与所关注的药品有关但是未能确 认的不利事件。'可被翻译为：13.Potential risk ICH Guideline E2F An untoward occurrence for which there is some basis for suspicion of an association with the medicinal product of interest but where this association has not been confirmed.\n\n根据上述已知信息，请将'有一定的依据怀疑与所关注的药品有关但是未能确认的不利事件。潜在风险的示例包括：在临床研究中尚未观察或解决的非临床安全性问题；在临床试验或流行病学研究中观察到的不良事件与对照组（安慰剂或活性物质或未暴露组）相比，在所关注的参数方面的差异程度引起怀疑，但不足以提示因果关系；已知与相同类别的其它产品相关的或可基于药 品的性质预期会发生的事件。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"An untoward occurrence for which there is some basis for suspicion of an association with the medicinal product of interest but where this association has not been confirmed. Examples of potential risks include:non-clinical safety concerns that have not been observed or resolved in clinical studies; adverse events observed in clinical trials or epidemiological studies for which the magnitude of the difference, compared with the comparator group (placebo or active substance, or unexposed group), on the parameter of interest raises a suspicion of, but is not large enough to suggest, a causal relationship; an event which is known to be associated with other products of the same class or which could be expected to occur based on the properties of the medicinal product."
    },
    {
        "instruction":"已知信息：\n'目标是协调制定最终标准草案。'可被翻译为：The objective will be to produce a final draft of those standards that need to be agreed.\n'参见最终规则， “透明度报告和医师所有权或 投资权益的报告， ”联邦公报, 第 78 卷, 2013 年 2 月 8 日,第 9458 页。'可被翻译为：See the final rule, “Transparency Reports and Reporting of Physician Ownership or Investment Interests,” Federal Register, Vol. 78, February 8, 2013, page 9458.\n'联邦公 报办公室会每天更新e-CFR中的内容。'可被翻译为：The Office of the Federal Register updates the material in the e-CFR on a daily basis.\n'CFR： 联邦法规编码（美国）'可被翻译为：CFR: Code of Federal Regulations. (USA)\n\n根据上述已知信息，请将'最终规则由联邦纪事办公室和政府出版局工作人员整合进CFR。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Final rules are integrated into the CFR by the Office of the Federal Register and Government Publishing Office staff."
    },
    {
        "instruction":"已知信息：\n'进口第一类体外诊断试剂备案，备案人向国家食品药品监督管理总局提交备案资料。'可被翻译为：To apply for filing of import class I in-vitro diagnostic reagents, the filing entity shall submit the filing documents to China Food and Drug Administration.\n'境内第一类医疗器械备案，备案人向设区的市级食品药品监督管理部门提交备案资料。'可被翻译为：To apply for filing of class I domestic medical devices, the filing entity shall submit the filing documents to the food and drug regulatory department of the city consisting of districts .\n'医疗器械备案是医疗器械备案人向食品药品监督管理部门提交备案资料，食品药品监督管理部门对提交的备案资料存档备查。'可被翻译为：Medical device filing is a process that the filing entity submits the filing documents to the food and drug regulatory department and the food and drug regulatory department files the filing documents submitted by the filing entity.\n'境内第一类体外诊断试剂备案，备案人向设区的市级食品药品监督管理部门提交备案资料。'可被翻译为：To apply for filing of class I in-vitro diagnostic reagent, the filing entity shall submit the filing documents to the food and drug regulatory department of the city consisting of districts .\n\n根据上述已知信息，请将'进口第一类医疗器械备案，备案人向国家食品药品监督管理总局提交备案资料。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"To apply for filing of import class I medical devices, the filing entity shall submit the filing documents to China Food and Drug Administration."
    },
    {
        "instruction":"已知信息：\n'患者报告的结果和健康相关的生活质量测量可能对治疗的评价有用。'可被翻译为：Patient-reported outcomes and health related quality of life measures may be useful for the evaluation of treatment.\n'更通用的健康相关生活质量（HRQOL）工具正在评估患者对疾病和治疗对日常生活、身体、心理和社会功能以及健康的影响的看法。'可被翻译为：More general Health-related quality of life (HRQOL) tools are assessing the patient’s perception of the impact of disease and treatment on daily life, physical, psychological and social functioning and well-being.\n'6.4. 健康相关生活质量（HR-QoL）'可被翻译为：6.4. Health related Quality of Life (HR-QoL)\n'此外，测定认知和功能、工具使用能力、执行功能以及健康相关生活质量，可以作为次要终点，从而对有效性进行全面评价。'可被翻译为：In addition, measures of cognition and function, instrumental activities, executive functions and health related quality of life should be included as secondary endpoints to contribute to the overall assessment of efficacy.\n\n根据上述已知信息，请将'健康相关生活质量的评估是一个有价值的疗效指标，在ALS的试验中可作为次要 终点，但HR-QoL工具的选择应当是有理有据的。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Measurement of Health Related Quality of Life is a valuable measure of therapeutic efficacy, which may be applied as a secondary endpoint in ALS trials. The choice of HR-QoL tool should be justified."
    },
    {
        "instruction":"已知信息：\n'例如，在某些情况下，加入原始数据而非推导出来的结论可能更为恰当。'可被翻译为：For example, inclusion of raw data rather than the derived conclusions may be appropriate in some situations.\n'其他参数的描述性统计学应适当。'可被翻译为：For the other parameters descriptive statistics would be appropriate.\n'（1）最大可行剂量（MFD），基于药物在溶媒中的物理化学特性（如果在该溶媒中的MFD与急性给药试验可达到的剂量相似；注释13）。'可被翻译为：i. Maximum Feasible Dose (MFD) based on physico-chemical properties of the drug in the vehicle (provided the MFD in that vehicle is similar to that achievable with acute administration; Note 13).\n'4 2002年 9月 列表总结 CTD中是否只应列出申请人认为明显的毒理学变 化？ CTD中只应列出明显的异常结果，这些可能包括与对照相比有统计学意义的差异及没有统计学意义的异常结果。'可被翻译为：4 Sept 2002 Tabulated Summary Are only toxicologically significant changes, as considered by applicants, to be tabulated in CTD? Only noteworthy findings should be tabulated in CTD. These might include statistically significant differences from controls, as well as noteworthy findings that are not statistically significant.\n\n根据上述已知信息，请将'（1）与阴性或溶媒对照组的数值相比有统计学意义的轻微增加，但是在该试验机构的合适的历史背景数据范围内。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"i. Small increases that are statistically significant compared with the negative or solvent control values but are within the confidence intervals of the appropriate historical control values for the testing facility."
    },
    {
        "instruction":"已知信息：\n'参考疗法 应合理选择参考方案，而且通常应该从最佳可用的、以证据为基础的治疗方案中进 行选择。'可被翻译为：Reference therapy The choice of reference regimen should be justified and normally this regimen should be selected from best available, evidence-based therapeutic options.\n'对于研究设计考虑，如入选和排除标准、适当的终点和预期的研究持续时间，应参考相关的治疗指导原则。'可被翻译为：For study design considerations, such as inclusion and exclusion criteria, appropriate endpoints and expected study duration, the relevant therapeutic guidelines should be consulted.\n'如果没有特定的活性药物可以用于治疗靶症状，可以选择基于当前可用的治疗选择的最佳支持治疗加上安慰剂作为对照。'可被翻译为：Placebo on top of best supportive care based on currently available treatment options is an acceptable comparator if no specific active drug is available to treat the targeted symptoms.\n'五种感染类型的研究可以通过证明试验药物不劣于适当的参比治疗方案来支持这一适应症，对此提供了详细指南。'可被翻译为：Detailed guidance is provided for studies in five types of infection in which it is accepted that indications for use can be supported by a demonstration of non-inferiority of the test agent to an appropriate comparative regimen.\n\n根据上述已知信息，请将'在选择治疗方案时， 应该基于一个或多个既往研究、 医学意见、适当的学术团体提出的该适应症的特定治疗指南以及在研究中心对参 比药物产生耐药性的预期发生率来考虑最佳可用治疗。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The regimen selected should be considered one of the best available treatments based on one or more of previous studies, medical opinion, indication- specific treatment guidelines from appropriate learned societies and the anticipated prevalence of resistance to the comparative agent at the investigative sites."
    },
    {
        "instruction":"已知信息：\n'所有成份都需要为预期疗效作出一定的贡献。'可被翻译为：All components are required to have an established contribution to the desired therapeutic effect.\n'每种成份均对疗效和安全性有贡献和\/或能增强（主要）活性物质的PK\/PD。'可被翻译为：each component contributes to efficacy and safety and\/or enhances PK\/PD of (main) active substance(s).\n'最终,对所有协变量的预估效果及其相关临床意义进行讨论。'可被翻译为：Ultimately, the estimation of any covariate effect should be discussed in relation to its clinical relevance.\n'A.判定药物活性成分的溶解度分类'可被翻译为：Determining Drug Substance Solubility Class\n\n根据上述已知信息，请将'a. 所有活性成分对所需治疗效果的相关贡献；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"a. relevant contribution of all active components to the desired therapeutic effect;"
    },
    {
        "instruction":"已知信息：\n'LBA的关键试剂包括（例如抗体、结合蛋白、肽）和对分析结果有直接影响的含酶组分。'可被翻译为：Critical reagents for LBAs include binding reagents (e.g., antibodies, binding proteins, peptides) and those containing enzymatic moieties that have a direct impact on the results of the assay.\n'关键试剂包括结合试剂（例如结合蛋白、适配子、抗体或偶联抗体）和含酶试剂，对分析结果有直接影响，因此必须确保关键试剂的质量。关键试剂通过与待测物结合，发生相互作用以产生与待测物浓度相关的仪器响应。应在分析方法中对关键试剂进行鉴定和规定。'可被翻译为：Critical reagents, including binding reagents (e.g., binding proteins, aptamers, antibodies or conjugated antibodies) and those containing enzymatic moieties, have direct impact on the results of the assay and, therefore, their quality should be assured. Critical reagents bind the analyte and, upon interaction, lead to an instrument signal corresponding to the analyte concentration. The critical reagents should be identified and defined in the assay method.\n'·LBA关键试剂变更（例如变更批号）'可被翻译为：• Changes in LBA critical reagents (e.g., lot-to-lot changes)\n'关键试剂'可被翻译为：critical reagent\n\n根据上述已知信息，请将'关键试剂：LBA的关键试剂包括结合试剂（例如抗体、结合蛋白、肽）和对分析结果有直接影响的含酶组分。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Critical Reagent: Critical reagents for LBAs include binding reagents (e.g., antibodies, binding proteins, peptides) and those containing enzymatic moieties that have a direct impact on the results of the assay."
    },
    {
        "instruction":"已知信息：\n'进行综合数据的中期分析时，在研究完成之前，应保持研究者盲态。'可被翻译为：In case of interim analyses of pooled data maintenance of investigator blindness should be maintained until completion of the study.\n'统计分析应按照前瞻性确定的统计分析计划进行，并且 应在临床研究报告（ICH E3临床研究报告）中注明偏离统计 分析计划的所有情况。'可被翻译为：The statistical analysis should be carried out in accordance with the prospectively defined analysis plan, and all deviations from the plan should be indicated in the study report (E3 Clinical Study Reports).\n'FDA建议及时进行这类披露，应在研究完成或终止后1年之内进行公开披露。（对于研究“完成”和“终止”的讨论，分别参见问题 86 和 87。）'可被翻译为：FDA recommends that all such disclosures occur promptly and that public disclosure after a study is completed or terminated occur within 1 year of the completion or termination date. (See also Questions 86 and 87 for discussion of study “completion” and “termination,” respectively.)\n'如果需要，该PK研究应在使用微量采样法的确定性研究之前完成。'可被翻译为：This PK study, if needed, should be completed prior to conducting definitive studies that will include the microsampling procedure.\n\n根据上述已知信息，请将'对于双盲研究，应在披露治疗分配之前确定完成统计分 析。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For double-blind studies, the statistical analysis plan should be finalised before treatment assignments are revealed."
    },
    {
        "instruction":"已知信息：\n'对于大多数微生物细胞，分析细胞在选择性培养基上生长情况就可用以确证宿主细胞库的宿主细胞种属特性。'可被翻译为：For most microbial cells, analysis of growth on selective media is usually adequate to confirm host cell identity at the species level for the host cell bank and the transformed cell bank.\n'这种广泛的入选可允许识别以及更好地表征疾病表型，使治疗研发更具可行性或必要性。'可被翻译为：This broad inclusion can allow identification and better characterization of disease phenotypes for which therapy development may be more feasible or needed.\n'还应使用增殖和非增殖条 件下培养的不同的细胞系和原代细胞，对细胞毒性进行评估。'可被翻译为：Cytotoxicity also should be assessed using various cell lines and primary cells cultured under proliferating and nonproliferating conditions.\n'• 生物试验、基于细胞的试验、免疫化学试验；'可被翻译为：• Biological assays, cell-based assays, immunochemical assays;\n\n根据上述已知信息，请将'在不同形式的基于细胞的试验中，选择了基于细胞的增殖试验，因 为广泛使用，并且具有充分表征的细胞系。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Out of different formats of cell- based assay, the cell-based proliferation assay was chosen as it is widely used and a well characterised cell line was available."
    }
]